<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Proteomics</journal-id><journal-id journal-id-type="iso-abbrev">J Proteomics</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of proteomics</journal-title></journal-title-group><issn pub-type="ppub">1874-3919</issn><issn pub-type="epub">1876-7737</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12503353</article-id><article-id pub-id-type="pmcid-ver">PMC12503353.1</article-id><article-id pub-id-type="pmcaid">12503353</article-id><article-id pub-id-type="pmcaiid">12503353</article-id><article-id pub-id-type="manuscript-id">NIHMS2114912</article-id><article-id pub-id-type="pmid">38777089</article-id><article-id pub-id-type="doi">10.1016/j.jprot.2024.105198</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2114912</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2114912</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SHIP1 modulation and proteome characterization of microglia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ahat</surname><given-names initials="E">Erpan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="Z">Zanyu</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="S">Shaoyou</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bui</surname><given-names initials="HH">Hai Hoang</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mason</surname><given-names initials="ER">Emily R.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soni</surname><given-names initials="DM">Disha M.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roth</surname><given-names initials="KD">Kenneth D</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chalmers</surname><given-names initials="MJ">Michael James</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oblak</surname><given-names initials="AL">Adrian L</given-names></name><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jie</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gutierrez</surname><given-names initials="JA">Jesus A</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Richardson</surname><given-names initials="T">Timothy</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Eli Lilly and Company, Indianapolis, USA.</aff><aff id="A2"><label>2</label>Department of Biostatistics &amp; Health Data Science, Indiana University School of Medicine, Indianapolis, USA.</aff><aff id="A3"><label>3</label>Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, USA.</aff><aff id="A4"><label>4</label>Department of Radiology &amp; Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA.</aff><aff id="A5"><label>5</label>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author Contributions</p><p id="P2">E.A., M.J.C, S.Y.C, A.L.O, T.R and J.A.G. designed the experiments; A.L.O prepared the primary microglia; S.Y.C generated the wildtype and INPP5D clones of HMC3 cells; E.A. performed the sample preparation and proteomics analysis. A.L.O performed the transcriptomics analysis. Z.S and J.Z performed the statistical analysis of the proteomics and transcriptomics data. H.H.B and K.D.R performed the lipidomic analysis. All authors discussed the results and contributed to the final manuscript.</p></fn><corresp id="CR1"><label>*</label><bold>Correspondence:</bold> Erpan Ahat: <email>ahat_erpan@lilly.com</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P37">Competing Interest</p><p id="P38">E.A., H.H.B., K.D.R., M.J.C, J.A.G. are the employees of Eli Lilly &amp; Company. The remaining authors declare no competing interests or conflict of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>30</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2024</year></pub-date><volume>302</volume><issue-id pub-id-type="pmc-issue-id">498442</issue-id><fpage>105198</fpage><lpage>105198</lpage><pub-history><event event-type="nihms-submitted"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2114912.pdf"/><abstract id="ABS1"><p id="P3">Microglia, the resident macrophage in brain, has gained significant attention due to their involvement in neurodegenerative diseases. Disease associated microglia (DAM) have been identified at sites of amyloid-beta plaques and neurodegeneration. Understanding microglial states in the aging brain has become crucial, especially with the discovery of numerous Alzheimer&#8217;s disease (AD) risk and protective variants in genes such as <italic toggle="yes">TREM2, CD33, APOE, ABCA7, PLCG2</italic>, and <italic toggle="yes">INPP5D</italic>, which are essential to microglia function<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. Here we present a thorough examination of microglia-like cell lines and primary mouse microglia at the proteomic and transcriptomic levels to help illuminate the roles these genes and the proteins they encode play in various cell states. This analysis serves as a guide to the exploration of potential therapeutic targets in the context of neurodegeneration. INPP5D, which encodes the SHIP1 protein, is essential for microglia function. SHIP1 has emerged as a target of interest having been nominated as a therapeutic target by three teams within the Accelerating Medicines Partnership for Alzheimer&#8217;s Disease (AMP-AD)<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. In this study, we compared the proteomic profiles of wildtype, SHIP1 heterozygous knockout, and homozygous knockout primary microglia. Our findings revealed significant proteomic alterations only in the homozygous knockout of the SHIP1 gene, revealing its impact on the microglial proteome. Additionally, we compared the proteomic and transcriptomic profiles of BV2 and HMC3 cells with primary mouse microglia because these cell lines are often used as microglial cellular models. Our results demonstrated a substantial similarity between the proteome of BV2 cells and mouse primary cells, while notable differences were observed between BV2 and human HMC3 cells, with some shared characteristics. Since SHIP1 functions as a lipid phosphatase that modulates phosphatidylinositol (PI) species, we conducted lipidomic analysis to quantify different phosphatidylinositols (PIs), phosphatidylinositol monophosphate (PIPs), and polyphosphoinositides (PPIs) in the HMC3 and BV2 cells. Under basal conditions, PI(3,4,5)P3 and PI(3,4)P2 species were detected at extremely low levels, making confident quantification challenging; however, PIP species within the overall pool were significantly changed upon SHIP1 overexpression in HMC3. This in-depth proteomic analysis of both mouse and human microglia, complemented by targeted lipidomic studies, enhances our understanding of these cellular models. The similarities between primary mouse microglia and the BV2 cell line is especially encouraging, supporting the use of this model for further investigations into the role that SHIP1 and other potential drug targets may play in the regulation of microglial states.</p></abstract><kwd-group><kwd>SHIP1</kwd><kwd>TREM2</kwd><kwd>microglia</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>neurodegeneration</kwd><kwd>proteomics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="systematic-review" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504467</article-id><article-id pub-id-type="pmcid-ver">PMC12504467.1</article-id><article-id pub-id-type="pmcaid">12504467</article-id><article-id pub-id-type="pmcaiid">12504467</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1598608</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Unveiling the glymphatic system&#8217;s impact on neurodegenerative diseases: a comprehensive bibliometric analysis (2012&#8211;2024)</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Younian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2971055/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Q">Qiangsheng</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Junyi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2752623/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="K">Kun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="L">Lanting</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ye</surname><given-names initials="F">Fan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Hubei University of Arts and Science</institution>, <addr-line>Xiangyang</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Anesthesiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science</institution>, <addr-line>Xiangyang</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Institute of Neuroscience and Brain Science, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science</institution>, <addr-line>Xiangyang</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/111489/overview" ext-link-type="uri">Geert Bultynck</ext-link>, KU Leuven, Belgium</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/175990/overview" ext-link-type="uri">Adriana Ximenes-da-Silva</ext-link>, Federal University of Alagoas, Brazil</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1789177/overview" ext-link-type="uri">Yuan Xu</ext-link>, Changzhou First People&#8217;s Hospital, China</p></fn><corresp id="c001">*Correspondence: Fan Ye, <email>fanye@hbuas.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1598608</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Wang, Liu, Wu, Meng, Zhou and Ye.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Liu, Wu, Meng, Zhou and Ye</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1598608.pdf"/><abstract><sec id="sec1"><title>Background</title><p>The glymphatic system is a crucial factor in the development of neurodegenerative diseases (NDs) and holds substantial promise for therapeutic strategies. However, despite its growing significance, detailed bibliometric investigations specifically targeting the interplay between the glymphatic system and NDs are still sparse. This study pioneers a comprehensive bibliometric analysis to delineate the intellectual framework and emerging trajectories in glymphatic system research associated with NDs.</p></sec><sec id="sec2"><title>Materials and methods</title><p>We conducted an exhaustive search of the literature on the glymphatic system and NDs using the Web of Science Core Collection (WoSCC), Scopus, and Pubmed Central (PMC) databases. VOSviewer was applied for bibliometric analysis and visualization to scrutinize geographical distribution, institutional distribution, inter-journal connections, and keyword prevalence. Additionally, CiteSpace was utilized to intuitively explore and analyze journal interactions and citation dynamics. The bibliometrix R package was employed to construct visualized networks of international collaborations, as well as the relationships among authors, keywords, and journals. Data visualization was further enhanced with the aid of the WPS Office.</p></sec><sec id="sec3"><title>Results</title><p>A total of 865 relevant publications were retrieved, covering 92 countries, 1,471 research institutions, and 367 academic journals. Over the past thirteen years, both the number of publications and citations related to the glymphatic system in NDs have shown a significant upward trend, with neuroscience being the primary research field. Chinese authors over the world published the largest number of articles, while China and United States rank the highest in terms of publication and citation counts, also both demonstrate extensive international collaboration. And the <italic toggle="yes">Frontiers series journal</italic> publishes the most papers in this field, while <italic toggle="yes">Brain</italic> is the most frequently cited journal. The University of Rochester is the top-producing institution with an internally well-known Chinese research group. Keyword analysis highlights the glymphatic system, Alzheimer&#8217;s disease (AD), cerebrospinal fluid, and aquaporin 4 (AQP4) as core topics, with AQP4 polarization identified as a key regulatory factor for metabolic waste clearance. The main NDs under investigation are AD and Parkinson&#8217;s disease (PD).</p></sec><sec id="sec4"><title>Conclusion</title><p>This study offers a comprehensive preliminary dissection of the research landscape, identifying current focal points and potential future directions in glymphatic system research related to NDs. By leveraging multiple bibliometric approaches, this study provides valuable insights into this burgeoning field.</p></sec></abstract><kwd-group><kwd>glymphatic system</kwd><kwd>neurodegenerative diseases</kwd><kwd>Aquaporin-4</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>bibliometrics</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. The research team formally acknowledges financial sponsorship encompassing investigation design, scholarly composition, and knowledge dissemination through ethical funding declaration protocols. This work was supported by the Natural Science Foundation of Hubei Province (2022CFB570), the Science and Technology Research Project of the Hubei Provincial Department of Health (WJ2023M158), and the Scientific Research Project of Hubei Provincial Department of Education (B2022171).</funding-statement></funding-group><counts><fig-count count="10"/><table-count count="8"/><equation-count count="0"/><ref-count count="67"/><page-count count="26"/><word-count count="14660"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Alzheimer's Disease and Related Dementias</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Neurodegenerative diseases (NDs) manifest through progressive neuronal degeneration in specific CNS regions, encompassing Alzheimer&#8217;s disease (AD), Parkinson&#8217;s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington&#8217;s disease (HD) (<xref rid="ref20" ref-type="bibr">Guo et al., 2022</xref>). These conditions share core neuropathological signatures including chronic neuroinflammation and pathological protein conglomerates. AD is pathologically defined by two hallmark features: extracellular deposition of <italic toggle="yes">&#946;</italic>-amyloid (A&#946;) plaques and intraneuronal accumulation of hyperphosphorylated Tau protein-laden neurofibrillary tangles, a dual pathogenic mechanism extensively corroborated in modern neuropathological paradigms (<xref rid="ref2" ref-type="bibr">Andrade-Guerrero et al., 2023</xref>). PD presents selective dopaminergic neuron loss within the substantia nigra pars compacta accompanied by <italic toggle="yes">&#945;</italic>-synuclein-enriched Lewy bodies (<xref rid="ref65" ref-type="bibr">Zhou et al., 2024</xref>). HD stems from abnormal Cytosine-Adenine-Guanine (CAG) trinucleotide expansion in the huntingtin (HTT) gene, driving progressive striatal and cortical neuron degeneration (<xref rid="ref13" ref-type="bibr">Chang et al., 2024</xref>; <xref rid="ref51" ref-type="bibr">Thipani Madhu et al., 2024</xref>). These pathogenic aggregates not only disrupt neuronal equilibrium but also amplify neural injury through innate immune activation and oxidative cascades (<xref rid="ref31" ref-type="bibr">Kritsilis et al., 2018</xref>). Of critical concern is the global surge in NDs prevalence due to population aging, which imposes an escalating socioeconomic strain on healthcare infrastructures (<xref rid="ref9" ref-type="bibr">Bhattacharya et al., 2022</xref>). NDs trigger irreversible neurological impairments including cognitive deterioration, motor deficits, and emotional dysregulation, which collectively degrade patients&#8217; functional independence. This clinical reality underscores the imperative to decode disease mechanisms and formulate precision interventions. The brain&#8217;s glymphatic network first mapped in 2012 through pioneering rodent studies serves as a macroscopic clearance pathway mediating cerebrospinal-interstitial fluid exchange (<xref rid="ref27" ref-type="bibr">Iliff et al., 2012</xref>). This pathway facilitates efficient clearance of neurotoxic metabolites like A&#946; and Tau proteins through arteriole pulsation-driven paravascular flux, a process modulated by astrocytic endfoot aquaporin 4 (AQP4) water channel polarization (<xref rid="ref39" ref-type="bibr">Naganawa et al., 2024</xref>). Notably, glymphatic activity exhibits circadian rhythmicity, with enhanced function during non-rapid eye movement sleep, suggesting that sleep disturbances may contribute to NDs progression via impaired metabolic clearance (<xref rid="ref19" ref-type="bibr">Gottesman et al., 2024</xref>). Accumulating evidence indicates that glymphatic dysfunction disrupts the homeostasis of pathogenic proteins (e.g., A&#946;, <italic toggle="yes">&#945;</italic>-synuclein), directly implicating this system in the etiopathogenesis of AD, PD, and other NDs (<xref rid="ref8" ref-type="bibr">Beschorner and Nedergaard, 2024</xref>; <xref rid="ref58" ref-type="bibr">Yamada and Iwatsubo, 2024</xref>). Thus, targeting glymphatic pathways emerges as a promising therapeutic strategy for NDs intervention. With the deepening understanding of the pathophysiological mechanisms of the glymphatic system, researchers are actively developing <italic toggle="yes">in vivo</italic> detection technologies to quantitatively assess its function. In recent years, advanced neuroimaging techniques such as dynamic contrast-enhanced MRI (DCE-MRI), diffusion tensor imaging along the perivascular space (DTI-ALPS), and ultra-high-resolution PET tracers have been employed to quantitatively evaluate human glymphatic transport efficiency in vivo. <xref rid="ref39" ref-type="bibr">Naganawa et al. (2024)</xref> and <xref rid="ref45" ref-type="bibr">Ringstad et al. (2018)</xref> successively used intrathecal gadolinium-enhanced DCE-MRI to map cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange in real time at a whole-brain scale, establishing standardized rate and clearance metrics. <xref rid="ref65" ref-type="bibr">Zhou et al. (2024)</xref> and <xref rid="ref42" ref-type="bibr">Premi et al. (2024)</xref> further applied DTI-ALPS and multimodal MRI to Parkinson&#8217;s disease and genetic frontotemporal dementia cohorts, respectively, demonstrating that reduced glymphatic transport efficiency significantly correlates with motor milestone risk and disease severity. <xref rid="ref54" ref-type="bibr">Wilson et al. (2020)</xref> and <xref rid="ref5" ref-type="bibr">Bah et al. (2023)</xref> proposed that novel PET tracers combined with computational fluid dynamics models could elucidate fluid dynamic alterations associated with aging and dementia at the molecular level, attributing glymphatic clearance impairment to diminished CSF pulsatility and reduced vascular compliance. These studies not only provide directly measurable glymphatic functional parameters but also establish a dual foundation&#8212;at both imaging and molecular levels&#8212;for clarifying the system&#8217;s mechanistic role in various NDs.</p><p>Bibliometrics, an interdisciplinary field employing mathematical and statistical methodologies to analyze academic literature (<xref rid="ref32" ref-type="bibr">Liu et al., 2024b</xref>; <xref rid="ref50" ref-type="bibr">Sun et al., 2023</xref>), provides systematic insights into knowledge structures, collaborative networks, research frontiers, and evolutionary trends within specific domains. Despite significant advancements in glymphatic research related to NDs, a comprehensive bibliometric analysis mapping the intellectual landscape of this field remains absent. This study pioneers the integration of CiteSpace (v6.3. R1), VOSviewer (v1.6.20), and Bibliometrix R package to conduct a multidimensional bibliometric analysis of original research articles on the glymphatic system in NDs published between 2012 and 2024. By constructing scientometric knowledge maps, we aim to delineate core research clusters, interdisciplinary intersections, and paradigm shifts, providing strategic guidance for future mechanistic explorations and translational applications in NDs research.</p></sec><sec sec-type="materials|methods" id="sec6"><label>2</label><title>Materials and methods</title><sec id="sec7"><label>2.1</label><title>Data collection</title><p>Selecting multiple academic databases and formulating an effective retrieval strategy are crucial for acquiring high-quality datasets. In this study, the WOSCC (Clarivate 2025-03-01), Scopus (Elsevier 2025-03-01), PMC (NLM 2025-03-01) were selected as the data sources to provide comprehensive support for the literature analysis. WOSCC, which encompasses the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts &amp; Humanities Citation Index (A&amp;HCI), and Emerging Sources Citation Index (ESCI), offers authoritative publications in the research field of the glymphatic system and neurodegenerative diseases. Scopus, recognized as the largest abstract and citation database covering a broad range of disciplines, provides extensive peer-reviewed literature. PMC, a full-text repository, offers free and open access to a growing archive of biomedical and life sciences journal literature indexed in PubMed. Given their extensive coverage and high-quality content, WOSCC, Scopus, and PMC were chosen as the primary data sources for this research.</p><p>To systematically obtain articles in this field, the search strategy employed the following Boolean query: TS&#8239;= (&#8220;glymphatic system&#8221; OR &#8220;glymphatic pathway&#8221; OR &#8220;Glymphatic Pathways&#8221; OR &#8220;Pathway, Glymphatic&#8221; OR &#8220;Glymphatic Clearance System&#8221; OR &#8220;glymphatic&#8221; OR &#8220;glial lymphatic&#8221; OR &#8220;Brain Perivascular Spaces&#8221; OR &#8220;Brain Perivascular Space&#8221; OR &#8220;Perivascular Space, Brain&#8221; OR &#8220;paravascular pathway&#8221;) AND TS&#8239;= (&#8220;Neurodegenerative Diseases&#8221; OR &#8220;Degenerative Diseases, Neurologic&#8221; OR&#8220;Neurologic Degenerative Disease&#8221; OR &#8220;Degenerative Neurologic Diseases&#8221; OR &#8220;Degenerative Neurologic Disease&#8221; OR &#8220;Neurologic Disease, Degenerative&#8221; OR &#8220;Neurologic Diseases, Degenerative&#8221; OR &#8220;Nervous System Degenerative Diseases&#8221; OR &#8220;Neurodegenerative Disorders&#8221; OR &#8220;Neurodegenerative Disorder&#8221; OR &#8220;Neurologic Degenerative Conditions&#8221; OR &#8220;Degenerative Condition, Neurologic&#8221; OR &#8220;Degenerative Conditions, Neurologic&#8221; OR &#8220;Neurologic Degenerative Condition&#8221; OR &#8220;Neurologic Degenerative Diseases&#8221; OR &#8220;Degenerative Diseases, Nervous System&#8221; OR &#8220;Degenerative Neurologic Disorders&#8221; OR &#8220;Degenerative Neurologic Disorder&#8221; OR &#8220;Neurologic Disorder, Degenerative&#8221; OR &#8220;Neurologic Disorders, Degenerative&#8221; OR &#8220;Degenerative Diseases, Spinal Cord&#8221; OR &#8220;Degenerative Diseases, Central Nervous System&#8221;OR &#8220;Alzheimer&#8217;s Disease&#8221; OR &#8220;Parkinson&#8217;s Disease&#8221; OR &#8220;Multiple Sclerosis&#8221; OR &#8220;Amyotrophic Lateral Sclerosis&#8221; OR &#8220;Huntington&#8217;s Disease&#8221;). The document types were specifically designated as &#8220;article&#8221; and &#8220;review article&#8221; to ensure the high quality of the data sources. Review articles were selected for their capacity to synthesize high-quality research findings, identify research gaps, and propose potential solutions. The publication date was restricted to the period from January 1, 2012, to December 31, 2024, and the language was limited to English. Initially, a total of 1,689 articles were retrieved, with 579 from the WOSCC, 773 from Scopus, and 337 from PMC. After removing duplicates and excluding articles that were unrelated to the theme or lacked essential information such as DOI, volume, start page, keywords, and references, a final dataset of 865 publications was retained for analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Study flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g001.jpg"><alt-text content-type="machine-generated">Flowchart depicting a bibliometric analysis process across four stages: Identification, Selection, Analysis, and Discussion. In Identification, databases like Web of Science, Scopus, and PubMed are searched for articles on the glymphatic system and neurodegenerative diseases, resulting in 1,689 hits. Selection steps involve removing duplicates and filtering out unrelated articles, narrowing it to 865 articles. Analysis involves data management with Microsoft Excel and Web of Science, using tools like CiteSpace, VOSviewer, and Biblioshiny for analysis. Discussion highlights global research trends, hot topics, and advantages and disadvantages.</alt-text></graphic></fig></sec><sec id="sec8"><label>2.2</label><title>Data analysis</title><p>For computational bibliometric evaluation, we employed three validated analytical frameworks: VOSviewer (v1.6.20), CiteSpace (v6.3. R1), and Bibliometrix R package (v4.1.3). The VOSviewer platform was configured to perform geospatial publication distribution profiling across geopolitical entities, institutional affiliations, and journal platforms, concurrently analyzing co-citation networks and term frequency matrices through predefined operational parameters: full-text enumeration methodology, multi-tiered weighting schema (document-based metrics for geopolitical/institutional/journal entities, citation-weighted indices for co-cited periodicals, frequency-adjusted measures for author-designated terminologies), association strength normalization protocols, and clustering criteria (resolution index&#8239;=&#8239;1.00, minimum node threshold&#8239;=&#8239;1, edge weight exclusio<italic toggle="yes">n</italic> =&#8239;0). The Java-architected CiteSpace environment facilitated temporal network decomposition through chronographic segmentation (2012&#8211;2024 with annual intervalization), g-index scaled network topology (<italic toggle="yes">k</italic>&#8239;=&#8239;14 coefficient), reference co-citation node typology, per-slice top-50 entry filtration, and Log-Likelihood Ratio clustering algorithm implementation, enabling dynamic visualization of journal-reference network architectures. The Bibliometrix R package, operating within RStudio 2023.03.1 (R v4.3.2 computational backend), executed international collaboration cartography and tripartite relationship visualization (author-keyword-journal nexus) alongside emergent term detection protocols constrained by temporal demarcation (2012&#8211;2024 baseline), lexical inclusion thresholds (minimum frequency&#8239;=&#8239;5, annual term quota&#8239;=&#8239;3). Supplementary bibliometric indicators encompassing publication volumetrics, authorship distribution patterns, and citation trajectory analyses were processed through WPS Office&#8217;s advanced analytical suite for graphical representation.</p></sec></sec><sec sec-type="results" id="sec9"><label>3</label><title>Results</title><sec id="sec10"><label>3.1</label><title>Fundamental quantitative data</title><p>865 articles written by 4,544 authors from 1,471 institutions in 92 countries were identified using the specified search strategy. Totaling 50,100 references from 7,138 different articles, these papers were published in 367 journals.</p></sec><sec id="sec11"><label>3.2</label><title>Quantitative analysis of publications</title><p>To reveal the development trends of glymphatic system research in the field of NDs, we integrated literature resources from three authoritative databases: Web of Science, Scopus, and PubMed Central. After a rigorous process of deduplication and screening, we included 865 high-quality articles for in-depth analysis. Through systematic categorization of publication types, our analysis revealed that original articles (<italic toggle="yes">n</italic> =&#8239;531, 61.39%) predominated over review articles (<italic toggle="yes">n</italic> =&#8239;334, 38.61%), with an approximate ratio of 1.59:1. This distribution underscores the field&#8217;s sustained emphasis on empirical investigation. From a macro-development perspective, as shown in <xref rid="fig2" ref-type="fig">Figure 2</xref>, the number of publications in this field has shown a significant upward trend, indicating a continuous increase in research activity. Based on the changes in annual publication volume, the research development from 2012 to 2024 can be divided into four phases: the initial phase (2012&#8211;2016), the early development phase (2017&#8211;2019), the rapid growth phase (2020&#8211;2023), and the current phase (2024 to present). During the initial phase, although the publication volume was low, these studies laid a crucial foundation for the in-depth exploration of the role of the glymphatic system in NDs. In the early development phase, there was a significant increase in publication volume compared to the initial phase, with an average annual output of approximately 125 articles. The rapid growth phase was characterized by a sharp increase in publication volume, with the number exceeding 150 articles in 2023. This marked acceleration reflects the growing attention from the academic community to the role of the glymphatic system in NDs. Notably, in 2024, the publication volume reached 233 articles, accounting for 40.2% of the total publications, and the growth trend shows no signs of slowing down. This trend indicates the increasing importance of the glymphatic system in NDs research, and it is anticipated that more relevant findings will be published in the future.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Annual output of research on glymphatic system in NDs from 2012 to 2024.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g002.jpg"><alt-text content-type="machine-generated">Bar chart showing the total number of publications from 2012 to 2024, divided into articles and reviews. Publication numbers increase sharply, peaking at 238 in 2024. The line graph overlays show a trend of increasing publication percentage, reaching 40.2% in 2024.</alt-text></graphic></fig></sec><sec id="sec12"><label>3.3</label><title>Distribution of research fields</title><p>The Web of Science database was utilized to analyze various research fields and identify the top 10 fields (<xref rid="fig3" ref-type="fig">Figure 3</xref>). In the study of the glymphatic system in NDs, Neuroscience (294 articles, accounting for 50.78%), Clinical Neurology (115 articles, 19.86%), and Biochemistry Molecular Biology (62 articles, 10.71%) are the primary research areas. Notably, Radiology Nuclear Medicine Medical Imaging (48 articles, 8.29%) also occupies a significant proportion. This indicates that research on the glymphatic system in NDs focuses not only on basic research and clinical translation but also on imaging assessment.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Distribution of major research fields in the study of the glymphatic system in NDs from 2012 to 2024.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g003.jpg"><alt-text content-type="machine-generated">Treemap displaying research field proportions with neurology areas predominant. Neurosciences hold the largest section with 294 units, followed by Clinical Neurology with 115. Other notable fields include Biochemistry Molecular Biology, Radiology Nuclear Medicine, and Cell Biology.</alt-text></graphic></fig></sec><sec id="sec13"><label>3.4</label><title>National and institutional analysis</title><p>In the field of glymphatic system research in NDs, a total of 865 articles were published by 1,471 different institutions across 92 countries. Based on the VOSviewer analysis platform, this study conducted a systematic quantitative analysis and visualized the research output in this field using the country of the first author as the statistical reference. The results show that the countries of the contributing authors span Asia, Europe, North America, and Australia (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref rid="fig4" ref-type="fig">Figure 4A</xref>). From a global regional perspective, Asia (504 articles, 48.23%), Europe (302 articles, 28.90%), and North America (218 articles, 20.86%) have emerged as the three primary contributors to academic output in this field, a distribution pattern that closely aligns with the global landscape of scientific and economic development. At the national level, China (351 articles, 33.59%, 23,411 citations) and the United States (215 articles, 20.57%, 30,531 citations) lead the way in both publication numbers and citation impact, and both countries exhibit extensive international collaboration. Following them are Italy (80 articles, 7.66%, 1,762 citations), Japan (68 articles, 6.51%, 3,723 citations), and Denmark (54 articles, 5.17%, 13,862 citations) (<xref rid="tab1" ref-type="table">Table 1</xref>). These five countries collectively serve as the cornerstone supporting foundational research on the glymphatic system in NDs. To enhance analytical precision, we established a publication threshold of &#8805;5 per country and consolidated synonymous entries, generating a collaborative network visualization comprising 19 countries to delineate both research productivity and inter-country partnership patterns (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Within this analytical framework, the size of each circle is proportional to a country&#8217;s publication output in the target research field; larger circles indicate higher publication volumes. The connecting lines represent collaboration intensity, with thicker lines denoting higher cooperation frequency. For instance, China, which has the largest publication volume, maintains strong research collaborations with the United States, the United Kingdom, Australia, and Netherlands. Meanwhile, the United States primarily engages in extensive cooperation with the China, Denmark, the United Kingdom, and South Korea. It is noteworthy that the countries participating in the international collaboration network are primarily developed countries (<xref rid="tab1" ref-type="table">Table 1</xref>). In addition, we have also compiled statistics on the top 20 institutions by publication volume, with Chinese universities consolidated into a single group (<xref rid="tab2" ref-type="table">Table 2</xref>). Overall, the group of Chinese universities has published the largest number of articles (109 articles, 30.70%). At the level of individual institutions, the University of Rochester in the United States ranks first with 38 published articles (accounting for 10.70%) and an impressive citation count of 11,989. This is followed by the University of Copenhagen in Denmark (22 articles, 6.20%) and Oregon Health &amp; Science University in the United States (17 articles, 4.79%). To further refine our investigation, we applied a publication threshold of &#8805;6 articles and selected 33 institutions from the initial 1,471 candidates. The data have been incorporated into a network visualization to illustrate the productivity and collaborative connections among institutions (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). In this diagram, the diameter of the circles is proportional to the output of each institution, with larger circles indicating greater output. It is evident that the Chinese university group makes the largest overall contribution, while among individual institutions, the University of Rochester has the highest output and citation frequency. The lines connecting circles are weighted according to the frequency of collaboration between institutions&#8212;thicker lines indicate closer and more frequent collaboration. For example, particularly close partnerships exist between the Chinese university group, the University of Rochester, and Oregon Health &amp; Science University. The University of Rochester and the University of Copenhagen also maintain strong cooperative ties. Notably, some institutions such as Massachusetts General Hospital and Eindhoven University of Technology have each published five or more articles, but have yet to establish significant collaborations with the core institutions in the field of glymphatic system and NDs research. With the increasing diversity of international collaborations and the rise of cross-border cooperation, communication and collaborative efforts among research institutions are expected to further intensify in the future.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Country ranking by publication frequency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Continents</th><th align="center" valign="top" rowspan="1" colspan="1">Country</th><th align="center" valign="top" rowspan="1" colspan="1">Counts</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">Total link strength</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="8" colspan="1">Asia (504,48.23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">China</td><td align="center" valign="middle" rowspan="1" colspan="1">351 (33.59%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23,411</td><td align="center" valign="middle" rowspan="1" colspan="1">26,309</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (6.51%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3,723</td><td align="center" valign="middle" rowspan="1" colspan="1">4,767</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (4.69%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1852</td><td align="center" valign="middle" rowspan="1" colspan="1">2,343</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (1.91%)</td><td align="center" valign="middle" rowspan="1" colspan="1">505</td><td align="center" valign="middle" rowspan="1" colspan="1">1,439</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pakistan</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.57%)</td><td align="center" valign="middle" rowspan="1" colspan="1">97</td><td align="center" valign="middle" rowspan="1" colspan="1">420</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Indonesia</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">155</td><td align="center" valign="middle" rowspan="1" colspan="1">246</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Turkey</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">155</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">India</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">148</td></tr><tr><td align="left" valign="middle" rowspan="18" colspan="1">Europe (302,28.90%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (7.66%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1762</td><td align="center" valign="middle" rowspan="1" colspan="1">4,888</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (5.17%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13,862</td><td align="center" valign="middle" rowspan="1" colspan="1">6,021</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (3.06%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4,756</td><td align="center" valign="middle" rowspan="1" colspan="1">2,781</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (3.06%)</td><td align="center" valign="middle" rowspan="1" colspan="1">376</td><td align="center" valign="middle" rowspan="1" colspan="1">1,455</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (2.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1847</td><td align="center" valign="middle" rowspan="1" colspan="1">2,543</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Finland</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (1.15%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,274</td><td align="center" valign="middle" rowspan="1" colspan="1">831</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Poland</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0.86%)</td><td align="center" valign="middle" rowspan="1" colspan="1">118</td><td align="center" valign="middle" rowspan="1" colspan="1">914</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">714</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">254</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">143</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.57%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">146</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.57%)</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">France</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0.48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">122</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Greece</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td><td align="center" valign="middle" rowspan="1" colspan="1">274</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Russia</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ireland</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">180</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hungary</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">109</td><td align="center" valign="middle" rowspan="1" colspan="1">116</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Austria</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">North America (218,20.86%)</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">215 (20.57%)</td><td align="center" valign="middle" rowspan="1" colspan="1">30,531</td><td align="center" valign="middle" rowspan="1" colspan="1">18,783</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">706</td><td align="center" valign="middle" rowspan="1" colspan="1">361</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Australia (21,2.01%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (2.01%)</td><td align="center" valign="middle" rowspan="1" colspan="1">994</td><td align="center" valign="middle" rowspan="1" colspan="1">1,576</td></tr></tbody></table></table-wrap><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p><bold>(A)</bold> World map and the number of publications in the four major continents; <bold>(B)</bold> National visualization analysis of glymphatic system in NDs; <bold>(C)</bold> Institutional visualization analysis of glymphatic system in NDs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g004.jpg"><alt-text content-type="machine-generated">Map and chart showing global scientific production data. Map indicates scientific production by country with shades of blue. Pie chart represents scientific production distribution: Asia (48.23%), Europe (28.90%), North America (20.86%), Australia (2.01%). Node graph displays international scientific collaboration: United States, China, Denmark, and others are connected, showing collaboration intensity and network between countries. Network visualization showing relationships among universities and institutions. Central nodes include "Chinese universities," "Univ Rochester," and "UCL," with interconnected lines indicating collaboration. Node size varies, reflecting network prominence. Labeled nodes include "Univ Copenhagen," "Harvard Med Sch," and "Monash Univ." The layout presents a web-like structure with distinct colored clusters on a dark background.</alt-text></graphic></fig><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Ranking of top 20 organizations based on publication frequency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Organization</th><th align="center" valign="top" rowspan="1" colspan="1">Country</th><th align="center" valign="top" rowspan="1" colspan="1">Counts</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">Total link strength</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Chinese Universities</td><td align="center" valign="middle" rowspan="1" colspan="1">China</td><td align="center" valign="middle" rowspan="1" colspan="1">109 (30.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8,268</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Rochester</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (10.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11,989</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Copenhagen</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (6.20%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3,693</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Oregon Health and Science University</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (4.79%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3,207</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">University College London</td><td align="center" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (4.51%)</td><td align="center" valign="middle" rowspan="1" colspan="1">607</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Nagoya University</td><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (3.66%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,063</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Yale School of Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (3.66%)</td><td align="center" valign="middle" rowspan="1" colspan="1">619</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Oslo</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (3.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3,847</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Lund University</td><td align="center" valign="middle" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (3.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">930</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Harvard Medical School</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (3.10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">552</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Southern California</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (3.10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">716</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Washington</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (3.10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">625</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">Monash University</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (2.82%)</td><td align="center" valign="middle" rowspan="1" colspan="1">367</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Copenhagen</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (2.82%)</td><td align="center" valign="middle" rowspan="1" colspan="1">561</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Rochester Medical Center</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (2.82%)</td><td align="center" valign="middle" rowspan="1" colspan="1">197</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">State University of New York at Stony Brook</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (2.54%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5,135</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Toronto</td><td align="center" valign="middle" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (2.25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">797</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">Johns Hopkins University</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (2.25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">111</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">University of Kentucky</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (2.25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">753</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">Eindhoven University of Technology</td><td align="center" valign="middle" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.97%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,589</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td></tr></tbody></table></table-wrap></sec><sec id="sec14"><label>3.5</label><title>Journals and co-cited journals analysis</title><p>VOSviewer was employed to analyze journals and co-cited journals (<xref rid="tab3" ref-type="table">Table 3</xref>). The analysis revealed that a total of 865 articles were published across 367 distinct academic journals. This paper presents the top 10 journals ranked by publication count. After consolidating the Frontiers series of journals, they merged them into a more cohesive and strategically significant core category&#8212;<italic toggle="yes">Frontiers.</italic> Within this new category, Frontiers tops the overall ranking in terms of publication volume, with 68 articles accounting for 31.3%. Among these, <italic toggle="yes">Frontiers in Aging Neuroscience</italic> (22 articles, 10.1%) and <italic toggle="yes">Frontiers in Neuroscience</italic> (21 articles, 9.7%) have played pivotal roles, emerging as the primary drivers of this success. They are followed by the <italic toggle="yes">International Journal of Molecular Sciences</italic> (29 articles, 13.4%), <italic toggle="yes">the Journal of Alzheimer&#8217;s Disease</italic> (21 articles, 9.7%), and <italic toggle="yes">the Journal of Cerebral Blood Flow and Metabolism</italic> (18 articles, 8.3%). The Journal Citation Reports (JCR), developed by Thomson Reuters, is an important metric for assessing the quality of academic journals. JCR categorizes journals into 176 different subject categories and ranks them into Q1, Q2, Q3, and Q4 based on their impact factors (<xref rid="ref33" ref-type="bibr">Liu et al., 2024a</xref>). Among the top 10 journals, all but <italic toggle="yes">Frontiers in Pharmacology</italic> and <italic toggle="yes">Frontiers in Immunology</italic> published more than 10 papers. Moreover, the majority of these journals are listed in the Q1 section of JCR. Hirsch developed the h-index to assess a journal&#8217;s impact on citations and productivity (<xref rid="ref24" ref-type="bibr">Hirsch, 2005</xref>). In order to reflect the journal&#8217;s importance in the area, the h-index calculates the number of papers (h) that have been referenced at least h times (<xref rid="ref25" ref-type="bibr">Hou et al., 2022</xref>). According to <xref rid="tab2" ref-type="table">Table 2</xref>, <italic toggle="yes">Neuroimage</italic> has the greatest h-index (H-index: 320), followed by Brain (H-index: 308). Among these journals, <italic toggle="yes">Frontiers</italic> leads in total citations (1,112 times), followed by <italic toggle="yes">Brain</italic> (986 times) and the <italic toggle="yes">Journal of Cerebral Blood Flow and Metabolism</italic> (749 times). Additionally, <italic toggle="yes">Brain</italic> has the highest impact factor (IF&#8239;=&#8239;11.9) among these journals. Among the top 10 co-cited journals, <italic toggle="yes">the Journal of Neuroscience</italic> was cited 1,601 times, ranking first, followed by <italic toggle="yes">Science</italic> (1,575 times) and <italic toggle="yes">Nature</italic> (1,367 times). Co-cited journals refer to journals that are cited together in the reference lists of two or more academic publications. If two journals are frequently cited together in the same set of papers, a co-citation relationship exists between them. Analyzing co-cited journals can reveal academic connections between journals, the developmental trajectory of research fields, and the intellectual structure of disciplines. Nine out of the top 10 co-cited journals belong to the Q1 JCR division, with Nature having the highest IF (IF&#8239;=&#8239;50.5). A density map can visually display journals and co-cited journals (<xref rid="fig5" ref-type="fig">Figure 5</xref>). Journal overlay maps can visually show the distribution of journals across disciplines; the first map is an overlay of citing journals (<xref rid="fig6" ref-type="fig">Figure 6A</xref>), and the second is an overlay of cited journals (<xref rid="fig6" ref-type="fig">Figure 6B</xref>). We found that the dual map overlay of journals can visually display the distribution of journals across disciplines and the evolution of citation trajectories. The distribution of journals and the connection between citing and cited journals are accurately depicted by the dual map coverage of journals in <xref rid="fig6" ref-type="fig">Figure 6C</xref>. Citation associations are indicated by the colored paths. Citing journals are displayed on the left map, and cited journals are displayed on the right map. Three primary reference paths are shown (<xref rid="fig6" ref-type="fig">Figure 6C</xref>). According to the current study, articles from the magazine &#8220;Molecular/Biology/Genetics&#8221; were frequently referenced by &#8220;Molecular/Biology/Immunology&#8221; and &#8220;Neurology/Sports/Ophthalmology.&#8221; Additionally, &#8220;Molecular/Biology/Immunology&#8221; frequently cited articles from the magazine &#8220;Psychology/Education/Social.&#8221;</p><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Top 10 most productive journals and co-cited journals: comparative analysis of publication output and citation impact.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Journals</th><th align="center" valign="top" rowspan="1" colspan="1">Counts</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">JCR (IF)<break/>(2023)</th><th align="center" valign="top" rowspan="1" colspan="1">H-index</th><th align="center" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Co-cited journals</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">JCR (IF)<break/>(2023)</th><th align="center" valign="top" rowspan="1" colspan="1">H-index</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="6" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Frontiers series (total)</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (31.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="6" colspan="1">1</td><td align="center" valign="middle" rowspan="6" colspan="1">Journal of neuroscience</td><td align="center" valign="middle" rowspan="6" colspan="1">1,601</td><td align="center" valign="middle" rowspan="6" colspan="1">Q1 (4.4)</td><td align="center" valign="middle" rowspan="6" colspan="1">422</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">frontiers in aging neuroscience</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (10.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">369</td><td align="center" valign="middle" rowspan="1" colspan="1">Q2 (4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">120</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">frontiers in neuroscience</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (9.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">339</td><td align="center" valign="middle" rowspan="1" colspan="1">Q2 (3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">153</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">frontiers in neurology</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (6.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td><td align="center" valign="middle" rowspan="1" colspan="1">Q3 (2.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">105</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">frontiers in pharmacology</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (2.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">247</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">frontiers in immunology</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (2.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">155</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">International journal of molecular sciences</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (13.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">432</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">114</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Science</td><td align="center" valign="middle" rowspan="1" colspan="1">1,575</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (44.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,058</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Journal of Alzheimers disease</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (9.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">447</td><td align="center" valign="middle" rowspan="1" colspan="1">Q2 (3.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">115</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Nature</td><td align="center" valign="middle" rowspan="1" colspan="1">1,367</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (50.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,096</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Journal of cerebral blood flow and metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (8.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">749</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">177</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurology</td><td align="center" valign="middle" rowspan="1" colspan="1">1,316</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (8.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">331</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Scientific reports</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (7.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">375</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (3.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">149</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" rowspan="1" colspan="1">1,315</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (11.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">308</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Fluids and barriers of the cns</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (7.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">120</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Journal of Alzheimers disease</td><td align="center" valign="middle" rowspan="1" colspan="1">823</td><td align="center" valign="middle" rowspan="1" colspan="1">Q2 (3.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">115</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (6.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">986</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (11.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">308</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuron</td><td align="center" valign="middle" rowspan="1" colspan="1">930</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (16.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">530</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurobiology of disease</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (5.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">587</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (5.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">151</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuroimage</td><td align="center" valign="middle" rowspan="1" colspan="1">924</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">320</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuroimage</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (5.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">268</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">320</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Annals of neurology</td><td align="center" valign="middle" rowspan="1" colspan="1">907</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (8.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">273</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain sciences</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (5.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (5.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">151</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Journal of cerebral blood flow and metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">830</td><td align="center" valign="middle" rowspan="1" colspan="1">Q1 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">177</td></tr></tbody></table></table-wrap><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Density map of journals associated with glymphatic system research in NDs; <bold>(A)</bold> Depicts periodicals meeting a threshold of &#8805;5 published articles (35 journals collectively); <bold>(B)</bold> Includes co-cited journals with &#8805;150 citations (79 journals aggregately).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g005.jpg"><alt-text content-type="machine-generated">Two density maps labeled A and B show clusters of journal names with varying prominence. In the top map (A), "frontiers" and "international journal of molec" are central. In the bottom map (B), "nature", "neuron", and "j neurosci" are central with a denser concentration of names around them. The maps visualize the connections and importance of different journals in a scholarly context.</alt-text></graphic></fig><fig position="float" id="fig6" orientation="portrait"><label>Figure 6</label><caption><p><bold>(A)</bold> The map overlay of citing journals regarding the glymphatic system in NDs; <bold>(B)</bold> The map overlay of cited journals regarding the glymphatic system in NDs; <bold>(C)</bold> Journal double-figure overlay of glymphatic system in NDs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g006.jpg"><alt-text content-type="machine-generated">Two network visualizations labeled A and B generated by VOSviewer. Clusters of nodes represent academic journals and their relationships based on citation data. Nodes are color-coded, indicating different clusters or research fields. Density and proximity of nodes suggest the interconnectedness of these journals. Colorful network diagram with nodes and curved lines connecting various scientific disciplines, such as physics, ecology, and medicine. Each node is labeled, representing research categories. Flow lines indicate relationships between fields, forming a complex, intertwined network on a dark background.</alt-text></graphic></fig></sec><sec id="sec15"><label>3.6</label><title>Authors and co-cited authors analysis</title><p>Co-cited authors refer to two or more authors being simultaneously cited by others or multiple papers, establishing a co-citation relationship. In <xref rid="fig7" ref-type="fig">Figures 7a</xref>,<xref rid="fig7" ref-type="fig">B</xref>, each node represents an author or co-cited author, with node size proportional to the number of publications or citation frequency. The connecting lines between nodes indicate the degree of collaboration between authors or co-cited authors, where thicker lines denote stronger collaborative ties. Nodes sharing the same color form a cluster. Denser and more extensive connections between two clusters signify closer collaboration. As shown in <xref rid="fig7" ref-type="fig">Figures 7a</xref>,<xref rid="fig7" ref-type="fig">B</xref>, authors and co-cited authors are distributed across several distinct clusters, with those within the same cluster demonstrating closer relationships. Furthermore, we first grouped all Chinese authors into a single &#8220;Chinese authors group,&#8221; which includes authors from an internally well-known Chinese research group. Utilizing VOSviewer, we incorporated 153 authors with more than three published articles into the authors&#8217; network. Analysis of the top 20 most influential authors worldwide revealed that the Chinese authors (351 articles, 61.69%, 23,411 citations) ranked first in terms of publication count, citation frequency, and total link strength. However, deeper examination of their academic output structure shows a predominant focus on original articles (86.32%), with review articles constituting only 13.68%. This output pattern contrasts sharply with their impact metrics: despite commanding a substantial lead in total output, their citations per paper stand at just 66.70. In comparison, Denmark&#8217;s Nedergaard M., while producing a smaller total output (45 articles), exhibits exceptional academic influence. With 11,995 cumulative citations and a total link strength of 5,111, their citations per paper reach 266.56, which is four times that of the Chinese authors. Notably, U. S. scholar Rashid Deane leads globally with 920.17 citations per paper, while the Nedergaard M.&#8217;s impact remains remarkable. Further analysis reveals the Nedergaard M. maintains a more balanced publication portfolio, with review articles accounting for 26.67% of their output&#8212;nearly double the Chinese authors&#8217; proportion (<xref rid="tab4" ref-type="table">Table 4</xref>). These differences are visually captured in the bubble chart (<xref rid="fig7" ref-type="fig">Figures 7A</xref>,<xref rid="fig7" ref-type="fig">b</xref>): the Chinese authors cluster in the &#8220;high-original/low-impact&#8221; quadrant (coordinates: X&#8239;=&#8239;13.68%, Y&#8239;=&#8239;86.32%), while the Nedergaard M. occupies the &#8220;balanced/high-impact&#8221; region (coordinates: X&#8239;=&#8239;26.67%, Y&#8239;=&#8239;73.33%). The bubble area (representing citations per paper) shows a four-fold difference between teams. <xref rid="tab4" ref-type="table">Table 4</xref> multidimensional comparative analysis quantifies these findings: the Chinese authors exemplify a &#8220;quantity-driven/original-focused&#8221; model, whereas the Nedergaard M. embodies a &#8220;quality-first/balanced-development&#8221; approach. To further analyze the situation of co-cited authors, we also combined all cited Chinese authors as &#8220;Co-cited Chinese authors.&#8221; A total of 79 authors who had been cited more than 50 times were selected to construct the co-citation network, from which the top 20 most frequently co-cited authors were identified for cluster analysis. The results indicated that all of these authors had been cited more than 150 citations. In Asia, the &#8220;Co-cited Chinese authors&#8221; had the highest total citations (3,271 citations) and the highest total link strength (112,789 TLS). Notably, Iliff, J. J. from the United States was the most frequently co-cited author (1,108 citations) with the highest total link strength (33,911 TLS), highlighting his significant academic impact and collaborative ties in the study of the glymphatic system in NDs (<xref rid="tab5" ref-type="table">Table 5</xref>).</p><fig position="float" id="fig7" orientation="portrait"><label>Figure 7</label><caption><p><bold>(A) (a)</bold> A VOSviewer-generated mapping framework depicting authors contributing to glymphatic system investigations in NDs; <bold>(b)</bold> Comparative analysis of publication impact between high-productivity Chinese authors and the Nedergaard M (bubble chart: X, review proportion; Y, article proportion; bubble size, citations per paper); <bold>(B)</bold> A VOSviewer-generated mapping framework depicting co-authors contributing to glymphatic system investigations in NDs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g007.jpg"><alt-text content-type="machine-generated">Diagram A consists of two visuals: (a) a network map with nodes and connecting lines displaying relationships among "Chinese authors" and various researchers, color-coded by clusters, and (b) a bubble chart showing "Chinese authors" and "Nedergaard, maiken" with axes labeled "Article proportion" and "Review proportion". Diagram B is a network map showing "co-cited Chinese authors" with connections to other researchers, highlighted with various colors indicating different clusters.</alt-text></graphic></fig><table-wrap position="float" id="tab4" orientation="portrait"><label>Table 4</label><caption><p>Top 20 authors and collaborative citations on glymphatic system in NDs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Continents</th><th align="center" valign="top" rowspan="1" colspan="1">Author</th><th align="center" valign="top" rowspan="1" colspan="1">Country</th><th align="center" valign="top" rowspan="1" colspan="1">Counts</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">Citations per paper</th><th align="center" valign="top" rowspan="1" colspan="1">Original article</th><th align="center" valign="top" rowspan="1" colspan="1">Review article</th><th align="center" valign="top" rowspan="1" colspan="1">Total link strength</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="5" colspan="1">Asia (390,68.54%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Chinese authors</td><td align="center" valign="middle" rowspan="1" colspan="1">China</td><td align="center" valign="middle" rowspan="1" colspan="1">351 (61.69%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23,411</td><td align="center" valign="middle" rowspan="1" colspan="1">66.70</td><td align="center" valign="middle" rowspan="1" colspan="1">303 (86.32%)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (13.68%)</td><td align="center" valign="middle" rowspan="1" colspan="1">26,309</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Taoka, Toshiaki</td><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (2.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,006</td><td align="center" valign="middle" rowspan="1" colspan="1">83.83</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (58.33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (41.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,149</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lee, Hedok</td><td align="center" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,602</td><td align="center" valign="middle" rowspan="1" colspan="1">178.00</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (66.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33.33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">906</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Naganawa, Shinji</td><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">838</td><td align="center" valign="middle" rowspan="1" colspan="1">93.11</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (44.44%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (55.55%)</td><td align="center" valign="middle" rowspan="1" colspan="1">891</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Choupan, Jeiran</td><td align="center" valign="middle" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td><td align="center" valign="middle" rowspan="1" colspan="1">8.67</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (88.89%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">372</td></tr><tr><td align="left" valign="middle" rowspan="10" colspan="1">North America (98,17.22%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Iliff, Jeffrey J.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (4.39%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,234</td><td align="center" valign="middle" rowspan="1" colspan="1">289.36</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (76.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (24.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3,173</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Benveniste, Helene</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (3.16%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5,854</td><td align="center" valign="middle" rowspan="1" colspan="1">325.22</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (72.22%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (27.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,325</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">De Leon, Mony J.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (1.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">93</td><td align="center" valign="middle" rowspan="1" colspan="1">11.63</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">614</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kelley, Douglas H.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (1.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">291</td><td align="center" valign="middle" rowspan="1" colspan="1">36.38</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">490</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mestre, Humberto</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (1.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,647</td><td align="center" valign="middle" rowspan="1" colspan="1">330.88</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1,390</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tannenbaum, Allen</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">780</td><td align="center" valign="middle" rowspan="1" colspan="1">111.43</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (42.86%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (57.14%)</td><td align="center" valign="middle" rowspan="1" colspan="1">618</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chopp, Michael</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">6.00</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (33.33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">163</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Claassen, Daniel o.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">147</td><td align="center" valign="middle" rowspan="1" colspan="1">24.50</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (100.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">244</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Deane, Rashid</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5,521</td><td align="center" valign="middle" rowspan="1" colspan="1">920.17</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (100.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2025</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Donahue, Manus J.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">147</td><td align="center" valign="middle" rowspan="1" colspan="1">24.50</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (100.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">244</td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">Europe (81,14.24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Nedergaard, Maiken</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (7.91%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11,995</td><td align="center" valign="middle" rowspan="1" colspan="1">266.56</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (73.33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (26.67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5,111</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Eide, per Kristian</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (1.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">673</td><td align="center" valign="middle" rowspan="1" colspan="1">67.30</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (80.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (20.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">570</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ringstad, Geir</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (1.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">665</td><td align="center" valign="middle" rowspan="1" colspan="1">66.50</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (70.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (30.00%)</td><td align="center" valign="middle" rowspan="1" colspan="1">687</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lundgaard, Iben</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1867</td><td align="center" valign="middle" rowspan="1" colspan="1">207.44</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (55.56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (44.44%)</td><td align="center" valign="middle" rowspan="1" colspan="1">910</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Wostyn, Peter</td><td align="center" valign="middle" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (57.14%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (42.86%)</td><td align="center" valign="middle" rowspan="1" colspan="1">143</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab5" orientation="portrait"><label>Table 5</label><caption><p>Top 20 co-cited authors and collaborative citations on glymphatic system in NDs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Continents</th><th align="center" valign="top" rowspan="1" colspan="1">Co-cited author</th><th align="center" valign="top" rowspan="1" colspan="1">country</th><th align="center" valign="top" rowspan="1" colspan="1">Citations</th><th align="center" valign="top" rowspan="1" colspan="1">Total link strength (TLS)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3" colspan="1">Asia (3,784,42.53%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Co-cited Chinese authors</td><td align="center" valign="middle" rowspan="1" colspan="1">China</td><td align="center" valign="middle" rowspan="1" colspan="1">3,271 (36.77%)</td><td align="center" valign="middle" rowspan="1" colspan="1">112,789</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Taoka, T.</td><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">353 (3.97%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12,545</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Naganawa, S.</td><td align="center" valign="middle" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">160 (1.80%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,426</td></tr><tr><td align="left" valign="middle" rowspan="7" colspan="1">North America (2,663,29.93%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Iliff, J. J.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">1,108 (12.45%)</td><td align="center" valign="middle" rowspan="1" colspan="1">33,911</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Louveau, A.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">392 (4.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,021</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kress, B. T.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">276 (3.10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9,602</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Da mesquita, S.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">259 (2.91%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9,506</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hablitz, L. M.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">233 (2.62%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8,831</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Benveniste, H.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">204 (2.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,948</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Plog, B. A.</td><td align="center" valign="middle" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">191 (2.15%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,621</td></tr><tr><td align="left" valign="middle" rowspan="10" colspan="1">Europe (2,450,27.54%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Mestre, H.</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">475 (5.34%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18,183</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ringstad, G.</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">288 (3.24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11,636</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Eide, P. K.</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">277 (3.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12,562</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nedergaard, M.</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">244 (2.74%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,982</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rasmussen, M. K.</td><td align="center" valign="middle" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" rowspan="1" colspan="1">223 (2.51%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,395</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Wardlaw, J. M.</td><td align="center" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" rowspan="1" colspan="1">219 (2.46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7,116</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jessen, N. A.</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">212 (2.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6,509</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Weller, R. O.</td><td align="center" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" rowspan="1" colspan="1">186 (2.09%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6,680</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aspelund, A.</td><td align="center" valign="middle" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" rowspan="1" colspan="1">174 (1.96%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6,616</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zeppenfeld, D. M.</td><td align="center" valign="middle" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" rowspan="1" colspan="1">152 (1.71%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5,020</td></tr></tbody></table></table-wrap></sec><sec id="sec16"><label>3.7</label><title>Co-occurrence of keywords analysis</title><p>Examining lexical co-occurrence, thematic clustering, and temporal evolution serves as a methodological approach to identify trending themes with rapidly evolving prominence. Visualization of these lexical patterns enables researchers to elucidate core priorities and intellectual trends within the discipline, supporting holistic comprehension of its evolutionary pathways. From a corpus of 865 publications, 5,346 distinct keywords were systematically identified through VOSviewer&#8217;s analytical framework. Since some words, such as &#8220;Alzheimer&#8217;s disease&#8221; and &#8220;Alzheime&#8217;s disease,&#8221; expressed the same meaning, these synonyms were combined in the analysis. The top 20 most frequent keywords are displayed in <xref rid="tab6" ref-type="table">Table 6</xref>. The keyword analysis identified &#8220;Glymphatic system&#8221; (695 occurrences) and &#8220;Alzheimer&#8217;s disease&#8221; (472 occurrences) as the highest-frequency terms, with subsequent prominence observed for &#8220;Human&#8221; (<italic toggle="yes">n</italic> =&#8239;217) &#8220;Cerebrospinal-fluid&#8221; (<italic toggle="yes">n</italic> =&#8239;215) and &#8220;brain&#8221; (<italic toggle="yes">n</italic> =&#8239;213). These lexical clusters delineate primary research frontiers in glymphatic pathway investigations related to NDs. Lexical network mapping via VOSviewer (<xref rid="fig8" ref-type="fig">Figure 8A</xref>) employed two normalization criteria: frequency (&#8805;15 occurrences) and semantic merging of equivalent terms, ultimately yielding a refined lexicon of 170 terms. Clustering of the network map based on keyword co-occurrence analysis was performed to reflect the basic knowledge structure of related research areas. CiteSpace software was used to cluster the keywords in the literature. This study utilized CiteSpace software and the log-likelihood ratio (LLR) method to cluster keywords from the literature, selecting g-index k&#8239;=&#8239;14 (the maximum value) to ensure high confidence and reduce noise. Under this strict threshold, 8 clusters were generated, while core themes remained clear (<xref rid="fig8" ref-type="fig">Figure 8B</xref>). The clustering modularity (Q) value was 0.4457, and the mean silhouette (S) was 0.796, indicating significant clustering structure (Q&#8239;&gt;&#8239;0.3) and efficient, credible clustering (S&#8239;&gt;&#8239;0.7). To assess robustness, we examined changes in Q, S, and Harmonic Mean (Q, S) across different k values (<xref rid="fig8" ref-type="fig">Figure 8C</xref>). As the k value decreased from 14 to 4, the number of clusters reduced, yet changes in Q and S stayed below 10%. Harmonic Mean (Q, S) remained stable, suggesting the overall clustering quality was consistent across various k values. Although the Harmonic Mean (Q, S) was below 0.6, the slight variations in Q and S demonstrate the robustness of the clustering results. The eight cluster labels are as follows: neurodegenerative diseases (#0), female (#1), Alzheimer&#8217;s disease (#2), brain lymphatic system (#3), blood&#8211;brain barrier (#4), lymphangiogenesis (#5), cognitive impairment (#6), and Virchow-Robin spaces (#7), detailed in <xref rid="tab7" ref-type="table">Table 7</xref>. The stability of core clustering themes further supports the robustness of the clustering results. When the frequency of a particular keyword increases sharply within a certain period, it is referred to as a burst keyword. This phenomenon provides important insights for identifying emerging research topics and hotspots in a given field (<xref rid="ref26" ref-type="bibr">Hou et al., 2023</xref>). <xref rid="fig8" ref-type="fig">Figure 8D</xref> displayed the top 25 keywords with the strongest citation bursts. The keyword with the highest citation burst was priority journal (15.6) from 2015 to 2020, followed by cerebral amyloid angiopathy (7.4) and interstitial fluid (6.96). The keywords with the longest duration of the strongest citation bursts were rat brain and central nervous system from 2012 to 2018. A timeline viewer for these keywords was constructed using CiteSpace. The timeline visualization categorizes keywords through temporal stratification, enabling chronological tracking of topic-specific developments across distinct research phases. <xref rid="fig8" ref-type="fig">Figure 8E</xref> illustrates the intellectual priorities and developmental pathways of glymphatic system studies in NDs.</p><table-wrap position="float" id="tab6" orientation="portrait"><label>Table 6</label><caption><p>The top 20 keywords related to glymphatic system in NDs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Keywords</th><th align="center" valign="top" rowspan="1" colspan="1">Occurrences</th><th align="center" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Keywords</th><th align="center" valign="top" rowspan="1" colspan="1">Occurrences</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Glymphatic system</td><td align="center" valign="middle" rowspan="1" colspan="1">695</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">Pathology</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer&#8217;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">472</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">Interstitial fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Human</td><td align="center" valign="middle" rowspan="1" colspan="1">217</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">Impairment</td><td align="center" valign="middle" rowspan="1" colspan="1">91</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Cerebrospinal-fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">215</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse model</td><td align="center" valign="middle" rowspan="1" colspan="1">87</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" rowspan="1" colspan="1">213</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">Magnetic resonance imaging</td><td align="center" valign="middle" rowspan="1" colspan="1">83</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Aquaporin 4</td><td align="center" valign="middle" rowspan="1" colspan="1">161</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">Amyloid-beta</td><td align="center" valign="middle" rowspan="1" colspan="1">82</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Clearance</td><td align="center" valign="middle" rowspan="1" colspan="1">128</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Nonhuman</td><td align="center" valign="middle" rowspan="1" colspan="1">114</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">Nuclear magnetic resonance imaging</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Sleep</td><td align="center" valign="middle" rowspan="1" colspan="1">110</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">107</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurodegeneration</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td></tr></tbody></table></table-wrap><fig position="float" id="fig8" orientation="portrait"><label>Figure 8</label><caption><p><bold>(A)</bold> The Co-occurrence analysis of all key words by VOSviewer (a keyword with &#8805;15 occurences, 170 keywords in total); <bold>(B)</bold> The cluster analysis of the keywords using CiteSpace; <bold>(C)</bold> Impact of varying g-index k on clustering quality indicators Q and S; <bold>(D)</bold> Top 25 keywords with the strongest ciatation bursts by CiteSpace; <bold>(E)</bold> CiteSpace visualization map of timeline viewer related to glymphatic system in NDs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g008.jpg"><alt-text content-type="machine-generated">A network visualization map displays interconnected keywords related to the glymphatic system, Alzheimer's disease, and cerebrospinal fluid, with clusters in red, yellow, and blue. A second map shows thematic clusters labeled with topics like degenerative disease and cognitive impairment, using different colors to indicate each area. Line graph and bar chart. The line graph shows index values for Modularity, Mean Silhouette, and Harmonic Mean across g-index k values. The bar chart lists the top 25 keywords with citation bursts from 2012 to 2024, highlighting significant keywords like "rat brain," "central nervous system," and "priority journal," with citation strengths and durations represented by colored bars. Visualization of research clusters from 2012 to 2024 based on citations and topics. Key areas include degenerative diseases, Alzheimer's disease, and the glymphatic system. Colors represent different themes, with nodes sized by significance. Prominent years are marked along the top.</alt-text></graphic></fig><table-wrap position="float" id="tab7" orientation="portrait"><label>Table 7</label><caption><p>Cluster analysis results of glymphatic system research in NDs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">ClusterID</th><th align="center" valign="top" rowspan="1" colspan="1">Silhouette</th><th align="center" valign="top" rowspan="1" colspan="1">mean (Year)</th><th align="left" valign="top" rowspan="1" colspan="1">Label (LSI)</th><th align="left" valign="top" rowspan="1" colspan="1">Label (LLR)</th><th align="left" valign="top" rowspan="1" colspan="1">Label (MI)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.618</td><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; central nervous system disease; mood disorder; perivascular space; transcription factor | s disease; endothelial cells; substantia nigra; gut microbiota; reactive oxygen speciess</td><td align="left" valign="middle" rowspan="1" colspan="1">Degenerative disease (16.66, 1.0E-4); female (13.78, 0.001); microglia (13.77, 0.001); male (13.08, 0.001); stem cell niche (11.02, 0.001)</td><td align="left" valign="middle" rowspan="1" colspan="1">Bacterial infection (0.94); 3 d cultures (0.94); c</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Magnetic resonance; systolic blood; apparent diffusion; diastolic blood; community dwelling | glymphatic system; magnetic resonance imaging; perivascular spaces; robin spaces; paravascular spaces</td><td align="left" valign="middle" rowspan="1" colspan="1">Female (37.71, 1.0E-4); male (32.65, 1.0E-4); aged (29.73, 1.0E-4); middle aged (27.66, 1.0E-4); longitudinal study (17.78, 1.0E-4)</td><td align="left" valign="middle" rowspan="1" colspan="1">18f-florzolotau (1.01); clearance syste</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.874</td><td align="center" valign="middle" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; perivascular spaces; choroid plexus; dural lymphatics; glymphatic pathways | alzheimers disease; 4d flow mri; mean blood flow; pulsatility index; brain tumorigenesis</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimers disease (70.79, 1.0E-4); interstitial fluid (27.52, 1.0E-4); clearance (25.86, 1.0E-4); aqp4 (23.42, 1.0E-4); mouse model (23.19, 1.0E-4)</td><td align="left" valign="middle" rowspan="1" colspan="1">Autoimmunity (1.17); chronic pain (1.17); coffee p</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.843</td><td align="center" valign="middle" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" rowspan="1" colspan="1">Cerebrospinal fluid; glymphatic pathway; perivascular space; animal models; glucocorticoid receptor | amyloid beta; blood brain; nuclear magnetic resonance; endothelial nitric oxide; beta adrenergic receptor</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimers disease (12.17, 0.001); glymphatic system (10.5, 0.005); animal model (8.92, 0.005); mouse (8.92, 0.005); mice (8.92, 0.005)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cell transport (0.7); cerebellum (0.7); chemistry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.828</td><td align="center" valign="middle" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; cerebrospinal fluid; waste clearance; transgenic mouse; sleep disorders | alzheimers disease; blood&#8211;brain barrier; reactive astrocytes; hyaluronic acid; plga nanoparticles</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system (25.93, 1.0E-4); blood&#8211;brain barrier (18.92, 1.0E-4); sleep (15.71, 1.0E-4); sleep deprivation (15.53, 1.0E-4); glymphatic (11.8, 0.001)</td><td align="left" valign="middle" rowspan="1" colspan="1">cerebrovascular activity (0.98); brain ventricles</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.781</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; perivascular spaces; paravascular spaces; magnetic resonance imaging; brain cysts | cerebrospinal fluid; blood brain; chronic kidney; renal replacement; nervous system</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimers disease (12.71, 0.001); lymphangiogenesis (9.37, 0.005); glioma (9.37, 0.005); subarachnoid hemorrhage (9.37, 0.005); lymphatic drainage (8.46, 0.005)</td><td align="left" valign="middle" rowspan="1" colspan="1">Neuroinvasive pathways (0.52); hydrocephalus (0.52)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.957</td><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; parkinsons disease; lewy bodies dementia; multisystem atrophy; circadian blood pressure patterns | s disease; sleep disorders; tau proteins; melatonin levels; cholinesterase inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">cognitive impairment (23.16, 1.0E-4); diagnosis (11.92, 0.001); alzheimer disease (11.66, 0.001); alzheimer&#8217;s disease (11.2, 0.001); dementia (8.69, 0.005)</td><td align="left" valign="middle" rowspan="1" colspan="1">cadherins (0.24); transgenic mice (0.24); neurosci</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.983</td><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic system; cerebral small vessel disease; enlarged perivascular spaces; impaired cognition; capillary rarefaction | perivascular space; multiple sclerosis; csf shunting; csf dynamic disturbances; glymphatic circulation</td><td align="left" valign="middle" rowspan="1" colspan="1">Virchow robin spaces (22.41, 1.0E-4); small vessel disease (15.83, 1.0E-4); blood brain barrier (bbb) (14.93, 0.001); perivascular space (pvs) (14.93, 0.001); cerebral small vessel disease (10.27, 0.005)</td><td align="left" valign="middle" rowspan="1" colspan="1">Spectral analysis (0.1); Glucocerebrosidase (0.1)</td></tr></tbody></table></table-wrap></sec><sec id="sec17"><label>3.8</label><title>Tripartite network analysis of author-keyword-journal interconnections</title><p>The tripartite network visualization methodology facilitates systematic integration and examination of multidimensional relationships between bibliometric entities through the construction of interconnected node-edge mappings. Applying this three-dimensional network analysis framework to bibliometric data, we established three interconnected domains: &#8220;Author&#8221; (left panel), &#8220;keyword&#8221; (central panel), and &#8220;journal&#8221; (right panel), generating an integrated &#8220;author-keyword-journal&#8221; knowledge architecture as visualized in <xref rid="fig9" ref-type="fig">Figure 9</xref>. The analysis reveals that the research hotspots are primarily concentrated in two core areas: the &#8220;Glymphatic system&#8221; and &#8220;Neurodegenerative diseases&#8221; (with a particular focus on &#8220;Alzheimer&#8217;s disease&#8221; and &#8220;Parkinson&#8217;s disease&#8221;). This highlights the significance and intrinsic connection between these two research directions. Additionally, high-frequency keywords also involve cutting-edge topics such as &#8220;cerebrospinal fluid,&#8221; &#8220;aquaporin-4,&#8221; &#8220;<italic toggle="yes">&#946;</italic>-amyloid,&#8221; and &#8220;sleep.&#8221; In the co-occurrence network analysis of authors and keywords, the research of Professors Nedergaard M. and Xiao M. is significantly associated with both the &#8220;glymphatic system&#8221; and &#8220;Alzheimer&#8217;s disease.&#8221; In contrast, Professor Iliff J. J. has focused his research on the relationship between &#8220;Aquaporin-4&#8221; and the Glymphatic system. The journal-keyword analysis indicates that studies on the &#8220;glymphatic system&#8221; are mainly published in three authoritative journals: <italic toggle="yes">International Journal of Molecular Sciences, Journal of Cerebral Blood Flow and Metabolism, and Frontiers in Aging Neuroscience</italic>. Research on &#8220;Alzheimer&#8217;s disease&#8221; exhibits a bimodal distribution in <italic toggle="yes">International Journal of Molecular Sciences</italic> and <italic toggle="yes">Journal of Alzheimer&#8217;s Disease.</italic> Studies related to &#8220;cerebrospinal fluid&#8221; are predominantly featured in <italic toggle="yes">Journal of Cerebral Blood Flow and Metabolism</italic>. Through this network topology analysis, not only have the influential core scholars in the field and their research directions been clearly identified, but also the important status of <italic toggle="yes">International Journal of Molecular Sciences</italic>, <italic toggle="yes">Journal of Alzheimer&#8217;s Disease</italic>, and <italic toggle="yes">Frontiers in Aging Neuroscience</italic> as key academic dissemination platforms driving the development of this discipline has been established.</p><fig position="float" id="fig9" orientation="portrait"><label>Figure 9</label><caption><p>Tripartite network visualization of author-keyword-journal relationships.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g009.jpg"><alt-text content-type="machine-generated">Sankey diagram visualizing the connections between authors (AU), disease/conditions (DE), and scientific journals (SO). Authors on the left, such as Xiao M and Nedergaard M, are linked to topics like the glymphatic system and Alzheimer's disease. These topics connect to journals like the International Journal of Molecular Sciences and Neuroimage. The diagram uses colored bars and flowing lines to illustrate relationships and contributions visually.</alt-text></graphic></fig></sec><sec id="sec18"><label>3.9</label><title>Co-cited references and reference bursts analysis</title><p>CiteSpace was utilized to identify the top ten most frequently cited references related to the glymphatic system in NDs (<xref rid="tab8" ref-type="table">Table 8</xref>). Each of these ten references has received 65 or more citations. Notably, the article ranked first is &#8220;Glymphatic failure as a final common pathway to dementia&#8221; by <xref rid="ref40" ref-type="bibr">Nedergaard and Goldman (2020)</xref> cited 106 times; the second is &#8220;Impaired glymphatic function and clearance of tau in an Alzheimer&#8217;s disease model&#8221; by <xref rid="ref23" ref-type="bibr">Harrison et al. (2020)</xref> cited 95 times; and the third is &#8220;The glymphatic pathway in neurological disorders&#8221; by Rasmussen MK et al., cited 93 times. From the citation counts of the top three articles, it is evident that the pathways and functions of the glymphatic system play a crucial role in the onset and progression of NDs. The analysis of citation bursts among references is a powerful tool for pinpointing documents that have garnered a sudden increase in citations over a particular timeframe. This not only highlights research hotspots but also delineates prevailing trends. It serves as a crucial guide for uncovering nascent themes and key research concentrations within a given domain. In this study, a total of 25 references with the most pronounced citation bursts were detected, as depicted in <xref rid="fig10" ref-type="fig">Figure 10</xref>. The top three most cited references are titled &#8220;Sleep Drives Metabolite Clearance from the Adult Brain&#8221; (Burst Strength: 27.5; published in 2013), &#8220;Impairment of paravascular clearance pathways in the Aging Brain&#8221; (Burst Strength: 24.1; published in 2014), and &#8220;Structural and functional features of central nervous system lymphatic vessels&#8221; (Burst Strength: 23.25; published in 2015). <xref rid="fig10" ref-type="fig">Figure 10</xref> displays that there are 12 articles with a citation period of more than 4&#8239;years, indicating that these articles have garnered more sustained attention. One article is currently still in the period of citation burst, which can reflect, to some extent, the developmental direction of glymphatic system research in NDs at present and in the future.</p><table-wrap position="float" id="tab8" orientation="portrait"><label>Table 8</label><caption><p>The top 10 co-cited references related to glymphatic system in NDs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Rank</th><th align="center" valign="top" rowspan="1" colspan="1">Year</th><th align="center" valign="top" rowspan="1" colspan="1">Author</th><th align="left" valign="top" rowspan="1" colspan="1">Title</th><th align="center" valign="top" rowspan="1" colspan="1">Journal</th><th align="center" valign="top" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Nedergaard M.</td><td align="left" valign="middle" rowspan="1" colspan="1">Glymphatic failure as a final common pathway to dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">Science</td><td align="center" valign="middle" rowspan="1" colspan="1">106</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Harrison Ian F.</td><td align="left" valign="middle" rowspan="1" colspan="1">Impaired glymphatic function and clearance of tau in an Alzheimer&#8217;s disease model</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Rasmussen M. K.</td><td align="left" valign="middle" rowspan="1" colspan="1">The glymphatic pathway in neurological disorders</td><td align="center" valign="middle" rowspan="1" colspan="1">Lancet Neurol</td><td align="center" valign="middle" rowspan="1" colspan="1">93</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Mestre H.</td><td align="left" valign="middle" rowspan="1" colspan="1">Aquaporin-4-dependent glymphatic solute transport in the rodent brain</td><td align="center" valign="middle" rowspan="1" colspan="1">Elife</td><td align="center" valign="middle" rowspan="1" colspan="1">87</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Zou W. Y.</td><td align="left" valign="middle" rowspan="1" colspan="1">Blocking meningeal lymphatic drainage aggravates Parkinson&#8217;s disease-like pathology in mice overexpressing mutated &#945;-synuclein</td><td align="center" valign="middle" rowspan="1" colspan="1">Transl Neurodegener</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Da Mesquita S.</td><td align="left" valign="middle" rowspan="1" colspan="1">Functional aspects of meningeal lymphatics in ageing and Alzheimer&#8217;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Nature</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Hablitz L. M.</td><td align="left" valign="middle" rowspan="1" colspan="1">Circadian control of brain glymphatic and lymphatic fluid flow</td><td align="center" valign="middle" rowspan="1" colspan="1">Nat commun</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Zeppenfeld D. M.</td><td align="left" valign="middle" rowspan="1" colspan="1">Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains</td><td align="center" valign="middle" rowspan="1" colspan="1">JAMA Neurol</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Mestre H.</td><td align="left" valign="middle" rowspan="1" colspan="1">Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">Nat commun</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Hablitz L. M.</td><td align="left" valign="middle" rowspan="1" colspan="1">Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia</td><td align="center" valign="middle" rowspan="1" colspan="1">Sci Adv</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td></tr></tbody></table></table-wrap><fig position="float" id="fig10" orientation="portrait"><label>Figure 10</label><caption><p>Citations burst dynamics: top 25 references analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1598608-g010.jpg"><alt-text content-type="machine-generated">Top 25 references with the strongest citation bursts are displayed in a table. Each entry includes author names, publication details, DOI links, citation burst strength, and a color-coded timeline from 2012 to 2024, indicating burst periods.</alt-text></graphic></fig></sec></sec><sec sec-type="discussion" id="sec19"><label>4</label><title>Discussion</title><sec id="sec20"><label>4.1</label><title>Global research trends</title><p>This study employs scientometric visualization tools to map temporal dynamics and intellectual focal points in glymphatic system research associated with NDs across the 2012&#8211;2024 period. Our findings reveal that during the initial period from 2012 to 2016, the publication volume remained relatively limited, yet this stage established essential groundwork for deciphering the glymphatic system&#8217;s role in NDs. The early developmental phase spanning 2017 to 2019 saw gradual growth in scholarly output, while the rapid expansion phase from 2020 to 2023 experienced a substantial rise in literature, signaling heightened academic interest. By 2024, annual publications surged to 233, representing a 1.47-fold increase compared to 2023, a trajectory suggesting sustained growth and cementing the glymphatic system as a pivotal focus for future NDs investigations. In terms of publication type structure, original articles dominate among the high-quality literature collected (accounting for approximately 61.39%), while review articles account for 38.61%. This structural feature indicates that the field is primarily driven by empirical and mechanistic investigations. However, as research continues to deepen, the number of review articles has gradually increased, providing a theoretical foundation and directional guidance for knowledge integration, frontier advancement, and paradigm shifts within the field. Overall, research on the glymphatic system and NDs has evolved from the initial stage of theoretical emergence and basic exploration to a period characterized by mechanistic refinement and comprehensive synthesis. In the future, with the continued accumulation of original research achievements and the ongoing emergence of high-impact review articles, this field is expected to accelerate toward a new stage marked by interdisciplinary integration, translational application, and theoretical leadership.</p><p>Research priorities center on foundational mechanisms, clinical translation, and imaging evaluation, with neuroscience accounting for the largest thematic share. Temporally, publication trends exhibit both chronological evolution and geographic-institutional stratification. From a temporal perspective, the publication trends not only reflect chronological evolution but also reveal distinct patterns of geographic and institutional stratification. Globally, research output is predominantly concentrated in four major regions: Asia, Europe, North America, and Australia. Among these, China and the United States lead in both publication volume and citation impact, followed by Italy and Japan. In terms of institutional contributions, Chinese universities account for the highest overall output (109 articles, 30.70%), with institutions from the United States and Denmark also ranking among the top performers. Notably, the University of Rochester in the United States stands out globally for both the number of publications and citation influence, further consolidating the country&#8217;s leading position in this field. Leading universities from Denmark and Japan have also demonstrated exceptional academic performance. Chinese universities maintain close collaborations with research institutions in other countries, underscoring China&#8217;s rapid progress and growing influence in the international academic community. However, some institutions, such as Massachusetts General Hospital and Eindhoven University of Technology in the Netherlands, have not yet established close cooperative relationships with core research institutions in China, the United States, and other major countries. Therefore, strengthening academic exchange and international collaboration is essential for advancing research on the glymphatic system and NDs worldwide. <xref rid="tab3" ref-type="table">Table 3</xref> presents the top 10 core journals related to glymphatic system and NDs research. Most of these journals are classified as JCR Q1, highlighting the strong academic impact and global standing of research in this area. Similarly, the majority of the top 10 most-cited journals also belong to JCR Q1, including well-regarded journals such as <italic toggle="yes">Brain</italic>, <italic toggle="yes">Journal of Cerebral Blood Flow and Metabolism</italic>, and <italic toggle="yes">Neurobiology of Disease</italic>. This not only demonstrates the high recognition that glymphatic system research has earned from the academic community, but also further confirms the significance of these journals within the field. Many high-quality, high-impact journals have shown a strong interest in this area, providing strong support for the dissemination and development of related research. Overall, our research findings will help researchers quickly and accurately identify suitable journals to obtain the latest advancements or publish articles in the field of the glymphatic system and NDs. Combined with the summary of the glymphatic system and NDs research field in <xref rid="fig3" ref-type="fig">Figure 3</xref> and the dual map overlay of journals in <xref rid="fig6" ref-type="fig">Figure 6C</xref>, it is evident that the system is currently shifting towards clinical translation and updates in imaging techniques. In addition, a systematic analysis of core authors and their co-citation networks in the global research field of the glymphatic system and NDs reveals that Chinese authors rank first worldwide in both the number of publications and total citations. However, their academic output is dominated by original articles, with a relatively low proportion of review papers, and the citation per paper is significantly lower than that of top teams from developed countries such as Denmark. For instance, although the total number of publications from the Nedergaard M. is less than that of the group of Chinese authors, their output features a more balanced structure and a higher proportion of review papers, resulting in an impressive average citation count of 266.56 per paper, which highlights a &#8220;quality-first and balanced development&#8221; research strategy. Further analysis of the collaboration network shows that, although Chinese authors demonstrate strong cohesion regionally, in-depth collaboration with leading international teams&#8212;particularly those represented by Iliff from the United States&#8212;remains insufficient. Therefore, it is recommended that Chinese authors, while continuing to strengthen their capacity for original research, further optimize their academic output structure, enhance the innovativeness and international impact of their research, and actively pursue high-level international collaborations. Such efforts will facilitate a shift from &#8220;quantity-driven&#8221; to &#8220;quality-led&#8221; development in the field. This strategic adjustment is of great significance for promoting theoretical innovation and achieving major breakthroughs in global research on the glymphatic system in NDs. Nevertheless, continuously improving the scientific rigor of research methods and deepening theoretical insight remain key to future academic advancement. At the same time, establishing cross-institutional collaborative networks and fostering synergistic innovation will be important strategies for driving paradigm shifts and realizing significant research progress.</p></sec><sec id="sec21"><label>4.2</label><title>Knowledge base</title><p>Co-citation analysis constitutes a rigorous methodological framework for quantifying conceptual linkages between scholarly publications. Frequent citation patterns typically denote seminal conceptual frameworks within a research domain, while primary investigations serve as critical vectors for disciplinary innovation. Our scientometric evaluation of 865 peer-reviewed studies addressing glymphatic-neurodegenerative interactions employed citation frequency thresholds to identify ten paradigm-defining works. The review &#8220;Glymphatic failure as a final common pathway to dementia&#8221; by <xref rid="ref40" ref-type="bibr">Nedergaard and Goldman (2020)</xref> published in <italic toggle="yes">Science</italic> in 2020 (cited 106 times), is the most frequently cited paper in this field. The authors propose that dysfunction of the glymphatic system may be a common pathological mechanism underlying various dementias, including Alzheimer&#8217;s disease and vascular dementia. The article summarizes both basic and clinical research, noting that with age, the glymphatic system&#8217;s ability to clear brain metabolic waste declines, leading to the accumulation of harmful proteins such as A&#946; and tau, which results in neuronal damage and cognitive decline. Sleep disturbances, cardiovascular risks like hypertension, and trauma can accelerate this process. Early improvement of glymphatic function is considered important for dementia prevention. The second highly cited article is &#8220;Impaired glymphatic function and clearance of tau in an Alzheimer&#8217;s disease model&#8221; by <xref rid="ref23" ref-type="bibr">Harrison et al. (2020)</xref> published in <italic toggle="yes">Brain</italic> in 2020. This study, using a P301S mutant tau mouse model, found that the glymphatic system&#8217;s clearance of tau was reduced by 40% compared to normal mice, closely associated with the loss of astrocytic AQP4 polarity. This leads to abnormal tau accumulation and neuronal loss, directly confirming the key link between the glymphatic system and tau pathology. The third article, published by <xref rid="ref43" ref-type="bibr">Rasmussen et al. (2018)</xref> in <italic toggle="yes">The Lancet Neurology</italic> in 2018, systematically reviews the role of the glymphatic system in Alzheimer&#8217;s disease, traumatic brain injury (TBI), stroke, and migraine. Glymphatic dysfunction is a common feature in these disorders; for example, reduced clearance in traumatic brain injury (TBI) leads to brain edema and accumulation of inflammatory products, while stagnant glymphatic flow during stroke worsens neuronal damage, highlighting its broad pathological significance. The fourth article, &#8220;Aquaporin-4-dependent glymphatic solute transport in the rodent brain&#8221; by <xref rid="ref36" ref-type="bibr">Mestre et al. (2018)</xref>, compared AQP4 knockout mice with wild-type mice and showed that AQP4 deficiency significantly reduces glymphatic flow speed and clearance efficiency, and increases A&#946; deposition, underscoring the central role of AQP4 in glymphatic transport. The fifth article by <xref rid="ref67" ref-type="bibr">Zou et al. (2019)</xref> published in <italic toggle="yes">Translational Neurodegeneration</italic> in 2019, showed that blocking meningeal lymphatic drainage in a Parkinson&#8217;s disease mouse model led to increased aggregation of <italic toggle="yes">&#945;</italic>-synuclein, greater loss of dopaminergic neurons in the substantia nigra, and worsened motor deficits, along with increased infiltration of peripheral immune cells into the brain. This suggests that the meningeal lymphatic system is involved in both the clearance of harmful proteins and the regulation of inflammation, playing an important role in Parkinson&#8217;s disease progression. The sixth article by <xref rid="ref15" ref-type="bibr">Da Mesquita et al. (2018)</xref>, published in <italic toggle="yes">Nature</italic> in 2018, found that aging and AD model mice exhibit degeneration and dysfunction of meningeal lymphatic vessels and reduced A&#946; clearance in the brain. Promoting lymphangiogenesis improved these indicators, indicating that degeneration of meningeal lymphatics is a key factor in AD-related protein accumulation. The seventh article by <xref rid="ref21" ref-type="bibr">Hablitz et al. (2020)</xref> published in <italic toggle="yes">Nature Communications</italic> in 2020, was the first to show that glymphatic and meningeal lymphatic flow rates in mice have a clear day-night rhythm, being higher at night than during the day. Disruption of circadian rhythms lowers A&#946; clearance, suggesting that sleep and circadian rhythms are important for glymphatic function and brain health. The eighth article by <xref rid="ref61" ref-type="bibr">Zeppenfeld et al. (2017)</xref> published in <italic toggle="yes">JAMA Neurology</italic> in 2017, analyzed postmortem brain tissue and found the loss of perivascular AQP4 polarity was much greater in AD patients than in controls and was associated with the Apolipoprotein E epsilon 4 allele (APOE &#949;4) genotype, indicating that AQP4 localization is closely related to glymphatic function and cognitive impairment in AD. The ninth article by <xref rid="ref36" ref-type="bibr">Mestre et al. (2018)</xref> published in <italic toggle="yes">Nature Communications</italic> in 2018, showed that hypertension reduces arterial pulsatility and cerebrospinal fluid flow, decreases A&#946; clearance, and impairs spatial memory, while antihypertensive treatment can partially reverse these effects. This highlights the importance of blood pressure control in preventing cognitive impairment. The tenth article by <xref rid="ref22" ref-type="bibr">Hablitz et al. (2019)</xref> published in <italic toggle="yes">Science Advances</italic> in 2019, demonstrated that under anesthesia, increased electroencephalogram delta waves and low heart rate enhance glymphatic flow in mice, which is associated with expansion of the interstitial space. This state mimics glymphatic activation during deep sleep and provides a theoretical basis for non-invasively modulating glymphatic function.</p><p>Overall, the ten most highly co-cited references based on annual average citations have not only laid a solid theoretical foundation for understanding the mechanistic link between NDs and the glymphatic system, but have also accelerated the translation of basic research into clinical applications. Published in JCR Q1 journals within the field, these high-impact articles&#8212;including comprehensive systematic reviews and pioneering empirical studies&#8212;primarily focus on the fundamental mechanisms of the glymphatic system in NDs, key discoveries using animal models, and early clinical evidence. Collectively, these works have played a leading role in elucidating the relationship between NDs and the glymphatic system.</p></sec><sec id="sec22"><label>4.3</label><title>Research hot spots and frontiers</title><p>Keyword analysis as an important tool for evaluating research hotspots and the evolution of scientific disciplines has revealed the current cutting-edge topics in the field of NDs for this study. A systematic review of high-frequency keywords such as &#8220;glymphatic system&#8221; &#8220;Alzheimer&#8217;s disease&#8221; &#8220;cerebrospinal fluid&#8221; &#8220;Aquaporin 4&#8221; &#8220;clearance&#8221; &#8220;sleep&#8221; and &#8220;pathology&#8221; demonstrates that current academic attention is primarily focused on the role of the glymphatic system in regulating cerebrospinal fluid dynamics metabolic waste clearance AQP4-related mechanisms and regulatory factors such as sleep&#8212;especially with regard to the specific mechanisms in major diseases like AD. Further keyword clustering analysis (<xref rid="fig8" ref-type="fig">Figure 8B</xref>; <xref rid="fig7" ref-type="fig">Table 7</xref>) more intuitively delineates the research directions and main connotations in this field. Specifically the eight clusters cover NDs as a whole (Cluster 0) sex-related factors (Cluster 1) Alzheimer&#8217;s disease (Cluster 2) glymphatic system mechanisms (Cluster 3) blood&#8211;brain barrier (Cluster 4) lymphangiogenesis (Cluster 5) cognitive impairment (Cluster 6) and specific cerebral structures such as Virchow-Robin spaces (Cluster 7). These clusters encompass research subjects regulatory factors mechanisms of action and also include specific anatomical structures and physiological pathways. Based on the above analysis future research should further focus on the following specific directions:</p><sec id="sec23"><label>4.3.1</label><title>Mechanistic insights into the glymphatic system&#8217;s role in NDs pathology</title><p>The glymphatic system is now recognized as the primary pathway for clearing metabolic waste and neurotoxic proteins&#8212;such as A&#946; and tau&#8212;from the brain, and significant clinical and preclinical evidence has linked its dysfunction to the onset and progression of NDs, including AD and PD (<xref rid="ref44" ref-type="bibr">Rehman et al., 2024</xref>; <xref rid="ref8" ref-type="bibr">Beschorner and Nedergaard, 2024</xref>). Advances such as functional MRI have enabled noninvasive assessment of glymphatic activity, revealing that both cerebrospinal fluid clearance and glymphatic flow decline with age, which correlates with increased brain aging and vulnerability to disease (<xref rid="ref34" ref-type="bibr">Malis et al., 2024</xref>; <xref rid="ref39" ref-type="bibr">Naganawa et al., 2024</xref>). Nonetheless, critical questions remain&#8212;particularly regarding the molecular underpinnings, dynamic regulation, and cooperative interactions between the glymphatic system, meningeal lymphatics, and other clearance pathways. Some researchers also emphasize anatomical and functional heterogeneity between human and animal models, which further complicates mechanistic conclusions (<xref rid="ref29" ref-type="bibr">Jessen et al., 2015</xref>; <xref rid="ref38" ref-type="bibr">Mestre et al., 2020</xref>). Extensive animal and translational studies demonstrate that impaired glymphatic function not only blocks the efflux of A&#946;, tau, and other toxic proteins&#8212;leading to their aberrant accumulation&#8212;but also exacerbates neuroinflammation and neuronal loss, thus advancing cognitive decline and acting as a final common pathway for diseases such as AD and PD (<xref rid="ref10" ref-type="bibr">Boland et al., 2018</xref>; <xref rid="ref43" ref-type="bibr">Rasmussen et al., 2018</xref>; <xref rid="ref40" ref-type="bibr">Nedergaard and Goldman, 2020</xref>; <xref rid="ref16" ref-type="bibr">Ding et al., 2021</xref>; <xref rid="ref28" ref-type="bibr">Ishida et al., 2022</xref>). Importantly, modifiable factors like exercise, especially high-intensity interval training, have been shown to enhance astrocytic AQP4 polarization and boost glymphatic clearance, whereas sleep disturbances substantially impair glymphatic activity and independently increase neurodegenerative risk (<xref rid="ref17" ref-type="bibr">Feng et al., 2023</xref>; <xref rid="ref19" ref-type="bibr">Gottesman et al., 2024</xref>). Despite growing recognition of the glymphatic system&#8217;s crucial involvement in the etiology and progression of NDs, key obstacles remain, including suboptimal imaging sensitivity, standardization issues, discrepancies between animal and human studies, limited mechanistic depth, and the uncertain clinical efficacy of targeted interventions. Moving forward, the field stands to benefit from large-scale human studies, innovative dynamic molecular imaging, and multicenter interventional trials to further advance foundational understanding and enable effective clinical translation.</p></sec><sec id="sec24"><label>4.3.2</label><title>The core role of AQP4 and its polarization in cerebrospinal fluid flow and clearance function</title><p>AQP4 is highly polarized and distributed at the perivascular end-feet of astrocytes, serving as the molecular basis for the exchange between cerebrospinal fluid (CSF) and interstitial fluid (ISF), and for the efficient transport of waste via the glymphatic system (<xref rid="ref27" ref-type="bibr">Iliff et al., 2012</xref>). A substantial body of research has demonstrated that the polarized state of AQP4 determines the efficiency with which CSF can drive the clearance of macromolecules such as A&#946;, tau, and <italic toggle="yes">&#945;</italic>-synuclein (<xref rid="ref36" ref-type="bibr">Mestre et al., 2018</xref>; <xref rid="ref28" ref-type="bibr">Ishida et al., 2022</xref>; <xref rid="ref18" ref-type="bibr">Gomolka et al., 2023</xref>; <xref rid="ref62" ref-type="bibr">Zhang et al., 2023</xref>). Genetic models have shown that both AQP4 knockout and loss of its polarization (e.g., Snta1 mutation) lead to impaired CSF-ISF exchange and waste accumulation, ultimately resulting in A&#946; plaque formation, tau deposition, and exacerbation of cognitive dysfunction (<xref rid="ref61" ref-type="bibr">Zeppenfeld et al., 2017</xref>; <xref rid="ref48" ref-type="bibr">Simon et al., 2022</xref>; <xref rid="ref18" ref-type="bibr">Gomolka et al., 2023</xref>). In human aging and in AD patients, loss of AQP4 polarization is highly correlated with cognitive decline, highlighting this molecular marker as a novel target for diagnosis and intervention (<xref rid="ref61" ref-type="bibr">Zeppenfeld et al., 2017</xref>). In models of neurological diseases such as PD, impaired AQP4 repolarization further aggravates &#945;-synuclein aggregation and inflammatory responses, suggesting its broad neuroprotective significance (<xref rid="ref62" ref-type="bibr">Zhang et al., 2023</xref>; <xref rid="ref47" ref-type="bibr">Si et al., 2024</xref>). The polarization of AQP4 is regulated by multiple factors, including protein complexes and matrix metalloproteinase Matrix metalloproteinase-9; targeted modulation of these pathways has been shown to partially restore glymphatic function and reverse pathological progression (<xref rid="ref47" ref-type="bibr">Si et al., 2024</xref>). Physiological interventions such as high-intensity training and circadian rhythm synchronization can also effectively enhance AQP4 polarization and promote brain waste clearance (<xref rid="ref21" ref-type="bibr">Hablitz et al., 2020</xref>; <xref rid="ref17" ref-type="bibr">Feng et al., 2023</xref>). However, it is important to note that the upstream regulatory networks of AQP4 polarization remain unclear, noninvasive and dynamic clinical monitoring tools are lacking, and interdisciplinary approaches such as AI imaging and biomarker analysis have yet to be widely applied&#8212;leaving translational pathways in need of further integration (<xref rid="ref37" ref-type="bibr">Mestre et al., 2017</xref>; <xref rid="ref1" ref-type="bibr">Abbott et al., 2018</xref>; <xref rid="ref43" ref-type="bibr">Rasmussen et al., 2018</xref>; <xref rid="ref7" ref-type="bibr">Benveniste et al., 2019</xref>). Future directions should focus on elucidating the dynamic regulatory mechanisms of AQP4 polarization, developing imaging and molecular monitoring systems, and achieving precision interventions and innovations in diagnosis and therapy targeting this new molecule.</p></sec><sec id="sec25"><label>4.3.3</label><title>Dialectical impact of the interaction between multidimensional regulatory factors and the coupling mechanism of the brain waste clearance system on the progression of neurological diseases</title><p>The brain waste clearance system comprises a complex, multilayered network that includes the glymphatic system, meningeal lymphatic vessels, the blood&#8211;brain barrier, and brain microstructures, and its function is regulated by the coordinated action of multiple endogenous and exogenous factors (<xref rid="ref59" ref-type="bibr">Yankova et al., 2021</xref>). High-quality deep sleep significantly enhances the metabolic waste clearance efficiency of the glymphatic system and CSF flow; during sleep, the interstitial space between brain cells expands substantially (by approximately 60%), facilitating faster CSF circulation and more efficient clearance of solute waste products such as A&#946; (with clearance efficiency approximately 2 times higher than during wakefulness) (<xref rid="ref56" ref-type="bibr">Xie et al., 2013</xref>). Conversely, sleep disturbances not only damage the glymphatic network but also directly undermine the blood&#8211;brain barrier, leading to inflammatory activation and abnormal protein accumulation, thus serving as risk factors for NDs (<xref rid="ref4" ref-type="bibr">Avilez-Avilez et al., 2024</xref>; <xref rid="ref19" ref-type="bibr">Gottesman et al., 2024</xref>; <xref rid="ref41" ref-type="bibr">Ozdinler, 2024</xref>). Similarly, aging induces an overall decline in CSF outflow and glymphatic efficiency, accompanied by expansion of perivascular spaces, microenvironmental dysregulation, and glial activation, which further impede waste clearance and provide both anatomical and molecular bases for cognitive dysfunction (<xref rid="ref3" ref-type="bibr">Andriuta et al., 2024</xref>; <xref rid="ref34" ref-type="bibr">Malis et al., 2024</xref>; <xref rid="ref57" ref-type="bibr">Xiong et al., 2024</xref>). Sex differences are also reflected in the expression of relevant genes, channel functions, and disease susceptibility, but mechanistic research at present remains insufficient. Notably, there exists a complex and dynamic coupling among clearance subsystems: disorders of meningeal lymphatics and microvascular structural damage often form a vicious cycle with waste accumulation and inflammatory activation, thereby accelerating the neurodegeneration process (<xref rid="ref12" ref-type="bibr">Cai et al., 2024</xref>; <xref rid="ref14" ref-type="bibr">Chen et al., 2024</xref>; <xref rid="ref53" ref-type="bibr">Wen et al., 2024</xref>; <xref rid="ref60" ref-type="bibr">Zedde and Pascarella, 2024</xref>). Although advanced imaging techniques can dynamically scan perivascular space changes, there is still a lack of direct evidence linking these with the microstructural&#8211;functional causal chain, which limits precise risk prediction and target identification (<xref rid="ref46" ref-type="bibr">Sacchi et al., 2024</xref>). Most existing studies are cross-sectional or single-factor investigations, lacking systematic, multimodal, dynamic, and longitudinal multi-factorial coupling models and integrated mechanism analysis. Future research should focus on synergistic analyses combining high-resolution multimodal imaging and molecular mechanisms, aiming to achieve multivariable, network-based, and precise interventions.</p></sec><sec id="sec26"><label>4.3.4</label><title>Translational applications of artificial intelligence (AI) modeling, imaging analysis, and novel neuroregulation Technologies in glymphatic system functional interventions</title><p>AI modeling and advanced multimodal imaging techniques are gradually transforming both the basic research and clinical translation landscape of the glymphatic system. AI-based machine learning can deeply explore risk prediction of core factors such as AQP4 polymorphisms (<xref rid="ref6" ref-type="bibr">Beer et al., 2024</xref>). In addition, AI-based velocimetry algorithms enable high-precision, noninvasive quantification of intracerebral cerebrospinal fluid dynamics parameters, providing a novel technical approach for elucidating brain clearance mechanisms in high-dimensional spaces and for early evaluation and classification of brain diseases such as AD (<xref rid="ref11" ref-type="bibr">Boster et al., 2023</xref>). The new generation of multimodal MRI (such as diffusion tensor imaging and perivascular space visualization) shows significant value in early screening and dynamic monitoring of disease progression in brain disorders such as autism, helping to identify the association between glymphatic dysfunction and the evolution of disease phenotypes (<xref rid="ref52" ref-type="bibr">Wang et al., 2023</xref>; <xref rid="ref49" ref-type="bibr">Soares et al., 2024</xref>). It is worth emphasizing that imaging-guided, subject-specific modeling of the glymphatic system not only provides an accurate reflection of each individual&#8217;s brain clearance function, but also reveals a close association between reduced glymphatic transport efficiency and increased amyloid deposition in the brain (<xref rid="ref30" ref-type="bibr">Johnson et al., 2023</xref>). This quantitative model offers a scientific basis for risk identification and precise intervention, and further promotes the in-depth understanding of the mechanisms underlying neurodegenerative diseases as well as individualized management. Moreover, neuroregulation techniques and Adeno-Associated Virus Serotype 1 (AAV1)-based delivery provide feasible pathways for targeted repair of the glymphatic network and gene therapy, with promising progress observed in both rat/human models and special environments (such as space) (<xref rid="ref55" ref-type="bibr">Wu et al., 2019</xref>; <xref rid="ref35" ref-type="bibr">Mathiesen et al., 2023</xref>; <xref rid="ref49" ref-type="bibr">Soares et al., 2024</xref>). However, challenges such as dynamic imaging resolution, clinical standardization, multifactorial mechanism modeling, and AI interpretability remain, leaving a gap between technological advances and precise intervention (<xref rid="ref62" ref-type="bibr">Zhang et al., 2023</xref>; <xref rid="ref66" ref-type="bibr">Zhu et al., 2023</xref>). In the future, it will be essential to strengthen the deep integration of multicenter, large-sample, dynamic longitudinal data with AI modeling, and to promote full-chain coordination and innovation across imaging, AI, neuroregulation, and molecular mechanism domains. Addressing challenges related to standardization and interpretability is crucial to support the precise and personalized management of glymphatic function and related NDs.</p><p>In summary, the glymphatic system and its molecular networks, especially AQP4 polarization, provide new theoretical and technological foundations for the etiology and intervention of NDs. Future research should focus on: (1) optimizing and standardizing <italic toggle="yes">in vivo</italic> imaging and molecular dynamic assessment for precise quantification of glymphatic function; (2) elucidating regulatory networks and cross-species mechanisms of key molecules such as AQP4 polarization; (3) integrating multidimensional regulatory factors and waste clearance to construct macro&#8211;micro dynamic coupling models; and (4) advancing the application of AI and imaging technologies in multi-center and diverse environments to improve early screening, targeted prevention, and personalized management of NDs. We look forward to more researchers joining the field to drive breakthroughs in brain health and disease prevention.</p></sec></sec><sec id="sec27"><label>4.4</label><title>Advantages and limitations</title><p>This study offers several distinct advantages. Firstly, this study is the first to conduct a scientometric analysis specifically focusing on the relationship between the glymphatic system and NDs. It provides a foundational basis and direction for systematic research in this field. Secondly, by integrating multiple scientometric methods, this study presents a comprehensive and multi-level refined analysis of research hotspots, temporal trends, and collaborative networks. This approach not only overcomes the limitations of traditional reviews, but also uncovers new potential connections between glymphatic mechanisms and NDs. Finally, we used data from Web of Science, Scopus, and PubMed Central, which significantly broadens the scope of the literature surveyed and improves the reliability and representativeness of the results.</p><p>Nevertheless, several limitations should be noted in this study. Firstly, this study only included literature published in English during the selection process, which may have resulted in the omission of important studies published in other languages. Secondly, citation counts are influenced by the time of publication, meaning that recently published studies in the current year that have not yet accumulated many citations may not have been fully represented. Despite these limitations, the literature analyzed in this study still provides a systematic overview of the latest research progress on the meningeal lymphatic system in the field of NDs, highlighting major research directions and future trends.</p></sec></sec><sec sec-type="conclusions" id="sec28"><label>5</label><title>Conclusion</title><p>This analytical framework provides a powerful tool for the systematic study of the knowledge diffusion pathways and cutting-edge advancements in the glymphatic system within NDs. Over the past thirteen years, research on the glymphatic system in NDs has shown a rapid developmental trend globally. The significant increase in the number of annual publications fully demonstrates that the importance of research in this field is becoming increasingly prominent. In this field, the most influential scholar is Nedergaard Maiken, the most representative journals are the Frontiers series, and the University of Rochester in the United States is the most influential institution. Current research hotspots are mainly focused on the metabolic clearance mechanisms mediated by AQP4 polarization, as well as the regulatory roles of sleep, aging, and inflammation. The primary disease models involved include AD and PD. The frontier research directions point towards non-invasive imaging technologies such as multimodal MRI (<xref rid="ref63" ref-type="bibr">Zhou, 2016</xref>) and AI-driven intervention paradigms as well as multiomic confirmations (<xref rid="ref64" ref-type="bibr">Zhou, 2021</xref>). Looking ahead, research on the glymphatic system in NDs should focus on promoting multicenter, large-sample international collaborative studies. This study examines the developmental trends of research on this topic from the perspective of bibliometrics and provides a comprehensive summary of the research hotspots in this field. Moreover, these findings also offer valuable references for researchers to select appropriate publication channels and establish scientific research partnerships.</p></sec></body><back><sec sec-type="author-contributions" id="sec29"><title>Author contributions</title><p>YW: Methodology, Writing &#8211; original draft, Validation, Data curation, Visualization, Investigation, Software, Formal analysis, Conceptualization, Resources, Writing &#8211; review &amp; editing. QL: Formal analysis, Conceptualization, Writing &#8211; original draft. JW: Methodology, Investigation, Writing &#8211; original draft. KM: Supervision, Formal analysis, Writing &#8211; review &amp; editing. LZ: Writing &#8211; review &amp; editing, Investigation, Methodology. FY: Validation, Supervision, Data curation, Writing &#8211; review &amp; editing, Funding acquisition.</p></sec><sec sec-type="COI-statement" id="sec31"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec32"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec33"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Pizzo</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thorne</surname><given-names>R. G.</given-names></name></person-group> (<year>2018</year>). <article-title>The role of brain barriers in fluid movement in the CNS: is there a &#8220;glymphatic&#8221; system?</article-title><source>Acta Neuropathol.</source><volume>135</volume>, <fpage>387</fpage>&#8211;<lpage>407</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-018-1812-4</pub-id>, PMID: <pub-id pub-id-type="pmid">29428972</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrade-Guerrero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Santiago-Balmaseda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeronimo-Aguilar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vargas-Rodr&#237;guez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cadena-Su&#225;rez</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>S&#225;nchez-Garibay</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Alzheimer&#8217;s disease: an updated overview of its genetics</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume>:<fpage>3754</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24043754</pub-id>, PMID: <pub-id pub-id-type="pmid">36835161</pub-id><pub-id pub-id-type="pmcid">PMC9966419</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andriuta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ottoy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruthirakuhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feliciano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dilliott</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Hegele</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases</article-title>. <source>Alzheimers Dement.</source><volume>20</volume>, <fpage>5800</fpage>&#8211;<lpage>5808</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.14081</pub-id>, PMID: <pub-id pub-id-type="pmid">38961774</pub-id><pub-id pub-id-type="pmcid">PMC11350014</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avilez-Avilez</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Medina-Flores</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>G&#243;mez-Gonzalez</surname><given-names>B.</given-names></name></person-group> (<year>2024</year>). <article-title>Sleep loss impairs blood-brain barrier function: cellular and molecular mechanisms</article-title>. <source>Vitam. Horm.</source><volume>126</volume>, <fpage>77</fpage>&#8211;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1016/bs.vh.2024.02.003</pub-id>, PMID: <pub-id pub-id-type="pmid">39029977</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bah</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Siler</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Cetas</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Alkayed</surname><given-names>N. J.</given-names></name></person-group> (<year>2023</year>). <article-title>Fluid dynamics in aging-related dementias</article-title>. <source>Neurobiol. Dis.</source><volume>177</volume>:<fpage>105986</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2022.105986</pub-id>, PMID: <pub-id pub-id-type="pmid">36603747</pub-id><pub-id pub-id-type="pmcid">PMC12369312</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elmenhorst</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drzezga</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Explainable artificial intelligence identifies an AQP4 polymorphism-based risk score associated with brain amyloid burden</article-title>. <source>Neurobiol. Aging</source><volume>143</volume>, <fpage>19</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2024.08.002</pub-id>, PMID: <pub-id pub-id-type="pmid">39208715</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benveniste</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Koundal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanggaard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wardlaw</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>The Glymphatic system and waste clearance with brain aging: a review</article-title>. <source>Gerontology</source><volume>65</volume>, <fpage>106</fpage>&#8211;<lpage>119</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000490349</pub-id>, PMID: <pub-id pub-id-type="pmid">29996134</pub-id><pub-id pub-id-type="pmcid">PMC6329683</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beschorner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Glymphatic system dysfunction in neurodegenerative diseases</article-title>. <source>Curr. Opin. Neurol.</source><volume>37</volume>, <fpage>182</fpage>&#8211;<lpage>188</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WCO.0000000000001252</pub-id>, PMID: <pub-id pub-id-type="pmid">38345416</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>G. A. B. E.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Swain</surname><given-names>S. S.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders</article-title>. <source>Materials (Basel)</source><volume>15</volume>:<fpage>804</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ma15030804</pub-id>, PMID: <pub-id pub-id-type="pmid">35160749</pub-id><pub-id pub-id-type="pmcid">PMC8837051</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boland</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mollereau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bezard</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>17</volume>, <fpage>660</fpage>&#8211;<lpage>688</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd.2018.109</pub-id>, PMID: <pub-id pub-id-type="pmid">30116051</pub-id><pub-id pub-id-type="pmcid">PMC6456907</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boster</surname><given-names>K. A. S.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ladr&#243;n-de-Guevara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Artificial intelligence velocimetry reveals in vivo flow rates, pressure gradients, and shear stresses in murine perivascular flows</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>120</volume>:<fpage>e2217744120</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2217744120</pub-id>, PMID: <pub-id pub-id-type="pmid">36989300</pub-id><pub-id pub-id-type="pmcid">PMC10083563</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Q.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: a vicious cycle</article-title>. <source>Neurobiol. Dis.</source><volume>192</volume>:<fpage>106426</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2024.106426</pub-id>, PMID: <pub-id pub-id-type="pmid">38331353</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.-P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Chern</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Metabolic dysregulation in Huntington&#8217;s disease: neuronal and glial perspectives</article-title>. <source>Neurobiol. Dis.</source><volume>201</volume>:<fpage>106672</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2024.106672</pub-id>, PMID: <pub-id pub-id-type="pmid">39306013</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The interplay between meningeal lymphatic vessels and Neuroinflammation in neurodegenerative diseases</article-title>. <source>Curr. Neuropharmacol.</source><volume>22</volume>, <fpage>1016</fpage>&#8211;<lpage>1032</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1570159X21666221115150253</pub-id>, PMID: <pub-id pub-id-type="pmid">36380442</pub-id><pub-id pub-id-type="pmcid">PMC10964105</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Mesquita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Louveau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaccari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cornelison</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Kingsmore</surname><given-names>K. M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Functional aspects of meningeal lymphatics in ageing and Alzheimer&#8217;s disease</article-title>. <source>Nature</source><volume>560</volume>, <fpage>185</fpage>&#8211;<lpage>191</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-018-0368-8</pub-id>, PMID: <pub-id pub-id-type="pmid">30046111</pub-id><pub-id pub-id-type="pmcid">PMC6085146</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>X.-B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-X.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson&#8217;s disease</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>411</fpage>&#8211;<lpage>418</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-020-01198-1</pub-id>, PMID: <pub-id pub-id-type="pmid">33462448</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>High-intensity interval training ameliorates Alzheimer&#8217;s disease-like pathology by regulating astrocyte phenotype-associated AQP4 polarization</article-title>. <source>Theranostics</source><volume>13</volume>, <fpage>3434</fpage>&#8211;<lpage>3450</lpage>. doi: <pub-id pub-id-type="doi">10.7150/thno.81951</pub-id>, PMID: <pub-id pub-id-type="pmid">37351177</pub-id><pub-id pub-id-type="pmcid">PMC10283053</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomolka</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Hablitz</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Giannetto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hauglund</surname><given-names>N. L.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Loss of aquaporin-4 results in glymphatic system dysfunction via brain-wide interstitial fluid stagnation</article-title>. <source>eLife</source><volume>12</volume>:<fpage>e82232</fpage>. doi: <pub-id pub-id-type="doi">10.7554/eLife.82232</pub-id>, PMID: <pub-id pub-id-type="pmid">36757363</pub-id><pub-id pub-id-type="pmcid">PMC9995113</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottesman</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Lutsey</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Benveniste</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Full</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Impact of sleep disorders and disturbed sleep on brain health: a scientific statement from the American Heart Association</article-title>. <source>Stroke</source><volume>55</volume>, <fpage>e61</fpage>&#8211;<lpage>e76</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STR.0000000000000453</pub-id>, PMID: <pub-id pub-id-type="pmid">38235581</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Microglia polarization from M1 to M2 in neurodegenerative diseases</article-title>. <source>Front. Aging Neurosci.</source><volume>14</volume>:<fpage>815347</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.815347</pub-id>, PMID: <pub-id pub-id-type="pmid">35250543</pub-id><pub-id pub-id-type="pmcid">PMC8888930</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hablitz</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Pl&#225;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giannetto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vinitsky</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>St&#230;ger</surname><given-names>F. F.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Circadian control of brain glymphatic and lymphatic fluid flow</article-title>. <source>Nat. Commun.</source><volume>11</volume>:<fpage>4411</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-020-18115-2</pub-id>, PMID: <pub-id pub-id-type="pmid">32879313</pub-id><pub-id pub-id-type="pmcid">PMC7468152</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hablitz</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Vinitsky</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>St&#230;ger</surname><given-names>F. F.</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>K. N.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia</article-title>. <source>Sci. Adv.</source><volume>5</volume>:<fpage>eaav5447</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.aav5447</pub-id>, PMID: <pub-id pub-id-type="pmid">30820460</pub-id><pub-id pub-id-type="pmcid">PMC6392807</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>I. F.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>O.</given-names></name><name name-style="western"><surname>Machhada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ohene</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nahavandi</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Impaired glymphatic function and clearance of tau in an Alzheimer&#8217;s disease model</article-title>. <source>Brain</source><volume>143</volume>, <fpage>2576</fpage>&#8211;<lpage>2593</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awaa179</pub-id>, PMID: <pub-id pub-id-type="pmid">32705145</pub-id><pub-id pub-id-type="pmcid">PMC7447521</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>J. E.</given-names></name></person-group> (<year>2005</year>). <article-title>An index to quantify an individual&#8217;s scientific research output</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume>, <fpage>16569</fpage>&#8211;<lpage>16572</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0507655102</pub-id>, PMID: <pub-id pub-id-type="pmid">16275915</pub-id><pub-id pub-id-type="pmcid">PMC1283832</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Su</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name></person-group> (<year>2022</year>). <article-title>Hotspots and trends in multiple myeloma bone diseases: a bibliometric visualization analysis</article-title>. <source>Front. Pharmacol.</source><volume>13</volume>:<fpage>1003228</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.1003228</pub-id>, PMID: <pub-id pub-id-type="pmid">36313356</pub-id><pub-id pub-id-type="pmcid">PMC9614215</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>A bibliometric and knowledge-map analysis of the glymphatic system from 2012 to 2022</article-title>. <source>Front. Mol. Neurosci.</source><volume>16</volume>:<fpage>1148179</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2023.1148179</pub-id>, PMID: <pub-id pub-id-type="pmid">37701852</pub-id><pub-id pub-id-type="pmcid">PMC10493282</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Plogg</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gundersen</surname><given-names>G. A.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#946;</article-title>. <source>Sci. Transl. Med.</source><volume>4</volume>:<fpage>147ra111</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3003748</pub-id>, PMID: <pub-id pub-id-type="pmid">22896675</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration</article-title>. <source>J. Exp. Med.</source><volume>219</volume>:<fpage>e20211275</fpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20211275</pub-id>, PMID: <pub-id pub-id-type="pmid">35212707</pub-id><pub-id pub-id-type="pmcid">PMC8932543</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Munk</surname><given-names>A. S. F.</given-names></name><name name-style="western"><surname>Lundgaard</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The Glymphatic system: a beginner&#8217;s guide</article-title>. <source>Neurochem. Res.</source><volume>40</volume>, <fpage>2583</fpage>&#8211;<lpage>2599</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-015-1581-6</pub-id>, PMID: <pub-id pub-id-type="pmid">25947369</pub-id><pub-id pub-id-type="pmcid">PMC4636982</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Abdelmalik</surname><given-names>M. R. A.</given-names></name><name name-style="western"><surname>Baidoo</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Badachhape</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>T. J. R.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S. S.</given-names></name></person-group> (<year>2023</year>). <article-title>Image-guided subject-specific modeling of glymphatic transport and amyloid deposition</article-title>. <source>Comput. Methods Appl. Mech. Eng.</source><volume>417</volume>:<fpage>116449</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cma.2023.116449</pub-id>, PMID: <pub-id pub-id-type="pmid">38249440</pub-id><pub-id pub-id-type="pmcid">PMC10798618</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kritsilis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rizou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Koutsoudaki</surname><given-names>P. N.</given-names></name><name name-style="western"><surname>Evangelou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gorgoulis</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Ageing, cellular senescence and neurodegenerative disease</article-title>. <source>Int. J. Mol. Sci.</source><volume>19</volume>:<fpage>2937</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms19102937</pub-id>, PMID: <pub-id pub-id-type="pmid">30261683</pub-id><pub-id pub-id-type="pmcid">PMC6213570</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024b</year>). <article-title>Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis</article-title>. <source>Front. Immunol.</source><volume>15</volume>:<fpage>1341596</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1341596</pub-id>, PMID: <pub-id pub-id-type="pmid">38380323</pub-id><pub-id pub-id-type="pmcid">PMC10876793</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2024a</year>). <article-title>Research trends and hotspots of ferroptosis in neurodegenerative diseases from 2013 to 2023: a bibliometrics study</article-title>. <source>Heliyon</source><volume>10</volume>:<fpage>e29418</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e29418</pub-id>, PMID: <pub-id pub-id-type="pmid">38638970</pub-id><pub-id pub-id-type="pmcid">PMC11024616</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Age-related decline of intrinsic cerebrospinal fluid outflow in healthy humans detected with non-contrast spin-labeling MR imaging</article-title>. <source>Magn. Reson. Med. Sci.</source><volume>23</volume>, <fpage>66</fpage>&#8211;<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.2463/mrms.mp.2022-0117</pub-id>, PMID: <pub-id pub-id-type="pmid">36529500</pub-id><pub-id pub-id-type="pmcid">PMC10838716</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathiesen</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Miyakoshi</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Cederroth</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Tserga</surname><given-names>E.</given-names></name><name name-style="western"><surname>Versteegh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bork</surname><given-names>P. A. R.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice</article-title>. <source>Sci. Transl. Med.</source><volume>15</volume>:<fpage>eabq3916</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.abq3916</pub-id>, PMID: <pub-id pub-id-type="pmid">37379370</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mestre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hablitz</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Aquaporin-4-dependent glymphatic solute transport in the rodent brain</article-title>. <source>eLife</source><volume>7</volume>:<fpage>e40070</fpage>. doi: <pub-id pub-id-type="doi">10.7554/eLife.40070</pub-id>, PMID: <pub-id pub-id-type="pmid">30561329</pub-id><pub-id pub-id-type="pmcid">PMC6307855</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mestre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kostrikov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R. I.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Perivascular spaces, glymphatic dysfunction, and small vessel disease</article-title>. <source>Clin. Sci. (Lond.)</source><volume>131</volume>, <fpage>2257</fpage>&#8211;<lpage>2274</lpage>. doi: <pub-id pub-id-type="doi">10.1042/CS20160381</pub-id>, PMID: <pub-id pub-id-type="pmid">28798076</pub-id><pub-id pub-id-type="pmcid">PMC5567781</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mestre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>The brain&#8217;s Glymphatic system: current controversies</article-title>. <source>Trends Neurosci.</source><volume>43</volume>, <fpage>458</fpage>&#8211;<lpage>466</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tins.2020.04.003</pub-id>, PMID: <pub-id pub-id-type="pmid">32423764</pub-id><pub-id pub-id-type="pmcid">PMC7331945</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naganawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>The Glymphatic system in humans: investigations with magnetic resonance imaging</article-title>. <source>Investig. Radiol.</source><volume>59</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1097/RLI.0000000000000969</pub-id>, PMID: <pub-id pub-id-type="pmid">36897826</pub-id><pub-id pub-id-type="pmcid">PMC11805491</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>S. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Glymphatic failure as a final common pathway to dementia</article-title>. <source>Science</source><volume>370</volume>, <fpage>50</fpage>&#8211;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.abb8739</pub-id>, PMID: <pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozdinler</surname><given-names>P. H.</given-names></name></person-group> (<year>2024</year>). <article-title>Sleep apnea and amyotrophic lateral sclerosis: cause, correlation, any relation?</article-title><source>Brain Sci.</source><volume>14</volume>:<fpage>978</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci14100978</pub-id>, PMID: <pub-id pub-id-type="pmid">39451992</pub-id><pub-id pub-id-type="pmcid">PMC11505663</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Diano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mattioli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cantoni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bocchetta</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study</article-title>. <source>Brain Commun</source><volume>6</volume>:<fpage>fcae185</fpage>. doi: <pub-id pub-id-type="doi">10.1093/braincomms/fcae185</pub-id>, PMID: <pub-id pub-id-type="pmid">39015769</pub-id><pub-id pub-id-type="pmcid">PMC11249959</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>The glymphatic pathway in neurological disorders</article-title>. <source>Lancet Neurol.</source><volume>17</volume>, <fpage>1016</fpage>&#8211;<lpage>1024</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30318-1</pub-id>, PMID: <pub-id pub-id-type="pmid">30353860</pub-id><pub-id pub-id-type="pmcid">PMC6261373</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehman</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Sehar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aldossari</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wani</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Glymphatic pathway: an emerging perspective in the pathophysiology of neurodegenerative diseases</article-title>. <source>Int. J. Geriatr. Psychiatry</source><volume>39</volume>:<fpage>e6104</fpage>. doi: <pub-id pub-id-type="doi">10.1002/gps.6104</pub-id>, PMID: <pub-id pub-id-type="pmid">38877354</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringstad</surname><given-names>G.</given-names></name><name name-style="western"><surname>Valnes</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Pripp</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Vatnehol</surname><given-names>S.-A. S.</given-names></name><name name-style="western"><surname>Emblem</surname><given-names>K. E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Brain-wide glymphatic enhancement and clearance in humans assessed with MRI</article-title>. <source>JCI Insight</source><volume>3</volume>:<fpage>e121537</fpage>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.121537</pub-id>, PMID: <pub-id pub-id-type="pmid">29997300</pub-id><pub-id pub-id-type="pmcid">PMC6124518</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>D&#8217;Agata</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arcaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carandini</surname><given-names>T.</given-names></name><name name-style="western"><surname>&#214;rzsik</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>A &#8220;glympse&#8221; into neurodegeneration: diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer&#8217;s disease and other dementias</article-title>. <source>Hum. Brain Mapp.</source><volume>45</volume>:<fpage>e26805</fpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.26805</pub-id><pub-id pub-id-type="pmid">39185685</pub-id><pub-id pub-id-type="pmcid">PMC11345637</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Si</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Matrix metalloproteinase-9 inhibition prevents aquaporin-4 depolarization-mediated glymphatic dysfunction in Parkinson&#8217;s disease</article-title>. <source>J. Adv. Res.</source><volume>56</volume>, <fpage>125</fpage>&#8211;<lpage>136</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jare.2023.03.004</pub-id>, PMID: <pub-id pub-id-type="pmid">36940850</pub-id><pub-id pub-id-type="pmcid">PMC10834796</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M. X.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>O.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Reemmer</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid &#946; plaque formation in mice</article-title>. <source>Alzheimer's Res Ther</source><volume>14</volume>:<fpage>59</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-022-00999-5</pub-id>, PMID: <pub-id pub-id-type="pmid">35473943</pub-id><pub-id pub-id-type="pmcid">PMC9040291</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soares</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waisberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sarker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tavakkoli</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Imaging in spaceflight associated neuro-ocular syndrome (SANS): current technology and future directions in modalities</article-title>. <source>Life Sci Space Res (Amst)</source><volume>42</volume>, <fpage>40</fpage>&#8211;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lssr.2024.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">39067989</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Knowledge mapping and emerging trends of ferroptosis in ischemia reperfusion injury research: a bibliometric analysis (2013-2022)</article-title>. <source>Heliyon</source><volume>9</volume>:<fpage>e20363</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e20363</pub-id>, PMID: <pub-id pub-id-type="pmid">37767486</pub-id><pub-id pub-id-type="pmcid">PMC10520329</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thipani Madhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balaji</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kandi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harikrishna</surname><given-names>G. V.</given-names></name><name name-style="western"><surname>Metta</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Role of the Glymphatic system in Alzheimer&#8217;s disease and treatment approaches: a narrative review</article-title>. <source>Cureus</source><volume>16</volume>:<fpage>e63448</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.63448</pub-id>, PMID: <pub-id pub-id-type="pmid">39077280</pub-id><pub-id pub-id-type="pmcid">PMC11285013</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>Application of multimodal MRI in the early diagnosis of autism Spectrum disorders: a review</article-title>. <source>Diagnostics (Basel)</source><volume>13</volume>:<fpage>3027</fpage>. doi: <pub-id pub-id-type="doi">10.3390/diagnostics13193027</pub-id>, PMID: <pub-id pub-id-type="pmid">37835770</pub-id><pub-id pub-id-type="pmcid">PMC10571992</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haacke</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name></person-group> (<year>2024</year>). <article-title>Contribution of direct cerebral vascular transport in brain substance clearance</article-title>. <source>Aging Dis.</source><volume>15</volume>, <fpage>584</fpage>&#8211;<lpage>600</lpage>. doi: <pub-id pub-id-type="doi">10.14336/AD.2023.0426</pub-id>, PMID: <pub-id pub-id-type="pmid">37611901</pub-id><pub-id pub-id-type="pmcid">PMC10917538</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Politis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>L. T.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel PET biomarkers to disentangle molecular pathways across age-related neurodegenerative diseases</article-title>. <source>Cells</source><volume>9</volume>:<fpage>2581</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells9122581</pub-id>, PMID: <pub-id pub-id-type="pmid">33276490</pub-id><pub-id pub-id-type="pmcid">PMC7761606</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>The glymphatic system delivery enhances the transduction efficiency of AAV1 to brain endothelial cells in adult mice</article-title>. <source>J. Neurosci. Methods</source><volume>328</volume>:<fpage>108441</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jneumeth.2019.108441</pub-id>, PMID: <pub-id pub-id-type="pmid">31574288</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thiyagarajan</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Sleep drives metabolite clearance from the adult brain</article-title>. <source>Science</source><volume>342</volume>, <fpage>373</fpage>&#8211;<lpage>377</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1241224</pub-id>, PMID: <pub-id pub-id-type="pmid">24136970</pub-id><pub-id pub-id-type="pmcid">PMC3880190</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Advances in the study of the glymphatic system and aging</article-title>. <source>CNS Neurosci. Ther.</source><volume>30</volume>:<fpage>e14803</fpage>. doi: <pub-id pub-id-type="doi">10.1111/cns.14803</pub-id>, PMID: <pub-id pub-id-type="pmid">38887168</pub-id><pub-id pub-id-type="pmcid">PMC11183173</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name></person-group> (<year>2024</year>). <article-title>Involvement of the glymphatic/meningeal lymphatic system in Alzheimer&#8217;s disease: insights into proteostasis and future directions</article-title>. <source>Cell. Mol. Life Sci.</source><volume>81</volume>:<fpage>192</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-024-05225-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38652179</pub-id><pub-id pub-id-type="pmcid">PMC11039514</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yankova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bogomyakova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tulupov</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance</article-title>. <source>Rev. Neurosci.</source><volume>32</volume>, <fpage>693</fpage>&#8211;<lpage>705</lpage>. doi: <pub-id pub-id-type="doi">10.1515/revneuro-2020-0106</pub-id>, PMID: <pub-id pub-id-type="pmid">33618444</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zedde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pascarella</surname><given-names>R.</given-names></name></person-group> (<year>2024</year>). <article-title>The cerebrovascular side of plasticity: microvascular architecture across health and neurodegenerative and vascular diseases</article-title>. <source>Brain Sci.</source><volume>14</volume>:<fpage>983</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci14100983</pub-id>, PMID: <pub-id pub-id-type="pmid">39451997</pub-id><pub-id pub-id-type="pmcid">PMC11506257</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeppenfeld</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haswell</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>D&#8217;Abreo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murchison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>J. F.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Association of Perivascular Localization of Aquaporin-4 with cognition and Alzheimer disease in aging brains</article-title>. <source>JAMA Neurol.</source><volume>74</volume>, <fpage>91</fpage>&#8211;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.4370</pub-id>, PMID: <pub-id pub-id-type="pmid">27893874</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.-Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>R.-T.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Interaction between the Glymphatic system and &#945;-Synuclein in Parkinson&#8217;s disease</article-title>. <source>Mol. Neurobiol.</source><volume>60</volume>, <fpage>2209</fpage>&#8211;<lpage>2222</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-023-03212-2</pub-id>, PMID: <pub-id pub-id-type="pmid">36637746</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <source>Functional neuroimaging with multiple modalities: Principles, device and applications</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Nova Science Publishers</publisher-name>.</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group> (<year>2021</year>). <source>Imaging and multiomic biomarker applications: Advances in early Alzheimer&#8217;s disease</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Nova Science Publishers</publisher-name>.</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Glymphatic system dysfunction and risk of clinical milestones in patients with Parkinson disease</article-title>. <source>Eur. J. Neurol.</source><volume>31</volume>:<fpage>e16521</fpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.16521</pub-id>, PMID: <pub-id pub-id-type="pmid">39425566</pub-id><pub-id pub-id-type="pmcid">PMC11554988</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>AQP4 is an emerging regulator of pathological pain: a narrative review</article-title>. <source>Cell. Mol. Neurobiol.</source><volume>43</volume>, <fpage>3997</fpage>&#8211;<lpage>4005</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10571-023-01422-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37864629</pub-id><pub-id pub-id-type="pmcid">PMC11407711</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Blocking meningeal lymphatic drainage aggravates Parkinson&#8217;s disease-like pathology in mice overexpressing mutated &#945;-synuclein</article-title>. <source>Transl Neurodegener</source><volume>8</volume>:<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40035-019-0147-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30867902</pub-id><pub-id pub-id-type="pmcid">PMC6396507</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomol Biomed</journal-id><journal-id journal-id-type="iso-abbrev">Biomol Biomed</journal-id><journal-id journal-id-type="pmc-domain-id">4372</journal-id><journal-id journal-id-type="pmc-domain">biomolbiomed</journal-id><journal-title-group><journal-title>Biomolecules and Biomedicine</journal-title></journal-title-group><issn pub-type="ppub">2831-0896</issn><issn pub-type="epub">2831-090X</issn><publisher><publisher-name>Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505531</article-id><article-id pub-id-type="pmcid-ver">PMC12505531.1</article-id><article-id pub-id-type="pmcaid">12505531</article-id><article-id pub-id-type="pmcaiid">12505531</article-id><article-id pub-id-type="pmid">40791147</article-id><article-id pub-id-type="doi">10.17305/bb.2025.12921</article-id><article-id pub-id-type="publisher-id">BB-26-240</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Gut microbial metabolites and the brain&#8211;gut axis in Alzheimer&#8217;s disease: A review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ji</surname><given-names initials="X">Xinchen</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-2815-113X</contrib-id><xref rid="aff1" ref-type="aff">1</xref><xref rid="cnt1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jian</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cnt1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lan</surname><given-names initials="T">Tianye</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="D">Dexi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7890-9212</contrib-id><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="P">Peng</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China</aff><aff id="aff2"><label>2</label>Department of Encephalopathy, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China</aff><aff id="aff3"><label>3</label>Department of Rehabilitation, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence to Tianye Lan: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:lantianye-x@163.com">lantianye-x@163.com</email>; Dexi Zhao: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:dexizhao1006@163.com">dexizhao1006@163.com</email> and Peng Xu: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:xupeng@ccucm.edu.cn">xupeng@ccucm.edu.cn</email></corresp><fn id="cnt1"><label>#</label><p>Xinchen Ji and Jian Wang contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2025</year></pub-date><volume>26</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">498542</issue-id><fpage>240</fpage><lpage>250</lpage><history><date date-type="received"><day>8</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>11</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Ji et al.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is available under a Creative Commons License (Attribution 4.0 International, as described at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bb-2025-12921.pdf"/><abstract><p>Alzheimer&#8217;s disease (AD) is increasingly recognized as a disorder that extends beyond the brain, with accumulating evidence implicating gut microbiota-derived metabolites in its onset and progression. This narrative review synthesises 92 peer-reviewed animal, human and meta-analytic studies published between 2010 and 2025 that investigated short-chain fatty acids (SCFAs), tryptophan-derived indoles and kynurenines, trimethylamine N-oxide (TMAO), and secondary bile acids in the context of AD. Collectively, the literature shows that SCFAs support blood&#8211;brain-barrier integrity, dampen microglial reactivity and enhance synaptic plasticity, yet can paradoxically amplify &#946;-amyloid (A&#946;) deposition under germ-free or supraphysiological conditions, highlighting the importance of host status and dosing. Beneficial indole metabolites such as indole-3-propionic acid counter oxidative stress, strengthen intestinal and cerebral barriers and suppress pro-inflammatory cascades, whereas a shift toward neurotoxic kynurenines correlates with cognitive decline. TMAO emerges as a consistently deleterious metabolite that aggravates endothelial dysfunction, neuroinflammation and A&#946; aggregation; dietary precursor restriction and microbial enzyme inhibitors are therefore being explored as mitigation strategies. Secondary bile acids and polyphenol derivatives further modulate mitochondrial bioenergetics and NF-&#954;B signalling, broadening the therapeutic landscape. Multi-omics profiling reveals that AD patients typically exhibit reduced SCFAs and indoles but elevated TMAO, changes that scale with Mini-Mental State Examination scores, brain atrophy and cerebrospinal A&#946;<sub>4</sub><sub>2</sub> levels. Early probiotic and faecal-microbiota-transplant trials have begun to normalise these metabolite profiles and yield modest cognitive benefits, underscoring translational potential. Altogether, gut-derived metabolites are not passive by-products but active modulators of neural, immune and metabolic circuits along the microbiota&#8211;gut&#8211;brain axis; their targeted manipulation and standardised metabolomic assessment could enable earlier diagnosis and precision microbiome-based interventions for AD, a promise that now warrants validation in large, longitudinal and mechanistically informed clinical studies.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>AD</kwd><kwd>brain&#8211;gut axis</kwd><kwd>gut microbial metabolites</kwd><kwd>mechanism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder primarily characterized by cognitive decline, memory impairment, language dysfunction, and deficits in executive functioning. The global prevalence of AD is steadily increasing, with projections indicating that the number of affected individuals could exceed 150 million by 2050, placing a substantial burden on public health systems and caregiving resources [<xref rid="ref1" ref-type="bibr">1</xref>]. Despite advancements in understanding the roles of genetic predisposition, &#946;-amyloid (A&#946;) deposition, and tau hyperphosphorylation, the etiology and pathogenesis of AD remain incompletely understood.</p><p>Recent research has highlighted the gut microbiota as a potential contributor to the development and progression of AD. As an essential &#8220;second genome&#8221; of the host, the gut microbiota plays a critical role in nutrient absorption, immune regulation, and metabolic homeostasis. Furthermore, it establishes a bidirectional communication network with the central nervous system through the microbiota&#8211;gut&#8211;brain (MGB) axis [<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref3" ref-type="bibr">3</xref>]. Accumulating evidence suggests that individuals with AD exhibit reduced gut microbial diversity, lower levels of beneficial microbial metabolites such as short-chain fatty acids (SCFAs), and an increased abundance of pro-inflammatory taxa, including <italic toggle="yes">Proteobacteria</italic> and <italic toggle="yes">Escherichia&#8211;Shigella</italic>. This pattern of dysbiosis is closely associated with neuroinflammation and neuronal apoptosis [<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>].</p><table-wrap position="float" id="TB1" orientation="portrait"><label>Table 1</label><caption><p>Summary of selected literature on gut microbial metabolites in Alzheimer&#8217;s disease research</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="left"/><col span="3" align="left"/><col span="4" align="left"/><col span="5" align="left"/><col span="6" align="left"/><col span="7" align="left"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Researchs</bold>
</th><th rowspan="1" colspan="1">
<bold>Metabolite/ mechanism</bold>
</th><th rowspan="1" colspan="1">
<bold>Study type</bold>
</th><th rowspan="1" colspan="1">
<bold>Model/sample</bold>
</th><th rowspan="1" colspan="1">
<bold>Intervention/ analysis</bold>
</th><th rowspan="1" colspan="1">
<bold>Key findings</bold>
</th><th rowspan="1" colspan="1">
<bold>Year</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Colombo et al. [<xref rid="ref73" ref-type="bibr">73</xref>]</td><td rowspan="1" colspan="1">SCFAs</td><td rowspan="1" colspan="1">Animal experiment</td><td rowspan="1" colspan="1">Germ-free (GF) vs SPF APPPS1 mice</td><td rowspan="1" colspan="1">Oral SCFA supplementation</td><td rowspan="1" colspan="1">SCFAs restored A&#946; plaque load and microglial activation in GF mice to SPF levels</td><td rowspan="1" colspan="1">2021</td></tr><tr valign="top"><td rowspan="1" colspan="1">Bowerman et al. [<xref rid="ref74" ref-type="bibr">74</xref>]</td><td rowspan="1" colspan="1">SCFAs</td><td rowspan="1" colspan="1">Animal experiment</td><td rowspan="1" colspan="1">APP/PS1 mice</td><td rowspan="1" colspan="1">Oral SCFAs supplementation</td><td rowspan="1" colspan="1">Altered gut microbiota diversity, but no significant changes in cognition or A&#946; pathology</td><td rowspan="1" colspan="1">2022</td></tr><tr valign="top"><td rowspan="1" colspan="1">Was&#233;n et al. [<xref rid="ref75" ref-type="bibr">75</xref>]</td><td rowspan="1" colspan="1">B. fragilis (Bacteroidota phylum)</td><td rowspan="1" colspan="1">Animal experiment</td><td rowspan="1" colspan="1">APP/PS1-21 and 5xFAD mice</td><td rowspan="1" colspan="1">B. fragilis administration or clearance</td><td rowspan="1" colspan="1">Increased A&#946; deposition, inhibited microglial clearance; antibiotic reversal observed</td><td rowspan="1" colspan="1">2024</td></tr><tr valign="top"><td rowspan="1" colspan="1">Gao et al. [<xref rid="ref28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">TMAO</td><td rowspan="1" colspan="1">Animal experiment</td><td rowspan="1" colspan="1">WT and APP/PS1 mice</td><td rowspan="1" colspan="1">Systemic TMAO injection</td><td rowspan="1" colspan="1">Promoted synaptic loss, A&#946; aggregation, and cognitive impairment</td><td rowspan="1" colspan="1">2022</td></tr><tr valign="top"><td rowspan="1" colspan="1">Long et al. [<xref rid="ref60" ref-type="bibr">60</xref>]</td><td rowspan="1" colspan="1">TMAO</td><td rowspan="1" colspan="1">Meta-analysis</td><td rowspan="1" colspan="1">7 cohort studies</td><td rowspan="1" colspan="1">Systematic review and pooled analysis</td><td rowspan="1" colspan="1">High TMAO levels significantly associated with cognitive impairment (OR &#8776; 1.39)</td><td rowspan="1" colspan="1">2024</td></tr><tr valign="top"><td rowspan="1" colspan="1">Zuo et al. [<xref rid="ref76" ref-type="bibr">76</xref>] (non-primary source)</td><td rowspan="1" colspan="1">SCFAs (mechanistic)</td><td rowspan="1" colspan="1">Review article</td><td rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> and animal studies</td><td rowspan="1" colspan="1">Literature synthesis</td><td rowspan="1" colspan="1">SCFAs regulate neuroinflammation via HDAC inhibition, GPCRs, immune modulation</td><td rowspan="1" colspan="1">2022</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Note:</italic> 1. Zuo et al. (2022) is a review article and does not present primary experimental data. Included for mechanistic reference. 2. Was&#233;n et al. reported microglial clearance impairment as a key mechanistic link between B. fragilis colonization and A&#946; accumulation. Abbreviations: GF: Germ-free; SPF: Specific pathogen-free; APP/PS1: Amyloid precursor protein/presenilin 1; SCFAs: Short-chain fatty acids; TMAO: Trimethylamine-N-oxide.</p></table-wrap-foot></table-wrap><p>The gut microbiota significantly influences brain function through various signaling pathways, including: (1) the neural pathway mediated by the vagus nerve; (2) the endocrine pathway that regulates the secretion of neurotransmitters such as cortisol and serotonin; (3) the immune pathway that activates microglia and pro-inflammatory cytokines; (4) the metabolic pathway involving microbial metabolites that can cross the blood-brain barrier (BBB); and (5) the barrier integrity pathway affecting both intestinal epithelium and BBB function [<xref rid="ref5" ref-type="bibr">5</xref>]. Preclinical and clinical studies provide preliminary evidence suggesting that gut dysbiosis may not only be a consequence of AD, but could also serve as a contributing pathogenic factor. In this context, investigating the interplay between gut microbiota and AD pathogenesis is essential for enhancing mechanistic understanding and identifying novel therapeutic targets. Microbiota-based interventions&#8212;such as probiotics, prebiotics, and fecal microbiota transplantation (FMT)&#8212;have shown promising cognitive benefits in AD animal models [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref6" ref-type="bibr">6</xref>]. Thus, elucidating the mechanisms of gut-brain communication, characterizing key metabolic pathways, and identifying actionable targets have become pivotal directions in current AD research.</p></sec><sec id="sec2"><title>Methods</title><p>To ensure transparency and reproducibility, we conducted a structured literature search across three electronic databases: PubMed, Web of Science, and Scopus. The search encompassed publications from January 2010 to May 2025 and utilized a combination of the following keywords and MeSH terms: &#8220;Alzheimer&#8217;s disease,&#8221; &#8220;gut microbiota,&#8221; &#8220;microbial metabolites,&#8221; &#8220;short-chain fatty acids (SCFAs),&#8221; &#8220;tryptophan,&#8221; &#8220;trimethylamine-N-oxide (TMAO),&#8221; &#8220;indole derivatives,&#8221; &#8220;polyphenols,&#8221; &#8220;bile acids,&#8221; and &#8220;brain&#8211;gut axis.&#8221;</p><p>Inclusion criteria were as follows: 1) Original research articles (including animal experiments, clinical studies, and meta-analyses) reporting on gut microbial metabolites in the context of Alzheimer&#8217;s disease; 2) Studies reporting outcomes such as cognitive function, A&#946; pathology, neuroinflammation, or gut&#8211;brain signaling mechanisms; 3) Articles published in English and in peer-reviewed journals.</p><p>Exclusion criteria included: 1) Non-peer-reviewed literature (e.g., conference abstracts and preprints); 2) Editorial opinions or commentaries; 3) Non-systematic narrative reviews, except those providing unique mechanistic insights.</p><p>The search initially retrieved 278 records. After screening titles and abstracts, 122 studies were selected for full-text review. Among these, 92 studies met all inclusion criteria and were included in the final synthesis. Representative studies were chosen based on scientific rigor, clarity of metabolite&#8211;AD associations, and mechanistic relevance, as summarized in <xref rid="TB1" ref-type="table">Table 1</xref>. To contextualize the strength of the included evidence, we employed the following hierarchy of study designs: human randomized controlled trials (RCTs) &gt; cohort studies &gt; animal experiments. Although several clinical studies and meta-analyses were identified, the majority of included research exhibited heterogeneous designs, varied outcome measures, and inconsistent reporting formats, which limited the feasibility of meaningful quantitative synthesis. Consequently, a formal meta-analysis was not conducted, and the present review remains narrative in nature.</p><sec id="sec2a"><title>Clinical and neuropathological features of Alzheimer&#8217;s disease</title><p>AD is a chronic, progressive neurodegenerative disorder primarily characterized by memory impairment as an initial symptom. Clinically, it progresses from mild cognitive decline to severe loss of daily functioning, ultimately leading to global dementia. According to the diagnostic framework established by the National Institute on Aging and the Alzheimer&#8217;s Association (NIA-AA), AD is classified into three stages: preclinical AD, mild cognitive impairment due to AD (MCI), and dementia due to AD [<xref rid="ref7" ref-type="bibr">7</xref>].</p><p>In the early stage, patients commonly exhibit recent memory loss, attention deficits, mild language impairment, and visuospatial disorientation. As the disease advances, emotional instability, personality changes, executive dysfunction, and neuropsychiatric symptoms, such as delusions, hallucinations, and aggression, may arise. In the terminal stage, patients typically lose the ability to live independently and become entirely reliant on caregivers.</p><p>Neuropathologically, the defining lesions of AD include the extracellular deposition of &#946;-amyloid (A&#946;) peptides, which form senile plaques, and the intracellular accumulation of hyperphosphorylated tau protein, which leads to neurofibrillary tangles (NFTs) [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. A&#946; is generated through the sequential cleavage of amyloid precursor protein (APP) by &#946;- and &#947;-secretases, with excessive aggregation believed to induce neurotoxicity, immune activation, synaptic dysfunction, and neuronal loss [<xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref10" ref-type="bibr">10</xref>]. NFTs, composed of abnormally phosphorylated tau, disrupt microtubule stability and axonal transport, with their spatial distribution strongly correlating with cognitive decline [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref11" ref-type="bibr">11</xref>]. Additionally, AD pathology is characterized by widespread neuronal loss, reduced synaptic density, microglial activation, and astrogliosis in affected brain regions [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref12" ref-type="bibr">12</xref>].</p><p>Neuroimaging studies have confirmed the characteristic progression of structural and functional brain changes in AD. Initially, atrophy is localized to the medial temporal lobe, particularly the hippocampus and parahippocampal gyrus, which are critically involved in memory consolidation [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>]. As AD progresses, cortical atrophy extends to the parietal, frontal, and posterior cingulate cortices. Functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) studies have revealed hypometabolism and disrupted functional connectivity in these regions, indicating pathological remodeling at the network level [<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref15" ref-type="bibr">15</xref>]. Furthermore, PET imaging utilizing A&#946;- or tau-specific tracers facilitates <italic toggle="yes">in vivo</italic> visualization of AD pathology, thereby enhancing early diagnosis and disease monitoring [<xref rid="ref16" ref-type="bibr">16</xref>].</p><p>Multiple risk factors have been associated with AD, including advanced age, genetic predisposition, such as the presence of the apolipoprotein E &#603;4 (ApoE &#603;4) allele, chronic metabolic conditions (e.g., diabetes and hypertension), detrimental lifestyle behaviors (e.g., physical inactivity and poor diet), and psychosocial factors (e.g., depression, social isolation) [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>]. Familial AD is uncommon and typically linked to early-onset cases caused by mutations in <italic toggle="yes">PSEN1</italic>, <italic toggle="yes">PSEN2</italic>, or <italic toggle="yes">APP</italic>. In contrast, sporadic AD constitutes the majority of cases and involves a multifactorial etiology that includes oxidative stress, mitochondrial dysfunction, calcium dysregulation, and chronic neuroinflammation [<xref rid="ref19" ref-type="bibr">19</xref>].</p><p>Notably, neuroinflammation has emerged as a central pathological mechanism in AD. Microglia, the primary immune effector cells in the brain, become activated in response to A&#946; deposition and release pro-inflammatory cytokines such as interleukin-1&#946; (IL-1&#946;) and tumor necrosis factor-alpha (TNF-&#945;), which exacerbate neurotoxicity [<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref20" ref-type="bibr">20</xref>].</p><p>In addition to genetic and lifestyle-related risk factors, increasing attention has been directed toward the gut microbiome as a modifiable factor in AD. This has led to a growing interest in the microbial metabolites produced by the gut microbiota and their potential roles in disease progression. Accumulating evidence suggests that gut microbiota dysbiosis may influence central immune and inflammatory responses via the gut&#8211;brain axis, potentially contributing to the pathology of early-stage AD.</p></sec><sec id="sec2b"><title>Overview of the biosynthesis and functional characteristics of gut microbial metabolites</title><p>The human gastrointestinal tract contains over 10<sup>1</sup><sup>4</sup> microorganisms, creating a highly diverse and complex ecological system. Through the fermentation of dietary components, mucin glycoproteins, and host secretions, gut microbiota produce a wide variety of low-molecular-weight metabolites [<xref rid="ref21" ref-type="bibr">21</xref>]. These metabolites not only support local intestinal homeostasis but can also traverse the intestinal barrier to affect distant organs, including the central nervous system, through neural, endocrine, and immune pathways [<xref rid="ref22" ref-type="bibr">22</xref>, <xref rid="ref23" ref-type="bibr">23</xref>]. Notable metabolites include short-chain fatty acids (SCFAs), tryptophan-derived metabolites, secondary bile acids, amine derivatives such as trimethylamine N-oxide (TMAO), and polyphenol-derived compounds. These molecules perform various biological functions, including signal transduction, energy regulation, immune modulation, and barrier maintenance. SCFAs, primarily acetate, propionate, and butyrate, are the principal fermentation products of indigestible carbohydrates by gut microbes [<xref rid="ref21" ref-type="bibr">21</xref>].</p><p>The production of SCFAs is contingent upon specific bacterial taxa, including <italic toggle="yes">Faecalibacterium prausnitzii</italic>, <italic toggle="yes">Roseburia</italic> spp., and <italic toggle="yes">Akkermansia muciniphila</italic>. SCFAs serve as vital energy sources for colonocytes and play a crucial role in regulating host immune responses, inflammatory signaling, and neurotransmitter synthesis. This regulation occurs through the activation of G protein-coupled receptors, such as GPR41 and GPR43, or through the inhibition of histone deacetylases (HDACs) [<xref rid="ref21" ref-type="bibr">21</xref>, <xref rid="ref24" ref-type="bibr">24</xref>]. Among these SCFAs, butyrate is particularly recognized for its ability to enhance intestinal barrier integrity, promote the differentiation of regulatory T cells, and suppress pro-inflammatory cytokines. Its neuroprotective potential has also garnered significant attention [<xref rid="ref21" ref-type="bibr">21</xref>].</p><p>Tryptophan, an essential amino acid, is metabolized by both host and microbial enzymes into various bioactive compounds. Specifically, gut bacteria convert tryptophan into indole and its derivatives, including indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and indolelactic acid (ILA). These metabolites can activate the aryl hydrocarbon receptor (AhR) and pregnane X receptor (PXR), thereby modulating inflammation, oxidative stress, and intestinal epithelial barrier function [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref25" ref-type="bibr">25</xref>]. Notably, some indole derivatives are capable of crossing the blood-brain barrier (BBB), influencing neuronal excitability and glial cell activation, which underscores their significant role in the modulation of brain function [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref26" ref-type="bibr">26</xref>].</p><p>TMAO is produced through the microbial metabolism of dietary choline, L-carnitine, and porphyrin compounds. Its precursor, trimethylamine (TMA), undergoes oxidation to form TMAO via hepatic flavin-containing monooxygenase 3 (FMO3). Elevated levels of TMAO have been positively linked to various chronic diseases, including cardiovascular disease, renal dysfunction, and neurodegenerative disorders. These associations are believed to involve mechanisms such as endothelial dysfunction, oxidative stress, and the activation of pro-inflammatory signaling pathways [<xref rid="ref27" ref-type="bibr">27</xref>, <xref rid="ref28" ref-type="bibr">28</xref>]. In the context of AD, increased TMAO levels have been associated with cognitive decline and A&#946; deposition. Additionally, the gut microbiota can metabolize dietary polyphenols into bioactive compounds, such as protocatechuic acid and phenylpropanoid derivatives. These metabolites play a role in free radical scavenging, modulation of low-grade inflammation, and neuroprotection [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>Microbial-derived secondary bile acids play a significant role in regulating host metabolism and immune responses through receptors such as the farnesoid X receptor (FXR) and Takeda G protein&#8211;coupled receptor 5 (TGR5) [<xref rid="ref23" ref-type="bibr">23</xref>]. The biosynthetic profile of these metabolites is shaped by host dietary habits, microbial composition, and the intestinal metabolic microenvironment. Their biological effects are influenced by molecular structure, concentration, receptor-binding capacity, and exhibit regional variations (e.g., between the colon and small intestine) as well as inter-individual differences. Recent advancements in metabolomics and multi-omics approaches have enabled a systematic analysis of these metabolic pathways, providing a theoretical framework for understanding the microbiota&#8211;gut&#8211;brain communication network.</p></sec><sec id="sec2c"><title>The microbiota&#8211;gut&#8211;brain axis: A bidirectional signaling network linking the gut microbiota to the brain</title><p>The microbiota&#8211;gut&#8211;brain (MGB) axis represents a complex, bidirectional communication system integrating neural, endocrine, immune, and metabolic networks that uphold homeostatic balance between the gut microbiota and the central nervous system (CNS). This system not only oversees gastrointestinal function but also significantly influences cognition, mood, stress responses, and neurodegeneration. Emerging evidence indicates that the gut microbiota impacts the CNS through various interconnected pathways, encompassing neural, endocrine, immune, metabolic, and barrier-associated mechanisms.</p></sec><sec id="sec2d"><title>Neural pathway</title><p>The neural pathway serves as the primary channel for gut-brain communication, primarily involving the vagus nerve and the enteric nervous system (ENS). The vagus nerve operates as a bidirectional conduit between the gut and the brain; its sensory terminals are located within the intestinal epithelium and muscularis, enabling the detection of microbial metabolites such as SCFAs and neuroactive compounds. These signals are transmitted to key brain regions, including the nucleus tractus solitarius, hypothalamus, and amygdala [<xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref31" ref-type="bibr">31</xref>].</p><p>The ENS can autonomously monitor luminal conditions and regulate gastrointestinal motility and secretion through local reflex arcs. Certain gut bacteria synthesize neurotransmitters or their precursors, including &#947;-aminobutyric acid (GABA), serotonin (5-HT), and dopamine, thereby influencing central neurotransmitter levels [<xref rid="ref32" ref-type="bibr">32</xref>]. Notably, GABA interacts with GABA_B receptors at vagal nerve terminals, inhibiting excitatory neuronal activity in the central nervous system (CNS) and creating a negative feedback loop [<xref rid="ref31" ref-type="bibr">31</xref>].</p><p>Although serotonin and dopamine are unable to cross the blood&#8211;brain barrier, their microbial precursors may indirectly affect central nervous function by activating vagal afferents or modulating the supply of precursors to the brain.</p></sec><sec id="sec2e"><title>Endocrine pathway</title><p>The gut functions as one of the largest endocrine organs, containing a significant number of enteroendocrine cells (EECs) that secrete hormones in response to microbial metabolites. SCFAs can activate GPR41 and GPR43 receptors on EECs, leading to the release of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). This process plays a crucial role in modulating appetite, glucose metabolism, and neuroprotection [<xref rid="ref33" ref-type="bibr">33&#8211;35</xref>].</p><p>SCFAs activate GPR41 and GPR43 receptors on EECs, stimulating the release of GLP-1 and PYY. This process modulates appetite, glucose metabolism, and neuroprotection. These hormones exert their effects by interacting with GLP-1 receptors in the pancreas and brain, enhancing insulin secretion, regulating hypothalamic activity, and promoting neuronal survival. Tryptophan-derived metabolites also influence the synthesis of melatonin and serotonin through endocrine pathways. Although these hormones do not cross the blood-brain barrier directly, they can affect brain function by acting on peripheral receptors and modulating vagal afferents and hypothalamic pathways [<xref rid="ref36" ref-type="bibr">36</xref>]. Specifically, GLP-1 and PYY influence hypothalamic-pituitary-adrenal (HPA) axis activity by regulating corticotropin-releasing hormone (CRH) expression in the hypothalamus and subsequent cortisol secretion, thereby affecting stress responses and neuroinflammation. Additionally, the gut microbiota modulates HPA axis responsiveness, impacting stress-related hormones such as cortisol, as well as central inflammation and synaptic plasticity.</p></sec><sec id="sec2f"><title>Immune pathway</title><p>The gut microbiota plays a crucial role in the development and functioning of the host immune system. It regulates the differentiation of dendritic cells, macrophages, and regulatory T cells (Tregs), thereby influencing both local and systemic immune responses. Short-chain fatty acids (SCFAs), particularly butyrate, promote Treg differentiation, inhibit pro-inflammatory Th17 cell activity, and reduce the production of cytokines such as IL-6, IL-1&#946;, and TNF-&#945; [<xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref38" ref-type="bibr">38</xref>]. Activated immune cells and circulating cytokines can affect neuroinflammatory states and activate microglia. Specifically, pro-inflammatory mediators such as interleukin-1&#946; (IL-1&#946;) and tumor necrosis factor-alpha (TNF-&#945;) can trigger microglial activation via NF-&#954;B signaling, leading to increased A&#946; accumulation and neuronal damage. Indole derivatives modulate immune responses and intestinal barrier integrity through the aryl hydrocarbon receptor (AhR) signaling pathway, playing a vital role in the immuno-neural axis [<xref rid="ref39" ref-type="bibr">39</xref>]. Upon activation by indole compounds, AhR translocates to the nucleus and regulates the expression of interleukin-22 (IL-22), which promotes mucosal healing and enhances the expression of epithelial tight junction proteins, thereby reinforcing gut barrier function and mitigating systemic inflammation [<xref rid="ref40" ref-type="bibr">40</xref>]. Furthermore, dysbiosis-induced translocation of microbial endotoxins, such as lipopolysaccharide (LPS), may increase systemic inflammation and BBB permeability, exacerbating CNS pathology [<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref41" ref-type="bibr">41</xref>].</p></sec><sec id="sec2g"><title>Metabolic pathway</title><p>Microbial metabolites&#8212;including SCFAs, tryptophan-derived compounds, secondary bile acids, TMAO, and polyphenol derivatives&#8212;play a crucial role in mediating host-microbiota interactions. Certain small metabolites, such as acetate and propionate, can traverse the BBB via systemic circulation, thereby directly influencing neuronal excitability and synaptic function [<xref rid="ref42" ref-type="bibr">42</xref>]. SCFAs have been shown to regulate neurotransmitter synthesis, neurogenesis, and the immune states of the central nervous system (CNS) through G protein-coupled receptor (GPR) signaling and histone deacetylase (HDAC) inhibition [<xref rid="ref43" ref-type="bibr">43</xref>]. Specifically, the activation of GPR41 and GPR43 by SCFAs modulates microglial activity and promotes the production of anti-inflammatory cytokines. Furthermore, HDAC inhibition by butyrate enhances the expression of brain-derived neurotrophic factor (BDNF), which supports neuronal differentiation [<xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref45" ref-type="bibr">45</xref>]. TMAO, a nitrogenous metabolite, is linked to cognitive impairment, A&#946; deposition, and neuroinflammation, potentially through mechanisms involving oxidative stress, endothelial dysfunction, and the upregulation of inflammatory mediators [<xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref46" ref-type="bibr">46</xref>]. Additionally, bile acid derivatives and microbial-converted polyphenols can influence neuronal energy metabolism and mitochondrial function, thereby contributing to the progression of neurodegenerative diseases [<xref rid="ref47" ref-type="bibr">47</xref>]. For example, secondary bile acids such as lithocholic acid (LCA) activate TGR5 receptors in neuronal and glial cells, promoting mitochondrial biogenesis and mitigating oxidative stress. Similarly, microbial metabolites of dietary polyphenols, such as urolithin A, enhance mitophagy and ATP production in neurons, thus providing neuroprotective effects [<xref rid="ref48" ref-type="bibr">48</xref>, <xref rid="ref49" ref-type="bibr">49</xref>].</p></sec><sec id="sec2h"><title>Barrier interaction pathway</title><p>This pathway highlights the collaborative function of the intestinal epithelial barrier and the BBB in sustaining the homeostasis of the microbiome-gut-brain (MGB) axis. An intact gut barrier, supported by tight junction proteins such as occludin and claudins, effectively prevents the translocation of pro-inflammatory molecules. However, microbial dysbiosis can compromise this barrier, allowing microbial products and cytokines to enter the bloodstream, which may result in CNS inflammation and disruption of the microenvironment. SCFAs enhance the expression of tight junction proteins, restore barrier architecture, and stabilize intestinal permeability [<xref rid="ref50" ref-type="bibr">50</xref>]. Concurrently, the integrity of the BBB is influenced by gut-derived signals. Research involving germ-free (GF) mice has demonstrated increased BBB permeability, which can be partially restored through SCFA supplementation. Additionally, microbial metabolites may further affect BBB transport properties and the neuroimmune microenvironment by interacting with cerebral endothelial cells, basement membranes, and astrocytic end-feet [<xref rid="ref51" ref-type="bibr">51</xref>].</p><p>Recent studies have enhanced our understanding of how gut microbiota modulates CNS glial cell function and neuroinflammation in AD. A comprehensive review by Caradonna et al. [<xref rid="ref52" ref-type="bibr">52</xref>] highlighted the regulatory effects of gut-derived signals on microglia, astrocytes, and oligodendrocytes through SCFA and cytokine-mediated pathways. Additionally, research indicated that the conditions of animal facilities (specific pathogen-free [SPF] vs specific pathogen-free with additional environmental controls [SOPF]) significantly influence amyloid pathology in 5XFAD mice via microbiota-dependent mechanisms, emphasizing the environmental impact on gut-brain communication [<xref rid="ref53" ref-type="bibr">53</xref>].</p></sec><sec id="sec2i"><title>Role of gut microbial metabolites in the pathogenesis of Alzheimer&#8217;s disease</title><p>AD encompasses multifactorial pathological processes, including A&#946; deposition, hyperphosphorylation of tau protein, neuronal apoptosis, neuroinflammation, and synaptic dysfunction. Emerging evidence indicates that gut microbial metabolites may influence these CNS pathologies through various mechanisms and may play a role in modulating disease progression, even in the early stages of AD. Certain metabolites are capable of crossing the BBB to directly impact neurons or indirectly influence neurodegenerative progression through inflammatory signaling, oxidative stress, and synaptic plasticity [<xref rid="ref54" ref-type="bibr">54</xref>, <xref rid="ref55" ref-type="bibr">55</xref>]. Notably, SCFAs, particularly butyrate, demonstrate neuroprotective potential in AD models by modulating immune responses and maintaining BBB integrity [<xref rid="ref51" ref-type="bibr">51</xref>].</p><p>Their context-dependent effects on microglial activation and A&#946; pathology highlight the significance of host status and treatment timing in therapeutic applications. Numerous studies have established the neuroprotective roles of SCFAs&#8212;particularly butyrate&#8212;in regulating inflammation, enhancing BBB integrity, and promoting synaptic plasticity; however, conflicting findings are also evident. For instance, Colombo et al. reported that SCFA supplementation in germ-free APPPS1 mice resulted in increased A&#946; plaque deposition and microglial activation, indicating a potentially detrimental context-dependent effect.</p><fig position="float" id="f1" orientation="portrait"><label>Figure 1.</label><caption><p><bold>Gut microbial metabolites regulate Alzheimer&#8217;s disease via immune, oxidative, and barrier-related mechanisms.</bold> Gut microbiota-derived metabolites influence AD through multiple pathways. SCFAs, especially butyrate, promote Treg differentiation, inhibit pro-inflammatory cytokines, and enhance BBB integrity, but may under certain conditions increase A&#946; deposition. Tryptophan metabolites (e.g., IPA) activate AhR signaling with antioxidant and anti-inflammatory effects. Polyphenol metabolites suppress NF-&#954;B and reduce oxidative stress. In contrast, TMA and TMAO impair BBB integrity, promote A&#946; accumulation, and exacerbate neuroinflammation, linking gut dysbiosis to AD pathology via the gut&#8211;brain axis. Abbreviations: AD: Alzheimer&#8217;s disease; SCFAs: Short-chain fatty acids; BBB: Blood&#8211;brain barrier; CH: Cholesterol; Treg: Regulatory T cells; AhR: Aryl hydrocarbon receptor; TMA: Trimethylamine; NF-&#954;B: Nuclear factor kappa-light-chain-enhancer of activated B cells; A&#946;: Beta-amyloid; TMAO: Trimethylamine N-oxide; IPA: Indole-3-propionic acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12921f1.jpg"/></fig><p>Several factors may account for these divergent outcomes. First, the germ-free status alters immune system maturation and brain development, potentially amplifying inflammatory responses to SCFA exposure. Second, the dosage and route of administration (e.g., bolus gavage vs gradual dietary intake) can differentially affect metabolic and immune responses. Third, the timing of intervention&#8212;specifically whether SCFAs are administered during early or late disease stages&#8212;may influence their impact on A&#946; pathology. Consequently, SCFAs may exert bidirectional effects in AD models, contingent upon host context, microbiota status, and treatment parameters. This duality emphasizes the need for meticulous experimental design and patient stratification in translational applications.</p><p>Tryptophan-derived metabolites also serve as critical molecular mediators of the gut&#8211;brain interaction. In AD mouse models, IPA and ILA activate the AhR signaling pathway, thereby enhancing both intestinal and cerebral barrier functions while suppressing microglial pro-inflammatory phenotypic transformation. Furthermore, IPA possesses antioxidant properties, scavenging reactive oxygen species (ROS) and alleviating oxidative stress-induced neuronal injury [<xref rid="ref56" ref-type="bibr">56</xref>, <xref rid="ref57" ref-type="bibr">57</xref>].</p><p>Tryptophan influences melatonin synthesis through the gut&#8211;pineal&#8211;CNS axis, which plays a crucial role in regulating circadian rhythms and providing neuroprotection. Disruptions in this process may accelerate the pathology of AD [<xref rid="ref58" ref-type="bibr">58</xref>]. Gut-derived amine metabolites, particularly TMAO, show a positive correlation with the development of AD. Research indicates that TMAO promotes neuroinflammatory responses, upregulates A&#946; precursor protein expression and cleavage, and increases A&#946; accumulation [<xref rid="ref46" ref-type="bibr">46</xref>]. Furthermore, TMAO compromises the integrity of cerebrovascular endothelial cells, leading to heightened BBB permeability and enhanced inflammatory signaling to the CNS. Elevated TMAO levels are inversely associated with cognitive function and may worsen neurodegeneration by impairing cholinergic neurotransmission, increasing oxidative stress, and disrupting mitochondrial function [<xref rid="ref59" ref-type="bibr">59</xref>, <xref rid="ref60" ref-type="bibr">60</xref>].</p><p>Polyphenol derivatives and secondary bile acids play significant roles in the pathogenesis of AD. Polyphenol metabolites have been shown to inhibit the NF-&#954;B signaling pathway, reduce the expression of proinflammatory cytokines, and enhance the activity of endogenous antioxidant enzyme systems in the brain, thereby mitigating oxidative damage [<xref rid="ref61" ref-type="bibr">61</xref>, <xref rid="ref62" ref-type="bibr">62</xref>]. Certain secondary bile acids modulate neuronal energy metabolism and lipid homeostasis through the TGR5 and FXR pathways; their dysregulation is closely linked to mitochondrial dysfunction and lipid abnormalities associated with AD [<xref rid="ref63" ref-type="bibr">63</xref>].</p><p>Multi-omics studies have identified significant changes in the gut microbial composition and metabolic profiles of AD patients. Compared to healthy controls, these individuals exhibit decreased levels of SCFAs, reduced biosynthesis of indole and polyphenol derivatives, and elevated levels of TMAO. These findings suggest that microbial metabolites may contribute to the pathogenesis of AD through multiple synergistic mechanisms [<xref rid="ref64" ref-type="bibr">64</xref>, <xref rid="ref65" ref-type="bibr">65</xref>]. Integrated metabolomic and transcriptomic analyses further demonstrate that dysregulated metabolic pathways are significantly associated with inflammatory markers and A&#946;-related gene expression in the brain, highlighting the central regulatory role of microbial metabolites in AD pathophysiology [<xref rid="ref66" ref-type="bibr">66</xref>]. Collectively, these findings emphasize that gut microbial metabolites are not merely mediators of microbiota-brain communication; rather, they may act as functional effectors involved in various pathological processes of AD, including neuroinflammation, oxidative stress, neurotransmitter metabolism, and BBB dysfunction. A schematic overview of these interactions is presented in <xref rid="f1" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec2j"><title>Clinical evidence of gut microbial metabolites in Alzheimer&#8217;s disease</title><p>With the advancement of the microbiota&#8211;gut&#8211;brain axis (MGB axis) theory, an increasing number of clinical translational studies have concentrated on gut microbial metabolites in AD. Numerous clinical observations, interventional trials, and metabolomic analyses have established a significant correlation between these metabolites and cognitive function, inflammatory status, and pathological protein levels in AD patients. This evidence provides a robust theoretical foundation for microbiota-targeted interventions in the context of Alzheimer&#8217;s disease.</p><p>Studies consistently demonstrate that levels of SCFAs are significantly reduced in both peripheral blood and fecal samples of patients with AD. In contrast, concentrations of TMAO are elevated, while levels of indole and its derivatives are diminished [<xref rid="ref67" ref-type="bibr">67</xref>]. These metabolic alterations are significantly correlated with Mini-Mental State Examination (MMSE) scores, brain atrophy, and A&#946;<sub>4</sub><sub>2</sub> levels. For instance, a case-cohort analysis from the AgeCoDe study in Germany, which included 805 older adults without dementia at baseline, found that no inflammatory markers effectively predicted the onset of dementia. However, certain indole-containing tryptophan metabolites and SCFAs&#8212;specifically isobutyric acid and 2-methylbutyric acid&#8212;were significantly associated with the progression to all-cause dementia, although SCFAs and TMAO were not independently predictive in adjusted models [<xref rid="ref68" ref-type="bibr">68</xref>].</p><p>Several interventional studies have investigated the functional roles of microbial metabolites in microbiota-based therapies, including probiotic supplementation and fecal microbiota transplantation (FMT). A double-blind randomized controlled trial conducted in Italy reported that a combined probiotic intervention&#8212;featuring <italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Bifidobacterium</italic> strains&#8212;significantly increased peripheral SCFA concentrations in patients with AD, which was accompanied by improved MMSE scores after 12 weeks [<xref rid="ref69" ref-type="bibr">69</xref>, <xref rid="ref70" ref-type="bibr">70</xref>]. Preliminary findings from a 2023 study in China further demonstrated that FMT could remodel gut microbial composition, restore SCFA and indole metabolic pathways, reduce inflammatory markers, and indicate a trend toward cognitive improvement [<xref rid="ref71" ref-type="bibr">71</xref>]. Additionally, metabolomic studies integrated with neuroimaging are advancing. A 2022 study in the United States employed ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC&#8211;MS/MS) to quantify metabolomic profiles and utilized positron emission tomography (PET) imaging to assess A&#946; burden. The results indicated that elevated plasma levels of indole-3-propionic acid (IPA) were associated with reduced A&#946; deposition, suggesting a neuroprotective role for this metabolite in regulating A&#946; pathology [<xref rid="ref72" ref-type="bibr">72</xref>].</p><p>Numerous translational experiments have sought to modulate microbial metabolic pathways through nutritional and pharmacological interventions. Supplementation with resistant starch, low-protein diets, and oral sodium butyrate has demonstrated efficacy in enhancing cognitive function and reducing neuroinflammation in animal models of AD. Additionally, these interventions have been associated with increased SCFA levels in healthy elderly individuals, providing preliminary evidence for the clinical feasibility of such approaches [<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref73" ref-type="bibr">73</xref>]. <xref rid="TB1" ref-type="table">Table 1</xref> presents a summary of key published studies, outlining changes in critical microbial metabolites&#8212;such as SCFAs and TMAO&#8212;in AD populations, along with relevant intervention strategies and their potential therapeutic effects. The significant findings on gut microbial metabolites in Alzheimer&#8217;s disease are detailed in <xref rid="TB1" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2k"><title>Potential therapeutic targets of gut-derived metabolites in Alzheimer&#8217;s disease</title><p>In recent years, the modulation of gut microbiota has emerged as a promising therapeutic strategy for AD. Targeting microbial metabolites offers a direct intervention at the microbe-brain interface. Various metabolites derived from gut microbiota have shown regulatory effects on critical AD-related pathological processes, including neuroinflammation, oxidative stress, and A&#946; metabolism. These metabolites may represent novel therapeutic targets for personalized interventions. The subsequent section delineates the therapeutic mechanisms and recent advancements in several key categories of microbial metabolites.</p></sec><sec id="sec2l"><title>Short-chain fatty acids (SCFAs)</title><p>SCFAs, particularly butyrate, have demonstrated therapeutic potential in AD by modulating inflammation, oxidative stress, and the integrity of the BBB. Butyrate promotes an anti-inflammatory microglial phenotype and enhances synaptic plasticity. Interventions such as oral sodium butyrate and probiotics that increase SCFA production are currently being investigated for their neuroprotective effects. Furthermore, butyrate facilitates the polarization of microglia toward the anti-inflammatory M2 phenotype while inhibiting the pro-inflammatory M1 activation commonly associated with AD [<xref rid="ref77" ref-type="bibr">77</xref>]. The oral administration of sodium butyrate and butyrate-producing probiotics is being explored as a potential therapeutic strategy [<xref rid="ref2" ref-type="bibr">2</xref>].</p></sec><sec id="sec2m"><title>Tryptophan-derived metabolites</title><p>Tryptophan metabolism plays a crucial role in gut-brain communication and occurs through three primary pathways: the kynurenine (KYN) pathway, serotonin synthesis, and microbial indole production. The KYN pathway and its metabolites are significant regulators of CNS inflammation and neurotoxicity, particularly in AD [<xref rid="ref78" ref-type="bibr">78</xref>]. In AD, tryptophan is predominantly metabolized into neurotoxic KYN derivatives, such as 3-hydroxykynurenine, due to the upregulation of indoleamine 2,3-dioxygenase (IDO), which contributes to neuronal damage and microglial activation [<xref rid="ref79" ref-type="bibr">79</xref>]. Concurrently, levels of neuroprotective metabolites like kynurenic acid (KYNA) decline, thereby disrupting metabolic homeostasis [<xref rid="ref80" ref-type="bibr">80</xref>, <xref rid="ref81" ref-type="bibr">81</xref>]. Consequently, therapeutic strategies are focused on redirecting tryptophan metabolism toward protective pathways while suppressing the production of neurotoxic byproducts.</p></sec><sec id="sec2n"><title>Indole derivatives</title><p>IPA is a gut microbial metabolite synthesized from tryptophan, predominantly by bacterial genera such as Clostridium and Bacteroides. In addition to its role in amyloid regulation, IPA modulates glial cell activity and suppresses neuroinflammatory gene expression in the hippocampus. Importantly, IPA can cross the BBB, inhibit A&#946; aggregation, and prevent neuronal apoptosis, thereby exhibiting significant neuroprotective effects [<xref rid="ref61" ref-type="bibr">61</xref>]. Strategies to enhance the production of indole derivatives&#8212;either through the supplementation of indole-producing bacteria or the administration of synthetic metabolites&#8212;have shown cognitive benefits and a reduction in pathology in AD models [<xref rid="ref56" ref-type="bibr">56</xref>].</p></sec><sec id="sec2o"><title>TMAO and other amine metabolites</title><p>Given its pathogenic role in AD, therapeutic strategies targeting the production of TMAO have emerged. These strategies include dietary restrictions on precursors such as choline and L-carnitine, as well as the use of microbial enzyme inhibitors. The objective of these approaches is to mitigate TMAO-induced neuroinflammation and disruption of the BBB.</p><p>A recent review by Oktaviono et al. [<xref rid="ref82" ref-type="bibr">82</xref>]. published in <italic toggle="yes">Biomolecules and Biomedicine</italic> elaborates on the pathophysiological roles of TMAO and discusses potential therapeutic modulation strategies within the context of AD, providing valuable mechanistic insights that complement our discussion. Concurrently, recent mechanistic and epidemiological studies have reinforced the detrimental role of TMAO in cognitive decline. A meta-analysis involving over 80,000 participants confirmed that elevated plasma TMAO is significantly associated with cognitive impairment, indicating an odds ratio of approximately 1.39 [<xref rid="ref59" ref-type="bibr">59</xref>]. <italic toggle="yes">In vivo</italic> studies have demonstrated that TMAO induces neuronal senescence, exacerbates oxidative stress, disrupts mTOR signaling, and exacerbates neuroinflammation [<xref rid="ref27" ref-type="bibr">27</xref>]. Furthermore, comprehensive reviews published between 2023 and 2024 have summarized TMAO&#8217;s negative impacts on endothelial and synaptic function and suggested potential therapeutic strategies that target dietary precursors and microbial enzymes [<xref rid="ref83" ref-type="bibr">83</xref>].</p></sec><sec id="sec2p"><title>Other gut-derived metabolites</title><p>Beyond the previously mentioned metabolites, secondary bile acids, such as deoxycholic acid and lithocholic acid, exert regulatory effects in AD by modulating energy metabolism, lipid homeostasis, and neurodevelopment through receptors including TGR5 and FXR [<xref rid="ref84" ref-type="bibr">84</xref>, <xref rid="ref85" ref-type="bibr">85</xref>]. Polyphenol-derived microbial metabolites have exhibited antioxidant, anti-inflammatory, and neuroprotective properties, potentially delaying AD progression by optimizing metabolic interactions [<xref rid="ref86" ref-type="bibr">86</xref>, <xref rid="ref87" ref-type="bibr">87</xref>]. Emerging candidates, such as GABA, N-acetylneuraminic acid, and short-chain hydroxy fatty acids, are also gaining prominence [<xref rid="ref88" ref-type="bibr">88</xref>]. Although these molecules are synthesized endogenously in the CNS, their peripheral microbial origins and modulatory potential are increasingly being investigated. Notably, elevated GABA levels have been linked to improved cognition in AD models, although the relationship between gut-derived GABA and central GABAergic signaling requires further elucidation [<xref rid="ref88" ref-type="bibr">88</xref>]. In summary, gut-derived metabolites play a crucial role as effector molecules in the pathogenesis of AD and represent promising targets for precision therapeutic interventions.</p></sec><sec id="sec2q"><title>Limitations and future directions</title><p>Emerging evidence supports the involvement of gut microbiota&#8211;derived metabolites in the pathogenesis and intervention of AD; however, several critical challenges must be addressed. First, most current studies rely on animal models or small-sample clinical trials, and their translational applicability and safety in large, diverse human populations have yet to be rigorously validated [<xref rid="ref89" ref-type="bibr">89</xref>]. Second, the brain&#8211;gut&#8211;microbiota axis constitutes a complex, multilayered communication network that encompasses neural, endocrine, immune, and metabolic pathways. Nevertheless, mechanistic insights into key signaling molecules and their spatiotemporal dynamics remain limited, particularly concerning differential responses across disease stages and individual variability. Furthermore, the levels of microbial metabolites are significantly influenced by extrinsic factors such as diet, age, and lifestyle, and there is currently no unified or standardized protocol for their detection, quantification, or clinical interpretation. This lack of standardization impedes the utilization of gut-derived metabolites as reliable non-invasive biomarkers in clinical settings.</p><p>Future research should incorporate multi-omics approaches&#8212;including metabolomics, metagenomics, and transcriptomics&#8212;to develop multi-pathway synergy models and clarify the dynamic interactions of metabolites in relation to disease progression. Longitudinal cohort studies are crucial for monitoring temporal fluctuations in metabolite profiles and identifying disease-specific signatures across various clinical and environmental contexts. Furthermore, precision microbiome-based interventions&#8212;such as targeted prebiotics, microbial modulation, fecal microbiota transplantation (FMT), and synthetic biological therapeutics&#8212;should be assessed within individualized evaluation frameworks. These strategies offer significant potential for early intervention and long-term management of AD, ultimately facilitating the advancement of personalized gut-brain therapeutics.</p></sec></sec><sec id="sec3"><title>Conclusion</title><p>The role of gut microbiota&#8211;derived metabolites in Alzheimer&#8217;s disease (AD) has gradually shifted from associative comorbidity observations to mechanistic investigations, revealing their potential as therapeutic targets. Metabolites such as short-chain fatty acids (SCFAs), tryptophan derivatives, indole compounds, and trimethylamine N-oxide (TMAO) are not only involved in regulating neuroinflammation, blood&#8211;brain barrier (BBB) integrity, and neurotransmitter metabolism, but also influence the onset and progression of AD through multiple brain&#8211;gut axis signaling pathways.An increasing body of clinical and translational evidence supports the utility of gut-derived metabolites as promising biomarkers and integral components of novel intervention strategies. Although challenges remain&#8212;particularly regarding the clarification of underlying mechanisms and the standardization of clinical applications&#8212;current findings have opened new avenues for early detection and precision treatment of AD. Furthermore, this line of research provides a robust theoretical and experimental foundation for optimizing future microbiome-based therapeutic approaches.</p></sec></body><back><ack><p>The authors sincerely thank all collaborators involved in the design and planning of this project.</p></ack><fn-group><fn fn-type="COI-statement"><p>Conflicts of interest: Authors declare no conflicts of interest.</p></fn><fn fn-type="supported-by"><p>Funding: This work was funded by the Jilin Provincial Department of Science and Technology under the Major Science and Technology Special Project for Major Disease Prevention and Control in Jilin Province (Grant No. 20210303004SF).</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>D-O</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Current understanding of the Alzheimer&#8217;s disease-associated microbiome and therapeutic strategies</article-title><source>Exp Mol Med</source><year>2024</year><volume>56</volume><issue>1</issue><fpage>86</fpage><lpage>94</lpage><comment>https://doi.org/10.1038/s12276-023-01146-2</comment><pub-id pub-id-type="pmid">38172602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-023-01146-2</pub-id><pub-id pub-id-type="pmcid">PMC10834451</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Mak</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Tan</surname><given-names>LKS</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CX</given-names></name><name name-style="western"><surname>Chan</surname><given-names>HH</given-names></name><name name-style="western"><surname>Yeow</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Microbiota&#8211;gut&#8211;brain axis and its therapeutic applications in neurodegenerative diseases</article-title><source>Signal Transduct Target Therapy</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>37</fpage><comment>https://doi.org/10.1038/s41392-024-01743-1</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01743-1</pub-id><pub-id pub-id-type="pmcid">PMC10869798</pub-id><pub-id pub-id-type="pmid">38360862</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romanenko</surname><given-names>M</given-names></name><name name-style="western"><surname>Kholin</surname><given-names>V</given-names></name><name name-style="western"><surname>Koliada</surname><given-names>A</given-names></name><name name-style="western"><surname>Vaiserman</surname><given-names>A</given-names></name></person-group><article-title>Nutrition, gut microbiota, and Alzheimer&#8217;s disease</article-title><source>Front Psychiatry</source><year>2021</year><volume>12</volume><fpage>712673</fpage><comment>https://doi.org/10.3389/fpsyt.2021.712673</comment><pub-id pub-id-type="pmid">34421687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.712673</pub-id><pub-id pub-id-type="pmcid">PMC8374099</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lwere</surname><given-names>K</given-names></name><name name-style="western"><surname>Muwonge</surname><given-names>H</given-names></name><name name-style="western"><surname>Sendagire</surname><given-names>H</given-names></name><name name-style="western"><surname>Sajatovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gumukiriza-Onoria</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: a case&#8211;control study</article-title><source>Medicine</source><year>2025</year><volume>104</volume><issue>16</issue><fpage>e42100</fpage><comment>https://doi.org/10.1097/MD.0000000000042100</comment><pub-id pub-id-type="pmid">40258729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000042100</pub-id><pub-id pub-id-type="pmcid">PMC12014080</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peddinti</surname><given-names>V</given-names></name><name name-style="western"><surname>Avaghade</surname><given-names>MM</given-names></name><name name-style="western"><surname>Suthar</surname><given-names>SU</given-names></name><name name-style="western"><surname>Rout</surname><given-names>B</given-names></name><name name-style="western"><surname>Gomte</surname><given-names>SS</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Gut instincts: unveiling the connection between gut microbiota and Alzheimer&#8217;s disease</article-title><source>Clin Nutr ESPEN</source><year>2024</year><volume>60</volume><fpage>266</fpage><lpage>80</lpage><comment>https://doi.org/10.1016/j.clnesp.2024.02.019</comment><pub-id pub-id-type="pmid">38479921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnesp.2024.02.019</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escobar</surname><given-names>YH</given-names></name><name name-style="western"><surname>O&#8217;Piela</surname><given-names>D</given-names></name><name name-style="western"><surname>Wold</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mackos</surname><given-names>AR</given-names></name></person-group><article-title>Influence of the microbiota-gut-brain axis on cognition in Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>87</volume><issue>1</issue><fpage>17</fpage><lpage>31</lpage><comment>https://doi.org/10.3233/JAD-215290</comment><pub-id pub-id-type="pmid">35253750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215290</pub-id><pub-id pub-id-type="pmcid">PMC10394502</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Buracchio</surname><given-names>T</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Graf</surname><given-names>A</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s association workgroup</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>8</issue><fpage>5143</fpage><lpage>69</lpage><comment>https://doi.org/10.1002/alz.13859</comment><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name name-style="western"><surname>Frosch</surname><given-names>MP</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>Neuropathological alterations in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2011</year><volume>1</volume><issue>1</issue><fpage>a006189</fpage><comment>https://doi.org/10.1101/cshperspect.a006189</comment><pub-id pub-id-type="pmid">22229116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006189</pub-id><pub-id pub-id-type="pmcid">PMC3234452</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><article-title>Neuropathology of the Alzheimer&#8217;s continuum: an update</article-title><source>Free Neuropathol</source><year>2020</year><volume>1</volume><fpage>32</fpage><comment>https://doi.org/10.17879/freeneuropathology-2020-3050</comment><pub-id pub-id-type="pmid">37283686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17879/freeneuropathology-2020-3050</pub-id><pub-id pub-id-type="pmcid">PMC10209886</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petit</surname><given-names>D</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>SG</given-names></name><name name-style="western"><surname>Zoltowska</surname><given-names>KM</given-names></name><name name-style="western"><surname>Enzlein</surname><given-names>T</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>NS</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>A</given-names></name><etal/></person-group><article-title>A&#946; profiles generated by Alzheimer&#8217;s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><issue>6</issue><fpage>2821</fpage><lpage>32</lpage><comment>https://doi.org/10.1038/s41380-022-01518-6</comment><pub-id pub-id-type="pmid">35365805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01518-6</pub-id><pub-id pub-id-type="pmcid">PMC9156411</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G</given-names></name><etal/></person-group><article-title>Simultaneous PET/fMRI detects distinctive alterations in functional connectivity and glucose metabolism of precuneus subregions in Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2021</year><volume>13</volume><fpage>737002</fpage><comment>https://doi.org/10.3389/fnagi.2021.737002</comment><pub-id pub-id-type="pmid">34630070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.737002</pub-id><pub-id pub-id-type="pmcid">PMC8498203</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microglia in Alzheimer&#8217;s disease: pathogenesis, mechanisms, and therapeutic potentials</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><fpage>1201982</fpage><comment>https://doi.org/10.3389/fnagi.2023.1201982</comment><pub-id pub-id-type="pmid">37396657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1201982</pub-id><pub-id pub-id-type="pmcid">PMC10309009</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sintini</surname><given-names>I</given-names></name><name name-style="western"><surname>Whitwell</surname><given-names>JL</given-names></name></person-group><article-title>Update on neuroimaging in Alzheimer&#8217;s disease</article-title><source>Curr Opin Neurol</source><year>2021</year><volume>34</volume><issue>4</issue><fpage>525</fpage><lpage>31</lpage><comment>https://doi.org/10.1097/WCO.0000000000000947</comment><pub-id pub-id-type="pmid">33928929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WCO.0000000000000947</pub-id><pub-id pub-id-type="pmcid">PMC8263471</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chouliaras</surname><given-names>L</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>JT</given-names></name></person-group><article-title>The use of neuroimaging techniques in the early and differential diagnosis of dementia</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><issue>10</issue><fpage>4084</fpage><lpage>97</lpage><comment>https://doi.org/10.1038/s41380-023-02215-8</comment><pub-id pub-id-type="pmid">37608222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02215-8</pub-id><pub-id pub-id-type="pmcid">PMC10827668</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G</given-names></name><etal/></person-group><article-title>Topographic metabolism-function relationships in Alzheimer&#8217;s disease: a simultaneous PET/MRI study</article-title><source>Hum Brain Mapp</source><year>2024</year><volume>45</volume><issue>2</issue><fpage>e26604</fpage><comment>https://doi.org/10.1002/hbm.26604</comment><pub-id pub-id-type="pmid">38339890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.26604</pub-id><pub-id pub-id-type="pmcid">PMC10964919</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mengel</surname><given-names>D</given-names></name><name name-style="western"><surname>Soter</surname><given-names>E</given-names></name><name name-style="western"><surname>Ott</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Leyva</surname><given-names>A</given-names></name><name name-style="western"><surname>Peters</surname><given-names>O</given-names></name><etal/></person-group><article-title>Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer&#8217;s disease</article-title><source>Mol Psychiatry.</source><year>2025</year><volume>30</volume><fpage>3150</fpage><lpage>9</lpage><comment>https://doi.org/10.1038/s41380-025-03021-0</comment><pub-id pub-id-type="pmid">40247130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-025-03021-0</pub-id><pub-id pub-id-type="pmcid">PMC12185333</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raulin</surname><given-names>A-C</given-names></name><name name-style="western"><surname>Doss</surname><given-names>SV</given-names></name><name name-style="western"><surname>Trottier</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Ikezu</surname><given-names>TC</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C-C</given-names></name></person-group><article-title>ApoE in Alzheimer&#8217;s disease: pathophysiology and therapeutic strategies</article-title><source>Mol Neurodegener</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>72</fpage><comment>https://doi.org/10.1186/s13024-022-00574-4</comment><pub-id pub-id-type="pmid">36348357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-022-00574-4</pub-id><pub-id pub-id-type="pmcid">PMC9644639</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>BC</given-names></name><name name-style="western"><surname>Choe</surname><given-names>YM</given-names></name><name name-style="western"><surname>Suh</surname><given-names>GH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>IG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><etal/></person-group><article-title>A combination of midlife diabetes mellitus and the apolipoprotein E &#603;4 allele increase risk for cognitive decline</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>1065117</fpage><comment>https://doi.org/10.3389/fnagi.2022.1065117</comment><pub-id pub-id-type="pmid">36466611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.1065117</pub-id><pub-id pub-id-type="pmcid">PMC9715424</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>H</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Res Ther</source><year>2025</year><volume>17</volume><issue>1</issue><fpage>54</fpage><comment>https://doi.org/10.1186/s13195-025-01702-0</comment><pub-id pub-id-type="pmid">40016812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01702-0</pub-id><pub-id pub-id-type="pmcid">PMC11866898</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamila</surname><given-names>P</given-names></name><name name-style="western"><surname>Kar</surname><given-names>K</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>R</given-names></name><name name-style="western"><surname>Sowmiya</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of neuroinflammation on the progression of Alzheimer&#8217;s disease and its significant ramifications for novel anti-inflammatory treatments</article-title><source>IBRO Neurosci Rep</source><year>2025</year><volume>18</volume><fpage>771</fpage><lpage>82</lpage><comment>https://doi.org/10.1016/j.ibneur.2025.05.005</comment><pub-id pub-id-type="pmid">40510290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ibneur.2025.05.005</pub-id><pub-id pub-id-type="pmcid">PMC12159511</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Jian</surname><given-names>Y-P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y-N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L-T</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H-H</given-names></name><etal/></person-group><article-title>Short-chain fatty acids in diseases</article-title><source>Cell Commun Signal</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>212</fpage><comment>https://doi.org/10.1186/s12964-023-01219-9</comment><pub-id pub-id-type="pmid">37596634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-023-01219-9</pub-id><pub-id pub-id-type="pmcid">PMC10436623</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhtar</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name><name name-style="western"><surname>Khan</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation</article-title><source>Anim Nutr</source><year>2022</year><volume>8</volume><fpage>350</fpage><lpage>60</lpage><comment>https://doi.org/10.1016/j.aninu.2021.11.005</comment><pub-id pub-id-type="pmid">35510031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aninu.2021.11.005</pub-id><pub-id pub-id-type="pmcid">PMC9040132</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>SA</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>PV</given-names></name></person-group><article-title>Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>32</issue><fpage>19376</fpage><lpage>87</lpage><comment>https://doi.org/10.1073/pnas.2000047117</comment><pub-id pub-id-type="pmid">32719140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2000047117</pub-id><pub-id pub-id-type="pmcid">PMC7431026</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parada Venegas</surname><given-names>D</given-names></name><name name-style="western"><surname>De la Fuente</surname><given-names>MK</given-names></name><name name-style="western"><surname>Landskron</surname><given-names>G</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Quera</surname><given-names>R</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>G</given-names></name><etal/></person-group><article-title>Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>277</fpage><comment>https://doi.org/10.3389/fimmu.2019.00277</comment><pub-id pub-id-type="pmid">30915065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00277</pub-id><pub-id pub-id-type="pmcid">PMC6421268</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>N</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name></person-group><article-title>The role of the tryptophan metabolites in gut microbiota-brain axis and potential treatments: a focus on ischemic stroke</article-title><source>Front Pharmacol</source><year>2025</year><volume>16</volume><fpage>1578018</fpage><comment>https://doi.org/10.3389/fphar.2025.1578018</comment><pub-id pub-id-type="pmid">40556758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1578018</pub-id><pub-id pub-id-type="pmcid">PMC12185428</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Microbiota-indole 3-propionic acid-brain axis mediates abnormal synaptic pruning of hippocampal microglia and susceptibility to ASD in IUGR offspring</article-title><source>Microbiome</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>245</fpage><comment>https://doi.org/10.1186/s40168-023-01656-1</comment><pub-id pub-id-type="pmid">37932832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-023-01656-1</pub-id><pub-id pub-id-type="pmcid">PMC10629055</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaqub</surname><given-names>A</given-names></name><name name-style="western"><surname>Vojinovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>MW</given-names></name><name name-style="western"><surname>Slagboom</surname><given-names>PE</given-names></name><name name-style="western"><surname>Ghanbari</surname><given-names>M</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia</article-title><source>Alzheimer&#8217;s Res Ther.</source><year>2024</year><volume>16</volume><issue>1</issue><comment>https://doi.org/10.1186/s13195-024-01480-1</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01480-1</pub-id><pub-id pub-id-type="pmcid">PMC11103865</pub-id><pub-id pub-id-type="pmid">38769578</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Decreased levels of circulating trimethylamine N-oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimer&#8217;s disease</article-title><source>Aging (Albany NY)</source><year>2019</year><volume>11</volume><issue>19</issue><fpage>8642</fpage><lpage>63</lpage><comment>https://doi.org/10.18632/aging.102352</comment><pub-id pub-id-type="pmid">31612864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102352</pub-id><pub-id pub-id-type="pmcid">PMC6814608</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Shafi</surname><given-names>S</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>PK</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of phytochemicals in modulating the gut microbiota: implications for health and disease</article-title><source>Med Microecol</source><year>2025</year><volume>24</volume><fpage>100125</fpage><comment>https://doi.org/10.1016/j.medmic.2025.100125</comment></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrut</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bragaru</surname><given-names>AM</given-names></name><name name-style="western"><surname>Munteanu</surname><given-names>AE</given-names></name><name name-style="western"><surname>Moldovan</surname><given-names>AD</given-names></name><name name-style="western"><surname>Moldovan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rusu</surname><given-names>E</given-names></name></person-group><article-title>Gut over mind: exploring the powerful gut-brain axis</article-title><source>Nutrients</source><year>2025</year><volume>17</volume><issue>5</issue><fpage>842</fpage><comment>https://doi.org/10.3390/nu17050842</comment><pub-id pub-id-type="pmid">40077713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu17050842</pub-id><pub-id pub-id-type="pmcid">PMC11901622</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dicks</surname><given-names>LMT</given-names></name></person-group><article-title>Gut bacteria and neurotransmitters</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><issue>9</issue><fpage>1838</fpage><comment>https://doi.org/10.3390/microorganisms10091838</comment><pub-id pub-id-type="pmid">36144440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms10091838</pub-id><pub-id pub-id-type="pmcid">PMC9504309</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pokusaeva</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C</given-names></name><name name-style="western"><surname>Luk</surname><given-names>B</given-names></name><name name-style="western"><surname>Uribe</surname><given-names>G</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oezguen</surname><given-names>N</given-names></name><etal/></person-group><article-title>GABA-producing bifidobacterium dentium modulates visceral sensitivity in the intestine</article-title><source>Neurogastroenterol Motil</source><year>2017</year><volume>29</volume><issue>1</issue><fpage>e12904</fpage><comment>https://doi.org/10.1111/nmo.12904</comment><pub-id pub-id-type="pmid">27458085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nmo.12904</pub-id><pub-id pub-id-type="pmcid">PMC5195897</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>T</given-names></name><name name-style="western"><surname>Vanslette</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hjorth</surname><given-names>SA</given-names></name><name name-style="western"><surname>B&#228;ckhed</surname><given-names>F</given-names></name></person-group><article-title>Microbial regulation of enteroendocrine cells</article-title><source>Med</source><year>2021</year><volume>2</volume><issue>5</issue><fpage>553</fpage><lpage>70</lpage><comment>https://doi.org/10.1016/j.medj.2021.03.018</comment><pub-id pub-id-type="pmid">35590233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medj.2021.03.018</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christiansen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Gabe</surname><given-names>MBN</given-names></name><name name-style="western"><surname>Svendsen</surname><given-names>B</given-names></name><name name-style="western"><surname>Dragsted</surname><given-names>LO</given-names></name><name name-style="western"><surname>Rosenkilde</surname><given-names>MM</given-names></name><name name-style="western"><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon</article-title><source>Amer J Physiol-Gastrointest Liver Physiol</source><year>2018</year><volume>315</volume><issue>1</issue><fpage>G53</fpage><lpage>65</lpage><comment>https://doi.org/10.1152/ajpgi.00346.2017</comment><pub-id pub-id-type="pmid">29494208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpgi.00346.2017</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#248;hr</surname><given-names>MK</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Gille</surname><given-names>A</given-names></name><name name-style="western"><surname>Egerod</surname><given-names>KL</given-names></name><name name-style="western"><surname>Engelstoft</surname><given-names>MS</given-names></name><name name-style="western"><surname>Husted</surname><given-names>AS</given-names></name><etal/></person-group><article-title>GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><issue>10</issue><fpage>3552</fpage><lpage>64</lpage><comment>https://doi.org/10.1210/en.2013-1142</comment><pub-id pub-id-type="pmid">23885020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2013-1142</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>K</given-names></name><name name-style="western"><surname>Mu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Farzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>WY</given-names></name></person-group><article-title>Tryptophan metabolism: a link between the gut microbiota and brain</article-title><source>Adv Nutr</source><year>2020</year><volume>11</volume><issue>3</issue><fpage>709</fpage><lpage>23</lpage><comment>https://doi.org/10.1093/advances/nmz127</comment><pub-id pub-id-type="pmid">31825083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/advances/nmz127</pub-id><pub-id pub-id-type="pmcid">PMC7231603</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>The role of short-chain fatty acids in inflammatory skin diseases</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>1083432</fpage><comment>https://doi.org/10.3389/fmicb.2022.1083432</comment><pub-id pub-id-type="pmid">36817115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2022.1083432</pub-id><pub-id pub-id-type="pmcid">PMC9932284</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>R</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>B-I</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>HM</given-names></name><name name-style="western"><surname>Sung</surname><given-names>HW</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name></person-group><article-title>Short chain fatty acids facilitate protective immunity by macrophages and T cells during acute fowl adenovirus-4 infection</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>17999</fpage><comment>https://doi.org/10.1038/s41598-023-45340-8</comment><pub-id pub-id-type="pmid">37865711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-45340-8</pub-id><pub-id pub-id-type="pmcid">PMC10590440</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A</given-names></name></person-group><article-title>Activation of aryl hydrocarbon receptor (AhR) in Alzheimer&#8217;s disease: role of tryptophan metabolites generated by gut host-microbiota</article-title><source>J Mol Med</source><year>2023</year><volume>101</volume><issue>3</issue><fpage>201</fpage><lpage>22</lpage><comment>https://doi.org/10.1007/s00109-023-02289-5</comment><pub-id pub-id-type="pmid">36757399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-023-02289-5</pub-id><pub-id pub-id-type="pmcid">PMC10036442</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelante</surname><given-names>T</given-names></name><name name-style="western"><surname>Iannitti</surname><given-names>RG</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>C</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Giovannini</surname><given-names>G</given-names></name><name name-style="western"><surname>Pieraccini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22</article-title><source>Immunity</source><year>2013</year><volume>39</volume><issue>2</issue><fpage>372</fpage><lpage>85</lpage><comment>https://doi.org/10.1016/j.immuni.2013.08.003</comment><pub-id pub-id-type="pmid">23973224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.08.003</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasarello</surname><given-names>K</given-names></name><name name-style="western"><surname>Cudnoch-Jedrzejewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Czarzasta</surname><given-names>K</given-names></name></person-group><article-title>Communication of gut microbiota and brain via immune and neuroendocrine signaling</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1118529</fpage><comment>https://doi.org/10.3389/fmicb.2023.1118529</comment><pub-id pub-id-type="pmid">36760508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2023.1118529</pub-id><pub-id pub-id-type="pmcid">PMC9907780</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Riordan</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Collins</surname><given-names>MK</given-names></name><name name-style="western"><surname>Moloney</surname><given-names>GM</given-names></name><name name-style="western"><surname>Knox</surname><given-names>EG</given-names></name><name name-style="western"><surname>Aburto</surname><given-names>MR</given-names></name><name name-style="western"><surname>F&#252;lling</surname><given-names>C</given-names></name><etal/></person-group><article-title>Short chain fatty acids: microbial metabolites for gut-brain axis signalling</article-title><source>Mol Cell Endocrinol</source><year>2022</year><volume>546</volume><fpage>111572</fpage><comment>https://doi.org/10.1016/j.mce.2022.111572</comment><pub-id pub-id-type="pmid">35066114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2022.111572</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>YP</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Frozza</surname><given-names>RL</given-names></name></person-group><article-title>The role of short-chain fatty acids from gut microbiota in gut-brain communication</article-title><source>Front Endocrinol (Lausanne)</source><year>2020</year><volume>11</volume><fpage>25</fpage><comment>https://doi.org/10.3389/fendo.2020.00025</comment><pub-id pub-id-type="pmid">32082260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2020.00025</pub-id><pub-id pub-id-type="pmcid">PMC7005631</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erny</surname><given-names>D</given-names></name><name name-style="western"><surname>Hrab&#283; de Angelis</surname><given-names>AL</given-names></name><name name-style="western"><surname>Jaitin</surname><given-names>D</given-names></name><name name-style="western"><surname>Wieghofer</surname><given-names>P</given-names></name><name name-style="western"><surname>Staszewski</surname><given-names>O</given-names></name><name name-style="western"><surname>David</surname><given-names>E</given-names></name><etal/></person-group><article-title>Host microbiota constantly control maturation and function of microglia in the CNS</article-title><source>Nat Neurosci</source><year>2015</year><volume>18</volume><issue>7</issue><fpage>965</fpage><lpage>77</lpage><comment>https://doi.org/10.1038/nn.4030</comment><pub-id pub-id-type="pmid">26030851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4030</pub-id><pub-id pub-id-type="pmcid">PMC5528863</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ward</surname><given-names>RE</given-names></name><name name-style="western"><surname>Martin</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>M</given-names></name><etal/></person-group><article-title>Butyrate improves insulin sensitivity and increases energy expenditure in mice</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><issue>7</issue><fpage>1509</fpage><lpage>17</lpage><comment>https://doi.org/10.2337/db08-1637</comment><pub-id pub-id-type="pmid">19366864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db08-1637</pub-id><pub-id pub-id-type="pmcid">PMC2699871</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><etal/></person-group><article-title>TMAO promotes dementia progression by mediating the PI3K/Akt/mTOR pathway</article-title><source>Tissue Cell</source><year>2023</year><volume>81</volume><fpage>102034</fpage><comment>https://doi.org/10.1016/j.tice.2023.102034</comment><pub-id pub-id-type="pmid">36753814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tice.2023.102034</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braga</surname><given-names>JD</given-names></name><name name-style="western"><surname>Thongngam</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumrungsee</surname><given-names>T</given-names></name></person-group><article-title>Gamma-aminobutyric acid as a potential postbiotic mediator in the gut&#8211;brain axis</article-title><source>NPJ Sci Food</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>16</fpage><comment>https://doi.org/10.1038/s41538-024-00253-2</comment><pub-id pub-id-type="pmid">38565567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41538-024-00253-2</pub-id><pub-id pub-id-type="pmcid">PMC10987602</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><name name-style="western"><surname>Travis</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Activation of TGR5 with INT-777 attenuates oxidative stress and neuronal apoptosis via cAMP/PKC&#949;/ALDH2 pathway after subarachnoid hemorrhage in rats</article-title><source>Free Radic Biol Med</source><year>2019 Nov 1</year><volume>143</volume><fpage>441</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">31493504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2019.09.002</pub-id><pub-id pub-id-type="pmcid">PMC6848789</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Palikaras</surname><given-names>K</given-names></name><name name-style="western"><surname>Adriaanse</surname><given-names>BA</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mitophagy inhibits amyloid-&#946; and tau pathology and reverses cognitive deficits in models of Alzheimer&#8217;s disease</article-title><source>Nat Neurosci</source><year>2019</year><volume>22</volume><issue>3</issue><fpage>401</fpage><lpage>12</lpage><comment>https://doi.org/10.1038/s41593-018-0332-9</comment><pub-id pub-id-type="pmid">30742114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0332-9</pub-id><pub-id pub-id-type="pmcid">PMC6693625</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Green</surname><given-names>RS</given-names></name><name name-style="western"><surname>Holzman</surname><given-names>IR</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers</article-title><source>J Nutr</source><year>2009</year><volume>139</volume><issue>9</issue><fpage>1619</fpage><lpage>25</lpage><comment>https://doi.org/10.3945/jn.109.104638</comment><pub-id pub-id-type="pmid">19625695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/jn.109.104638</pub-id><pub-id pub-id-type="pmcid">PMC2728689</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braniste</surname><given-names>V</given-names></name><name name-style="western"><surname>Al-Asmakh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>C</given-names></name><name name-style="western"><surname>Anuar</surname><given-names>F</given-names></name><name name-style="western"><surname>Abbaspour</surname><given-names>A</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>M</given-names></name><etal/></person-group><article-title>The gut microbiota influences blood-brain barrier permeability in mice</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><issue>263</issue><fpage>263ra158</fpage><comment>https://doi.org/10.1126/scitranslmed.3009759</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3009759</pub-id><pub-id pub-id-type="pmcid">PMC4396848</pub-id><pub-id pub-id-type="pmid">25411471</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caradonna</surname><given-names>E</given-names></name><name name-style="western"><surname>Nemni</surname><given-names>R</given-names></name><name name-style="western"><surname>Bifone</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandolfo</surname><given-names>P</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>L</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>L</given-names></name><etal/></person-group><article-title>The brain-gut axis, an important player in Alzheimer and Parkinson disease: a narrative review</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><issue>14</issue><fpage>4130</fpage><comment>https://doi.org/10.3390/jcm13144130</comment><pub-id pub-id-type="pmid">39064171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13144130</pub-id><pub-id pub-id-type="pmcid">PMC11278248</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismeurt-Walmsley</surname><given-names>C</given-names></name><name name-style="western"><surname>Giannoni</surname><given-names>P</given-names></name><name name-style="western"><surname>Servant</surname><given-names>F</given-names></name><name name-style="western"><surname>Mekki</surname><given-names>LN</given-names></name><name name-style="western"><surname>Baranger</surname><given-names>K</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>S</given-names></name><etal/></person-group><article-title>The same but different: impact of animal facility sanitary status on a transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>mBio</source><year>2025</year><volume>16</volume><issue>5</issue><fpage>e0400124</fpage><comment>https://doi.org/10.1128/mbio.04001-24</comment><pub-id pub-id-type="pmid">40243365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mbio.04001-24</pub-id><pub-id pub-id-type="pmcid">PMC12077201</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govindarajan</surname><given-names>N</given-names></name><name name-style="western"><surname>Agis-Balboa</surname><given-names>RC</given-names></name><name name-style="western"><surname>Walter</surname><given-names>J</given-names></name><name name-style="western"><surname>Sananbenesi</surname><given-names>F</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>A</given-names></name></person-group><article-title>Sodium butyrate improves memory function in an Alzheimer&#8217;s disease mouse model when administered at an advanced stage of disease progression</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>26</volume><issue>1</issue><fpage>187</fpage><lpage>97</lpage><comment>https://doi.org/10.3233/JAD-2011-110080</comment><pub-id pub-id-type="pmid">21593570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2011-110080</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogt</surname><given-names>NM</given-names></name><name name-style="western"><surname>Kerby</surname><given-names>RL</given-names></name><name name-style="western"><surname>Dill-McFarland</surname><given-names>KA</given-names></name><name name-style="western"><surname>Harding</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Merluzzi</surname><given-names>AP</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Gut microbiome alterations in Alzheimer&#8217;s disease</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>13537</fpage><comment>https://doi.org/10.1038/s41598-017-13601-y</comment><pub-id pub-id-type="pmid">29051531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-13601-y</pub-id><pub-id pub-id-type="pmcid">PMC5648830</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The gut metabolite indole-3-propionic acid activates ERK1 to restore social function and hippocampal inhibitory synaptic transmission in a 16p11.2 microdeletion mouse model</article-title><source>Microbiome</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>66</fpage><comment>https://doi.org/10.1186/s40168-024-01755-7</comment><pub-id pub-id-type="pmid">38549163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-024-01755-7</pub-id><pub-id pub-id-type="pmcid">PMC10976717</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y-X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L-L</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X-Q</given-names></name></person-group><article-title>Gut microbiota-host lipid crosstalk in Alzheimer&#8217;s disease: implications for disease progression and therapeutics</article-title><source>Mol Neurodegener</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>35</fpage><comment>https://doi.org/10.1186/s13024-024-00720-0</comment><pub-id pub-id-type="pmid">38627829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00720-0</pub-id><pub-id pub-id-type="pmcid">PMC11020986</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MAS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tryptophan metabolism in Alzheimer disease with the involvement of microglia and astrocyte crosstalk and gut-brain axis</article-title><source>Aging Disease</source><year>2024</year><volume>15</volume><issue>5</issue><fpage>2168</fpage><lpage>90</lpage><comment>https://doi.org/10.14336/AD.2024.0134</comment><pub-id pub-id-type="pmid">38916729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2024.0134</pub-id><pub-id pub-id-type="pmcid">PMC11346405</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis</article-title><source>Front Aging Neurosci</source><year>2024</year><volume>16</volume><fpage>1465457</fpage><comment>https://doi.org/10.3389/fnagi.2024.1465457</comment><pub-id pub-id-type="pmid">39430973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2024.1465457</pub-id><pub-id pub-id-type="pmcid">PMC11486729</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide aggravated cognitive impairment from APP/PS1 mice and protective roles of voluntary exercise</article-title><source>Neurochem Int</source><year>2023</year><volume>162</volume><fpage>105459</fpage><comment>https://doi.org/10.1016/j.neuint.2022.105459</comment><pub-id pub-id-type="pmid">36460238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2022.105459</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konopelski</surname><given-names>P</given-names></name><name name-style="western"><surname>Mogilnicka</surname><given-names>I</given-names></name></person-group><article-title>Biological effects of indole-3-propionic acid, a gut microbiota-derived metabolite, and its precursor tryptophan in mammals&#8217; health and disease</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>3</issue><fpage>1222</fpage><comment>https://doi.org/10.3390/ijms23031222</comment><pub-id pub-id-type="pmid">35163143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23031222</pub-id><pub-id pub-id-type="pmcid">PMC8835432</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Gaamouch</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Benefits of dietary polyphenols in Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>1019942</fpage><comment>https://doi.org/10.3389/fnagi.2022.1019942</comment><pub-id pub-id-type="pmid">36583187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.1019942</pub-id><pub-id pub-id-type="pmcid">PMC9792677</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heumel</surname><given-names>S</given-names></name><name name-style="western"><surname>de Rezende Rodovalho</surname><given-names>V</given-names></name><name name-style="western"><surname>Urien</surname><given-names>C</given-names></name><name name-style="western"><surname>Specque</surname><given-names>F</given-names></name><name name-style="western"><surname>Brito Rodrigues</surname><given-names>P</given-names></name><name name-style="western"><surname>Robil</surname><given-names>C</given-names></name><etal/></person-group><article-title>Shotgun metagenomics and systemic targeted metabolomics highlight indole-3-propionic acid as a protective gut microbial metabolite against influenza infection</article-title><source>Gut Microbes</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>2325067</fpage><comment>https://doi.org/10.1080/19490976.2024.2325067</comment><pub-id pub-id-type="pmid">38445660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2024.2325067</pub-id><pub-id pub-id-type="pmcid">PMC10936607</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Vemuganti</surname><given-names>V</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>JF</given-names></name><name name-style="western"><surname>Ulland</surname><given-names>TK</given-names></name><name name-style="western"><surname>Rey</surname><given-names>FE</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>BB</given-names></name></person-group><article-title>Gut microbial metabolism in Alzheimer&#8217;s disease and related dementias</article-title><source>Neurotherapeutics</source><year>2024</year><volume>21</volume><issue>6</issue><fpage>e00470</fpage><comment>https://doi.org/10.1016/j.neurot.2024.e00470</comment><pub-id pub-id-type="pmid">39462700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurot.2024.e00470</pub-id><pub-id pub-id-type="pmcid">PMC11585892</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gohel</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Bykova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer&#8217;s disease</article-title><source>Cell Rep</source><year>2024</year><volume>43</volume><issue>5</issue><fpage>114128</fpage><comment>https://doi.org/10.1016/j.celrep.2024.114128</comment><pub-id pub-id-type="pmid">38652661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.114128</pub-id><pub-id pub-id-type="pmcid">PMC11968202</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name><name name-style="western"><surname>Hai</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>Multi-omics data reveals aberrant gut microbiota-host glycerophospholipid metabolism in association with neuroinflammation in APP/PS1 mice</article-title><source>Gut Microbes</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>2282790</fpage><comment>https://doi.org/10.1080/19490976.2023.2282790</comment><pub-id pub-id-type="pmid">37992400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2023.2282790</pub-id><pub-id pub-id-type="pmcid">PMC10730179</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Al-Nusaif</surname><given-names>M</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name></person-group><article-title>The potential of the gut microbiome for identifying Alzheimer&#8217;s disease diagnostic biomarkers and future therapies</article-title><source>Front Neurosci.</source><year>2023</year><volume>17</volume><fpage>1130730</fpage><comment>https://doi.org/10.3389/fnins.2023.1130730</comment><pub-id pub-id-type="pmid">37179559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1130730</pub-id><pub-id pub-id-type="pmcid">PMC10174259</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oluwagbemigun</surname><given-names>K</given-names></name><name name-style="western"><surname>Anesi</surname><given-names>A</given-names></name><name name-style="western"><surname>Vrhovsek</surname><given-names>U</given-names></name><name name-style="western"><surname>Mattivi</surname><given-names>F</given-names></name><name name-style="western"><surname>Martino Adami</surname><given-names>P</given-names></name><name name-style="western"><surname>Pentzek</surname><given-names>M</given-names></name><etal/></person-group><article-title>An investigation into the relationship of circulating gut microbiome molecules and inflammatory markers with the risk of incident dementia in later life</article-title><source>Mol Neurobiol</source><year>2024</year><volume>61</volume><issue>12</issue><fpage>9776</fpage><lpage>93</lpage><comment>https://doi.org/10.1007/s12035-023-03513-6</comment><pub-id pub-id-type="pmid">37605096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03513-6</pub-id><pub-id pub-id-type="pmcid">PMC11584436</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment</article-title><source>Geriatr Nurs</source><year>2023</year><volume>51</volume><fpage>167</fpage><lpage>75</lpage><comment>https://doi.org/10.1016/j.gerinurse.2023.03.006</comment><pub-id pub-id-type="pmid">36990042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gerinurse.2023.03.006</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhgarjand</surname><given-names>C</given-names></name><name name-style="western"><surname>Vahabi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shab-Bidar</surname><given-names>S</given-names></name><name name-style="western"><surname>Etesam</surname><given-names>F</given-names></name><name name-style="western"><surname>Djafarian</surname><given-names>K</given-names></name></person-group><article-title>Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer&#8217;s disease: a randomized, double-blind, and placebo-controlled study</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>1032494</fpage><comment>https://doi.org/10.3389/fnagi.2022.1032494</comment><pub-id pub-id-type="pmid">36389063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.1032494</pub-id><pub-id pub-id-type="pmcid">PMC9647197</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments</article-title><source>Front Cell Infect Microbiol</source><year>2023</year><volume>13</volume><fpage>1103189</fpage><comment>https://doi.org/10.3389/fcimb.2023.1103189</comment><pub-id pub-id-type="pmid">37113132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2023.1103189</pub-id><pub-id pub-id-type="pmcid">PMC10127103</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaleck&#253;</surname><given-names>K</given-names></name><name name-style="western"><surname>German</surname><given-names>DC</given-names></name><name name-style="western"><surname>Montillo</surname><given-names>AA</given-names></name><name name-style="western"><surname>Bottiglieri</surname><given-names>T</given-names></name></person-group><article-title>Targeted metabolomic analysis in Alzheimer&#8217;s disease plasma and brain tissue in non-hispanic whites</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>86</volume><issue>4</issue><fpage>1875</fpage><lpage>95</lpage><comment>https://doi.org/10.3233/JAD-215448</comment><pub-id pub-id-type="pmid">35253754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215448</pub-id><pub-id pub-id-type="pmcid">PMC9108583</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>AV</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>RK</given-names></name><name name-style="western"><surname>Llovera</surname><given-names>G</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V</given-names></name><name name-style="western"><surname>Roth</surname><given-names>S</given-names></name><name name-style="western"><surname>Heindl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Microbiota-derived short chain fatty acids modulate microglia and promote A&#946; plaque deposition</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e59826</fpage><comment>https://doi.org/10.7554/eLife.59826</comment><pub-id pub-id-type="pmid">33845942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.59826</pub-id><pub-id pub-id-type="pmcid">PMC8043748</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zajac</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>BC</given-names></name><name name-style="western"><surname>Braun</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Green</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Morganti</surname><given-names>JM</given-names></name><name name-style="western"><surname>Estus</surname><given-names>S</given-names></name></person-group><article-title>Exogenous short chain fatty acid effects in APP/PS1 mice</article-title><source>Front Neurosci</source><year>2022</year><volume>16</volume><fpage>873549</fpage><comment>https://doi.org/10.3389/fnins.2022.873549</comment><pub-id pub-id-type="pmid">35860296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.873549</pub-id><pub-id pub-id-type="pmcid">PMC9289923</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Was&#233;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Beauchamp</surname><given-names>LC</given-names></name><name name-style="western"><surname>Vincentini</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>LeServe</surname><given-names>DS</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer&#8217;s disease mouse models</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>3872</fpage><comment>https://doi.org/10.1038/s41467-024-47683-w</comment><pub-id pub-id-type="pmid">38719797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-47683-w</pub-id><pub-id pub-id-type="pmcid">PMC11078963</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senarath</surname><given-names>RMUS</given-names></name><name name-style="western"><surname>Burton</surname><given-names>M</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>WMKT</given-names></name><name name-style="western"><surname>Jayasena</surname><given-names>V</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>WMADB</given-names></name></person-group><article-title>Role of short chain fatty acids on astrocytes and microglia in Alzheimer&#8217;s disease brain</article-title><source>Int J Food Sci Technol</source><year>2024</year><volume>59</volume><issue>9</issue><fpage>5902</fpage><lpage>11</lpage><comment>https://doi.org/10.1111/ijfs.17380</comment></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>XH</given-names></name><name name-style="western"><surname>Xie</surname><given-names>RY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SD</given-names></name><name name-style="western"><surname>Tang</surname><given-names>HD</given-names></name></person-group><article-title>Mechanisms of short-chain fatty acids derived from gut microbiota in Alzheimer&#8217;s disease</article-title><source>Aging Dis</source><year>2022</year><volume>13</volume><issue>4</issue><fpage>1252</fpage><lpage>66</lpage><comment>https://doi.org/10.14336/AD.2021.1215</comment><pub-id pub-id-type="pmid">35855330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2021.1215</pub-id><pub-id pub-id-type="pmcid">PMC9286902</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intestinal endogenous metabolites affect neuroinflammation in 5&#215;FAD mice by mediating &#8220;gut-brain&#8221; axis and the intervention with Chinese medicine</article-title><source>Alzheimer&#8217;s Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>222</fpage><comment>https://doi.org/10.1186/s13195-024-01587-5</comment><pub-id pub-id-type="pmid">39396997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01587-5</pub-id><pub-id pub-id-type="pmcid">PMC11472645</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>BS</given-names></name><name name-style="western"><surname>Inam</surname><given-names>ME</given-names></name><name name-style="western"><surname>Enduru</surname><given-names>N</given-names></name><name name-style="western"><surname>Quevedo</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>The kynurenine pathway in Alzheimer&#8217;s disease: a meta-analysis of central and peripheral levels</article-title><source>Braz J Psychiatry</source><year>2023</year><volume>45</volume><issue>3</issue><fpage>286</fpage><lpage>97</lpage><comment>https://doi.org/10.47626/1516-4446-2022-2962</comment><pub-id pub-id-type="pmid">36754068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.47626/1516-4446-2022-2962</pub-id><pub-id pub-id-type="pmcid">PMC10288481</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savonije</surname><given-names>K</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>DF</given-names></name></person-group><article-title>The role of tryptophan metabolism in Alzheimer&#8217;s disease</article-title><source>Brain Sci</source><year>2023</year><volume>13</volume><issue>2</issue><fpage>292</fpage><comment>https://doi.org/10.3390/brainsci13020292</comment><pub-id pub-id-type="pmid">36831835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci13020292</pub-id><pub-id pub-id-type="pmcid">PMC9954102</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cespedes</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>KR</given-names></name><name name-style="western"><surname>Maruff</surname><given-names>P</given-names></name><name name-style="western"><surname>Rembach</surname><given-names>A</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Trounson</surname><given-names>B</given-names></name><etal/></person-group><article-title>Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-&#946;</article-title><source>Neurobiol Dis</source><year>2022</year><volume>171</volume><fpage>105783</fpage><comment>https://doi.org/10.1016/j.nbd.2022.105783</comment><pub-id pub-id-type="pmid">35675895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2022.105783</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oktaviono</surname><given-names>YH</given-names></name><name name-style="western"><surname>Dyah Lamara</surname><given-names>A</given-names></name><name name-style="western"><surname>Saputra</surname><given-names>PBT</given-names></name><name name-style="western"><surname>Arnindita</surname><given-names>JN</given-names></name><name name-style="western"><surname>Pasahari</surname><given-names>D</given-names></name><name name-style="western"><surname>Saputra</surname><given-names>ME</given-names></name><etal/></person-group><article-title>The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: a literature review</article-title><source>Biomol Biomed</source><year>2023</year><volume>23</volume><issue>6</issue><fpage>936</fpage><lpage>48</lpage><comment>https://doi.org/10.17305/bb.2023.8893</comment><pub-id pub-id-type="pmid">37337893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bb.2023.8893</pub-id><pub-id pub-id-type="pmcid">PMC10655873</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>The role of gut microbiota-derived trimethylamine N-oxide in the pathogenesis and treatment of mild cognitive impairment</article-title><source>Int J Mol Sci</source><year>2025</year><volume>26</volume><issue>3</issue><fpage>1373</fpage><comment>https://doi.org/10.3390/ijms26031373</comment><pub-id pub-id-type="pmid">39941141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26031373</pub-id><pub-id pub-id-type="pmcid">PMC11818489</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemi</surname><given-names>L</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Liang-Feng</surname><given-names>L</given-names></name><name name-style="western"><surname>Min</surname><given-names>L</given-names></name><name name-style="western"><surname>Wenyong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tiangang</surname><given-names>L</given-names></name></person-group><article-title>Gut microbiota-derived bile acids promote gamma-secretase activity through interactions with nicastrin subunits</article-title><comment>arXiv:231007233. [Preprint]. 2023.</comment><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://arxiv.org/abs/2310.07233" ext-link-type="uri">https://arxiv.org/abs/2310.07233</ext-link>.</comment></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleishman</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>97</fpage><comment>https://doi.org/10.1038/s41392-024-01811-6</comment><pub-id pub-id-type="pmid">38664391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01811-6</pub-id><pub-id pub-id-type="pmcid">PMC11045871</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Voineskos</surname><given-names>AN</given-names></name><name name-style="western"><surname>Foussias</surname><given-names>G</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sav</surname><given-names>A</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>S</given-names></name><etal/></person-group><article-title>Using digital tools to engage patients with psychosis and their families in research: survey recruitment and completion in an early psychosis intervention program</article-title><source>JMIR Ment Health</source><year>2021</year><volume>8</volume><issue>5</issue><fpage>e24567</fpage><comment>https://doi.org/10.2196/24567</comment><pub-id pub-id-type="pmid">34057421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/24567</pub-id><pub-id pub-id-type="pmcid">PMC8204241</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Gaamouch</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HY</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Benefits of dietary polyphenols in Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>1019942</fpage><comment>https://doi.org/10.3389/fnagi.2022.1019942</comment><pub-id pub-id-type="pmid">36583187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.1019942</pub-id><pub-id pub-id-type="pmcid">PMC9792677</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicente-Zurdo</surname><given-names>D</given-names></name><name name-style="western"><surname>G&#243;mez-Mej&#237;a</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosales-Conrado</surname><given-names>N</given-names></name><name name-style="western"><surname>Le&#243;n-Gonz&#225;lez</surname><given-names>ME</given-names></name></person-group><article-title>A comprehensive analytical review of polyphenols: evaluating neuroprotection in Alzheimer&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>11</issue><fpage>5906</fpage><comment>https://doi.org/10.3390/ijms25115906</comment><pub-id pub-id-type="pmid">38892094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25115906</pub-id><pub-id pub-id-type="pmcid">PMC11173253</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Olst</surname><given-names>L</given-names></name><name name-style="western"><surname>Roks</surname><given-names>SJM</given-names></name><name name-style="western"><surname>Kamermans</surname><given-names>A</given-names></name><name name-style="western"><surname>Verhaar</surname><given-names>BJH</given-names></name><name name-style="western"><surname>van der Geest</surname><given-names>AM</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Contribution of gut microbiota to immunological changes in Alzheimer&#8217;s disease</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>683068</fpage><comment>https://doi.org/10.3389/fimmu.2021.683068</comment><pub-id pub-id-type="pmid">34135909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.683068</pub-id><pub-id pub-id-type="pmcid">PMC8200826</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">1401</journal-id><journal-id journal-id-type="pmc-domain">frontneurology</journal-id><journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504080</article-id><article-id pub-id-type="pmcid-ver">PMC12504080.1</article-id><article-id pub-id-type="pmcaid">12504080</article-id><article-id pub-id-type="pmcaiid">12504080</article-id><article-id pub-id-type="doi">10.3389/fneur.2025.1670016</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Gait characteristics and factors associated with fall risk in patients with dementia with Lewy bodies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Su</surname><given-names initials="Z">Zhou</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2834616/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="M">Mengran</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuai</surname><given-names initials="J">Jun</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yi</surname><given-names initials="T">Tingting</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2794222/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="Y">Yuechang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="C">Congcong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2746478/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="J">Junyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tian</surname><given-names initials="X">Xiaojun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University</institution>, <addr-line>Xinxiang, Henan</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>School of Education, University of Bristol</institution>, <addr-line>Bristol</addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University</institution>, <addr-line>Xinxiang, Henan</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1291308/overview" ext-link-type="uri">Nelson De Oliveira Manzanza</ext-link>, Newcastle University, United Kingdom</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3163647/overview" ext-link-type="uri">Sung-Woo Kim</ext-link>, Yonsei University Wonju College of Medicine, Republic of Korea</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3166640/overview" ext-link-type="uri">Swapno Aditya</ext-link>, University of Wollongong, Australia</p></fn><corresp id="c001">*Correspondence: Zhou Su, <email>suzhou369@163.com</email></corresp><fn fn-type="equal" id="fn0001"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480842</issue-id><elocation-id>1670016</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Su, Liu, Kuai, Yi, Zheng, Wang, Peng and Tian.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Su, Liu, Kuai, Yi, Zheng, Wang, Peng and Tian</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fneur-16-1670016.pdf"/><abstract><sec id="sec1"><title>Objective</title><p>To investigate the association between gait parameters and cognitive decline in patients with dementia with Lewy bodies (DLB) and evaluate the impact of gait abnormalities on fall risk.</p></sec><sec id="sec2"><title>Methods</title><p>This cross-sectional study enrolled 63 DLB patients. Gait analysis, including gait speed, stride length, gait symmetry, and swing time, was performed using a pressure-sensing walkway. Cognitive function was assessed using the MoCA and MMSE. Spearman correlation analysis and multiple linear regression models were used to examine the relationship between gait parameters and cognitive function. Logistic regression models, adjusted for potential confounders, were employed to analyze the effect of gait abnormalities on fall risk.</p></sec><sec id="sec3"><title>Results</title><p>Gait speed showed significant positive correlations with MoCA score (<italic toggle="yes">p</italic>&#8239;=&#8239;0.001) and stride length (<italic toggle="yes">p</italic>&#8239;=&#8239;0.003), and a positive correlation with MMSE score (<italic toggle="yes">p</italic>&#8239;=&#8239;0.005). Gait symmetry was weakly positively correlated with MMSE score (<italic toggle="yes">p</italic>&#8239;=&#8239;0.027). Patients with MoCA scores below 20 exhibited a 22% reduction in gait speed (<italic toggle="yes">p</italic>&#8239;=&#8239;0.002), shortened stride length (<italic toggle="yes">p</italic>&#8239;=&#8239;0.001), decreased gait symmetry (<italic toggle="yes">p</italic>&#8239;=&#8239;0.034), and prolonged swing time (<italic toggle="yes">p</italic>&#8239;=&#8239;0.021) compared to those with higher scores. Logistic regression analysis revealed that for each 1 standard deviation decrease in gait speed, fall risk increased by 33% (<italic toggle="yes">p</italic>&#8239;=&#8239;0.001). For each 1-cm decrease in stride length, fall risk increased by 21% (<italic toggle="yes">p</italic>&#8239;=&#8239;0.025). For each 1-unit decrease in gait symmetry, fall risk increased by 28% (<italic toggle="yes">p</italic>&#8239;=&#8239;0.007). Patients with a history of falls demonstrated more pronounced gait deterioration. Specifically, patients with more than 2 falls exhibited a 13% reduction in stride length (<italic toggle="yes">p</italic>&#8239;=&#8239;0.011) and a 12% prolongation in swing time (<italic toggle="yes">p</italic>&#8239;=&#8239;0.022).</p></sec><sec id="sec4"><title>Conclusion</title><p>Gait abnormalities are associated with cognitive decline, and reduced gait speed and gait asymmetry are markers of cognitive decline and increased fall risk in patients with established DLB.</p></sec></abstract><kwd-group><kwd>dementia with Lewy bodies</kwd><kwd>gait analysis</kwd><kwd>cognitive function</kwd><kwd>fall risk</kwd><kwd>gait parameters</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Joint construction project of Henan Medical Science and Technology Research Program [grant numbers LHGJ20240484, LHGJ20230499].</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="7"/><equation-count count="0"/><ref-count count="39"/><page-count count="8"/><word-count count="6130"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Movement Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Dementia with Lewy bodies (DLB) is the second most prevalent neurodegenerative dementia after Alzheimer&#8217;s disease (AD) (<xref rid="ref1" ref-type="bibr">1</xref>), characterized by heterogeneous clinical features encompassing cognitive decline, motor disturbances, and neuropsychiatric symptoms (<xref rid="ref2" ref-type="bibr">2</xref>), with 68% experiencing recurrent falls causing fractures (35%), hospitalization (28%), or triple mortality risk versus non-fallers (<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>). In recent years, falls among DLB patients have garnered increasing clinical attention due to their profound impact on autonomy and significant association with severe injury and mortality (<xref rid="ref5" ref-type="bibr">5</xref>).</p><p>Gait control represents a highly integrated neural network process. Concurrent pathological damage across multiple nodes of this network results in pervasive gait abnormalities (<xref rid="ref6" ref-type="bibr">6</xref>). In AD, reduced gait speed and increased stride time variability correlate with executive and memory deficits, tied to atrophy in the inferior parietal lobule and middle temporal gyrus. In Parkinson&#8217;s disease (PD), reduced stride length, gait variability, and freezing of gait reflect attentional and executive dysfunction due to basal ganglia and frontal cortex pathology. These findings highlight gait as a marker of cognitive decline in AD and PD. However, DLB-specific gait-cognition relationships, despite unique neuropathology such as <italic toggle="yes">&#945;</italic>-synuclein and beta-amyloid, remain underexplored, with preliminary evidence suggesting distinct gait patterns like high stride-length variability (<xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref8" ref-type="bibr">8</xref>). The motor-cognitive impairment in DLB fundamentally reflects widespread pathology within the cortico-basal ganglia-cerebellar circuitry, drives accelerated functional decline, and impairs postural control (<xref rid="ref9" ref-type="bibr">9&#8211;11</xref>).</p><p>Preliminary evidences suggest patients exhibit unique spatiotemporal gait patterns (e.g., high stride-length variability during dual-tasking), but quantitative validation is lacking (<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref13" ref-type="bibr">13</xref>). Crucially, no studies have concurrently modeled gait parameters, cognitive trajectories, and fall risk in DLB using instrumented analysis&#8212;a gap limiting early intervention. To address these gaps, we employed GAITRite<sup>&#174;</sup> instrumented walkway analysis&#8212;a gold standard for quantifying spatiotemporal parameters (speed, stride length, symmetry)&#8212;paired with standardized cognitive assessment (MoCA, MMSE) and fall tracking. The objective of this study was to investigate the association between gait parameters and cognitive decline in patients with DLB and to evaluate the impact of gait abnormalities on fall risk. This approach overcomes subjectivity in clinical scales while capturing multidimensional gait-cognition interactions. While our study focuses on patients with confirmed DLB, gait analysis may hold potential for early detection and intervention in future studies involving prodromal DLB populations. In this study, we hypothesized that in DLB patients, specific gait parameters would be significantly associated with cognitive decline, as measured by MoCA and MMSE scores. These gait abnormalities would independently predict increased fall risk, reflecting underlying motor-cognitive network dysfunction.</p></sec><sec sec-type="methods" id="sec6"><label>2</label><title>Methods</title><sec id="sec7"><label>2.1</label><title>Subject characteristics</title><p>This cross-sectional observational study enrolled 63 patients diagnosed with DLB at the Department of Neurology outpatient and inpatient units of our hospital between January 2020 and June 2024. The mean age of the patients was 62.8&#8239;&#177;&#8239;6.5&#8239;years. Among the patients, 30 (47.6%) were male. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA, mean score 19.6&#8239;&#177;&#8239;4.3) and Mini-Mental State Examination (MMSE, mean score 22.8&#8239;&#177;&#8239;3.7). Demographic and clinical characteristics of the patients are summarized in <xref rid="tab1" ref-type="table">Table 1</xref>. DLB patients were diagnosed according to the fourth criteria for the diagnosis and management of dementia with Lewy bodies (<xref rid="ref2" ref-type="bibr">2</xref>). These patients were initially present with at least two core clinical features of DLB (fluctuating cognition, visual hallucinations, parkinsonism, and/or rapid eye movement sleep behavior disorder) or one core clinical feature with at least one indicative biomarker including reduced dopamine transporter uptake in the basal ganglia demonstrated by single-photon emission computed tomography (SPECT) or positron emission tomography-computed tomography (PET), abnormal (low uptake) 123-Iodine-MIBG myocardial scintigraphy, and RBD screening questionnaire (RBD-SQ) and/or polysomnographic confirmation of RBD. The enrolled patients showed relative preservation of medial temporal lobe structures on MRI and/or CT. All clinical diagnoses of dementia were confirmed by consensus agreement of at least two experienced neurologists, following a case review according to the protocol. Patients meeting any of the following exclusion criteria were excluded from this study: (1) patients with other severe neurodegenerative disorders, such as Alzheimer&#8217;s disease, Parkinson&#8217;s disease, or Huntington&#8217;s disease; (2) patients with severe motor impairment precluding independent walking or participation in gait analysis; (3) patients with a history of stroke, major surgery, or other serious illness significantly affecting gait within the past 6&#8239;months; (4) patients with profound cognitive impairment rendering them unable to cooperate with cognitive testing; (5) patients or their legal representatives refusing to participate or withdrawing informed consent. This study was approved by the Medical Ethics Committee of our hospital (Approval No.: [EC-024-523]). Informed consent was obtained from all participants or their legal guardians in accordance with the ethical principles of the Helsinki Declaration.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the DLB participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th align="center" valign="top" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> =&#8239;63)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">62.8&#8239;&#177;&#8239;6.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (male <italic toggle="yes">n</italic>, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (47.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Disease duration, years</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5&#8239;&#177;&#8239;1.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hypertension, yes (<italic toggle="yes">n</italic>, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (33.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes mellitus, yes (<italic toggle="yes">n</italic>, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (20.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Heart disease, yes (<italic toggle="yes">n</italic>, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (15.9%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Use of anti-parkinsonism medication, yes (<italic toggle="yes">n</italic>, %)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (46.0%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">History of falls (past 6&#8239;months)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (68.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Recurrent falls (&#8805;2 falls)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (23.8%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MoCA score</td><td align="center" valign="middle" rowspan="1" colspan="1">19.6&#8239;&#177;&#8239;4.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMSE score</td><td align="center" valign="middle" rowspan="1" colspan="1">22.8&#8239;&#177;&#8239;3.7</td></tr></tbody></table><table-wrap-foot><p>DLB, Dementia with Lewy bodies; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment.</p></table-wrap-foot></table-wrap></sec><sec id="sec8"><label>2.2</label><title>Data collection of cognitive function, gait and fall risk assessment</title><p>Cognitive function was assessed by trained neuropsychological assessors using the Montreal Cognitive Assessment (MoCA) (<xref rid="ref14" ref-type="bibr">14</xref>) and Mini-Mental State Examination (MMSE) (<xref rid="ref15" ref-type="bibr">15</xref>).</p><p>Gait assessment was performed using the GAITRite<sup>&#174;</sup> system, a pressure-sensitive walkway, to precisely record gait parameters (<xref rid="ref16" ref-type="bibr">16</xref>). Patients wore comfortable shoes and walked an 8-meter distance on the walkway, completing three round trips. The average value from the three trials was used for analysis. The system automatically recorded the following gait parameters: Gait Speed (m/s): Reflecting overall motor function and serving as a key indicator of mobility (<xref rid="ref17" ref-type="bibr">17</xref>). Stride Length (cm): The distance covered in a single stride, indicative of gait regularity and step stability (<xref rid="ref18" ref-type="bibr">18</xref>). Gait Symmetry: Quantified using the Symmetry Index (SI), calculated based on the difference in step length between the left and right feet. A value closer to 1 indicates better symmetry (<xref rid="ref19" ref-type="bibr">19</xref>). Swing Time (s): The duration of the swing phase for each step, reflecting gait fluidity and balance control (<xref rid="ref20" ref-type="bibr">20</xref>).</p><p>Fall Risk Assessment: Fall History Questionnaire: Patients or their caregivers retrospectively reported fall incidents occurring within the past 6&#8239;months. Details recorded included frequency, timing, circumstances, and severity of falls. Based on the number of falls, patients were categorized into: &#8220;No Falls&#8221; (0 falls), &#8220;Occasional Falls&#8221; (1&#8211;2 falls), and &#8220;Recurrent Falls&#8221; (&#8805;3 falls). Tinetti Balance and Gait Assessment: This standardized scale, with a maximum total score of 28 points, comprises two subsections: Gait (score range: 0&#8211;12) and Balance (score range: 0&#8211;16). Lower total scores indicate a higher risk of falls.</p></sec><sec id="sec9"><label>2.3</label><title>Statistical analyses</title><p>All statistical analyses and data management were performed using SPSS 26.0 for Mac (IBM Corporation, Armonk, NY, United States). Continuous variables were expressed as mean &#177; standard deviation (SD) when normally distributed or as median (interquartile range) for non-normally distributed data. Categorical variables were summarized as frequencies (n) with percentages (%) and analyzed using <italic toggle="yes">&#967;</italic><sup>2</sup> test as appropriate. Spearman correlation analysis was performed to examine the association between gait parameters and cognitive function scores. Multivariable logistic regression analysis was employed to evaluate the impact of gait abnormalities on fall risk, adjusting for potential confounding factors. One-way analysis of variance (ANOVA) was performed to comparisons among groups involving normally distributed data. <italic toggle="yes">Post hoc</italic> pairwise comparisons were conducted using either Tukey&#8217;s Honestly Significant Difference (HSD) test or the Bonferroni correction for multiple comparisons. For comparisons among groups involving non-normally distributed data, the Kruskal&#8211;Wallis <italic toggle="yes">H</italic> test was used. Post-hoc pairwise comparisons were subsequently performed using Dunn&#8217;s test with appropriate adjustment for multiple comparisons. All <italic toggle="yes">p</italic>-values reported are two-tailed, and <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05 was considered statistically significant.</p><p>To ensure our study was adequately powered to detect clinically meaningful associations, <italic toggle="yes">a priori</italic> power calculations were performed based on expected effect sizes for key outcomes. For the multivariable logistic regression model (predicting fall risk), with an observed odds ratio of 1.33 for gait speed and a baseline fall prevalence of 68.3% (based on our data, 43/63 (68.3%) of participants had a history of falls), the analysis achieved 87% power (at <italic toggle="yes">&#945;</italic>&#8239;=&#8239;0.05), well above the conventional 80% threshold. For the one-way ANOVA (comparing gait parameters across fall-frequency groups), with an effect size of <italic toggle="yes">f</italic>&#8239;=&#8239;0.41, the analysis achieved 93% power at &#945;&#8239;=&#8239;0.05. These results demonstrate that our sample size (<italic toggle="yes">n</italic>&#8239;=&#8239;63) was sufficient to detect the clinically relevant effects.</p><p>The associations between gait parameters and cognitive function (MoCA/MMSE scores) were first explored using unadjusted Spearman rank correlation analysis. To control for potential confounders and to ensure methodological consistency with the fall risk analysis, these associations were further assessed using multiple linear regression models, adjusting for the same covariates employed in the logistic regression models (i.e., age, sex, DLB disease duration). The variance inflation factor (VIF) was examined for all models to confirm the absence of multicollinearity (all VIF&#8239;&lt;&#8239;2.0).</p></sec></sec><sec sec-type="results" id="sec10"><label>3</label><title>Results</title><p>Gait parameters were analyzed for 63 DLB patients. Mean gait parameters were as follows: gait speed, 0.92&#8239;&#177;&#8239;0.18&#8239;m/s; stride length, 56.7&#8239;&#177;&#8239;7.5&#8239;cm; gait symmetry index, 0.88&#8239;&#177;&#8239;0.09; and swing time, 1.02&#8239;&#177;&#8239;0.15&#8239;s. Detailed gait characteristics of the patients are presented in <xref rid="tab2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Gait characteristics of the DLB participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th align="center" valign="top" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> =&#8239;63)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed, m/s</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92&#8239;&#177;&#8239;0.18</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Stride length, cm</td><td align="center" valign="middle" rowspan="1" colspan="1">56.7&#8239;&#177;&#8239;7.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait symmetry index</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88&#8239;&#177;&#8239;0.09</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Swing time, s</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02&#8239;&#177;&#8239;0.15</td></tr></tbody></table><table-wrap-foot><p>DLB, Dementia with Lewy bodies.</p></table-wrap-foot></table-wrap><p>Association analysis revealed significant associations between specific gait parameters and cognitive function scores (<xref rid="tab3" ref-type="table">Table 3</xref>). Gait speed demonstrated significant positive correlations with both MoCA score (<italic toggle="yes">r</italic>&#8239;=&#8239;0.48, <italic toggle="yes">p</italic>&#8239;=&#8239;0.001) and MMSE score (<italic toggle="yes">r</italic>&#8239;=&#8239;0.35, <italic toggle="yes">p</italic>&#8239;=&#8239;0.005). Stride length also showed significant positive correlations with MoCA score (<italic toggle="yes">r</italic>&#8239;=&#8239;0.42, <italic toggle="yes">p</italic>&#8239;=&#8239;0.003) and MMSE score (<italic toggle="yes">r</italic>&#8239;=&#8239;0.33, <italic toggle="yes">p</italic>&#8239;=&#8239;0.017). A weak positive correlation was observed between gait symmetry and MMSE score (<italic toggle="yes">r</italic>&#8239;=&#8239;0.30, <italic toggle="yes">p</italic>&#8239;=&#8239;0.027). After adjusting for age, sex, and disease duration, multiple linear regression models confirmed that slower gait speed and shorter stride length remained significantly associated with lower MoCA (<italic toggle="yes">&#946;</italic> =&#8239;0.43, 95% CI: 0.15 to 0.71, <italic toggle="yes">p</italic> =&#8239;0.003; <italic toggle="yes">&#946;</italic> =&#8239;0.38, 95% CI: 0.10 to 0.66, <italic toggle="yes">p</italic> =&#8239;0.009) and MMSE (<italic toggle="yes">&#946;</italic> =&#8239;0.31, 95% CI: 0.03 to 0.59, <italic toggle="yes">p</italic> =&#8239;0.031; <italic toggle="yes">&#946;</italic> =&#8239;0.28, 95% CI: 0.00 to 0.56, <italic toggle="yes">p</italic> =&#8239;0.049) scores. The association between gait symmetry and MMSE score was attenuated but trended toward significance (<italic toggle="yes">&#946;</italic> =&#8239;0.25, 95% CI: &#8722;0.03 to 0.53, <italic toggle="yes">p</italic> =&#8239;0.082).</p><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Association between gait parameters and cognitive function scores in DLB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Gait parameter</th><th align="center" valign="top" colspan="2" rowspan="1">Unadjusted analysis</th><th align="center" valign="top" colspan="3" rowspan="1">Adjusted analysis (linear regression)</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Spearman&#8217;s <italic toggle="yes">&#961;</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">&#946;</italic> (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th><th align="center" valign="top" rowspan="1" colspan="1">Adjusted <italic toggle="yes">R</italic><sup>2</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" colspan="6" rowspan="1">MoCA score</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed (m/s)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 (0.15 to 0.71)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Stride length (cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38 (0.10 to 0.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait symmetry index</td><td align="center" valign="middle" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18 (&#8722;0.10 to 0.46)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.205</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Swing time (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.073</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.15 (&#8722;0.43 to 0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.291</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="middle" colspan="6" rowspan="1">MMSE score</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed (m/s)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31 (0.03 to 0.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Stride length (cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 (0.00 to 0.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait symmetry index</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25 (&#8722;0.03 to 0.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Swing time (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.12 (&#8722;0.40 to 0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.391</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr></tbody></table><table-wrap-foot><p>DLB, Dementia with Lewy bodies; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; <italic toggle="yes">P</italic>&#8239;&lt;&#8239;0.05 significant difference.</p><p>Adjusted for age, sex, DLB disease duration; &#946; represents the change in cognitive score per unit increase in the gait parameter; CI, confidence interval.</p></table-wrap-foot></table-wrap><p>Patients exhibiting slower gait speed had significantly worse cognitive function. Notably, those with MoCA scores below 20 displayed pronounced gait impairments compared to patients with higher scores (<xref rid="tab4" ref-type="table">Table 4</xref>). This group exhibited a mean 22% reduction in gait speed (<italic toggle="yes">p</italic>&#8239;=&#8239;0.002), significantly shortened stride length (<italic toggle="yes">p</italic>&#8239;=&#8239;0.001), decreased gait symmetry (<italic toggle="yes">p</italic>&#8239;=&#8239;0.034), and prolonged swing time (<italic toggle="yes">p</italic>&#8239;=&#8239;0.021).</p><table-wrap position="float" id="tab4" orientation="portrait"><label>Table 4</label><caption><p>Comparison of gait parameters between DLB patients grouped by MoCA score.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Gait parameter</th><th align="center" valign="top" rowspan="1" colspan="1">MoCA &#8805;20 (<italic toggle="yes">n</italic> =&#8239;32)</th><th align="center" valign="top" rowspan="1" colspan="1">MoCA &lt;20 (<italic toggle="yes">n</italic> =&#8239;31)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed (m/s)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95&#8239;&#177;&#8239;0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74&#8239;&#177;&#8239;0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">3.291</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Stride length (cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">59.8&#8239;&#177;&#8239;6.7</td><td align="center" valign="middle" rowspan="1" colspan="1">47.5&#8239;&#177;&#8239;5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">4.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gait symmetry index</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91&#8239;&#177;&#8239;0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78&#8239;&#177;&#8239;0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">2.152</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Swing time (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96&#8239;&#177;&#8239;0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10&#8239;&#177;&#8239;0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">2.323</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td></tr></tbody></table><table-wrap-foot><p>DLB, Dementia with Lewy bodies; MoCA, Montreal Cognitive Assessment; <italic toggle="yes">P</italic>&#8239;&lt;&#8239;0.05 significant difference.</p></table-wrap-foot></table-wrap><p>Multivariable logistic regression analysis, adjusted for age, sex, DLB disease duration, and cognitive scores, identified specific gait abnormalities as significant independent predictors of increased fall risk (<xref rid="fig1" ref-type="fig">Figure 1</xref>). For each 1-standard deviation (SD) decrease in gait speed, fall risk increased by 33% (OR&#8239;=&#8239;1.33, 95% CI: 1.12&#8211;1.59, <italic toggle="yes">p</italic>&#8239;=&#8239;0.001). Each 1-cm decrease in stride length was associated with a 21% increase in fall risk (OR&#8239;=&#8239;1.21, 95% CI: 1.03&#8211;1.44, <italic toggle="yes">p</italic>&#8239;=&#8239;0.025). Furthermore, each 1-unit decrease in gait symmetry corresponded to a 28% increase in fall risk (OR&#8239;=&#8239;1.28, 95% CI: 1.07&#8211;1.49, <italic toggle="yes">p</italic>&#8239;=&#8239;0.007).</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Logistic regression analysis of fall risk predictors in DLB patients. Multivariable logistic regression analysis, adjusted for age, sex, DLB disease duration, and cognitive scores, identified specific gait abnormalities as significant independent predictors of increased fall risk.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fneur-16-1670016-g001.jpg"><alt-text content-type="machine-generated">Forest plot showing odds ratios and confidence intervals for different gait parameters: swing time (1.14, 0.94&#8211;1.31, p=0.062), gait symmetry index (1.28, 1.07&#8211;1.49, p=0.007), stride length (1.21, 1.03&#8211;1.44, p=0.025), and gait speed (1.33, 1.12&#8211;1.59, p=0.001). Horizontal lines represent confidence intervals across a scale from 0.8 to 1.8.</alt-text></graphic></fig><p>Analysis of fall frequency confirmed that gait deterioration was more severe in patients with a history of falls. Specifically, patients experiencing recurrent falls (&#8805; 2 falls) showed significant gait abnormalities compared to those with no falls (<xref rid="tab5" ref-type="table">Tables 5</xref>, <xref rid="tab6" ref-type="table">6</xref>): a 13% reduction in stride length (<italic toggle="yes">p</italic>&#8239;=&#8239;0.011) and a 12% prolongation in swing time (<italic toggle="yes">p</italic>&#8239;=&#8239;0.022).</p><table-wrap position="float" id="tab5" orientation="portrait"><label>Table 5</label><caption><p>Gait parameter changes by fall frequency groups in DLB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Fall frequency</th><th align="center" valign="top" rowspan="1" colspan="1">Gait speed (m/s)</th><th align="center" valign="top" rowspan="1" colspan="1">Stride length (cm)</th><th align="center" valign="top" rowspan="1" colspan="1">Swing time (s)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">No falls</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96&#8239;&#177;&#8239;0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">58.5&#8239;&#177;&#8239;6.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98&#8239;&#177;&#8239;0.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occasional falls<break/>(1&#8211;2 falls)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90&#8239;&#177;&#8239;0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">55.3&#8239;&#177;&#8239;7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05&#8239;&#177;&#8239;0.16</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Recurrent falls<break/>(&#8805;3 falls)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84&#8239;&#177;&#8239;0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">51.3&#8239;&#177;&#8239;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10&#8239;&#177;&#8239;0.18</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANOVA</td><td align="center" valign="middle" rowspan="1" colspan="1">4.219</td><td align="center" valign="middle" rowspan="1" colspan="1">5.132</td><td align="center" valign="middle" rowspan="1" colspan="1">4.357</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">P-</italic>value</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td></tr></tbody></table><table-wrap-foot><p>DLB, Dementia with Lewy bodies; <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05 significant difference.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="tab6" orientation="portrait"><label>Table 6</label><caption><p><italic toggle="yes">Post hoc</italic> pairwise comparisons of gait parameters by fall frequency groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Gait parameter</th><th align="left" valign="top" rowspan="1" colspan="1">Comparison</th><th align="center" valign="top" rowspan="1" colspan="1">Tukey <italic toggle="yes">q</italic>-statistic</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th><th align="center" valign="top" rowspan="1" colspan="1">Partial <italic toggle="yes">&#951;</italic><sup>2</sup></th><th align="center" valign="top" rowspan="1" colspan="1">Cohen&#8217;s <italic toggle="yes">d</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3" colspan="1">Gait speed (m/s)</td><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Occasional falls</td><td align="center" valign="middle" rowspan="1" colspan="1">3.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td><td align="center" valign="top" rowspan="1" colspan="1">0.047</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">4.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="top" rowspan="1" colspan="1">0.091</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occasional vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">3.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="top" rowspan="1" colspan="1">0.069</td><td align="center" valign="top" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">Stride length (cm)</td><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Occasional falls</td><td align="center" valign="middle" rowspan="1" colspan="1">4.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="top" rowspan="1" colspan="1">0.086</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">5.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="top" rowspan="1" colspan="1">0.134</td><td align="center" valign="top" rowspan="1" colspan="1">1.24</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occasional vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">3.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="top" rowspan="1" colspan="1">0.081</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">Swing time (s)</td><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Occasional falls</td><td align="center" valign="middle" rowspan="1" colspan="1">3.98</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">4.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.095</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occasional vs. Recurrent falls</td><td align="center" valign="middle" rowspan="1" colspan="1">3.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">0.80</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">P</italic>&#8239;&lt;&#8239;0.05 significant difference.</p></table-wrap-foot></table-wrap><p>As shown in <xref rid="tab7" ref-type="table">Table 7</xref>, the correlation between gait speed and MoCA score was strong (Cohen&#8217;s <italic toggle="yes">d</italic> =&#8239;1.12). One-way ANOVA comparing gait parameters across fall-frequency groups (no falls, 1&#8211;2 falls, &#8805;3 falls) revealed significant differences in stride length (<italic toggle="yes">F</italic> =&#8239;5.132, <italic toggle="yes">p</italic> =&#8239;0.014, partial <italic toggle="yes">&#951;</italic><sup>2</sup> =&#8239;0.146), indicating a large effect size. <italic toggle="yes">Post hoc</italic> Tukey&#8217;s HSD tests showed that patients with recurrent falls (&#8805;3) had a 13% reduction in stride length compared to the no-fall group (<italic toggle="yes">p</italic> =&#8239;0.011, Cohen&#8217;s <italic toggle="yes">d</italic> =&#8239;1.24) and a 12% prolongation in swing time (<italic toggle="yes">p</italic> =&#8239;0.022, Cohen&#8217;s <italic toggle="yes">d</italic> =&#8239;0.98). Multivariable logistic regression identified gait speed (OR&#8239;=&#8239;1.33 per 1-SD decrease, <italic toggle="yes">p</italic> =&#8239;0.001) and stride length (OR&#8239;=&#8239;1.21 per 1-cm decrease, <italic toggle="yes">p</italic> =&#8239;0.025) as significant predictors of fall risk.</p><table-wrap position="float" id="tab7" orientation="portrait"><label>Table 7</label><caption><p>Effect sizes for key study findings.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Analysis method</th><th align="left" valign="top" rowspan="1" colspan="1">Comparison/predictor</th><th align="center" valign="top" rowspan="1" colspan="1">Statistical result</th><th align="center" valign="top" rowspan="1" colspan="1">Effect size metric</th><th align="center" valign="top" rowspan="1" colspan="1">Effect size value</th><th align="center" valign="top" rowspan="1" colspan="1">Interpretation</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Spearman correlation</td><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed vs. MoCA score</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">r</italic> =&#8239;0.48, <italic toggle="yes">p</italic> =&#8239;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">Cohen&#8217;s <italic toggle="yes">d</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">d</italic> =&#8239;1.12</td><td align="center" valign="middle" rowspan="1" colspan="1">Large</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Spearman correlation</td><td align="left" valign="middle" rowspan="1" colspan="1">Stride length vs. MoCA score</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">r</italic> =&#8239;0.42, <italic toggle="yes">p</italic> =&#8239;0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">Cohen&#8217;s <italic toggle="yes">d</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">d</italic> =&#8239;0.93</td><td align="center" valign="middle" rowspan="1" colspan="1">Large</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Logistic regression</td><td align="left" valign="middle" rowspan="1" colspan="1">Gait speed (per 1 SD &#8595;)</td><td align="center" valign="middle" rowspan="1" colspan="1">OR&#8239;=&#8239;1.33, <italic toggle="yes">p</italic> =&#8239;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">Odds ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33</td><td align="center" valign="middle" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Logistic regression</td><td align="left" valign="middle" rowspan="1" colspan="1">Stride Length (per 1&#8239;cm &#8595;)</td><td align="center" valign="middle" rowspan="1" colspan="1">OR&#8239;=&#8239;1.21, <italic toggle="yes">p</italic> =&#8239;0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">Odds ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21</td><td align="center" valign="middle" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">One-way ANOVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Stride length (between groups)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">F</italic> =&#8239;5.132, <italic toggle="yes">p</italic> =&#8239;0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">Partial eta squared (&#951;<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">&#951;</italic><sup>2</sup> =&#8239;0.146</td><td align="center" valign="middle" rowspan="1" colspan="1">Large</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Post hoc</italic> (Tukey)</td><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. &#8805;3 falls (stride length)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic> =&#8239;0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">Cohen&#8217;s <italic toggle="yes">d</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">d</italic> =&#8239;1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">Large</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Post hoc</italic> (Tukey)</td><td align="left" valign="middle" rowspan="1" colspan="1">No falls vs. &#8805;3 falls (swing time)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic> =&#8239;0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">Cohen&#8217;s <italic toggle="yes">d</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">d&#8239;=&#8239;0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">Large</td></tr></tbody></table><table-wrap-foot><p>Effect size interpretation: Cohen&#8217;s <italic toggle="yes">d</italic>: 0.2 (small), 0.5 (medium), 0.8 (large); Partial <italic toggle="yes">&#951;</italic><sup>2</sup>: 0.01 (small), 0.06 (medium), 0.14 (large). Odds Ratio (OR)&#8239;&gt;&#8239;1 indicates increased risk; OR&#8239;=&#8239;1.33 corresponds to a 33% increased risk.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec11"><label>4</label><title>Discussion</title><p>Our study hypothesized that specific gait parameters in patients with DLB would exhibit a significant association with cognitive decline and predict an increased risk of falls, thereby reflecting dysfunction within the motor-cognitive network. The findings of our study largely supported this hypothesis. Reduced gait speed and stride length strongly correlated with lower MoCA scores. Critically, gait abnormalities independently predicted fall risk: each 1-SD decrease in speed increased falls by 33%, while a 1-cm stride reduction raised risk by 21%. An association emerged between fall frequency and gait decline: recurrent fallers showed 13% shorter stride length and 12% longer swing time versus non-fallers. These findings position gait analysis as a dual biomarker for cognitive and motor risk stratification in DLB.</p><p>The association between reduced gait velocity and executive dysfunction identified in this study aligns with recent findings in AD (<xref rid="ref21" ref-type="bibr">21</xref>). The study has demonstrated that slower gait velocity correlates significantly with atrophy in the inferior parietal lobule, middle temporal gyrus, and insular cortex during the AD prodromal stage (<xref rid="ref21" ref-type="bibr">21</xref>, <xref rid="ref22" ref-type="bibr">22</xref>). This relationship may be particularly pronounced in DLB due to its characteristic dual pathological burden of both <italic toggle="yes">&#945;</italic>-synuclein and beta-amyloid (<xref rid="ref10" ref-type="bibr">10</xref>). Aberrant &#945;-synuclein deposition not only disrupts motor regulation in the basal ganglia but also spreads via limbic pathways to the prefrontal cortex, impairing executive functions. This dual pathology likely underlies the stronger gait-cognition association observed in DLB patients compared to those with pure AD or PD (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>).</p><p>Gait control represents a highly integrated neural network process (<xref rid="ref9" ref-type="bibr">9</xref>). Reduced gait symmetry may directly reflect asymmetric dopaminergic degeneration within the basal ganglia&#8212;a pathological feature similar to PD but more extensive in DLB (<xref rid="ref23" ref-type="bibr">23</xref>). Recent neuroimaging evidence reveals significantly weakened frontal-basal ganglia functional connectivity during walking tasks in DLB patients, providing direct support for a shared neural substrate underlying both executive dysfunction and gait slowing (<xref rid="ref24" ref-type="bibr">24</xref>).</p><p>This study found that DLB patients with MoCA scores &lt;20 exhibited a 22% reduction in gait velocity&#8212;a significantly greater decline than the approximately 15% observed in prodromal AD patients (<xref rid="ref25" ref-type="bibr">25</xref>). This disparity may stem from DLB&#8217;s characteristic widespread neurotransmitter deficits (involving dopamine, acetylcholine, and other systems), driving simultaneous rapid deterioration of motor and cognitive functions (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>). Gait parameters, particularly stride time variability during dual-task walking, may serve as sensitive indicators for monitoring cognitive decline in DLB (<xref rid="ref26" ref-type="bibr">26</xref>).</p><p>Fall risk in DLB arises from multilevel neurological dysfunction. Concurrent damage to these structures (such as basal ganglia, brainstem reticular formations, cerebellum, and prefrontal cortex.) impairs postural adjustments (<xref rid="ref3" ref-type="bibr">3&#8211;5</xref>). In our study, multivariate logistic regression analysis demonstrated that gait speed, step length, and gait symmetry index were significant predictors of fall risk. Nevertheless, further cross-validation or external validation is required to assess the generalizability of the predictive performance of these gait parameters. Notably, reduced stride length emerged as an independent fall risk factor&#8212;a seemingly paradoxical finding that reflects compensatory adaptation (<xref rid="ref27" ref-type="bibr">27</xref>). When sensing impaired balance, patients instinctively adopt a cautious gait strategy: shortening steps, slowing speed, and increasing double-limb support time (<xref rid="ref5" ref-type="bibr">5</xref>). However, this fear-driven adaptation disrupts natural gait rhythm, further impairing coordination (<xref rid="ref28" ref-type="bibr">28</xref>). This fundamentally differs from PD&#8217;s festinating gait, where primary motor control failure occurs (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref29" ref-type="bibr">29</xref>).</p><p>The association between gait parameters and cognitive function suggests that gait abnormalities in DLB may reflect underlying disruptions in the motor-cognitive network. This relationship is clinically significant in understanding fall risk, as cognitive impairments can exacerbate gait disturbances, such as reduced gait speed and shortened stride length, thereby increasing the likelihood of postural instability and falls (<xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref31" ref-type="bibr">31</xref>). Moreover, after adjusting for multiple confounding variables, the same gait features&#8212;particularly decreased speed and stride length&#8212;were found to be independently linked to both poorer cognitive performance and a higher risk of falls. These findings suggest that a shared neuropathophysiological mechanism may exist, potentially involving dysfunction of the corticostriatal pathway, which manifests as gait deterioration. Such gait changes not only serve as indicators of brain health but also directly contribute to adverse functional outcomes, including falls. Logistic regression analyses further confirmed that gait speed, stride length, and gait symmetry independently predict fall risk, highlighting their clinical relevance. In summary, these findings support the use of gait parameters as potential biomarkers for cognitive decline and fall risk in DLB, reflecting the disease&#8217;s broader pathological processes and underscoring their utility in clinical risk stratification and intervention planning.</p><p>Gait deterioration and falls form a self-reinforcing cycle. Patients with prior falls exhibited a 13% reduction in stride length and 12% prolongation of swing time, with greater severity following recurrent falls. This represents the neuromotor manifestation of post-fall syndrome: diminished activity confidence, disuse muscle atrophy, and vestibular dysfunction collectively worsen gait control (<xref rid="ref27" ref-type="bibr">27</xref>). DLB patients&#8217; impaired visuospatial function and hallucinations markedly reduce environmental hazard awareness, increasing fall risk in complex settings (<xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref31" ref-type="bibr">31</xref>). Compared to AD, gait slowing emerges earlier in DLB and correlates more strongly with executive dysfunction (<xref rid="ref32" ref-type="bibr">32</xref>, <xref rid="ref33" ref-type="bibr">33</xref>). Unlike PD&#8217;s characteristic &#8220;freezing of gait,&#8221; DLB typically presents with global gait parameter deterioration (<xref rid="ref34" ref-type="bibr">34&#8211;36</xref>). Temporally, DLB exhibits a biphasic deterioration trajectory in gait-cognition relationships: gait slowing appears early alongside attentional/executive decline; subsequently, gait symmetry and variability worsen with progressive basal ganglia and posterior cortical involvement (<xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref38" ref-type="bibr">38</xref>). This pattern suggests gait metrics could serve as DLB staging biomarkers.</p><p>Although DLB shares pathological features with both PD and AD, the evidence on whether it exhibits a distinct gait pattern remains conflicting, limiting the utility of gait analysis for differential diagnosis. While some studies find no significant differences in spatiotemporal parameters such as reduced velocity and decreased stride length between DLB and AD (<xref rid="ref32" ref-type="bibr">32</xref>), recent research suggests DLB exhibits greater gait variability, asymmetry, and postural control deficits, reflecting executive and visuospatial impairments (<xref rid="ref33" ref-type="bibr">33</xref>). Compared to PD dementia, DLB gait overlaps significantly, with heightened asymmetry distinguishing it from AD but not reliably from PD (<xref rid="ref39" ref-type="bibr">39</xref>). Future studies combining gait analysis with neuroimaging and biomarkers are needed to clarify DLB-specific gait signatures.</p><p>This present study has several limitations. First, its cross-sectional design inherently precludes causal inferences regarding the temporal sequence between gait deterioration and cognitive decline. Second, a modest sample size from a single center limits generalizability to broader DLB populations. Third, the absence of neuroimaging correlates hinders direct verification of neural circuit disruptions underlying gait-cognitive associations. Fourth, inadequate control for medication effects&#8212;particularly acute dopaminergic impacts of anti-Parkinsonian agents&#8212;may confound long-term gait trajectory analyses. Future studies should implement longitudinal cohort designs with biannual gait-cognitive assessments over &#8805;3&#8239;years to establish temporal dynamics, integrate multimodal neuroimaging (e.g., DTI for white matter integrity; resting-state fMRI for network connectivity) to map neural substrates of gait-cognition coupling, and deploy wearable inertial sensors for continuous home-based monitoring, capturing real-world fall risk factors during daily activities. Fifth, our primary analysis used absolute measures for gait symmetry and swing time without normalizing for individual step length or gait cycle duration, respectively. This may limit the clinical interpretability of these parameters, as the significance of absolute differences in step length or swing time varies with overall gait characteristics. Future research should prioritize longitudinal studies incorporating normalized gait metrics, such as step length&#8211;adjusted gait symmetry and swing time as a percentage of the gait cycle, to account for inter-individual variability in gait characteristics. Finally, incorporating dual-task walking paradigms could further elucidate cognitive-motor interactions in DLB, enhancing the sensitivity of gait as a biomarker for cognitive decline and fall risk.</p></sec><sec sec-type="conclusions" id="sec12"><label>5</label><title>Conclusion</title><p>Gait parameters, especially speed, stride length, and symmetry, serve as sensitive biomarkers for cognitive decline and fall risk in DLB. Their disruption reflects diffuse pathology across motor-cognitive networks. Clinical implementation of gait assessment can stratify risk and guide targeted interventions. Future research must validate these metrics in longitudinal cohorts and integrate them with digital health technologies for proactive DLB management.</p></sec></body><back><ack><p>The authors are grateful to all those who participated in this study.</p></ack><sec sec-type="data-availability" id="sec13"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="sec14"><title>Ethics statement</title><p>The studies involving humans were approved by Medical Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec15"><title>Author contributions</title><p>ZS: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. ML: Data curation, Formal analysis, Methodology, Software, Writing &#8211; original draft, Writing &#8211; review &amp; editing. JK: Data curation, Formal analysis, Methodology, Software, Writing &#8211; original draft. TY: Data curation, Investigation, Writing &#8211; original draft. YZ: Data curation, Investigation, Writing &#8211; original draft. CW: Data curation, Investigation, Writing &#8211; original draft. JP: Data curation, Funding acquisition, Investigation, Writing &#8211; original draft. XT: Supervision, Validation, Visualization, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec17"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec18"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec19"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>JP</given-names></name><name name-style="western"><surname>McKeith</surname><given-names>IG</given-names></name><name name-style="western"><surname>Burn</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>D</given-names></name><name name-style="western"><surname>Bamford</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>New evidence on the management of Lewy body dementia</article-title>. <source>Lancet Neurol</source>. (<year>2019</year>) <volume>19</volume>:<fpage>157</fpage>&#8211;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30153-X</pub-id><pub-id pub-id-type="pmid">31519472</pub-id><pub-id pub-id-type="pmcid">PMC7017451</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKeith</surname><given-names>IG</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JP</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium</article-title>. <source>Neurology</source>. (<year>2017</year>) <volume>89</volume>:<fpage>88</fpage>&#8211;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004058</pub-id>, PMID: <pub-id pub-id-type="pmid">28592453</pub-id><pub-id pub-id-type="pmcid">PMC5496518</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allan</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>CG</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>EN</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>RA</given-names></name></person-group>. <article-title>Incidence and prediction of falls in dementia: a prospective study in older people</article-title>. <source>PLoS One</source>. (<year>2009</year>) <volume>4</volume>:<fpage>e5521</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0005521</pub-id>, PMID: <pub-id pub-id-type="pmid">19436724</pub-id><pub-id pub-id-type="pmcid">PMC2677107</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joza</surname><given-names>S</given-names></name><name name-style="western"><surname>Camicioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Ba</surname><given-names>F</given-names></name></person-group>. <article-title>Falls in synucleinopathies</article-title>. <source>Can J Neurol Sci</source>. (<year>2020</year>) <volume>47</volume>:<fpage>30</fpage>&#8211;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1017/cjn.2019.287</pub-id>, PMID: <pub-id pub-id-type="pmid">31452470</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirono</surname><given-names>N</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Kazui</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanimukai</surname><given-names>S</given-names></name><name name-style="western"><surname>Hanihara</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fall-related injuries in dementia with Lewy bodies (DLB) and Alzheimer's disease</article-title>. <source>Eur J Neurol</source>. (<year>2000</year>) <volume>7</volume>:<fpage>77</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-1331.2000.00021.x</pub-id>, PMID: <pub-id pub-id-type="pmid">10809918</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arber</surname><given-names>S</given-names></name><name name-style="western"><surname>Costa</surname><given-names>RM</given-names></name></person-group>. <article-title>Networking brainstem and basal ganglia circuits for movement</article-title>. <source>Nat Rev Neurosci</source>. (<year>2022</year>) <volume>23</volume>:<fpage>342</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41583-022-00581-w</pub-id>, PMID: <pub-id pub-id-type="pmid">35422525</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mak</surname><given-names>E</given-names></name><name name-style="western"><surname>Reid</surname><given-names>RI</given-names></name><name name-style="western"><surname>Przybelski</surname><given-names>SA</given-names></name><name name-style="western"><surname>Fought</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lesnick</surname><given-names>TG</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer's disease copathologies</article-title>. <source>NPJ Parkinsons Dis</source>. (<year>2025</year>) <volume>11</volume>:<fpage>124</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41531-025-00944-x</pub-id>, PMID: <pub-id pub-id-type="pmid">40355490</pub-id><pub-id pub-id-type="pmcid">PMC12069582</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tisserand</surname><given-names>A</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>F</given-names></name><name name-style="western"><surname>Mondino</surname><given-names>M</given-names></name><name name-style="western"><surname>Muller</surname><given-names>C</given-names></name><name name-style="western"><surname>Durand</surname><given-names>H</given-names></name><name name-style="western"><surname>Demuynck</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Who am I with my Lewy bodies? The insula as a core region of the self-concept networks</article-title>. <source>Alzheimers Res Ther</source>. (<year>2024</year>) <volume>16</volume>:<fpage>85</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-024-01447-2</pub-id>, PMID: <pub-id pub-id-type="pmid">38641653</pub-id><pub-id pub-id-type="pmcid">PMC11027417</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminiti</surname><given-names>SP</given-names></name><name name-style="western"><surname>Galli</surname><given-names>A</given-names></name><name name-style="western"><surname>Jonghi-Lavarini</surname><given-names>L</given-names></name><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Nicastro</surname><given-names>N</given-names></name><name name-style="western"><surname>Chiti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Mapping brain metabolism, connectivity and neurotransmitters topography in early and late onset dementia with lewy bodies</article-title>. <source>Parkinsonism Relat Disord</source>. (<year>2024</year>) <volume>122</volume>:<fpage>106061</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.parkreldis.2024.106061</pub-id>, PMID: <pub-id pub-id-type="pmid">38430691</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>MC</given-names></name><name name-style="western"><surname>Tovar-Rios</surname><given-names>DA</given-names></name><name name-style="western"><surname>Alves</surname><given-names>G</given-names></name><name name-style="western"><surname>Dalen</surname><given-names>I</given-names></name><name name-style="western"><surname>Williams-Gray</surname><given-names>CH</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cognitive and motor decline in dementia with Lewy bodies and Parkinson's disease dementia</article-title>. <source>Mov Disord Clin Pract</source>. (<year>2023</year>) <volume>10</volume>:<fpage>980</fpage>&#8211;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mdc3.13752</pub-id>, PMID: <pub-id pub-id-type="pmid">37332651</pub-id><pub-id pub-id-type="pmcid">PMC10272890</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>EN</given-names></name><name name-style="western"><surname>Allan</surname><given-names>LM</given-names></name><name name-style="western"><surname>Molloy</surname><given-names>S</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>JT</given-names></name><name name-style="western"><surname>McKeith</surname><given-names>IG</given-names></name></person-group>. <article-title>Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2006</year>) <volume>77</volume>:<fpage>585</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.2005.081711</pub-id>, PMID: <pub-id pub-id-type="pmid">16614017</pub-id><pub-id pub-id-type="pmcid">PMC2117449</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amboni</surname><given-names>M</given-names></name><name name-style="western"><surname>Iuppariello</surname><given-names>L</given-names></name><name name-style="western"><surname>Iavarone</surname><given-names>A</given-names></name><name name-style="western"><surname>Fasano</surname><given-names>A</given-names></name><name name-style="western"><surname>Palladino</surname><given-names>R</given-names></name><name name-style="western"><surname>Rucco</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study</article-title>. <source>J Neurol</source>. (<year>2018</year>) <volume>265</volume>:<fpage>2211</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-018-8973-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30014240</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Cognitive frailty and falls in Chinese elderly people: a population-based longitudinal study</article-title>. <source>Eur J Neurol</source>. (<year>2021</year>) <volume>28</volume>:<fpage>381</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.14572</pub-id>, PMID: <pub-id pub-id-type="pmid">33030300</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasreddine</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>NA</given-names></name><name name-style="western"><surname>B&#233;dirian</surname><given-names>V</given-names></name><name name-style="western"><surname>Charbonneau</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>V</given-names></name><name name-style="western"><surname>Collin</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source>. (<year>2005</year>) <volume>53</volume>:<fpage>695</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53221.x</pub-id>, PMID: <pub-id pub-id-type="pmid">15817019</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>MF</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>SE</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>PR</given-names></name></person-group>. <article-title>Mini-mental state</article-title>. <source>J Psychiatr Res</source>. (<year>1975</year>) <volume>12</volume>:<fpage>189</fpage>&#8211;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id>, PMID: <pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menz</surname><given-names>HB</given-names></name><name name-style="western"><surname>Latt</surname><given-names>MD</given-names></name><name name-style="western"><surname>Tiedemann</surname><given-names>A</given-names></name><name name-style="western"><surname>Mun San Kwan</surname><given-names>M</given-names></name><name name-style="western"><surname>Lord</surname><given-names>SR</given-names></name></person-group>. <article-title>Reliability of the GAITRite walkway system for the quantification of temporo-spatial parameters of gait in young and older people</article-title>. <source>Gait Posture</source>. (<year>2004</year>) <volume>20</volume>:<fpage>20</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0966-6362(03)00068-7</pub-id><pub-id pub-id-type="pmid">15196515</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Studenski</surname><given-names>S</given-names></name><name name-style="western"><surname>Perera</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>K</given-names></name><name name-style="western"><surname>Inzitari</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Gait speed and survival in older adults</article-title>. <source>JAMA</source>. (<year>2011</year>) <volume>305</volume>:<fpage>50</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2010.1923</pub-id>, PMID: <pub-id pub-id-type="pmid">21205966</pub-id><pub-id pub-id-type="pmcid">PMC3080184</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verghese</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name><name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Xue</surname><given-names>X</given-names></name></person-group>. <article-title>Quantitative gait dysfunction and risk of cognitive decline and dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2007</year>) <volume>78</volume>:<fpage>929</fpage>&#8211;<lpage>35</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.2006.106914</pub-id>, PMID: <pub-id pub-id-type="pmid">17237140</pub-id><pub-id pub-id-type="pmcid">PMC1995159</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannakou</surname><given-names>E</given-names></name><name name-style="western"><surname>Fotiadou</surname><given-names>S</given-names></name><name name-style="western"><surname>Gourgoulis</surname><given-names>V</given-names></name><name name-style="western"><surname>Mavrommatis</surname><given-names>G</given-names></name><name name-style="western"><surname>Aggelousis</surname><given-names>N</given-names></name></person-group>. <article-title>A comparative analysis of symmetry indices for spatiotemporal gait features in early Parkinson's disease</article-title>. <source>Neurol Int</source>. (<year>2023</year>) <volume>15</volume>:<fpage>1129</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.3390/neurolint15030070</pub-id>, PMID: <pub-id pub-id-type="pmid">37755361</pub-id><pub-id pub-id-type="pmcid">PMC10535875</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>S</given-names></name><name name-style="western"><surname>Galna</surname><given-names>B</given-names></name><name name-style="western"><surname>Rochester</surname><given-names>L</given-names></name></person-group>. <article-title>Moving forward on gait measurement: toward a more refined approach</article-title>. <source>Mov Disord</source>. (<year>2013</year>) <volume>28</volume>:<fpage>1534</fpage>&#8211;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.25545</pub-id>, PMID: <pub-id pub-id-type="pmid">24132841</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyer</surname><given-names>AH</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B</given-names></name><name name-style="western"><surname>Kennelly</surname><given-names>SP</given-names></name></person-group>. <article-title>Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD</article-title>. <source>BMC Geriatr</source>. (<year>2020</year>) <volume>20</volume>:<fpage>117</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12877-020-01531-w</pub-id>, PMID: <pub-id pub-id-type="pmid">32228468</pub-id><pub-id pub-id-type="pmcid">PMC7106668</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Yin</surname><given-names>WW</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>SL</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Li</surname><given-names>MX</given-names></name><etal/></person-group>. <article-title>Distinctive gait variations and neuroimaging correlates in Alzheimer's disease and cerebral small vessel disease</article-title>. <source>J Cachexia Sarcopenia Muscle</source>. (<year>2024</year>) <volume>15</volume>:<fpage>2717</fpage>&#8211;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcsm.13616</pub-id>, PMID: <pub-id pub-id-type="pmid">39551947</pub-id><pub-id pub-id-type="pmcid">PMC11634515</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>J</given-names></name><name name-style="western"><surname>Landes</surname><given-names>RD</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>L</given-names></name><name name-style="western"><surname>Virmani</surname><given-names>T</given-names></name></person-group>. <article-title>Tandem gait step-width increases more rapidly in more severely affected people with Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source>. (<year>2024</year>) <volume>127</volume>:<fpage>107078</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.parkreldis.2024.107078</pub-id>, PMID: <pub-id pub-id-type="pmid">39096549</pub-id><pub-id pub-id-type="pmcid">PMC11449637</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>D</given-names></name></person-group>. <article-title>Structural imaging in dementia with Lewy bodies: the potential of multivariate data analysis</article-title>. <source>Psychiatry Res Neuroimaging</source>. (<year>2020</year>) <volume>306</volume>:<fpage>111180</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pscychresns.2020.111180</pub-id>, PMID: <pub-id pub-id-type="pmid">32948404</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muir</surname><given-names>SW</given-names></name><name name-style="western"><surname>Speechley</surname><given-names>M</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J</given-names></name><name name-style="western"><surname>Borrie</surname><given-names>M</given-names></name><name name-style="western"><surname>Gopaul</surname><given-names>K</given-names></name><name name-style="western"><surname>Montero-Odasso</surname><given-names>M</given-names></name></person-group>. <article-title>Gait assessment in mild cognitive impairment and Alzheimer's disease: the effect of dual-task challenges across the cognitive spectrum</article-title>. <source>Gait Posture</source>. (<year>2012</year>) <volume>35</volume>:<fpage>96</fpage>&#8211;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gaitpost.2011.08.014</pub-id>, PMID: <pub-id pub-id-type="pmid">21940172</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soysal</surname><given-names>P</given-names></name><name name-style="western"><surname>Koc Okudur</surname><given-names>S</given-names></name><name name-style="western"><surname>Uslu</surname><given-names>F</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L</given-names></name></person-group>. <article-title>Functional loss and worsening geriatric assessment parameters are more common in dementia with Lewy bodies than Alzheimer's disease</article-title>. <source>Psychogeriatrics</source>. (<year>2023</year>) <volume>23</volume>:<fpage>77</fpage>&#8211;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1111/psyg.12905</pub-id>, PMID: <pub-id pub-id-type="pmid">36349708</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kudo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>A</given-names></name><name name-style="western"><surname>Endo</surname><given-names>N</given-names></name></person-group>. <article-title>Risk factors for falls in community-dwelling patients with Alzheimer's disease and dementia with Lewy bodies: walking with visuocognitive impairment may cause a fall</article-title>. <source>Dement Geriatr Cogn Disord</source>. (<year>2009</year>) <volume>27</volume>:<fpage>139</fpage>&#8211;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000198688</pub-id>, PMID: <pub-id pub-id-type="pmid">19182481</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Low</surname><given-names>LF</given-names></name><name name-style="western"><surname>Schwenk</surname><given-names>M</given-names></name><name name-style="western"><surname>Mills</surname><given-names>N</given-names></name><name name-style="western"><surname>Gwynn</surname><given-names>JD</given-names></name><name name-style="western"><surname>Clemson</surname><given-names>L</given-names></name></person-group>. <article-title>Review of gait, cognition, and fall risks with implications for fall prevention in older adults with dementia</article-title>. <source>Dement Geriatr Cogn Disord</source>. (<year>2019</year>) <volume>48</volume>:<fpage>17</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000504340</pub-id>, PMID: <pub-id pub-id-type="pmid">31743907</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montero-Odasso</surname><given-names>M</given-names></name><name name-style="western"><surname>Speechley</surname><given-names>M</given-names></name><name name-style="western"><surname>Muir-Hunter</surname><given-names>SW</given-names></name><name name-style="western"><surname>Sarquis-Adamson</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sposato</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hachinski</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Motor and cognitive trajectories before dementia: results from gait and brain study</article-title>. <source>J Am Geriatr Soc</source>. (<year>2018</year>) <volume>66</volume>:<fpage>1676</fpage>&#8211;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jgs.15341</pub-id>, PMID: <pub-id pub-id-type="pmid">29608780</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>NE</given-names></name><name name-style="western"><surname>Kegelmeyer</surname><given-names>DA</given-names></name><name name-style="western"><surname>Kloos</surname><given-names>AD</given-names></name><name name-style="western"><surname>Linder</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>A</given-names></name><name name-style="western"><surname>Kataki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease</article-title>. <source>Gait Posture</source>. (<year>2016</year>) <volume>50</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gaitpost.2016.08.009</pub-id>, PMID: <pub-id pub-id-type="pmid">27544062</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Noma</surname><given-names>H</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Postural control characteristics in Alzheimer's disease, dementia with Lewy bodies, and vascular dementia</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. (<year>2024</year>) <volume>79</volume>:<fpage>glae061</fpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/glae061</pub-id>, PMID: <pub-id pub-id-type="pmid">38412449</pub-id><pub-id pub-id-type="pmcid">PMC10949438</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merory</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wittwer</surname><given-names>JE</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></name><name name-style="western"><surname>Webster</surname><given-names>KE</given-names></name></person-group>. <article-title>Quantitative gait analysis in patients with dementia with Lewy bodies and Alzheimer's disease</article-title>. <source>Gait Posture</source>. (<year>2007</year>) <volume>26</volume>:<fpage>414</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gaitpost.2006.10.006</pub-id>, PMID: <pub-id pub-id-type="pmid">17161601</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elasfar</surname><given-names>S</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>H</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Fields</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kantarci</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Identifying gait differences between Alzheimer's disease and dementia with Lewy bodies and their associations with regional amyloid deposition</article-title>. <source>Alzheimers Dement</source>. (<year>2025</year>) <volume>21</volume>:<fpage>e14351</fpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.14351</pub-id>, PMID: <pub-id pub-id-type="pmid">39868511</pub-id><pub-id pub-id-type="pmcid">PMC11815204</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matinolli</surname><given-names>M</given-names></name><name name-style="western"><surname>Korpelainen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Sotaniemi</surname><given-names>KA</given-names></name><name name-style="western"><surname>Myllyl&#228;</surname><given-names>VV</given-names></name><name name-style="western"><surname>Korpelainen</surname><given-names>R</given-names></name></person-group>. <article-title>Recurrent falls and mortality in Parkinson's disease: a prospective two-year follow-up study</article-title>. <source>Acta Neurol Scand</source>. (<year>2011</year>) <volume>123</volume>:<fpage>193</fpage>&#8211;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-0404.2010.01386.x</pub-id>, PMID: <pub-id pub-id-type="pmid">20545629</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>DD</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JT</given-names></name></person-group>. <article-title>Brain network oscillations during gait in Parkinson's disease</article-title>. <source>Front Hum Neurosci</source>. (<year>2020</year>) <volume>14</volume>:<fpage>568703</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnhum.2020.568703</pub-id>, PMID: <pub-id pub-id-type="pmid">33192399</pub-id><pub-id pub-id-type="pmcid">PMC7645204</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palermo</surname><given-names>G</given-names></name><name name-style="western"><surname>Frosini</surname><given-names>D</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>A</given-names></name><name name-style="western"><surname>Giuntini</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazzucchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Del Prete</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Freezing of gait and dementia in parkinsonism: a retrospective case-control study</article-title>. <source>Brain Behav</source>. (<year>2019</year>) <volume>9</volume>:<fpage>e01247</fpage>. doi: <pub-id pub-id-type="doi">10.1002/brb3.1247</pub-id>, PMID: <pub-id pub-id-type="pmid">31074064</pub-id><pub-id pub-id-type="pmcid">PMC6577616</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sainsily-Cesarus</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>E</given-names></name><name name-style="western"><surname>Landre</surname><given-names>L</given-names></name><name name-style="western"><surname>Botzung</surname><given-names>A</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>L</given-names></name><name name-style="western"><surname>Demuynck</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Dementia with Lewy bodies and gait neural basis: a cross-sectional study</article-title>. <source>Alzheimer's Res Ther</source>. (<year>2024</year>) <volume>16</volume>:<fpage>170</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-024-01539-z</pub-id>, PMID: <pub-id pub-id-type="pmid">39080741</pub-id><pub-id pub-id-type="pmcid">PMC11287986</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Peavy</surname><given-names>GM</given-names></name></person-group>. <article-title>Associations among Braak stage, parkinsonian gait, cognition, and functional status in autopsy-confirmed dementia with Lewy bodies</article-title>. <source>Int J Geriatr Psychiatry</source>. (<year>2019</year>) <volume>34</volume>:<fpage>738</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1002/gps.5080</pub-id>, PMID: <pub-id pub-id-type="pmid">30729576</pub-id><pub-id pub-id-type="pmcid">PMC6461356</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mc Ardle</surname><given-names>R</given-names></name><name name-style="western"><surname>Galna</surname><given-names>B</given-names></name><name name-style="western"><surname>Donaghy</surname><given-names>P</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Rochester</surname><given-names>L</given-names></name></person-group>. <article-title>Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?</article-title><source>Alzheimers Dement</source>. (<year>2019</year>) <volume>15</volume>:<fpage>1367</fpage>&#8211;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2019.06.4953</pub-id>, PMID: <pub-id pub-id-type="pmid">31548122</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="pmc-domain-id">2593</journal-id><journal-id journal-id-type="pmc-domain">frontcdb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504367</article-id><article-id pub-id-type="pmcid-ver">PMC12504367.1</article-id><article-id pub-id-type="pmcaid">12504367</article-id><article-id pub-id-type="pmcaiid">12504367</article-id><article-id pub-id-type="doi">10.3389/fcell.2025.1650884</article-id><article-id pub-id-type="publisher-id">1650884</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Primary cilia in the mature brain: emerging roles in Alzheimer&#8217;s disease pathogenesis</article-title><alt-title alt-title-type="left-running-head">Huang et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fcell.2025.1650884" ext-link-type="uri">10.3389/fcell.2025.1650884</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="AS">Alexis Shiying</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2115437/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="ASM">Amy Sze Man</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1455334/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hor</surname><given-names initials="CHH">Catherine Hong Huan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><xref rid="fn1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2747882/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Chemistry, Hong Kong Baptist University</institution>, <addr-line>Hong Kong</addr-line>, <country>Hong Kong SAR, China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Neurobiology, Care Sciences and Society, Karolinska Institute</institution>, <addr-line>Huddinge</addr-line>, <country>Sweden</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University</institution>, <addr-line>Hong Kong</addr-line>, <country>Hong Kong SAR, China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/409088/overview" ext-link-type="uri">Xuelin Lou</ext-link>, Medical College of Wisconsin, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/107543/overview" ext-link-type="uri">Maria-Paz Marzolo</ext-link>, Pontificia Universidad Cat&#243;lica de Chile, Chile</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1135994/overview" ext-link-type="uri">Torben Mentrup</ext-link>, Technical University Dresden, Germany</p></fn><corresp id="c001">*Correspondence: Catherine Hong Huan Hor, <email>catherinehor@hkbu.edu.hk</email></corresp><fn fn-type="other" id="fn1"><label>
<sup>&#8224;</sup>
</label><p>ORCID: Catherine Hong Huan Hor, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-7467-2243" ext-link-type="uri">orcid.org/0000-0002-7467-2243</ext-link>
</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">480890</issue-id><elocation-id>1650884</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Huang, Li and Hor.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Huang, Li and Hor</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcell-13-1650884.pdf"/><abstract><p>Primary cilia are microtubule-based structures that resemble antennae and function as sensory organelles. Dysfunction of primary cilia has been linked to various age-related conditions. Alzheimer&#8217;s disease, which affects more than 38.5 million individuals worldwide, is a prominent neurodegenerative disorder, with aging being its most significant risk factor. In this review, we provide an overview of current findings on the role of primary cilia in the mature brain and the mechanisms by which alteration of primary cilia may influence the progression of Alzheimer&#8217;s disease. Growing evidence reveals that primary cilia in the mature brain play dynamic roles in cell type, region, and age-dependent manners. In Alzheimer&#8217;s disease, anomalies in primary cilia functions and morphology are closely associated with key pathologies. However, the exact mechanisms remain unclear. Future studies on neuronal and glial cilia dynamics during aging and neurodegeneration are essential to explore their potential as therapeutic targets.</p></abstract><kwd-group><kwd>primary cilia</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>pathogenesis</kwd><kwd>G protein-coupled receptors</kwd><kwd>A&#946; plaques</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was funded by Hong Kong Baptist University Seed Fund to Catherine Hong-Huan HOR, and Collaborative Research Fund #C2103-20G from Hong Kong Research Grant Council to Catherine Hong-Huan HOR.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Membrane Traffic and Organelle Dynamics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is a neurodegenerative disorder characterized by the presence of amyloid-&#946; (A&#946;) plaques and tau neurofibrillary tangles, resulting in progressive cognitive impairment, with aging being the most significant risk factor (<xref rid="B34" ref-type="bibr">Knopman et al., 2021</xref>). Beyond A&#946; and tau pathology, AD progression involves disruptions in cellular homeostasis, notably affecting endosomal-lysosomal clearance (<xref rid="B47" ref-type="bibr">Nixon, 2017</xref>). Recent research has implicated primary cilia dysfunction in the pathogenesis of AD (<xref rid="B42" ref-type="bibr">Ma et al., 2022</xref>), suggesting that these organelles play a critical role in aging and age-related brain disorders.</p><p>The primary cilium is a microtubule-based, non-motile organelle that extends from the surface of most mammalian cells (<xref rid="B71" ref-type="bibr">Wheatley et al., 1996</xref>). The ciliary membrane extends continuously from the plasma membrane but is notably enriched with ion channels, G-protein-coupled receptors (GPCRs), and essential components of signaling pathways like Sonic Hedgehog (Shh) and Wnt (<xref rid="B48" ref-type="bibr">Pala et al., 2017</xref>). This composition allows the primary cilium to serve as a non-synaptic sensory and signaling organelle. The primary cilium is also a dynamic structure, with its assembly and disassembly regulated during the cell cycle and in response to developmental cues (<xref rid="B50" ref-type="bibr">Plotnikova et al., 2009</xref>).</p><p>Primary cilia play essential roles in brain development and neurogenesis (<xref rid="B26" ref-type="bibr">Hasenpusch-Theil and Theil, 2021</xref>). Notably, primary cilia function as essential signaling hubs for pathways such as Shh, which is crucial for neural tube patterning and the expansion of neural progenitor populations (<xref rid="B77" ref-type="bibr">Zaidi et al., 2022</xref>). In the mature brain, primary cilia are typically located on the soma or dendrites of neurons (<xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>), where they serve as sensory organelles that integrate local environmental cues, thereby influencing neurotransmission and synaptic plasticity. For example, primary cilia are enriched with neuropeptide receptors such as somatostatin receptor 3 (SSTR3), which modulate excitatory synaptic input onto neocortical pyramidal neurons (<xref rid="B62" ref-type="bibr">Tereshko et al., 2021</xref>). Additionally, proper cilia assembly is necessary for the formation of glutamatergic synapses with entorhinal cortical projections, as demonstrated by Kumamoto et al. in newborn dentate granule cells of 5-week-old female C57 mice (<xref rid="B37" ref-type="bibr">Kumamoto et al., 2012</xref>).</p><p>Intriguingly, recent studies begin shedding lights on the key mechanisms that connect primary cilia dysfunction to AD progression. This review integrates studies using cells from the cortex and hippocampus of rodents and humans, alongside rodent models, to elucidate the primary cilia&#8217;s roles in the central nervous system. We discuss the heterogeneity in morphology in the mature brain, with an emphasis on variations across cell types, brain regions, and age-related changes. We also review current findings on the functions of neuronal ciliary-localized GPCRs. Furthermore, we highlight the relevance of primary cilia to AD pathology and identify key gaps in knowledge that warrant further investigation.</p></sec><sec id="s2"><title>The structure of the primary cilium</title><p>The primary cilium is a complex organelle composed of the basal body, axoneme, and transition zone.</p><p>The basal body is evolutionarily conserved, derived from the mother centriole, and is crucial for the initial assembly of the cilium. It consists of a barrel-shaped structure made of nine triplet microtubules, along with subdistal appendages and nine strut-like distal appendages (also called transition fibers). These distal appendages anchor the basal body to the membrane at the cilium&#8217;s base (<xref rid="B51" ref-type="bibr">Reiter and Leroux, 2017</xref>).</p><p>The axoneme, surrounded by a membrane that is continuous with the plasma membrane, consists of nine circumferentially arranged microtubule doublets that extend from the basal body into the extracellular space. This structure can vary along the length of the cilium, with the number of microtubule doublets and the diameter decreasing towards the tip (<xref rid="B60" ref-type="bibr">Sun et al., 2019</xref>; <xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>).</p><p>Between the basal body and the axoneme, a region called transition zone serves as gatekeeper to control proteins in or out of the cilium (<xref rid="B38" ref-type="bibr">Lechtreck, 2015</xref>). The transportation of proteins to the primary cilium membrane is a tightly regulated process. The transition zone contains distinct Y-shaped structures that link the ciliary membrane to the axoneme. These structures are believed to establish or maintain a diffusion barrier, regulating the movement of membrane-associated soluble proteins (<xref rid="B4" ref-type="bibr">Awata et al., 2014</xref>). The selective function of the transition zone relies on multiple complexes (<xref rid="B49" ref-type="bibr">Park and Leroux, 2022</xref>). Apart from these complexes, intraflagellar transport (IFT) trains are responsible for the bidirectional transport of proteins and other molecules along the axonemal microtubules of the cilium (<xref rid="B27" ref-type="bibr">Hesketh et al., 2022</xref>). This system consists of two main complexes: IFT-A (e.g., IFT140) and IFT-B (e.g., IFT88, IFT20), alongside motor proteins kinesin-2 and dynein-2, facilitate the active transport of membrane proteins, such as receptors and ion channels, into and out of the cilium (<xref rid="B33" ref-type="bibr">Klena and Pigino, 2022</xref>; <xref rid="B63" ref-type="bibr">van den Hoek et al., 2022</xref>). IFT trains bind to traffic cargos either directly or via associating factors. IFT-A interacts with tubby family protein 3 (TULP3) to promote GPCRs trafficking into the cilium (<xref rid="B45" ref-type="bibr">Mukhopadhyay et al., 2010</xref>; <xref rid="B5" ref-type="bibr">Badgandi et al., 2017</xref>). The BBSome, a protein complex composed of eight Bardet-Biedl syndrome (BBS) proteins and directly interacts with IFT subcomplexes, is required for retrograde trafficking of GPCRs in and out of primary cilia (<xref rid="B8" ref-type="bibr">Berbari et al., 2008</xref>; <xref rid="B72" ref-type="bibr">Wingfield et al., 2018</xref>; <xref rid="B74" ref-type="bibr">Ye et al., 2018</xref>). Together, these components underscore the intricate interplay of transport, sorting, and stabilization that defines the primary cilium as a specialized signaling hub (<xref rid="B70" ref-type="bibr">Wei et al., 2012</xref>).</p></sec><sec id="s3"><title>Primary cilia in the mature brain</title><p>In the human brain, primary cilia occupy 0.03% of cortical volume (<xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>). For a long time, it was believed that primary cilia were present in neurons and astrocytes in the brains of adult humans and rodents (<xref rid="B10" ref-type="bibr">Bishop et al., 2007</xref>; <xref rid="B76" ref-type="bibr">Yoshimura et al., 2011</xref>; <xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>), but were absent from microglia and oligodendrocytes (<xref rid="B57" ref-type="bibr">Sipos et al., 2018</xref>). This understanding has been recently updated by findings that demonstrate the presence of primary cilia on microglia (<xref rid="B41" ref-type="bibr">Liao et al., 2023</xref>; <xref rid="B75" ref-type="bibr">Yeo et al., 2023</xref>). Primary cilia can also be found in choroid plexus cells in the adult mouse brain (<xref rid="B10" ref-type="bibr">Bishop et al., 2007</xref>).</p><p>Primary cilia in the brain can be identified using molecular markers such as adenylate cyclase 3 (AC3), ADP-ribosylation factor-like protein 13B (ARL13B), and certain GPCRs, all of which are enriched within the ciliary membrane. However, their expression exhibits cell-type-specific variability. AC3 is widely used to label neuronal primary cilia, although it also labels a subset of astrocytic cilia in the human, rat, and mouse cerebral cortex (<xref rid="B76" ref-type="bibr">Yoshimura et al., 2011</xref>; <xref rid="B57" ref-type="bibr">Sipos et al., 2018</xref>). In contrast, Arl13b is more commonly used for astrocytic cilia but has also been detected in a limited population of neuronal cilia (<xref rid="B57" ref-type="bibr">Sipos et al., 2018</xref>; <xref rid="B19" ref-type="bibr">Dupuy et al., 2023</xref>). Quantitative analyses in adult C57 mice show that 78% of neurons exhibit AC3-positive primary cilia, while 47% are Arl13b-positive; conversely, 88% of astrocytes are Arl13b-positive, and nearly half express AC3-positive cilia (<xref rid="B32" ref-type="bibr">Kasahara et al., 2014</xref>). Regional differences have also been reported. In the mouse brain, for example, only 38% of astrocytes in the corpus callosum are Arl13b-positive, despite most astrocytes elsewhere bearing a single Arl13b-labeled primary cilium (<xref rid="B68" ref-type="bibr">Wang et al., 2024</xref>). Several GPCRs, including SSTR3, melanin-concentrating hormone receptor 1 (MCHR1), and 5-hydroxytryptamine receptor 6 (5-HT<sub>6</sub> receptor), also serve as markers for neuronal primary cilia and have been used to investigate cilia-dependent signaling pathways (<xref rid="B18" ref-type="bibr">Domire and Mykytyn, 2009</xref>). For instance, an <italic toggle="yes">in vitro</italic> study using primary hippocampal cultures has demonstrated the presence of primary cilia on both neurons and astrocytes from newborn mice after 7 days of serum-free culture (<xref rid="B7" ref-type="bibr">Berbari et al., 2007</xref>). In this study, cilia were visualized using two common markers: AC3 and Sstr3. Notably, the choice of marker had a significant influence on cilia detection. In neurons, AC3 labeled nearly three times more cilia than Sstr3. Furthermore, while approximately 50% of astrocytes exhibited AC3-positive primary cilia, Sstr3 was completely absent from these cells (<xref rid="B7" ref-type="bibr">Berbari et al., 2007</xref>). These findings highlight not only the utility of primary cell culture in studying cilia and the importance of selecting appropriate markers, as detection can vary substantially across cell types and between different markers within the same cell population.</p><sec id="s3-1"><title>Primary cilia in distinct neuronal subtypes and brain regions</title><p>Primary cilia in the brain exhibit notable morphological variations, including differences in length, spatial distribution, and microtubule architecture.</p><p>Neuronal primary cilia, unlike the typical 9 + 0 microtubule arrangement, display highly diverse microtubule architectures, with variable numbers of microtubule doublets along their length (<xref rid="B56" ref-type="bibr">Sheu et al., 2022</xref>; <xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>). Furthermore, proteins with diverse lifespans coexist within the basal body and axoneme of neuronal primary cilia, suggesting dynamic turnover (<xref rid="B3" ref-type="bibr">Arrojo et al., 2019</xref>). In neurons, primary cilia exhibit diverse characteristics across brain regions and subtypes. In the cerebral cortex, primary cilia of upper-layer neurons are significantly longer than those in lower layers. Quantitative analysis reveals that interneuron primary cilia have an average length of 5.8 &#177; 0.2 &#181;m, while projection neuron cilia measure 7.4 &#177; 0.6 &#181;m on average. Most cortical neuronal cilia are positioned closer to dendrites than axons, suggesting a functional orientation, and up to 56% possess a ciliary pocket at their base, indicative of active vesicle transport and docking at the ciliary base (<xref rid="B73" ref-type="bibr">Wu et al., 2024</xref>). In the hippocampus of adult (3&#8211;8 months old) male mice, AC3-labeled primary cilia are abundant in the pyramidal cell layers of the CA1 and CA3 regions, as well as in the granular cell layer of the dentate gyrus (DG) (<xref rid="B66" ref-type="bibr">Wang et al., 2011</xref>). Within the CA1-CA3 molecular layer, neuronal primary cilia are radially oriented, with those in CA1 being the longest, averaging 8.9 &#181;m, and typically originating from the soma (<xref rid="B64" ref-type="bibr">Vien et al., 2023</xref>). Additionally, 5-HT<sub>6</sub> receptor-rich primary cilia of CA1 pyramidal neurons form synaptic connections with brainstem serotonergic axons, with approximately 35% of neuronal primary cilia in close apposition to these axons, accounting for about 50% of axon-ciliary synapses (<xref rid="B56" ref-type="bibr">Sheu et al., 2022</xref>). This suggests a specialized role of primary cilia in serotonergic signaling.</p><p>Primary cilia on astrocytes also display significant morphological plasticity. Astrocyte primary cilia showed a regional difference in length, with the longest found in the CA1 region of the hippocampus, averaging 3.8 &#177; 0.07 &#181;m (<xref rid="B68" ref-type="bibr">Wang et al., 2024</xref>). Ciliary morphology in astrocytes is also sensitive to their physiological state. In C3-positive reactive astrocytes, primary cilia become significantly longer, even though the rates of cilia formation remain unchanged (<xref rid="B44" ref-type="bibr">Muhamad et al., 2024</xref>).</p><p>Recent studies have investigated how ciliary length and ciliation rates vary with the age of mice. In the neocortex of CD1 strain mice, the length of AC3-labeled primary cilia varies by cortical layer and reaches its full extent after 3 months, with no significant gender differences observed (<xref rid="B2" ref-type="bibr">Arellano et al., 2012</xref>). A study using sv129/C57/BL6 female mice reported that ciliary length and ciliation rates of Sstr3-labeled primary cilia in the dentate granule cell layer remain stable from 6 to 24 months of age (<xref rid="B15" ref-type="bibr">Chakravarthy et al., 2012</xref>). However, a study shows clear age-related changes in the hippocampus. In C57 BL/6J mice, primary ciliary lengths in the DG, CA1, and CA3 regions increased significantly from 6 to 15 months of age (CA1 and CA3: AC3/Mchr1 double-labeled, DG: AC3-labeled) (<xref rid="B36" ref-type="bibr">Kobayashi et al., 2022</xref>). Similarly, in aged male F344 x BN rats, AC3-labeled primary cilia in the CA1 and CA3 hippocampal regions are longer compared to young rats, while no changes in the ciliation rates and ciliary length were observed in the neocortex and DG (<xref rid="B22" ref-type="bibr">Guadiana et al., 2016</xref>).</p></sec><sec id="s3-2"><title>Neuronal G protein-coupled receptors on the ciliary membrane and their functional impact</title><p>GPCRs localized to the ciliary membrane of neurons play critical roles in signaling. Notable GPCRs identified on primary cilia include MCHR1, SSTR3, and 5-HT<sub>6</sub> receptor, which regulate processes such as memory, synaptic plasticity, and neuronal excitability (<xref rid="B18" ref-type="bibr">Domire and Mykytyn, 2009</xref>) (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>G protein-coupled receptors (GPCRs) express at neuronal primary cilia. The neuronal primary cilium consists of the basal body, axoneme, and transition zone. Its microtubule architecture is highly diverse, with variable numbers of doublets along the ciliary shaft. Protein entry and exit are regulated by the transition zone and transition fibers, together with the intraflagellar transport (IFT) machinery, which mediates kinesin-2&#8211;dependent anterograde and dynein-2&#8211;dependent retrograde transport. The BBSome complex acts as a cargo adaptor for retrograde trafficking of transmembrane proteins, including GPCRs. Neuronal primary cilia can be visualized with markers such as adenylate cyclase 3 (AC3) and several ciliary GPCRs, including somatostatin receptor 3 (SSTR3), melanin-concentrating hormone receptor 1 (MCHR1), and 5-hydroxytryptamine receptor 6 (5-HT<sub>6</sub> receptor). Created in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">BioRender</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-13-1650884-g001.jpg"><alt-text content-type="machine-generated">Diagram of a cilium structure showing components such as the ciliary membrane, axoneme, and basal body. Labels identify receptors including 5-HT&#8326; receptor, AC3, SSTR3, MCHR1, and GPCR. Intracellular and extracellular spaces are marked, along with proteins Kinesin-2 and Dynein-2. Other parts labeled are Y-link, transition zone, transition fiber, ciliary pocket, subdistal appendage, and BBsome. Arrows indicate movement direction.</alt-text></graphic></fig><p>MCHR1 is extensively found in the brains of mice and rats, showing a very similar distribution (<xref rid="B17" ref-type="bibr">Diniz et al., 2020</xref>). In the mouse brain, Mchr1 localizes to neuronal cilia across various regions (<xref rid="B21" ref-type="bibr">Green et al., 2012</xref>; <xref rid="B17" ref-type="bibr">Diniz et al., 2020</xref>). In the cerebral cortex, Mchr1 exhibits a layer-specific distribution that spans layers 2 to 6 (<xref rid="B17" ref-type="bibr">Diniz et al., 2020</xref>). Its presence is particularly notable in the hippocampus, where Mchr1-positive primary cilia are abundant in the stratum pyramidale of the CA regions, showing the greatest density in CA1, a reduced density in CA2, and minimal presence in CA3 (<xref rid="B17" ref-type="bibr">Diniz et al., 2020</xref>). This pattern is mirrored in rats, where Mchr1 is prominent in the neuronal cilia of CA1, and CA3 regions, but not in the DG. Notably, nearly all cilia in the CA1 region that express AC3 also co-express Mchr1. The correlation is striking in the rat CA1 region, where over 87% of AC3-labeled neuronal cilia are also Mchr1-positive, whereas only about 2% of AC3-labeled neuronal cilia in the DG co-express Mchr1. The length of Mchr1-bearing cilia also varies by region, being significantly longer in CA1 than in CA3 and the DG (<xref rid="B35" ref-type="bibr">Kobayashi et al., 2021</xref>). The trafficking of MCHR1 to the primary cilium is a tightly regulated process. Jouberin, encoded by the Abelson-helper integration site 1 (<italic toggle="yes">AHI1</italic>), localized at the ciliary transition zone, is essential for this process in neurons. In <italic toggle="yes">Ahi1</italic>
<sup>&#8722;/&#8722;</sup> mice, primary cilia are fewer but longer in the hippocampus, with reduced Mchr1 ciliary localization, though total Mchr1 levels and plasma membrane trafficking remain unaffected (<xref rid="B28" ref-type="bibr">Hsiao et al., 2021</xref>). The protein tubby is also involved for moving Mchr1 to the primary cilia of hippocampal neurons (<xref rid="B59" ref-type="bibr">Sun et al., 2012</xref>). MCHR1 signaling is involved in ciliary morphology alteration. In rat brain slices, treatment with melanin-concentrating hormone (MCH) induces Gi/o- and Akt-dependent shortening of cilia in the CA1 region, but not cilia in the CA3. Fasting for 48 h in C57 mice did not change Mchr1 mRNA expression level, but reduced cilia lengths in the CA1 region (<xref rid="B35" ref-type="bibr">Kobayashi et al., 2021</xref>). In the mouse hippocampus (CA1 and CA2), within the neuronal primary cilia, Mchr1 colocalizes and interacts with Sstr3 (<xref rid="B21" ref-type="bibr">Green et al., 2012</xref>), suggesting functional cross-talk between signaling pathways.</p><p>Among the five somatostatin receptor subtypes, SSTR3 is unique for its selective localization to neuronal cilia (<xref rid="B54" ref-type="bibr">Schulz et al., 2000</xref>; <xref rid="B20" ref-type="bibr">Einstein et al., 2010</xref>; <xref rid="B69" ref-type="bibr">Wang et al., 2025</xref>). Tubby is reported to be essential for Sstr3 trafficking to primary cilia of neurons in the hippocampus and some cortical regions (<xref rid="B59" ref-type="bibr">Sun et al., 2012</xref>). In adult Wistar rat brains, Sstr3-marked cilia are present in several regions, including the cerebral cortex, the pyramidal layer of the hippocampal CA regions, and the granule cell layer of the DG (<xref rid="B25" ref-type="bibr">H&#228;ndel et al., 1999</xref>). While an earlier study reported that <italic toggle="yes">Sstr3</italic>-knockout does not alter the number or overall structure of primary cilia in the CA1 region of mice (<xref rid="B20" ref-type="bibr">Einstein et al., 2010</xref>), recent work by Wang et al. demonstrated that Sstr3 specifically regulates ciliary length. Overexpression of Sstr3 in mouse primary hippocampal neurons elongated primary cilia in a dose-dependent manner, whereas knockdown markedly shortened them (<xref rid="B69" ref-type="bibr">Wang et al., 2025</xref>). Primary ciliary Sstr3 is essential for cognitive and synaptic function. Einstein et al. reported that <italic toggle="yes">Sstr3</italic>-knockout mice exhibit significantly reduced basal cyclic adenosine monophosphate (cAMP) levels in the hippocampus, impaired object recognition memory with a longer retention interval (1 h), and disrupted forskolin-induced long-term potentiation (LTP) compared to wild-type mice (<xref rid="B20" ref-type="bibr">Einstein et al., 2010</xref>). Wang et al. provided similar evidence, showing that <italic toggle="yes">Sstr3</italic> deletion impairs spatial memory in the Morris water maze, decreases LTP, reduces both the amplitude and frequency of miniature excitatory post-synaptic currents (mEPSCs), and leads to loss of dendritic spines, affecting both the number and volume of mushroom spines in the CA1 region. Sstr3 also regulates axon initial segment (AIS) structure and plasticity: knockout shortens axon initial segment length and abolishes positional plasticity, while re-expression restores axon initial segment morphology. Similar axon initial segment length changes were observed upon manipulation of other ciliary proteins, including 5-HT<sub>6</sub> receptor and Ift88. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of wild-type mice and <italic toggle="yes">Sstr3</italic>-knockout mice revealed that <italic toggle="yes">Sstr3</italic> deletion significantly affects multiple regulatory pathways, including endocytosis, PI3K-Akt signalling, and cAMP signalling. These disruptions reduce Akt-dependent cyclic AMP-response element binding protein (CREB)-mediated transcription at the axon initial segment, specifically downregulating ankyrin G, the master organiser of the axon initial segment. Hippocampal neurons from <italic toggle="yes">Sstr3</italic>-knockout mice displayed diminished cilia-related calcium dynamics and took longer to reach peak response compared to wild-type neurons. Since calcium signalling reflects ciliary activity, these results suggest that Sstr3 is essential for ciliary function (<xref rid="B69" ref-type="bibr">Wang et al., 2025</xref>). Sstr3 has also been observed to colocalize with the p75 neurotrophin receptor (p75<sup>NTR</sup>) in the primary cilia of cells in the cortex and hippocampus, with peak abundance in the DG (<xref rid="B14" ref-type="bibr">Chakravarthy et al., 2010</xref>). However, the functional significance of their interaction remains to be explored.</p><p>The 5-HT<sub>6</sub> receptor is primarily found on the ciliary membranes of neurons in the brain (<xref rid="B24" ref-type="bibr">Hamon et al., 1999</xref>; <xref rid="B11" ref-type="bibr">Brailov et al., 2000</xref>; <xref rid="B56" ref-type="bibr">Sheu et al., 2022</xref>). Studies on 5-HT<sub>6</sub> receptor knockout (5-HT<sub>6</sub>KO) mice have yielded varied results in ciliary morphology. One study reported that primary cilia in the cortex, hippocampus, and striatum of 5-HT<sub>6</sub>KO mice were significantly shorter compared to wild-type mice (<xref rid="B19" ref-type="bibr">Dupuy et al., 2023</xref>). In contrast, another reported no change in the ciliary length of primary cilia in the hippocampus of 5-HT<sub>6</sub>KO mice (<xref rid="B61" ref-type="bibr">Sun et al., 2021</xref>). Overexpression of homologous 5-HT<sub>6</sub> receptors in primary cultured hippocampal neurons significantly increased cilia number and length, while knockdown only reduced ciliary length (<xref rid="B29" ref-type="bibr">Hu et al., 2017</xref>; <xref rid="B67" ref-type="bibr">Wang et al., 2019</xref>). High levels of heterologous 5-HT<sub>6</sub> receptor expression increased the receptor&#8217;s presence outside of the primary cilia without altering the morphology of the primary cilia (<xref rid="B12" ref-type="bibr">Brodsky et al., 2017</xref>). In primary striatal neurons from 5-HT<sub>6</sub>KO mice, reintroduction of 5-HT<sub>6</sub> receptors restored their primary ciliary localization without altering the overall ciliation rate, led to elongation of neuronal primary cilia, and significantly increased the average total dendritic length (<xref rid="B39" ref-type="bibr">Lesiak et al., 2018</xref>). Manipulating 5-HT<sub>6</sub> receptor expression also affects axonal morphology. Overexpression of 5-HT<sub>6</sub> receptors reduced axonal length to approximately 75% of that in wild-type neurons, whereas downregulation of 5-HT<sub>6</sub> receptor expression led to increased axonal length (<xref rid="B67" ref-type="bibr">Wang et al., 2019</xref>). Loss of the 5-HT<sub>6</sub> receptor results in significant functional alterations, including increased action potential firing frequency and a shortened axon initial segment in hippocampal pyramidal neurons, as well as heightened anxiety and cognitive impairments in 5-HT<sub>6</sub>KO mice (<xref rid="B61" ref-type="bibr">Sun et al., 2021</xref>). Similarly, an independent study reported that modulation of 5-HT<sub>6</sub> receptor expression regulates axon initial segment length in cultured mouse hippocampal neurons, with overexpression increasing and knockout decreasing axon initial segment length (<xref rid="B69" ref-type="bibr">Wang et al., 2025</xref>). Conversely, overexpression of 5-HT<sub>6</sub> receptors in mouse hippocampal neurons leads to decreased neuronal excitability, characterized by reduced peak amplitudes of single action potentials and fewer spikes compared to controls (<xref rid="B67" ref-type="bibr">Wang et al., 2019</xref>). Pharmacological studies have further explored the critical role of ciliary localization of the 5-HT<sub>6</sub> receptor in its function. In cultured mouse striatal neurons, treatment with SB-399885 (5-HT<sub>6</sub> receptor antagonist) shortened primary cilia with no impact on their ciliation. Crucially, this effect is absent in striatal neurons from 5-HT<sub>6</sub>KO, demonstrating that the drug&#8217;s effect is dependent on the presence of the receptor on the primary cilium. Treatment with WAY-208466 (5-HT<sub>6</sub> receptor agonist) did not affect primary cilia length in cultured mouse striatal neurons (<xref rid="B12" ref-type="bibr">Brodsky et al., 2017</xref>). These studies collectively illustrate that the 5-HT<sub>6</sub> receptor, acting from the primary cilium, serves as a regulator of neuronal structure, excitability, and function.</p></sec></sec><sec id="s4"><title>Alterations of primary cilia in AD mouse models</title><p>Although no studies have yet characterized primary cilia in postmortem human AD brain tissue, various transgenic mouse models have provided critical insights into primary ciliary alterations associated with AD pathology (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F2" ref-type="fig">Figure 2</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Alterations of primary cilia in AD models.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Model/Cell type</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Brain region</th><th align="center" rowspan="1" colspan="1">Cell type</th><th align="center" rowspan="1" colspan="1">Ciliary marker</th><th align="center" rowspan="1" colspan="1">Ciliary alterations<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody valign="top"><tr><td rowspan="4" align="left" colspan="1">APP/PS1</td><td align="left" rowspan="1" colspan="1">6-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8593;</p></list-item><list-item><p>&#8226; 5-HT<sub>6</sub> receptor&#8593;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B29" ref-type="bibr">Hu et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">12-month</td><td align="left" rowspan="1" colspan="1">Near A&#946; plaques</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595;compared to longer distances</p></list-item></list>
</td><td rowspan="3" align="left" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">12-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Sstr3&#8593;</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2, 6, and 12-month</td><td align="left" rowspan="1" colspan="1">Hippocampal CA1</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8593; with age, but elongation halts after A&#946; accumulation onset</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">APP<sup>NL&#8722;G-F</sup>
</td><td align="left" rowspan="1" colspan="1">6, 13, and 15-month</td><td align="left" rowspan="1" colspan="1">Hippocampal CA1 or CA3</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; No age-dependent length change</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Kobayashi et al. (2022)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">APPswe/PSEN1dE9</td><td align="left" rowspan="1" colspan="1">6&#8211;8-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">Dentate granule cell</td><td align="left" rowspan="1" colspan="1">Sstr3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length unchanged</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Chakravarthy et al. (2012)</xref>
</td></tr><tr><td rowspan="4" align="left" colspan="1">5&#215;FAD</td><td align="left" rowspan="1" colspan="1">4-month</td><td align="left" rowspan="1" colspan="1">Near A&#946; plaques</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595; compared to longer distances</p></list-item></list>
</td><td rowspan="3" align="left" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1, 2, and 6-month</td><td align="left" rowspan="1" colspan="1">Hippocampal CA1</td><td align="left" rowspan="1" colspan="1">Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8593; with age, but elongation halts after A&#946; accumulation onset</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">12-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Sstr3&#8593;</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6-month</td><td align="left" rowspan="1" colspan="1">Cortex and lateral septum</td><td align="left" rowspan="1" colspan="1">Microglia</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595;</p></list-item><list-item><p>&#8226; Ciliation rate&#8595;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B75" ref-type="bibr">Yeo et al. (2023)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tau P301S</td><td align="left" rowspan="1" colspan="1">3&#8211;4-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">Dentate granule cell</td><td align="left" rowspan="1" colspan="1">Sstr3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length unchanged</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Chakravarthy et al. (2012)</xref>
</td></tr><tr><td rowspan="2" align="left" colspan="1">3&#215;Tg</td><td align="left" rowspan="1" colspan="1">12-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Sstr3&#8593;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6&#8211;24-month</td><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">Dentate granule cell</td><td align="left" rowspan="1" colspan="1">Sstr3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595; with age</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Chakravarthy et al. (2012)</xref>
</td></tr><tr><td rowspan="2" align="left" colspan="1">Intracerebroventricular injection<break/> of LPS in C57BL/6 mice</td><td rowspan="2" align="left" colspan="1">8&#8211;10-week</td><td align="left" rowspan="1" colspan="1">Hippocampal CA1</td><td align="left" rowspan="1" colspan="1">Pyramidal Neuron</td><td align="left" rowspan="1" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595; 1 day after injection</p></list-item><list-item><p>&#8226; Arl13b &#8595; 3 days after injection</p></list-item></list>
</td><td rowspan="2" align="left" colspan="1">
<xref rid="B6" ref-type="bibr">Baek et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hippocampus</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Arl13b&#8595; 3 days after injection</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-treated HT22</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">Mouse hippocampal neuronal cell line</td><td align="left" rowspan="1" colspan="1">Arl13b</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595; after 1-h treatment</p></list-item><list-item><p>&#8226; Arl13b&#8595; after 6-h treatment</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B6" ref-type="bibr">Baek et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-treated astrocyte</td><td align="left" rowspan="1" colspan="1">Postnatal-7 pup</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">Primary mouse astrocyte</td><td align="left" rowspan="1" colspan="1">Arl13b</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8593; in both astrocytes and C3-positive astrocytes</p></list-item><list-item><p>&#8226; Ciliation rate unchanged</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Muhamad et al. (2024)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#946;<sub>1-42</sub> treated neuron</td><td rowspan="2" align="left" colspan="1">Embryonic day 18 mouse embryos</td><td rowspan="2" align="left" colspan="1">&#8212;</td><td rowspan="2" align="left" colspan="1">Primary hippocampal neuron</td><td rowspan="2" align="left" colspan="1">AC3</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length&#8595;</p></list-item><list-item><p>&#8226; Ciliation rate unchanged</p></list-item></list>
</td><td rowspan="2" align="left" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Exogenous or endogenous overexpression of Tau in neuron</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Length unchanged</p></list-item><list-item><p>&#8226; Ciliation rate unchanged</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>Unless specified, these were compared to age-matched controls.</p></fn><fn><p>LPS, lipopolysaccharide; MIF, macrophage migration inhibitory factor.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Changes in primary cilia across different cell types in AD models. This schematic highlights key changes in primary cilia among various cell types in AD models. Neurons experience age-related primary ciliary elongation, which is halted by A&#946; accumulation. Treatment with A&#946;<sub>1-42</sub> reduces primary ciliary length, while tau overexpression does not influence primary cilia length or ciliation rate. Neuronal exposure to LPS also causes primary ciliary shortening. Microglia show decreased primary ciliary length and fewer primary cilia in 5xFAD. Astrocytes have longer primary cilia after LPS treatment, but their ciliation rate remains unchanged. These findings emphasize that primary cilia remodeling in AD is specific to cell type and context. Created in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">BioRender</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-13-1650884-g002.jpg"><alt-text content-type="machine-generated">Flowchart showing the effects of aging, A&#946; accumulation, A&#946; plaques, Tau, and LPS on various neural cells. Conditions like aging and A&#946; affect receptor expression, cell length, and ciliation rate. Annotations include cell types: neuron, dentate granule cell, pyramidal neuron, microglia, astrocyte, and A&#946; plaque. Changes include increased 5-HT6 receptor and SSTR3, halted elongation after A&#946; accumulation, and variable effects on length and ciliation.</alt-text></graphic></fig><p>Primary cilia length appears to be dynamically altered in response to A&#946; plaque deposition, potentially reflecting a protective or compensatory mechanism against neurotoxic stress. In the brains of 12-month-old amyloid precursor protein/presenilin-1 (APP/PS1) and 4-month-old 5 &#215; FAD mice, AC3-labeled neuronal primary cilia are significantly shorter in regions adjacent to A&#946; plaques compared to more distant areas. In the hippocampal CA1 region of both models, neuronal primary cilia length gradually increases with age but ceases to elongate following the onset of A&#946; accumulation (<xref rid="B23" ref-type="bibr">Guo et al., 2025</xref>).</p><p>Expression changes in primary cilia-localized GPCRs further highlight potential signaling dysregulation in AD mouse models, which may link ciliary alterations to broader pathological cascades. In APP/PS1 mice, hippocampal neurons exhibited elongated primary cilia with elevated expression of the ciliary 5-HT<sub>6</sub> receptor. Notably, treatment with the 5-HT<sub>6</sub> receptor antagonist SB-271046 ameliorated cognitive deficits in APP/PS1 mice (<xref rid="B29" ref-type="bibr">Hu et al., 2017</xref>), suggesting that dysregulated ciliary signaling may contribute to memory impairments. Similarly, Sstr3 expression was significantly elevated in the hippocampus of 12-month-old APP/PS1, 5 &#215; FAD, and 3 &#215; Tg mice relative to wild-type controls (<xref rid="B23" ref-type="bibr">Guo et al., 2025</xref>).</p><p>Aging effects on primary cilia in AD mouse models diverge from those in wild-type mice, indicating that AD pathology may override normal age-related ciliary dynamics, potentially accelerating neuronal vulnerability. For instance, APP<sup>NL&#8722;G-F</sup> mice showed no age-dependent elongation of neuronal primary cilia in the CA1 or CA3 regions, unlike wild-type mice (<xref rid="B36" ref-type="bibr">Kobayashi et al., 2022</xref>). Similarly, Chakravarthy et al. reported that the length of Sstr3-labeled cilia in hippocampal granule cells remains unchanged in APPswe/PSEN1dE9 (6&#8211;8 months) and Tau P301S (3&#8211;4 months) mice compared to age-matched wild-type controls, whereas 3xTg mice exhibit significantly shorter cilia across multiple ages (6&#8211;24 months), pointing to model-specific disruptions (<xref rid="B15" ref-type="bibr">Chakravarthy et al., 2012</xref>).</p><p>Primary cilia alterations extend beyond neurons to immune cells, underscoring a potential role in AD-associated neuroinflammation that may integrate with other pathological features. In 6-month-old 5xFAD mice, AC3-positive microglial primary cilia were significantly reduced in the lateral septum and absent in the cortex, with microglia in the lateral septum exhibited shorter primary cilia compared to age-matched wild-type controls (<xref rid="B75" ref-type="bibr">Yeo et al., 2023</xref>). Further evidence from Baek et al. demonstrated that, 1 day after intracerebroventricular injection of lipopolysaccharide (LPS) in C57BL/6 mice, there was a reduction in both the length of AC3-labeled primary cilia and the expression of Arl13b in the hippocampus, accompanied by increased levels of inflammatory mediators, including Cox2 and iNOS. In contrast, toll-like receptor 4 (<italic toggle="yes">Tlr4</italic>) knockout mice show increased primary ciliary length and elevated Arl13b expression following LPS administration, without significant changes in Cox2 and iNOS levels. Similar effects occur <italic toggle="yes">in vitro</italic>: HT22 hippocampal cells exhibit shortened primary cilia after just 1 h of LPS exposure, with marked Arl13b reduction after 6 h, while LPS does not significantly alter Arl13b expression level in primary neurons from <italic toggle="yes">Tlr4</italic>
<sup>
<italic toggle="yes">&#8722;/&#8722;</italic>
</sup> mice. In kinesin family member 3A (<italic toggle="yes">Kif3a</italic>) knockdown HT22 cells, 24-h LPS exposure fails to elicit an inflammatory response but results in a slight increase in Arl13b expression (<xref rid="B6" ref-type="bibr">Baek et al., 2017</xref>), suggesting that intact primary ciliary signaling may be required for efficient neuroinflammatory activation.</p><p>Emerging evidence also implicates primary cilia in protein clearance mechanisms, suggesting a speculative link to AD&#8217;s hallmark protein accumulations and cellular stress responses. In 5xFAD mice, macrophage migration inhibitory factor (MIF) localizes to both dystrophic axons near A&#946; plaques and to the basal end of AC3-positive cilia in the hippocampus. The accumulation of MIF around the nucleus, together with ubiquitin, implies that primary cilia may facilitate neuronal clearance processes, potentially contributing to axonal dystrophy and extracellular vesicle accumulation within axonal spheroids (<xref rid="B31" ref-type="bibr">Jang et al., 2023</xref>).</p><p>Taken together, these studies suggest that primary cilia undergo context-dependent remodeling in AD models, which may serve as a marker of local pathological stress or a functional modulator of neuronal and glial responses. Whether these changes are protective, maladaptive, or a combination of both remains unresolved, but the accumulating evidence highlights primary cilia as active participants in AD pathogenesis, warranting further investigation into their mechanistic roles and therapeutic potential.</p></sec><sec id="s5"><title>The role of primary cilium in aging, cognition, and AD pathogenesis</title><p>Primary cilia have emerged as multifunctional organelles involved in proteostasis, neuroinflammation, and cognitive processes, thereby intersecting with multiple aspects of AD pathogenesis.</p><p>Aging is well established as a major risk factor for AD. Rivagorda et al. reported that the age-related decline in autophagy machinery in hippocampal neurons, which contributes to memory deficits, is associated with a marked reduction in primary cilium components, including Ift20, Ift88, and Kif3a, at both the mRNA and protein levels in the hippocampus of aged (16-month-old) C57 mice. Restoration of Ift20 expression in the hippocampus was sufficient to enhance autophagy activity in the CA3 region and reverse age-related cognitive deficits. Complementing these findings, the osteocalcin receptor GPR158 was found to be localized to the primary cilium of hippocampal neurons, where it mediates osteocalcin-regulated autophagy. Mechanistically, this effect depended on a primary cilium-CREB signaling pathway. Together, these findings emphasize the primary cilium&#8211;autophagy axis as a signaling route between blood-borne factors and neurons, providing new insight into the mechanisms underlying age-related cognitive decline (<xref rid="B53" ref-type="bibr">Rivagorda et al., 2025</xref>).</p><p>Disruption of primary cilia-related proteins across diverse brain cell types&#8212;including neurons, glia, and neural stem cells&#8212;results in cognitive deficits (<xref rid="T2" ref-type="table">Tables 2</xref>, <xref rid="T3" ref-type="table">3</xref>). Hippocampal and cortical neuron-specific <italic toggle="yes">Ift88</italic> knockdown selectively impairs aversive and recognition memory while sparing spatial memory, and is accompanied by increased paired-pulse facilitation without changes in LTP, as shown by field excitatory postsynaptic potential recordings (<xref rid="B9" ref-type="bibr">Berbari et al., 2014</xref>). Beyond neurons, IFT88 is also critical in glial cells: astrocyte-specific <italic toggle="yes">Ift88</italic> knockout prevents the induction of C3-positive astrocytes by LPS or cytokine mixture (IL-1&#945;, TNF&#945;, and C1q) and protects against LPS-induced cognitive impairment observed in wild-type mice (<xref rid="B44" ref-type="bibr">Muhamad et al., 2024</xref>). Consistently, global <italic toggle="yes">Ift88</italic> knockout mice exhibit broad neurological impairments, including learning deficits, sleep architecture alteration, reduced electroencephalogram power, and diminished phase-amplitude coupling (<xref rid="B58" ref-type="bibr">Strobel et al., 2025</xref>). Other cilia-related proteins also impact memory. Knockout of AC3 impairs memory for temporally dissociative passive avoidance but does not affect contextual fear memory and short-term memory for novel object recognition (<xref rid="B66" ref-type="bibr">Wang et al., 2011</xref>). Conditional postnatal ablation of <italic toggle="yes">Ift20</italic> in mature dentate granule cells impairs hippocampus-dependent contextual memory and enhances LTP at mossy fiber synapses, a phenotype also observed with Kif3a disruption models (<xref rid="B52" ref-type="bibr">Rhee et al., 2016</xref>). Additionally, <italic toggle="yes">Ift20</italic> deletion in adult GFAP<sup>+</sup> neural stem/progenitor cells reduces AC3-marked primary cilia in radial neural stem cells and decreases amplifying progenitor proliferation in hippocampal DG, without affecting quiescent progenitors or radial neural stem cells. This correlates with impaired spatial novelty recognition and heightened hippocampus-independent cue conditioning responses (<xref rid="B1" ref-type="bibr">Amador-Arjona et al., 2011</xref>). Collectively, these findings underscore the indispensable role of primary ciliary proteins in cognitive processes.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Primary cilium-related genes and their functional roles in different cell.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Cell type</th><th align="center" rowspan="1" colspan="1">Primary cilium-related genes</th><th align="center" rowspan="1" colspan="1">Genetic manipulation</th><th align="center" rowspan="1" colspan="1">Experimental models</th><th align="center" rowspan="1" colspan="1">Functional outcomes</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Neuron</td><td rowspan="3" align="center" colspan="1">
<italic toggle="yes">Ift88</italic>
</td><td rowspan="3" align="center" colspan="1">knockdown</td><td align="left" rowspan="1" colspan="1">Primary mouse hippocampal neuron</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; CD63-positive extracellular vesicle containing A&#946; release&#8595;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Jang et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Microglia</td><td align="left" rowspan="1" colspan="1">BV2</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Microglial activation markers&#8595;</p></list-item><list-item><p>&#8226; Phagocytic activity&#8593;</p></list-item><list-item><p>&#8226; A&#946;-containing EV release&#8593;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B75" ref-type="bibr">Yeo et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Astrocyte</td><td align="left" rowspan="1" colspan="1">Primary mouse astrocyte</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Cytokine mixture (IL-1&#945;, TNF&#945;, and C1q)- or LPS-induced C3-positive astrocytes&#8595;</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Muhamad et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Neuron</td><td rowspan="2" align="center" colspan="1">
<italic toggle="yes">Sstr3</italic>
</td><td rowspan="2" align="center" colspan="1">knockout</td><td rowspan="2" align="left" colspan="1">
<italic toggle="yes">Sstr3</italic>
<sup>&#8722;/&#8722;</sup> &#215; 5 &#215; FAD</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Apoptosis&#8593; in CA1 region</p></list-item><list-item><p>&#8226; Number of swollen axonal structures surrounding A&#946; plaques&#8593;</p></list-item></list>
</td><td rowspan="2" align="left" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Microglia</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Activation&#8593; in CA1 region</p></list-item><list-item><p>&#8226; Aggregation around A&#946;&#8595;</p></list-item></list>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Neural stem/progenitor cells</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Ift20</italic>
</td><td align="center" rowspan="1" colspan="1">knockout</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Ift20</italic>
<sup>
<italic toggle="yes">flox/flox</italic>
</sup> under control of the mGFAP-Cre</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; AC3-marked primary cilia in radial neural stem cells&#8595;</p></list-item><list-item><p>&#8226; Amplifying progenitor proliferation&#8595; in hippocampal DG</p></list-item><list-item><p>&#8226; Quiescent progenitors or radial neural stem cells are not affected</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B1" ref-type="bibr">Amador-Arjona et al. (2011)</xref>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Primary cilium-related genes and their cognitive and pathological roles in mouse models.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Genes</th><th align="center" rowspan="1" colspan="1">Genetic models</th><th align="center" rowspan="1" colspan="1">Cognitive impacts</th><th align="center" rowspan="1" colspan="1">Roles in AD pathology</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Sstr3</italic>
</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Sstr3</italic>
<sup>&#8722;/&#8722;</sup> &#215; 5 &#215; FAD</td><td align="center" rowspan="1" colspan="1">Not studied</td><td align="center" rowspan="1" colspan="1">&#8226; A&#946; aggregation&#8593;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B23" ref-type="bibr">Guo et al. (2025)</xref>
</td></tr><tr><td rowspan="3" align="center" colspan="1">
<italic toggle="yes">Ift88</italic>
</td><td align="center" rowspan="1" colspan="1">Knockout mice</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Learning deficits</p></list-item><list-item><p>&#8226; Electroencephalogram power&#8595; and diminished phase-amplitude coupling</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B58" ref-type="bibr">Strobel et al. (2025)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Hippocampal and cortical neuron-specific knockdown mice</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Aversive and recognition memory impaired</p></list-item><list-item><p>&#8226; Paired-pulse facilitation &#8593; with no changes in LTP</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Berbari et al. (2014)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Astrocyte-specific knockout mice</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; LPS-induced cognitive impairment&#8595;</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Muhamad et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">AC3</italic>
</td><td align="center" rowspan="1" colspan="1">Knockout mice</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Memory for temporally dissociative passive avoidance&#8595;</p></list-item><list-item><p>&#8226; Contextual fear memory and short-term memory for novel object recognition not affected</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B66" ref-type="bibr">Wang et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Kif3a</italic>
</td><td align="center" rowspan="1" colspan="1">Expression of a dominant negative Kif3a in mature dentate granule cells in mice, via stereotaxic injection of AAV9-DIO-dnKif3A into adult dentate gyrus</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Hippocampus-dependent contextual memory&#8595;</p></list-item><list-item><p>&#8226; LTP at mossy fiber synapses&#8593;</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="2" align="center" colspan="1">
<xref rid="B52" ref-type="bibr">Rhee et al. (2016)</xref>
</td></tr><tr><td rowspan="3" align="center" colspan="1">
<italic toggle="yes">Ift20</italic>
</td><td align="center" rowspan="1" colspan="1">Postnatal deletion: <italic toggle="yes">IFT20</italic>
<sup>
<italic toggle="yes">foxl/flox</italic>
</sup> mice stereotaxically injected with AAV-CaMKII-eGFP-Cre virus at adult dentate gyrus</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Hippocampus-dependent contextual memory&#8595;</p></list-item><list-item><p>&#8226; LTP at mossy fiber synapses&#8593;</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">Ift20</italic>
<sup>
<italic toggle="yes">flox/flox</italic>
</sup> under control of the mGFAP-Cre</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Spatial novelty recognition&#8595;</p></list-item><list-item><p>&#8226; Hippocampus-independent cue conditioning responses&#8593;</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B1" ref-type="bibr">Amador-Arjona et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Aged C57 mice (16-month-old)</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#8226; Autophagy machinery&#8595; in hippocampal neurons</p></list-item><list-item><p>&#8226; Memory deficits</p></list-item><list-item><p>&#8226; Restoring Ift20 levels in the hippocampus enhanced autophagy activity in the CA3 region and reverse age-related cognitive deficits</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">
<xref rid="B53" ref-type="bibr">Rivagorda et al. (2025)</xref>
</td></tr></tbody></table></table-wrap><p>Primary cilia have been implicated in the regulation of extracellular vesicle (EV) transport, which is critical for the clearance of A&#946;. Disruption of primary cilia by <italic toggle="yes">Ift88</italic> knockdown in primary hippocampal neurons reduced CD63-positive EV release, resulting in intracellular A&#946; accumulation and enhanced extracellular A&#946; uptake, thereby linking primary ciliary dysfunction to AD pathology (<xref rid="B31" ref-type="bibr">Jang et al., 2023</xref>). In microglia, <italic toggle="yes">Ift88</italic> knockdown reduced activation potential, enhanced phagocytic activity, and promoted A&#946;-containing EV release, linking primary ciliary function to neuroinflammatory responses (<xref rid="B75" ref-type="bibr">Yeo et al., 2023</xref>). Together, these findings suggest that ciliary dysfunction may impair cooperative mechanisms of A&#946; clearance across neuronal and glial compartments.</p><p>Ciliary morphology is directly influenced by amyloid pathology. Consistent with findings from AD model mice, <italic toggle="yes">in vitro</italic> data show that A&#946; reduces primary cilia length. Exogenous A&#946;<sub>1</sub>&#8211;<sub>42</sub> exposure shortened the primary cilia of cultured mouse neurons without affecting the ciliation rates, whereas tau overexpression does not alters ciliary length or ciliation rate (<xref rid="B23" ref-type="bibr">Guo et al., 2025</xref>), suggesting a selective vulnerability to A&#946;. Intriguingly, hippocampal neurons derived from multiple transgenic AD mouse models (APP/PS1, 5 &#215; FAD, and 3 &#215; Tg) exhibit elongated cilia during early <italic toggle="yes">in vitro</italic> development (Day 7), even before detectable A&#946; deposition or altered secretion (<xref rid="B23" ref-type="bibr">Guo et al., 2025</xref>). This temporal dissociation suggests that primary ciliary remodeling may represent an early event preceding overt amyloid pathology.</p><p>Functional study suggests that primary ciliary GPCRs play a role in regulating plaque pathology. In offspring of <italic toggle="yes">Sstr3</italic> knockout mice crossed with 5 &#215; FAD mice (Sstr3<sup>&#8722;/&#8722;</sup> &#215; 5 &#215; FAD, 4 months old), the loss of the primary ciliary-localized receptor Sstr3 worsened A&#946; accumulation, increased hippocampal neuronal apoptosis, and heightened microglial reactivity in the CA1 region. However, paradoxically, it reduced microglial clustering around A&#946; plaques compared to 5 &#215; FAD controls (<xref rid="B23" ref-type="bibr">Guo et al., 2025</xref>). This highlights that primary cilia-dependent GPCR signaling is involved in neuroimmune dynamics in AD.</p><p>Growing evidence indicates that primary cilia influence diverse pathological processes in AD&#8212;ranging from tau pathology and cerebrospinal fluid dysregulation to cellular responses to hypoxia&#8212;that collectively contribute to disease progression. Tau pathology, characterized by abnormal hyperphosphorylation and aggregation of tau protein, is a central hallmark of AD. The neurotrophin receptor p75<sup>NTR</sup>, which mediates A&#946;-induced tau phosphorylation, may act in part through the primary ciliary compartment, suggesting a role for primary cilia in modulating tau-related signaling pathways (<xref rid="B14" ref-type="bibr">Chakravarthy et al., 2010</xref>; <xref rid="B55" ref-type="bibr">Shen et al., 2019</xref>). Disruption of CSF dynamics, which impairs the clearance of metabolic waste and A&#946;, has also been implicated in AD. In the choroid plexus epithelium, primary cilia act as clustered chemosensors that regulate CSF production, and the neuropeptide FF receptor 2, localized to primary cilia, modulates fluid transcytosis in these cells (<xref rid="B46" ref-type="bibr">Narita et al., 2010</xref>). Cellular responses to hypoxia, another contributing factor in AD pathogenesis, are also linked to ciliary function. Under hypoxic conditions, neuronal primary cilia elongated and exhibited increased levels of Ift88 while hypoxia-inducible factor-2&#945; accumulates within the primary cilium and interacts with Ift88 (<xref rid="B40" ref-type="bibr">Leu et al., 2023</xref>). In rat models of chronic cerebral hypoperfusion&#8212;a hypoxia-related condition&#8212;astrocytic primary cilia are shortened, but physical exercise restores ciliary length and density (<xref rid="B13" ref-type="bibr">Cao et al., 2022</xref>). Together, these findings suggest that primary cilia play diverse roles across multiple AD-related pathologies. However, direct studies in AD models remain limited, highlighting a significant knowledge gap and the need for further mechanistic investigation.</p></sec><sec id="s6"><title>Discussion and conclusion</title><p>Primary cilia are dynamic organelles that coordinate signaling, inter-organelle communication, and extracellular interactions across neurons, glia, and choroid plexus epithelial cells. They exhibit notable morphological diversity&#8212;including variations in length, spatial distribution, and microtubule architecture&#8212;which is further influenced by age, brain region, and cell type. Primary ciliary-localized GPCRs and other signaling proteins regulate key neural processes such as memory, synaptic plasticity, and neuronal excitability, yet the mechanistic consequences of their precise ciliary positioning remain incompletely understood.</p><p>In the context of AD, primary cilia are increasingly recognized as key players in disease-related processes. In transgenic AD models, neuronal and glial cilia exhibit region- and cell-type-specific morphological alterations, ranging from elongation to shortening, often associated with AD-linked genetic mutations (<xref rid="T1" ref-type="table">Table 1</xref>). Separately, disruption of ciliary components or signaling proteins&#8212;including Ift88, Ift20, Kif3a, and ciliary GPCRs&#8212;induces structural changes that are accompanied by impaired A&#946; clearance, altered neuroinflammatory responses, and cognitive deficits (<xref rid="T2" ref-type="table">Tables 2</xref>, <xref rid="T3" ref-type="table">3</xref>). Mechanistic evidence indicates that these effects involve ciliary GPCR signaling, autophagy-related pathways, and inter-organelle communication, particularly via extracellular vesicle trafficking, highlighting the central role of primary cilia in coordinating cellular functions relevant to AD pathology. These findings position primary cilia not merely as structural organelles but as active modulators of the interplay between A&#946; accumulation, neuroinflammation, and neural circuit dysfunction. APP, which is cleaved by &#946;- and &#947;-secretases to generate A&#946;, has been shown to localize to primary cilia in NIH3T3 and HeLa cells (<xref rid="B65" ref-type="bibr">Vorobyeva and Saunders, 2018</xref>; <xref rid="B16" ref-type="bibr">Chebli et al., 2021</xref>). However, whether APP similarly localizes to primary cilia in brain-resident cells remains unclear. A deeper understanding of primary ciliary function across diverse AD models may reveal novel therapeutic targets for intervention.</p><p>Beyond A&#946; pathology, primary cilia intersect with multiple AD-relevant processes, including tau signaling, cerebrospinal fluid regulation, autophagy, and cellular responses to hypoxia, reflecting their broad functional involvement. Primary cilia also engage in dynamic interactions with other cellular organelles, shaping cellular function under both physiological and pathological conditions. For example, astrocytic mitochondrial dysfunction disrupts ciliary structure (<xref rid="B30" ref-type="bibr">Ignatenko et al., 2023</xref>), and extracellular vesicles released from primary cilia carry biomarkers&#8212;such as NADPH-cytochrome P450 reductase, Topoisomerase II Alpha, and CD151&#8212;that interact with AD-related proteins including APP, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, and Cathepsin B (<xref rid="B43" ref-type="bibr">Mohieldin et al., 2021</xref>). These observations suggest that primary cilia act not only as sensory hubs but also as mediators of inter-organelle crosstalk, potentially maintaining neuronal integrity and modulating neurodegenerative processes. Nevertheless, many findings remain correlational, and it is unclear whether ciliary remodeling represents a causal driver or a compensatory response to cellular stress. Discrepancies across models, differences between neuronal and glial cilia, and limited validation in human brain tissue further highlight the need for cautious interpretation. Collectively, these data indicate that primary cilia contribute to AD through diverse mechanisms, underscoring the need for further mechanistic studies to clarify their molecular roles and therapeutic potential.</p><p>Despite these gaps, primary cilia emerge as integrative hubs that coordinate intracellular signaling, inter-organelle communication, and extracellular interactions, thereby influencing cognitive function and modulating neurodegenerative processes. Future research should focus on: (1) dissecting cell-type- and brain region-specific ciliary mechanisms, including the role of individual ciliary proteins; (2) clarifying the temporal sequence of ciliary remodeling relative to amyloid and tau pathology and other AD-related stressors; and (3) evaluating the therapeutic potential of cilia-targeted interventions in translational and human-relevant models. Addressing these questions will be essential to establish whether primary cilia act as causal drivers, compensatory responders, or both in AD pathogenesis, and may ultimately reveal novel strategies for modulating neurodegeneration through ciliary pathways.</p></sec></body><back><ack><p>The authors thank Hong Kong Baptist University for Seed Fund support to Catherine Hong-Huan HOR, and Hong Kong Research Grant Council for Collaborative Research Fund support to Catherine Hong-Huan HOR.</p></ack><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>AH: Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. AL: Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. CH: Writing &#8211; review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that Generative AI was used in the creation of this manuscript. ChatGPT.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amador-Arjona</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ginbey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pazour</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Enikolopov</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Primary cilia regulate proliferation of amplifying progenitors in adult hippocampus: implications for learning and memory</article-title>. <source>J. Neurosci.</source><volume>31</volume> (<issue>27</issue>), <fpage>9933</fpage>&#8211;<lpage>9944</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1062-11.2011</pub-id><pub-id pub-id-type="pmid">21734285</pub-id><pub-id pub-id-type="pmcid">PMC3758574</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arellano</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Guadiana</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Breunig</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rakic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarkisian</surname><given-names>M. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Development and distribution of neuronal cilia in mouse neocortex</article-title>. <source>J. Comp. Neurol.</source><volume>520</volume> (<issue>4</issue>), <fpage>848</fpage>&#8211;<lpage>873</lpage>. <pub-id pub-id-type="doi">10.1002/cne.22793</pub-id><pub-id pub-id-type="pmid">22020803</pub-id><pub-id pub-id-type="pmcid">PMC3325766</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arrojo</surname><given-names>E. D. R.</given-names></name><name name-style="western"><surname>Lev-Ram</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramachandra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deerinck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bushong</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Age mosaicism across multiple scales in adult tissues</article-title>. <source>Cell Metab.</source><volume>30</volume> (<issue>2</issue>), <fpage>343</fpage>&#8211;<lpage>351.e343</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2019.05.010</pub-id><pub-id pub-id-type="pmid">31178361</pub-id><pub-id pub-id-type="pmcid">PMC7289515</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awata</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Standley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lechtreck</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Bellv&#233;</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Pazour</surname><given-names>G. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>NPHP4 controls ciliary trafficking of membrane proteins and large soluble proteins at the transition zone</article-title>. <source>J. Cell Sci.</source><volume>127</volume> (<issue>Pt 21</issue>), <fpage>4714</fpage>&#8211;<lpage>4727</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.155275</pub-id><pub-id pub-id-type="pmid">25150219</pub-id><pub-id pub-id-type="pmcid">PMC4215714</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badgandi</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.-h.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Loriot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Tubby family proteins are adapters for ciliary trafficking of integral membrane proteins</article-title>. <source>J. Cell Biol.</source><volume>216</volume> (<issue>3</issue>), <fpage>743</fpage>&#8211;<lpage>760</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201607095</pub-id><pub-id pub-id-type="pmid">28154160</pub-id><pub-id pub-id-type="pmcid">PMC5350516</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M. H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Primary cilia modulate TLR4-mediated inflammatory responses in hippocampal neurons</article-title>. <source>J. Neuroinflammation</source><volume>14</volume> (<issue>1</issue>), <fpage>189</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-0958-7</pub-id><pub-id pub-id-type="pmid">28927423</pub-id><pub-id pub-id-type="pmcid">PMC5606072</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbari</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Askwith</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Mykytyn</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Hippocampal neurons possess primary cilia in culture</article-title>. <source>J. Neurosci. Res.</source><volume>85</volume> (<issue>5</issue>), <fpage>1095</fpage>&#8211;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21209</pub-id><pub-id pub-id-type="pmid">17304575</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbari</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Askwith</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Mykytyn</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Bardet&#8211;Biedl syndrome proteins are required for the localization of G protein-coupled receptors to primary cilia</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>105</volume>(<issue>11</issue>)<bold>,</bold><fpage>4242</fpage>&#8211;<lpage>4246</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0711027105</pub-id><pub-id pub-id-type="pmid">18334641</pub-id><pub-id pub-id-type="pmcid">PMC2393805</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbari</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Malarkey</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Yazdi</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>McNair</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Kippe</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Croyle</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Hippocampal and cortical primary cilia are required for aversive memory in mice</article-title>. <source>PLoS One</source><volume>9</volume> (<issue>9</issue>), <fpage>e106576</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0106576</pub-id><pub-id pub-id-type="pmid">25184295</pub-id><pub-id pub-id-type="pmcid">PMC4153651</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Berbari</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mykytyn</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Type III adenylyl cyclase localizes to primary cilia throughout the adult mouse brain</article-title>. <source>J. Comp. Neurol.</source><volume>505</volume> (<issue>5</issue>), <fpage>562</fpage>&#8211;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1002/cne.21510</pub-id><pub-id pub-id-type="pmid">17924533</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brailov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bancila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brisorgueil</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Miquel</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Hamon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verg&#233;</surname><given-names>D.</given-names></name></person-group> (<year>2000</year>). <article-title>Localization of 5-HT(6) receptors at the plasma membrane of neuronal cilia in the rat brain</article-title>. <source>Brain Res.</source><volume>872</volume> (<issue>1-2</issue>), <fpage>271</fpage>&#8211;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-8993(00)02519-1</pub-id><pub-id pub-id-type="pmid">10924708</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brodsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lesiak</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Croicu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohenca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Neumaier</surname><given-names>J. F.</given-names></name></person-group> (<year>2017</year>). <article-title>5-HT(6) receptor blockade regulates primary cilia morphology in striatal neurons</article-title>. <source>Brain Res.</source><volume>1660</volume>, <fpage>10</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2017.01.010</pub-id><pub-id pub-id-type="pmid">28087224</pub-id><pub-id pub-id-type="pmcid">PMC5392252</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Physical exercise-induced astrocytic neuroprotection and cognitive improvement through primary cilia and mitogen-activated protein kinases pathway in rats with chronic cerebral hypoperfusion</article-title>. <source>Front. Aging Neurosci.</source><volume>14</volume>, <fpage>866336</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2022.866336</pub-id><pub-id pub-id-type="pmid">35721009</pub-id><pub-id pub-id-type="pmcid">PMC9198634</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarthy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#233;nard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chiarini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dal Pr&#224;</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>The p75 neurotrophin receptor is localized to primary cilia in adult murine hippocampal dentate gyrus granule cells</article-title>. <source>Biochem. Biophysical Res. Commun.</source><volume>401</volume> (<issue>3</issue>), <fpage>458</fpage>&#8211;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2010.09.081</pub-id><pub-id pub-id-type="pmid">20875398</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarthy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#233;nard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>T.</given-names></name><name name-style="western"><surname>LaFerla</surname><given-names>F. M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Reduction of the immunostainable length of the hippocampal dentate granule cells&#8217; primary cilia in 3xAD-transgenic mice producing human A&#946;1-42 and tau</article-title>. <source>Biochem. Biophysical Res. Commun.</source><volume>427</volume> (<issue>1</issue>), <fpage>218</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.09.056</pub-id><pub-id pub-id-type="pmid">22995307</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chebli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rahmati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Edeman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oldfors</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The localization of amyloid precursor protein to ependymal cilia in vertebrates and its role in ciliogenesis and brain development in zebrafish</article-title>. <source>Sci. Rep.</source><volume>11</volume> (<issue>1</issue>), <fpage>19115</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-98487-7</pub-id><pub-id pub-id-type="pmid">34580355</pub-id><pub-id pub-id-type="pmcid">PMC8476544</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diniz</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Battagello</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Bono</surname><given-names>B. S. M.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J. G. P.</given-names></name><name name-style="western"><surname>Motta-Teixeira</surname><given-names>L. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Ciliary melanin-concentrating hormone receptor 1 (MCHR1) is widely distributed in the murine CNS in a sex-independent manner</article-title>. <source>J. Neurosci. Res.</source><volume>98</volume> (<issue>10</issue>), <fpage>2045</fpage>&#8211;<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.24651</pub-id><pub-id pub-id-type="pmid">32530066</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domire</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Mykytyn</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Markers for neuronal cilia</article-title>. <source>Methods Cell Biol.</source><volume>91</volume>, <fpage>111</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/s0091-679x(08)91006-2</pub-id><pub-id pub-id-type="pmid">20409783</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupuy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prieur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pizzoccaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Margarido</surname><given-names>C.</given-names></name><name name-style="western"><surname>Valjent</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bockaert</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Spatiotemporal dynamics of 5-HT(6) receptor ciliary localization during mouse brain development</article-title>. <source>Neurobiol. Dis.</source><volume>176</volume>, <fpage>105949</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2022.105949</pub-id><pub-id pub-id-type="pmid">36496200</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Einstein</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Hon</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Regan</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Reddi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Melnikoff</surname><given-names>D. E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Somatostatin signaling in neuronal cilia is critical for object recognition memory</article-title>. <source>J. Neurosci.</source><volume>30</volume> (<issue>12</issue>), <fpage>4306</fpage>&#8211;<lpage>4314</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.5295-09.2010</pub-id><pub-id pub-id-type="pmid">20335466</pub-id><pub-id pub-id-type="pmcid">PMC3842454</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mykytyn</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Heteromerization of ciliary G protein-coupled receptors in the mouse brain</article-title>. <source>PLoS One</source><volume>7</volume> (<issue>9</issue>), <fpage>e46304</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0046304</pub-id><pub-id pub-id-type="pmid">23029470</pub-id><pub-id pub-id-type="pmcid">PMC3459911</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guadiana</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Filho</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Sequeira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Semple-Rowland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Type 3 adenylyl cyclase and somatostatin receptor 3 expression persists in aged rat neocortical and hippocampal neuronal cilia</article-title>. <source>Front. Aging Neurosci.</source><volume>8</volume>, <fpage>127</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2016.00127</pub-id><pub-id pub-id-type="pmid">27303293</pub-id><pub-id pub-id-type="pmcid">PMC4885836</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name></person-group> (<year>2025</year>). <article-title>Changes of the primary cilia in Alzheimer's disease pathogenesis</article-title>. <source>Eur. J. Neurosci.</source><volume>61</volume> (<issue>9</issue>), <fpage>e70125</fpage>. <pub-id pub-id-type="doi">10.1111/ejn.70125</pub-id><pub-id pub-id-type="pmid">40329506</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doucet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lef&#232;vre</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miquel</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Lanfumey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Insausti</surname><given-names>R.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors</article-title>. <source>Neuropsychopharmacology</source><volume>21</volume> (<issue>2 Suppl. l</issue>), <fpage>68s</fpage>&#8211;<lpage>76s</lpage>. <pub-id pub-id-type="doi">10.1016/s0893-133x(99)00044-5</pub-id><pub-id pub-id-type="pmid">10432491</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;ndel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stanarius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schreff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Erdtmann-Vourliotis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Selective targeting of somatostatin receptor 3 to neuronal cilia</article-title>. <source>Neuroscience</source><volume>89</volume> (<issue>3</issue>), <fpage>909</fpage>&#8211;<lpage>926</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(98)00354-6</pub-id><pub-id pub-id-type="pmid">10199624</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasenpusch-Theil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Theil</surname><given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>The multifaceted roles of primary cilia in the development of the cerebral cortex</article-title>. <source>Front. Cell Dev. Biol.</source><volume>9</volume>, <fpage>630161</fpage>&#8211;<lpage>632021</lpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.630161</pub-id><pub-id pub-id-type="pmid">33604340</pub-id><pub-id pub-id-type="pmcid">PMC7884624</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesketh</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Toropova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A. J.</given-names></name></person-group> (<year>2022</year>). <article-title>IFT-A structure reveals carriages for membrane protein transport into cilia</article-title>. <source>Cell</source><volume>185</volume> (<issue>26</issue>), <fpage>4971</fpage>&#8211;<lpage>4985.e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2022.11.010</pub-id><pub-id pub-id-type="pmid">36462505</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Estrada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ferland</surname><given-names>R. J.</given-names></name></person-group> (<year>2021</year>). <article-title>The transition zone protein AHI1 regulates neuronal ciliary trafficking of MCHR1 and its downstream signaling pathway</article-title>. <source>J. Neurosci.</source><volume>41</volume> (<issue>17</issue>), <fpage>3932</fpage>&#8211;<lpage>3943</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.2993-20.2021</pub-id><pub-id pub-id-type="pmid">33741721</pub-id><pub-id pub-id-type="pmcid">PMC8084322</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function</article-title>. <source>Alzheimers Res. Ther.</source><volume>9</volume> (<issue>1</issue>), <fpage>76</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-017-0304-4</pub-id><pub-id pub-id-type="pmid">28931427</pub-id><pub-id pub-id-type="pmcid">PMC5607612</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ignatenko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Malinen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rybas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vihinen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nikkanen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kononov</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Mitochondrial dysfunction compromises ciliary homeostasis in astrocytes</article-title>. <source>J. Cell Biol.</source><volume>222</volume> (<issue>1</issue>), <fpage>e202203019</fpage>. <pub-id pub-id-type="doi">10.1083/jcb.202203019</pub-id><pub-id pub-id-type="pmid">36383135</pub-id><pub-id pub-id-type="pmcid">PMC9674092</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer&#8217;s disease</article-title>. <source>Acta Neuropathol. Commun.</source><volume>11</volume> (<issue>1</issue>), <fpage>142</fpage>. <pub-id pub-id-type="doi">10.1186/s40478-023-01637-3</pub-id><pub-id pub-id-type="pmid">37667395</pub-id><pub-id pub-id-type="pmcid">PMC10478284</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Asanuma</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Visualization of astrocytic primary cilia in the mouse brain by immunofluorescent analysis using the cilia marker Arl13b</article-title>. <source>Acta Med. Okayama</source><volume>68</volume> (<issue>6</issue>), <fpage>317</fpage>&#8211;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.18926/amo/53020</pub-id><pub-id pub-id-type="pmid">25519025</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klena</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pigino</surname><given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Structural biology of cilia and intraflagellar transport</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source><volume>38</volume>, <fpage>103</fpage>&#8211;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-120219-034238</pub-id><pub-id pub-id-type="pmid">35767872</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B. T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Alzheimer disease</article-title>. <source>Nat. Rev. Dis. Prim.</source><volume>7</volume> (<issue>1</issue>), <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sekino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koganezawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shirao</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Properties of primary cilia in melanin-concentrating hormone receptor 1-bearing hippocampal neurons <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>
</article-title>. <source>Neurochem. Int.</source><volume>142</volume>, <fpage>104902</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2020.104902</pub-id><pub-id pub-id-type="pmid">33197527</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kohbuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koganezawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sekino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shirao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saido</surname><given-names>T. C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Impairment of ciliary dynamics in an APP knock-in mouse model of Alzheimer's disease</article-title>. <source>Biochem. Biophysical Res. Commun.</source><volume>610</volume>, <fpage>85</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2022.04.050</pub-id><pub-id pub-id-type="pmid">35453040</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Janoschka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takemaru</surname><given-names>K.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A role for primary cilia in glutamatergic synaptic integration of adult-born neurons</article-title>. <source>Nat. Neurosci.</source><volume>15</volume> (<issue>3</issue>), <fpage>399</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3042</pub-id><pub-id pub-id-type="pmid">22306608</pub-id><pub-id pub-id-type="pmcid">PMC3288565</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechtreck</surname><given-names>K. F.</given-names></name></person-group> (<year>2015</year>). <article-title>IFT-cargo interactions and protein transport in cilia</article-title>. <source>Trends Biochem. Sci.</source><volume>40</volume> (<issue>12</issue>), <fpage>765</fpage>&#8211;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2015.09.003</pub-id><pub-id pub-id-type="pmid">26498262</pub-id><pub-id pub-id-type="pmcid">PMC4661101</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesiak</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohenca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Croicu</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Neumaier</surname><given-names>J. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Restoration of physiological expression of 5-HT(6) receptor into the primary cilia of null mutant neurons lengthens both primary cilia and dendrites</article-title>. <source>Mol. Pharmacol.</source><volume>94</volume> (<issue>1</issue>), <fpage>731</fpage>&#8211;<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1124/mol.117.111583</pub-id><pub-id pub-id-type="pmid">29678909</pub-id><pub-id pub-id-type="pmcid">PMC5987994</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Denda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wrobeln</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fandrey</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Hypoxia-inducible factor-2alpha affects the MEK/ERK signaling pathway via primary cilia in connection with the intraflagellar transport protein 88 homolog</article-title>. <source>Mol. Cell Biol.</source><volume>43</volume> (<issue>4</issue>), <fpage>174</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1080/10985549.2023.2198931</pub-id><pub-id pub-id-type="pmid">37074220</pub-id><pub-id pub-id-type="pmcid">PMC10153011</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Resveratrol inhibits activation of microglia after stroke through triggering translocation of Smo to primary cilia</article-title>. <source>J. Pers. Med.</source><volume>13</volume> (<issue>2</issue>), <fpage>268</fpage>. <pub-id pub-id-type="doi">10.3390/jpm13020268</pub-id><pub-id pub-id-type="pmid">36836502</pub-id><pub-id pub-id-type="pmcid">PMC9961736</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kutchy</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meigs</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Primary cilia and ciliary signaling pathways in aging and age-related brain disorders</article-title>. <source>Neurobiol. Dis.</source><volume>163</volume>, <fpage>105607</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2021.105607</pub-id><pub-id pub-id-type="pmid">34979259</pub-id><pub-id pub-id-type="pmcid">PMC9280856</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohieldin</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Alachkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nauli</surname><given-names>S. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Novel biomarkers of ciliary extracellular vesicles interact with ciliopathy and Alzheimer's associated proteins</article-title>. <source>Commun. Integr. Biol.</source><volume>14</volume> (<issue>1</issue>), <fpage>264</fpage>&#8211;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1080/19420889.2021.2017099</pub-id><pub-id pub-id-type="pmid">34992713</pub-id><pub-id pub-id-type="pmcid">PMC8726672</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhamad</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Masutani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Toriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Astrocyte-specific inhibition of the primary cilium suppresses C3 expression in reactive astrocyte</article-title>. <source>Cell Mol. Neurobiol.</source><volume>44</volume> (<issue>1</issue>), <fpage>48</fpage>. <pub-id pub-id-type="doi">10.1007/s10571-024-01482-5</pub-id><pub-id pub-id-type="pmid">38822888</pub-id><pub-id pub-id-type="pmcid">PMC11144130</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chih</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Scales</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia</article-title>. <source>Genes Dev.</source><volume>24</volume> (<issue>19</issue>), <fpage>2180</fpage>&#8211;<lpage>2193</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1966210</pub-id><pub-id pub-id-type="pmid">20889716</pub-id><pub-id pub-id-type="pmcid">PMC2947770</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawate</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kakinuma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Multiple primary cilia modulate the fluid transcytosis in choroid plexus epithelium</article-title>. <source>Traffic</source><volume>11</volume> (<issue>2</issue>), <fpage>287</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2009.01016.x</pub-id><pub-id pub-id-type="pmid">19958467</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nixon</surname><given-names>R. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease</article-title>. <source>FASEB J.</source><volume>31</volume> (<issue>7</issue>), <fpage>2729</fpage>&#8211;<lpage>2743</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201700359</pub-id><pub-id pub-id-type="pmid">28663518</pub-id><pub-id pub-id-type="pmcid">PMC6137496</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pala</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alomari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nauli</surname><given-names>S. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Primary cilium-dependent signaling mechanisms</article-title>. <source>Int. J. Mol. Sci.</source><volume>18</volume> (<issue>11</issue>), <fpage>2272</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18112272</pub-id><pub-id pub-id-type="pmid">29143784</pub-id><pub-id pub-id-type="pmcid">PMC5713242</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>M. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Composition, organization and mechanisms of the transition zone, a gate for the cilium</article-title>. <source>EMBO Rep.</source><volume>23</volume> (<issue>12</issue>), <fpage>e55420</fpage>. <pub-id pub-id-type="doi">10.15252/embr.202255420</pub-id><pub-id pub-id-type="pmid">36408840</pub-id><pub-id pub-id-type="pmcid">PMC9724682</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Plotnikova</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Pugacheva</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Golemis</surname><given-names>E. A.</given-names></name></person-group> (<year>2009</year>). &#8220;<article-title>Chapter 7 - primary cilia and the cell cycle</article-title>,&#8221; in <source>Methods in cell biology</source>. Editor <person-group person-group-type="editor"><name name-style="western"><surname>Sloboda</surname><given-names>R. D.</given-names></name></person-group> (<publisher-name>Academic Press</publisher-name>), <fpage>137</fpage>&#8211;<lpage>160</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0091-679X(08)94007-3</pub-id><pub-id pub-id-type="pmcid">PMC2852269</pub-id><pub-id pub-id-type="pmid">20362089</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiter</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>M. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Genes and molecular pathways underpinning ciliopathies</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>18</volume> (<issue>9</issue>), <fpage>533</fpage>&#8211;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.60</pub-id><pub-id pub-id-type="pmid">28698599</pub-id><pub-id pub-id-type="pmcid">PMC5851292</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirschen</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Depletion of primary cilia from mature dentate granule cells impairs hippocampus-dependent contextual memory</article-title>. <source>Sci. Rep.</source><volume>6</volume>, <fpage>34370</fpage>. <pub-id pub-id-type="doi">10.1038/srep34370</pub-id><pub-id pub-id-type="pmid">27678193</pub-id><pub-id pub-id-type="pmcid">PMC5039642</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivagorda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romeo-Guitart</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blanchet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mailliet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boitez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>A primary cilia-autophagy axis in hippocampal neurons is essential to maintain cognitive resilience</article-title>. <source>Nat. Aging</source><volume>5</volume> (<issue>3</issue>), <fpage>450</fpage>&#8211;<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-024-00791-0</pub-id><pub-id pub-id-type="pmid">39984747</pub-id><pub-id pub-id-type="pmcid">PMC11922775</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name><name name-style="western"><surname>H&#228;ndel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schreff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>H&#246;llt</surname><given-names>V.</given-names></name></person-group> (<year>2000</year>). <article-title>Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies</article-title>. <source>J. Physiology-Paris</source><volume>94</volume> (<issue>3</issue>), <fpage>259</fpage>&#8211;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/S0928-4257(00)00212-6</pub-id><pub-id pub-id-type="pmid">11088003</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.-W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.-Y.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>X.-L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Neurotrophin receptor p75 mediates amyloid &#946;-induced tau pathology</article-title>. <source>Neurobiol. Dis.</source><volume>132</volume>, <fpage>104567</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2019.104567</pub-id><pub-id pub-id-type="pmid">31394202</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheu</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Upadhyayula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dupuy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A serotonergic axon-cilium synapse drives nuclear signaling to alter chromatin accessibility</article-title>. <source>Cell</source><volume>185</volume> (<issue>18</issue>), <fpage>3390</fpage>&#8211;<lpage>3407.e18</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2022.07.026</pub-id><pub-id pub-id-type="pmid">36055200</pub-id><pub-id pub-id-type="pmcid">PMC9789380</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sipos</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>Komoly</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#193;cs</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Quantitative comparison of primary cilia marker expression and length in the mouse brain</article-title>. <source>J. Mol. Neurosci.</source><volume>64</volume> (<issue>3</issue>), <fpage>397</fpage>&#8211;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-018-1036-z</pub-id><pub-id pub-id-type="pmid">29464516</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strobel</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2025</year>). <article-title>Temporal ablation of the ciliary protein IFT88 alters normal brainwave patterns</article-title>. <source>Sci. Rep.</source><volume>15</volume> (<issue>1</issue>), <fpage>347</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-83432-1</pub-id><pub-id pub-id-type="pmid">39747370</pub-id><pub-id pub-id-type="pmcid">PMC11697071</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bulgakov</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>McGinnis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Tubby is required for trafficking G protein-coupled receptors to neuronal cilia</article-title>. <source>Cilia</source><volume>1</volume> (<issue>1</issue>), <fpage>21</fpage>. <pub-id pub-id-type="doi">10.1186/2046-2530-1-21</pub-id><pub-id pub-id-type="pmid">23351594</pub-id><pub-id pub-id-type="pmcid">PMC3599646</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Bowser</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Pentecost</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Three-dimensional architecture of epithelial primary cilia</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume> (<issue>19</issue>), <fpage>9370</fpage>&#8211;<lpage>9379</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1821064116</pub-id><pub-id pub-id-type="pmid">31004057</pub-id><pub-id pub-id-type="pmcid">PMC6511023</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2021</year>). <article-title>5-HT6R null mutatrion induces synaptic and cognitive defects</article-title>. <source>Aging Cell</source><volume>20</volume> (<issue>6</issue>), <fpage>e13369</fpage>. <pub-id pub-id-type="doi">10.1111/acel.13369</pub-id><pub-id pub-id-type="pmid">33960602</pub-id><pub-id pub-id-type="pmcid">PMC8208783</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tereshko</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cary</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Turrigiano</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Ciliary neuropeptidergic signaling dynamically regulates excitatory synapses in postnatal neocortical pyramidal neurons</article-title>. <source>eLife</source><volume>10</volume>, <fpage>e65427</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.65427</pub-id><pub-id pub-id-type="pmid">33650969</pub-id><pub-id pub-id-type="pmcid">PMC7952091</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Hoek</surname><given-names>H.</given-names></name><name name-style="western"><surname>Klena</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Alvarez Viar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Righetto</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Schaffer</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>
<italic toggle="yes">In situ</italic> architecture of the ciliary base reveals the stepwise assembly of intraflagellar transport trains</article-title>. <source>Science</source><volume>377</volume> (<issue>6605</issue>), <fpage>543</fpage>&#8211;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1126/science.abm6704</pub-id><pub-id pub-id-type="pmid">35901159</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vien</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Ta</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Onay</surname><given-names>T.</given-names></name><name name-style="western"><surname>DeCaen</surname><given-names>P. G.</given-names></name></person-group> (<year>2023</year>). <article-title>Primary cilia TRP channel regulates hippocampal excitability</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>120</volume> (<issue>22</issue>), <fpage>e2219686120</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2219686120</pub-id><pub-id pub-id-type="pmid">37216541</pub-id><pub-id pub-id-type="pmcid">PMC10235993</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vorobyeva</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Amyloid-&#946; interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure</article-title>. <source>Cilia</source><volume>7</volume> (<issue>1</issue>), <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s13630-018-0059-y</pub-id><pub-id pub-id-type="pmid">30140428</pub-id><pub-id pub-id-type="pmcid">PMC6098584</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>D. R.</given-names></name></person-group> (<year>2011</year>). <article-title>The type 3 adenylyl cyclase is required for novel object learning and extinction of contextual memory: role of cAMP signaling in primary cilia</article-title>. <source>J. Neurosci.</source><volume>31</volume> (<issue>15</issue>), <fpage>5557</fpage>&#8211;<lpage>5561</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.6561-10.2011</pub-id><pub-id pub-id-type="pmid">21490195</pub-id><pub-id pub-id-type="pmcid">PMC3091825</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Cilia function is associated with axon initial segment morphology</article-title>. <source>Biochem. Biophysical Res. Commun.</source><volume>516</volume> (<issue>1</issue>), <fpage>15</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.172</pub-id><pub-id pub-id-type="pmid">31186137</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Primary cilia signaling in astrocytes mediates development and regional-specific functional specification</article-title>. <source>Nat. Neurosci.</source><volume>27</volume> (<issue>9</issue>), <fpage>1708</fpage>&#8211;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-024-01726-z</pub-id><pub-id pub-id-type="pmid">39103557</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pashang</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>The primary cilia are associated with the axon initial segment in neurons</article-title>. <source>Adv. Sci. (Weinh)</source><volume>12</volume> (<issue>9</issue>), <fpage>e2407405</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202407405</pub-id><pub-id pub-id-type="pmid">39804991</pub-id><pub-id pub-id-type="pmcid">PMC11884599</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>The BBSome controls IFT assembly and turnaround in cilia</article-title>. <source>Nat. Cell Biol.</source><volume>14</volume> (<issue>9</issue>), <fpage>950</fpage>&#8211;<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2560</pub-id><pub-id pub-id-type="pmid">22922713</pub-id><pub-id pub-id-type="pmcid">PMC3434251</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheatley</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Strugnell</surname><given-names>G. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Expression of primary cilia in mammalian cells</article-title>. <source>Cell Biol. Int.</source><volume>20</volume> (<issue>1</issue>), <fpage>73</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1006/cbir.1996.0011</pub-id><pub-id pub-id-type="pmid">8936410</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wingfield</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Lechtreck</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Lorentzen</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>Trafficking of ciliary membrane proteins by the intraflagellar transport/BBSome machinery</article-title>. <source>Essays Biochem.</source><volume>62</volume> (<issue>6</issue>), <fpage>753</fpage>&#8211;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1042/ebc20180030</pub-id><pub-id pub-id-type="pmid">30287585</pub-id><pub-id pub-id-type="pmcid">PMC6737936</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Descant</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Shapson-Coe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Januszewski</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Mapping of neuronal and glial primary cilia contactome and connectome in the human cerebral cortex</article-title>. <source>Neuron</source><volume>112</volume> (<issue>1</issue>), <fpage>41</fpage>&#8211;<lpage>55.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2023.09.032</pub-id><pub-id pub-id-type="pmid">37898123</pub-id><pub-id pub-id-type="pmcid">PMC10841524</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nager</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Nachury</surname><given-names>M. V.</given-names></name></person-group> (<year>2018</year>). <article-title>BBSome trains remove activated GPCRs from cilia by enabling passage through the transition zone</article-title>. <source>J. Cell Biol.</source><volume>217</volume> (<issue>5</issue>), <fpage>1847</fpage>&#8211;<lpage>1868</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201709041</pub-id><pub-id pub-id-type="pmid">29483145</pub-id><pub-id pub-id-type="pmcid">PMC5940304</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Primary cilia-mediated regulation of microglial secretion in Alzheimer&#8217;s disease</article-title>. <source>Front. Mol. Biosci.</source><volume>10</volume>, <fpage>1250335</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2023.1250335</pub-id><pub-id pub-id-type="pmid">37942288</pub-id><pub-id pub-id-type="pmcid">PMC10627801</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawate</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Signaling through the primary cilium affects glial cell survival under a stressed environment</article-title>. <source>Glia</source><volume>59</volume> (<issue>2</issue>), <fpage>333</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21105</pub-id><pub-id pub-id-type="pmid">21125655</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaidi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chinnappa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>F.</given-names></name></person-group> (<year>2022</year>). <article-title>Primary cilia influence progenitor function during cortical development</article-title>. <source>Cells</source><volume>11</volume> (<issue>18</issue>), <fpage>2895</fpage>. <pub-id pub-id-type="doi">10.3390/cells11182895</pub-id><pub-id pub-id-type="pmid">36139475</pub-id><pub-id pub-id-type="pmcid">PMC9496791</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="pmc-domain-id">1589</journal-id><journal-id journal-id-type="pmc-domain">dee</journal-id><journal-id journal-id-type="publisher-id">DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type="epub">1664-5464</issn><publisher><publisher-name>Karger Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12503466</article-id><article-id pub-id-type="pmcid-ver">PMC12503466.1</article-id><article-id pub-id-type="pmcaid">12503466</article-id><article-id pub-id-type="pmcaiid">12503466</article-id><article-id pub-id-type="doi">10.1159/000547113</article-id><article-id pub-id-type="publisher-id">547113</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Spatial Patterns of Cerebral Blood Flow in Alzheimer&#8217;s Disease Identified by the Subtype and Stage Inference Algorithm</article-title><alt-title alt-title-type="short">CBF Spatial Patterns in AD</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2792256</contrib-id><name name-style="western"><surname>Ota</surname><given-names initials="M">Miho</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2792257</contrib-id><name name-style="western"><surname>Nakayama</surname><given-names initials="K">Kenjiro</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2792258</contrib-id><name name-style="western"><surname>Kitabatake</surname><given-names initials="A">Ayako</given-names></name><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2792259</contrib-id><name name-style="western"><surname>Takahashi</surname><given-names initials="T">Takumi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2792260</contrib-id><name name-style="western"><surname>Nemoto</surname><given-names initials="K">Kiyotaka</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2792261</contrib-id><name name-style="western"><surname>Arai</surname><given-names initials="T">Tetsuaki</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><aff id="aff1">
<label>a</label>Department of Psychiatry, Division of Clinical Medicine, Institute of Medicine, University of Tsukuba, <city>Tsukuba</city>, <country>Japan</country></aff><aff id="aff2">
<label>b</label>Doctoral Program in Medical Sciences, Graduate School of Comprehensive Human Science, University of Tsukuba, <city>Tsukuba</city>, <country>Japan</country></aff><aff id="aff3">
<label>c</label>University of Tsukuba Hospital, <city>Tsukuba</city>, <country>Japan</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Miho Ota, <email>ota@md.tsukuba.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>15</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">479575</issue-id><fpage>108</fpage><lpage>118</lpage><history><date date-type="received"><day>9</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2025</year></date><date date-type="subscription-year"><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://karger.com/Services/OpenAccessLicense">https://karger.com/Services/OpenAccessLicense</ext-link>). Usage and distribution for commercial purposes requires written permission.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dee-2025-0015-0001-547113.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Much research has focused on the deposition of amyloid and tau proteins in the Alzheimer&#8217;s disease (AD) brain, but many amyloid and tau models assumed a single spatial progression of amyloid and tau accumulation. We estimated the changing patterns of an indirect biomarker, i.e., the cerebral blood flow (CBF), in AD, and we discuss the pathological process of AD.</p></sec><sec><title>Methods</title><p>The participants were 341 patients who visited our hospital&#8217;s outpatient department for memory loss (146 males, 195 females): 115 diagnosed with AD, 176 diagnosed with mild cognitive impairment, and 50 diagnosed with subjective cognitive decline. For the evaluation of disease-related changes in their CBF, the patients underwent 99mTc-ethyl cysteinate dimer single-photon emission computed tomography scans. We differentiated the subtypes of CBF in AD by using a machine-learning algorithm called the &#8220;Subtype and Stage Inference (SuStaIn)&#8221;algorithm.</p></sec><sec><title>Results</title><p>When we divided the data into two groups, the SuStaIn algorithm identified two different CBF subtypes: the typical AD pattern and a cortical pattern with hippocampal sparing.</p></sec><sec><title>Conclusion</title><p>We observed two subtypes of the pattern of change in the CBF of individuals with AD, and these subtypes were highly similar to previous findings derived from SuStaIn algorithm applied differing neuroimaging modalities. Such subtyping derived from CBF imaging might have clinical utility in the treatment of AD.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>In this study, we focused on the disease-related changes of the cerebral blood flow (CBF) in AD, and we discuss the pathological processing patterns of AD. The participants were 341 patients who visited our hospital&#8217;s outpatient department for memory loss. To evaluate the disease-related changes in CBF, the participants underwent 99mTc-ethyl cysteinate dimer single photon emission computed tomography (ECD-SPECT) scans. We differentiated the subtypes of CBF in AD by using a machine-learning algorithm called subtype and stage inference (SuStaIn). SuStaIn can reach a longitudinal inference from cross-sectional data and is thus beneficial for validating the chronic course of disease. When we divided the data into two groups, the SuStaIn algorithm identified two different CBF subtypes: the typical AD pattern, and another atypical CBF pattern. We observed two subtypes of the pattern of change in the CBF in individuals with AD, and these subtypes were almost the same as the previous findings. Such subtyping derived from CBF imaging might have clinical utility in the treatment of AD.</p></abstract><kwd-group><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Frontal variant Alzheimer&#8217;s disease</kwd><kwd>Posterior cortical atrophy</kwd><kwd>SPECT</kwd><kwd>Subtype and Stage Inference</kwd></kwd-group><funding-group><funding-statement>This study was not supported by any sponsor or funder.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><ref-count count="39"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>accessibilitySummary</meta-name><meta-value>WCAG 2.1 Level AA</meta-value></custom-meta><custom-meta><meta-name>accessibility-pdf-ua-compliance</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>To understand the pathogenesis of Alzheimer&#8217;s disease (AD), many researchers have focused on the depositions of amyloid and tau proteins in the brain. In 1991, an autopsy study by Braak and Braak revealed that the neuropathological change in individuals with AD is not at random; rather, the change shows a characteristic pattern [<xref rid="B1" ref-type="bibr">1</xref>]. Since that study, several research groups have investigated amyloid and tau positron emission tomography (PET) findings in AD, and the distribution patterns of amyloid and tau deposits were confirmed [<xref rid="B2" ref-type="bibr">2</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>]. However, some studies have indicated that there are recognizable patterns to the spread of amyloid and tau deposits in the pathology of AD, depending on the age of onset and stage of disease progression. For example, according to investigations that focused on the subjects&#8217; age at the onset of AD, individuals with early-onset AD (defined as developing before the age of 65 years) and those with late-onset AD (&#8805;65 years) exhibited several differences in their clinical symptoms such as aphasia, family history, and prognosis [<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B8" ref-type="bibr">8</xref>] and differences in their neuropathology [<xref rid="B9" ref-type="bibr">9</xref>]. Other groups also described the specific patterns of AD pathology that deviate from the Braak staging scheme [<xref rid="B1" ref-type="bibr">1</xref>], e.g., posterior cortical atrophy (PCA) [<xref rid="B10" ref-type="bibr">10</xref>] and the frontal variant pattern [<xref rid="B11" ref-type="bibr">11</xref>]. Frontal and occipital variant reduction in the cerebral blood flow (CBF) was clearly observed in frontotemporal lobar degeneration and in dementia with Lewy bodies. It is very important to differentiate these disorders in clinical settings.</p><p>The Subtype and Stage Inference (SuStaIn) algorithm is an unsupervised machine-learning algorithm that was recently developed to uncover data-driven disease phenotypes with temporal progression patterns, i.e., disease subtypes and stages [<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B15" ref-type="bibr">15</xref>]. The SuStaIn algorithm can reach a longitudinal inference from cross-sectional data [<xref rid="B13" ref-type="bibr">13</xref>] and is thus beneficial for validating the chronic courses of diseases. Many SuStaIn studies focusing on AD have described patterns of the pathological processes of amyloid accumulation [<xref rid="B16" ref-type="bibr">16</xref>], tau protein accumulation [<xref rid="B15" ref-type="bibr">15</xref>], and regional gray matter volume reductions [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. However, to date there have been no SuStaIn studies regarding the identification of a reduction in CBF, which is an indirect biomarker of AD pathology. Further, some recent studies showed that CBF reduction drove the accumulation of amyloid and tau protein [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. These points may indicate that there are some patterns of regional CBF changes, similar to the variety of amyloid and tau accumulation patterns. We used the SuStaIn algorithm to investigate the trends of CBF changes in the brains of patients with AD in this study. We hypothesized that we would observe three or more trends of CBF change, as in earlier SuStaIn studies of AD [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Patients</title><p>We retrospectively enrolled patients who visited our hospital&#8217;s outpatient department for memory loss and underwent the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale-revised (WMS-R), and 99mTc-ethyl cysteinate dimer single-photon emission computed tomography (99mTC-ECD) during the period from January 2015 to February 2023. All of the patients were diagnosed with AD by a trained psychiatrist (MO, MT, TT, or TA) using the diagnostic criteria of AD outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [<xref rid="B20" ref-type="bibr">20</xref>]. The diagnosis of mild cognitive impairment (MCI) (referred to as &#8220;mild neurocognitive disorder&#8221; in the DSM-5) was made based on both the DSM-5 criteria [<xref rid="B20" ref-type="bibr">20</xref>], the MMSE scores 24&#8211;30 points, and abnormal memory function documented by scoring within education-adjusted ranges on the &#8220;delayed free recall&#8221; section of Story A from the WMS-R Logical Memory II subtest (LM2a) [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>].</p><p>In the interview for study enrollment, outpatients without abnormal memory function and showing subjective cognitive impairment were classified as having subjective cognitive decline (SCD). A final total of 341 patients (146 males, 195 females) met the enrollment criteria and took part in the study: 115 patients who were diagnosed with AD, 176 diagnosed with MCI, and 50 diagnosed with SCD. Nine patients with AD were unable to finish the LM2a. The characteristics of the patients are summarized in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Clinical characteristics of the patients (<italic toggle="yes">n</italic> = 341) in the three groups based on the subtypes of spatial patterns of CBF in AD identified by the Subtype and Stage Inference (SuStaIn) algorithm</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">Pre-0</th><th rowspan="1" colspan="1">Pre-1</th><th rowspan="1" colspan="1">Pre-2</th><th rowspan="1" colspan="1">Pre-3</th><th rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SCD/MCI/AD</td><td rowspan="1" colspan="1">33/61/27</td><td rowspan="1" colspan="1">13/48/41</td><td rowspan="1" colspan="1">4/60/32</td><td rowspan="1" colspan="1">0/7/15</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">Male/female</td><td rowspan="1" colspan="1">52/69</td><td rowspan="1" colspan="1">37/65</td><td rowspan="1" colspan="1">48/48</td><td rowspan="1" colspan="1">9/13</td><td rowspan="1" colspan="1">0.147</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">75.7&#177;7.6</td><td rowspan="1" colspan="1">70.1&#177;7.7<sup>a</sup></td><td rowspan="1" colspan="1">73.3&#177;8.9<sup>a,c</sup></td><td rowspan="1" colspan="1">68.6&#177;7.9<sup>c</sup></td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Education, years</td><td rowspan="1" colspan="1">13.1&#177;2.8</td><td rowspan="1" colspan="1">12.7&#177;2.8<sup>a,b</sup></td><td rowspan="1" colspan="1">13.8&#177;3.2<sup>a</sup></td><td rowspan="1" colspan="1">14.5&#177;2.7<sup>b</sup></td><td rowspan="1" colspan="1">0.010</td></tr><tr><td rowspan="1" colspan="1">Onset of illness, years</td><td rowspan="1" colspan="1">72.3&#177;8.2</td><td rowspan="1" colspan="1">66.9&#177;8.2<sup>a</sup></td><td rowspan="1" colspan="1">70.9&#177;8.5<sup>a,c</sup></td><td rowspan="1" colspan="1">65.9&#177;8.0<sup>c</sup></td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Orientation, time</td><td rowspan="1" colspan="1">4.4&#177;1.2</td><td rowspan="1" colspan="1">3.7&#177;1.5<sup>b</sup></td><td rowspan="1" colspan="1">4.1&#177;1.2<sup>c</sup></td><td rowspan="1" colspan="1">2.9&#177;1.8<sup>b,c</sup></td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Orientation, place</td><td rowspan="1" colspan="1">4.7&#177;0.6</td><td rowspan="1" colspan="1">4.2&#177;1.1<sup>b</sup></td><td rowspan="1" colspan="1">4.3&#177;1.1<sup>c</sup></td><td rowspan="1" colspan="1">3.0&#177;1.5<sup>b,c</sup></td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Registration</td><td rowspan="1" colspan="1">2.9&#177;0.4</td><td rowspan="1" colspan="1">2.9&#177;0.3<sup>b</sup></td><td rowspan="1" colspan="1">2.9&#177;0.5</td><td rowspan="1" colspan="1">2.7&#177;0.8<sup>b</sup></td><td rowspan="1" colspan="1">0.047</td></tr><tr><td rowspan="1" colspan="1">Attention/calculation</td><td rowspan="1" colspan="1">3.9&#177;1.3</td><td rowspan="1" colspan="1">3.5&#177;1.6<sup>b</sup></td><td rowspan="1" colspan="1">3.7&#177;1.5<sup>c</sup></td><td rowspan="1" colspan="1">2.1&#177;2.0<sup>b,c</sup></td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Recall</td><td rowspan="1" colspan="1">2.0&#177;1.0</td><td rowspan="1" colspan="1">1.6&#177;1.3<sup>b</sup></td><td rowspan="1" colspan="1">1.4&#177;1.1<sup>c</sup></td><td rowspan="1" colspan="1">0.5&#177;0.7<sup>b,c</sup></td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Naming</td><td rowspan="1" colspan="1">2.0&#177;0.0</td><td rowspan="1" colspan="1">2.0&#177;0.1<sup>b</sup></td><td rowspan="1" colspan="1">1.9&#177;0.3</td><td rowspan="1" colspan="1">1.8&#177;0.6<sup>$</sup></td><td rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">Repetition</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">1.0&#177;0.2<sup>b</sup></td><td rowspan="1" colspan="1">0.9&#177;0.3<sup>c</sup></td><td rowspan="1" colspan="1">0.8&#177;0.4<sup>b,c</sup></td><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">Three-stage verbal command</td><td rowspan="1" colspan="1">2.5&#177;0.7</td><td rowspan="1" colspan="1">2.6&#177;0.7<sup>b</sup></td><td rowspan="1" colspan="1">2.6&#177;0.7<sup>c</sup></td><td rowspan="1" colspan="1">1.9&#177;1.1<sup>b,c</sup></td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Written command</td><td rowspan="1" colspan="1">1.0&#177;0.1</td><td rowspan="1" colspan="1">1.0&#177;0.2<sup>b</sup></td><td rowspan="1" colspan="1">1.0&#177;0.1<sup>c</sup></td><td rowspan="1" colspan="1">0.8&#177;0.4<sup>b,c</sup></td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Writing</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">1.0&#177;0.2<sup>b</sup></td><td rowspan="1" colspan="1">0.9&#177;0.2<sup>c</sup></td><td rowspan="1" colspan="1">0.8&#177;0.4<sup>b,c</sup></td><td rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">Construction</td><td rowspan="1" colspan="1">0.9&#177;0.3</td><td rowspan="1" colspan="1">0.9&#177;0.3</td><td rowspan="1" colspan="1">0.8&#177;0.4</td><td rowspan="1" colspan="1">0.7&#177;0.5</td><td rowspan="1" colspan="1">0.045</td></tr><tr><td rowspan="1" colspan="1">MMSE total score</td><td rowspan="1" colspan="1">26.1&#177;3.6</td><td rowspan="1" colspan="1">24.3&#177;4.8<sup>b</sup></td><td rowspan="1" colspan="1">24.5&#177;0.5<sup>c</sup></td><td rowspan="1" colspan="1">17.9&#177;7.3<sup>b,c</sup></td><td rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>AD, Alzheimer&#8217;s disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SCD, subjective cognitive decline.</p></fn><fn><p>
<sup>a</sup>
<italic toggle="yes">p</italic> &lt; 0.05 between Pre-1 and -2 after the post hoc <italic toggle="yes">t</italic>-test.</p></fn><fn><p>
<sup>b</sup>
<italic toggle="yes">p</italic> &lt; 0.05 between Pre-1 and -3 after the post hoc <italic toggle="yes">t</italic>-test.</p></fn><fn><p>
<sup>c</sup>
<italic toggle="yes">p</italic> &lt; 0.05 between Pre-2 and -3 after the post hoc <italic toggle="yes">t</italic>-test.</p></fn></table-wrap-foot></table-wrap><p>Opt-out informed consent protocol was used for use or collection of participant data for research purposes. This study was approved by the Ethics Committee of the University of Tsukuba Hospital, Japan (approval number: R02-070, date of decision: August 21, 2024) and performed in accord with the Declaration of Helsinki. Patients&#8217; informed consent was not required for this retrospective analysis. After the patients were informed in writing about the study, they were given the opportunity to withdraw from the study at any time.</p></sec><sec id="s2-2"><title>SPECT Data Acquisition and Analysis</title><p>For the measurement of regional (r)CBF, each patient received an intravenous injection of 600 MBq of 99mTC-ECD and was then scanned by a multidetector SPECT machine (E.CAM; Siemens Medical, Malvern, PA) and a high-solution collimator (LEHR; Siemens Medical). The details have been described [<xref rid="B23" ref-type="bibr">23</xref>]. For the normalization of each patient&#8217;s rCBF data, we first normalized the individual rCBF images by using the software package Statistical Parametric Mapping 12 (SPM12, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fil.ion.ucl.ac.uk/spm/" ext-link-type="uri">https://www.fil.ion.ucl.ac.uk/spm/</ext-link>) running on MATLAB R2021b (MathWorks, Natick, MA), using the reference template &#8220;SPECT.nii&#8221;, which is the standard image for SPM12.</p><p>Each normalized image was smoothed with a Gaussian kernel with a full width at half maximum of 6 mm. Next, we used WFU_PickAtlas (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://fmri.wfubmc.edu/software/PickAtlas" ext-link-type="uri">http://fmri.wfubmc.edu/software/PickAtlas</ext-link>) to make region of interest (ROI) masks based on the Talairach Daemon database and to extract desired ROI values individually. We made 15 ROIs (bilateral frontal, lateral temporal, medial temporal, parietal, occipital, precuneus, posterior cingulate gyri, and the gray matter of both cerebellar hemispheres) to calculate the standardized uptake value ratio with the cerebellar value as the reference.</p></sec><sec id="s2-3"><title>SuStaIn Analysis</title><p>The SuStaIn algorithm is described elsewhere [<xref rid="B13" ref-type="bibr">13</xref>]. Z-scores are used for the machine-learning analysis [<xref rid="B13" ref-type="bibr">13</xref>], and we calculated the z-scores from the standardized uptake value ratios of the 50 patients with SCD, controlling for age and sex. We then entered the z-scores of all 341 patients into the SuStaIn algorithm (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/ucl-pond/pySuStaIn" ext-link-type="uri">https://github.com/ucl-pond/pySuStaIn</ext-link>). Preliminarily, we set the maximum number of subtypes as 3. To determine the optimal number of subtypes, we performed 10-fold cross-validation, and the model fit was evaluated with the use of the cross-validation information criterion (CVIC) [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B24" ref-type="bibr">24</xref>]. For the cross-validation set, we set 25 starting points for expectation maximization and 100,000 Markov Chain Monte Carlo iterations for estimating model uncertainty. The SuStaIn algorithm (hereafter, &#8220;SuStaIn&#8221;) categorized the patients into subtypes and reached different progression stages over time.</p></sec><sec id="s2-4"><title>Statistical Analyses</title><p>Sex and diagnostic differences in patient characteristics among the subtypes divided by the SuStaIn were analyzed by chi-square test. Characteristic differences among the subtypes were subjected to an analysis of variance. We evaluated the difference in MMSE subscores among the subtypes by performing an analysis of covariance controlling for age, sex, and education. SPSS Statistics for Windows 23.0 software (SPSS Japan, Tokyo) was used for the statistical analyses. The stage 0 patients were excluded from the subtyping, as that stage is equivalent for each subtype.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>As described above, we set the maximum number of subtypes as 3 to determine the optimal number of subtypes in a preliminary analysis. The SuStaIn algorithm inferred three subtypes, which are depicted in <xref rid="F1" ref-type="fig">Figure 1</xref>. The first disease subtype (hereafter, &#8220;Pre-1&#8221;) is characterized by CBF abnormalities (z-score = &#8722;1) that are observed first in the precuneus, and then a reduction of CBF occurs in the parietal, temporal regions, and hippocampus. The Pre-1 subtype was observed in 102 patients (46% of the total patient series).</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>Inference of the three subtypes and their staging by the SuStaIn algorithm. The use of SuStaIn inferred the z-score progression patterns for each subtype calculated from cross-sectional data. Color shades indicate the probability of a decrease in the z-score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dee-2025-0015-0001-547113_F01.jpg"/></fig><p>The second disease subtype (hereafter, &#8220;Pre-2&#8221;) shows CBF abnormalities in the precuneus and parietal region (z-score = &#8722;1). The Pre-2 subtype was identified in 96 patients (44%). The CBF in the hippocampus is relatively preserved. The third subtype (hereafter, &#8220;Pre-3&#8221;) shows a CBF reduction in the brain&#8217;s frontal and temporal regions. This subtype was observed in 22 patients (10%). As shown in <xref rid="T1" ref-type="table">Table 1</xref>, there were significant differences in age, education, onset of illness, MMSE total score, and the subtest scores of the MMSE among the Pre-1, -2, and -3 patients after Bonferroni correction. SuStaIn revealed that the cross-validation information criterion value was lowest when the number of subtypes for the model was two (<xref rid="F2" ref-type="fig">Fig. 2</xref>), and we thus set the number of subtypes as two.</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Relationship between the cross-validation information criterion (CVIC) scores and the number of subtypes. The results obtained with the SuStaIn algorithm demonstrated that the CVIC was lowest when the number of subtypes for the model was two.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dee-2025-0015-0001-547113_F02.jpg"/></fig><p>The characteristics of the patients in two subtypes are summarized in <xref rid="T2" ref-type="table">Table 2</xref>. There were significant differences in sex, age, education, onset of illness, and the Construction score of the MMSE between the first and second disease subtypes (hereafter, &#8220;Uni-1&#8221; and &#8220;Uni-2&#8221;) after Bonferroni correction. The SuStaIn algorithm divided the data into two subtypes, depicted in <xref rid="F3" ref-type="fig">Figure 3</xref>. Uni-1 is characterized by CBF abnormalities (z-score = &#8722;1) that are observed first in the frontal and temporal regions, and hippocampus; then a reduction of CBF occurs in the parietal region and posterior cingulate cortex. Uni-1 was observed in 128 patients (58% of the total patient series) (<xref rid="T2" ref-type="table">Table 2</xref>). Uni-2 showed CBF abnormalities in the parietal region and precuneus (z-score = &#8722;1). Uni-2 was identified in 92 patients (48%). The CBF in the hippocampus is relatively preserved in this subtype.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Clinical characteristics of the participants (<italic toggle="yes">n</italic> = 341) in the two groups based on the subtypes of spatial patterns of CBF in AD identified by the Subtype and Stage Inference (SuStaIn) algorithm</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">Uni-0</th><th rowspan="1" colspan="1">Uni-1</th><th rowspan="1" colspan="1">Uni-2</th><th rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SCD/MCI/AD</td><td rowspan="1" colspan="1">32/62/27</td><td rowspan="1" colspan="1">14/60/54</td><td rowspan="1" colspan="1">4/54/34</td><td rowspan="1" colspan="1">0.098</td></tr><tr><td rowspan="1" colspan="1">Male/female</td><td rowspan="1" colspan="1">52/69</td><td rowspan="1" colspan="1">45/83</td><td rowspan="1" colspan="1">49/43</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">75.8&#177;7.5</td><td rowspan="1" colspan="1">69.8&#177;8.1</td><td rowspan="1" colspan="1">73.5&#177;8.5</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Education, years</td><td rowspan="1" colspan="1">13.1&#177;2.8</td><td rowspan="1" colspan="1">12.9&#177;2.8</td><td rowspan="1" colspan="1">14.0&#177;3.2</td><td rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="1" colspan="1">Onset of illness, years</td><td rowspan="1" colspan="1">72.4&#177;8.1</td><td rowspan="1" colspan="1">66.7&#177;8.4</td><td rowspan="1" colspan="1">71.0&#177;8.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Orientation, time</td><td rowspan="1" colspan="1">4.4&#177;1.2</td><td rowspan="1" colspan="1">3.7&#177;1.5</td><td rowspan="1" colspan="1">3.9&#177;1.3</td><td rowspan="1" colspan="1">0.408</td></tr><tr><td rowspan="1" colspan="1">Orientation, place</td><td rowspan="1" colspan="1">4.7&#177;0.6</td><td rowspan="1" colspan="1">4.0&#177;1.2</td><td rowspan="1" colspan="1">4.2&#177;1.2</td><td rowspan="1" colspan="1">0.923</td></tr><tr><td rowspan="1" colspan="1">Registration</td><td rowspan="1" colspan="1">2.9&#177;0.4</td><td rowspan="1" colspan="1">2.9&#177;0.5</td><td rowspan="1" colspan="1">2.9&#177;0.3</td><td rowspan="1" colspan="1">0.672</td></tr><tr><td rowspan="1" colspan="1">Attention/calculation</td><td rowspan="1" colspan="1">3.9&#177;1.3</td><td rowspan="1" colspan="1">3.3&#177;1.7</td><td rowspan="1" colspan="1">3.5&#177;1.6</td><td rowspan="1" colspan="1">0.918</td></tr><tr><td rowspan="1" colspan="1">Recall</td><td rowspan="1" colspan="1">2.0&#177;1.0</td><td rowspan="1" colspan="1">1.5&#177;1.3</td><td rowspan="1" colspan="1">1.4&#177;1.1</td><td rowspan="1" colspan="1">0.406</td></tr><tr><td rowspan="1" colspan="1">Naming</td><td rowspan="1" colspan="1">2.0&#177;0.0</td><td rowspan="1" colspan="1">1.9&#177;0.3</td><td rowspan="1" colspan="1">1.9&#177;0.4</td><td rowspan="1" colspan="1">0.521</td></tr><tr><td rowspan="1" colspan="1">Repetition</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">0.9&#177;0.3</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">0.790</td></tr><tr><td rowspan="1" colspan="1">Three-stage verbal command</td><td rowspan="1" colspan="1">2.5&#177;0.7</td><td rowspan="1" colspan="1">2.5&#177;0.8</td><td rowspan="1" colspan="1">2.5&#177;0.7</td><td rowspan="1" colspan="1">0.791</td></tr><tr><td rowspan="1" colspan="1">Written command</td><td rowspan="1" colspan="1">1.0&#177;0.1</td><td rowspan="1" colspan="1">1.0&#177;0.2</td><td rowspan="1" colspan="1">1.0&#177;0.2</td><td rowspan="1" colspan="1">0.948</td></tr><tr><td rowspan="1" colspan="1">Writing</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">1.0&#177;0.2</td><td rowspan="1" colspan="1">0.9&#177;0.2</td><td rowspan="1" colspan="1">0.594</td></tr><tr><td rowspan="1" colspan="1">Construction</td><td rowspan="1" colspan="1">0.9&#177;0.3</td><td rowspan="1" colspan="1">0.9&#177;0.3</td><td rowspan="1" colspan="1">0.8&#177;0.4</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td rowspan="1" colspan="1">MMSE total score</td><td rowspan="1" colspan="1">26.1&#177;3.6</td><td rowspan="1" colspan="1">23.5&#177;5.8</td><td rowspan="1" colspan="1">24.1&#177;5.1</td><td rowspan="1" colspan="1">0.961</td></tr></tbody></table><table-wrap-foot><fn><p>SCD, subjective cognitive impairment; MCI, mild cognitive impairment; AD, Alzheimer&#8217;s disease; MMSE, Mini-Mental State Examination.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p>Inference of two subtypes and their staging by the SuStaIn algorithm. The use of SuStaIn inferred the z-score progression patterns for each subtype calculated from cross-sectional data. Color shades indicate the probability of a decrease in the z-score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dee-2025-0015-0001-547113_F03.jpg"/></fig><p>In light of these data, we noted that there was scarce laterality of the CBF pattern in this study population. We then merged the data of bilateral hemispheres and reanalyzed the data by using the SuStaIn algorithm. SuStaIn divided the data into two subtypes, shown in <xref rid="F4" ref-type="fig">Figure 4</xref>. The first disease subtype (hereafter, &#8220;Bil-1&#8221;) is characterized by CBF abnormalities (z-score = &#8722;1) that are observed first in the frontal, lateral temporal, and hippocampus, and then a reduction of CBF occurs in the parietal region, precuneus, and posterior cingulate cortex. Bil-1 was observed in 219 patients (64% of the total patient series). The second disease subtype (hereafter, &#8220;Bil-2&#8221;) shows CBF abnormalities in the parietal region and precuneus (z-score = &#8722;1). Bil-2 was identified in 122 patients (33%). The CBF in the hippocampus is relatively preserved in this subtype.</p><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p>
<bold>a</bold> Relationship between the cross-validation information criterion (CVIC) scores and the number of subtypes. <bold>b</bold> Inference of two subtypes and their staging. The use of the SuStaIn algorithm inferred the z-score progression patterns for each subtype calculated from cross-sectional data. Color shades indicate the probability of a decrease in the z-score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dee-2025-0015-0001-547113_F04.jpg"/></fig><p>We next evaluated the differences in the patient characteristics according to the disease subtypes. To reduce the noise, we applied the subtype probability threshold. We included only cases with a subtype probability &gt;0.7. The characteristics of the patients in these groups are summarized in <xref rid="T3" ref-type="table">Table 3</xref>. There were significant differences in education and recall score of MMSE between the Bil-1 and Bil-2 groups after Bonferroni correction.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Clinical characteristics of the participants in the two subtypes and subtype 0 (stage = 0) based on the subtypes of spatial patterns of CBF (merge left + right) identified by the Subtype and Stage Inference (SuStaIn) algorithm</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">Bil-0 stage probability per sample over 0.7</th><th rowspan="1" colspan="1">Bil-1 stage probability per sample over 0.7</th><th rowspan="1" colspan="1">Bil-2 stage probability per sample over 0.7</th><th rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SCD/MCI/AD</td><td rowspan="1" colspan="1">8/28/14</td><td rowspan="1" colspan="1">3/46/32</td><td rowspan="1" colspan="1">4/20/13</td><td rowspan="1" colspan="1">0.313</td></tr><tr><td rowspan="1" colspan="1">Male/female</td><td rowspan="1" colspan="1">26/23</td><td rowspan="1" colspan="1">41/40</td><td rowspan="1" colspan="1">15/22</td><td rowspan="1" colspan="1">0.328</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">77.5&#177;1.2</td><td rowspan="1" colspan="1">71.9&#177;0.9</td><td rowspan="1" colspan="1">70.6&#177;1.4</td><td rowspan="1" colspan="1">0.434</td></tr><tr><td rowspan="1" colspan="1">Education, years</td><td rowspan="1" colspan="1">13.1&#177;0.5</td><td rowspan="1" colspan="1">14.1&#177;0.4</td><td rowspan="1" colspan="1">12.5&#177;0.5</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">Onset of illness, years</td><td rowspan="1" colspan="1">73.4&#177;8.2</td><td rowspan="1" colspan="1">69.3&#177;8.5</td><td rowspan="1" colspan="1">66.7&#177;8.8</td><td rowspan="1" colspan="1">0.127</td></tr><tr><td rowspan="1" colspan="1">Orientation, time</td><td rowspan="1" colspan="1">4.1 + 1.3</td><td rowspan="1" colspan="1">3.9 + 1.4</td><td rowspan="1" colspan="1">3.8 + 1.7</td><td rowspan="1" colspan="1">0.897</td></tr><tr><td rowspan="1" colspan="1">Orientation, place</td><td rowspan="1" colspan="1">4.7 + 0.6</td><td rowspan="1" colspan="1">4.1 + 1.3</td><td rowspan="1" colspan="1">4.2 + 1.2</td><td rowspan="1" colspan="1">0.252</td></tr><tr><td rowspan="1" colspan="1">Registration</td><td rowspan="1" colspan="1">2.8 + 0.5</td><td rowspan="1" colspan="1">2.9 + 0.5</td><td rowspan="1" colspan="1">2.9 + 0.3</td><td rowspan="1" colspan="1">0.452</td></tr><tr><td rowspan="1" colspan="1">Attention/calculation</td><td rowspan="1" colspan="1">3.9 + 1.5</td><td rowspan="1" colspan="1">3.4 + 1.7</td><td rowspan="1" colspan="1">3.8 + 1.6</td><td rowspan="1" colspan="1">0.123</td></tr><tr><td rowspan="1" colspan="1">Recall</td><td rowspan="1" colspan="1">1.8 + 1.1</td><td rowspan="1" colspan="1">1.3 + 1.1</td><td rowspan="1" colspan="1">1.9 + 1.2</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">Naming</td><td rowspan="1" colspan="1">2.0 + 0.0</td><td rowspan="1" colspan="1">1.9 + 0.4</td><td rowspan="1" colspan="1">1.9 + 0.2</td><td rowspan="1" colspan="1">0.491</td></tr><tr><td rowspan="1" colspan="1">Repetition</td><td rowspan="1" colspan="1">0.9 + 0.4</td><td rowspan="1" colspan="1">0.9 + 0.3</td><td rowspan="1" colspan="1">0.9 + 0.3</td><td rowspan="1" colspan="1">0.470</td></tr><tr><td rowspan="1" colspan="1">Three-stage verbal command</td><td rowspan="1" colspan="1">2.4 + 0.6</td><td rowspan="1" colspan="1">2.5 + 0.7</td><td rowspan="1" colspan="1">2.5 + 0.7</td><td rowspan="1" colspan="1">0.772</td></tr><tr><td rowspan="1" colspan="1">Written command</td><td rowspan="1" colspan="1">1.0 + 0.0</td><td rowspan="1" colspan="1">1.0 + 0.2</td><td rowspan="1" colspan="1">0.9 + 0.2</td><td rowspan="1" colspan="1">0.670</td></tr><tr><td rowspan="1" colspan="1">Writing</td><td rowspan="1" colspan="1">0.9 + 0.3</td><td rowspan="1" colspan="1">0.9 + 0.2</td><td rowspan="1" colspan="1">1.0 + 0.0</td><td rowspan="1" colspan="1">0.093</td></tr><tr><td rowspan="1" colspan="1">Construction</td><td rowspan="1" colspan="1">0.9 + 0.4</td><td rowspan="1" colspan="1">0.8 + 0.4</td><td rowspan="1" colspan="1">0.8 + 0.4</td><td rowspan="1" colspan="1">0.200</td></tr><tr><td rowspan="1" colspan="1">MMSE total score</td><td rowspan="1" colspan="1">25.3 + 4</td><td rowspan="1" colspan="1">23.6 + 5.9</td><td rowspan="1" colspan="1">24.9 + 5.2</td><td rowspan="1" colspan="1">0.094</td></tr></tbody></table><table-wrap-foot><fn><p>AD, Alzheimer&#8217;s disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SCD, subjective cognitive decline.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>We detected two subtypes of the pattern of changes in the CBF in the brains of patients with AD: the typical AD pattern and a cortical pattern with hippocampal sparing. Although there were several examples of nonconforming cases, the pathological progression in AD has principally been described by a single model for many years [<xref rid="B1" ref-type="bibr">1</xref>]. To our knowledge, the present study is the first to use a machine-learning algorithm to clarify multiple pathological processing patterns of the CBF in the AD brain.</p><p>Among the SuStaIn studies of AD, two investigations focused on changes in the gray matter volume together with the disease progression; one investigation revealed three atrophic subtypes, i.e., a typical atrophic hippocampus pattern, a cortical pattern, and a subcortical pattern [<xref rid="B13" ref-type="bibr">13</xref>], and the other detected the typical atrophic hippocampus pattern, a hippocampal-sparing pattern, and a limbic-predominant pattern [<xref rid="B17" ref-type="bibr">17</xref>]. An amyloid PET study described three subtypes: frontal, parietal, and occipital subtypes [<xref rid="B16" ref-type="bibr">16</xref>]. It is well known that senile plaques do not distribute in the hippocampus at earlier stages of AD [<xref rid="B25" ref-type="bibr">25</xref>], and this SuStaIn study using amyloid PET did not consider amyloid deposition in the hippocampus [<xref rid="B16" ref-type="bibr">16</xref>]. A tau PET study detected four subtypes: the limbic subtype was the most frequent and presented with many characteristics that are typically associated with AD, including medial temporal pathology with a Braak-like progression of tau spread, and the others were a medial temporal lobe-sparing pattern, a posterior pattern, and a lateral temporal pattern [<xref rid="B15" ref-type="bibr">15</xref>]. Considering these reports and the present findings, it may be possible to infer that there are some CBF change subtypes that are compatible with the previous findings (such as the typical changing pattern including the hippocampus and precuneus) and cortical changing patterns with hippocampus-sparing.</p><p>Regarding the cortical pattern with hippocampus-sparing, some studies of early-onset AD demonstrated cortical dysfunction with preserved hippocampus [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. The authors of a review noted that PCA most often presents at an early age, usually between 50 and 65 years [<xref rid="B28" ref-type="bibr">28</xref>], and it was reported that roughly 1%&#8211;6% of individuals with AD experienced an early illness onset [<xref rid="B29" ref-type="bibr">29</xref>]. Late-onset PCA (after age 65) also occurs, and it accounted for 17.5% of a multicenter PCA cohort with &gt;300 participants [<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Histopathological studies of posterior-variant AD have demonstrated numerous senile plaques and neurofibrillary tangles, particularly in the parietotemporal and/or occipital association area [<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>]. A meta-analysis of neuroimaging studies of the brain morphometry in PCA revealed that the brain atrophy in PCA is predominantly in the posterior cortical region, whereas atrophy in typical AD is mostly in the hippocampus and parahippocampal regions [<xref rid="B34" ref-type="bibr">34</xref>]. Our present analyses confirmed that the Bil-2 group&#8217;s MMSE &#8220;recall&#8221; score was significantly higher than that of Bil-1 group. This result is consistent with a report that memory impairment is not noticeable in early-onset MCI [<xref rid="B35" ref-type="bibr">35</xref>]. We also observed that the present Bil-2 group showed a younger onset of illness compared to the Bil-1 group at the trend level. Differences in the age of onset for different subtypes should be clarified in future investigations with additional samples.</p><p>Our study has some limitations to address. First, although the patients were diagnosed based on the DSM-5 diagnostic criteria, more recent diagnostic criteria for AD require an ATN (&#946;-amyloid, tau, neurodegeneration) classification [<xref rid="B36" ref-type="bibr">36</xref>]. We did not evaluate the deposition of amyloid or that of tau protein in this study, but our findings did not differ significantly from previous pathology findings. Future analyses should include a confirmation of biomarkers such as amyloid accumulation.</p><p>In addition, the frontal variant type of AD has been described as rare atypical AD [<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>], and it was reported to exhibit structural changes and dysfunction of the frontal lobe [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. The exact prevalence of this AD type is unknown, but it has been estimated to be present in approx. 1 in 50 people who have AD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alzheimers.org.uk" ext-link-type="uri">https://www.alzheimers.org.uk</ext-link>). The ratio of patients who were classified as having the Pre-3 pattern in the present study was low, and the SuStaIn algorithm results indicated that it was plausible to classify the AD group into two subtypes in this study. Future studies with larger patient samples could clarify the existence of the frontal variant type of AD.</p><p>In conclusion, our use of the SuStaIn algorithm identified subtypes of the pattern of changes in the CBF in patients with AD. These subtypes showed the same patterns of amyloid and tau accumulation as well as the pattern of cortical atrophy. It is hoped that such subtyping derived from CBF imaging will provide clinical feedback in terms of AD patients&#8217; treatment responses and prognoses.</p></sec><sec sec-type="statement of ethics" id="s5"><title>Statement of Ethics</title><p>Opt-out informed consent protocol was used for use or collection of participant data for research purposes. This study was approved by the Ethics Committee of the University of Tsukuba Hospital, Japan (Approval No.: R02-070, date of decision: August 21, 2024) and performed in accord with the Declaration of Helsinki. The patient&#8217;s informed consent was not required for this retrospective analysis. After the patients were informed in writing about the study, they were given the opportunity to withdraw from the study at any time.</p></sec><sec sec-type="COI-statement" id="s6"><title>Conflict of Interest Statement</title><p>The authors have no conflicts of interest to declare.</p></sec><sec sec-type="funding sources" id="s7"><title>Funding Sources</title><p>This study was not supported by any sponsor or funder.</p></sec><sec sec-type="author contributions" id="s8"><title>Author Contributions</title><p>M.O., K.N., and T.A. designed the study. M.O., A.K., T.T., K.N., and T.A. acquired the data. M.O. and A.K. analyzed the data and wrote the article. K.N. and T.A. revised the article. All authors contributed to and have approved the final manuscript.</p></sec></body><back><sec sec-type="data-availability" id="s12"><title>Data Availability Statement</title><p>The data obtained in this study are not publicly available for ethical reasons. Further inquiries can be directed to the corresponding author.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braak</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Braak</surname><given-names>E</given-names></string-name></person-group>. <article-title>Neuropathological stageing of Alzheimer-related changes</article-title>. <source>Acta Neuropathol</source>. <year>1991</year>;<volume>82</volume>(<issue>4</issue>):<fpage>239</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blazhenets</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Frings</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>S&#246;rensen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>PT</given-names></string-name>; <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></person-group>. <article-title>Principal-component analysis-based measures of PET data closely reflect neuropathologic staging schemes</article-title>. <source>J Nucl Med</source>. <year>2021</year>;<volume>62</volume>(<issue>6</issue>):<fpage>855</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">33097630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.120.252783</pub-id><pub-id pub-id-type="pmcid">PMC8729867</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HQ</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>YX</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study</article-title>. <source>Transl Psychiatry</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>483</fpage>.<pub-id pub-id-type="pmid">34537810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01602-5</pub-id><pub-id pub-id-type="pmcid">PMC8449785</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Macedo</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Tissot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Therriault</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Servaes</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Arias</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>The use of Tau PET to stage Alzheimer disease according to the Braak staging framework</article-title>. <source>J Nucl Med</source>. <year>2023</year>;<volume>64</volume>(<issue>8</issue>):<fpage>1171</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">37321820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.122.265200</pub-id><pub-id pub-id-type="pmcid">PMC10394315</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Therriault</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Lussier</surname><given-names>FZ</given-names></string-name>, <string-name name-style="western"><surname>Tissot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chamoun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bezgin</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Biomarker modeling of Alzheimer's disease using PET-based Braak staging</article-title>. <source>Nat Aging</source>. <year>2022</year>;<volume>2</volume>(<issue>6</issue>):<fpage>526</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">37118445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-022-00204-0</pub-id><pub-id pub-id-type="pmcid">PMC10154209</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Binetti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Magni</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Padovani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cappa</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Bianchetti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Trabucchi</surname><given-names>M</given-names></string-name></person-group>. <article-title>Neuropsychological heterogeneity in mild Alzheimer's disease</article-title>. <source>Dementia</source>. <year>1993</year>;<volume>4</volume>(<issue>6</issue>):<fpage>321</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8136895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000107340</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chui</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>VW</given-names></string-name>, <string-name name-style="western"><surname>Moy</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Clinical subtypes of dementia of the Alzheimer type</article-title>. <source>Neurology</source>. <year>1985</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1544</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">4058744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.35.11.1544</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seltzer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sherwin</surname><given-names>I</given-names></string-name></person-group>. <article-title>A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two?</article-title><source>Arch Neurol</source>. <year>1983</year>;<volume>40</volume>(<issue>3</issue>):<fpage>143</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">6830452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.1983.04050030037006</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></string-name></person-group>. <article-title>Morphometrical comparison of neurofibrillary tangles and senile plaques in Alzheimer's disease and the senile dementia of Alzheimer type</article-title>. <source>Neuropathology</source>. <year>1995</year>;<volume>15</volume>(<issue>1&#8211;2</issue>):<fpage>21</fpage>&#8211;<lpage>6</lpage>.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crutch</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Schott</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Snowden</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></string-name>, <etal/></person-group>. <article-title>Consensus classification of posterior cortical atrophy</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>13</volume>(<issue>8</issue>):<fpage>870</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">28259709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2017.01.014</pub-id><pub-id pub-id-type="pmcid">PMC5788455</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pijnenburg</surname><given-names>YA</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Cohn-Sheehy</surname><given-names>BI</given-names></string-name>, <string-name name-style="western"><surname>Scheltens</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>JW</given-names></string-name>, <etal/></person-group>. <article-title>The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>Pt 9</issue>):<fpage>2732</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">26141491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv191</pub-id><pub-id pub-id-type="pmcid">PMC4623840</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Convery</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Peakman</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Todd</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Characterizing the clinical features and atrophy patterns of MAPT-related frontotemporal dementia with disease progression modeling</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>97</volume>(<issue>9</issue>):<fpage>e941</fpage>&#8211;<lpage>e952</lpage>.<pub-id pub-id-type="pmid">34158384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012410</pub-id><pub-id pub-id-type="pmcid">PMC8408507</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Marinescu</surname><given-names>RV</given-names></string-name>, <string-name name-style="western"><surname>Oxtoby</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Firth</surname><given-names>NC</given-names></string-name>, <etal/></person-group>. <article-title>Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>4273</fpage>.<pub-id pub-id-type="pmid">30323170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-05892-0</pub-id><pub-id pub-id-type="pmcid">PMC6189176</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eshaghi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Wijeratne</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Prados</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Narayanan</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>2078</fpage>.<pub-id pub-id-type="pmid">33824310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22265-2</pub-id><pub-id pub-id-type="pmcid">PMC8024377</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vogel</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Oxtoby</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Strandberg</surname><given-names>OT</given-names></string-name>, <etal/></person-group>. <article-title>Four distinct trajectories of tau deposition identified in Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>5</issue>):<fpage>871</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">33927414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01309-6</pub-id><pub-id pub-id-type="pmcid">PMC8686688</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wottschel</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Mastenbroek</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Schoenmakers</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Heeman</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Spatial-temporal patterns of beta-amyloid accumulation: a subtype and stage inference model analysis</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>17</issue>):<fpage>e1692</fpage>&#8211;<lpage>e1703</lpage>.<pub-id pub-id-type="pmid">35292558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200148</pub-id><pub-id pub-id-type="pmcid">PMC9071373</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Archetti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Oxtoby</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>M&#229;rtensson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Westman</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Inter-cohort validation of SuStaIn model for Alzheimer's disease</article-title>. <source>Front Big Data</source>. <year>2021</year>;<volume>4</volume>:<fpage>661110</fpage>.<pub-id pub-id-type="pmid">34095821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fdata.2021.661110</pub-id><pub-id pub-id-type="pmcid">PMC8173213</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Korte</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nortley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Attwell</surname><given-names>D</given-names></string-name></person-group>. <article-title>Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <year>2020</year>;<volume>140</volume>(<issue>6</issue>):<fpage>793</fpage>&#8211;<lpage>810</lpage>.<pub-id pub-id-type="pmid">32865691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02215-w</pub-id><pub-id pub-id-type="pmcid">PMC7666276</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swinford</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Risacher</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Vosmeier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Deardorff</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chumin</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Dzemidzic</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2023</year>;<volume>130</volume>:<fpage>103</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">37499587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2023.06.014</pub-id><pub-id pub-id-type="pmcid">PMC10529454</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>DSM-V: diagnostic and statistical manual of mental disorders</source>. <edition>5th ed</edition>. <publisher-loc>Washington, D.C</publisher-loc>: <publisher-name>American Psychiatric Press</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Edmonds</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Eppig</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weigand</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Early versus late MCI: improved MCI staging using a neuropsychological approach</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>5</issue>):<fpage>699</fpage>&#8211;<lpage>708</lpage>.<pub-id pub-id-type="pmid">30737119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.12.009</pub-id><pub-id pub-id-type="pmcid">PMC6511470</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>Geda</surname><given-names>YE</given-names></string-name>, <string-name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></string-name>, <etal/></person-group>. <article-title>Mild cognitive impairment: ten years later</article-title>. <source>Arch Neurol</source>. <year>2009</year>;<volume>66</volume>(<issue>12</issue>):<fpage>1447</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">20008648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2009.266</pub-id><pub-id pub-id-type="pmcid">PMC3081688</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boku</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ota</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nemoto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Numata</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kitabatake</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>The multicomponent day-care program prevents volume reduction in a memory-related brain area in patients with mild cognitive impairment</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2022</year>;<volume>51</volume>(<issue>2</issue>):<fpage>120</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">35320811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000522654</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Clement</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [<sup>18</sup>F]Florzolotau PET imaging and subtype/stage inference algorithm</article-title>. <source>EBioMedicine</source>. <year>2023</year>;<volume>97</volume>:<fpage>104835</fpage>.<pub-id pub-id-type="pmid">37839135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104835</pub-id><pub-id pub-id-type="pmcid">PMC10590768</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Flory</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Damasio</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Van Hoesen</surname><given-names>GW</given-names></string-name></person-group>. <article-title>The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease</article-title>. <source>Cereb Cortex</source>. <year>1991</year>;<volume>1</volume>:<fpage>103</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">1822725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/1.1.103</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Pievani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Testa</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sabattoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bresciani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bonetti</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The topography of grey matter involvement in early and late onset Alzheimer's disease</article-title>. <source>Brain</source>. <year>2007</year>;<volume>130</volume>(<issue>Pt 3</issue>):<fpage>720</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">17293358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl377</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kemp</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bolt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rowden</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2003</year>;<volume>74</volume>(<issue>6</issue>):<fpage>715</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12754337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.74.6.715</pub-id><pub-id pub-id-type="pmcid">PMC1738480</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pelak</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Mahmood</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abe-Ridgway</surname><given-names>K</given-names></string-name></person-group>. <article-title>Perspectives and a systematic scoping review on longitudinal profiles of posterior cortical atrophy syndrome</article-title>. <source>Curr Neurol Neurosci Rep</source>. <year>2022</year>;<volume>22</volume>(<issue>11</issue>):<fpage>803</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">36242715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-022-01238-y</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Bird</surname><given-names>TD</given-names></string-name></person-group>. <article-title>Alzheimer disease overview</article-title>. <year>1998</year> [updated 2018 Dec 20]. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Adam</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mirzaa</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Amemiya</surname><given-names>A</given-names></string-name></person-group>, eds. <source>GeneReviews<sup>&#174;</sup> [internet]</source>. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; <fpage>1993</fpage>&#8211;<lpage>2024</lpage>.<pub-id pub-id-type="pmid">20301340</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schott</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Crutch</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Carrasquillo</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Uphill</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shakespeare</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>NS</given-names></string-name>, <etal/></person-group>. <article-title>Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>8</issue>):<fpage>862</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26993346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.01.010</pub-id><pub-id pub-id-type="pmcid">PMC4982482</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crutch</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lehmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schott</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>NC</given-names></string-name></person-group>. <article-title>Posterior cortical atrophy</article-title>. <source>Lancet Neurol</source>. <year>2012</year>;<volume>11</volume>(<issue>2</issue>):<fpage>170</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22265212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(11)70289-7</pub-id><pub-id pub-id-type="pmcid">PMC3740271</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hof</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Vogt</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Bouras</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways</article-title>. <source>Vis Res</source>. <year>1997</year>;<volume>37</volume>(<issue>24</issue>):<fpage>3609</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">9425534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0042-6989(96)00240-4</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levine</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname><given-names>CM</given-names></string-name></person-group>. <article-title>The visual variant of Alzheimer's disease: a clinicopathologic case study</article-title>. <source>Neurology</source>. <year>1993</year>;<volume>43</volume>(<issue>2</issue>):<fpage>305</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">8437694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.43.2.305</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alves</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sampaio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>OF</given-names></string-name></person-group>. <article-title>Posterior cortical atrophy and Alzheimer's disease: a meta-analytic review of neuropsychological and brain morphometry studies</article-title>. <source>Brain Imaging Behav</source>. <year>2013</year>;<volume>7</volume>(<issue>3</issue>):<fpage>353</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">23690254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-013-9236-1</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Cheong</surname><given-names>HK</given-names></string-name>, <etal/></person-group>. <article-title>Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: a five-year longitudinal study</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2010</year>;<volume>29</volume>(<issue>3</issue>):<fpage>213</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">20332639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000278422</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jack</surname><given-names>CRJ</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></string-name>, <etal/></person-group>. <article-title>NIA-AA Research Framework: toward a biological definition of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dubois</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Jacova</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria</article-title>. <source>Lancet Neurol</source>. <year>2014</year>;<volume>13</volume>(<issue>6</issue>):<fpage>614</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">24849862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70090-0</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Salo</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Savage</surname><given-names>G</given-names></string-name></person-group>. <article-title>Frontal variant Alzheimer's disease: a systematic narrative synthesis</article-title>. <source>Cortex</source>. <year>2023</year>;<volume>166</volume>:<fpage>121</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">37356113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cortex.2023.05.007</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nabizadeh</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pirahesh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Aarabi</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Wennberg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pini</surname><given-names>L</given-names></string-name></person-group>. <article-title>Behavioral and dysexecutive variant of Alzheimer's disease: insights from structural and molecular imaging studies</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e29420</fpage>.<pub-id pub-id-type="pmid">38638964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e29420</pub-id><pub-id pub-id-type="pmcid">PMC11024599</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70769" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505193</article-id><article-id pub-id-type="pmcid-ver">PMC12505193.1</article-id><article-id pub-id-type="pmcaid">12505193</article-id><article-id pub-id-type="pmcaiid">12505193</article-id><article-id pub-id-type="doi">10.1002/alz.70769</article-id><article-id pub-id-type="publisher-id">ALZ70769</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Diagnostic potential of near&#8208;infrared spectroscopy in mild cognitive impairment and neurodegenerative disorders: Implications for resource&#8208;limited settings</article-title></title-group><contrib-group><contrib id="alz70769-cr-0001" contrib-type="author"><name name-style="western"><surname>Osei</surname><given-names initials="GN">George Nkrumah</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-5379-963X</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70769-cr-0002" contrib-type="author"><name name-style="western"><surname>Bockarie</surname><given-names initials="A">Ansumana</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1173-1493</contrib-id><xref rid="alz70769-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70769-cr-0003" contrib-type="author"><name name-style="western"><surname>Akpalu</surname><given-names initials="A">Albert</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4802-9852</contrib-id><xref rid="alz70769-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70769-cr-0004" contrib-type="author"><name name-style="western"><surname>Adueming</surname><given-names initials="POW">Peter Osei&#8208;Wusu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0564-5011</contrib-id><xref rid="alz70769-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70769-cr-0005" contrib-type="author"><name name-style="western"><surname>Antwi</surname><given-names initials="MH">Maxwell Hubert</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5997-9829</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70769-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70769-cr-0006" contrib-type="author"><name name-style="western"><surname>Appiah</surname><given-names initials="F">Foster</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-6365-5213</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70769-cr-0007" contrib-type="author"><name name-style="western"><surname>Kpelle</surname><given-names initials="L">Linus</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-4045-1364</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70769-cr-0008" contrib-type="author"><name name-style="western"><surname>Donkor</surname><given-names initials="DM">David Mawutor</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-2923-3873</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70769-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Simpong</surname><given-names initials="DL">David Larbi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9194-3762</contrib-id><xref rid="alz70769-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>dsimpong@ucc.edu.gh</email></address></contrib></contrib-group><aff id="alz70769-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Laboratory Science</named-content>
<named-content content-type="organisation-division">School of Allied Health Sciences</named-content>
<institution>University of Cape Coast</institution>
<city>Cape Coast</city>
<country country="GH">Ghana</country>
</aff><aff id="alz70769-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine and Therapeutics, School of Medical Sciences</named-content>
<institution>University of Cape Coast</institution>
<city>Cape Coast</city>
<country country="GH">Ghana</country>
</aff><aff id="alz70769-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University of Ghana Medical School</institution>
<city>Accra</city>
<country country="GH">Ghana</country>
</aff><aff id="alz70769-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Laser and Fibre Optics Centre, School of Physical Sciences</named-content>
<institution>University of Cape Coast</institution>
<city>Cape Coast</city>
<country country="GH">Ghana</country>
</aff><aff id="alz70769-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Laboratory Science, Faculty of Health Sciences</named-content>
<institution>Koforidua Technical University</institution>
<city>Koforidua</city>
<country country="GH">Ghana</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/> David Larbi Simpong, Department of Medical Laboratory Sciences, College of Health and Allied Sciences, P.M.B. University Post Office, No. 9 Odamten Road, University of Cape Coast, Cape Coast, Ghana.<break/> Email: <email>dsimpong@ucc.edu.gh</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="470">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70769</elocation-id><history><date date-type="rev-recd"><day>08</day><month>9</month><year>2025</year></date><date date-type="received"><day>25</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70769.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70769.pdf"/><abstract><title>Abstract</title><sec id="alz70769-sec-0010"><title>BACKGROUND</title><p>Near&#8208;infrared spectroscopy (NIRS) is emerging as a promising tool for early detection of mild cognitive impairment (MCI) and neurodegenerative diseases, especially where advanced imaging is limited.</p></sec><sec id="alz70769-sec-0020"><title>METHODOLOGY</title><p>This systematic review investigates NIRS's diagnostic capabilities. Adhering to Preferred Reporting Items for Systematic Reviews and Meta&#8208;Analyses guidelines, we conducted a comprehensive review of studies using NIRS for cognitive assessment in MCI and neurodegenerative conditions.</p></sec><sec id="alz70769-sec-0030"><title>RESULTS/DISCUSSION</title><p>NIRS effectively assesses cognitive function, identifying reduced prefrontal connectivity in MCI and subjective cognitive decline (SCD). Interestingly, while SCD patients maintain stronger brain network integrity, NIRS reveals decreased oxyhemoglobin levels in Alzheimer's disease (AD) patients&#8217; dorsolateral prefrontal cortex. Combining NIRS with graph analysis, cognitive tasks, and machine learning significantly boosts diagnostic accuracy. Moreover, NIRS can differentiate between neurodegenerative disorders and, with concurrent electroencephalography, offers enhanced understanding of brain connectivity issues in AD. Our findings emphasize NIRS's considerable potential to improve cognitive assessment and neurodegeneration diagnosis.</p></sec><sec id="alz70769-sec-0040"><title>Highlights</title><p>
<list list-type="bullet" id="alz70769-list-0001"><list-item><p>Mild cognitive impairment (MCI) individuals show disruptions in neurovascular coupling and functional connectivity, particularly in the dorsolateral prefrontal cortex during near&#8208;infrared spectroscopy (NIRS) assessments.</p></list-item><list-item><p>Significant reductions in oxyhemoglobin (HbO<sub>2</sub>) levels are observed in the dorsolateral prefrontal cortex of amnestic MCI (aMCI) individuals compared to healthy controls.</p></list-item><list-item><p>Individuals with subjective cognitive decline (SCD) show lower HbO<sub>2</sub> levels than healthy individuals, while aMCI individuals show even more pronounced reductions.</p></list-item><list-item><p>The dorsolateral prefrontal cortex is identified as a critical area for Alzheimer's disease (AD) assessment using NIRS, correlating with cognitive performance.</p></list-item><list-item><p>Differences in Broca's area activation during language tasks help distinguish behavioral variant frontotemporal dementia from AD, revealing unique cognitive profiles through NIRS.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70769-kwd-0001">Alzheimer's disease</kwd><kwd id="alz70769-kwd-0002">functional connectivity</kwd><kwd id="alz70769-kwd-0003">mild cognitive impairment</kwd><kwd id="alz70769-kwd-0004">near&#8208;infrared spectroscopy</kwd><kwd id="alz70769-kwd-0005">neurodegenerative diseases</kwd><kwd id="alz70769-kwd-0006">oxyhemoglobin</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="25"/><word-count count="14502"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70769-cite-0001"><string-name name-style="western"><surname>Osei</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Bockarie</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Akpalu</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Diagnostic potential of near&#8208;infrared spectroscopy in mild cognitive impairment and neurodegenerative disorders: Implications for resource&#8208;limited settings</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70769</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70769</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70769-sec-0050"><label>1</label><title>BACKGROUND</title><p>Neurodegenerative diseases (NDDs) are a group of progressive and debilitating neurological disorders characterized by the gradual loss of neuronal structure and function, resulting in cognitive, motor, and behavioral impairments.<xref rid="alz70769-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> While not a natural part of aging, these conditions result from complex gene&#8211;environment interactions that substantially influence an individual's susceptibility.<xref rid="alz70769-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> NDDs, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Lewy body dementia (LBD), and frontotemporal dementia (FTD), collectively affect &gt; 40 million individuals globally, representing a significant and growing public health concern.<xref rid="alz70769-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Mild cognitive impairment (MCI), a clinical condition characterized by cognitive decline beyond normal aging yet without significant impact on daily functioning, serves as an intermediate stage between normal cognition and several NDDs.<xref rid="alz70769-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> However, detecting MCI remains challenging due to high misclassification rates. Cerebrospinal fluid (CSF) biomarkers have a 24% MCI misclassification rate, while traditional screening tools such as the Mini&#8208;Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are culturally insensitive, leading to diagnostic limitations.<xref rid="alz70769-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70769-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70769-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>AD, the most prevalent NDD, remains without cure and continues to impose a growing medical and socio&#8208;economic burden. Its pathogenesis is multifactorial, with neural alterations occurring at nearly every cellular level.<xref rid="alz70769-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Clinically, AD is primarily marked by impaired recent memory, which progressively leads to deficits in other cognitive functions, including speech, orientation, judgment, executive function, and behavioral regulation, ultimately affecting daily activities.<xref rid="alz70769-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Research on the global impact of AD suggests that early detection and treatment of cognitive impairment in its initial stages can delay AD onset by 5 years.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> This delay could lead to a nearly 57% reduction in dementia cases while also cutting annual medical insurance costs by almost half. Beyond AD, FTD is associated with atrophy of the frontal and temporal lobes, while dementia with Lewy bodies is characterized by the presence of Lewy body inclusions and accompanying motor disturbances. PD primarily affects motor control but also leads to significant cognitive changes over time.<xref rid="alz70769-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70769-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Several brain diagnostic platforms for neurodegeneration detection and cognitive decline have surfaced, and over the past two decades, near&#8208;infrared spectroscopy (NIRS) has revolutionized neuroscience, providing new ways to study human brain function.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> This technology offers a balance of moderate temporal resolution and fine spatial resolution, making it a powerful tool for studying brain activity and circulatory dynamics with precision. NIRS enables brain imaging by detecting differences in the absorption spectra of oxyhemoglobin (HbO<sub>2</sub>) and deoxyhemoglobin (HbR) as near&#8208;infrared light passes through the cerebral cortex.<xref rid="alz70769-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> This technique reflects hemodynamic responses triggered by neuronal activity, relying on the principle of neurovascular coupling. An increase in blood flow to a region of neural activation leads to a rise in HbO<sub>2</sub> concentration while HbR levels decrease due to the wash&#8208;out effect of blood circulation, collectively serving as an indirect marker of brain cell activation.<xref rid="alz70769-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70769-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>Magnetic resonance imaging (MRI) and computed tomography (CT) are strongly recommended for the early evaluation of NDDs, while positron emission tomography (PET) and single photon emission computed tomography (SPECT) are used for more complex cases. However, these imaging methods face challenges such as radiation safety concerns, the need for highly trained personnel, and the high costs of investment and maintenance, which limit their widespread use.<xref rid="alz70769-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> NIRS has demonstrated strong consistency with MRI, PET, and electroencephalography (EEG) in brain network studies while offering several distinct advantages. NIRS measurements of these hemoglobin responses have been found to align spatially and temporally with the blood oxygen level&#8211;dependent signal detected by MRI.<xref rid="alz70769-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> NIRS also provides superior spatial resolution and is less susceptible to motion artifacts compared to EEG. Additionally, it offers better temporal resolution than MRI and PET, allowing precise detection of hemodynamic changes for continuous real&#8208;time monitoring of the cerebral cortex.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Unlike MRI, NIRS is compatible with individuals who have metal accessories or implants, does not require confinement in a small space reducing the risk of claustrophobia, and does not produce disruptive noise.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Compared to PET, NIRS is more portable, eliminates the risk of ionizing radiation exposure, and is significantly more cost effective. Moreover, unlike EEG, NIRS does not require a conductive medium, enhancing user comfort.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Over the past few decades, there has been a growing interest in using NIRS for cognitive assessment, particularly in the early detection of NDDs. For NDD diagnosis in resource&#8208;constrained settings, NIRS stands out as a potential game changer. This portable and cost&#8208;effective neuroimaging tool overcomes some of the limitations of costly MRI and PET scans often unavailable in resource&#8208;constrained settings. Because NIRS is non&#8208;invasive and safe, it enables frequent monitoring of dementia progression and treatment without patient discomfort or radiation. Its user&#8208;friendly nature and portability mean it can be widely applied in various clinical and community environments, including hard&#8208;to&#8208;reach rural areas. Furthermore, NIRS's capacity to detect hemodynamic brain changes provides critical early diagnostic information on vascular and metabolic dysfunctions. Despite promising advancements, existing studies remain heterogeneous in terms of design, population characteristics, and research methodologies, creating challenges in synthesizing evidence and drawing definitive conclusions. This review aims to address these gaps by systematically evaluating how NIRS has been used in assessing cognitive decline related to MCI and various NDDs. By identifying patterns, methodological variations, and emerging trends, this study highlights the potential of NIRS as a reliable tool for improving diagnostic accuracy and efficiency. Furthermore, it lays a foundation for future investigations into the use of NIRS in diagnosing conditions such as MCI, AD, and PD, ultimately contributing to the advancement of early intervention strategies and precision medicine in NDDs.<xref rid="alz70769-fig-0001" ref-type="fig">&#8195;</xref>
</p></sec><sec id="alz70769-sec-0060"><label>2</label><title>METHODOLOGY</title><p>This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta&#8208;Analyses (PRISMA) guidelines. The methodology was registered in PROSPERO (ID: CRD42025634879) before initiating the literature search.<xref rid="alz70769-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> A comprehensive search was performed across PubMed, Scopus, and Google Scholar databases until May 2025 using keywords such as &#8220;cognitive impairment,&#8221; &#8220;neurodegenerative disease,&#8221; &#8220;Alzheimer's disease,&#8221; &#8220;diagnosis,&#8221; &#8220;detection,&#8221; and &#8220;near&#8208;infrared spectroscopy&#8221; to ensure a focused selection of studies relevant to the application of NIRS in MCI and NDD diagnosis and monitoring. A detailed search strategy is provided as supplementary material in supporting information.</p><p>Studies that examined human subjects with cognitive impairment or neurodegenerative disorders using NIRS as a diagnostic or investigative tool were included. Eligible studies comprised original research, including clinical trials, cohort, case&#8211;control, and cross&#8208;sectional studies that evaluated the effectiveness, accuracy, and reliability of NIRS in detecting cognitive impairment or NDDs. Studies were excluded if they used animal models, involved in vitro procedures, were not published in English, did not focus on NIRS, or lacked relevant outcome data. The exclusion of studies published in non&#8208;English languages was due to challenges in accurately interpreting and critically appraising them, as well as limited resources for translation. To ensure relevance and incorporate the latest advancements in neuroimaging technologies, the review focused on studies published from 2015 onward. Filtering results to this timeframe allowed for a more up&#8208;to&#8208;date assessment of NIRS in cognitive assessment. Additionally, reference lists of the included studies were examined to identify further relevant publications from the same period.</p><p>Data extraction and synthesis were conducted systematically. Two independent reviewers screened titles and abstracts for eligibility, with ambiguous studies reviewed by a third investigator. Full&#8208;text assessments were conducted in the second stage, and a third reviewer resolved uncertainties. The PRISMA flowchart documents the selection process (Figure&#160;<xref rid="alz70769-fig-0001" ref-type="fig">1</xref>). Extracted data included study design, sample size, population characteristics, NIRS techniques, type of neurocognitive disorder, and key findings (Table&#160;<xref rid="alz70769-tbl-0001" ref-type="table">1</xref>). Findings of studies were summarized using a narrative synthesis due to expected heterogeneity precluding quantitative pooling. The expected sources of heterogeneity included clinical differences (variations in participant characteristics, interventions, or outcomes), methodological differences (study design variations), and statistical differences.</p><fig position="float" fig-type="FIGURE" id="alz70769-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Preferred Reporting Items for Systematic Reviews and Meta&#8208;Analyses flow diagram of the screening and selection of studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70769-g002.jpg"/></fig><table-wrap position="float" id="alz70769-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Representative summary of included studies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Country of study</th><th align="left" rowspan="1" colspan="1">Sample size</th><th align="left" rowspan="1" colspan="1">Types of techniques used</th><th align="left" rowspan="1" colspan="1">Type of neurocognitive disorder</th><th align="left" rowspan="1" colspan="1">Key findings</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Pu et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Prospective, cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">246 participants (55 normal controls, 80 SCD patients, and 111 MCI patients)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS and</p>
<p>machine learning</p>
</td><td align="left" rowspan="1" colspan="1">SCD and MCI</td><td align="left" rowspan="1" colspan="1">Analysis of activated PFC during cognitive scale performance, combined with subject&#8208;wise cross&#8208;validation, revealed that as cognitive function declines, prefrontal connectivity becomes less stable. Additionally, individuals with SCD and MCI exhibit reduced communication between the left and right sides of the prefrontal cortex.</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Tso&#8208;Yen et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Prospective, cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">205 healthy and MCI participants</td><td align="left" rowspan="1" colspan="1">fNIRS and GBIT</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Cognitive performance assessed using MMSE revealed a noticeable decline with age, highlighting age&#8208;related cognitive decline. Additionally, HbO<sub>2</sub> and HbR patterns observed during the 3 minute GBIT test varied with age, especially in individuals &gt; 75 years, suggesting changes in neural activity over time.</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Petrillo et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Prospective, cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">83 participants (17 HCs, 37 cognitively normal, 29 MCI)</td><td align="left" rowspan="1" colspan="1">fNIRS, dual&#8208;tasking</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Cognitively healthy individuals exhibited higher complexity in brain activity signals while older individuals with cognitive impairment exhibit reduced signal complexity, reflecting declines in neural processing efficiency.</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Ate&#351; et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Turkey</td><td align="left" rowspan="1" colspan="1">246 participants (20 normal controls, 20 AD patients)</td><td align="left" rowspan="1" colspan="1">fNIRS, cognitive tasks</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Individuals with AD showed increased activity in the left ventral PFC during the positive emotional words condition compared to HCs. Similarly, heightened activation was observed in the right ventrolateral PFC in AD patients during the neutral words condition.</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Mol et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Switzerland and Netherlands</td><td align="left" rowspan="1" colspan="1">202 participants (108 cognitively normal, 37 MCI, and 57 AD)</td><td align="left" rowspan="1" colspan="1">NIRS and TCD</td><td align="left" rowspan="1" colspan="1">MCI, AD</td><td align="left" rowspan="1" colspan="1">Varying correlations between NIRS&#8208; and TCD&#8208;derived cerebral autoregulation measures were observed, with low correlations (0.22&#8211;0.30) during supine rest and stronger correlations (0.46&#8211;0.61) during repeated sit&#8208;to&#8208;stand transitions in cognitively impaired patients.</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Herrmann et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Prospective, observational, long&#8208;term follow&#8208;up study</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">471 participants (424 healthy and 47 MCI)</td><td align="left" rowspan="1" colspan="1">fNIRS and VSEP</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">NIRS analysis during verbal fluency and visuospatial tasks showed lower HbO<sub>2</sub> levels in the frontotemporal cortex of cognitively impaired individuals. Additionally, VSEP revealed prolonged latencies in cognitively impaired individuals.</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Vermeij et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">Interventional, longitudinal study</td><td align="left" rowspan="1" colspan="1">Netherlands</td><td align="left" rowspan="1" colspan="1">35 participants (21 healthy older adults and 14 MCI patients)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">MCI patients exhibited maximum HbO<sub>2</sub> increase at lower WM load compared to healthy older adults, who showed peak activation at higher WM load (2&#8208;back). However, the HbR response did not provide a clear pattern.</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Talamonti et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Longitudinal study</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">32 participants (24 HCs and 8 MCI patients)</td><td align="left" rowspan="1" colspan="1">NIRS, dual&#8208;task walking paradigm</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Regular physical activity was associated with improved cognitive performance and more efficient brain oxygenation over 1 year, with a stronger impact observed in individuals with MCI, though benefits were also evident in healthy adults.</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Xu et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">40 participants (21 older adults diagnosed with MCI and 19 healthy older adults)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Older adults with MCI demonstrated significantly lower balance control than healthy older adults, especially under dual&#8208;task conditions. Additionally, individuals with MCI exhibited higher PFC activation, suggesting increased neural effort to compensate for balance deficits.</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Z. Yang et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">24 participants (17 AD patients and 7 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, Verbal Fluency Task</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Significant differences in cerebral hemodynamic responses between AD patients and the control group were found, with AD patients exhibiting decreased HbO<sub>2</sub> concentrations. The decline in FC was primarily observed in the dorsolateral PFC and other brain regions.</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Metzger et&#160;al.,&#160;2016</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">24 participants (8 AD patients, 8 bvFTD patients, and 8 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, Verbal Fluency Task</td><td align="left" rowspan="1" colspan="1">
<p>AD and</p>
<p>bvFTD</p>
</td><td align="left" rowspan="1" colspan="1">AD patients exhibit a significantly weaker activation pattern in key brain regions, including the dorsolateral PFC, supplementary motor area, and Wernicke's area during the Verbal Fluency Task, particularly in the left hemisphere. In contrast, bvFTD patients display distinct activation variations, characterized by increased activity in Broca's area.</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">J. Kim et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Prospective, interventional, short&#8208;term longitudinal study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">97 participants (28 cognitively normal, 32 preclinical AD, 21 MCI, and 16 AD)</td><td align="left" rowspan="1" colspan="1">Olfactory&#8208;stimulation fNIRS</td><td align="left" rowspan="1" colspan="1">AD, MCI</td><td align="left" rowspan="1" colspan="1">Significant differences in oxygenation levels in the orbitofrontal cortex were observed, with reductions in patients with cognitive impairment, including mild AD and MCI, becoming more pronounced as cognitive severity increases.</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">J. Kim et&#160;al.,&#160;2023</td><td align="left" rowspan="1" colspan="1">Post hoc and prospective diagnostic pilot trial</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">
<p>133 participants (55 cognitively normal, 41 MCI, and 21 AD)</p>
</td><td align="left" rowspan="1" colspan="1">Olfactory&#8208;stimulation fNIRS, machine learning</td><td align="left" rowspan="1" colspan="1">AD, MCI</td><td align="left" rowspan="1" colspan="1">Machine learning models leveraging olfactory&#8208;stimulated oxygenation differences in the orbitofrontal cortex through fNIRS demonstrated superior accuracy in diagnosing MCI and AD.</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Ferdinando et&#160;al.,&#160;2023</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Finland</td><td align="left" rowspan="1" colspan="1">22 participants (8 AD and 14 age&#8208;matched healthy subjects)</td><td align="left" rowspan="1" colspan="1">MRI&#8208;compatible novel multiwavelength fNIRS</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">In the cardiac band, healthy individuals exhibit greater time&#8208;domain lag variation in HbR&#8208;CSF, dHbR&#8208;CSF, HbR&#8208;dCSF, and dHbR&#8208;dCSF pairs compared to AD patients. Additionally, venous HbR blood signal coupling with CSF is more variable in healthy individuals, whereas in AD patients, it becomes more uniform. Under fast sampling conditions with minimal overlapping windows, the HbR&#8208;CSF coupling in AD patients gradually shifts to a monotonous pattern over time.</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">M&#305;zrak et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Observational case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Turkey</td><td align="left" rowspan="1" colspan="1">30 participants (14 AD and 16 age&#8208;matched healthy subjects)</td><td align="left" rowspan="1" colspan="1">fNIRS, Verbal Fluency Task</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">
<p>Increased interhemispheric connectivity was found in HCs compared to AD patients.</p>
<p>AD patients exhibit persistent functional hemispheric asymmetry.</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">Q. Li et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Short&#8208;term longitudinal experimental study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">
<p>97 healthy and</p>
<p>cognitively impaired participants</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">Cognitive Impairment</td><td align="left" rowspan="1" colspan="1">Open skill exercises significantly enhance cognitive inhibition, leading to improved attention capacity, self&#8208;regulation, and adaptability to environmental changes. In contrast, closed skill exercises are more effective in strengthening working memory, optimizing information processing, and enhancing storage capacity within cognitive functions.</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Oyama et&#160;al.,&#160;2018</td><td align="left" rowspan="1" colspan="1">
<p>Cross&#8208;sectional design</p>
</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">202 participants (108 normal, 55 MCI, and 39 severe cognitive impairment)</td><td align="left" rowspan="1" colspan="1">TRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">
<p>A significant positive correlation between MMSE and SO<sub>2</sub> in the left PFC</p>
<p>(<italic toggle="yes">r</italic>&#160;= 0.38, <italic toggle="yes">P</italic>&#160;&lt; 0.01) and the right PFC was observed.</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">T. lok Lee et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study design</td><td align="left" rowspan="1" colspan="1">Hong Kong</td><td align="left" rowspan="1" colspan="1">
<p>151 participants</p>
<p>(37 with normal cognition, 86 with SMC [29 with severe SMC], 15 with aMCI, and 13 with naMCI)</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">
<p>MCI, SMC</p>
</td><td align="left" rowspan="1" colspan="1">Individuals with aMCI exhibited significantly lower levels of HbO<sub>2</sub> compared to those with normal cognition, while severe SMC also correlated with reduced HbO<sub>2</sub> levels.</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">Owens et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional observational study</td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">40 participants (20 MCI and 20 age&#8208;matched HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Individuals with MCI exhibit a significant decline in neurovascular coupling within the left dorsolateral PFC compared to cognitively normal individuals. Additionally, FC in the left dorsolateral PFC is significantly reduced in MCI.</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Ung et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">
<p>61 participants (31 age&#8208;matched HCs, 12 patients with MCI, and 18 mild AD)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, visuospatial working memory task</p>
</td><td align="left" rowspan="1" colspan="1">MCI, mild AD</td><td align="left" rowspan="1" colspan="1">Patients with MCI demonstrated hyperactivation in the PFC at moderate task loads (HbO levels increased significantly). As task difficulty increased, the MCI group showed significant increases in HbO levels, while the AD group maintained static levels.</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Y. L. Chan et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">42 participants (26 age&#8208;matched HCs and 16 individuals diagnosed with mild AD)</td><td align="left" rowspan="1" colspan="1">fNIRS and OMSTs</td><td align="left" rowspan="1" colspan="1">Mild AD</td><td align="left" rowspan="1" colspan="1">Wavelet analysis for motion artifact correction with OMSTs for network binarization improves the reliability of FC assessments using fNIRS. This method highlights distinct connectivity patterns, showing that individuals in the mild AD group exhibited impaired FC.</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Oyama &amp; Sakatani, 2022</td><td align="left" rowspan="1" colspan="1">Observational cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">250 participants (115 patients with MCI and 135 HC)</td><td align="left" rowspan="1" colspan="1">Time&#8208;resolved NIRS, machine learning</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The deep neural network model using time&#8208;resolved NIRS data demonstrated lower mean absolute error and mean absolute percentage error compared to predictions based on blood test data.</td></tr><tr><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">Yu et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">
<p>46 participants (23 HCs and 23 with MCI)</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">MCI group exhibited greater prefrontal functional connectivity compared to HCs, suggesting compensatory mechanisms.</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">E. Kim et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">60 participants (31 HCs, 11 patients with MCI, and 18 AD)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI, AD</td><td align="left" rowspan="1" colspan="1">The Delayed Matching&#8208;to&#8208;Sample task showed significantly higher HbO<sub>2</sub> concentrations in the MCI group, whereas the Digit Span Task showed no significant differences.</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">Takahashi et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">132 participants (102 elderly individuals [61 with MCI and 41 without MCI] and 30 young controls)</td><td align="left" rowspan="1" colspan="1">NIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The finger&#8208;tapping task appeared cognitively demanding for elderly individuals, including those with MCI, as indicated by sustained HbO<sub>2</sub> levels.</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">Paraskevaidi et&#160;al.,&#160;2018</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">United Kingdom</td><td align="left" rowspan="1" colspan="1">284 participants (111 AD patients and 173 HCs)</td><td align="left" rowspan="1" colspan="1">NIRS</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Statistical analysis identified significant spectral differences between healthy controls and AD. Furthermore, multivariate classification models (PCA&#8208;QDA) achieved high classification accuracy for AD individuals, with 92.8% accuracy, 87.5% sensitivity, and 96.1% specificity.</td></tr><tr><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">A. S. Chan et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Pilot randomized controlled trial</td><td align="left" rowspan="1" colspan="1">Hong Kong</td><td align="left" rowspan="1" colspan="1">40 participants (18 MCI and 22 HCs)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, photobiomodulation intervention</p>
</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Photobiomodulation improved visual memory performance and reduced hemodynamic response during tasks in older adults with MCI.</td></tr><tr><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">C. Zhang et&#160;al.,&#160;2023</td><td align="left" rowspan="1" colspan="1">Prospective cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">127 participants (64 MCI and 63 HCs)</td><td align="left" rowspan="1" colspan="1">Multi&#8208;dimensional fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">3D time&#8208;point HbO<sub>2</sub> features provided the highest accuracy for detecting MCI, with 80.77% test accuracy, 76.92% sensitivity, and 83.33% precision. Additionally, HbO<sub>2</sub> features were more effective than HbR features.</td></tr><tr><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">S. Park et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Double&#8208;blind, randomized controlled pilot study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">21 MCI patients (10 participants inhaled saline [control], while the phytoncide group had 11 participants exposed to phytoncide)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The phytoncide group showed a significant improvement in Stroop task performance, while the saline group showed no significant change. Hemodynamic attenuation was observed in the left VLPFC of the phytoncide group.</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Tian et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Observational cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">56 participants (22 patients with MCI and 34 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, Verbal Fluency Task</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The HC group demonstrated significantly higher HbR concentrations in the left parietal lobule and left inferior parietal lobule during the category verbal fluency task compared to the MCI group</td></tr><tr><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">Salzman et&#160;al.,&#160;2023</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional pilot study</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">20 participants (10 SCD and 10 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">SCD</td><td align="left" rowspan="1" colspan="1">Participants exhibited slower response times during dual&#8208;task gait compared to single&#8208;task condition. In non&#8208;SCD group, gait speed was significantly slower in the dual&#8208;task condition compared to the single task.</td></tr><tr><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">Perpetuini et&#160;al.,&#160;2019</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">22 participants (11 early AD and 11 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, Clock Drawing Test, Digit Span Test, and Corsi Block Tapping Test</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">The Clock Drawing Test effectively differentiated between AD patients and healthy controls, while the Digit Span Test and Corsi Block Tapping Test did not show significant distinctions between the two groups.</td></tr><tr><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">Perpetuini et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">35 participants (17 AD and 18 healthy controls)</td><td align="left" rowspan="1" colspan="1">fNIRS, EEG</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Conditional entropy EEG&#8208;fNIRS metrics proved to be the most predictive across all tasks, particularly excelling during ROCF (recall), outperforming both EEG and fNIRS complexity metrics independently.</td></tr><tr><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">Teo et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">58 participants (26 healthy, 23 SMC, 9 dementia)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">SMC, dementia</td><td align="left" rowspan="1" colspan="1">During single&#8208;task gait, individuals with dementia showed a significantly higher HbO<sub>2</sub> response compared to HCs and those with SMC, with no major differences between the latter two groups. However, in dual&#8208;task gait, SMC participants exhibited an increase in HbO<sub>2</sub>, while those with dementia showed a decline.</td></tr><tr><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">Bjerkan et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Slovenia</td><td align="left" rowspan="1" colspan="1">39 participants (19 AD and 20 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, EEG, electrocardiography (ECG), and respiration effort analysis</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Phase coherence between instantaneous heart rate (IHR) and fNIRS signals was observed in the 0.052&#8211;0.6&#160;Hz range, while respiration&#8211;fNIRS coherence occurred mostly in the 0.145&#8211;0.6&#160;Hz range, with a consistent time lag of &#8776; 2.5 seconds between oscillators. Notably, the AD group exhibited reduced IHR&#8211;fNIRS coherence across all channels</td></tr><tr><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">R. Li et&#160;al.,&#160;2018</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">30 participants (8 HCs and 9 MCI individuals, 6 mild AD, 7 moderate/severe AD)</td><td align="left" rowspan="1" colspan="1">fNIRS, Digit Verbal Span Task</td><td align="left" rowspan="1" colspan="1">MCI and AD</td><td align="left" rowspan="1" colspan="1">The HC group exhibited a typical response with a rapid increase in HbO<sub>2</sub> concentration followed by a return to baseline, whereas the MCI group showed a delayed and mild rise, and AD groups demonstrated a noticeable decline and delay in activation.</td></tr><tr><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">D. Yang et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">24 participants (9 HCs and 15 MCI individuals).</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">MCI patients exhibited a marked reduction in HbO concentrations during the N&#8208;back and Verbal Fluency Tasks (<italic toggle="yes">P</italic>&#160;&lt; 0.001), whereas their response to the Stroop task remained similar to that of healthy controls (<italic toggle="yes">P</italic>&#160;= 0.06825).</td></tr><tr><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">Z. Wang et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">54 participants (38 HCs and 16 cognitive impaired individuals)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">Cognitive impairment</td><td align="left" rowspan="1" colspan="1">Gait analysis revealed that step length in healthy participants was significantly longer than in cognitively impaired individuals (<italic toggle="yes">P</italic>&#160;&lt; 0.01) during single&#8208;task walking. In dual&#8208;task walking, normal subjects exhibited greater step length, speed, and frequency than cognitively impaired individuals, with step length showing statistical significance (<italic toggle="yes">P</italic>&#160;&lt; 0.05).</td></tr><tr><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">Ho et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">140 participants (53 age&#8208;matched HCs and 83 asymptomatic AD, 50 prodromal AD, and 9 AD dementia)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">While brain activation remained similar in healthy individuals and AD patients during resting conditions, cognitive tasks revealed distinct differences, with prodromal AD patients exhibiting lower activation compared to HCs and asymptomatic AD.</td></tr><tr><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">J. H. Park, 2023</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">136 participants (84 HCs and 52 MCI)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, Verbal Digit Span Task</p>
</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">fNIRS analysis revealed significantly reduced HbO levels in the left and right prefrontal cortex of MCI patients during cognitive tasks.</td></tr><tr><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">Z. Wang et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">33 participants (20 MCI and 13 SCD)</td><td align="left" rowspan="1" colspan="1">fNIRS, Verbal Fluency Tasks</td><td align="left" rowspan="1" colspan="1">MCI, SCD</td><td align="left" rowspan="1" colspan="1">FC analysis during resting&#8208;state fNIRS revealed that SCD patients exhibited stronger FC patterns compared to MCI patients. During the verbal fluency task, SCD patients showed higher HbO<sub>2</sub> concentration in the frontal lobe compared to MCI patients.</td></tr><tr><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">M. Kim et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">99 participants (54 HCs and 45 preclinical subjects who were amyloid beta positive)</td><td align="left" rowspan="1" colspan="1">fNIRS during a mixed phonemic and semantic verbal fluency task.</td><td align="left" rowspan="1" colspan="1">Preclinical AD</td><td align="left" rowspan="1" colspan="1">Preclinical AD individuals exhibited significantly higher interhemispheric FC of HbO<sub>2</sub> during P1 compared to HC participants. Furthermore, a notable decline in interhemispheric FC of HbO<sub>2</sub> was observed in the preclinical AD group between P1 and S1, whereas the HC group showed no such reduction.</td></tr><tr><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">Choi et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Retrospective observational case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">28 participants (19 MCI patients and 9 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">In the PFC, HbR activation levels gradually declined over time during Stroop task performance, with a notable reduction observed in the left dorsolateral PFC and frontopolar cortex in MCI patients at the 6 month follow&#8208;up.</td></tr><tr><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">J. Wang et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">73 participants (19 patients with PD&#8208;MCI, 21 with PD&#8208; NC, and 33 age&#8208;matched HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS during the Stroop Color&#8208;Word Test</td><td align="left" rowspan="1" colspan="1">PD</td><td align="left" rowspan="1" colspan="1">The FC analysis revealed that patients with PD&#8208;MCI exhibited significantly higher regional strength measures (S<sub>l</sub>, S<sub>r</sub>) and global efficiency compared to HC during the color&#8208;word incongruent test. Additionally, RS<sub>r</sub> demonstrated predictive value in distinguishing PD&#8208;MCI from PD&#8208;NC.</td></tr><tr><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">Ruan et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">53 participants (28 inpatients with AD and 25 with LBD)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS&#8208;based verbal fluency task, blood biomarker analysis</p>
</td><td align="left" rowspan="1" colspan="1">AD, LBD</td><td align="left" rowspan="1" colspan="1">Compared to the LBD group, the mean HbO<sub>2</sub> concentrations were significantly lower in the AD group in the left temporal cortex, right dorsolateral PFC, and right temporal cortex.</td></tr><tr><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">D. Yang et&#160;al.,&#160;2019</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">24 participants (15 MCI patients and 9 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Findings showed that the left PFC exhibited significantly higher HbO<sub>2</sub> concentration changes in HCs compared to MCI patients across all tasks, with HCs displaying an earlier increase.</td></tr><tr><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">Keles et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Turkey</td><td align="left" rowspan="1" colspan="1">39 participants (21 AD patients and 18 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Resting&#8208;state bilateral PFC activation was significantly reduced in AD patients compared to HCs, with the dorsolateral PFC demonstrating the highest relative activation in HC.</td></tr><tr><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">Tang &amp; Chan, 2018</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">61 participants (18 mild AD patients, 12 MCI, and 31 normal aging individuals)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">Mild AD, MCI</td><td align="left" rowspan="1" colspan="1">FC in normal aging was primarily concentrated in the left and middle PFC, shifting toward the right hemisphere in MCI and becoming evenly distributed in AD.</td></tr><tr><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">Bonilauri et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">
<p>39 participants (13 early PD patients and 26 moderate PD)</p>
</td><td align="left" rowspan="1" colspan="1">Whole&#8208;head fNIRS</td><td align="left" rowspan="1" colspan="1">PD</td><td align="left" rowspan="1" colspan="1">Early PD patients showed increased activity in both left and right secondary visual cortices. In contrast, mild PD patients exhibited greater activation in the right PFC.</td></tr><tr><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">Uemura et&#160;al.,&#160;2016</td><td align="left" rowspan="1" colspan="1">Case&#8208;control study</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">130 participants (64 older adults with aMCI and 66 cognitively HCs)</td><td align="left" rowspan="1" colspan="1">Multi&#8208;channel fNIRS</td><td align="left" rowspan="1" colspan="1">aMCI</td><td align="left" rowspan="1" colspan="1">Subjects with aMCI showed reduced activation in the bilateral dorsolateral cortex during memory retrieval.</td></tr><tr><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">Marmarelis et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">46 aMCI patients, 20 age&#8208;matched controls [TCD group]; 43 aMCI patients, 22 age&#8208;matched controls (NIRS group)</td><td align="left" rowspan="1" colspan="1">TCD, NIRS</td><td align="left" rowspan="1" colspan="1">aMCI</td><td align="left" rowspan="1" colspan="1">While dynamic cerebral autoregulation remained intact, MCI patients demonstrated significantly reduced vasomotor reactivity in response to CO<sub>2</sub> changes, with more pronounced impairments in TOI/NIRS measurements.</td></tr><tr><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">Nakamura et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional observational study</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">63 participants (28 MCI and 35 non&#8208;dementia control)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, working memory tasks</p>
</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The fNIRS index effectively differentiates MCI patients from HCs, showing high sensitivity (94%) and specificity (88%) for cognitive decline.</td></tr><tr><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">Greco et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">129 participants (20 autopsy&#8208;confirmed AD patients, 12 MCI patients, and 13 age&#8208;matched controls)</td><td align="left" rowspan="1" colspan="1">NIRS</td><td align="left" rowspan="1" colspan="1">AD, MCI</td><td align="left" rowspan="1" colspan="1">
<p>NIRS can effectively differentiate AD and MCI patients from controls using specific spectral features at 860 and 895&#160;nm.</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">Nguyen et&#160;al.,&#160;2019b</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">134 participants (42 with MCI and 53 cognitively HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS with cognitive tasks</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">During the verbal fluency task, the HC group demonstrated significantly stronger inter&#8208;hemispheric connectivity compared to intra&#8208;hemispheric connectivity. In contrast, the MCI group showed no significant difference between inter&#8208; and intra&#8208;hemispheric connectivity but exhibited lower inter&#8208;hemispheric connectivity across multiple tasks.</td></tr><tr><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">Huang et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Prospective cross&#8208;sectional pilot study</td><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">
<p>131 participants (63 on&#8208;stroke with normal cognitive function, 47 stroke with normal cognitive function,</p>
<p>6 non&#8208;stroke with cognitive dysfunction, and 15 stroke with cognitive dysfunction)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, Wisconsin Card Sorting Test</p>
</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">High&#8208;scoring groups (cognitively normal) showed increased HbO<sub>2</sub> and decreased deoxygenated hemoglobin, whereas low&#8208;scoring groups (MCI) exhibited increases in both oxygenated hemoglobin and deoxygenated hemoglobin</td></tr><tr><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">Csipo et&#160;al.,&#160;2021</td><td align="left" rowspan="1" colspan="1">Prospective cross&#8208;sectional observational study</td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">
<p>14 healthy young adults</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">
<p>MCI indirectly studied through cognitive workload responses</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS assessments revealed increased HbO<sub>2</sub> in the prefrontal cortex, particularly in the left dorsolateral PFC and motor cortex, during the 2&#8208;back condition.</td></tr><tr><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">Katzorke et&#160;al.,&#160;2018</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional observational study</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">110 participants (55 healthy individuals and 55 MCI)</td><td align="left" rowspan="1" colspan="1">fNIRS during verbal fluency tasks</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Individuals with MCI exhibited a significantly reduced hemodynamic response in the inferior frontotemporal cortex during the category verbal fluency task compared to HCs (<italic toggle="yes">P</italic>&#160;= 0.010).</td></tr><tr><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">R. Li, Rui, et&#160;al.,&#160;2019</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">32 participants (16 aMCI patients and 16 age&#8208; and education&#8208;matched HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, graph&#8208;based network metrics</td><td align="left" rowspan="1" colspan="1">aMCI</td><td align="left" rowspan="1" colspan="1">aMCI patients showed higher integration and segregation in brain networks compared to HCs, with significant network alterations in frontal, temporal, and parietal regions.</td></tr><tr><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">K. Lee et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Randomized controlled pilot study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">64 participants (43 adults with cognitive decline and 21 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS and machine learning&#8208;based classification, photobiomodulation intervention</td><td align="left" rowspan="1" colspan="1">Cognitive decline</td><td align="left" rowspan="1" colspan="1">Significant cognitive improvements were observed in most metrics after transcranial photobiomodulation treatment, except for the Digit Span Test&#8208;Backward and the Digit Symbol Coding test.</td></tr><tr><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">Mei et&#160;al.,&#160;2024</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">120 older adults (30 MCI, 28 LBD, 30 AD, and 32 cognitively normal individuals)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">AD, LBD</td><td align="left" rowspan="1" colspan="1">The mean FC of the frontal and temporal lobe in resting state was significantly less in the AD (0.19&#160;&#177;&#160;0.11) group than in the MCI (0.23&#160;&#177;&#160;0.11), LBD (0.29&#160;&#177;&#160;0.12), and cognitively normal (0.40&#160;&#177;&#160;0.11) groups (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001).&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">Yoon et&#160;al.,&#160;201)</td><td align="left" rowspan="1" colspan="1">Observational cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">35 participants (20 normal elderly people and 15 patients with MCI)</td><td align="left" rowspan="1" colspan="1">fNIRS, two&#8208;back test, Korean color word Stroop test, and semantic verbal fluency task</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">In the Stroop test, right&#8208;sided hyperactivation was observed in the naMCI and normal groups, with the highest mean change in HbO<sub>2</sub> in the naMCI group, followed by the normal group and the aMCI group.</td></tr><tr><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">D. Yang &amp; Hong, 2021</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">24 subjects (15 MCI patients and 9 HC participants)</td><td align="left" rowspan="1" colspan="1">fNIRS, graph theory analysis, and traditional machine learning approach</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The feature representation&#8208;based transfer learning demonstrated improved accuracy in both the 30 second and 90 second cases, achieving 81.27% and 76.73%, respectively.</td></tr><tr><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">Yeung et&#160;al.,&#160;2016</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">Hong Kong</td><td align="left" rowspan="1" colspan="1">52 participants (26 older adults with MCI and 26 older adults with normal cognition)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The MCI group, unlike the normal cognition group, did not exhibit significantly increased frontal activations bilaterally when WM load increased. Compared to the normal cognition group, the MCI group had similar frontal activations at low load (<italic toggle="yes">p</italic>&#160;&gt; 0.05 on all channels) but reduced activations at high load.</td></tr><tr><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">You et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">37 participants (18 individuals with MCI, and 19 healthy individuals)</td><td align="left" rowspan="1" colspan="1">fNIRS, upper limb multimodal tasks</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Resting&#8208;state brain activation and FC analyses revealed reduced activation and connectivity in MCI individuals, particularly in the left and right motor cortices and between frontal and motor regions.</td></tr><tr><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">Polak et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">A prospective, observational, long&#8208;term follow&#8208;up study</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">604 healthy, AD, and MCI participants</td><td align="left" rowspan="1" colspan="1">fNIRS and VSEP</td><td align="left" rowspan="1" colspan="1">AD, MCI</td><td align="left" rowspan="1" colspan="1">MCI was identified in 12.3% of participants, while AD patients exhibited reduced oxygenation levels, as measured by fNIRS, and both AD and MCI individuals showed significantly prolonged VSEP latencies.</td></tr><tr><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">Perpetuini et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">22 participants (11 healthy participants and 11 early AD patients)</td><td align="left" rowspan="1" colspan="1">fNIRS, free and cued selective reminding test</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Significant differences in multiscale entropy, measured using fNIRS, were observed between AD patients and HCs during the delayed free recall phase of the free and cued selective reminding test. These differences were specifically localized to Brodmann areas 9 and 46, which are regions of the brain associated with working memory functions.</td></tr><tr><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">S. Zhang et&#160;al.,&#160;2022</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">128 participants (64 patients with aMCI and 64 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">aMCI</td><td align="left" rowspan="1" colspan="1">aMCI patients exhibited a marked reduction in FC throughout the brain, with notable impairments in the bilateral prefrontal, parietal, occipital, and right temporal lobes.</td></tr><tr><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">Sharon et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">
<p>Prospective case&#8211;control study</p>
</td><td align="left" rowspan="1" colspan="1">Israel</td><td align="left" rowspan="1" colspan="1">60 participants (34 patients with PD and 26 older adults)</td><td align="left" rowspan="1" colspan="1">fNIRS, obstacle negotiation task</td><td align="left" rowspan="1" colspan="1">PD</td><td align="left" rowspan="1" colspan="1">Prefrontal activation patterns in PD patients progressively increase across all phases of obstacle crossing, with significantly greater activation compared to healthy older adults, especially during and after the crossing phase.</td></tr><tr><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">J. H. Park, 2024</td><td align="left" rowspan="1" colspan="1">
<p>Prospective cross&#8208;sectional study</p>
</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">230 participants (82 subjects with MCI and 148 HCs)</td><td align="left" rowspan="1" colspan="1">
<p>fNIRS, CNNs, 2&#8208;back task</p>
</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Significant differences in averaged HbO<sub>2</sub> values between MCI and HC groups were found, and the CNN model could better discriminate MCI with over 89.57% accuracy than the Korean version of the Montreal Cognitive Assessment (MoCA).</td></tr><tr><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">Yoo et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Prospective case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">
<p>26 participants (15 MCI and 11 HCs)</p>
</td><td align="left" rowspan="1" colspan="1">fNIRS, two&#8208;back, Stroop, and semantic verbal fluency tasks</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Region of interest selection identified key activated channels for each task, revealing that MCI patients exhibited no activation in the ventrolateral PFC compared to HCs.</td></tr><tr><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">Cicalese et&#160;al.,&#160;2020</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">29 participants (8 HCs, 8 MCI, and 8 patients with mild AD and 7 with moderate/severe AD)</td><td align="left" rowspan="1" colspan="1">EEG and fNIRS</td><td align="left" rowspan="1" colspan="1">MCI, AD</td><td align="left" rowspan="1" colspan="1">Hybrid EEG&#8208;fNIRS model significantly outperforms unimodal EEG and fNIRS approaches in classifying subjects based on AD progression.</td></tr><tr><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">R. Li, Nguyen, et&#160;al.,&#160;2019</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">14 participants (8 HCs and patients with mild AD)</td><td align="left" rowspan="1" colspan="1">EEG and fNIRS</td><td align="left" rowspan="1" colspan="1">Mild AD</td><td align="left" rowspan="1" colspan="1">EEG&#8208;fNIRS approach applied during a digit verbal span task reveals weaker cortical connectivity alterations associated in mild AD patients.</td></tr><tr><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Yap et&#160;al.,&#160;2017</td><td align="left" rowspan="1" colspan="1">Case&#8211;control study</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">61 participants (31 HCs, 12 patients with MCI, and 18 patients with mild AD)</td><td align="left" rowspan="1" colspan="1">fNIRS, semantic verbal fluency task</td><td align="left" rowspan="1" colspan="1">MCI, mild AD</td><td align="left" rowspan="1" colspan="1">MCI exhibited a greater mean activation of both the right and left PFC, followed by HCs and mild AD. Analysis showed that in the left PFC, the time taken for HCs to achieve the activation level was shorter than MCI and mild AD.</td></tr><tr><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">Bu et&#160;al.,&#160;2019</td><td align="left" rowspan="1" colspan="1">Cross&#8208;sectional study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">54 participants (26 with MCI and 28 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">The coupling strength of right PFC left PFC and left PFC to right occipital lobe as well as left PFC to left occipital lobe, right occipital lobe to left PFC and right PFC to left occipital lobe in MCI group were significantly lower than those in the control group.</td></tr><tr><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">C. Fan et&#160;al.,&#160;2025</td><td align="left" rowspan="1" colspan="1">Observational case&#8211;control study</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">136 participants (73 patients with MCI and 63 HCs)</td><td align="left" rowspan="1" colspan="1">fNIRS, Stroop test</td><td align="left" rowspan="1" colspan="1">MCI</td><td align="left" rowspan="1" colspan="1">Individuals with MCI and healthy controls exhibited increased cortical activation in the dorsolateral PFC, ventrolateral PFC, and parietal lobe while completing the Stroop task.</td></tr></tbody></table><table-wrap-foot><fn id="alz70769-tbl1-note-0001"><p>Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; bvFTD, behavioral&#8208;variant frontotemporal dementia; CNN, convolutional neural network; CSF, cerebrospinal fluid; dCSF, first derivative of cerebrospinal fluid; dHbR, first derivative of deoxygenated hemoglobin; FC, functional connectivity; fNIRS, functional near&#8208;infrared spectroscopy; EEG, electroencephalography; GBIT, Game&#8208;Based Intelligence Test; HbO<sub>2</sub>, oxyhemoglobin; HbR, deoxyhemoglobin; HC, healthy control; LBD, Lewy body disease; MCI, mild cognitive impairment; MMSE, Mini&#8208;Mental State Examination; MRI, magnetic resonance imaging; naMCI, non&#8208;amnestic mild cognitive impairment; NIRS, near&#8208;infrared spectroscopy; OMST, orthogonal minimal spanning tree; PD, Parkinson's disease; PD&#8208;MCI, Parkinson's disease with mild cognitive impairment; PD&#8208;NC, Parkinson's disease normal cognition; PFC, prefrontal cortex; ROCF, Rey&#8211;Osterrieth complex figure; SCD, subjective cognitive decline; SMC, subjective memory complaint; TCD, transcranial Doppler; TOI, tissue oxygenation index; TRS, time&#8208;resolved near0infrared spectroscopy; VLPLC, ventrolateral prefrontal cortex; VSEP, vagus somatosensory evoked potential; WM, white matter.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Quality of included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies&#8208;2 (QUADAS&#8208;2) tool, which assesses risk of bias and concerns regarding applicability across four key domains. The patient selection domain assesses whether participants were recruited appropriately and without bias such as avoiding inappropriate exclusions. The index test domain evaluates whether the diagnostic test under evaluation was conducted and interpreted without prior knowledge of the results of the reference standard. The reference standard domain evaluates whether the standard used to confirm the target condition was likely to correctly classify the condition, and whether its interpretation was performed independently of the index test. Finally, the flow and timing domain considers whether all participants received the same reference standard and whether the interval between the index test and reference standard was appropriate to avoid misclassification. A visual summary of these evaluations is presented in Figure <xref rid="alz70769-supinfo-0001" ref-type="">S1</xref> in supporting information. Studies deemed high quality demonstrated well&#8208;defined patient selection, objective diagnostic testing, independent reference standard application, transparent timing, and minimal bias. Two reviewers independently assessed study quality, resolving discrepancies through discussion, with a third reviewer mediating when necessary. Because this systematic review relied on previously published, publicly accessible data, formal ethical approval was not required.</p></sec><sec id="alz70769-sec-0070"><label>3</label><title>RESULTS AND DISCUSSION</title><p>The reviewed studies predominantly focused on populations with MCI (<italic toggle="yes">n</italic>&#160;=&#160;49), followed by AD (<italic toggle="yes">n</italic>&#160;=&#160;28), subjective cognitive decline (SCD)/subjective memory decline (SMD, <italic toggle="yes">n</italic>&#160;=&#160;5), PD (<italic toggle="yes">n</italic>&#160;=&#160;3), LBD (<italic toggle="yes">n</italic>&#160;=&#160;2), and FTD (<italic toggle="yes">n</italic>&#160;=&#160;1). Geographically, most studies were conducted in East Asia (<italic toggle="yes">n</italic>&#160;=&#160;46), with additional contributions from Western Europe (<italic toggle="yes">n</italic>&#160;=&#160;16), North America (<italic toggle="yes">n</italic>&#160;=&#160;7), Southeast Asia (<italic toggle="yes">n</italic>&#160;=&#160;5), and the Middle East (<italic toggle="yes">n</italic>&#160;=&#160;1). In terms of study design, there were 41 cross&#8208;sectional studies, 25 case&#8211;control studies, 6 longitudinal studies, and 6 randomized pilot trials. These pilot trials represent small&#8208;scale, preliminary study designed to assess the feasibility, usability, and initial diagnostic performance of the device in a target population.</p><sec id="alz70769-sec-0080"><label>3.1</label><title>Principles and applications of NIRS in neuroimaging and cognitive assessment</title><p>NIRS operates on the principle that near&#8208;infrared (NIR) light can penetrate human tissues with minimal interference. As NIR light travels, it undergoes absorption by chromophores, such as hemoglobin, or scattering within the tissue, with scattering occurring significantly more frequently.<xref rid="alz70769-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> This mechanism forms the foundation of NIRS as a non&#8208;invasive neuroimaging technique for monitoring brain activity.</p><p>Neurovascular coupling ensures that increased brain activity leads to heightened oxygen consumption and a corresponding rise in cerebral blood flow, which alters local concentrations of HbO<sub>2</sub> and HbR.<xref rid="alz70769-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> NIRS uses specific NIR wavelengths to measure these fluctuations, using distinct absorption properties of HbO<sub>2</sub> and HbR to evaluate cerebral oxygenation.<xref rid="alz70769-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Spectral markers at 895 and 860&#160;nm help differentiate AD, MCI, and healthy controls, with the 895&#160;nm signal being particularly indicative of early&#8208;stage MCI and the 860&#160;nm signal becoming more prominent in later AD progression.<xref rid="alz70769-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>The deployment of laser diodes through fiber optic bundles allows NIRS to target specific brain regions, such as the prefrontal and parietal cortices, using optodes strategically placed following the international EEG 10&#8208;20 system. A secondary optode, positioned 4&#160;cm laterally, enables a refined analysis of the reflected light, which is processed via a photomultiplier tube linked to a photon counter.<xref rid="alz70769-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70769-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Raw intensity signals are converted into HbO<sub>2</sub> and HbR concentrations using the modified Beer&#8211;Lambert Law, with standard correction techniques such as Butterworth filtering and detrending algorithms applied to reduce physiological noise and phase distortions.<xref rid="alz70769-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70769-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70769-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>Functional NIRS (fNIRS), an advancement of NIRS with more optodes, enables extensive analysis of brain activity during cognitive tasks. The prefrontal cortex (PFC), occupying &#8776; 29% of the total cerebral cortex volume, plays a central role in higher order cognitive functions, including attention, executive processing, memory, language, and visuospatial skills.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> It interacts with the hippocampus through functional connectivity (FC) networks, facilitating generalization of knowledge and supporting cognitive domains.<xref rid="alz70769-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p></sec><sec id="alz70769-sec-0090"><label>3.2</label><title>Validation of NIRS as a reliable neuroimaging tool for cognitive assessment</title><p>NIRS has demonstrated strong consistency with well&#8208;established neuroimaging techniques, including MRI, PET, EEG, and transcranial Doppler (TCD). NIRS measurements show a high spatial and temporal correlation with the blood oxygen level&#8211;dependent signal detected by MRI in brain network studies.<xref rid="alz70769-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Similarly, cerebral autoregulation (CA) measures derived from NIRS strongly correlate with TCD results, particularly during repeated sit&#8208;to&#8208;stand transitions in cognitively impaired patients, confirming its reliability in monitoring cerebrovascular function.<xref rid="alz70769-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>Advancements in machine learning have further enhanced NIRS&#8208;based diagnostics. Models incorporating olfactory&#8208;stimulated oxygenation differences in the orbitofrontal cortex have demonstrated superior accuracy in distinguishing MCI and AD.<xref rid="alz70769-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Additionally, time&#8208;resolved NIRS studies have shown significant positive correlations between MMSE scores and oxygen saturation (SO<sub>2</sub>) levels with a 91.5% accuracy in the left and right PFC,<xref rid="alz70769-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> reinforcing its sensitivity in cognitive assessments. Convolutional neural network (CNN)&#8211;based NIRS models have also demonstrated &gt; 89.57% accuracy in distinguishing MCI, surpassing the performance of the Korean version of the MoCA. Notably, the highest accuracy of 96.09% was achieved using the HbO<sub>2</sub> slope measured from the left PFC within a 20 to 60 second time window.<xref rid="alz70769-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Similarly, multi&#8208;dimensional NIRS has demonstrated strong classification accuracy for MCI, achieving 80.77% test accuracy, 76.92% sensitivity, and 83.33% precision.<xref rid="alz70769-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The NIRS index has further demonstrated high sensitivity (94%) and specificity (88%) in distinguishing MCI patients from healthy controls.<xref rid="alz70769-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>Blood&#8208;based NIRS has additionally emerged as a promising biomarker&#8208;driven approach for AD detection. Multivariate classification models of blood&#8208;based NIRS have achieved 92.8% accuracy, 87.5% sensitivity, and 96.1% specificity, highlighting its potential for minimally invasive diagnostics.<xref rid="alz70769-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Recent studies have also shown that NIRS can detect AD with a sensitivity of 0.76 and a specificity of 0.68. Additionally, when assessing the severity of AD using five or fewer measurement channels, NIRS achieved a sensitivity of 0.75 and a specificity of 0.72, indicating promising potential in low&#8208;resource diagnostic settings.<xref rid="alz70769-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Studies indicate that SPECT achieves a sensitivity of 77% and specificity of 89% for diagnosing AD, whereas PET scans consistently demonstrate both sensitivity and specificity at 86%.<xref rid="alz70769-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> When data are pooled across multiple studies, PET maintains an overall sensitivity of 86%, specificity of 84%, and accuracy of 85%. In comparison, pooled findings for SPECT report a sensitivity of 76% and specificity of 84%.<xref rid="alz70769-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70769-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> These diagnostic metrics align closely with the sensitivity and specificity scores reported for NIRS, supporting its role as a reliable, non&#8208;invasive, and clinically relevant neuroimaging modality in AD assessment.</p></sec><sec id="alz70769-sec-0100"><label>3.3</label><title>Application of NIRS in MCI and SCD</title><p>Among studies focusing on MCI and SCD, cross&#8208;sectional designs were most commonly used (<italic toggle="yes">n</italic>&#160;=&#160;36), followed by case&#8211;control (<italic toggle="yes">n</italic>&#160;=&#160;9), longitudinal (<italic toggle="yes">n</italic>&#160;=&#160;5), and randomized pilot trials (<italic toggle="yes">n</italic>&#160;=&#160;3). Geographically, the majority of research was conducted in East Asia (<italic toggle="yes">n</italic>&#160;=&#160;37), with further contributions from North America (<italic toggle="yes">n</italic>&#160;=&#160;7), Southeast Asia (<italic toggle="yes">n</italic>&#160;=&#160;4), and Western Europe (<italic toggle="yes">n</italic>&#160;=&#160;5). MCI and SCD are widely recognized as early indicators that precede AD and other forms of dementia.<xref rid="alz70769-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70769-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70769-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Early&#8208;stage cognitive impairment is characterized by declining function in the cerebral task&#8208;positive network, accompanied by weakened FC among the frontal, temporal, and parietal lobes.<xref rid="alz70769-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70769-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> The PFC, particularly the dorsolateral region, plays a central role in memory processing, which is impacted in both amnestic MCI (aMCI) and SMD.<xref rid="alz70769-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Its hemodynamic response, measured through NIRS, provides a reliable region for assessing cognitive function.<xref rid="alz70769-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70769-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70769-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> While normal aging increases prefrontal activation as a compensatory mechanism, MCI individuals experience greater task&#8208;related declines and weakened prefrontal compensatory networks.<xref rid="alz70769-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70769-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="alz70769-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</p><p>NIRS assessments during working memory cognitive tasks, such as the N&#8208;back Working Memory Task reveal significant disruptions in neurovascular coupling and FC, particularly in the left dorsolateral prefrontal cortex (LDLPFC), among individuals with MCI.<xref rid="alz70769-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="alz70769-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> NIRS measures during visual memory span, verbal digit span task, and retrieval tasks also show significant lower HbO<sub>2</sub> levels in the dorsolateral PFC of aMCI individuals but not in non&#8208;aMCI (naMCI) individuals.<xref rid="alz70769-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70769-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70769-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="alz70769-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Complementing this, baseline NIRS findings during the Verbal Fluency Task also reveal distinct alterations in frontotemporal activation patterns that may serve as early indicators of cognitive decline but findings were not mirrored in the clock&#8208;hand&#8208;angle discrimination task.<xref rid="alz70769-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="alz70769-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Although overall Stroop task performance appears similar between individuals with MCI and healthy controls,<xref rid="alz70769-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> task duration significantly impacts the observed neural responses. During the early stage (0&#8211;15 seconds), both MCI and healthy controls groups exhibit similar cortical activation. However, in the late stage (15&#8211;30 seconds), MCI individuals show compensatory increases in HbO<sub>2</sub> levels, particularly in the ventrolateral PFC and parietal lobe, indicating enhanced neural engagement in response to sustained cognitive demand.<xref rid="alz70769-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> On the other hand, naMCI individuals exhibit hyperactivation during Stroop tests in the right prefrontal region.<xref rid="alz70769-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</p><p>In contrast, two&#8208;back and Stroop tasks have also revealed a lack of activation in the ventrolateral PFC of MCI individuals.<xref rid="alz70769-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> These contrasting findings may stem from the heterogeneous nature of MCI, which can vary by subtype and severity. Moreover, activation of the ventrolateral PFC depends on the integrity of its FC, contributing to the observed differences in brain activation patterns. Walking tasks have also shown no significant differences in overall FC between cognitively impaired and cognitively healthy groups.<xref rid="alz70769-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Additionally, the finger&#8208;tapping task despite its cognitive demand has demonstrated limited discriminatory power in NIRS assessments of MCI with MCI individuals exhibiting sustained HbO<sub>2</sub> levels, indicating that these task does not effectively distinguish between cognitive impairment and normal aging.<xref rid="alz70769-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> The distinct nature of aMCI and naMCI necessitates targeted cognitive tests and PFC&#8208;specific assessments for improved diagnostic accuracy. These findings further highlight the critical need for the deliberate selection of cognitive tasks that align with the specific neurophysiological changes targeted in NIRS assessments, thereby enhancing the sensitivity and precision of early&#8208;stage diagnostic evaluations.</p><p>Compared to single tasks during NIRS assessments, which may not impose sufficient cognitive demand to clearly differentiate cognitively normal individuals from those with MCI, dual&#8208;task paradigms have yielded a greater number of significant findings, enhancing the distinction between MCI and healthy controls.<xref rid="alz70769-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70769-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Dual&#8208;task results reveal significant intergroup differences in HbO<sub>2</sub> values across all channels including those near the primary sensory, visuomotor, anterior PFC, and dorsolateral PFC regions among healthy young adult, cognitively normal, and MCI groups.<xref rid="alz70769-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70769-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> These differences may not be detectable with single&#8208;task NIRS assessment. Additionally, during classification analysis, deep learning (CNN) models have significantly showed improved classification accuracy (90.62%) compared to linear models (76.7%).<xref rid="alz70769-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> On the other hand, increasing task loads in a visual working memory task reveal neural compensation in MCI patients. At moderate task loads, hyperactivation in the PFC suggests preserved compensatory mechanisms, enabling sustained cognitive performance.<xref rid="alz70769-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz70769-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="alz70769-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> As task difficulty rises, the MCI group continues to show elevated HbO<sub>2</sub> levels, suggesting their ability to engage neural compensation under manageable cognitive demands.<xref rid="alz70769-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="alz70769-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
</p><p>Studies on FC further highlight disruptions in neural pathways as a core characteristic of cognitive impairment.<xref rid="alz70769-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz70769-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="alz70769-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> Reduced interregional connectivity between the PFC and occipital lobes has been observed across multiple time intervals in the MCI group in resting state, indicating disrupted communication pathways in these key cognitive and visual processing areas.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70769-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="alz70769-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Unlike the widespread FC disruptions observed in dementia, early cognitive impairment presents localized abnormalities,<xref rid="alz70769-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> offering a unique diagnostic opportunity. These altered connectivity patterns especially in MCI patients can also be demonstrated by graph&#8208;based NIRS network analysis.<xref rid="alz70769-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> The NIRS index, derived from logistic regression, has also proven valuable for assessing cognitive decline during working memory tasks.<xref rid="alz70769-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Integrating NIRS with the Game&#8208;Based Intelligence Test (GBIT) further enhances MCI detection. By using HbO<sub>2</sub> and HbR parameters, a transformed cubic polynomial function can be constructed, in which coefficients serve as key markers for identifying MCI.<xref rid="alz70769-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>Time&#8208;resolved NIRS (TRS) also offers a stress&#8208;free evaluation method using a deep neural network for PFC assessment.<xref rid="alz70769-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70769-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> TRS enables rapid measurement of HbO<sub>2</sub>, HbR, total Hb, and oxygen saturation (SO<sub>2</sub>), which correlates strongly with MMSE scores, reinforcing its potential for cognitive screening.<xref rid="alz70769-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70769-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Moreover, NIRS has been integrated into intervention studies, providing valuable insights into cognitive impairment progression and rehabilitation strategies.<xref rid="alz70769-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="alz70769-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>, <xref rid="alz70769-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>, <xref rid="alz70769-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="alz70769-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>, <xref rid="alz70769-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="alz70769-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Importantly, HbO<sub>2</sub> has proven to be a more reliable indicator of cortical activation than HbR due to its superior signal&#8208;to&#8208;noise ratio (SNR).<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70769-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="alz70769-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> This suggests that HbO<sub>2</sub> in prefrontal hemodynamics is a more reliable indicator of neural activity in functional assessments when using NIRS.</p><p>Individuals with SCD perceive a decline in their cognitive abilities compared to their previous normal state, even though their symptoms do not yet meet the clinical criteria for MCI.<xref rid="alz70769-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> NIRS integrated with machine learning techniques offers a powerful approach for analyzing PFC activation during cognitive tasks in such individuals. Subject&#8208;wise cross&#8208;validation has revealed that as cognitive function declines, the stability of prefrontal connectivity weakens. Individuals with SCD showed reduced interaction between the left and right regions of the PFC, with this decline in connectivity being less pronounced than in the MCI group compared to healthy controls. <xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Additionally, SCD patients exhibit a stronger FC pattern across frontal lobe channels during the resting state, suggesting more preserved brain network integrity. Furthermore, SCD patients demonstrate higher overall average HbO<sub>2</sub> concentrations in the frontal lobe during verbal fluency tasks, reflecting a greater neural response to cognitive challenges compared to MCI patients.<xref rid="alz70769-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> Notably, the dorsolateral PFC (DLPFC) and orbitofrontal cortex are the most affected regions in SCD and MCI.<xref rid="alz70769-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Elevated HbO<sub>2</sub> levels have been observed in individuals with SCD compared to non&#8208;SCD participants during both single&#8208; and dual&#8208;task gait paradigms.<xref rid="alz70769-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> In contrast, no significant differences in left PFC activation were found between healthy controls and individuals with subjective memory complaints (SMCs) during similar gait tasks.<xref rid="alz70769-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> However, participants exhibiting more pronounced SMC demonstrated reduced HbO<sub>2</sub> levels in the PFC during a visual memory span task.<xref rid="alz70769-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Collectively, these findings emphasize the utility of prefrontal hemodynamic responses as sensitive biomarkers for cognitive assessment, revealing a subtle yet progressive decline in neural efficiency associated with increasing memory&#8208;related concerns. The distinction between SCD and MCI is crucial for early intervention, as SCD represents a subjective perception of cognitive decline without meeting clinical MCI criteria.<xref rid="alz70769-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> Therefore, in&#8208;depth FC analyses incorporating machine learning algorithms and graph theory, combined with HbO<sub>2</sub> characteristics using NIRS during resting&#8208;state and cognitive tasks, can facilitate differentiation between MCI, SCD, and cognitively healthy individuals.<xref rid="alz70769-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70769-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> A visual summary of the application of NIRS in assessing brain function in individuals with MCI and SCD is shown in Figure&#160;<xref rid="alz70769-fig-0002" ref-type="fig">2</xref>.</p><fig position="float" fig-type="FIGURE" id="alz70769-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>A visual overview of near&#8208;infrared (NIR) spectroscopy (NIRS) applications in evaluating brain function among individuals with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). It features several cognitive task&#8208;based NIRS paradigms including the N&#8208;back Working Memory Task, Verbal Digit Span, Visual Memory Span, Retrieval Tasks, and Stroop Task used to probe neurovascular dynamics. Findings highlight disrupted neurovascular coupling and reduced functional connectivity predominantly in the left dorsolateral prefrontal cortex (LDLPFC) in MCI, with reduced oxyhemoglobin (HbO<sub>2</sub>) levels in amnestic MCI (aMCI) and compensatory hyperactivation in the right prefrontal cortex observed in non&#8208;aMCI (naMCI). In contrast, SCD individuals show milder impairments in the dorsolateral and orbitofrontal cortices, with slight HbO<sub>2</sub> reductions compared to MCI individuals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70769-g001.jpg"/></fig></sec><sec id="alz70769-sec-0110"><label>3.4</label><title>Application of NIRS in AD</title><p>Among studies investigating AD, case&#8211;control designs were most prevalent (<italic toggle="yes">n</italic>&#160;=&#160;15), followed by cross&#8208;sectional (<italic toggle="yes">n</italic>&#160;=&#160;10), longitudinal (<italic toggle="yes">n</italic>&#160;=&#160;2), and randomized pilot trials (<italic toggle="yes">n</italic>&#160;=&#160;1). Geographically, research efforts were concentrated in East Asia (<italic toggle="yes">n</italic>&#160;=&#160;11) and Western Europe (<italic toggle="yes">n</italic>&#160;=&#160;11), with additional contributions from Southeast Asia (<italic toggle="yes">n</italic>&#160;=&#160;4) and North America (<italic toggle="yes">n</italic>&#160;=&#160;2). NIRS also offers an effective method for the early detection of AD and guiding personalized treatment strategies.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> The correlation between NIRS&#8208;derived indicators such as activation levels, mean hemoglobin concentration, and FC of resting brain networks and clinical assessment scores suggests that NIRS has significant potential as a routine clinical tool for monitoring cognitive function, tracking AD progression, and evaluating rehabilitation outcomes.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70769-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>, <xref rid="alz70769-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>
</p><p>During cognitive tasks, NIRS enables precise identification of differences in brain activity patterns. Verbal fluency tests assess key cognitive functions, including executive function, processing speed, word retrieval, and memory.<xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> NIRS signals from the frontal region during verbal fluency tasks reveal distinct HbO<sub>2</sub> response patterns between AD patients and healthy controls, with AD patients demonstrating reduced HbO<sub>2</sub> concentrations in the dorsolateral prefrontal and superior temporal gyrus,<xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> premotor cortex, Broca's area, and prefrontal areas.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70769-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> In contrast, evidence from a similar verbal fluency task study observed no significant activation differences in the PFC between mild AD and healthy controls.<xref rid="alz70769-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> This discrepancy suggests that neurovascular alterations in early AD may be more subtle or variable across individuals. However, mixed phonemic and semantic verbal fluency tasks assessed with NIRS offer promising avenues for detecting preclinical AD stages by measuring interhemispheric FC trends during repeated cognitive trials.<xref rid="alz70769-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> Additionally, AD patients exhibit increased activation in the left ventral PFC during positive emotional word processing, while increased activity in the right ventrolateral PFC is observed during neutral word conditions, reflecting distinct neural processing mechanisms.<xref rid="alz70769-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>
</p><p>Moreover, resting&#8208;state activation in bilateral prefrontal regions is notably lower in AD patients compared to healthy individuals, with the dorsolateral PFC showing the highest relative activity in healthy controls.<xref rid="alz70769-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Feature priority analysis highlights the LDLPFC as a critical region for distinguishing AD patients from cognitively healthy individuals. Subregional observations reveal that FC declines are most pronounced in the DLPFC, while connectivity in parietal areas remains relatively preserved and correlates positively with broader cognitive network integration.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70769-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="alz70769-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> These connectivity deficits may be associated with amyloid beta (A&#946;) deposition, as evidenced by PET studies revealing amyloid accumulation in the frontal, parietal, temporal, and occipital cortices during the early stages of AD.<xref rid="alz70769-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> Furthermore, diminished connectivity strength is predominantly observed in left prefrontal brain regions, potentially influenced by right&#8208;handedness,<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> an aspect that merits further investigation. Reduced left&#8208;hemisphere activation during verbal fluency tasks further emphasizes the asymmetric progression of brain atrophy in AD.<xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>This increased unilateral hemisphere impact in AD is largely driven by the asymmetric progression of brain atrophy, which disrupts the normal asymmetries established during development.<xref rid="alz70769-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> Age&#8208;related cognitive decline leads to reduced hemispheric lateralization, yet NIRS in resting&#8208;state verbal tasks consistently reveals lower interhemispheric FC in AD patients.<xref rid="alz70769-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref>, <xref rid="alz70769-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> These disruptions, particularly affecting the premotor cortex, supplementary motor cortex, primary motor cortex, inferior parietal cortex, primary somatosensory cortex, and supramarginal gyrus, suggest that NIRS&#8208;based assessment of interhemispheric connectivity may provide valuable insights into AD progression.<xref rid="alz70769-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> Furthermore, increasing task load as a means to induce neural compensation in visual working memory tasks fails to produce substantial changes in bilateral PFC activation among mild AD patients. This pattern reflects diminished neural compensation mechanisms under cognitive demand, as prefrontal activation remains relatively stable with minimal signs of increased engagement, suggesting an impaired ability to recruit additional neural resources in response to task complexity.<xref rid="alz70769-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>
</p><p>The reduction in HbO<sub>2</sub> concentrations in the prefrontal lobe can also be assessed using NIRS through the sample entropy metric, particularly in tests evaluating visuospatial and short&#8208;term memory functions.<xref rid="alz70769-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> Among these assessments, the Clock Drawing Test, which evaluates visuo&#8208;constructive and visuo&#8208;spatial abilities, has demonstrated high reliability in distinguishing AD patients from healthy individuals, whereas the Digit Span Test and Corsi Block Tapping Test have not shown significant differentiation between groups.<xref rid="alz70769-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> This reduction, possibly linked to vascular dysfunction, impairs local cerebral blood flow during cognitive processing, delaying expected fluctuations in oxygenation.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Alternatively, AD&#8208;related neurodegeneration may lead to functional reorganization, requiring compensatory blood flow adjustments in other brain regions to maintain function, thereby increasing overall oxygen consumption.<xref rid="alz70769-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70769-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</p><p>The integration of deep learning models with NIRS further enhances classification accuracy in AD diagnosis by identifying distinct changes in brain activation. Prodromal AD patients demonstrate reduced activation compared to healthy individuals and asymptomatic AD, highlighting early cognitive decline, although differentiation between asymptomatic AD and AD dementia remains challenging in resting&#8208;state activation.<xref rid="alz70769-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> Additionally, gradual declines in HbO<sub>2</sub> concentration during verbal span tasks correspond with disease progression from MCI to severe AD.<xref rid="alz70769-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref> Advancements such as wavelet&#8208;based motion artifact correction and orthogonal minimal spanning tree network binarization techniques improve the reliability of NIRS&#8208;based connectivity assessments, providing robust insights into AD&#8208;related network impairments.<xref rid="alz70769-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref>
</p><p>Olfactory dysfunction is another hallmark of AD, primarily attributed to plaque and tangle accumulation in the olfactory bulb and inner olfactory cortex, which play essential roles in memory formation.<xref rid="alz70769-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref> Olfactory&#8208;stimulated NIRS reveals significant reductions in orbitofrontal cortex oxygenation levels, corresponding with cognitive performance scores and reinforcing the link between olfactory dysfunction and AD pathology.<xref rid="alz70769-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref> Machine learning&#8211;enhanced olfactory&#8208;stimulated NIRS further improves classification accuracy in distinguishing MCI from AD.<xref rid="alz70769-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p><p>Beyond neuroimaging, NIRS applied to blood plasma samples presents a novel and minimally invasive technique for early AD detection. Blood serves as a rich biological medium due to the semi&#8208;permeability of the blood&#8211;brain barrier, allowing molecular exchange between the brain and peripheral circulation, alongside the daily absorption of 500&#160;mL of CSF into the bloodstream.<xref rid="alz70769-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> Plasma is extracted through centrifugation at 2000&#160;rpm for 10 minutes at 4&#176;C, aliquoted, and stored at &#8722;80&#176;C until spectroscopic analysis.<xref rid="alz70769-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Before testing, samples are thawed, applied to infrared&#8208;reflective glass slides, and dried overnight at room temperature. Statistical analyses of plasma&#8208;based NIRS data have identified significant spectral differences between healthy controls and AD patients, achieving 92.8% classification accuracy, 87.5% sensitivity, and 96.1% specificity.<xref rid="alz70769-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> This method presents a highly precise and non&#8208;invasive approach for detecting AD&#8208;related blood signatures.</p><p>Overall, NIRS has proven capable of analyzing a wide range of complex neural and biochemical variables, demonstrating high specificity and sensitivity in AD detection (Figure&#160;<xref rid="alz70769-fig-0003" ref-type="fig">3</xref>). Its integration into routine clinical assessments may enhance diagnostic precision, facilitate disease monitoring, and improve therapeutic interventions for individuals with AD.</p><fig position="float" fig-type="FIGURE" id="alz70769-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>A visual illustration of near&#8208;infrared (NIR) spectroscopy (NIRS) applications in detecting Alzheimer's disease (AD). The dorsolateral prefrontal cortex (DLPFC) represents a critical area of interest, highlighting reduced brain activation at rest, diminished oxygenated hemoglobin during verbal fluency tasks, and decline in functional connectivity in patients with AD. The infographic also showcases the emerging use of NIRS in blood plasma analysis for minimally invasive AD biomarker detection. A plasma&#8208;based NIRS system presents with high diagnostic accuracy of 92.8% accuracy, sensitivity of 87.5%, and specificity of 96.1%. HbO<sub>2</sub>, oxyhemoglobin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70769-g003.jpg"/></fig></sec><sec id="alz70769-sec-0120"><label>3.5</label><title>Application of NIRS in PD and LBD</title><p>Cognitive decline in PD affects various domains, including executive function, visuospatial skills, and memory. It is primarily characterized by deficits in executive processing, such as impaired conflict detection, reduced selective attention, and diminished inhibitory control.<xref rid="alz70769-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref> Whole&#8208;head NIRS applied as an ecological monitoring tool for cortical activity also provides insights into neural activation patterns associated with PD progression. Early PD patients demonstrate increased activation in both the left and right secondary visual cortices, while individuals with mild PD show stronger activation in the right PFC, reflecting functional adaptations in response to disease severity.<xref rid="alz70769-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref> Furthermore, prefrontal activation progressively increases across all phases of obstacle crossing in PD patients, with significantly greater activation compared to healthy older adults, particularly during and after the crossing phase.<xref rid="alz70769-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref> Notably, PD patients display increased prefrontal activation when encountering unexpected obstacles, whereas activation levels remain comparable to healthy individuals during anticipated obstacle crossings.<xref rid="alz70769-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref> These findings suggest an increased reliance on prefrontal cortical engagement for motor planning and execution in PD, underscoring NIRS as a valuable tool for monitoring cerebral adaptations during dynamic movement. Moreover, HbO<sub>2</sub> provides a more precise measure of task&#8208;related cortical engagement compared to HbR between PD patients and healthy controls.</p><p>FC assessments using NIRS during the Stroop Color&#8208;Word Test have revealed distinct neural processing differences among PD patients with MCI (PD&#8208;MCI), those with normal cognition (PD&#8208;NC), and healthy controls.<xref rid="alz70769-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> PD&#8208;MCI individuals exhibited increased regional strength measures (RSr and RSl) and global efficiency (GE) during the color&#8208;word incongruent condition, with RSr reflecting the regional strength of the right PFC, emerging as a key predictive marker for distinguishing PD&#8208;MCI from PD&#8208;NC.<xref rid="alz70769-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> The neural framework of inhibitory control operates within a right&#8208;lateralized network involving the presupplementary motor area, inferior frontal gyrus, and subthalamic nucleus, reinforcing the critical role of right&#8208;hemisphere neural structures in PD&#8208;MCI.<xref rid="alz70769-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref> Attentional processing relies on two key brain networks: the ventral network, made up of right frontoparietal regions that help shift attention, and the dorsal network, which includes both sides of the frontoparietal cortex and supports sustained focus through top&#8208;down control.<xref rid="alz70769-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref> Together, these systems highlight the right&#8208;sided dominance of brain activity often seen in individuals with PD&#8208;MCI.</p><p>LBD shares several clinical characteristics with AD, including impairments in memory, learning, orientation, comprehension, judgment, language, and visuospatial function. Increased Lewy body density contributes significantly to verbal fluency deterioration. Compared to AD patients, individuals with LBD exhibit superior verbal learning abilities but experience greater difficulty with verbal forgetting and recency effects, distinguishing them from AD in cognitive assessments.<xref rid="alz70769-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> NIRS measurements indicate that LBD patients show higher HbO<sub>2</sub> concentrations in the left temporal cortex, right DLPFC, and right temporal cortex during verbal fluency tasks than AD patients, suggesting improved cerebral oxygenation in these regions.<xref rid="alz70769-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref> Furthermore, integrating NIRS assessments with blood biomarkers enhances diagnostic accuracy, with LBD patients exhibiting higher &#945;&#8208;synuclein expression and lower A&#946;42 levels compared to AD patients.<xref rid="alz70769-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref>
</p></sec><sec id="alz70769-sec-0130"><label>3.6</label><title>Application of NIRS in FTD</title><p>The behavioral variant of FTD (bvFTD) is recognized as the most common form of frontotemporal lobar degeneration.<xref rid="alz70769-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref> fNIRS has been instrumental in identifying distinct cortical activation patterns associated with bvFTD during cognitive assessments such as the verbal fluency task. While AD typically elicits activation in the DLPFC and superior temporal gyrus, bvFTD is marked by increased activity in Broca's area located in the posterior portion of the left inferior frontal gyrus, suggesting potential compensatory mechanisms or alternative neural processing pathways in speech and language production.<xref rid="alz70769-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> As Broca's area plays a central role in language formation, grammar, and sentence construction, its differential activation pattern may offer a distinctive biomarker for differentiating FTD from AD in clinical and research contexts.</p></sec><sec id="alz70769-sec-0140"><label>3.7</label><title>Synergetic and future application of NIRS and other diagnostic platforms in dementia detection</title><p>Recent advancements in neuroimaging have underscored the utility of NIRS and multimodal techniques in detecting cerebral alterations associated with AD. Temporal stability in the coupling between cortical hemodynamic signals and CSF water signals varies across time windows and overlaps. Using a sliding window cross&#8208;correlation approach, MRI&#8208;compatible multiwavelength NIRS identifies marked differences in hemodynamic&#8211;CSF coupling patterns, particularly within the cardiac frequency band, between AD patients and healthy individuals.<xref rid="alz70769-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Healthy participants exhibit greater time&#8208;domain variability in venous HbR&#8208;CSF signal pairings (HbR&#8208;CSF, dHbR&#8208;CSF), whereas AD patients demonstrate more uniform coupling,<xref rid="alz70769-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> possibly due to cerebrovascular stiffness and impaired CSF regulation resulting from vascular pathology and tissue atrophy.<xref rid="alz70769-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref>, <xref rid="alz70769-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref>
</p><p>To further elucidate neurophysiological dysfunction in AD, integrative approaches combining EEG and NIRS have proven effective. EEG offers high temporal resolution of cortical electrical signals, while NIRS provides hemodynamic insights, and their synchronization achieved through time&#8208;locked triggers and standardized cap configurations enables simultaneous monitoring of neural and vascular responses.<xref rid="alz70769-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref> When applied during cognitive tasks such as the digit verbal span, this EEG&#8211;NIRS fusion captures weakened cortical connectivity in AD, with EEG features localizing primarily to the left parietal region and NIRS features in the right frontal cortex.<xref rid="alz70769-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>, <xref rid="alz70769-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref>
</p><p>Entropy&#8208;based analyses further strengthen this framework by using sample entropy to evaluate neural signal unpredictability and conditional entropy to assess the interdependence between EEG and NIRS signals. These complexity metrics have demonstrated superior classification accuracy in working memory assessments especially during the recall phase of the Rey&#8211;Osterrieth Complex Figure test compared to unimodal approaches.<xref rid="alz70769-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref> Moreover, hybrid EEG&#8211;NIRS models outperform EEG or NIRS alone in differentiating AD stages.<xref rid="alz70769-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref>
</p><p>Broadening this integrative scope, multimodal imaging incorporating EEG, NIRS, electrocardiography (ECG), and respiratory effort monitoring reveals additional physiological dysregulation in AD. Findings show altered neurovascular coherence, reduced brain oxygenation power, and impaired autonomic responses, including decreased instantaneous heart rate (IHR)&#8211;NIRS coherence and disrupted respiratory&#8211;NIRS relationships.<xref rid="alz70769-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref> These anomalies are particularly evident across neurogenic, myogenic, and endothelial frequency bands, reinforcing the value of multi&#8208;system assessments in tracking AD progression.</p><p>CA, the mechanism stabilizing cerebral blood flow through arteriolar response to blood pressure changes, also exhibits changes in AD.<xref rid="alz70769-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> CA works alongside neurovascular coupling, which increases local blood flow based on neural activity and is influenced by systemic and cerebral CO<sub>2</sub> levels.<xref rid="alz70769-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref> While static CA eludes traditional imaging modalities, dynamic CA evaluated via TCD or NIRS can reveal real&#8208;time vascular reactivity. NIRS&#8208; and TCD&#8208;derived CA measures demonstrate stronger correlations during sit&#8208;to&#8208;stand transitions than during resting states in cognitively impaired individuals, suggesting that dynamic tasks enhance sensitivity for detecting cerebrovascular dysfunction associated with AD.<xref rid="alz70769-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70769-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref> Together, these findings highlight the expanding role of NIRS, alone and in multimodal integration, as a powerful tool for non&#8208;invasive investigation of cortical connectivity, vascular dynamics, and autonomic regulation in AD, MCI, and other NDDs.</p><p>Despite the promising applications of NIRS in cognitive assessment and NDD detection, NIRS faces several limitations that affect its reliability and interpretation. Instrumental challenges, including low spatial resolution, and poor SNR, which can result from inadequate hardware choices or set&#8208;up, can lead to issues like cross&#8208;talk and contamination from superficial tissues.<xref rid="alz70769-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Methodologically, the complexity of data processing poses another hurdle, as consistent preprocessing and reporting standards are lacking across studies.<xref rid="alz70769-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> This complicates comparisons and undermines reproducibility. Moreover, physiological artifacts such as heartbeat and breathing can interfere with brain oxygen signals, further distorting results.<xref rid="alz70769-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Future research should explore correction techniques such as adaptive filtering or multimodal data fusion to minimize physiological noise and improve signal precision. Integrating machine learning and automation offers promise for enhancing data clarity, but the field still requires greater standardization and refinement to overcome these challenges. Standardization of protocols would enhance reproducibility and improve cross&#8208;study validation, allowing for more reliable conclusions about NIRS&#8208;based biomarkers for cognitive assessment. Additionally, systemic physiological factors including metabolic disorders, vascular aging, blood oxygenation levels, and cerebrovascular reactivity, can affect hemoglobin absorption and scattering properties, potentially influencing NIRS readings and introducing confounding variables.</p><p>Moving forward, large&#8208;scale validation studies, incorporating multimodal imaging approaches (EEG fNIRS, PET fNIRS) and longitudinal monitoring, will be essential for establishing NIRS as a routine diagnostic modality in NDD detection and cognitive function assessment. Additionally, NIRS is particularly well suited for use in low&#8208;resource settings due to its non&#8208;invasive nature, portability, and cost effectiveness. Unlike traditional imaging techniques like MRI or CT scans, NIRS requires minimal infrastructure and can be easily set up in various environments, such as clinics. NIRS systems cost between $24,000 and $500,000, making them significantly more affordable than conventional neuroimaging methods. By comparison, MRI scanners can cost &#8776; $1.4 to $1.5 million, based on reports from the UK and Belgium.<xref rid="alz70769-bib-0121" ref-type="bibr">
<sup>121</sup>
</xref> These comparisons underscore the economic feasibility of NIRS, especially in resource&#8208;limited settings in which access to high&#8208;cost neuroimaging infrastructure remains a challenge. Also, its ability to provide real&#8208;time monitoring of brain activity without the need for extensive training makes it accessible for health&#8208;care workers in these regions. Moreover, NIRS is less sensitive to motion, allowing for more naturalistic testing conditions, which is crucial for accurately assessing cognitive function in diverse populations. These features collectively enhance the feasibility and effectiveness of early dementia detection in resource&#8208;limited areas.</p></sec></sec><sec id="alz70769-sec-0150"><label>4</label><title>CONCLUSION</title><p>NIRS is a powerful, non&#8208;invasive tool for assessing cognition across MCI, SCD, and various neurodegenerative conditions like AD, PD, LBD, and FTD. Critically, NIRS accurately detects altered neurovascular coupling, FC deficits, and hemodynamic responses during cognitive tasks, enhancing early diagnosis and differentiation among disease subtypes, a significant advantage in resource&#8208;limited settings in which advanced neuroimaging is often unavailable or prohibitively expensive.</p><p>Multimodal approaches, combining NIRS with techniques like EEG and TCD, significantly improve diagnostic accuracy and expand clinical utility, offering more comprehensive assessments with potentially fewer logistical hurdles than traditional methods. Additionally, blood&#8208;based NIRS shows promise for AD detection, reinforcing its potential in biomarker development and providing a highly accessible screening method for populations with limited access to specialized clinics. As research progresses, NIRS continues to evolve as a crucial tool for both diagnosis and monitoring, supporting early intervention and deepening our understanding of cognitive decline. Future research should prioritize longitudinal studies to track NIRS marker progression across disease stages. Furthermore, investigating NIRS findings in diverse ethnic groups, particularly underrepresented populations, is essential for a more inclusive understanding of neurological conditions and ensuring the equitable application of NIRS technology especially in low&#8208;resource environments.</p></sec><sec id="alz70769-sec-0160"><title>AUTHOR CONTRIBUTIONS</title><p>
<italic toggle="yes">Conceptualization</italic>: George Nkrumah Osei, Ansumana Bockarie, Peter Osei&#8208;Wusu Adueming and David Larbi Simpong. <italic toggle="yes">Methodology and Investigation</italic>: George Nkrumah Osei, Ansumana Bockarie, Albert Akpalu, Maxwell Hubert Antwi, Foster Appiah, Linus Kpelle, David Mawutor Donkor and David Larbi Simpong. <italic toggle="yes">Supervision</italic>: Ansumana Bockarie, Peter Osei&#8208;Wusu Adueming and David Larbi Simpong. <italic toggle="yes">Writing &#8211; original draft</italic>: George Nkrumah Osei, Maxwell Hubert Antwi, Foster Appiah, Linus Kpelle, David Mawutor Donkor and David Larbi Simpong. All authors revised the manuscript critically for important intellectual content. All authors read and agreed with the final manuscript.</p></sec><sec sec-type="COI-statement" id="alz70769-sec-0180"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest. Author disclosures are available in the <xref rid="alz70769-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70769-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70769-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70769-s001.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70769-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70769-s003.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70769-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70769-s002.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70769-sec-0170"><title>ACKNOWLEDGMENTS</title><p>The authors have no acknowledgments to make. The authors received no funding for this work.</p></ack><sec sec-type="data-availability" id="alz70769-sec-0200"><title>DATA AVAILABILITY STATEMENT</title><p>No data were used for the research described in the article.</p></sec><ref-list id="alz70769-bibl-0001"><title>REFERENCES</title><ref id="alz70769-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70769-cite-0002"><string-name name-style="western"><surname>P&#233;rez&#8208;Carri&#243;n</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Posadas</surname><given-names>I</given-names></string-name>. <article-title>Dendrimers in neurodegenerative diseases</article-title>. <source>Processes</source>. <year>2023</year>;<volume>11</volume>(<issue>2</issue>):<fpage>319</fpage>.</mixed-citation></ref><ref id="alz70769-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70769-cite-0003"><string-name name-style="western"><surname>Donkor</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Marfo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bockarie</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Genetic and environmental risk factors for dementia in African adults: a systematic review</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>4</issue>):<elocation-id>e70220</elocation-id>.<pub-id pub-id-type="pmid">40289851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70220</pub-id><pub-id pub-id-type="pmcid">PMC12035544</pub-id></mixed-citation></ref><ref id="alz70769-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70769-cite-0004"><string-name name-style="western"><surname>Wood</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Winslow</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Strasser</surname><given-names>SD</given-names></string-name>. <article-title>Systems biology of neurodegenerative diseases</article-title>. <source>Integr Biol</source>. <year>2015</year>;<volume>7</volume>(<issue>7</issue>):<fpage>758</fpage>&#8208;<lpage>775</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5ib00031a</pub-id><pub-id pub-id-type="pmcid">PMC4587766</pub-id><pub-id pub-id-type="pmid">26065845</pub-id></mixed-citation></ref><ref id="alz70769-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70769-cite-0005"><string-name name-style="western"><surname>Anderson</surname><given-names>ND</given-names></string-name>. <article-title>State of the science on mild cognitive impairment (MCI)</article-title>. <source>CNS Spectr</source>. <year>2019</year>;<volume>24</volume>(<issue>1</issue>):<fpage>78</fpage>&#8208;<lpage>87</lpage>.<pub-id pub-id-type="pmid">30651152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1092852918001347</pub-id></mixed-citation></ref><ref id="alz70769-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70769-cite-0006"><string-name name-style="western"><surname>Ashendorf</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Alosco</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Bing&#8208;Canar</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Clinical utility of select neuropsychological assessment battery tests in predicting functional abilities in dementia</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2018</year>;<volume>33</volume>(<issue>5</issue>):<fpage>530</fpage>&#8208;<lpage>540</lpage>.<pub-id pub-id-type="pmid">29126099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acx100</pub-id><pub-id pub-id-type="pmcid">PMC6116785</pub-id></mixed-citation></ref><ref id="alz70769-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70769-cite-0007"><string-name name-style="western"><surname>Tso&#8208;Yen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chun&#8208;Feng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hong&#8208;Wa</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ying&#8208;Fang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei&#8208;Hsun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shinn&#8208;Jang</surname><given-names>H</given-names></string-name>. <article-title>Recognition of mild cognitive impairment in older adults using a polynomial regression model based on prefrontal cortex hemoglobin oxygenation</article-title>. <source>Exp Gerontol</source>. <year>2024</year>;<volume>198</volume>(<issue>September</issue>):<elocation-id>112637</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2024.112637</pub-id><pub-id pub-id-type="pmid">39577711</pub-id></mixed-citation></ref><ref id="alz70769-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70769-cite-0008"><string-name name-style="western"><surname>Simpong</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Osei</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>RO</given-names></string-name>, et&#160;al. <article-title>Exploration of demographic prevalence of mild cognitive impairment using Montreal cognitive assessment: a cross&#8208;sectional pilot study in the Cape Coast Metropolis, Ghana</article-title>. <source>IBRO Neurosci Rep</source>. <year>2024</year>;<volume>17</volume>:<fpage>480</fpage>&#8208;<lpage>484</lpage>.<pub-id pub-id-type="pmid">39717872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ibneur.2024.11.008</pub-id><pub-id pub-id-type="pmcid">PMC11665373</pub-id></mixed-citation></ref><ref id="alz70769-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70769-cite-0009"><string-name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rousseau</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Belzile&#8208;Marsolais</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>A scoping review of alzheimers Disease hypotheses: an array of Uni&#8208;and multi&#8208;factorial theories</article-title>. <source>J Alzheimer's Dis</source>. <year>2024</year>;<volume>99</volume>(<issue>3</issue>):<fpage>843</fpage>&#8208;<lpage>856</lpage>.<pub-id pub-id-type="pmid">38788067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230772</pub-id><pub-id pub-id-type="pmcid">PMC11191496</pub-id></mixed-citation></ref><ref id="alz70769-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70769-cite-0010"><string-name name-style="western"><surname>Femminella</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Thayanandan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Calsolaro</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Imaging and molecular mechanisms of Alzheimer's disease: a review</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>12</issue>):<fpage>3702</fpage>.<pub-id pub-id-type="pmid">30469491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19123702</pub-id><pub-id pub-id-type="pmcid">PMC6321449</pub-id></mixed-citation></ref><ref id="alz70769-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70769-cite-0011"><string-name name-style="western"><surname>Pu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Screening tools for subjective cognitive decline and mild cognitive impairment based on task&#8208;state prefrontal functional connectivity: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Neuroimage</source>. <year>2025</year>;<volume>310</volume>(<issue>February 2024</issue>):<elocation-id>121130</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2025.121130</pub-id><pub-id pub-id-type="pmid">40058532</pub-id></mixed-citation></ref><ref id="alz70769-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70769-cite-0012"><string-name name-style="western"><surname>Butters</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bale</surname><given-names>G</given-names></string-name>. <article-title>A promising tool to explore functional impairment in neurodegeneration: a systematic review of near&#8208;infrared spectroscopy in dementia</article-title>. <source>Ageing Res Rev</source>. <year>2023</year>;<volume>90</volume>:<elocation-id>101992</elocation-id>.<pub-id pub-id-type="pmid">37356550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.101992</pub-id></mixed-citation></ref><ref id="alz70769-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70769-cite-0013"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Diagnosis and management of dementia</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>322</volume>(<issue>16</issue>):<fpage>1589</fpage>&#8208;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">31638686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.4782</pub-id><pub-id pub-id-type="pmcid">PMC7462122</pub-id></mixed-citation></ref><ref id="alz70769-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70769-cite-0014"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Comparative study of brain functional imaging of brain in patients with mild to moderate Alzheimer's disease based on functional near infrared spectroscopy</article-title>. <source>BMC Neurol</source>. <year>2025</year>;<volume>25</volume>(<issue>1</issue>):<fpage>186</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12883-024-03989-2</pub-id><pub-id pub-id-type="pmid">40289104</pub-id><pub-id pub-id-type="pmcid">PMC12036162</pub-id></mixed-citation></ref><ref id="alz70769-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70769-cite-0015"><string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Mild cognitive impairment estimation based on functional near&#8208;infrared spectroscopy</article-title>. <source>J Biophotonics</source>. <year>2024</year>;<volume>17</volume>(<issue>1</issue>):<elocation-id>e202300251</elocation-id>.<pub-id pub-id-type="pmid">37697821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jbio.202300251</pub-id></mixed-citation></ref><ref id="alz70769-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70769-cite-0016"><string-name name-style="western"><surname>Chen</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heugel</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Functional near&#8208;infrared spectroscopy and its clinical application in the field of neuroscience: advances and future directions</article-title>. <source>Front Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>724</fpage>.<pub-id pub-id-type="pmid">32742257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00724</pub-id><pub-id pub-id-type="pmcid">PMC7364176</pub-id></mixed-citation></ref><ref id="alz70769-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70769-cite-0017"><string-name name-style="western"><surname>Wijeakumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huppert</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Magnotta</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Buss</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>JP</given-names></string-name>. <article-title>Validating an image&#8208;based fNIRS approach with fMRI and a working memory task</article-title>. <source>Neuroimage</source>. <year>2017</year>;<volume>147</volume>:<fpage>204</fpage>&#8208;<lpage>218</lpage>.<pub-id pub-id-type="pmid">27939793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.12.007</pub-id></mixed-citation></ref><ref id="alz70769-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70769-cite-0018"><string-name name-style="western"><surname>Ferdinando</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Moradi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Korhonen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kiviniemi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Myllyl&#228;</surname><given-names>T</given-names></string-name>. <article-title>Altered cerebrovascular&#8208;CSF coupling in Alzheimer's disease measured by functional near&#8208;infrared spectroscopy</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-023-48965-x</pub-id><pub-id pub-id-type="pmid">38102188</pub-id><pub-id pub-id-type="pmcid">PMC10724150</pub-id></mixed-citation></ref><ref id="alz70769-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70769-cite-0019"><string-name name-style="western"><surname>Metzger</surname><given-names>FG</given-names></string-name>, <string-name name-style="western"><surname>Schopp</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Haeussinger</surname><given-names>FB</given-names></string-name>, et&#160;al. <article-title>Brain activation in frontotemporal and Alzheimer's dementia: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Alzheimer's Res Ther</source>. <year>2016</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-016-0224-8</pub-id><pub-id pub-id-type="pmid">27931245</pub-id><pub-id pub-id-type="pmcid">PMC5146884</pub-id></mixed-citation></ref><ref id="alz70769-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="alz70769-cite-0020">Accessed January 06, 2025.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.crd.york.ac.uk" ext-link-type="uri">www.crd.york.ac.uk</ext-link>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/</ext-link></mixed-citation></ref><ref id="alz70769-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70769-cite-0021"><string-name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Quaresima</surname><given-names>V</given-names></string-name>. <article-title>A brief review on the history of human functional near&#8208;infrared spectroscopy (fNIRS) development and fields of application</article-title>. <source>Neuroimage</source>. <year>2012</year>;<volume>63</volume>(<issue>2</issue>):<fpage>921</fpage>&#8208;<lpage>935</lpage>.<pub-id pub-id-type="pmid">22510258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.03.049</pub-id></mixed-citation></ref><ref id="alz70769-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70769-cite-0022"><string-name name-style="western"><surname>Scholkmann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kleiser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Metz</surname><given-names>AJ</given-names></string-name>, et&#160;al. <article-title>A review on continuous wave functional near&#8208;infrared spectroscopy and imaging instrumentation and methodology</article-title>. <source>Neuroimage</source>. <year>2014</year>;<volume>85</volume>:<fpage>6</fpage>&#8208;<lpage>27</lpage>.<pub-id pub-id-type="pmid">23684868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2013.05.004</pub-id></mixed-citation></ref><ref id="alz70769-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70769-cite-0023"><string-name name-style="western"><surname>Katzorke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zeller</surname><given-names>JBM</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>LD</given-names></string-name>, et&#160;al. <article-title>Reduced activity in the right inferior frontal gyrus in elderly APOE&#8208;E4 carriers during a verbal fluency task</article-title>. <source>Front Hum Neurosci</source>. <year>2017</year>;<volume>11</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">28220068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2017.00046</pub-id><pub-id pub-id-type="pmcid">PMC5292419</pub-id></mixed-citation></ref><ref id="alz70769-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70769-cite-0024"><string-name name-style="western"><surname>Greco</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>McKee</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Kowall</surname><given-names>NW</given-names></string-name>, <string-name name-style="western"><surname>Hanlon</surname><given-names>EB</given-names></string-name>. <article-title>Near&#8208;infrared optical spectroscopy in vivo distinguishes subjects with Alzheimer's disease from age&#8208;matched controls</article-title>. <source>J Alzheimer's Dis</source>. <year>2021</year>;<volume>82</volume>(<issue>2</issue>):<fpage>791</fpage>&#8208;<lpage>802</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-201021</pub-id><pub-id pub-id-type="pmid">34092628</pub-id><pub-id pub-id-type="pmcid">PMC8385529</pub-id></mixed-citation></ref><ref id="alz70769-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70769-cite-0025"><string-name name-style="western"><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Butters</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Collins&#8208;Jones</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bale</surname><given-names>G</given-names></string-name>. <article-title>Illuminating neurodegeneration: a future perspective on near&#8208;infrared spectroscopy in dementia research</article-title>. <source>Neurophotonics</source>. <year>2023</year>;<volume>10</volume>(<issue>2</issue>):<elocation-id>23514</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.NPh.10.2.023514</pub-id><pub-id pub-id-type="pmcid">PMC9917719</pub-id><pub-id pub-id-type="pmid">36788803</pub-id></mixed-citation></ref><ref id="alz70769-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70769-cite-0026"><string-name name-style="western"><surname>Pinti</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Scholkmann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burgess</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tachtsidis</surname><given-names>I</given-names></string-name>. <article-title>Current status and issues regarding pre&#8208;processing of fNIRS neuroimaging data: an investigation of diverse signal filtering methods within a general linear model framework</article-title>. <source>Front Hum Neurosci</source>. <year>2019</year>;<volume>12</volume>:<fpage>505</fpage>.<pub-id pub-id-type="pmid">30687038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2018.00505</pub-id><pub-id pub-id-type="pmcid">PMC6336925</pub-id></mixed-citation></ref><ref id="alz70769-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70769-cite-0027"><string-name name-style="western"><surname>Yang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>KS</given-names></string-name>. <article-title>Quantitative assessment of resting&#8208;state for mild cognitive impairment detection: a functional near&#8208;infrared spectroscopy and deep learning approach</article-title>. <source>J Alzheimer's Dis</source>. <year>2021</year>;<volume>80</volume>(<issue>2</issue>):<fpage>647</fpage>&#8208;<lpage>663</lpage>.<pub-id pub-id-type="pmid">33579839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201163</pub-id></mixed-citation></ref><ref id="alz70769-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70769-cite-0028"><string-name name-style="western"><surname>Domanski</surname><given-names>APF</given-names></string-name>, <string-name name-style="western"><surname>Kucewicz</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Distinct hippocampal&#8208;prefrontal neural assemblies coordinate memory encoding, maintenance, and recall</article-title>. <source>Curr Biol</source>. <year>2023</year>;<volume>33</volume>(<issue>7</issue>):<fpage>1220</fpage>&#8208;<lpage>1236</lpage>.<pub-id pub-id-type="pmid">36898372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2023.02.029</pub-id><pub-id pub-id-type="pmcid">PMC10728550</pub-id></mixed-citation></ref><ref id="alz70769-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70769-cite-0029"><string-name name-style="western"><surname>Mol</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Meskers</surname><given-names>CGM</given-names></string-name>, <string-name name-style="western"><surname>Sanders</surname><given-names>ML</given-names></string-name>, et&#160;al. <article-title>Cerebral autoregulation assessed by near&#8208;infrared spectroscopy: validation using transcranial Doppler in patients with controlled hypertension, cognitive impairment and controls</article-title>. <source>Eur J Appl Physiol</source>. <year>2021</year>;<volume>121</volume>(<issue>8</issue>):<fpage>2165</fpage>&#8208;<lpage>2176</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00421-021-04681-w</pub-id><pub-id pub-id-type="pmid">33860383</pub-id><pub-id pub-id-type="pmcid">PMC8260523</pub-id></mixed-citation></ref><ref id="alz70769-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70769-cite-0030"><string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Quantification of identifying cognitive impairment using olfactory&#8208;stimulated functional near&#8208;infrared spectroscopy with machine learning: a post hoc analysis of a diagnostic trial and validation of an external additional trial</article-title>. <source>Alzheimer's Res Ther</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-023-01268-9</pub-id><pub-id pub-id-type="pmid">37481573</pub-id><pub-id pub-id-type="pmcid">PMC10362671</pub-id></mixed-citation></ref><ref id="alz70769-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70769-cite-0031"><string-name name-style="western"><surname>Oyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sakatani</surname><given-names>K</given-names></string-name>. <article-title>Prediction of MMSE score using time&#8208;resolved near&#8208;infrared spectroscopy</article-title>. <source>Adv Exp Med Biol</source>. <year>2018</year>;<volume>1072</volume>:<fpage>145</fpage>&#8208;<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-3-319-91287-5_23</pub-id><pub-id pub-id-type="pmid">30178337</pub-id></mixed-citation></ref><ref id="alz70769-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70769-cite-0032"><string-name name-style="western"><surname>Park</surname><given-names>JH</given-names></string-name>. <article-title>Classification of mild cognitive impairment using functional near&#8208;infrared spectroscopy&#8208;derived biomarkers with convolutional neural networks</article-title>. <source>Psychiatry Investig</source>. <year>2024</year>;<volume>21</volume>(<issue>3</issue>):<fpage>294</fpage>&#8208;<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.30773/pi.2023.0409</pub-id><pub-id pub-id-type="pmcid">PMC10990628</pub-id><pub-id pub-id-type="pmid">38569587</pub-id></mixed-citation></ref><ref id="alz70769-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70769-cite-0033"><string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>CC</given-names></string-name>, et&#160;al. <article-title>Comparing multi&#8208;dimensional fNIRS features using Bayesian optimization&#8208;based neural networks for mild cognitive impairment (MCI) detection</article-title>. <source>IEEE Trans Neural Syst Rehabil Eng</source>. <year>2023</year>;<volume>31</volume>:<fpage>1019</fpage>&#8208;<lpage>1029</lpage>. doi:<pub-id pub-id-type="doi">10.1109/TNSRE.2023.3236007</pub-id><pub-id pub-id-type="pmid">37018710</pub-id></mixed-citation></ref><ref id="alz70769-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70769-cite-0034"><string-name name-style="western"><surname>Nakamura</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yomota</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ito</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>A novel cognitive function scale using functional near&#8208;infrared spectroscopy for evaluating cognitive dysfunction</article-title>. <source>J Alzheimer's Dis</source>. <year>2021</year>;<volume>81</volume>(<issue>4</issue>):<fpage>1579</fpage>&#8208;<lpage>1588</lpage>.<pub-id pub-id-type="pmid">33967049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210072</pub-id><pub-id pub-id-type="pmcid">PMC8293658</pub-id></mixed-citation></ref><ref id="alz70769-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70769-cite-0035"><string-name name-style="western"><surname>Paraskevaidi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morais</surname><given-names>CLM</given-names></string-name>, <string-name name-style="western"><surname>Freitas</surname><given-names>DLD</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based near&#8208;infrared spectroscopy for the rapid low&#8208;cost detection of Alzheimer's disease</article-title>. <source>Analyst</source>. <year>2018</year>;<volume>143</volume>(<issue>24</issue>):<fpage>5959</fpage>&#8208;<lpage>5964</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c8an01205a</pub-id><pub-id pub-id-type="pmid">30183030</pub-id></mixed-citation></ref><ref id="alz70769-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70769-cite-0036"><string-name name-style="western"><surname>Keles</surname><given-names>HO</given-names></string-name>, <string-name name-style="western"><surname>Karakulak</surname><given-names>EZ</given-names></string-name>, <string-name name-style="western"><surname>Hanoglu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Omurtag</surname><given-names>A</given-names></string-name>. <article-title>Screening for Alzheimer's disease using prefrontal resting&#8208;state functional near&#8208;infrared spectroscopy</article-title>. <source>Front Hum Neurosci</source>. <year>2022</year>;<volume>16</volume>:<elocation-id>1061668</elocation-id>.<pub-id pub-id-type="pmid">36518566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2022.1061668</pub-id><pub-id pub-id-type="pmcid">PMC9742284</pub-id></mixed-citation></ref><ref id="alz70769-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70769-cite-0037"><string-name name-style="western"><surname>Ferrando</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Damian</surname><given-names>A</given-names></string-name>. <article-title>Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: still a valid option?</article-title>. <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>629442</elocation-id>.<pub-id pub-id-type="pmid">34040574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.629442</pub-id><pub-id pub-id-type="pmcid">PMC8141564</pub-id></mixed-citation></ref><ref id="alz70769-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70769-cite-0038"><string-name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Imaging markers for Alzheimer disease: which vs how</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>81</volume>(<issue>5</issue>):<fpage>487</fpage>&#8208;<lpage>500</lpage>.<pub-id pub-id-type="pmid">23897875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31829d86e8</pub-id><pub-id pub-id-type="pmcid">PMC3776529</pub-id></mixed-citation></ref><ref id="alz70769-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70769-cite-0039"><string-name name-style="western"><surname>Strand</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Knapskog</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Persson</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>9</issue>):<elocation-id>e0204436</elocation-id>.<pub-id pub-id-type="pmid">30240425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0204436</pub-id><pub-id pub-id-type="pmcid">PMC6150521</pub-id></mixed-citation></ref><ref id="alz70769-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70769-cite-0040"><string-name name-style="western"><surname>Cheng</surname><given-names>YWen</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname><given-names>MJ</given-names></string-name>. <article-title>From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2017</year>:<fpage>491</fpage>&#8208;<lpage>498</lpage>.<pub-id pub-id-type="pmid">28243102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S123428</pub-id><pub-id pub-id-type="pmcid">PMC5317337</pub-id></mixed-citation></ref><ref id="alz70769-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70769-cite-0041"><string-name name-style="western"><surname>Liew</surname><given-names>TM</given-names></string-name>. <article-title>Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia</article-title>. <source>Alzheimers Res Ther</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>135</fpage>.<pub-id pub-id-type="pmid">33109275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00699-y</pub-id><pub-id pub-id-type="pmcid">PMC7592368</pub-id></mixed-citation></ref><ref id="alz70769-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70769-cite-0042"><string-name name-style="western"><surname>Melrose</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Jimenez</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Riskin&#8208;Jones</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Alterations to task positive and task negative networks during executive functioning in mild cognitive impairment</article-title>. <source>NeuroImage Clin</source>. <year>2018</year>;<volume>19</volume>:<fpage>970</fpage>&#8208;<lpage>981</lpage>.<pub-id pub-id-type="pmid">30003034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2018.06.014</pub-id><pub-id pub-id-type="pmcid">PMC6039844</pub-id></mixed-citation></ref><ref id="alz70769-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70769-cite-0043"><string-name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gwak</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Investigation of brain functional connectivity in patients with mild cognitive impairment: a functional near&#8208;infrared spectroscopy (fNIRS) study</article-title>. <source>J Biophotonics</source>. <year>2019</year>;<volume>12</volume>(<issue>9</issue>):<fpage>1</fpage>&#8208;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jbio.201800298</pub-id><pub-id pub-id-type="pmid">30963713</pub-id></mixed-citation></ref><ref id="alz70769-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70769-cite-0044"><string-name name-style="western"><surname>Barbey</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Koenigs</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grafman</surname><given-names>J</given-names></string-name>. <article-title>Dorsolateral prefrontal contributions to human working memory</article-title>. <source>cortex</source>. <year>2013</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1195</fpage>&#8208;<lpage>1205</lpage>.<pub-id pub-id-type="pmid">22789779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cortex.2012.05.022</pub-id><pub-id pub-id-type="pmcid">PMC3495093</pub-id></mixed-citation></ref><ref id="alz70769-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70769-cite-0045"><string-name name-style="western"><surname>lo</surname><given-names>Lee</given-names></string-name>T, k, <string-name name-style="western"><surname>L</surname><given-names>Guo</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>AS</given-names></string-name>. <article-title>fNIRS as a biomarker for individuals with subjective memory complaints and MCI</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5170</fpage>&#8208;<lpage>5182</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13897</pub-id><pub-id pub-id-type="pmid">38837656</pub-id><pub-id pub-id-type="pmcid">PMC11350052</pub-id></mixed-citation></ref><ref id="alz70769-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70769-cite-0046"><string-name name-style="western"><surname>You</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>. <article-title>Application of upper limb multimodal tasks combined with fNIRS technology in the assessment of mild cognitive impairment</article-title>. <source>J Biophotonics</source>. <year>2025</year>;<volume>18</volume>(<issue>7</issue>):<elocation-id>e202500020</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/jbio.202500020</pub-id><pub-id pub-id-type="pmid">40364662</pub-id></mixed-citation></ref><ref id="alz70769-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70769-cite-0047"><string-name name-style="western"><surname>St George</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Hinder</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Puri</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Callisaya</surname><given-names>ML</given-names></string-name>. <article-title>Functional near&#8208;infrared spectroscopy reveals the compensatory potential of pre&#8208;frontal cortical activity for standing balance in young and older adults</article-title>. <source>Neuroscience</source>. <year>2021</year>;<volume>452</volume>:<fpage>208</fpage>&#8208;<lpage>218</lpage>.<pub-id pub-id-type="pmid">33197501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2020.10.027</pub-id></mixed-citation></ref><ref id="alz70769-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70769-cite-0048"><string-name name-style="western"><surname>Vermeij</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kessels</surname><given-names>RPC</given-names></string-name>, <string-name name-style="western"><surname>Heskamp</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Simons</surname><given-names>EMF</given-names></string-name>, <string-name name-style="western"><surname>Dautzenberg</surname><given-names>PLJ</given-names></string-name>, <string-name name-style="western"><surname>Claassen</surname><given-names>JAHR</given-names></string-name>. <article-title>Prefrontal activation may predict working&#8208;memory training gain in normal aging and mild cognitive impairment</article-title>. <source>Brain Imaging Behav</source>. <year>2017</year>;<volume>11</volume>(<issue>1</issue>):<fpage>141</fpage>&#8208;<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11682-016-9508-7</pub-id><pub-id pub-id-type="pmid">26843001</pub-id><pub-id pub-id-type="pmcid">PMC5415588</pub-id></mixed-citation></ref><ref id="alz70769-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70769-cite-0049"><string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>. <article-title>Brain activation during standing balance control in dual&#8208;task paradigm and its correlation among older adults with mild cognitive impairment: a fNIRS study</article-title>. <source>BMC Geriatr</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12877-024-04772-1</pub-id><pub-id pub-id-type="pmid">38341561</pub-id><pub-id pub-id-type="pmcid">PMC10859010</pub-id></mixed-citation></ref><ref id="alz70769-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70769-cite-0050"><string-name name-style="western"><surname>Owens</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Mukli</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Neurovascular coupling, functional connectivity, and cerebrovascular endothelial extracellular vesicles as biomarkers of mild cognitive impairment</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5590</fpage>&#8208;<lpage>5606</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14072</pub-id><pub-id pub-id-type="pmid">38958537</pub-id><pub-id pub-id-type="pmcid">PMC11350141</pub-id></mixed-citation></ref><ref id="alz70769-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70769-cite-0051"><string-name name-style="western"><surname>Csipo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lipecz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mukli</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Increased cognitive workload evokes greater neurovascular coupling responses in healthy young adults</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>(<issue>5 May</issue>):<fpage>1</fpage>&#8208;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0250043</pub-id><pub-id pub-id-type="pmcid">PMC8133445</pub-id><pub-id pub-id-type="pmid">34010279</pub-id></mixed-citation></ref><ref id="alz70769-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70769-cite-0052"><string-name name-style="western"><surname>Yang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>SH</given-names></string-name>, et&#160;al. <article-title>Detection of mild cognitive impairment using convolutional neural network: temporal&#8208;feature maps of functional near&#8208;infrared spectroscopy</article-title>. <source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>(<issue>May</issue>):<fpage>1</fpage>&#8208;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2020.00141</pub-id><pub-id pub-id-type="pmid">32508627</pub-id><pub-id pub-id-type="pmcid">PMC7253632</pub-id></mixed-citation></ref><ref id="alz70769-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70769-cite-0053"><string-name name-style="western"><surname>Uemura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shimada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Doi</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Reduced prefrontal oxygenation in mild cognitive impairment during memory retrieval</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2016</year>;<volume>31</volume>(<issue>6</issue>):<fpage>583</fpage>&#8208;<lpage>591</lpage>.<pub-id pub-id-type="pmid">26387497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4363</pub-id></mixed-citation></ref><ref id="alz70769-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70769-cite-0054"><string-name name-style="western"><surname>Park</surname><given-names>JH</given-names></string-name>. <article-title>Can the fNIRS&#8208;derived neural biomarker better discriminate mild cognitive impairment than a neuropsychological screening test?</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>(<issue>April</issue>):<fpage>1</fpage>&#8208;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2023.1137283</pub-id><pub-id pub-id-type="pmcid">PMC10126359</pub-id><pub-id pub-id-type="pmid">37113573</pub-id></mixed-citation></ref><ref id="alz70769-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70769-cite-0055"><string-name name-style="western"><surname>Herrmann</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Wuttke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Breuninger</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Functional near&#8208;infrared spectroscopy and vagus somatosensory evoked potentials add to the power of established parameters such as poor cognitive performance, dsyosmia and APOe genotype to predict cognitive decline over 8 years in the elderly</article-title>. <source>J Neural Transm</source>. <year>2024</year>:<fpage>455</fpage>&#8208;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-024-02859-y</pub-id>. Published online.<pub-id pub-id-type="pmid">39535568</pub-id><pub-id pub-id-type="pmcid">PMC11870936</pub-id></mixed-citation></ref><ref id="alz70769-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70769-cite-0056"><string-name name-style="western"><surname>Katzorke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zeller</surname><given-names>JBM</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>LD</given-names></string-name>, et&#160;al. <article-title>Decreased hemodynamic response in inferior frontotemporal regions in elderly with mild cognitive impairment</article-title>. <source>Psychiatry Res&#8212;Neuroimaging</source>. <year>2018</year>;<volume>274</volume>(<issue>January</issue>):<fpage>11</fpage>&#8208;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pscychresns.2018.02.003</pub-id><pub-id pub-id-type="pmid">29472145</pub-id></mixed-citation></ref><ref id="alz70769-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70769-cite-0057"><string-name name-style="western"><surname>Fan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Brain compensatory activation during Stroop task in patients with mild cognitive impairment: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Front Aging Neurosci</source>. <year>2025</year>;<volume>17</volume>(<issue>February</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2025.1470747</pub-id><pub-id pub-id-type="pmcid">PMC11842388</pub-id><pub-id pub-id-type="pmid">39990105</pub-id></mixed-citation></ref><ref id="alz70769-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70769-cite-0058"><string-name name-style="western"><surname>Yoon</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>JK</given-names></string-name>, et&#160;al. <article-title>Neural compensatory response during complex cognitive function tasks in mild cognitive impairment: a near&#8208;infrared spectroscopy study</article-title>. <source>Neural Plast</source>. <year>2019</year>;<volume>2019</volume>(<issue>1</issue>):<elocation-id>7845104</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2019/7845104</pub-id><pub-id pub-id-type="pmid">31320893</pub-id><pub-id pub-id-type="pmcid">PMC6607700</pub-id></mixed-citation></ref><ref id="alz70769-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70769-cite-0059"><string-name name-style="western"><surname>Yoo</surname><given-names>SHyeon</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>SWoo</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>MJun</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>YIl</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>KS</given-names></string-name>. <article-title>Diagnosis of mild cognitive impairment using cognitive tasks: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Curr Alzheimer Res</source>. <year>2020</year>;<volume>17</volume>(<issue>13</issue>):<fpage>1145</fpage>&#8208;<lpage>1160</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1567205018666210212154941</pub-id><pub-id pub-id-type="pmid">33583382</pub-id></mixed-citation></ref><ref id="alz70769-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70769-cite-0060"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Assessment of brain function in patients with cognitive impairment based on fNIRS and gait analysis</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>(<issue>May</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2022.799732</pub-id><pub-id pub-id-type="pmcid">PMC9170988</pub-id><pub-id pub-id-type="pmid">35686022</pub-id></mixed-citation></ref><ref id="alz70769-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70769-cite-0061"><string-name name-style="western"><surname>Takahashi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sakurai</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kodama</surname><given-names>N</given-names></string-name>. <article-title>Prefrontal cerebral oxygenated hemoglobin concentration during the category fluency and finger&#8208;tapping tasks in adults with and without mild cognitive impairment: a near&#8208;infrared spectroscopy study</article-title>. <source>Brain Sci</source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.3390/brainsci12121636</pub-id><pub-id pub-id-type="pmcid">PMC9775273</pub-id><pub-id pub-id-type="pmid">36552096</pub-id></mixed-citation></ref><ref id="alz70769-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70769-cite-0062"><string-name name-style="western"><surname>Petrillo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ehsani</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Akbas</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dagar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Toosizadeh</surname><given-names>N</given-names></string-name>. <article-title>Differences in brain function entropy due to cognitive impairment: application of functional near infrared spectroscopy measures during dual&#8208;tasking</article-title>. <source>Int J Psychophysiol</source>. <year>2024</year>;<volume>211</volume>:<elocation-id>112558</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ijpsycho.2025.112558</pub-id><pub-id pub-id-type="pmid">40120943</pub-id></mixed-citation></ref><ref id="alz70769-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70769-cite-0063"><string-name name-style="western"><surname>Yang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>CS</given-names></string-name>. <article-title>Evaluation of neural degeneration biomarkers in the prefrontal cortex for early identification of patients with mild cognitive impairment: an fNIRS study</article-title>. <source>Front Hum Neurosci</source>. <year>2019</year>;<volume>13</volume>(<issue>September</issue>):<fpage>1</fpage>&#8208;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnhum.2019.00317</pub-id><pub-id pub-id-type="pmid">31551741</pub-id><pub-id pub-id-type="pmcid">PMC6743351</pub-id></mixed-citation></ref><ref id="alz70769-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70769-cite-0064"><string-name name-style="western"><surname>Yu</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Prefrontal functional connectivity analysis of cognitive decline for early diagnosis of mild cognitive impairment: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Biomed Opt Express</source>. <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>1725</fpage>. doi:<pub-id pub-id-type="doi">10.1364/boe.382197</pub-id><pub-id pub-id-type="pmid">32341843</pub-id><pub-id pub-id-type="pmcid">PMC7173911</pub-id></mixed-citation></ref><ref id="alz70769-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70769-cite-0065"><string-name name-style="western"><surname>Ung</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Yap</surname><given-names>KH</given-names></string-name>, et&#160;al. <article-title>Assessing neural compensation with visuospatial working memory load using near&#8208;infrared imaging</article-title>. <source>IEEE Trans Neural Syst Rehabil Eng</source>. <year>2020</year>;<volume>28</volume>(<issue>1</issue>):<fpage>13</fpage>&#8208;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1109/TNSRE.2019.2956459</pub-id><pub-id pub-id-type="pmid">31794398</pub-id></mixed-citation></ref><ref id="alz70769-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70769-cite-0066"><string-name name-style="western"><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Refined prefrontal working memory network as a neuromarker for Alzheimer's disease</article-title>. <source>Biomed Opt Express</source>. <year>2021</year>;<volume>12</volume>(<issue>11</issue>):<fpage>7199</fpage>. doi:<pub-id pub-id-type="doi">10.1364/boe.438926</pub-id><pub-id pub-id-type="pmid">34858710</pub-id><pub-id pub-id-type="pmcid">PMC8606140</pub-id></mixed-citation></ref><ref id="alz70769-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70769-cite-0067"><string-name name-style="western"><surname>Yeung</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Sze</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Reduced frontal activations at high working memory load in mild cognitive impairment: near&#8208;infrared spectroscopy</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2016</year>;<volume>42</volume>(<issue>5&#8208;6</issue>):<fpage>278</fpage>&#8208;<lpage>296</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000450993</pub-id><pub-id pub-id-type="pmid">27784013</pub-id></mixed-citation></ref><ref id="alz70769-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70769-cite-0068"><string-name name-style="western"><surname>Du</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>. <article-title>Disrupted anterior and posterior hippocampal structural networks correlate impaired verbal memory and spatial memory in different subtypes of mild cognitive impairment</article-title>. <source>Eur J Neurol</source>. <year>2021</year>;<volume>28</volume>(<issue>12</issue>):<fpage>3955</fpage>&#8208;<lpage>3964</lpage>.<pub-id pub-id-type="pmid">34310802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15036</pub-id></mixed-citation></ref><ref id="alz70769-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70769-cite-0069"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>. <article-title>Early screening model for mild cognitive impairment based on resting&#8208;state functional connectivity: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Neurophotonics</source>. <year>2022</year>;<volume>9</volume>(<issue>4</issue>):<elocation-id>45010</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.NPh.9.4.045010</pub-id><pub-id pub-id-type="pmcid">PMC9722394</pub-id><pub-id pub-id-type="pmid">36483024</pub-id></mixed-citation></ref><ref id="alz70769-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70769-cite-0070"><string-name name-style="western"><surname>Bu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>. <article-title>Effective connectivity in subjects with mild cognitive impairment as assessed using functional near&#8208;infrared spectroscopy</article-title>. <source>Am J Phys Med Rehabil</source>. <year>2019</year>;<volume>98</volume>(<issue>6</issue>):<fpage>438</fpage>&#8208;<lpage>445</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PHM.0000000000001118</pub-id><pub-id pub-id-type="pmid">30557156</pub-id></mixed-citation></ref><ref id="alz70769-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70769-cite-0071"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Functional connectivity changes across the spectrum of subjective cognitive decline, amnestic mild cognitive impairment and Alzheimer's disease</article-title>. <source>Front Neuroinform</source>. <year>2019</year>;<volume>13</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">31105548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2019.00026</pub-id><pub-id pub-id-type="pmcid">PMC6491896</pub-id></mixed-citation></ref><ref id="alz70769-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70769-cite-0072"><string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>Functional network alterations in patients with amnestic mild cognitive impairment characterized using functional near&#8208;infrared spectroscopy</article-title>. <source>IEEE Trans Neural Syst Rehabil Eng</source>. <year>2019</year>;<volume>28</volume>(<issue>1</issue>):<fpage>123</fpage>&#8208;<lpage>132</lpage>.<pub-id pub-id-type="pmid">31804939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TNSRE.2019.2956464</pub-id></mixed-citation></ref><ref id="alz70769-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70769-cite-0073"><string-name name-style="western"><surname>Oyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sakatani</surname><given-names>K</given-names></string-name>. <article-title>Machine learning&#8208;based assessment of cognitive impairment using time&#8208;resolved near&#8208;infrared spectroscopy and basic blood test</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>12</volume>(<issue>January</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2021.624063</pub-id><pub-id pub-id-type="pmcid">PMC8828578</pub-id><pub-id pub-id-type="pmid">35153965</pub-id></mixed-citation></ref><ref id="alz70769-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70769-cite-0074"><string-name name-style="western"><surname>Murayama</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Brugnera</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Compare</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sakatani</surname><given-names>K</given-names></string-name>. <article-title>Relation between cognitive function and baseline concentrations of hemoglobin in prefrontal cortex of elderly people measured by time&#8208;resolved near&#8208;infrared spectroscopy</article-title>. <source>Adv Exp Med Biol</source>. <year>2017</year>;<volume>977</volume>:<fpage>269</fpage>&#8208;<lpage>276</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-3-319-55231-6_37</pub-id><pub-id pub-id-type="pmid">28685456</pub-id></mixed-citation></ref><ref id="alz70769-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70769-cite-0075"><string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Comparative effectiveness of open and closed skill exercises on cognitive function in young adults: a fNIRS study</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-70614-0</pub-id><pub-id pub-id-type="pmid">39251657</pub-id><pub-id pub-id-type="pmcid">PMC11385981</pub-id></mixed-citation></ref><ref id="alz70769-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70769-cite-0076"><string-name name-style="western"><surname>Chan</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Hamblin</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Cheung</surname><given-names>MC</given-names></string-name>. <article-title>Photobiomodulation enhances memory processing in older adults with mild cognitive impairment: a functional near&#8208;infrared spectroscopy study</article-title>. <source>J Alzheimer's Dis</source>. <year>2021</year>;<volume>83</volume>(<issue>4</issue>):<fpage>1471</fpage>&#8208;<lpage>1480</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-201600</pub-id><pub-id pub-id-type="pmid">33998541</pub-id></mixed-citation></ref><ref id="alz70769-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70769-cite-0077"><string-name name-style="western"><surname>Park</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name>. <article-title>Effects of phytoncide inhalation on stroop task performance in patients with mild cognitive impairment: an fNIRS pilot study</article-title>. <source>Clin Psychopharmacol Neurosci</source>. <year>2024</year>;<volume>23</volume>(<issue>1</issue>):<fpage>42</fpage>&#8208;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.9758/cpn.24.1157</pub-id><pub-id pub-id-type="pmid">39820111</pub-id><pub-id pub-id-type="pmcid">PMC11747736</pub-id></mixed-citation></ref><ref id="alz70769-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="alz70769-cite-0078"><string-name name-style="western"><surname>Choi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Keum</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>JH</given-names></string-name>. <article-title>Effectiveness of Korean medicine treatments in improving cognitive function and prefrontal cortex activity in older individuals with mild cognitive impairment: retrospective observational study</article-title>. <source>Front Neurol</source>. <year>2024</year>;<volume>15</volume>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2024.1440111</pub-id><pub-id pub-id-type="pmcid">PMC11557411</pub-id><pub-id pub-id-type="pmid">39539667</pub-id></mixed-citation></ref><ref id="alz70769-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="alz70769-cite-0079"><string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Machine&#8208;learning&#8208;based prediction of photobiomodulation effects on older adults with cognitive decline using functional near&#8208;infrared spectroscopy</article-title>. <source>IEEE Trans Neural Syst Rehabil Eng</source>. <year>2024</year>;<volume>32</volume>:<fpage>3710</fpage>&#8208;<lpage>3718</lpage>. doi:<pub-id pub-id-type="doi">10.1109/TNSRE.2024.3469284</pub-id><pub-id pub-id-type="pmid">39331542</pub-id></mixed-citation></ref><ref id="alz70769-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="alz70769-cite-0080"><string-name name-style="western"><surname>Talamonti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gagnon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vincent</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Exploring cognitive and brain oxygenation changes over a 1&#8208;year period in physically active individuals with mild cognitive impairment: a longitudinal fNIRS pilot study</article-title>. <source>BMC Geriatr</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12877-022-03306-x</pub-id><pub-id pub-id-type="pmid">35941561</pub-id><pub-id pub-id-type="pmcid">PMC9361664</pub-id></mixed-citation></ref><ref id="alz70769-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="alz70769-cite-0081"><string-name name-style="western"><surname>Esmaeili</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nejati</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Shati</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vatan</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Chehrehnegar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Foroughan</surname><given-names>M</given-names></string-name>. <article-title>Attentional network changes in subjective cognitive decline</article-title>. <source>Aging Clin Exp Res</source>. <year>2022</year>;<volume>34</volume>(<issue>4</issue>):<fpage>847</fpage>&#8208;<lpage>855</lpage>.<pub-id pub-id-type="pmid">34705251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-021-02005-8</pub-id></mixed-citation></ref><ref id="alz70769-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="alz70769-cite-0082"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Research on the application of functional near&#8208;infrared spectroscopy in differentiating subjective cognitive decline and mild cognitive impairment</article-title>. <source>Front Aging Neurosci</source>. <year>2024</year>;<volume>16</volume>(<issue>December</issue>):<fpage>1</fpage>&#8208;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2024.1469620</pub-id><pub-id pub-id-type="pmcid">PMC11703808</pub-id><pub-id pub-id-type="pmid">39777048</pub-id></mixed-citation></ref><ref id="alz70769-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="alz70769-cite-0083"><string-name name-style="western"><surname>Salzman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tob&#243;n</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Perreault</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Farhat</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fraser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Q</given-names></string-name>. <article-title>Using cognitive&#8208;motor dual&#8208;tasks and functional near&#8208;infrared spectroscopy to characterize older adults with and without subjective cognitive decline</article-title>. <source>J Alzheimer's Dis</source>. <year>2023</year>;<volume>95</volume>(<issue>4</issue>):<fpage>1497</fpage>&#8208;<lpage>1508</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-230469</pub-id><pub-id pub-id-type="pmid">37718810</pub-id></mixed-citation></ref><ref id="alz70769-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="alz70769-cite-0084"><string-name name-style="western"><surname>Teo</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Rantalainen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nuzum</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Valente</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Macpherson</surname><given-names>H</given-names></string-name>. <article-title>Altered prefrontal cortex responses in older adults with subjective memory complaints and dementia during dual&#8208;task gait: an fNIRS study</article-title>. <source>Eur J Neurosci</source>. <year>2021</year>;<volume>53</volume>(<issue>4</issue>):<fpage>1324</fpage>&#8208;<lpage>1333</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ejn.14989</pub-id><pub-id pub-id-type="pmid">32979289</pub-id></mixed-citation></ref><ref id="alz70769-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="alz70769-cite-0085"><string-name name-style="western"><surname>Li</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>. <article-title>Cognitive function assessment and prediction for subjective cognitive decline and mild cognitive impairment</article-title>. <source>Brain Imaging Behav</source>. <year>2022</year>;<volume>16</volume>(<issue>2</issue>):<fpage>645</fpage>&#8208;<lpage>658</lpage>.<pub-id pub-id-type="pmid">34491529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-021-00545-1</pub-id></mixed-citation></ref><ref id="alz70769-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="alz70769-cite-0086"><string-name name-style="western"><surname>Mei</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Functional connectivity and cerebral cortex activation during the resting state and verbal fluency tasks for patients with mild cognitive impairment, Lewy body dementia, and Alzheimer's disease: a multi&#8208;channel fNIRS study</article-title>. <source>J Psychiatr Res</source>. <year>2024</year>;<volume>179</volume>:<fpage>379</fpage>&#8208;<lpage>387</lpage>.<pub-id pub-id-type="pmid">39383643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2024.09.049</pub-id></mixed-citation></ref><ref id="alz70769-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="alz70769-cite-0087"><string-name name-style="western"><surname>Polak</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>LD</given-names></string-name>, et&#160;al. <article-title>Near&#8208;infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study</article-title>. <source>J Neural Transm</source>. <year>2017</year>;<volume>124</volume>(<issue>11</issue>):<fpage>1473</fpage>&#8208;<lpage>1488</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-017-1781-0</pub-id><pub-id pub-id-type="pmid">28864837</pub-id></mixed-citation></ref><ref id="alz70769-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="alz70769-cite-0088"><string-name name-style="western"><surname>Yap</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Ung</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Ebenezer</surname><given-names>EGM</given-names></string-name>, et&#160;al. <article-title>Visualizing hyperactivation in neurodegeneration based on prefrontal oxygenation: a comparative study of mild Alzheimer's disease, mild cognitive impairment, and healthy controls</article-title>. <source>Front Aging Neurosci</source>. <year>2017</year>;<volume>9</volume>:<fpage>287</fpage>.<pub-id pub-id-type="pmid">28919856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2017.00287</pub-id><pub-id pub-id-type="pmcid">PMC5585736</pub-id></mixed-citation></ref><ref id="alz70769-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="alz70769-cite-0089"><string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Alteration of prefrontal functional connectivity in preclinical Alzheimer's disease: an fNIRS study</article-title>. <source>Front Aging Neurosci</source>. <year>2025</year>;<volume>17</volume>:<elocation-id>1507180</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2025.1507180</pub-id><pub-id pub-id-type="pmid">40134533</pub-id><pub-id pub-id-type="pmcid">PMC11933025</pub-id></mixed-citation></ref><ref id="alz70769-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="alz70769-cite-0090"><string-name name-style="western"><surname>Ate&#351;</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Cang&#246;z</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>&#214;zel K&#305;z&#305;l</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Baskak</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baran</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>&#214;zg&#252;ven</surname><given-names>HD</given-names></string-name>. <article-title>Frontal activity during a verbal emotional working memory task in patients with Alzheimer's disease: a functional near&#8208;infrared spectroscopy study</article-title>. <source>Psychiatry Res&#8212;Neuroimaging</source>. <year>2017</year>;<volume>261</volume>:<fpage>29</fpage>&#8208;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pscychresns.2016.12.013</pub-id><pub-id pub-id-type="pmid">28126617</pub-id></mixed-citation></ref><ref id="alz70769-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="alz70769-cite-0091"><string-name name-style="western"><surname>Tang</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>YL</given-names></string-name>. <article-title>Functional connectivity analysis on mild Alzheimer's disease, mild cognitive impairment and normal aging using fNIRS</article-title>. <source>Proc Annu Int Conf IEEE Eng Med Biol Soc EMBS</source>. <year>2018</year>;<volume>2018</volume>:<fpage>17</fpage>&#8208;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1109/EMBC.2018.8512186</pub-id><pub-id pub-id-type="pmid">30440330</pub-id></mixed-citation></ref><ref id="alz70769-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="alz70769-cite-0092"><string-name name-style="western"><surname>Koychev</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hofer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>N</given-names></string-name>. <article-title>Correlation of Alzheimer disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers</article-title>. <source>J Nucl Med</source>. <year>2020</year>;<volume>61</volume>(<issue>10</issue>):<fpage>1413</fpage>&#8208;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">32764121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.119.230458</pub-id></mixed-citation></ref><ref id="alz70769-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="alz70769-cite-0093"><string-name name-style="western"><surname>M&#305;zrak</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Dikmen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hano&#287;lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>&#350;akul</surname><given-names>BU</given-names></string-name>. <article-title>Investigation of hemispheric asymmetry in Alzheimer's disease patients during resting state revealed BY fNIRS</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-62281-y</pub-id><pub-id pub-id-type="pmid">38862632</pub-id><pub-id pub-id-type="pmcid">PMC11166983</pub-id></mixed-citation></ref><ref id="alz70769-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="alz70769-cite-0094"><string-name name-style="western"><surname>Dolcos</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Cabeza</surname><given-names>R</given-names></string-name>. <article-title>Hemispheric asymmetry and aging: right hemisphere decline or asymmetry reduction</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2002</year>;<volume>26</volume>(<issue>7</issue>):<fpage>819</fpage>&#8208;<lpage>825</lpage>.<pub-id pub-id-type="pmid">12470693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0149-7634(02)00068-4</pub-id></mixed-citation></ref><ref id="alz70769-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="alz70769-cite-0095"><string-name name-style="western"><surname>Perpetuini</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bucco</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zito</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Merla</surname><given-names>A</given-names></string-name>. <article-title>Study of memory deficit in Alzheimer's disease by means of complexity analysis of fNIRS signal</article-title>. <source>Neurophotonics</source>. <year>2017</year>;<volume>5</volume>(<issue>01</issue>):<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1117/1.nph.5.1.011010</pub-id><pub-id pub-id-type="pmcid">PMC5613221</pub-id><pub-id pub-id-type="pmid">28983489</pub-id></mixed-citation></ref><ref id="alz70769-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="alz70769-cite-0096"><string-name name-style="western"><surname>Perpetuini</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chiarelli</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Cardone</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Complexity of frontal cortex fNIRS can support Alzheimer disease diagnosis in memory and visuo&#8208;spatial tests</article-title>. <source>Entropy</source>. <year>2019</year>;<volume>21</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.3390/e21010026</pub-id><pub-id pub-id-type="pmcid">PMC7514130</pub-id><pub-id pub-id-type="pmid">33266742</pub-id></mixed-citation></ref><ref id="alz70769-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="alz70769-cite-0097"><string-name name-style="western"><surname>Park</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></string-name>. <article-title>The aging mind: neuroplasticity in response to cognitive training</article-title>. <source>Dialogues Clin Neurosci</source>. <year>2013</year>;<volume>15</volume>(<issue>1</issue>):<fpage>109</fpage>&#8208;<lpage>119</lpage>.<pub-id pub-id-type="pmid">23576894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31887/DCNS.2013.15.1/dpark</pub-id><pub-id pub-id-type="pmcid">PMC3622463</pub-id></mixed-citation></ref><ref id="alz70769-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="alz70769-cite-0098"><string-name name-style="western"><surname>Ho</surname><given-names>TKK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Deep learning&#8208;based multilevel classification of Alzheimer's disease using non&#8208;invasive functional near&#8208;infrared spectroscopy</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>(<issue>April</issue>):<fpage>1</fpage>&#8208;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2022.810125</pub-id><pub-id pub-id-type="pmcid">PMC9087351</pub-id><pub-id pub-id-type="pmid">35557842</pub-id></mixed-citation></ref><ref id="alz70769-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="alz70769-cite-0099"><string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>Early detection of Alzheimer's disease using non&#8208;invasive near&#8208;infrared spectroscopy</article-title>. <source>Front Aging Neurosci</source>. <year>2018</year>;<volume>10</volume>:<fpage>366</fpage>.<pub-id pub-id-type="pmid">30473662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2018.00366</pub-id><pub-id pub-id-type="pmcid">PMC6237862</pub-id></mixed-citation></ref><ref id="alz70769-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="alz70769-cite-0100"><string-name name-style="western"><surname>Chan</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Ung</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Kiguchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>TB</given-names></string-name>. <article-title>Automated thresholding method for fNIRS&#8208;based functional connectivity analysis: validation with a case study on Alzheimer's disease</article-title>. <source>IEEE Trans Neural Syst Rehabil Eng</source>. <year>2020</year>;<volume>28</volume>(<issue>8</issue>):<fpage>1691</fpage>&#8208;<lpage>1701</lpage>.<pub-id pub-id-type="pmid">32746314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TNSRE.2020.3007589</pub-id></mixed-citation></ref><ref id="alz70769-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="alz70769-cite-0101"><string-name name-style="western"><surname>Alotaibi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lessard&#8208;Beaudoin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Loudghi</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Decrease in olfactory cortex volume and alterations in caspase expression in the olfactory bulb in the pathogenesis of Alzheimer's disease</article-title>. <source>Alzheimer&#8217;s Dement</source>. <year>2020</year>;<volume>16</volume>(<issue>S6</issue>):<elocation-id>e039789</elocation-id>.</mixed-citation></ref><ref id="alz70769-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="alz70769-cite-0102"><string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yon</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Novel diagnostic tools for identifying cognitive impairment using olfactory&#8208;stimulated functional near&#8208;infrared spectroscopy: patient&#8208;level, single&#8208;group, diagnostic trial</article-title>. <source>Alzheimer's Res Ther</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-022-00978-w</pub-id><pub-id pub-id-type="pmid">35260170</pub-id><pub-id pub-id-type="pmcid">PMC8905807</pub-id></mixed-citation></ref><ref id="alz70769-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="alz70769-cite-0103"><string-name name-style="western"><surname>Hye</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lynham</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thambisetty</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Proteome&#8208;based plasma biomarkers for Alzheimer's disease</article-title>. <source>Brain</source>. <year>2006</year>;<volume>129</volume>(<issue>11</issue>):<fpage>3042</fpage>&#8208;<lpage>3050</lpage>.<pub-id pub-id-type="pmid">17071923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl279</pub-id></mixed-citation></ref><ref id="alz70769-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="alz70769-cite-0104"><string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Batzu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Halliday</surname><given-names>GM</given-names></string-name>, et&#160;al. <article-title>Parkinson disease&#8208;associated cognitive impairment</article-title>. <source>Nat Rev Dis Prim</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>47</fpage>.<pub-id pub-id-type="pmid">34210995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00280-3</pub-id></mixed-citation></ref><ref id="alz70769-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="alz70769-cite-0105"><string-name name-style="western"><surname>Bonilauri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sangiuliano Intra</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rossetto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Borgnis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Baselli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Baglio</surname><given-names>F</given-names></string-name>. <article-title>Whole&#8208;head functional near&#8208;infrared spectroscopy as an ecological monitoring tool for assessing cortical activity in Parkinson's disease patients at different stages</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>23</issue>):<fpage>1</fpage>&#8208;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms232314897</pub-id><pub-id pub-id-type="pmcid">PMC9736501</pub-id><pub-id pub-id-type="pmid">36499223</pub-id></mixed-citation></ref><ref id="alz70769-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="alz70769-cite-0106"><string-name name-style="western"><surname>Sharon</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kurz</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bernad&#8208;Elazari</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Which obstacle attributes place additional demands on higher&#8208;level cognitive function in patients with Parkinson's disease?</article-title>. <source>Park Relat Disord</source>. <year>2020</year>;<volume>78</volume>(<issue>December 2019</issue>):<fpage>178</fpage>&#8208;<lpage>183</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.08.002</pub-id><pub-id pub-id-type="pmid">32927415</pub-id></mixed-citation></ref><ref id="alz70769-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="alz70769-cite-0107"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>A signature combining brain functional connectivity with executive and motor function for general cognitive decline in Parkinson's disease</article-title>. <source>Front Neurol</source>. <year>2025</year>;<volume>16</volume>(<issue>February</issue>):<fpage>1</fpage>&#8208;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2025.1434733</pub-id><pub-id pub-id-type="pmcid">PMC11879828</pub-id><pub-id pub-id-type="pmid">40046673</pub-id></mixed-citation></ref><ref id="alz70769-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="alz70769-cite-0108"><string-name name-style="western"><surname>Aron</surname><given-names>AR</given-names></string-name>. <article-title>From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses</article-title>. <source>Biol Psychiatry</source>. <year>2011</year>;<volume>69</volume>(<issue>12</issue>):<fpage>e55</fpage>&#8208;<lpage>e68</lpage>.<pub-id pub-id-type="pmid">20932513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2010.07.024</pub-id><pub-id pub-id-type="pmcid">PMC3039712</pub-id></mixed-citation></ref><ref id="alz70769-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="alz70769-cite-0109"><string-name name-style="western"><surname>Fan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McCandliss</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Fossella</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Flombaum</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Posner</surname><given-names>MI</given-names></string-name>. <article-title>The activation of attentional networks</article-title>. <source>Neuroimage</source>. <year>2005</year>;<volume>26</volume>(<issue>2</issue>):<fpage>471</fpage>&#8208;<lpage>479</lpage>.<pub-id pub-id-type="pmid">15907304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2005.02.004</pub-id></mixed-citation></ref><ref id="alz70769-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="alz70769-cite-0110"><string-name name-style="western"><surname>Wajman</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Cecchini</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Bertolucci</surname><given-names>PHF</given-names></string-name>, <string-name name-style="western"><surname>Mansur</surname><given-names>LL</given-names></string-name>. <article-title>Quanti&#8208;qualitative components of the semantic verbal fluency test in cognitively healthy controls, mild cognitive impairment, and dementia subtypes</article-title>. <source>Appl Neuropsychol Adult</source>. <year>2019</year>;<volume>26</volume>(<issue>6</issue>):<fpage>533</fpage>&#8208;<lpage>542</lpage>.<pub-id pub-id-type="pmid">30375889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23279095.2018.1465426</pub-id></mixed-citation></ref><ref id="alz70769-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="alz70769-cite-0111"><string-name name-style="western"><surname>Ruan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>C</given-names></string-name>. <article-title>Relationships among cortical activation, cognition, and blood biomarkers in two types of dementia determined using functional near&#8208;infrared spectroscopy</article-title>. <source>Front Neurol</source>. <year>2025</year>;<volume>16</volume>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2025.1488420</pub-id><pub-id pub-id-type="pmcid">PMC12036480</pub-id><pub-id pub-id-type="pmid">40297861</pub-id></mixed-citation></ref><ref id="alz70769-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="alz70769-cite-0112"><string-name name-style="western"><surname>Piguet</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Hornberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mioshi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></string-name>. <article-title>Behavioural&#8208;variant frontotemporal dementia: diagnosis, clinical staging, and management</article-title>. <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>(<issue>2</issue>):<fpage>162</fpage>&#8208;<lpage>172</lpage>.<pub-id pub-id-type="pmid">21147039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(10)70299-4</pub-id></mixed-citation></ref><ref id="alz70769-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="alz70769-cite-0113"><string-name name-style="western"><surname>Rajna</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mattila</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Huotari</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Cardiovascular brain impulses in Alzheimer's disease</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>(<issue>7</issue>):<fpage>2214</fpage>&#8208;<lpage>2226</lpage>.<pub-id pub-id-type="pmid">33787890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab144</pub-id><pub-id pub-id-type="pmcid">PMC8422353</pub-id></mixed-citation></ref><ref id="alz70769-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="alz70769-cite-0114"><string-name name-style="western"><surname>Pini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pievani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Brain atrophy in Alzheimer's disease and aging</article-title>. <source>Ageing Res Rev</source>. <year>2016</year>;<volume>30</volume>:<fpage>25</fpage>&#8208;<lpage>48</lpage>.<pub-id pub-id-type="pmid">26827786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2016.01.002</pub-id></mixed-citation></ref><ref id="alz70769-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="alz70769-cite-0115"><string-name name-style="western"><surname>Gr&#228;ssler</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Herold</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Dordevic</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Multimodal measurement approach to identify individuals with mild cognitive impairment: study protocol for a cross&#8208;sectional trial</article-title>. <source>BMJ Open</source>. <year>2021</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2020-046879</pub-id><pub-id pub-id-type="pmcid">PMC8154928</pub-id><pub-id pub-id-type="pmid">34035103</pub-id></mixed-citation></ref><ref id="alz70769-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="alz70769-cite-0116"><string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Potter</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>Dynamic cortical connectivity alterations associated with Alzheimer's disease: an EEG and fNIRS integration study</article-title>. <source>NeuroImage Clin</source>. <year>2019</year>;<volume>21</volume>(<issue>November 2018</issue>):<elocation-id>101622</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2018.101622</pub-id><pub-id pub-id-type="pmid">30527906</pub-id><pub-id pub-id-type="pmcid">PMC6411655</pub-id></mixed-citation></ref><ref id="alz70769-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="alz70769-cite-0117"><string-name name-style="western"><surname>Cicalese</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ahmadi</surname><given-names>MB</given-names></string-name>, et&#160;al. <article-title>An EEG&#8208;fNIRS hybridization technique in the four&#8208;class classification of alzheimer's disease</article-title>. <source>J Neurosci Methods</source>. <year>2020</year>;<volume>336</volume>:<elocation-id>108618</elocation-id>.<pub-id pub-id-type="pmid">32045572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneumeth.2020.108618</pub-id><pub-id pub-id-type="pmcid">PMC7376762</pub-id></mixed-citation></ref><ref id="alz70769-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="alz70769-cite-0118"><string-name name-style="western"><surname>Perpetuini</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chiarelli</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Filippini</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Working memory decline in Alzheimer's disease is detected by complexity analysis of multimodal EEG&#8208;fnirs</article-title>. <source>Entropy</source>. <year>2020</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1</fpage>&#8208;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.3390/e22121380</pub-id><pub-id pub-id-type="pmcid">PMC7762102</pub-id><pub-id pub-id-type="pmid">33279924</pub-id></mixed-citation></ref><ref id="alz70769-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="alz70769-cite-0119"><string-name name-style="western"><surname>Bjerkan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Megli&#269;</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lancaster</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Neurovascular phase coherence is altered in Alzheimer's disease</article-title>. <source>Brain Commun</source>. <year>2025</year>;<volume>7</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcaf007</pub-id><pub-id pub-id-type="pmcid">PMC11852277</pub-id><pub-id pub-id-type="pmid">40008330</pub-id></mixed-citation></ref><ref id="alz70769-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="alz70769-cite-0120"><string-name name-style="western"><surname>Meng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gelb</surname><given-names>AW</given-names></string-name>. <article-title>Regulation of cerebral autoregulation by carbon dioxide</article-title>. <source>Surv Anesthesiol</source>. <year>2015</year>;<volume>59</volume>(<issue>6</issue>):<fpage>265</fpage>&#8208;<lpage>266</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000506</pub-id><pub-id pub-id-type="pmid">25401418</pub-id></mixed-citation></ref><ref id="alz70769-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="alz70769-cite-0121"><string-name name-style="western"><surname>Marmarelis</surname><given-names>VZ</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Tarumi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>. <article-title>Comparison of model&#8208;based indices of cerebral autoregulation and vasomotor reactivity using transcranial doppler versus near&#8208;infrared spectroscopy in patients with amnestic mild cognitive impairment</article-title>. <source>J Alzheimer's Dis</source>. <year>2017</year>;<volume>56</volume>(<issue>1</issue>):<fpage>89</fpage>&#8208;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-161004</pub-id><pub-id pub-id-type="pmid">27911329</pub-id><pub-id pub-id-type="pmcid">PMC5240580</pub-id></mixed-citation></ref><ref id="alz70769-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="alz70769-cite-0122"><string-name name-style="western"><surname>Wald</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>McDaniel</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Witzel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stockmann</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Cooley</surname><given-names>CZ</given-names></string-name>. <article-title>Low&#8208;cost and portable MRI</article-title>. <source>J Magn Reson Imaging</source>. <year>2020</year>;<volume>52</volume>(<issue>3</issue>):<fpage>686</fpage>&#8208;<lpage>696</lpage>.<pub-id pub-id-type="pmid">31605435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.26942</pub-id><pub-id pub-id-type="pmcid">PMC10644353</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuroscience</journal-id><journal-id journal-id-type="iso-abbrev">Neuroscience</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">0306-4522</issn><issn pub-type="epub">1873-7544</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505156</article-id><article-id pub-id-type="pmcid-ver">PMC12505156.1</article-id><article-id pub-id-type="pmcaid">12505156</article-id><article-id pub-id-type="pmcaiid">12505156</article-id><article-id pub-id-type="manuscript-id">NIHMS2111435</article-id><article-id pub-id-type="pmid">40912354</article-id><article-id pub-id-type="doi">10.1016/j.neuroscience.2025.08.062</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2111435</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2111435</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>AlzFormer: Video-based space-time attention model for early diagnosis of Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4070-1058</contrib-id><name name-style="western"><surname>Akan</surname><given-names initials="T">Taymaz</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akan</surname><given-names initials="S">Sara</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2462-6166</contrib-id><name name-style="western"><surname>Alp</surname><given-names initials="S">Sait</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ledbetter</surname><given-names initials="CR">Christina Raye</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhuiyan</surname><given-names initials="MAN">Mohammad Alfrad Nobel</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><on-behalf-of>for the Alzheimer&#8217;s Disease Neuroimaging Initiative<xref rid="FN1" ref-type="author-notes">1</xref></on-behalf-of></contrib-group><aff id="A1"><label>a</label>Department of Medicine, LSU Health Shreveport, Shreveport, LA, USA</aff><aff id="A2"><label>b</label>Department of Software Engineering, Faculty of Engineering, Istanbul Topkap&#305; University, Istanbul, Turkey</aff><aff id="A3"><label>c</label>Department of Computer Engineering, Faculty of Engineering, Istanbul Galata University, Istanbul, Turkey</aff><aff id="A4"><label>d</label>Department of Artificial Intelligence Engineering, Trabzon 61335, Turkey</aff><aff id="A5"><label>e</label>Department of Neurosurgery, LSU Health Shreveport, Shreveport, LA, USA</aff><author-notes><fn id="FN1"><label>1</label><p id="P1">The longitudinal data used in preparation for this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/" ext-link-type="uri">http://adni.loni.usc.edu</ext-link>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf" ext-link-type="uri">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>.</p></fn><corresp id="CR1"><label>*</label>Corresponding author at: Division of Clinical Informatics, Department of Medicine, Louisiana State University Health Sciences Center, PO Box 33932, Shreveport, LA 71130-3932, USA. <email>Nobel.Bhuiyan@lsuhs.edu</email> (M.A. Nobel Bhuiyan).</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><volume>585</volume><issue-id pub-id-type="pmc-issue-id">498505</issue-id><fpage>133</fpage><lpage>143</lpage><pub-history><event event-type="nihms-submitted"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2111435.pdf"/><abstract id="ABS1"><p id="P2">Early and accurate Alzheimer&#8217;s disease (AD) diagnosis is critical for effective intervention, but it is still challenging due to neurodegeneration&#8217;s slow and complex progression. Recent studies in brain imaging analysis have highlighted the crucial roles of deep learning techniques in computer-assisted interventions for diagnosing brain diseases. In this study, we propose AlzFormer, a novel deep learning framework based on a space&#8211;time attention mechanism, for multiclass classification of AD, MCI, and CN individuals using structural MRI scans. Unlike conventional deep learning models, we used spatiotemporal self-attention to model inter-slice continuity by treating T1-weighted MRI volumes as sequential inputs, where slices correspond to video frames. Our model was fine-tuned and evaluated using 1.5 T MRI scans from the ADNI dataset. To ensure the anatomical consistency of all the MRI data, All MRI volumes were pre-processed with skull stripping and spatial normalization to MNI space. AlzFormer achieved an overall accuracy of 94 % on the test set, with balanced class-wise F1-scores (AD: 0.94, MCI: 0.99, CN: 0.98) and a macro-average AUC of 0.98. We also utilized attention map analysis to identify clinically significant patterns, particularly emphasizing subcortical structures and medial temporal regions implicated in AD. These findings demonstrate the potential of transformer-based architectures for robust and interpretable classification of brain disorders using structural MRI.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>TimeSformer</kwd><kwd>Spatiotemporal</kwd><kwd>Attention</kwd><kwd>Deep learning</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P3">Dementia diagnostics are complex and require a significant amount of time following the onset of the first clinical symptoms. The average time required for the process is 2.8 years for late-onset dementia and 4.4 years for young-onset dementia (<xref rid="R40" ref-type="bibr">Van Vliet et al., 2013</xref>). Alzheimer&#8217;s disease (AD), the most common form of dementia, is a progressive and irreversible neurodegenerative condition marked by gradual deterioration in memory and cognitive function. Neuropathological changes related to AD are now believed to begin up to two decades prior to the emergence of clinical symptoms (<xref rid="R5" ref-type="bibr">Alp et al., 2024</xref>; <xref rid="R19" ref-type="bibr">Gelir et al., 2024</xref>). Early diagnosis of cognitive status is essential for the management and treatment of AD. Advancements in brain imaging techniques like Magnetic Resonance Imaging (MRI) have significantly impacted the diagnosis and prognosis of brain disorders in computer-assisted interventions (<xref rid="R17" ref-type="bibr">Fan et al., 2008</xref>). Therefore, many computer-aided approaches have been developed to enable more precise and efficient AD diagnosis (<xref rid="R23" ref-type="bibr">Jain et al., 2019</xref>; <xref rid="R15" ref-type="bibr">Ebrahimighahnavieh et al., 2020</xref>; <xref rid="R14" ref-type="bibr">Ebrahimi et al., 2021</xref>; <xref rid="R4" ref-type="bibr">Alinsaif et al., 2021</xref>; <xref rid="R31" ref-type="bibr">Loddo et al., 2022</xref>; <xref rid="R25" ref-type="bibr">Khojaste-Sarakhsi et al., 2022</xref>; <xref rid="R28" ref-type="bibr">Lin et al., 2023</xref>; <xref rid="R34" ref-type="bibr">Rangaraju et al., 2024</xref>; <xref rid="R12" ref-type="bibr">Chua et al., 2025</xref>).</p><p id="P4">Machine learning provides a structured approach for the automatic classification of brain disorders by learning complex and subtle patterns from high-dimensional neuroimaging data. From a technical standpoint, this task typically involves three key stages: pre-processing, feature extraction, and classifier learning. These components are crucial for effectively analyzing brain imaging data and supporting clinical diagnosis (<xref rid="R39" ref-type="bibr">Suk et al., 2017</xref>). On the other hand, deep learning (DL) eliminates the need for manual feature engineering by learning task-specific representations directly from the raw input data. Rather than depending on predefined features, DL models extract informative patterns during training in a label-guided, end-to-end manner. As a result, the learned features are directly optimized for the classification objective, which makes DL especially effective for complex and high-dimensional modalities such as brain MRI.</p><p id="P5">MRI is a complex modality that requires various strategies to manage and analyze volumetric brain data. These include voxel-based (<xref rid="R6" ref-type="bibr">Armana&#241;zas et al., 2017</xref>; <xref rid="R9" ref-type="bibr">Basaia et al., 2019</xref>; <xref rid="R38" ref-type="bibr">Solana-Lavalle and Rosas-Romero, 2021</xref>; <xref rid="R32" ref-type="bibr">Nemoto et al., 2021</xref>; <xref rid="R16" ref-type="bibr">Estudillo-Romero et al., 2022</xref>; <xref rid="R21" ref-type="bibr">Guan et al., 2022</xref>), region-of-interest (ROI)-based (<xref rid="R37" ref-type="bibr">Shinde et al., 2019</xref>; <xref rid="R1" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="R18" ref-type="bibr">Feng et al., 2022</xref>; <xref rid="R36" ref-type="bibr">Shi et al., 2022</xref>), patch-based (<xref rid="R20" ref-type="bibr">Goenka and Tiwari, 2022</xref>; <xref rid="R29" ref-type="bibr">Liu et al., 2023</xref>; <xref rid="R22" ref-type="bibr">Huang and Qiu, 2024</xref>), and slice-based (<xref rid="R14" ref-type="bibr">Ebrahimi et al., 2021</xref>; <xref rid="R42" ref-type="bibr">Zhang et al., 2022</xref>; <xref rid="R35" ref-type="bibr">Sharma et al., 2022</xref>; <xref rid="R7" ref-type="bibr">Avram et al., 2024</xref>; <xref rid="R2" ref-type="bibr">Akan et al., 2023</xref>) methods. Voxel-based approaches analyze the entire brain volume but involve high computational costs and may lose crucial contextual information. ROI-based methods focus on specific brain regions typically affected by neurodegenerative diseases (NDDs), but they may overlook abnormalities in other areas. Patch-based methods examine small segments of brain images, which can help detect early signs of disease with fine-grained detail. Slice-based approaches divide volumetric brain data into two-dimensional slices, but they often fail to capture spatial dependencies between adjacent slices, which are crucial for understanding disease progression. Despite these limitations, each method contributes valuable insights into brain pathology.</p><p id="P6">Nevertheless, one of the overarching challenges in MRI-based brain analysis remains the high dimensionality of the data, contrasted with the relatively small number of available labeled samples. While transfer learning is often used to address this limitation, most pre-trained models are based on 2D natural images and do not capture the spatial continuity present in 3D brain MRI. Slice-based approaches frequently rely on such 2D models, which limits their ability to model volumetric context. As a result, the transferability of these models to medical imaging tasks remains constrained. To overcome this, we propose leveraging pre-trained video models originally designed to handle sequential and spatiotemporal information and fine-tuning them on MRI data. By treating the MRI volume as a sequence of slices, these models can exploit inter-slice dependencies in a way that aligns more naturally with the structure of brain imaging data.</p><p id="P7">Following the trends and successes in medical image analysis and deep learning, convolutional neural networks (CNN) have become increasingly popular in recent years. Still, they have not been shown to outperform conventional classifiers significantly. Most CNN studies perform no to minimal pre-processing of structural MRI scans as input for their classifier. In contrast, others employ more extensive pre-processing strategies that have proven successful for conventional classifiers, such as gray matter (GM) density maps. Although CNNs are designed to extract high-level features from raw imaging data, dedicated pre-processing that enhances disease-related features may improve the learning process for complex tasks, reducing model complexity and allowing for a more stable learning process. It is still unclear whether CNNs outperform conventional classifiers in AD classification and whether they benefit from extensive MRI pre-processing (<xref rid="R11" ref-type="bibr">Bron et al., 2021</xref>).</p><p id="P8">Recent studies, however, have shown that using DL models trained on MRI volumes can improve AD classification accuracy. E.g., (<xref rid="R27" ref-type="bibr">Lian et al., 2020</xref>) proposed a hierarchical CNN designed to potentially learn both local and global features from 3D MRI volumes while achieving 90 % accuracy in AD vs. CN classification. (<xref rid="R8" ref-type="bibr">Backstrom et al., 2018</xref>) used a 3D ConvNet and emphasized the importance of patient-specific data splitting to prevent data leakage. Their findings revealed a performance gap of up to 10 % between random and subject-level splits, emphasizing the need for rigorous evaluation protocols. Wen et al. (<xref rid="R41" ref-type="bibr">Wen et al., 2020</xref>) further reported that nearly half of the published deep learning models for AD had data leakage, which was primarily caused by improper longitudinal data partitioning.</p><p id="P9">Recently, Transformer-based architectures have emerged as an alternative to CNNs for vision tasks, offering several advantages for modeling long-range dependencies and sequential information. Transformers have less restrictive inductive biases compared to CNNs. This broadens the range of functions they can represent (<xref rid="R13" ref-type="bibr">Cordonnier et al., 2019</xref>; <xref rid="R43" ref-type="bibr">Zhao et al., 2020</xref>) and makes them more appropriate for large-scale datasets requiring fewer strong inductive priors. Second, convolutional kernels have been designed to capture short-range spatiotemporal information; however, they cannot model dependencies that expand beyond the receptive field. Unlike CNNs, which primarily rely on local receptive fields, Transformers utilize attention mechanisms to capture global context, making them well-suited for processing medical imaging data with spatial or temporal structure. In particular, video-based Transformers can model sequential relationships across MRI slices, providing a natural way to exploit inter-slice continuity without requiring full 3D convolutions. Finally, transformers are faster to train than 3D convolutional networks, can achieve significantly better test efficiency (with a slight loss in accuracy), and can be used on far longer video clips (i.e., more MRI slices). Motivated by these properties, we explore using a pre-trained video Transformer model fine-tuned for the classification of AD, MCI, and CN using slice-based MRI data.</p><p id="P10">Recent studies have begun to explore the potential of Transformer models for neuroimaging-based classification tasks. E.g., Liu et al. (<xref rid="R29" ref-type="bibr">Liu et al., 2023</xref>) proposed the Multi-Modal Mixing Transformer (3MT), a cascaded attention architecture that amalgamates 3D MRI with as many as 12 clinical features. During training, 3MT uses a modality dropout mechanism, which allows it to remain robust in the face of missing data. The model attained cutting-edge results in both AD classification and mild cognitive impairment conversion tasks, with generalization validated on the AIBL dataset without the need for retraining. Additional studies, including (<xref rid="R26" ref-type="bibr">Kushol et al., 2022</xref>), have investigated dual-transformer methodologies functioning in spatial and frequency domains, thereby substantiating the efficacy of Transformers for AD-related imaging tasks.</p></sec><sec id="S2"><title>Materials and method</title><sec id="S3"><title>Study population</title><p id="P11">We used two datasets from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu" ext-link-type="uri">adni.loni.usc.edu</ext-link>). The ADNI was launched in 2003 as a public&#8211;private partnership led by Principal Investigator Michael W. Weiner, MD. Its primary objective is to determine whether clinical and neuropsychological assessments, serial magnetic resonance imaging (MRI), positron emission tomography (PET), and other biological markers can be integrated to track the progression of mild cognitive impairment (MCI) and early Alzheimer&#8217;s disease (AD). For the most up-to-date information, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.adni-info.org/" ext-link-type="uri">https://www.adni-info.org</ext-link>.</p><p id="P12">Our model was trained and evaluated using T1-weighted MRI scans from the &#8220;ADNI1: Complete 1Yr 1.5 T&#8221; data collection. The training set comprised 1951 scans (82 %), including 600 cognitively normal (NC), 946 with mild cognitive impairment (MCI), and 405 with Alzheimer&#8217;s disease (AD). The test set consisted of 342 scans (18 %) with 105 NC, 166 MCI, and 71 AD cases. Across both sets, participants had a mean age of 75 &#177; 6.6 years, with a balanced sex distribution: 1341 male and 953 female subjects. Further demographic details are summarized in <xref rid="T1" ref-type="table">Table 1</xref>.</p></sec><sec id="S4"><title>Pre-processing</title><p id="P13">Several steps are involved in the processing and analysis of sMRI data. The images must be aligned, registered to a standard template like MNI space, segmented into various tissue types like gray matter, white matter, and cerebrospinal fluid, and then subjected to voxel-based analyses (See <xref rid="F1" ref-type="fig">Fig. 1</xref>). Since image registration helps standardize MRI scans using a fixed-size template, it is essential to guarantee these images&#8217; spatial alignment.</p><p id="P14">To standardize the coordinates and align all of the images in a common reference frame, we used the Montreal Neurological Institute (MNI) space. To wrap MRI scans into the MNI-152 space, skull stripping, normalization, and image registration were carried out using CAT-12 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://neuro-jena.github.io/cat" ext-link-type="uri">https://neuro-jena.github.io/cat</ext-link>), a toolbox extension of SPM12 (<xref rid="R33" ref-type="bibr">Penny et al., 2011</xref>) designed for structural MRI pre-processing. The selection was also limited to the central 32 slices containing significant slices. The rest of the slices were excluded due to background information (None-brain area) unrelated to brain tissue.</p></sec><sec id="S5"><title>Classification</title><p id="P15">Video classification involves learning spatial and temporal patterns by analyzing visual features within individual frames (spatial) and changes across frames over time (temporal). TimeSformer (<xref rid="R10" ref-type="bibr">Bertasius et al., 2021</xref>) is a convolution-free approach to video classification based on self-attention over space and time. We fine-tuned TimeSformer to perform classification on MRI volume for AD diagnosis. In our context, each T1-weighted brain MRI volume is treated as a temporal sequence of 2D coronal slices, where each slice corresponds to a single &#8220;frame.&#8221; Our method, AlzFormer, enables direct spatiotemporal feature learning from sequences of MRI slice-level patches, capturing both intra-slice spatial patterns and inter-slice temporal dependencies critical for modeling progressive neurodegeneration.</p><p id="P16">Video classification involves learning spatial and temporal patterns by analyzing visual features within individual frames (spatial) and changes across frames over time (temporal). TimeSformer is a convolution-free approach to video classification based on self-attention over space and time. We fine-tuned TimeSformer to perform classification on MRI volume for AD diagnosis. In our context, each T1-weighted brain MRI volume is treated as a temporal sequence of 2D coronal slices, where each slice corresponds to a single &#8220;frame.&#8221; Our method, AlzFormer, enables direct spatiotemporal feature learning from sequences of MRI slice-level patches, capturing both intra-slice spatial patterns and inter-slice temporal dependencies critical for modeling progressive neurodegeneration.</p><p id="P17">Each MRI volume was sliced into 2D coronal images and tokenized into non-overlapping patches (e.g., 16 &#215; 16 pixels). These patches were flattened and linearly projected into embeddings, followed by the addition of learnable spatial and temporal positional encodings. The resulting patch embeddings were passed through the transformer layers of TimeSformer, where self-attention is computed separately across spatial and temporal dimensions. This design allows the model to capture local anatomical features and their dependencies across slices jointly.</p><p id="P18">We initialized the model with weights pre-trained on the Kinetics-400 (<xref rid="R24" ref-type="bibr">Kay et al., 2017</xref>) video dataset for training. We replaced the final classification layer to perform multiclass classification across three diagnostic categories: AD, MCI, and CN. We used cross-entropy loss function. Only the last transformer layer (layer 11) and the final classification head were unfrozen during fine-tuning. At the same time, the rest of the model remained frozen to preserve general visual representations learned from large-scale video data. The complete TimeSformer model contains approximately 121 million parameters, but we restricted training to 10,044,675 trainable parameters corresponding only to the last transformer layer and the classification head. The training was conducted using the AdamW optimizer with a learning rate 1e-4 and a weight decay of 1e-4. In addition, we utilized a Cosine Annealing Learning Rate Scheduler to gradually reduce the learning rate following a cosine function and improve convergence. In addition, the best-performing model (based on validation accuracy) was checkpointed for downstream use. An overview of the proposed classification pipeline using the fine-tuned TimeSformer model is illustrated in <xref rid="F1" ref-type="fig">Fig. 1</xref>.</p></sec></sec><sec id="S6"><title>Result</title><sec id="S7"><title>Classification performance</title><p id="P19">Classification performance was quantified by the classification accuracy, precision, recall f1-score, area under the curve (AUC), and accuracy. The models were optimized on the training set; the test set was applied only to assess the final model.</p><p id="P20">On the test set, AlzFormer achieved an overall accuracy of 97 %. As shown in <xref rid="T2" ref-type="table">Table 2</xref>, and confusion matrix <xref rid="F3" ref-type="fig">Fig. 3 (a)</xref>, the F1-scores for the three classes were 0.94 for AD, 0.99 for MCI, and 0.98 for cognitively normal (CN). The macro and weighted-average F1-scores were both 0.97, indicating balanced performance through the classes. Notably, no CN cases were misclassified as AD, and vice versa, indicating strong class separability between healthy controls and patients with dementia.</p><p id="P21">We computed the macro-averaged receiver operating characteristic (ROC) curve to assess the model&#8217;s discriminative performance across all classes. As illustrated in <xref rid="F3" ref-type="fig">Fig. 3 (b)</xref>, the model achieved a high AUC of 1, indicating excellent capability to distinguish between the three diagnostic categories. The steep rise in the curve close to the origin indicates a low false positive rate and high overall sensitivity across the classes.</p><p id="P22">We further compared the performance of a couple of baseline models, including CNN-BiLSTM, CNN-Transformer, ViT-BiLSTM, and ViT-Transformer, with our proposed model, AlzFormer. As shown in <xref rid="T3" ref-type="table">Table 3</xref>, AlzFormer outperforms all other models, achieving the highest accuracy, precision, recall, and F-score, demonstrating its effectiveness in Alzheimer&#8217;s disease classification. Moreover, the spider plot (See <xref rid="F2" ref-type="fig">Fig. 2</xref>) visually illustrates that <bold>AlzFormer</bold> consistently outperforms all baseline models, achieving superior scores in every metric, which further confirms the quantitative results presented in <xref rid="T3" ref-type="table">Table 3</xref>.</p><p id="P23">Based on overall performance across all metrics, AlzFormer ranks first, with ViT-Transformer coming in second with 0.91 accuracy and 0.90 F1-score. With identical scores (0.90 accuracy and 0.89 F1-score), CNN-BiLSTM and CNN-Transformer are tied for third place, while ViT-BiLSTM ranks lowest with slightly lower recall and F1-score (0.89). This ranking underscores the benefit of integrating spatial and temporal attention in AlzFormer to achieve precise and resilient MRI-based classification.</p></sec><sec id="S8"><title>Model analysis and representation</title><p id="P24">We visualized class-specific attention maps over the input MRI slices for CN, MCI, and AD cases to better understand the model&#8217;s decision-making process. As shown in <xref rid="F4" ref-type="fig">Figs. 4</xref>&#8211;<xref rid="F6" ref-type="fig">6</xref>, the TimeSformer model attends to distinct brain regions depending on the diagnostic category.</p><p id="P25">As illustrated in <xref rid="F4" ref-type="fig">Fig. 4</xref>, the model&#8217;s attention in a representative AD subject primarily focuses on the medial temporal lobe, particularly the hippocampus and Para hippocampal gyrus, across central coronal slices. Additional regions receiving attention include the putamen, thalamus, and posterior cingulate cortex, indicating the model&#8217;s sensitivity to both limbic and subcortical structures affected by AD. These patterns are consistent with established neuropathological progression and highlight the model&#8217;s ability to capture clinically relevant features.</p><p id="P26">As shown in <xref rid="F5" ref-type="fig">Fig. 5</xref>, the model&#8217;s attention in a representative MCI subject is more diffusely distributed than AD, with a prominent focus on medial temporal structures, including the hippocampus and the putamen, thalamus, and posterior cingulate cortex. These activations reflect early-stage alterations commonly associated with MCI, indicating that the model captures subtle changes in limbic and subcortical regions before progressing to AD.</p><p id="P27">As shown in <xref rid="F6" ref-type="fig">Fig. 6</xref>, the model&#8217;s attention in a representative cognitively normal subject appears more dispersed and less concentrated in canonical Alzheimer&#8217;s-related regions. Mild activations are observed in areas such as the putamen, precuneus, and occipital cortex but without the strong or consistent focus seen in MCI or AD cases. This pattern suggests the model recognizes the absence of pathological hallmarks and distributes attention more broadly, potentially reflecting the lower discriminative need in the absence of disease.</p><p id="P28">It is important to note that while the attention heatmaps frequently highlight regions such as the hippocampus and thalamus&#8212;structures commonly implicated in AD&#8212;they are <bold>not disease-specific</bold>. Similar structural changes may also occur during normal aging or in other neurodegenerative conditions. The attention maps simply reflect the regions that the model found statistically useful for classification within the given data distribution, rather than exclusive AD biomarkers. This distinction is critical for proper interpretation of model explanations.</p><p id="P29">To have better visual comparison across clinical groups, <xref rid="F7" ref-type="fig">Fig. 7</xref> presents attention heatmaps at the 48<sup>th</sup> slice from three different representative subjects corresponding to the CN, MCI, and AD classes. This fixed-slice view allows direct assessment of how the model distributes spatial attention at the same anatomical location. The medial temporal region, which is commonly impacted by structural degeneration, is the primary focus of attention in the AD subject. The MCI subject shows more diffuse and bilateral attention, reflecting intermediate anatomical changes, while the CN subject exhibits low-intensity and spatially uniform attention. These differences show that the model adjusts spatial attention to group-specific structural MRI anatomical features.</p><p id="P30"><xref rid="F8" ref-type="fig">Fig. 8</xref> illustrates the temporal attention heatmaps at sagittal slice 48 for AD, MCI, and CN. The CN subject&#8217;s attention seems to be low-intensity and diffuse, suggesting that there is minimal focus in all three spatial dimensions. In contrast, the MCI subject shows slightly more structured yet sparse activation, particularly along horizontal bands. Notably, the AD subject exhibits more focused and intense temporal attention distributed along consistent spatial regions. This implies that the model has acquired the ability to selectively focus on temporally informative regions, which may be indicative of pathological progression as captured by slice-level dynamics.</p><p id="P31"><xref rid="F11" ref-type="fig">Fig. 11</xref>. Chord diagrams illustrate feature similarity patterns after PCA-based dimensionality reduction for each diagnostic group: (a) AD, (b) MCI, and (c) CN. Each diagram visualizes pairwise cosine similarity between principal components of extracted features. 60 components were selected using PCA to retain the most informative dimensions of the feature space. The AD subject exhibits more focused and localized feature interactions, while MCI and CN subjects demonstrate broader, more diffuse connectivity patterns, reflecting differing representational structures across diagnostic stages.</p><p id="P32">Transformers are inherently permutation-invariant and thus require positional information to model spatial or sequential relationships in the input data. In TimeSformer, this is achieved through learned positional embeddings. We visualized the similarity between positional embeddings by computing pairwise dot-product similarity across patch indices to understand how spatial structure is captured. In <xref rid="F9" ref-type="fig">Fig. 9 (a)</xref>, the similarity matrix&#8217;s diagonal structure indicates the positional encoding&#8217;s spatial locality. Patches that are close together in the original image tend to have more similar positional embeddings, allowing the model to preserve relative spatial information even without convolutions.</p><p id="P33">The non-overlapping patches from MRI slices were used in the TimeSformer model to flatten each patch. We then applied a linear projection to convert the patches into an embedding. While these projections are not convolutional filters in the classical sense, visualizing them reveals structured and interpretable patterns. <xref rid="F9" ref-type="fig">Fig. 9 (b)</xref> shows that many projection weights resemble edge detectors, circular patterns, or textured gradients&#8212;like the early-layer kernels of CNNs. This indicated that, despite lacking explicit convolutions, TimeSformer still captured localized spatial structure and provided informative representations for brain disorder classification.</p><p id="P34">We analyzed the mean attention distance (MAD) across attention heads and transformer blocks to investigate the spatial behavior of the model. The attention model&#8217;s local and global patterns were measured using MAD. For each token, the geometric distance to all other tokens is weighted by the corresponding attention scores and then averaged across all tokens. As shown in <xref rid="F10" ref-type="fig">Fig. 10</xref>, we compute the MAD for each attention head across all transformer blocks of AlzFormer. The early layers from nearby tokens identified localized attention, and global attention patterns were identified using deeper layers. This gradual receptive field expansion captures fine-grained local features and global context across the MRI slices.</p></sec></sec><sec id="S9"><title>Discussion</title><p id="P35">This work aimed to explore using video-based deep learning models to diagnose AD. More specifically, we examine whether video modeling approaches that treat sequential MRI scans as video frames can effectively capture spatiotemporal patterns for classifying individuals into AD, MCI, and CN categories. The model was trained and evaluated on 1.5 Tesla MRI scan data from the public ADNI dataset. AlzFormer achieved 94 % accuracy on a test set, with F1-scores of 0.94 for AD, 0.99 for MCI, and 0.99 for CN, indicating balanced performance across the classes, with macro and weighted-average F1-scores of 0.97.</p><p id="P36">We compared AlzFormer with four state-of-the-art models: CNN-BiLSTM, CNN-Transformer, ViT-BiLSTM, and ViT-Transformer in order to evaluate its effectiveness. These models were consistently outperformed by AlzFormer in all evaluation metrics. It was the foremost model in terms of classification accuracy, precision, recall, and F1-score, with ViT-Transformer following as the second-best model. This comparative analysis highlights the enhanced efficacy of AlzFormer in modeling 3D brain MRI data, according to its spatiotemporal attention mechanism.</p><p id="P37">Although deep learning models have proved remarkable performance in brain disorder classification tasks, they are commonly called &#8220;black-box&#8221; systems because they are unable to interpret the results. This limitation raises concerns, particularly in clinical applications where understanding model decisions is essential. We addressed this problem by visualizing attention heatmaps for representative subjects from each diagnostic group across MRI slices (<xref rid="F4" ref-type="fig">Figs. 4</xref>&#8211;<xref rid="F6" ref-type="fig">6</xref>). These visualizations reveal which brain regions the model focuses on during prediction, revealing spatial patterns that influence classification outcomes. The heatmaps, which highlight discriminative regions, show that the model does not learn unquestioningly but rather captures disease-relevant features in the input. This promotes trust in model behavior and allows for neuroscientific validation of learned representations.</p><p id="P38">Transformers, particularly in video-based configurations, present potential for MRI-based classification. Using spatiotemporal self-attention, these models can learn inter-slice temporal relationships and intra-slice spatial features. This is an essential capability for capturing the progressive nature of neurodegenerative diseases. Our approach utilizes this architecture by treating MRI volumes as sequences of slices, allowing the model to exploit structural continuity without the complexity of full 3D convolutions. Additionally, using a pre-trained video model reduces reliance on extensive medical records and enables effective transfer learning from natural video domains. Regardless of the advantages of the transformer model, it requires a significant amount of time for computation, including extensive fine-tuning and pre-processing. Another limitation of our current model setup is it requires high-resolution MRI or MRI slices from 96 to form a meaningful spatiotemporal sequence. The model&#8217;s performance may degrade in clinical settings with lower-resolution acquisitions or fewer slices of MRI. However, pre-trained TimeSformer variants designed for shorter input sequences (e.g., 16 slices) offer potential compatibility.</p><p id="P39">Despite our proposed model&#8217;s high performance, this study has a few limitations. First, our approach is solely based on structural MRI data and does not take into account multimodal inputs like clinical scores, cognitive assessments, or genetic biomarkers, which could improve diagnostic accuracy and clinical utility. Second, our model uses cross-sectional classification and does not account for disease progression, such as transitions from CN to MCI or MCI to AD. Modeling longitudinal changes necessitates follow-up imaging and progression labels, which are absent in our current dataset.</p><p id="P40">Future research should investigate the incorporation of multimodal data, encompassing cognitive assessments and genetic information, to enhance classification robustness and clinical significance. Furthermore, the integration of longitudinal MRI data would facilitate the creation of models capable of forecasting disease progression from CN to MCI and from MCI to AD. Progression-aware models may offer earlier and more tailored insights into disease trajectories, enhancing both diagnosis and prognosis in clinical environments.</p></sec><sec id="S10"><title>Conclusion</title><p id="P41">In this study, we introduced AlzFormer, a video-based deep learning framework that leverages spatiotemporal self-attention to classify Alzheimer&#8217;s disease, mild cognitive impairment, and cognitively normal subjects using structural MRI. By treating MRI volumes as slice-level sequences and fine-tuning a pre-trained TimeSformer model, our approach effectively captured intra-slice spatial features and inter-slice dependencies. AlzFormer&#8217;s overall accuracy on the test set was 94 %, with balanced class-wise F1-scores (AD: 0.94, MCI: 0.99, CN: 0.98) and an AUC of 1. This high classification performance on a test set demonstrates strong generalization under inter-scanner and inter-site variability. Furthermore, attention-based interpretability analyses revealed disease-relevant activation patterns, confirming that the model is clinically relevant. For future work, we may use longitudinal data to model disease trajectories over time, as AD is, by nature, a progressive process. This would allow for early-stage diagnosis and tracking of Alzheimer&#8217;s&#8217; progression.</p></sec></body><back><ack id="S11"><title>Acknowledgments</title><p id="P42">Data collection and sharing for this project were funded by the Alzheimer&#8217;s&#8217; Disease Neuroimaging Initiative (ADNI), the National Institutes of Health (Grant U01 AG024904), and the DOD ADNI Department of Defense (award number W81XWH-12&#8211;2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer&#8217;s&#8217; Association; Alzheimer&#8217;s&#8217; Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Co.; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Co.; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC; Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fnih.org/" ext-link-type="uri">http://www.fnih.org</ext-link>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer&#8217;s&#8217; Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.</p><sec id="S12"><title>Funding</title><p id="P43">This work was supported by an Institutional Development Award (IDeA) from the National Institutes of General Medical Sciences NIH under grant number P20GM121307 to MANB, NIH grants R01HL172970, R01HL145753, R01HL145753&#8211;01S1, and R01HL145753&#8211;03S1 to MSB; and Institutional Development Award (IDeA) from the National Institutes of General Medical Sciences of the NIH under grant number P20GM121307 and R01HL149264 to CGK. This project is also partially supported by Ike Muslow, MD, Endowed Chair in Healthcare Informatics of LSU Health Sciences Center Shreveport.</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P45">Declaration of Competing Interest</p><p id="P46">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn><fn fn-type="COI-statement" id="FN3"><p id="P47"><bold>Competing Interests:</bold> The authors declare no potential competing interests.</p></fn><fn id="FN4"><p id="P48">CRediT authorship contribution statement</p><p id="P49"><bold>Taymaz Akan:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Methodology, Conceptualization. <bold>Sara Akan:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Sait Alp:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Christina Raye Ledbetter:</bold> Writing &#8211; review &amp; editing. <bold>Mohammad Alfrad Nobel Bhuiyan:</bold> Writing &#8211; review &amp; editing.</p></fn><fn id="FN5"><p id="P50"><bold>Ethical Approval and Consent to participate:</bold> Not applicable.</p></fn><fn id="FN6"><p id="P51"><bold>Human Ethics:</bold> Not applicable.</p></fn><fn id="FN7"><p id="P52"><bold>Consent for publication:</bold> Not applicable.</p></fn><fn id="FN8"><p id="P53">Replication of results</p><p id="P54">The codes and data used are available on request to enable the method proposed in the manuscript to be replicated by readers.</p></fn></fn-group><sec sec-type="data-availability" id="S13"><title>Data availability</title><p id="P44">The data are available on the ADNI website for download.</p></sec><ref-list><title>References</title><ref id="R1"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name>, <year>2020</year>. <article-title>Ensemble of ROI-based convolutional neural network classifiers for staging the Alzheimer disease spectrum from magnetic resonance imaging</article-title>. <source>PLoS One</source><volume>15</volume> (<issue>12</issue>), <fpage>e0242712</fpage>. <pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0242712</pub-id>.<pub-id pub-id-type="pmid">33290403</pub-id><pub-id pub-id-type="pmcid">PMC7723284</pub-id></mixed-citation></ref><ref id="R2"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Akan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alp</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>MAN</given-names></name>, <conf-date>2023</conf-date>. <source>Vision Transformers and Bi-LSTM for Alzheimer&#8217;s Disease Diagnosis from 3D MRI</source>. In <conf-name>2023 Congress in Computer Science, Computer Engineering, &amp; Applied Computing (CSCE)</conf-name> (pp. <fpage>530</fpage>&#8211;<lpage>535</lpage>). <publisher-name>IEEE</publisher-name>.</mixed-citation></ref><ref id="R3"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Akan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alp</surname><given-names>S</given-names></name>, &amp; <name name-style="western"><surname>Bhuiyan</surname><given-names>MAN</given-names></name>, <conf-date>2023</conf-date>. <source>Vision Transformers and Bi-LSTM for Alzheimer&#8217;s Disease Diagnosis from 3D MRI</source>. In <conf-name>2023 Congress in Computer Science, Computer Engineering, &amp; Applied Computing (CSCE)</conf-name> (pp. <fpage>530</fpage>&#8211;<lpage>535</lpage>). <publisher-name>IEEE</publisher-name>.</mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><name name-style="western"><surname>Alinsaif</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name>, <year>2021</year>. <article-title>3D shearlet-based descriptors combined with deep features for the classification of Alzheimer&#8217;s disease based on MRI data</article-title>. <source>Comput. Biol. Med</source>. <volume>138</volume>, <fpage>104879</fpage>.<pub-id pub-id-type="pmid">34598071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2021.104879</pub-id></mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><name name-style="western"><surname>Alp</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Akan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Disbrow</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Conrad</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Vanchiere</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>MAN</given-names></name>, <year>2024</year>. <article-title>Joint transformer architecture in brain 3D MRI classification: its application in Alzheimer&#8217;s disease classification</article-title>. <source>Sci. Rep</source>. <volume>14</volume> (<issue>1</issue>), <fpage>8996</fpage>.<pub-id pub-id-type="pmid">38637671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-59578-3</pub-id><pub-id pub-id-type="pmcid">PMC11026447</pub-id></mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><name name-style="western"><surname>Arma&#241;anzas</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Iglesias</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Morales</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Alonso-Nanclares</surname><given-names>L</given-names></name>, <year>2017</year>. <article-title>Voxel-based diagnosis of Alzheimer&#8217;s disease using classifier ensembles</article-title>. <source>IEEE J. Biomed. Health Inform</source>. <volume>21</volume> (<issue>3</issue>), <fpage>778</fpage>&#8211;<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1109/JBHI.2016.2538559</pub-id>.<pub-id pub-id-type="pmid">28113481</pub-id></mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><name name-style="western"><surname>Avram</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Durmus</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rakocz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Corradetti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>An</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Nittala</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Halperin</surname><given-names>E</given-names></name>, <year>2024</year>. <article-title>Accurate prediction of disease-risk factors from volumetric medical scans by a deep vision model pre-trained with 2D scans</article-title>. <source>Nat. Biomed. Eng</source>. <volume>2024</volume>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-024-01257-9</pub-id>.<pub-id pub-id-type="pmid">39354052</pub-id></mixed-citation></ref><ref id="R8"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Backstrom</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nazari</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>IYH</given-names></name>, <name name-style="western"><surname>Jakola</surname><given-names>AS</given-names></name>, <conf-date>2018</conf-date>. <source>An efficient 3D deep convolutional network for Alzheimer&#8217;s disease diagnosis using MR images</source>. <conf-name>Proceedings - International Symposium on Biomedical Imaging, 2018-April</conf-name>, <fpage>149</fpage>&#8211;<lpage>153</lpage>. doi: <pub-id pub-id-type="doi">10.1109/ISBI.2018.8363543</pub-id>.</mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><name name-style="western"><surname>Basaia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Agosta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Canu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Magnani</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Santangelo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name>, <year>2019</year>. <article-title>Automated classification of Alzheimer&#8217;s disease and mild cognitive impairment using a single MRI and deep neural networks</article-title>. <source>NeuroImage: Clinical</source><volume>21</volume>, <fpage>101645</fpage>. <pub-id pub-id-type="doi">10.1016/J.NICL.2018.101645</pub-id>.<pub-id pub-id-type="pmid">30584016</pub-id><pub-id pub-id-type="pmcid">PMC6413333</pub-id></mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bertasius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Torresani</surname><given-names>L</given-names></name>, <year>2021</year>. <article-title>Is space-time attention all you need for video understanding?</article-title><source>In ICML</source> (Vol. <volume>2</volume>, p. <fpage>4</fpage>).</mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bron</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Papma</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Jiskoot</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Venkatraghavan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Linders</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Claassen</surname><given-names>JAHR</given-names></name>, <year>2021</year>. <article-title>Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer&#8217;s disease</article-title>. <source>NeuroImage: Clinical</source><volume>31</volume>, <fpage>102712</fpage>.<pub-id pub-id-type="pmid">34118592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2021.102712</pub-id><pub-id pub-id-type="pmcid">PMC8203808</pub-id></mixed-citation></ref><ref id="R12"><mixed-citation publication-type="journal"><name name-style="western"><surname>Chua</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Antochi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Toma</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CL</given-names></name>, <year>2025</year>. <article-title>Utilizing deep learning to predict Alzheimer&#8217;s disease and mild cognitive impairment with optical coherence tomography</article-title>. <source>Alzheimer&#8217;s &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source><volume>17</volume> (<issue>1</issue>), <fpage>e70041</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.70041</pub-id><pub-id pub-id-type="pmcid">PMC11730192</pub-id><pub-id pub-id-type="pmid">39811700</pub-id></mixed-citation></ref><ref id="R13"><mixed-citation publication-type="journal"><name name-style="western"><surname>Cordonnier</surname><given-names>J-B</given-names></name>, <name name-style="western"><surname>Loukas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jaggi</surname><given-names>M</given-names></name>, <year>2019</year>. <article-title>On the relationship between self-attention and convolutional layers</article-title>. <source>arXiv preprint arXiv</source>:1911.03584.</mixed-citation></ref><ref id="R14"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ebrahimi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chiong</surname><given-names>R</given-names></name>, <year>2021</year>. <article-title>Deep sequence modelling for Alzheimer&#8217;s disease detection using MRI</article-title>. <source>Comput. Biol. Med</source>. <volume>134</volume>, <fpage>104537</fpage>. <pub-id pub-id-type="doi">10.1016/J.COMPBIOMED.2021.104537</pub-id>.<pub-id pub-id-type="pmid">34118752</pub-id></mixed-citation></ref><ref id="R15"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ebrahimighahnavieh</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chiong</surname><given-names>R</given-names></name>, <year>2020</year>. <article-title>Deep learning to detect Alzheimer&#8217;s disease from neuroimaging: a systematic literature review</article-title>. <source>Comput. Methods Programs Biomed</source>. <volume>187</volume>, <fpage>105242</fpage>. <pub-id pub-id-type="doi">10.1016/J.CMPB.2019.105242</pub-id>.<pub-id pub-id-type="pmid">31837630</pub-id></mixed-citation></ref><ref id="R16"><mixed-citation publication-type="journal"><name name-style="western"><surname>Estudillo-Romero</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Haegelen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jannin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>JSH</given-names></name>, <year>2022</year>. <article-title>Voxel-based diktiometry: Combining convolutional neural networks with voxel-based analysis and its application in diffusion tensor imaging for Parkinson&#8217;s disease</article-title>. <source>Hum. Brain Mapp</source>. <volume>43</volume> (<issue>16</issue>), <fpage>4835</fpage>&#8211;<lpage>4851</lpage>. <pub-id pub-id-type="doi">10.1002/HBM.26009</pub-id>.<pub-id pub-id-type="pmid">35841274</pub-id><pub-id pub-id-type="pmcid">PMC9582380</pub-id></mixed-citation></ref><ref id="R17"><mixed-citation publication-type="journal"><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Batmanghelich</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Davatzikos</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name>, <year>2008</year>. <article-title>Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline</article-title>. <source>Neuroimage</source><volume>39</volume> (<issue>4</issue>), <fpage>1731</fpage>&#8211;<lpage>1743</lpage>.<pub-id pub-id-type="pmid">18053747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2007.10.031</pub-id><pub-id pub-id-type="pmcid">PMC2861339</pub-id></mixed-citation></ref><ref id="R18"><mixed-citation publication-type="journal"><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <year>2022</year>. <article-title>Extracting ROI-based contourlet subband energy feature from the sMRI image for Alzheimer&#8217;s disease classification. IEEE/ACM Trans</article-title>. <source>Comput. Biol. Bioinf</source>. <volume>19</volume> (<issue>3</issue>), <fpage>1627</fpage>&#8211;<lpage>1639</lpage>. <pub-id pub-id-type="doi">10.1109/TCBB.2021.3051177</pub-id>.<pub-id pub-id-type="pmid">33434134</pub-id></mixed-citation></ref><ref id="R19"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gelir</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Akan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alp</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gecili</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Disbrow</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>(ADNI)</surname><given-names>ADNI</given-names></name>, <year>2024</year>. <article-title>Machine learning approaches for predicting progression to Alzheimer&#8217;s disease in patients with mild cognitive impairment</article-title>. <source>J. Med. Biol. Eng</source>. <fpage>1</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40846-024-00918-z</pub-id><pub-id pub-id-type="pmcid">PMC11876274</pub-id><pub-id pub-id-type="pmid">40046733</pub-id></mixed-citation></ref><ref id="R20"><mixed-citation publication-type="journal"><name name-style="western"><surname>Goenka</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>S</given-names></name>, <year>2022</year>. <article-title>AlzVNet: a volumetric convolutional neural network for multiclass classification of Alzheimer&#8217;s disease through multiple neuroimaging computational approaches</article-title>. <source>Biomed. Signal Process. Control</source><volume>74</volume>, <fpage>103500</fpage>. <pub-id pub-id-type="doi">10.1016/J.BSPC.2022.103500</pub-id>.</mixed-citation></ref><ref id="R21"><mixed-citation publication-type="journal"><name name-style="western"><surname>Guan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <year>2022</year>. <article-title>A parallel attention-augmented bilinear network for early magnetic resonance imaging-based diagnosis of Alzheimer&#8217;s disease</article-title>. <source>Hum. Brain Mapp</source>. <volume>43</volume> (<issue>2</issue>), <fpage>760</fpage>&#8211;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1002/HBM.25685</pub-id>.<pub-id pub-id-type="pmid">34676625</pub-id><pub-id pub-id-type="pmcid">PMC8720194</pub-id></mixed-citation></ref><ref id="R22"><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>A</given-names></name>, <year>2024</year>. <article-title>Ensemble vision transformer for dementia diagnosis</article-title>. <source>IEEE J. Biomed. Health Inform</source>. <pub-id pub-id-type="doi">10.1109/JBHI.2024.3412812</pub-id>.<pub-id pub-id-type="pmid">38889030</pub-id></mixed-citation></ref><ref id="R23"><mixed-citation publication-type="journal"><name name-style="western"><surname>Jain</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Aggarwal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hemanth</surname><given-names>DJ</given-names></name>, <year>2019</year>. <article-title>Convolutional neural network based Alzheimer&#8217;s disease classification from magnetic resonance brain images</article-title>. <source>Cogn. Syst. Res</source>. <volume>57</volume>, <fpage>147</fpage>&#8211;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/J.COGSYS.2018.12.015</pub-id>.</mixed-citation></ref><ref id="R24"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kay</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Carreira</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Simonyan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hillier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vijayanarasimhan</surname><given-names>S</given-names></name>, &#8230; <name name-style="western"><surname>Natsev</surname><given-names>P</given-names></name>, <year>2017</year>. <article-title>The kinetics human action video dataset</article-title>. <source>arXiv preprint arXiv</source>: 1705.06950.</mixed-citation></ref><ref id="R25"><mixed-citation publication-type="journal"><name name-style="western"><surname>Khojaste-Sarakhsi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haghighi</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Ghomi</surname><given-names>SMTF</given-names></name>, <name name-style="western"><surname>Marchiori</surname><given-names>E</given-names></name>, <year>2022</year>. <article-title>Deep learning for Alzheimer&#8217;s disease diagnosis: a survey</article-title>. <source>Artif. Intell. Med</source>. <volume>130</volume>, <fpage>102332</fpage>. <pub-id pub-id-type="doi">10.1016/J.ARTMED.2022.102332</pub-id>.<pub-id pub-id-type="pmid">35809971</pub-id></mixed-citation></ref><ref id="R26"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Kushol</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Masoumzadeh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kalra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>YH</given-names></name>, <conf-date>2022</conf-date>. <source>Addformer: Alzheimer&#8217;s disease detection from structural mri using fusion transformer</source>. <conf-name>Proceedings - International Symposium on Biomedical Imaging, 2022-March</conf-name>. doi: <pub-id pub-id-type="doi">10.1109/ISBI52829.2022.9761421</pub-id>.</mixed-citation></ref><ref id="R27"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lian</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>D</given-names></name>, <year>2020</year>. <article-title>Hierarchical fully convolutional network for joint atrophy localization and Alzheimer&#8217;s disease diagnosis using structural MRI</article-title>. <source>IEEE Trans. Pattern Anal. Mach. Intell</source>. <volume>42</volume> (<issue>4</issue>), <fpage>880</fpage>&#8211;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1109/TPAMI.2018.2889096</pub-id>.<pub-id pub-id-type="pmid">30582529</pub-id><pub-id pub-id-type="pmcid">PMC6588512</pub-id></mixed-citation></ref><ref id="R28"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J</given-names></name>, <conf-date>2023</conf-date>. <source>Attention-based Efficient Classification for 3D MRI image of Alzheimer&#8217;s Disease</source>. In: <conf-name>In Proceedings of the 2023 6th International Conference on Sensors, Signal and Image Processing</conf-name>, pp. <fpage>34</fpage>&#8211;<lpage>39</lpage>.</mixed-citation></ref><ref id="R29"><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>To</surname><given-names>XV</given-names></name>, <name name-style="western"><surname>Nasrallah</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Chandra</surname><given-names>SS</given-names></name>, <year>2023</year>. <article-title>Cascaded multi-modal mixing transformers for Alzheimer&#8217;s disease classification with incomplete data</article-title>. <source>Neuroimage</source><volume>277</volume>, <fpage>120267</fpage>. <pub-id pub-id-type="doi">10.1016/J.NEUROIMAGE.2023.120267</pub-id>.<pub-id pub-id-type="pmid">37422279</pub-id></mixed-citation></ref><ref id="R30"><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Sheng</surname><given-names>B</given-names></name>, <year>2023</year>. <article-title>Patch-based deep multi-modal learning framework for Alzheimer&#8217;s disease diagnosis using multi-view neuroimaging</article-title>. <source>Biomed. Signal Process. Control</source><volume>80</volume>, <fpage>104400</fpage>. <pub-id pub-id-type="doi">10.1016/J.BSPC.2022.104400</pub-id>.</mixed-citation></ref><ref id="R31"><mixed-citation publication-type="journal"><name name-style="western"><surname>Loddo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Buttau</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Di Ruberto</surname><given-names>C</given-names></name>, <year>2022</year>. <article-title>Deep learning based pipelines for Alzheimer&#8217;s disease diagnosis: a comparative study and a novel deep-ensemble method</article-title>. <source>Comput. Biol. Med</source>. <volume>141</volume>, <fpage>105032</fpage>. <pub-id pub-id-type="doi">10.1016/J.COMPBIOMED.2021.105032</pub-id>.<pub-id pub-id-type="pmid">34838263</pub-id></mixed-citation></ref><ref id="R32"><mixed-citation publication-type="journal"><name name-style="western"><surname>Nemoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sakaguchi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kasai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hotta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kamei</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Noguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Asada</surname><given-names>T</given-names></name>, <year>2021</year>. <article-title>Differentiating dementia with lewy bodies and Alzheimer&#8217;s disease by deep learning to structural MRI</article-title>. <source>J. Neuroimaging</source><volume>31</volume> (<issue>3</issue>), <fpage>579</fpage>&#8211;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1111/JON.12835</pub-id>.<pub-id pub-id-type="pmid">33476487</pub-id></mixed-citation></ref><ref id="R33"><mixed-citation publication-type="book"><name name-style="western"><surname>Penny</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Friston</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Ashburner</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Kiebel</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Nichols</surname><given-names>TE</given-names></name>, <year>2011</year>. <source>Statistical parametric mapping: the analysis of functional brain images</source>. <publisher-name>Elsevier</publisher-name>.</mixed-citation></ref><ref id="R34"><mixed-citation publication-type="journal"><name name-style="western"><surname>Rangaraju</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chinnadurai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Natarajan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Raja</surname><given-names>V</given-names></name>, <year>2024</year>. <article-title>Dual attention aware octave convolution network for early-stage Alzheimer&#8217;s disease detection</article-title>. <source>Information Technology and Control</source><volume>53</volume> (<issue>1</issue>), <fpage>302</fpage>&#8211;<lpage>316</lpage>.</mixed-citation></ref><ref id="R35"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Goel</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tanveer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Murugan</surname><given-names>R</given-names></name>, <year>2022</year>. <article-title>FDN-ADNet: Fuzzy LS-TWSVM based deep learning network for prognosis of the Alzheimer&#8217;s disease using the sagittal plane of MRI scans</article-title>. <source>Appl. Soft Comput</source>. <volume>115</volume>, <fpage>108099</fpage>. <pub-id pub-id-type="doi">10.1016/J.ASOC.2021.108099</pub-id>.</mixed-citation></ref><ref id="R36"><mixed-citation publication-type="journal"><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>K</given-names></name>, <year>2022</year>. <article-title>Classification of Parkinson&#8217;s disease using a region-of-interest- and resting-state functional magnetic resonance imaging-based radiomics approach</article-title>. <source>Brain Imaging Behav</source>. <volume>16</volume> (<issue>5</issue>), <fpage>2150</fpage>&#8211;<lpage>2163</lpage>. <pub-id pub-id-type="doi">10.1007/S11682-022-00685-Y/FIGURES/6</pub-id>.<pub-id pub-id-type="pmid">35650376</pub-id></mixed-citation></ref><ref id="R37"><mixed-citation publication-type="journal"><name name-style="western"><surname>Shinde</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Saboo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kaushick</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Saini</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pal</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Ingalhalikar</surname><given-names>M</given-names></name>, <year>2019</year>. <article-title>Predictive markers for Parkinson&#8217;s disease using deep neural nets on neuromelanin sensitive MRI. NeuroImage</article-title>: <source>Clinical</source><volume>22</volume>, <fpage>101748</fpage>. <pub-id pub-id-type="doi">10.1016/J.NICL.2019.101748</pub-id>.<pub-id pub-id-type="pmcid">PMC6417260</pub-id><pub-id pub-id-type="pmid">30870733</pub-id></mixed-citation></ref><ref id="R38"><mixed-citation publication-type="journal"><name name-style="western"><surname>Solana-Lavalle</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rosas-Romero</surname><given-names>R</given-names></name>, <year>2021</year>. <article-title>Classification of PPMI MRI scans with voxel-based morphometry and machine learning to assist in the diagnosis of Parkinson&#8217;s disease</article-title>. <source>Comput. Methods Programs Biomed</source>. <volume>198</volume>, <fpage>105793</fpage>. <pub-id pub-id-type="doi">10.1016/J.CMPB.2020.105793</pub-id>.<pub-id pub-id-type="pmid">33099263</pub-id></mixed-citation></ref><ref id="R39"><mixed-citation publication-type="journal"><name name-style="western"><surname>Suk</surname><given-names>H-I</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S-W</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name>, <year>2017</year>. <article-title>Deep ensemble learning of sparse regression models for brain disease diagnosis</article-title>. <source>Med. Image Anal</source>. <volume>37</volume>, <fpage>101</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="pmid">28167394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2017.01.008</pub-id><pub-id pub-id-type="pmcid">PMC5808465</pub-id></mixed-citation></ref><ref id="R40"><mixed-citation publication-type="journal"><name name-style="western"><surname>Van Vliet</surname><given-names>D</given-names></name>, <name name-style="western"><surname>De Vugt</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Bakker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pijnenburg</surname><given-names>YAL</given-names></name>, <name name-style="western"><surname>Vernooij-Dassen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Koopmans</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Verhey</surname><given-names>FRJ</given-names></name>, <year>2013</year>. <article-title>Time to diagnosis in young-onset dementia as compared with late-onset dementia</article-title>. <source>Psychol. Med</source>. <volume>43</volume> (<issue>2</issue>), <fpage>423</fpage>&#8211;<lpage>432</lpage>.<pub-id pub-id-type="pmid">22640548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291712001122</pub-id></mixed-citation></ref><ref id="R41"><mixed-citation publication-type="journal"><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thibeau-Sutre</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Diaz-Melo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Samper-Gonz&#225;lez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Routier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bottani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Colliot</surname><given-names>O</given-names></name>, <year>2020</year>. <article-title>Convolutional neural networks for classification of Alzheimer&#8217;s disease: Overview and reproducible evaluation</article-title>. <source>Med. Image Anal</source>. <volume>63</volume>, <fpage>101694</fpage>. <pub-id pub-id-type="doi">10.1016/J.MEDIA.2020.101694</pub-id>.<pub-id pub-id-type="pmid">32417716</pub-id></mixed-citation></ref><ref id="R42"><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>He</surname><given-names>X</given-names></name>, <year>2022</year>. <article-title>Diagnosis of Alzheimer&#8217;s disease based on regional attention with sMRI gray matter slices</article-title>. <source>J. Neurosci. Methods</source><volume>365</volume>, <fpage>109376</fpage>. <pub-id pub-id-type="doi">10.1016/J.JNEUMETH.2021.109376</pub-id>.<pub-id pub-id-type="pmid">34627926</pub-id></mixed-citation></ref><ref id="R43"><mixed-citation publication-type="confproc"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koltun</surname><given-names>V</given-names></name>, <conf-date>2020</conf-date>. <source>Exploring self-attention for image recognition</source>. In: <conf-name>In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition</conf-name>, pp. <fpage>10076</fpage>&#8211;<lpage>10085</lpage>.</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p id="P55">Overview of the proposed AD classification pipeline. T1-weighted MRI scans are pre-processed and spatially normalized to a standard template. The processed volumes are then converted into sequential slices and treated as video-like inputs to a fine-tuned TimeSformer model, which performs multiclass classification into AD, MCI, and CN categories.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p id="P56">Radar plot comparing the performance of baseline models and the proposed AlzFormer architecture across four evaluation metrics: Accuracy, Precision, Recall, and F-score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p id="P57"><bold>(a)</bold> Normalized confusion matrix showing the proportion of predicted versus true labels on the test set. <bold>(b)</bold> Macro-averaged ROC curve for the classification of AD, MCI, and CN on the test set. The model achieved a macro-average AUC of 1, indicating high discriminative performance across all classes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p id="P58">Attention maps for a representative Alzheimer&#8217;s disease subject.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Fig. 5.</label><caption><p id="P59">Attention maps for a representative mild cognitive impairment subject.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0005.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Fig. 6.</label><caption><p id="P60">Attention maps for a representative cognitively normal subject.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0006.jpg"/></fig><fig position="float" id="F7" orientation="portrait"><label>Fig. 7.</label><caption><p id="P61">Attention heatmaps at the 85th slice for representative CN, MCI, and AD subjects, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0007.jpg"/></fig><fig position="float" id="F8" orientation="portrait"><label>Fig. 8.</label><caption><p id="P62">Temporal attention heatmaps for a representative sagittal slice (slice 48) across CN, MCI, and AD subjects.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0008.jpg"/></fig><fig position="float" id="F9" orientation="portrait"><label>Fig. 9.</label><caption><p id="P63"><bold>(a)</bold> Dot-product similarity between learned positional embeddings of the AlzFormer model. A clear diagonal pattern suggests that the model captures spatial locality, with nearby patches having more similar positional encodings. <bold>(b)</bold> Visualization of the learned projection filters from the input embedding layer of the TimeSformer model.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0009.jpg"/></fig><fig position="float" id="F10" orientation="portrait"><label>Fig. 10.</label><caption><p id="P64">Mean attention distance across attention heads and transformer blocks in the AlzFormer model. Each dot represents the average spatial distance a head attends to, revealing the transition from local to global attention patterns throughout the network.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0010.jpg"/></fig><fig position="float" id="F11" orientation="portrait"><label>Fig. 11.</label><caption><p id="P65">Chord diagrams showing feature connectivity patterns for each diagnostic group: (a) AD, (b) MCI, and (c) CN. Each arc represents a feature pair with strong interactions captured by the attention mechanism.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2111435-f0011.jpg"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1</label><caption><p id="P66">The details of data collections.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Set</th><th align="left" valign="top" rowspan="1" colspan="1"># MRI Scans</th><th align="left" valign="top" rowspan="1" colspan="1">NC</th><th align="left" valign="top" rowspan="1" colspan="1">MCI</th><th align="left" valign="top" rowspan="1" colspan="1">AD</th><th align="left" valign="top" rowspan="1" colspan="1">Male</th><th align="left" valign="top" rowspan="1" colspan="1">Female</th><th align="left" valign="top" rowspan="1" colspan="1">Age (years)</th></tr><tr><th align="left" valign="top" colspan="9" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ADNI1: Complete 1Yr 1.5 T (82 %)</td><td align="left" valign="top" rowspan="1" colspan="1">Train</td><td align="left" valign="top" rowspan="1" colspan="1">1951</td><td align="left" valign="top" rowspan="1" colspan="1">600</td><td align="left" valign="top" rowspan="1" colspan="1">946</td><td align="left" valign="top" rowspan="1" colspan="1">405</td><td align="left" valign="top" rowspan="1" colspan="1">1341</td><td align="left" valign="top" rowspan="1" colspan="1">953</td><td align="left" valign="top" rowspan="1" colspan="1">75 &#177; 6.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADNI1: Complete 1Yr 1.5 T (18 %)</td><td align="left" valign="top" rowspan="1" colspan="1">Test</td><td align="left" valign="top" rowspan="1" colspan="1">342</td><td align="left" valign="top" rowspan="1" colspan="1">105</td><td align="left" valign="top" rowspan="1" colspan="1">166</td><td align="left" valign="top" rowspan="1" colspan="1">71</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p id="P67">Classification performance of AlzFormer on the test set (&#8220;ADNI1: Complete 3Yr 3 T&#8221;). Reported metrics include precision, recall, and F1-score for each class: AD, MCI, and CN. Overall accuracy, macro average, and weighted average scores are also provided.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Classes</th><th align="left" valign="top" rowspan="1" colspan="1">Precision</th><th align="left" valign="top" rowspan="1" colspan="1">Recall</th><th align="left" valign="top" rowspan="1" colspan="1">F1- score</th><th align="left" valign="top" rowspan="1" colspan="1">Support</th></tr><tr><th align="left" valign="top" colspan="5" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">0 (AD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.94</td><td align="left" valign="top" rowspan="1" colspan="1">0.95</td><td align="left" valign="top" rowspan="1" colspan="1">71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1 (MCI)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">105</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2 (CN)</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">166</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Accuracy</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">342</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Macro avg</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">342</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted avg</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">342</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p id="P68">Performance comparison of different architectures for Alzheimer&#8217;s disease classification.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Architecture</th><th align="left" valign="top" rowspan="1" colspan="1">ACC</th><th align="left" valign="top" rowspan="1" colspan="1">Precision</th><th align="left" valign="top" rowspan="1" colspan="1">Recall</th><th align="left" valign="top" rowspan="1" colspan="1">F-score</th></tr><tr><th align="left" valign="top" colspan="5" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CNN-Bi-LSTM (<xref rid="R2" ref-type="bibr">Akan et al., 2023</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNN-Transformer (<xref rid="R5" ref-type="bibr">Alp et al., 2024</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ViT-Bi-LSTM (<xref rid="R2" ref-type="bibr">Akan et al., 2023</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ViT-Transformer (<xref rid="R5" ref-type="bibr">Alp et al., 2024</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">0.91</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.91</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>AlzFormer</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.97</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.97</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.97</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.97</bold>
</td></tr></tbody></table></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Dev Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Curr Dev Nutr</journal-id><journal-id journal-id-type="pmc-domain-id">3465</journal-id><journal-id journal-id-type="pmc-domain">cdn</journal-id><journal-title-group><journal-title>Current Developments in Nutrition</journal-title></journal-title-group><issn pub-type="epub">2475-2991</issn><publisher><publisher-name>American Society for Nutrition</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505662</article-id><article-id pub-id-type="pmcid-ver">PMC12505662.1</article-id><article-id pub-id-type="pmcaid">12505662</article-id><article-id pub-id-type="pmcaiid">12505662</article-id><article-id pub-id-type="doi">10.1016/j.cdnut.2025.107543</article-id><article-id pub-id-type="pii">S2475-2991(25)03005-7</article-id><article-id pub-id-type="publisher-id">107543</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiome, Metagenomics, Metaproteomics, and Xenometabolomics</subject></subj-group></article-categories><title-group><article-title>Comparing Mediterranean and Western Diets: Cognitive and Microbiota Effects in Middle-Aged Rats</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Solch-Ottaiano</surname><given-names initials="RJ">Rebecca J</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Harper</surname><given-names initials="C">Colin</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Prats</surname><given-names initials="M">Madison</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Engler-Chiurazzi</surname><given-names initials="EB">Elizabeth B</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Ouvrier</surname><given-names initials="B">Blake</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Ismael</surname><given-names initials="S">Saifudeen</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Bix</surname><given-names initials="G">Gregory</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Maraganore</surname><given-names initials="DM">Demetrius M</given-names></name><email>dmaraganore@tulane.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>1</label>Department of Neurology, Tulane University School of Medicine, New Orleans, LA, United States</aff><aff id="aff2"><label>2</label>Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, United States</aff><aff id="aff3"><label>3</label>Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, LA, United States</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>dmaraganore@tulane.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>9</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498260</issue-id><elocation-id>107543</elocation-id><history><date date-type="received"><day>2</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>As the global population continues to age, cognitive decline has emerged as a major area of concern. Modifiable lifestyle factors, such as diet, have been associated with the trajectory of brain aging. Dietary patterns such as the Western diet (WD) have been linked to cognitive decline, whereas a Mediterranean diet (MeDi) promotes healthy brain aging.</p></sec><sec><title>Objectives</title><p>This study aimed to compare the effects of MeDi and WD on gut microbiota and cognitive health in middle-aged rats. Our hypothesis was that the MeDi, when introduced to middle-aged rats, would maintain cognitive health and produce a distinct gut microbiota composition relative to a WD.</p></sec><sec><title>Methods</title><p>Twelve-month-old male Fischer344 rats were randomly assigned to MeDi, WD, or chow (<italic toggle="yes">n</italic> = 10/group). After 12 wk, fecal samples were collected for 16S rRNA gene sequencing to assess microbial composition. Animals completed the following neurobehavioral assessments, including Y-maze, Morris Water Maze, and Radial Arm Water Maze. At the end of the study, the hippocampus was analyzed for gene and protein expression related to barrier integrity, glial cell activity, and neuroplasticity.</p></sec><sec><title>Results</title><p>There were trending differences in cognitive function in MeDi rats relative to WD rats. Rats exhibited distinct diet-dependent microbial phenotypes with 28 differentially abundant bacteria, including <italic toggle="yes">Blautia</italic>, <italic toggle="yes">Clostridia</italic> UCG-014, <italic toggle="yes">Clostridium innocuum</italic> group, <italic toggle="yes">Faecalibacterium</italic>, and <italic toggle="yes">Bifidobacterium</italic>. This was accompanied by changes in hippocampal gene expression of glial cell activity, including glial fibrillary acidic protein, ionized calcium binding protein, and triggering receptor expressed on myeloid cells 2. Blood&#8211;brain barrier integrity and neuroplasticity were maintained during the short-term dietary intervention.</p></sec><sec><title>Conclusions</title><p>A longer diet duration may be needed to elicit robust differences in cognitive function driven by the changes in microbiota and neurobiology. This study highlights that a short-term diet introduced in middle age has trending effects on cognitive performance but significantly impacts gut microbiota composition and gene expression of biomarkers of brain health.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Mediterranean diet</kwd><kwd>Western diet</kwd><kwd>gut microbiota</kwd><kwd>memory</kwd><kwd>cognitive function</kwd><kwd>aging</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0045">BDNF</term><def><p>brain-derived neurotrophic factor</p></def></def-item><def-item><term id="kwrd0055">IBA-1</term><def><p>ionized calcium binding protein</p></def></def-item><def-item><term id="kwrd0065">GFAP</term><def><p>glial fibrillary acidic protein</p></def></def-item><def-item><term id="kwrd0075">MeDi</term><def><p>Mediterranean diet</p></def></def-item><def-item><term id="kwrd0085">MWM</term><def><p>Morris Water Maze</p></def></def-item><def-item><term id="kwrd0095">PSD-95</term><def><p>postynaptic density protein-95</p></def></def-item><def-item><term id="kwrd0105">TREM2</term><def><p>triggering receptor expressed on myeloid cells 2</p></def></def-item><def-item><term id="kwrd0115">WMC</term><def><p>working memory correct</p></def></def-item><def-item><term id="kwrd0125">WMI</term><def><p>working memory incorrect</p></def></def-item><def-item><term id="kwrd0135">WRAM</term><def><p>water arm water maze</p></def></def-item><def-item><term id="kwrd0145">WD</term><def><p>Western diet</p></def></def-item><def-item><term id="kwrd0155">ZO-1</term><def><p>zonula occludens-1</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">There is expected to be unprecedented growth in the number of persons living aged 65 y or older worldwide, with that population expected to more than double from 2021 to 2050, to 1.6 billion [<xref rid="bib1" ref-type="bibr">1</xref>]. Survey evidence suggests that the greatest fear of this aging population is cognitive decline [<xref rid="bib2" ref-type="bibr">2</xref>]. It is well-established that modifiable lifestyle factors such as unhealthy diet, smoking, and physical inactivity can be modified to promote healthy brain aging [<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>]. In aging adults, the Mediterranean diet (MeDi) is associated with slower rates of cognitive decline, improvements in cognition, and reduced atrophy in brain regions important for memory [<xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>]. Yet, adherence to the MeDi is suboptimal in the United States, as observed in neurology clinical practices [<xref rid="bib11" ref-type="bibr">11</xref>]. By contrast, adherence to a &#8220;Westernized&#8221; dietary pattern is evident globally [<xref rid="bib12" ref-type="bibr">12</xref>]. Components of this diet include higher consumption of foods that are calorie-dense and with a decrease in fiber and nutrients, and with lower consumption of fruits and vegetables. Adherence to a Western diet (WD) has been implicated in the development of obesity, diabetes, and coronary artery disease, which are risk factors for cognitive decline [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>].</p><p id="p0015">Diet has a direct role in shaping gut microbiota composition, with changes occurring daily[<xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>]. Diet-modulated gut microbiota may exert its effect on body and brain health through various mechanisms. One method of gut&#8211;brain communication is through the production of short-chain fatty acids and neurotransmitters by microbes that stimulate the ends of vagal nerves. Gut microbiota and byproducts such as short-chain fatty acids can also communicate with the immune system [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>]. Adherence to particular diets, such as the WD, is associated with obesity and shifts in microbiota composition [<xref rid="bib19" ref-type="bibr">19</xref>]. This may include the loss of beneficial bacteria, an increase in pathogenic bacteria, and a reduction in short-chain fatty acids [<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib21" ref-type="bibr">21</xref>]. This could contribute to a systemic and neuroinflammatory response, which has been associated with cognitive impairments [<xref rid="bib18" ref-type="bibr">18</xref>]. This highlights the importance of diet-modulated gut microbiota composition in the gut&#8211;brain axis.</p><p id="p0020">Accumulating evidence supports the involvement of the gut&#8211;brain axis in unhealthy brain aging, strongly implicating that shifts in gut microbial composition correlate with cognitive impairment [<xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>]. In cross-sectional studies, it was found that the microbiota of patients with mild cognitive impairment is dissimilar to that of individuals with normal cognition and that certain bacteria are associated with cognitive performance [<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>]. The MeDi may be neuroprotective through the microbiota it fosters, as there is an inverse relationship between the MeDi and neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease [<xref rid="bib6" ref-type="bibr">6</xref>]. A 1-y intervention study found that MeDi-modulated microbes are associated with improved cognitive function and reduced inflammatory markers [<xref rid="bib28" ref-type="bibr">28</xref>]. We were the first to report that MeDi-modulated microbiota was associated with better cognitive performance relative to a WD, in young rats that translated to the age of young adults (&#8764;18 y of age) [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>]. Evidence of MeDi-associated neuroprotection has mainly been reported in cross-sectional or cohort studies with limited clinical trials [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>]. Most studies have focused on the association between MeDi adherence in aging adults [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib31" ref-type="bibr">31</xref>], but it is important to understand the impact of adulthood and midlife dietary adherence on cognition. This is particularly important as adherence to the MeDi during these time periods has been associated with slower cognitive decline and better cognitive function [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>]. None of these studies have examined the relationship between MeDi adherence on gut microbiota and cognitive function in midlife. Therefore, the association between diet-modulated cognitive and gut microbiota in midlife should be explored.</p><p id="p0020s">Our study builds on our previous findings in young rats to compare the effects of MeDi and WD on cognitive performance and gut microbiota in an older animal model by utilizing middle-aged rats (12.5-mo-old). The hypothesis was that the MeDi, when introduced to rats of middle age, would maintain cognitive health and produce a distinct gut microbiota composition relative to the WD. We chose to study middle-aged rats to translate our findings on the effects of diet on diet-induced cognition and gut microbiota to middle-aged humans [<xref rid="bib30" ref-type="bibr">30</xref>].</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Animal husbandry</title><p id="p0025">The study was conducted with 1 cohort. Twelve-month-old male Fischer 344 rats (<italic toggle="yes">n</italic> = 30) were obtained from the National Institute on Aging rodent colony (Charles River Laboratories) and acclimated for 2 wk before the start of the study. Rats were placed in a climate-controlled room on a 12-h light/dark cycle and were pair-housed by diet type. Rats were provided ad libitum water and chow through wire top feeders. Food weight was measured twice weekly to assess food intake. Old food was then removed and refreshed with new food twice weekly. Body weights were measured weekly, and food consumption as an indicator of energy intake was measured biweekly throughout the study. All procedures were approved by Tulane University Institutional Animal Care and Use Committee and adhered to NIH standards.</p></sec><sec id="sec2.2"><title>Animal diet</title><p id="p0030">Rats (<italic toggle="yes">n</italic> = 10/group) were randomly assigned to either the WD (15% protein, 50% carbohydrate, 35% fat; Research Diets D12052705C), the MeDi (12% protein, 45% carbohydrate, 43% fat; Research Diets, D12052702G), or a standard chow diet (25% protein, 62% carbohydrate, 13% fat; PicoLab Rodent Diet 20; 5053). The aim of the study was to compare the MeDi to the WD. Therefore, the chow was used as a reference/positive control for the MeDi. Rats consumed the respective diets for 12 wk before undergoing behavioral assessments from weeks 12 to 16 (<xref rid="fig1" ref-type="fig">Figure 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>Study design. Male Fischer344 rats (12.5 mo) were randomly assigned to a Western diet, Mediterranean diet, or chow (positive control) for 12 wk. After 12 wk, fecal samples were collected and animals began neurobehavioral assessments. Assessments took place from weeks 12 to 16. Following the end of behavior, tissues were collected for analysis.</p></caption><alt-text id="alttext0015">FIGURE 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0035">The WD was formulated from the USDA&#8217;s 2008 Dietary Assessment of Major Food Trends, and the traditional MeDi was based on the FAO&#8217;s Food Balance Sheets from Greece in 1961 [<xref rid="bib35" ref-type="bibr">35</xref>]. Although the percentages of macronutrients are similar between diets, the primary ingredient sources differ. For example, the primary fat source for MeDi is olive oil, and the WD is butter. The omega&#8722;6:omega&#8722;3 ratio for the MeDi was 2:1, and the WD was 11:1. The MeDi contained 63.4 g/kg of fiber (cellulose, 47.6; inulin 15.8), whereas the WD contained 27.9 g/kg of fiber (cellulose, 21.0; inulin, 6.9). Diets were vitamin and mineral matched. As obesity and related consequences are risk factors for cognitive impairment [<xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>], the MeDi and WD diets were kcal (4.3 kcal/g) matched. The chow diet was 4.11 kcal/g and 3.02 kcal/g for gross energy and metabolizable energy, respectively. All diets were in pellet form. Dietary information for the WD and MeDi can be found in <xref rid="appsec1" ref-type="sec">Supplemental Table 1</xref>.</p></sec><sec id="sec2.3"><title>Behavioral assessments</title><p id="p0040">A battery of neurobehavioral assessments was used to test aspects of short- and long-term learning and memory. Tests were given in ascending order of cognitive demand: <italic toggle="yes">1</italic>) Y-maze, <italic toggle="yes">2</italic>) Morris Water Maze (MWM), and <italic toggle="yes">3</italic>) water radial arm maze (WRAM). All behavioral testing took place between 07:00 and 17:00 in a dimly lit room. Rats were tested in cohorts of 10, with each diet group represented within each cohort. The order of go for each diet alternated and differed within each cohort. For example, cohort 1 order was chow, WD, MeDi, chow, and WD, cohort 2 order was MeDi, chow, WD, MeDi, and chow, and cohort 3 was WD, MeDi, chow, WD, and MeDi, with each rat in the cage tested before moving to the next diet. For all tests, spatial cues consisted of 6 different shapes placed around the apparatus. A video camera above the mazes was used to track the animals using a software program (AnyMaze, 6.35) for all tests.</p></sec><sec id="sec2.4"><title>Y-maze</title><p id="p0045">The spontaneous alternation Y-maze was utilized to capture short-term recognition memory [<xref rid="bib39" ref-type="bibr">39</xref>]. Animals were acclimated to the room for 60 min before testing. The Y-maze apparatus (Stoelting) consists of 3 arms (10 cm wide, 50 cm long, 20 cm high) connected in the shape of a Y. One at a time, rats were placed in the start arm facing the wall and were allowed to explore freely for 10 min. Entry into each arm was recorded. A correct alternation score was calculated as the number of times the 3 arms were sequentially entered. Total alternations were derived as the number of total arm entries minus 2. The % correct alternations is the number of correct alternations divided by the total number of alternations made. Between rats, the maze was sprayed with 90% ethanol, wiped clean, and allowed to dry for 30 s.</p></sec><sec id="sec2.5"><title>Morris water maze</title><p id="p0050">To test spatial reference memory, the MWM was utilized. A tank (1.8 m diameter) filled with room temperature water and colored black with nontoxic paint for all water maze testing. The apparatus was virtually divided into 4 quadrants (North, East, South, and West). A hidden platform was placed in the Southwest quadrant and remained in this fixed location throughout the duration of the testing. Each day, the animal was placed in the maze facing the tank wall from any of the 4 start locations and had 60 s to locate the hidden platform. Animals were tracked using cameras and ANY-maze video tracking software to ensure unbiased data collection. If an animal did not locate a platform by 60 s, it was gently led to it by the experimenter. Once found, animals stayed on the platform for 15 s and were returned to a heated cage until the subsequent trial. The animals were given 4 trials per day for 7 d. On the seventh day, animals were given an additional 60 s probe trial where the platform was removed. This trial evaluated whether the animals localized the platform to the spatial location as animals who had learned the platform location were expected to spend the greatest percent of distance in the target quadrant [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib41" ref-type="bibr">41</xref>]. Probe trial data were analyzed for group differences in the percent time spent in the target quadrant compared with the percent time spent in the opposite quadrant. To assess cognitive flexibility in learning and perseveration, animals underwent 2 d of reversal testing following day 5. The platform was placed in the opposite quadrant. Animals underwent 4 trials per day for 2 d and, on the last day, had a 60 s reversal probe trial.</p></sec><sec id="sec2.6"><title>Water radial arm maze</title><p id="p0055">An 8-arm WRAM was used to measure discrete components of memory, including spatial working and reference memory. A tank (1.8 m diameter) was filled with water at room temperature and colored black with nontoxic paint. Escape platforms were placed at the end of 4 arms &#8764; 2 cm below the water. Animals were randomly assigned to 1 of the 4-baited arm combinations, and this assignment remained constant throughout the experiment. All animals were released from the same start arm facing the tank wall, and had 90 s to reach an escape platform. If an animal did not find a platform within the 90 s, it was gently led to the nearest platform. Once on the platform, animals remained on it for 15 s and then were returned to a heated cage for 30 s. Between an animal&#8217;s trial, the just-chosen platform was removed. A daily session consisted of these events until all 4 platforms were located. Therefore, a daily session consisted of 4 trials per session for each animal. Each animal was given 1 session per day for 10 consecutive days. Arm entries were considered when the body of the rat (not including the tail) entered the arm and were collected by a single investigator. Independently, 2 investigators quantified discrete error types for each daily session as done previously [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. Working memory correct (WMC) errors were first and repeated entries into any arm from which a platform had been removed during that day&#8217;s session. Reference memory errors were the first entries into any arm that never contained a platform. Working memory incorrect (WMI) errors were repeated entries into reference memory arms. Trial 1 WMC errors were not included in the analysis, as it is not possible to make a WMC error on the first trial of each day. Total errors were calculated as the sum of the 3 error types.</p><sec id="sec2.6.1"><title>Visible platform</title><p id="p0060">As the MWM and WRAM tests rely on proper eyesight to appropriately learn the spatial tasks, a visible platform test was performed at the end of the study using the tracking system as previously done [<xref rid="bib29" ref-type="bibr">29</xref>]. Briefly, spatial cues around the room were removed, and a visible platform (painted white to contrast the black water with a small flag attached to the platform) was placed &#8764; 2 cm above the water in a fixed location. Animals underwent 6 trials where they were placed in the maze from 4 different start locations. Latency to reach the platform was evaluated to determine any sight-dependent learning disability.</p></sec></sec><sec id="sec2.7"><title>Microbial analysis</title><sec id="sec2.7.1"><title>DNA extraction and 16S rRNA gene sequencing</title><p id="p0065">Fresh fecal samples were collected 2 d before behavioral assessments started in week 12 using an aseptic technique and stored in a &#8211;80&#176;C freezer until analysis. One WD rat did not provide a sample. Fecal DNA was extracted using the Quick-DNA Fecal/Soil Microbe Microprep Kit (Zymo Research) according to the manufacturer's protocol. DNA was quantified using Qubit (Invitrogen) and was above the minimum amount of DNA needed for Illumina 16s library preparation (12 ng/&#956;L). The Illumina 16S metagenomic sequencing library preparation guide was followed, and the 16S V3 and V4 gene regions were amplified using forward (5&#8242;-TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG CCT ACG GGN GGC WGC AG-3&#8242;) and reverse (5&#8242;-GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA GGA CTA CHV GGG TAT CTA ATC C-3&#8242;) primers [<xref rid="bib42" ref-type="bibr">42</xref>]. The samples were then multiplexed with the Illumina Nextera UDIs. The libraries were quantified using Qubit (Invitrogen), and all samples were above the minimum concentration for library preparation (10 ng/&#956;L) except for the blank, which was 0 ng/&#956;L. The resulting libraries were sequenced on an Illumina MiSeq using the MiSeq v2 (300-cycle) reagent kit. Raw pair-ended 16S rRNA gene sequences were demultiplexed and merged by Quantitative Insights Into Microbial Ecology 2 (version 2024.5) framework core function [<xref rid="bib43" ref-type="bibr">43</xref>]. There were between 132,642 and 240,245 read pairs generated per sample (median: 186,437; mean: 183,461) for a total of 5,136,910 read pairs following sequencing. The blank had 14,426 read pairs generated. Binning of operational taxonomic units was done at 99% similarity using the Silva 138 pretrained classifier [<xref rid="bib44" ref-type="bibr">44</xref>]. Align-to-tree-mafft-fasttree was used to create a phylogenetic tree for diversity analyses.</p><p id="p0070">Microbial data were analyzed using the R program (2024.09.0+375). Samples with low reads (&#8804;10,000) were not included, resulting in 1 sample from the WD being excluded from the analysis. &#945;-Diversity indices (Shannon, Simpson, and Chao1) were calculated using the R package Vegan [<xref rid="bib45" ref-type="bibr">45</xref>]. Kruskal&#8211;Wallis rank-sum test with uncorrected Dunn&#8217;s test was used to compare &#945;-diversity for each index between diet groups. Differences in principal coordinate analyses were analyzed via permutational multivariate analysis of variance with the Adonis function in the vegan package using bray, weighted UniFrac, and unweighted UniFrac distances. Differences in relative abundance between diets at the genus level were determined by the linear discriminant analysis (LDA) effect size (LEfSe) method with a false discovery rate of 0.1 [<xref rid="bib46" ref-type="bibr">46</xref>].</p></sec></sec><sec id="sec2.8"><title>Western blot</title><p id="p0075">A portion of frozen hippocampus (5 mg) was homogenized in 350 &#956;L of lysate buffer Radioimmunoprecipitation Assay (RIPA) buffer with protease inhibitor cocktail; Thermo Fisher #8990 and Selleckchem #B14001, respectively). A bicinchoninic acid assay (BCA) protein assay (Thermo Fisher: Pierce BCA Protein Assay Kit, #23225) was used to determine protein concentration. Samples were then prepared to have a concentration of 30 &#956;g diluted with lysate buffer and 4&#215; loading dye, which included 4&#215; Laemmli Sample Buffer (Bio-Rad, #1610747) and beta-mercaptoethanol. Samples were vortexed, centrifuged, and heated at 97&#176;C for 5 min before 20 &#956;L of each sample was separated by SDS-PAGE on a TGX, 4%&#8211;15%, 18-well gel at 120V. The gel was then transferred onto a polyvinylidene difluoride (PVDF) membrane using a TransBlot Turbo Transfer System (Bio-Rad 1704150EDU). After transferring, the membrane was washed in methanol and Everyblot blocking buffer (Bio-Rad, #12010020) before being cut and incubated with diluted primary antibodies (Everyblot Blocking Buffer, Bio-Rad #12010020; <xref rid="tbl1" ref-type="table">Table 1</xref>) overnight at 4&#176;C. The membrane was then washed with wash buffer (1&#215; TBS-Tween 20 0.2%), then incubated for 1 h at room temperature with diluted secondary antibodies (Everyblot Blocking Buffer, Bio-Rad #12010020; <xref rid="tbl1" ref-type="table">Table 1</xref>) before being washed again and imaged on a ChemiDoc MP imager using a chemiluminescence solution (Thermo Fisher: SuperSignal West Pico PLUS Chemiluminescent Substrate). Blot quantification was performed using NIH ImageJ software. There was no difference in the housekeeping genes GAPDH or tubulin between groups.<table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1</label><caption><p>Primary and secondary antibodies.</p></caption><alt-text id="alttext0065">TABLE 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Antibody name</th><th colspan="1" rowspan="1">Host</th><th colspan="1" rowspan="1">Dilution</th><th colspan="1" rowspan="1">Catalog #</th><th colspan="1" rowspan="1">Company</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Primary antibodies</td></tr><tr><td colspan="1" rowspan="1">&#160;ZO-1</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">61-7300</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="1" rowspan="1">&#160;BDNF</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">NB100-98682</td><td colspan="1" rowspan="1">Novus Biologicals</td></tr><tr><td colspan="1" rowspan="1">&#160;GFAP</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">Ab68428</td><td colspan="1" rowspan="1">Abcam</td></tr><tr><td colspan="1" rowspan="1">&#160;GAPDH</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:10,000</td><td colspan="1" rowspan="1">GTX100118</td><td colspan="1" rowspan="1">GeneTex</td></tr><tr><td colspan="1" rowspan="1">&#160;IBA-1</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">ET1705-78</td><td colspan="1" rowspan="1">Huabio</td></tr><tr><td colspan="1" rowspan="1">&#160;CD11b</td><td colspan="1" rowspan="1">Rabbit</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">PA5-79532</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="1" rowspan="1">&#160;PSD-95</td><td colspan="1" rowspan="1">Mouse</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">MA1046</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="1" rowspan="1">&#160;Occludin</td><td colspan="1" rowspan="1">Mouse</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">33-1500</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="1" rowspan="1">&#160;Tubulin</td><td colspan="1" rowspan="1">Mouse</td><td colspan="1" rowspan="1">1:10,000</td><td colspan="1" rowspan="1">62204</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="1" rowspan="1">&#160;Claudin 5</td><td colspan="1" rowspan="1">Mouse</td><td colspan="1" rowspan="1">1:1000</td><td colspan="1" rowspan="1">35-2500</td><td colspan="1" rowspan="1">ThermoFischer</td></tr><tr><td colspan="5" rowspan="1">Secondary antibodies</td></tr><tr><td colspan="1" rowspan="1">&#160;Goat anti-mouse IgG H&amp;L (HRP)</td><td colspan="1" rowspan="1">Goat</td><td colspan="1" rowspan="1">1:5000</td><td colspan="1" rowspan="1">Ab6789</td><td colspan="1" rowspan="1">Abcam</td></tr><tr><td colspan="1" rowspan="1">&#160;Goat anti-rabbit IgG H&amp;L (HRP)</td><td colspan="1" rowspan="1">Goat</td><td colspan="1" rowspan="1">1:5000</td><td colspan="1" rowspan="1">Ab6721</td><td colspan="1" rowspan="1">Abcam</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: BDNF, brain-derived neurotrophic factor; IBA-1, ionized calcium binding protein; GFAP, glial fibrillary acidic protein; PSD-95, postsynaptic density protein-95; ZO-1, zonula occludens-1.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.9"><title>qPCR</title><p id="p0080">A portion of frozen hippocampus (15 mg) was homogenized in Trizol Lysis Reagent (Thermo Fisher # 15596026). RNA was extracted according to the RNA extraction kit instructions (RNeasy Plus Mini Kit; Qiagen, #74134). RNA was converted to cDNA using an iscript reverse transcriptase master mix (Bio-Rad, #1708841). Gene expression was conducted with QuantStudio 3-Real-Time PCR Systems (Life Technologies) using TaqMan PCR Master Mix and specified probes (Thermo Fischer Scientific) for <italic toggle="yes">Claudin-5</italic> (Rn01753146_s1), <italic toggle="yes">Occludin</italic> (Rn00580064_m1), <italic toggle="yes">ionized calcium binding adaptor molecule 1</italic> (<italic toggle="yes">IBA-1</italic>; Rn03993468_g1), <italic toggle="yes">triggering receptor expressed on myeloid cells 2</italic> (<italic toggle="yes">TREM2</italic>; Rn01512170_m1), <italic toggle="yes">glial fibrillary acidic protein</italic> (<italic toggle="yes">GFAP</italic>; Rn01253033_m1), <italic toggle="yes">postsynaptic density protein-95</italic> (<italic toggle="yes">PSD95</italic>; Rn00571479_m1)<italic toggle="yes">, brain-derived neurotrophic factor</italic> (<italic toggle="yes">BDNF</italic>; Rn02531967_s1), and <italic toggle="yes">GAPDH</italic> (Rn01775763; housekeeping gene). There was no difference in GAPDH gene expression between groups. Data were analyzed and presented as a fold change of WD (control for analysis). The chow diet is presented in the graph as a positive control.</p></sec><sec id="sec2.10"><title>Statistical analysis</title><p id="p0085">The chow diet group serves as a positive control to the MeDi; therefore, for all analyses, the chow diet group was included in the main model but was not included in post-hoc comparisons as the study objective was to determine differences between the MeDi and WD groups. All results are represented as mean &#177; SEM, and statistical significance was predefined as <italic toggle="yes">P</italic> &lt; 0.05. Assumptions of normality and homogeneity were checked prior to analyses. All statistical analyses were analyzed using Prism software (Graphpad Software, Inc., Version 10, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.graphpad.com" id="intref0010">www.graphpad.com</ext-link>). Data were analyzed by 1-way or 2-way repeated measures analysis of variance for test-specific groups between dietary groups, where appropriate. Fischer&#8217;s least significant difference for comparisons was applied where appropriate. Fisher&#8217;s exact test, with odds ratio for effect size calculation, was used for the contingency table of Y-maze ratios. Post-hoc analysis values, including chow group, can be found in <xref rid="appsec1" ref-type="sec">Supplemental Table 2</xref>.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Physiological measurements did not differ by diet</title><p id="p0090">As obesity is a risk factor for cognitive impairment [<xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>], kcal intake and weight were measured throughout the study. There was no difference in kcal intake or weight between rats in the MeDi group relative to the WD groups. Across weeks, rats gained weight until week 12 when neurobehavioral assessments started. At week 12, rats had a reduction in weight across testing (<xref rid="fig2" ref-type="fig">Figure 2</xref>A), which also coincided with reduced energy intake (kcal; <xref rid="fig2" ref-type="fig">Figure 2</xref>B). From weeks 12&#8211;16, neurobehavioral assessments were conducted, and rats spent fewer hours in their home cage, which may have contributed to a reduction in food consumption. Additionally, due to the nature of the testing, the rats were also more active, which could also contribute to the observed weight loss. The changes in weight, food consumed, and kcal intake did not differ between rats in the MeDi and WD groups.<fig id="fig2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>Weight in grams (A, B) and kilocalories (C, D) did not differ between diet groups. Kcal consumption was calculated per animal: [(grams consumed &#8727; kcal/g of diet)/2)]. Two-way repeated measure ANOVA with diet, week, and their interactions was performed. Data are represented as mean&#8201;&#177;&#8201;SEM. Chow (<italic toggle="yes">n</italic> = 10). ANOVA, analysis of variance; MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 10); WD, Western diet (<italic toggle="yes">n</italic> = 10).</p></caption><alt-text id="alttext0020">FIGURE 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec3.2"><title>Short- and long-term memory is not overtly impacted by diet</title><p id="p0095">A set of neurobehavioral assessments was selected to assess a short-term dietary intervention of a MeDi on cognitive function in middle-aged male rats relative to a WD. A test of the visible platform was conducted to determine eyesight. One animal from the MeDi group and one animal from the WD group were excluded from subsequent analyses due to determined visual impairment.</p><p id="p0100">Y-maze was utilized to measure short-term recognition memory. Y-maze percent correct alternations and total alternations did not differ between rats in the MeDi or WD group (<xref rid="fig3" ref-type="fig">Figure 3</xref>). The MeDi group had an average score of 70.68%, whereas the WD group had an average of 60.69%. It should be noted that poor cognitive performance is indicated by a score of &lt;50%, and competency is indicated by a score of &#8805;66%. The MeDi group had 9/10 rats, whereas the WD group had 5/9 rats reach a score of 50% (Fisher&#8217;s Exact, <italic toggle="yes">P</italic> = 0.14; effect size, odds ratio =7.2). The MeDi group had 4/9 rats and the WD group had 3/9 rats reach a score of 66% (Fisher&#8217;s exact, <italic toggle="yes">P</italic> = 1.0; effect size, odds ratio = 1.6). Although not statistically significant, there was a large effect size at the 50% level for MeDi rats to have a score &gt;50%.<fig id="fig3" position="float" orientation="portrait"><label>FIGURE 3</label><caption><p>Percent correct alternations (A) and total alternations (B) measured by the Y-maze did not differ between diets. A correct alternation score was calculated as the number of times the 3 arms were sequentially entered. The percent correct alternations is the number of correct alternations divided by the total number of alternations made. One-way ANOVA was performed. Data are represented as mean&#8201;&#177;&#8201;SEM. Chow (<italic toggle="yes">n</italic> = 10); ANOVA, analyis of variance; MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 9); WD, Western diet (<italic toggle="yes">n</italic> = 9).</p></caption><alt-text id="alttext0025">FIGURE 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0105">Following the Y-maze, the MWM was utilized to assess spatial learning and reference memory. There was a trend (<italic toggle="yes">P</italic> = 0.08) for the MeDi group to have a shorter latency to reach the platform regardless of day (<xref rid="fig4" ref-type="fig">Figure 4</xref>A, B). There was no difference by day between rats in the MeDi and WD groups. There was a significant difference by day (<italic toggle="yes">P</italic> &lt; 0.0001), indicating that animals learned the neurobehavioral task across days. The probe trial was conducted as a fifth trial on day 5 to assess learning of the task. There was no difference in rats in the MeDi group relative to the WD group for platform localization in the probe trial (<xref rid="fig4" ref-type="fig">Figure 4</xref>C). Additionally, both diet groups indicated learning of the task as groups spent significantly more time in the platform quadrant compared with the opposite quadrant (<italic toggle="yes">P</italic> &lt; 0.0001; <xref rid="fig3" ref-type="fig">Figure 3</xref>C).<fig id="fig4" position="float" orientation="portrait"><label>FIGURE 4</label><caption><p>There was a trend for MeDi rats to reach the platform quicker than the WD rats during the MWM and reversal MWM phase. Overall, all groups exhibited learning. MWM testing included latency to the platform across days (A), latency to the platform by diet (B), and percent time in the target quadrant during probe test (C). MWM reversal testing included latency to the platform over 2 d (D), latency to the platform by diet (E), and percent time in the target quadrant during the probe test (F). Two-way repeated measure ANOVA with diet, day, or quadrant, and their interactions was performed. Data are represented as mean&#8201;&#177;&#8201;SEM. Chow (<italic toggle="yes">n</italic> = 10); ANOVA, analysis of variance; MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 9); WD, Western diet (<italic toggle="yes">n</italic> = 9). #<italic toggle="yes">P</italic> = 0.08. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">P</italic> &lt; 0.0001. MWM, Morris Water Maze.</p></caption><alt-text id="alttext0030">FIGURE 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0110">To assess cognitive flexibility, a 2-d reversal MWM was conducted. There was a trend for the MeDi group to have a shorter latency to reach the platform regardless of day relative to the WD group (<italic toggle="yes">P</italic> = 0.089). Additionally, there was a statistically significant difference by day (<italic toggle="yes">P</italic> &lt; 0.001) indicating that both groups were able to learn new information and demonstrated cognitive flexibility at similar levels (<xref rid="fig4" ref-type="fig">Figure 4</xref>D, E). When conducting the probe test, there was no difference by diet or platform location (new compared with old; <xref rid="fig4" ref-type="fig">Figure 4</xref>F), suggesting that animals were spending equal time in the new target quadrant and the quadrant that at one point had a platform. There was no difference between animals in each diet group for swim speed for MWM and MWM reversal (<xref rid="appsec1" ref-type="sec">Supplemental Figure 1</xref>).</p><p id="p0115">After MWM, animals were assessed for aspects of short- and long-term memory, including spatial, working, and reference memory, using the 8-arm WRAM over 11 d. There was no difference in WMC, WMI, reference memory, or total errors between the animals in the MeDi and WD groups (<xref rid="fig5" ref-type="fig">Figure 5</xref>).<fig id="fig5" position="float" orientation="portrait"><label>FIGURE 5</label><caption><p>There were no differences by diet in the water radial arm water (WRAM) maze behavioral assessment. Total (A, B), working memory correct (WMC; C, D), working memory incorrect (WMI, E, F), and reference (G, H) memory errors did not differ. Total memory error is the sum of WMC, WMI, and reference memory. Two-Way Repeated Measure ANOVA with Diet, Day, and their interactions were performed. Data are represented as mean&#8201;&#177;&#8201;S.E.M. Chow (<italic toggle="yes">n</italic> = 10), MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 9); WD, Western diet (<italic toggle="yes">n</italic> = 9).</p></caption><alt-text id="alttext0035">FIGURE 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0120">Y-maze and MWM data indicate rats may be starting to develop diet-dependent cognitive performance differences. Taken together with a more cognitively demanding test such as the WRAM, the diets do not overtly impact aspects of short- and long-term memory. A longer diet duration may be necessary to evoke diet-dependent cognitive changes.</p></sec><sec id="sec3.3"><title>Gut microbiota is modulated by diets</title><p id="p0125">The primary modifier of gut microbiota composition is dietary intake [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. Therefore, we explored the impact of short-term MeDi and WD on gut microbiota composition. &#945;-Diversity is used to assess richness (number of taxa), evenness (relative abundance of those taxa), or both within samples. &#945;-Diversity was assessed by 3 indices: Shannon (richness and evenness), Simpson (evenness), and Chao1 (richness). Shannon (<italic toggle="yes">P</italic> = 0.028), Simpson (<italic toggle="yes">P</italic> = 0.0.025), and Chao1 (<italic toggle="yes">P</italic> = 0.001) were significantly higher in the MeDi group relative to the WD group. This suggests that the MeDi induced changes to &#945;-diversity relative to a WD (<xref rid="fig6" ref-type="fig">Figure 6</xref>A&#8211;C).<fig id="fig6" position="float" orientation="portrait"><label>FIGURE 6</label><caption><p>Diet modulation results in distinct phenotypes. There was a trend or significant difference for Simpson (A), Shannon (B), and Chao1 (C) &#945;-diversities to differ by diet. Additionally, &#946;-diversity differed by diet including Bray&#8211;Curtis dissimilarity (D), weighted UniFrac (E), and for unweighted UniFrac (F). Kruskal&#8211;Wallis Rank Sum Test was used for differences in &#9082;-diversity, and data are represented as IQR (A&#8211;C). Permutational multivariate analysis of variance using distance matrices was used to determine differences in &#946;-diversity (D, E). Ellipses represent a 95% confidence level. Chow (<italic toggle="yes">n</italic> = 10); MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 10); WD, Western diet (<italic toggle="yes">n</italic> = 8). &#8727;&#8727;&#8727;<italic toggle="yes">P</italic> = 0.001, &#8727;<italic toggle="yes">P</italic> &lt; 0.03.</p></caption><alt-text id="alttext0040">FIGURE 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0130">Further evidence of distinct diet-modulated gut microbiota was demonstrated through differences in &#946;-diversity. &#946;-Diversity estimates similarity or dissimilarity between populations or groups (i.e., diet). Bray&#8211;Curtis dissimilarity, used to determine differences accounting for abundance and presence/ absence, was significantly different between diets (<xref rid="fig6" ref-type="fig">Figure 6</xref>D). Phylogenetic relatedness was considered by conducting weighted and unweighted UniFrac analysis. Unweighted UniFrac, accounting for presence/absence, was significantly different between the MeDi rats and WD rats (<xref rid="fig6" ref-type="fig">Figure 6</xref>E). Weighted UniFrac, accounting for taxa abundance, was also significantly different between the WD and MeDi groups (<xref rid="fig6" ref-type="fig">Figure 6</xref>F). Altogether, these data indicate the development of diet-dependent microbial phenotypes after short-term consumption of a MeDi and WD in middle-aged rats.</p><p id="p0135">The most abundant taxa at the phylum and genus levels are displayed in <xref rid="fig7" ref-type="fig">Figure 7</xref>A,B. To expand on diet-dependent differences in microbial composition, LEfSe analysis was conducted at the genus level. Analyses indicated 28 differentially abundant genera between the diet groups. Twenty-three genera were higher in the MeDi rats relative to the WD rats indicating strong diet-dependent differences between diets (<xref rid="fig8" ref-type="fig">Figure 8</xref>). The most differentially abundant genera [LDA score (log 10) &gt; 4] included <italic toggle="yes">Blautia</italic> and <italic toggle="yes">Clostridia</italic> UCG-014 in the MeDi group and <italic toggle="yes">Clostridium innocuum</italic> group, <italic toggle="yes">Faecalibacterium,</italic> and <italic toggle="yes">Bifidobacterium</italic> in the WD group (<xref rid="appsec1" ref-type="sec">Supplemental Table 3</xref>). This indicates that diet can have differential effects on beneficial bacteria such as short-chain fatty acid producers including <italic toggle="yes">Blautia, Faecalibacterium,</italic> and <italic toggle="yes">Bifidobacterium.</italic> Differentially abundant genera were also calculated between MeDi and chow rats and WD and chow rats and are displayed in <xref rid="appsec1" ref-type="sec">Supplemental Tables 4 and 5</xref>.<fig id="fig7" position="float" orientation="portrait"><label>FIGURE 7</label><caption><p>The most abundant phyla (A) and the top 10 most abundant genera (B) by diet. Chow (<italic toggle="yes">n</italic> = 10); MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 10); WD, Western diet (<italic toggle="yes">n</italic> = 8).</p></caption><alt-text id="alttext0045">FIGURE 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig><fig id="fig8" position="float" orientation="portrait"><label>FIGURE 8</label><caption><p>Diet resulted in 28 differentially abundant genera between the MeDi and WD. Relative abundance and LDA values as determined via LEfSe. LDA, linear discriminant analysis; LEfSe, linear discriminant analysis effect size; MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 10); WD, Western diet (<italic toggle="yes">n</italic> = 8).</p></caption><alt-text id="alttext0050">FIGURE 8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p></sec><sec id="sec3.4"><title>Hippocampal barrier integrity is not modified by short-term dietary consumption</title><p id="p0140">A short-term high-energy diet can impact blood&#8211;brain barrier integrity [<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib50" ref-type="bibr">50</xref>]. To determine the effect of a short-term MeDi relative to a WD on barrier integrity, we evaluated gene and protein expression of tight junction proteins. Gene expression of <italic toggle="yes">Occludin</italic> (<italic toggle="yes">P</italic> = 0.03) was higher in MeDi rats compared with WD rats, but <italic toggle="yes">Claudin-5</italic> did not differ between diets (<xref rid="fig9" ref-type="fig">Figure 9</xref>A,B). Furthermore, protein levels of occludin, zonula occludens-1 (ZO-1), and Claudin-5 did not differ between the MeDi and WD (<xref rid="fig10" ref-type="fig">Figure 10</xref>A, C&#8211;E). Lane 1 of the Claudin-5 and lane 15 of ZO-1 Western blots were not included due to dots on the strip (<xref rid="fig10" ref-type="fig">Figure 10</xref>A). Analysis was conducted both with and without the lanes included, and the results were unchanged. Altogether, barrier integrity was not modified in the hippocampus after short-term dietary consumption.<fig id="fig9" position="float" orientation="portrait"><label>FIGURE 9</label><caption><p>Gene expression of barrier integrity, glial activity, neuroplasticity, and housekeeping had no differences between diets in hippocampal tissue. Fold change analysis for barrier integrity (A, B), glial activity (C-F), and neuroplasticity (G, H). One-way ANOVA was performed. Data are represented as mean&#8201;&#177;&#8201;SEM. &#8727;<italic toggle="yes">P</italic> &lt; 0.05, &#8727;&#8727;<italic toggle="yes">P</italic> &lt; 0.01, #<italic toggle="yes">P</italic> = 0.07. Chow (<italic toggle="yes">n</italic> = 4&#8211;5); MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 4&#8211;5); WD, Western diet (<italic toggle="yes">n</italic> = 4&#8211;5). ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor; GFAP, glial fibrillary acidic protein; IBA-1, ionized calcium binding adaptor molecule 1; PSD-95, postsynaptic density protein-95; TREM2, triggering receptor expressed on myeloid cells 2.</p></caption><alt-text id="alttext0055">FIGURE 9</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr9.jpg"/></fig><fig id="fig10" position="float" orientation="portrait"><label>FIGURE 10</label><caption><p>Western blot of the hippocampus for markers of barrier integrity, glial activity, neuroplasticity, and housekeeping had no differences between diets. Western blot images (A, B) and fold change analysis for barrier integrity (C-E), glial activity (F-H), and neuroplasticity (I-K). One-way ANOVA was performed. Data are represented as mean&#8201;&#177;&#8201;SEM. Chow (<italic toggle="yes">n</italic> = 5); MeDi, Mediterranean diet (<italic toggle="yes">n</italic> = 5); WD, Western diet (<italic toggle="yes">n</italic> = 5). #<italic toggle="yes">P</italic> = 0.08. ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor; GFAP, glial fibrillary acidic protein; IBA-1, ionized calcium binding adaptor molecule 1; PSD-95, postsynaptic density protein-95; ZO-1, zonula occludens-1.</p></caption><alt-text id="alttext0060">FIGURE 10</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr10.jpg"/></fig></p></sec><sec id="sec3.5"><title>Hippocampal glial cell activity differed by diet at the level of gene but not protein expression</title><p id="p0145">Astrocytes and microglia are regulators of neuroinflammation and play a role in healthy brain aging. To determine the effect of a short-term MeDi relative to a WD on glial cell activity, we evaluated gene and protein expression of astrocytes, microglia, and a marker of microglial activation by measuring <italic toggle="yes">GFAP</italic>, <italic toggle="yes">IBA-1</italic>, and <italic toggle="yes">C</italic>D<italic toggle="yes">11b</italic>, respectively (<xref rid="fig9" ref-type="fig">Figure 9</xref>C&#8211;F). <italic toggle="yes">GFAP</italic> gene expression was decreased (<italic toggle="yes">P</italic> = 0.021) and <italic toggle="yes">IBA-</italic>1 gene expression was increased (<italic toggle="yes">P</italic> = 0.004) in MeDi rats compared with WD rats. To further characterize the increase in <italic toggle="yes">IBA-1</italic>, markers of phagocytic activity, <italic toggle="yes">TREM2</italic> and <italic toggle="yes">C</italic>D<italic toggle="yes">11b,</italic> were measured. There was an increase in gene expression of <italic toggle="yes">TREM2</italic> (<italic toggle="yes">P</italic> = 0.002) and a trend for <italic toggle="yes">C</italic>D<italic toggle="yes">11b</italic> to be increased (<italic toggle="yes">P</italic> = 0.071) in MeDi rats compared with WD rats. However, the analysis of <italic toggle="yes">TREM2</italic> was conducted with an outlier removed using the Robust OUTlier detection test (ROUT) method (value = 0.26, mean = 1.478, SD = 0.283). When the outlier was included in the analysis, there was no difference between diet groups (<italic toggle="yes">P</italic> = 0.164; <xref rid="appsec1" ref-type="sec">Supplemental Figure 2</xref>). Protein expression of glial cell activity markers was inconsistent with RNA expression. IBA-1 and GFAP protein expression were not altered by diet. For CD11b there was an opposite trend for protein and gene expression; CD11b protein expression was decreased in MeDi rats relative to WD rats (<xref rid="fig10" ref-type="fig">Figure 10</xref>A, B, F&#8211;H). Taken together, these gene and protein expression results suggest that there are subtle differences in glial cell activity at the level of gene expression but not protein expression. This could indicate upregulation of glial cell mRNA levels to compensate for protein clearance within the MeDi rats or a potential differential effect of diet on mRNA translation to protein.</p></sec><sec id="sec3.6"><title>Hippocampal neuroplasticity is not modified by short-term dietary consumption</title><p id="p0150">Neuroplasticity is important for learning and memory but is negatively impacted by aging and diet [<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib52" ref-type="bibr">52</xref>]. To determine the effect of a short-term MeDi relative to a WD on neuroplasticity, we evaluated PSD-95 and BDNF gene and protein expression. Gene expression of <italic toggle="yes">PSD-95</italic> and <italic toggle="yes">BDNF</italic> did not differ between diets (<xref rid="fig10" ref-type="fig">Figure 10</xref>A, B, I&#8211;K). Protein expression of PSD-95 and pro- and truncated-BDNF did not differ between the MeDi and WD animals (<xref rid="fig9" ref-type="fig">Figure 9</xref>G, H). Overall, this indicates that a short-term diet did not impact markers of neuroplasticity in MeDi rats relative to WD rats.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0155">This study is the first to compare in middle-aged rats the effects of a short-term MeDi relative to a WD on cognitive performance, gut microbiota, and markers related to brain health in the hippocampus. Our hypothesis was that MeDi, when introduced to middle-aged rats, would maintain cognitive health and produce a distinct gut microbiota composition relative to a WD. The hypothesis was partially supported by the results. After a 12-wk dietary intervention, there were only trend differences in cognitive performance. On Y-maze testing, MeDi rats had a mean score of 70.68% indicating competency (&gt;66%), whereas the WD rats did not (60.69%), and the MeDi rats had 7.2-fold higher odds of reaching a score of 50% or greater. MeDi rats had a trend toward shorter latency in MWM and MWM reversal testing relative to WD rats. These results indicated that rats may be starting to develop diet-dependent cognitive performance differences. However, there was no difference in % correct alternations in Y-maze or error types for WRAM between diets. Taken together, short-term consumption of the WD did not lead to statistically significant differences in cognition; however, trends in analysis suggest the potential for WD to impair aspects of short- and long-term memory. The short-term diet produced distinct diet-dependent microbial phenotypes exhibited by differences in &#945;- and &#946;-diversity and 28 differentially abundant bacteria, including <italic toggle="yes">Blautia</italic>, <italic toggle="yes">Clostridia</italic> UCG-014, <italic toggle="yes">Clostridium innocuum</italic> group, <italic toggle="yes">Faecalibacterium,</italic> and <italic toggle="yes">Bifidobacterium</italic>. We also found changes in gene expression, but not protein expression, related to glial cell activity, including <italic toggle="yes">GFAP</italic>, <italic toggle="yes">IBA-1</italic>, and <italic toggle="yes">TREM2</italic> in the hippocampus of middle-aged rats. Additional markers related to blood-brain barrier integrity, glial cell activity, or neuroplasticity did not differ between diets.</p><p id="p0160">Overall, animals did not differ in kcal consumed across weeks of the study. During the first 2 wk of the study, rats consuming the WD and MeDi had a higher kcal intake. This observation was not seen with the chow diet and may be due to the novelty of the MeDi and WD. This was also observed in our previous study in young rats and in mice consuming a high-fat (lard) diet [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib53" ref-type="bibr">53</xref>]. Kcal intake is often reported by mean in a bar plot for all weeks, which may not visualize this increase at the beginning of a study. Additionally, there was no difference in animal weight between groups. This was anticipated as diets were kcal matched, as obesity is an independent risk factor for cognitive impairment [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>]. The importance of the quality of dietary intake, not calorie intake, was demonstrated in 2 clinical studies where adherence to the MeDi resulted in lower total, high-density lipoprotein, and low-density lipoprotein cholesterol levels. Additionally, there was a higher abundance of taxa that were positively associated with better cognitive function and negatively correlated with markers of inflammation independent of energy intake [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib54" ref-type="bibr">54</xref>]. Using kcal-matched diets in this study allowed for the determination of the effects of the composition of a dietary pattern regardless of caloric intake.</p><p id="p0165">Our previous research indicated that young male rats fed a MeDi for 14 wk had better cognitive performance and flexibility relative to young male rats fed a WD for 14 wk [<xref rid="bib29" ref-type="bibr">29</xref>]. In that study, when descriptively comparing the 2 studies, Y-maze scores were similar. However, for the MWM platform, the MeDi young rats performed similarly, but the WD young rats exhibited poorer performance (&lt;40%), whereas the middle-aged WD rats exhibited greater learning of the platform location. For the WRAM, across days, the WD rats exhibited similar total errors regardless of age, whereas the MeDi young rats had fewer errors than the middle-aged MeDi rats. As the rats in the previous study were young, they may have been more susceptible to the impact of diet, resulting in more robust behavioral differences than those observed in the middle-aged rats here. In the younger rats, the MeDi and WD were introduced at 10-wk of age, and in this study, those diets were introduced at 12 mo of age. It is possible that in this study, the feeding of animals for 12 mo with a chow diet may have increased resilience against the adverse cognitive effects of a short-term WD.</p><p id="p0170">A meta-analysis of rodent studies concluded that diets high in fat, sugar, or both have negative effects on hippocampal-dependent spatial learning and memory in both mice and rats [<xref rid="bib55" ref-type="bibr">55</xref>]. However, the majority of those studies were completed in young rats, with only 1 study using aged rats (24 mo of age) [<xref rid="bib55" ref-type="bibr">55</xref>]. This suggests that there may be time points when dietary pattern adherence is critical for cognitive performance. Dietary pattern adherence during youth and adulthood has been associated with cognitive health during midlife. The time point at which the dietary interventions are started in the lifespan of rodent studies may be a critical factor for consideration [<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib57" ref-type="bibr">57</xref>]. Similar to our study, 7-mo-old male Sprague Dawley rats consuming a high-fat diet (45%) exhibited differences in microbial composition but not cognitive performance after 8 wk [<xref rid="bib58" ref-type="bibr">58</xref>], supporting the notion that a short-term diet does not mitigate the cognitive benefits of a long-term diet. The effects of age of diet onset and duration of diets need to be further elucidated in nutrition-related aging research.</p><p id="p0175">In this study, there were diet-dependent microbial phenotypes exhibited in rats after 12 wk of the MeDi and WD. MeDi rats exhibited changes in &#945;-diversity, including an increase in Simpson, Shannon, and Chao1 measurements relative to WD rats. &#945;-Diversity is commonly associated with overall health, with higher diversity indicating generally better metabolic health [<xref rid="bib59" ref-type="bibr">59</xref>]. These findings also build upon previous research in rodents and nonhuman primates exhibiting increases in measures of &#945;-diversity with a MeDi relative to a WD [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib61" ref-type="bibr">61</xref>]. Human studies of a MeDi intervention reported mixed findings with most studies indicating an increase or no change in &#945;-diversity relative to the comparator diet [<xref rid="bib6" ref-type="bibr">6</xref>]. The variability in the comparator diets may have contributed to mixed &#945;-diversity findings, whereas the rodent and nonhuman primate studies are controlled to a standard WD. It is important to note that &#945;-diversity alone does not represent overall health, as animal and human studies have shown contradictory &#945;-diversity results for disease states [<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib63" ref-type="bibr">63</xref>]. &#945;-Diversity results should be reported in conjunction with compositional differences between the diets to elucidate which bacteria may be driving the &#945;-diversity measurements.</p><p id="p0180">There were substantial differences in bacteria between the MeDi and WD, including 28 differentially abundant bacteria. <italic toggle="yes">Blautia</italic> was 1 bacterium found to be increased with the MeDi relative to the WD in our study. This bacterium has also been identified to be decreased in neurodegenerative diseases and increased with adherence to a MeDi in clinical studies [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib64" ref-type="bibr">64</xref>]. It is proposed to have potential probiotic properties through supporting mucus growth, modulation of high-fat diet-induced obesity metabolism and inflammation, and immune system interactions [<xref rid="bib65" ref-type="bibr">[65]</xref>, <xref rid="bib66" ref-type="bibr">[66]</xref>, <xref rid="bib67" ref-type="bibr">[67]</xref>, <xref rid="bib68" ref-type="bibr">[68]</xref>]. This is in addition to the increase in other genera associated with MeDi adherence or components of the MeDi, such as fiber, polyphenols, or polyunsaturated fatty acid intake, including <italic toggle="yes">Clostridium, Holdemania,</italic> and <italic toggle="yes">Ruminococcus</italic> [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib69" ref-type="bibr">[69]</xref>, <xref rid="bib70" ref-type="bibr">[70]</xref>, <xref rid="bib71" ref-type="bibr">[71]</xref>]. However, it is important to remember that the species and strain of the bacteria are critical, as this can lead to different functionality of the bacteria. For example, 2 unclassified <italic toggle="yes">Blautia</italic> genera were identified as both increasing and decreasing with adherence to the MeDi in the same study [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib68" ref-type="bibr">68</xref>]. The importance of specificity is also important as bacteria often associated with health benefits were increased with the WD, including <italic toggle="yes">Bifidobacterium and Faecalibacterium</italic>. The findings of an increase in <italic toggle="yes">Bifidobacterium</italic> were consistent with our previous findings in young male rats fed the WD [<xref rid="bib29" ref-type="bibr">29</xref>]. <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Faecalibacterium</italic> can ferment simple carbohydrates, which are found in high amounts in the WD [<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib73" ref-type="bibr">73</xref>]. The overabundance of this substrate may promote its growth. Although these beneficial genera were increased with the WD, the reduction of other fiber-fermenting and health-associated genera, such as <italic toggle="yes">Clostridium, Holdemania,</italic> and <italic toggle="yes">Ruminococcus</italic>, is essential to consider. The differential growth of bacteria between diets may be due to substrate availability. For example, 1 study demonstrated that <italic toggle="yes">Bifidobacterium</italic> increased with the intake of fiber, polyphenols, and a fiber + polyphenol blend, whereas <italic toggle="yes">Dorea</italic> was substrate selective and increased with only the polyphenols or fiber+ polyphenol blend [<xref rid="bib71" ref-type="bibr">71</xref>]. The WD may induce a shift away from a balanced and diverse microbiota composition that is observed within MeDi rats because of different substrate availability.</p><p id="p0185">The MeDi has been associated with brain health and neuroprotection [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib31" ref-type="bibr">31</xref>]. By contrast, a diet high in saturated fats such as lard has been implicated in damaging changes to barrier integrity, glial cell activity, and neuroplasticity [<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib74" ref-type="bibr">74</xref>,<xref rid="bib75" ref-type="bibr">75</xref>]. Our data indicated differences in mRNA levels of glial cells, but not barrier integrity or neuroplasticity gene expression, in MeDi rats relative to WD rats after a short-term dietary intervention. This included an increase in <italic toggle="yes">IBA-1</italic> and <italic toggle="yes">TREM2</italic> and a decrease in <italic toggle="yes">GFAP</italic> gene expression in MeDi rats relative to WD rats. Although the change in astrocyte expression is consistent with diets high in fat [<xref rid="bib74" ref-type="bibr">74</xref>,<xref rid="bib76" ref-type="bibr">76</xref>], the increased expression of microglia suggests a potential activation of microglia with the MeDi or, conversely, a suppression of microglia with the WD. An increase in microglia has been demonstrated with other modifiable lifestyle factors such as exercise and environmental enrichment [<xref rid="bib77" ref-type="bibr">77</xref>,<xref rid="bib78" ref-type="bibr">78</xref>]. An increase in microglia may be protective in certain contexts as microglia are responsible for maintaining homeostasis and clearing debris. Furthermore, TREM2 can modulate microglia-mediated inflammation, promoting an anti-inflammatory response [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>]. Dietary components such as polyphenols and omega-3 polyunsaturated fatty acids, also found in our MeDi, may promote the shift toward an anti-inflammatory microglia phenotype [<xref rid="bib70" ref-type="bibr">70</xref>,<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib81" ref-type="bibr">81</xref>]. Aspects of the MeDi, including olive oil and polyphenols, may contribute to the increase in gene expression of <italic toggle="yes">IBA-1</italic> and <italic toggle="yes">TREM2</italic> in MeDi rats relative to WD rats. However, these differences were observed at the RNA but not at the protein level. As the ventral and lateral regions of the hippocampus were not separated for analysis, there could be potential region-specific differences in these markers that warrant further exploration. Additionally, this could also suggest that mechanisms related to translation of mRNA to protein may be impacted between diets; or that the short-term diets caused reductions in protein levels that triggered increased gene expression to maintain homeostasis. A longer study duration may have potentiated the differences in gene and protein levels in our study. A time-course study is of interest to determine temporal changes in mRNA and protein levels of glial cells.</p><p id="p0190">This study presents novel findings as it is the first to assess in middle-aged rats the effects of a MeDi on cognition, microbiota, and biomarkers of brain health compared with a WD. Use of diets that are modeled on human dietary intake of a MeDi and WD increases the translatability and clinical relevance of the study. However, there are limitations to the study, including the use of only male rats and a nonpurified control diet. Male rats were selected in this study to control for hormonal differences that may increase variability in model development; however, this limits the translatability of the study to the population as a whole. It will be important to determine if there are differential effects of the diet on brain health due to sex. Our study aimed to only compare the MeDi and WD with the chow diet as a reference, and not a comparator. However, a purified diet was not used as the reference/positive control diet to the MeDi. Nonpurified diets may decrease reproducibility between studies, as &#8220;standard&#8221; laboratory chows can greatly differ between manufacturers [<xref rid="bib82" ref-type="bibr">82</xref>,<xref rid="bib83" ref-type="bibr">83</xref>]. Future studies will utilize a purified diet as the reference group to increase reproducibility. Additionally, we recognize that the dietary patterns of a MeDi or WD can have varied intake of micro- and macronutrients by day or by individual. Therefore, as this diet was formulated based on dietary records, it represents 1 interpretation of a WD and MeDi.</p><p id="p0195">In conclusion, we found that short-term MeDi and WD did not lead to statistically significant differences in cognition; however, trends in analysis suggest the potential for WD to impair cognitive function in middle-aged male rats, in contrast to our previous study in young rats, where the diets had more pronounced effects [<xref rid="bib29" ref-type="bibr">29</xref>]. Diets resulted in distinct gut microbial compositions with changes in &#945;-diversity, &#946;-diversity, and various genera. WD was associated with an increase in the expression of genes encoding proteins associated with astrocytic activity, and MeDi was associated with an increase in the expression of genes associated with glial activity. However, the protein levels of these astrocytic and glial markers did not differ by diet. Our results suggest that a longer diet duration or earlier implementation of the diet in the rat lifespan may be needed to elucidate differences between the MeDi and WD, as well as larger sample sizes.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0200">The authors&#8217; responsibilities were as follows &#8211; RJS-O, EBE-G, GB, DMM: designed the research; RJS-O, CH, MP, BO, SI: conducted the research; RJS-O: analyzed the data and wrote the first manuscript draft; and all authors: read, edited, and approved the final version.</p></sec><sec sec-type="data-availability" id="sec6"><title>Data availability</title><p id="p0205">The data that support the findings of this study are openly available in <funding-source id="gs3">National Center for Biotechnology</funding-source> Information (NCBI)-Sequence Read Archive (<funding-source id="gs4">SRA</funding-source>) at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra" id="intref0015">https://www.ncbi.nlm.nih.gov/sra</ext-link>, reference number PRJNA1289902 (16S rRNA sequencing dataset). Additional data described in the manuscript, code book, and analytic code will be made available upon request.</p></sec><sec id="sec7"><title>Funding</title><p id="p0210">Research reported in this publication was supported by the <funding-source id="gs1">National Institute of General Medical Sciences</funding-source> of the <funding-source id="gs2">NIH</funding-source> under Award Number P20GM103629. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflict of interest</title><p id="p0215">DMM and RJS-O are inventors for US provisional patent 63/733,817 (Filed 13 Dec. 2024), entitled "Microbiota Compositions and Methods for Using the Same to Prevent or Treat Cognitive Decline." The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><collab>United Nations Department of Economic and Social Affairs</collab></person-group><part-title>Leaving No One Behind In An Ageing World. World Social Report 2023</part-title><year>2019</year><publisher-name>World Population Ageing</publisher-name><publisher-loc>Nueva York</publisher-loc></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Coradduzza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sedda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cruciani</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Miglio</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nivoli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Age-related cognitive decline, focus on microbiome: a systematic review and meta-analysis</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume><issue>18</issue><year>2023</year><object-id pub-id-type="publisher-id">13680</object-id><pub-id pub-id-type="doi">10.3390/ijms241813680</pub-id><pub-id pub-id-type="pmcid">PMC10531012</pub-id><pub-id pub-id-type="pmid">37761988</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scarmeas</surname><given-names>N.</given-names></name></person-group><article-title>Dietary patterns in Alzheimer's disease and cognitive aging</article-title><source>Curr. Alzheimer Res.</source><volume>8</volume><issue>5</issue><year>2011</year><fpage>510</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.2174/156720511796391836</pub-id><pub-id pub-id-type="pmid">21605048</pub-id><pub-id pub-id-type="pmcid">PMC3283139</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Poulter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burch</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bulpitt</surname><given-names>C.</given-names></name></person-group><article-title>Smoking, dementia and cognitive decline in the elderly, a systematic review</article-title><source>BMC Geriatr</source><volume>8</volume><year>2008</year><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1471-2318-8-36</pub-id><pub-id pub-id-type="pmid">19105840</pub-id><pub-id pub-id-type="pmcid">PMC2642819</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name></person-group><article-title>Modifiable lifestyle factors and cognitive reserve: a systematic review of current evidence</article-title><source>Ageing Res. Rev.</source><volume>74</volume><year>2022</year><object-id pub-id-type="publisher-id">101551</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2021.101551</pub-id><pub-id pub-id-type="pmcid">PMC8794051</pub-id><pub-id pub-id-type="pmid">34952208</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Solch</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Aigbogun</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Voyiadjis</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Talkington</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Darensbourg</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: a systematic review</article-title><source>J. Neurol. Sci.</source><volume>434</volume><year>2022</year><object-id pub-id-type="publisher-id">120166</object-id><pub-id pub-id-type="doi">10.1016/j.jns.2022.120166</pub-id><pub-id pub-id-type="pmid">35144237</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Lapiscina</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Clavero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Estruch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salas-Salvad&#243;</surname><given-names>J.</given-names></name><name name-style="western"><surname>San Juli&#225;n</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial</article-title><source>J. Neurol. Neurosurg. Psychiatry.</source><volume>84</volume><issue>12</issue><year>2013</year><fpage>1318</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-304792</pub-id><pub-id pub-id-type="pmid">23670794</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Valls-Pedret</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sala-Vila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serra-Mir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corella</surname><given-names>D.</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Gonz&#225;lez</surname><given-names>M.&#193;.</given-names></name><etal/></person-group><article-title>Mediterranean diet and age-related cognitive decline: a randomized clinical trial, JAMA Int</article-title><source>Med</source><volume>175</volume><issue>7</issue><year>2015</year><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.1668</pub-id><pub-id pub-id-type="pmid">25961184</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Ballarini</surname><given-names>T.</given-names></name><name name-style="western"><surname>Melo van Lent</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolfsgruber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Altenstein</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mediterranean diet, Alzheimer disease biomarkers, and brain atrophy in old age</article-title><source>Neurology</source><volume>96</volume><issue>24</issue><year>2021</year><fpage>e2920</fpage><lpage>e2932</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000012067</pub-id><pub-id pub-id-type="pmid">33952652</pub-id><pub-id pub-id-type="pmcid">PMC8253566</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Hardman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Macpherson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scholey</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pipingas</surname><given-names>A.</given-names></name></person-group><article-title>Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials</article-title><source>Front. Nutr.</source><volume>3</volume><year>2016</year><fpage>22</fpage><pub-id pub-id-type="doi">10.3389/fnut.2016.00022</pub-id><pub-id pub-id-type="pmid">27500135</pub-id><pub-id pub-id-type="pmcid">PMC4956662</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fosnacht Morgan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Munson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yucus</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Use of an electronic medical record to track adherence to the Mediterranean diet in a US neurology clinical practice</article-title><source>Mayo Clin. Proc. Innov. Qual. Outcomes.</source><volume>2</volume><issue>1</issue><year>2018</year><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.mayocpiqo.2017.12.003</pub-id><pub-id pub-id-type="pmid">30225432</pub-id><pub-id pub-id-type="pmcid">PMC6124331</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>da Costa</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>da Concei&#231;&#227;o Nepomuceno</surname><given-names>G.</given-names></name><name name-style="western"><surname>da Silva Pereira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>B.F.T.</given-names></name></person-group><article-title>Worldwide dietary patterns and their association with socioeconomic data: an ecological exploratory study</article-title><source>Global Health</source><volume>18</volume><issue>1</issue><year>2022</year><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s12992-022-00820-w</pub-id><pub-id pub-id-type="pmid">35279165</pub-id><pub-id pub-id-type="pmcid">PMC8917745</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Oikonomou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Psaltopoulou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Georgiopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Siasos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kokkou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antonopoulos</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Western dietary pattern is associated with severe coronary artery disease</article-title><source>Angiology</source><volume>69</volume><issue>4</issue><year>2018</year><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1177/0003319717721603</pub-id><pub-id pub-id-type="pmid">28731359</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Medina-Rem&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirwan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lamuela-Ravent&#243;s</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Estruch</surname><given-names>R.</given-names></name></person-group><article-title>Dietary patterns and the risk of obesity, type 2 diabetes mellitus, cardiovascular diseases, asthma, and neurodegenerative diseases</article-title><source>Crit. Rev. Food Sci. Nutr.</source><volume>58</volume><issue>2</issue><year>2018</year><fpage>262</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1080/10408398.2016.1158690</pub-id><pub-id pub-id-type="pmid">27127938</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Carmody</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Gootenberg</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Button</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>Diet rapidly and reproducibly alters the human gut microbiome</article-title><source>Nature</source><volume>505</volume><issue>7484</issue><year>2014</year><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature12820</pub-id><pub-id pub-id-type="pmid">24336217</pub-id><pub-id pub-id-type="pmcid">PMC3957428</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Lyte</surname><given-names>J.M.</given-names></name></person-group><article-title>Eating for 3.8 &#215; 10(13): examining the impact of diet and nutrition on the microbiota-gut-brain axis through the lens of microbial endocrinology</article-title><source>Front. Endocrinol. (Lausanne).</source><volume>9</volume><year>2018</year><fpage>796</fpage><pub-id pub-id-type="doi">10.3389/fendo.2018.00796</pub-id><pub-id pub-id-type="pmid">30761092</pub-id><pub-id pub-id-type="pmcid">PMC6361751</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Zmora</surname><given-names>N.</given-names></name><name name-style="western"><surname>Suez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E.</given-names></name></person-group><article-title>You are what you eat: diet, health and the gut microbiota</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><volume>16</volume><issue>1</issue><year>2019</year><fpage>35</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/s41575-018-0061-2</pub-id><pub-id pub-id-type="pmid">30262901</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Leigh</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.J.</given-names></name></person-group><article-title>Diet, inflammation and the gut microbiome: mechanisms for obesity-associated cognitive impairment</article-title><source>Biochim. Biophys. Acta Mol. Basis. Dis.</source><volume>1866</volume><issue>6</issue><year>2020</year><object-id pub-id-type="publisher-id">165767</object-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165767</pub-id><pub-id pub-id-type="pmid">32171891</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Statovci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aguilera</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacSharry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Melgar</surname><given-names>S.</given-names></name></person-group><article-title>The impact of Western diet and nutrients on the microbiota and immune response at mucosal interfaces</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>838</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00838</pub-id><pub-id pub-id-type="pmid">28804483</pub-id><pub-id pub-id-type="pmcid">PMC5532387</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Agus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Denizot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Th&#233;venot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinez-Medina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Massier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sauvanet</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Western diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive E. coli infection and intestinal inflammation</article-title><source>Sci. Rep.</source><volume>6</volume><issue>1</issue><year>2016</year><object-id pub-id-type="publisher-id">19032</object-id><pub-id pub-id-type="doi">10.1038/srep19032</pub-id><pub-id pub-id-type="pmcid">PMC4705701</pub-id><pub-id pub-id-type="pmid">26742586</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Malesza</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Malesza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walkowiak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mussin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walkowiak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aringazina</surname><given-names>R.</given-names></name><etal/></person-group><article-title>High-fat, Western-style diet, systemic inflammation, and gut microbiota: a narrative review</article-title><source>Cells</source><volume>10</volume><issue>11</issue><year>2021</year><fpage>3164</fpage><pub-id pub-id-type="doi">10.3390/cells10113164</pub-id><pub-id pub-id-type="pmid">34831387</pub-id><pub-id pub-id-type="pmcid">PMC8619527</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota</article-title><source>Alzheimer&#8217;s Dement.</source><volume>15</volume><issue>10</issue><year>2019</year><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.07.002</pub-id><pub-id pub-id-type="pmid">31434623</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mulak</surname><given-names>A.</given-names></name></person-group><article-title>Brain-gut-microbiota axis in Alzheimer's disease</article-title><source>J. Neurogastroenterol. Motil.</source><volume>25</volume><issue>1</issue><year>2019</year><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5056/jnm18087</pub-id><pub-id pub-id-type="pmid">30646475</pub-id><pub-id pub-id-type="pmcid">PMC6326209</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>D'Amato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Cesare Mannelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lucarini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Man</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Le Gall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Branca</surname><given-names>J.J.V.</given-names></name><etal/></person-group><article-title>Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients</article-title><source>Microbiome</source><volume>8</volume><issue>1</issue><year>2020</year><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s40168-020-00914-w</pub-id><pub-id pub-id-type="pmid">33004079</pub-id><pub-id pub-id-type="pmcid">PMC7532115</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Khine</surname><given-names>W.W.T.</given-names></name><name name-style="western"><surname>Voong</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>T.K.S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rane</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Mental awareness improved mild cognitive impairment and modulated gut microbiome</article-title><source>Aging (Albany NY)</source><volume>12</volume><issue>23</issue><year>2020</year><fpage>24371</fpage><lpage>24393</lpage><pub-id pub-id-type="doi">10.18632/aging.202277</pub-id><pub-id pub-id-type="pmid">33318317</pub-id><pub-id pub-id-type="pmcid">PMC7762482</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Saji</surname><given-names>N.</given-names></name><name name-style="western"><surname>Murotani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hisada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuduki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan</article-title><source>Sci. Rep.</source><volume>9</volume><issue>1</issue><year>2019</year><object-id pub-id-type="publisher-id">19227</object-id><pub-id pub-id-type="doi">10.1038/s41598-019-55851-y</pub-id><pub-id pub-id-type="pmcid">PMC6920432</pub-id><pub-id pub-id-type="pmid">31852995</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Debroy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shikany</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meirelles</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Association of the gut microbiota with cognitive function in midlife</article-title><source>JAMA Netw. Open</source><volume>5</volume><issue>2</issue><year>2022</year><object-id pub-id-type="publisher-id">e2143941</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.43941</pub-id><pub-id pub-id-type="pmcid">PMC8826173</pub-id><pub-id pub-id-type="pmid">35133436</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Rampelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeffery</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Capri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries</article-title><source>Gut</source><volume>69</volume><issue>7</issue><year>2020</year><fpage>1218</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319654</pub-id><pub-id pub-id-type="pmid">32066625</pub-id><pub-id pub-id-type="pmcid">PMC7306987</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Solch-Ottaiano</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Engler-Chiurazzi</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wasson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogbonna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ouvrier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Comparison between two divergent diets, Mediterranean and Western, on gut microbiota and cognitive function in young Sprague Dawley rats</article-title><source>Gut Microbes Rep</source><volume>1</volume><issue>1</issue><year>2024</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/29933935.2024.2439490</pub-id><pub-id pub-id-type="pmcid">PMC11800364</pub-id><pub-id pub-id-type="pmid">39916748</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeddi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kashfi</surname><given-names>K.</given-names></name></person-group><article-title>The laboratory rat: age and body weight matter</article-title><source>Excli. J.</source><volume>20</volume><year>2021</year><fpage>1431</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.17179/excli2021-4072</pub-id><pub-id pub-id-type="pmid">34737685</pub-id><pub-id pub-id-type="pmcid">PMC8564917</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Fekete</surname><given-names>M.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fekete</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Buda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szappanos</surname><given-names>&#193;.</given-names></name><etal/></person-group><article-title>The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer&#8217;s disease: a meta-analysis</article-title><source>GeroScience</source><volume>47</volume><issue>3</issue><year>2025</year><fpage>3111</fpage><lpage>3130</lpage><pub-id pub-id-type="doi">10.1007/s11357-024-01488-3</pub-id><pub-id pub-id-type="pmid">39797935</pub-id><pub-id pub-id-type="pmcid">PMC12181514</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Nooyens</surname><given-names>A.C.J.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Bas</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Boxtel</surname><given-names>M.P.J.</given-names></name><name name-style="western"><surname>Picavet</surname><given-names>H.S.J.</given-names></name><etal/></person-group><article-title>Adherence to dietary guidelines and cognitive decline from middle age: the Doetinchem Cohort Study</article-title><source>Am. J. Clin. Nutr.</source><volume>114</volume><issue>3</issue><year>2021</year><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqab109</pub-id><pub-id pub-id-type="pmid">34004676</pub-id><pub-id pub-id-type="pmcid">PMC8408878</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Gauci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Arnoldy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lassemillante</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Scholey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pipingas</surname><given-names>A.</given-names></name></person-group><article-title>Dietary patterns in middle age: effects on concurrent neurocognition and risk of age-related cognitive decline</article-title><source>Nutr. Rev.</source><volume>80</volume><issue>5</issue><year>2022</year><fpage>1129</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1093/nutrit/nuab047</pub-id><pub-id pub-id-type="pmid">34392373</pub-id><pub-id pub-id-type="pmcid">PMC8990759</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Dearborn-Tomazos</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Association of dietary patterns in midlife and cognitive function in later life in US adults without dementia</article-title><source>JAMA Netw. Open</source><volume>2</volume><issue>12</issue><year>2019</year><object-id pub-id-type="publisher-id">e1916641</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.16641</pub-id><pub-id pub-id-type="pmcid">PMC6902753</pub-id><pub-id pub-id-type="pmid">31800068</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Barrington</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Wulfridge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>S.Y.F.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Improving metabolic health through precision dietetics in mice</article-title><source>Genetics</source><volume>208</volume><issue>1</issue><year>2018</year><fpage>399</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1534/genetics.117.300536</pub-id><pub-id pub-id-type="pmid">29158425</pub-id><pub-id pub-id-type="pmcid">PMC5753872</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Prickett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stolwyk</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>L.</given-names></name></person-group><article-title>Neuropsychological functioning in mid-life treatment-seeking adults with obesity: a cross-sectional study</article-title><source>Obes. Surg.</source><volume>28</volume><issue>2</issue><year>2018</year><fpage>532</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1007/s11695-017-2894-0</pub-id><pub-id pub-id-type="pmid">28849437</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Gunstad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Spitznagel</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>E.</given-names></name></person-group><article-title>Elevated body mass index is associated with executive dysfunction in otherwise healthy adults</article-title><source>Compr. Psychiatry.</source><volume>48</volume><issue>1</issue><year>2007</year><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.comppsych.2006.05.001</pub-id><pub-id pub-id-type="pmid">17145283</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>L.</given-names></name><name name-style="western"><surname>Micoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>B.</given-names></name></person-group><article-title>Obesity, putative biological mediators, and cognitive function in a national sample of children and adolescents</article-title><source>Prev. Med.</source><volume>150</volume><year>2021</year><object-id pub-id-type="publisher-id">106659</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2021.106659</pub-id><pub-id pub-id-type="pmid">34097950</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Engler-Chiurazzi</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Cavendish</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Povroznik</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>D.D.</given-names></name><etal/></person-group><article-title>Over-expression of miR-34a induces rapid cognitive impairment and Alzheimer's disease-like pathology</article-title><source>Brain Res</source><volume>1721</volume><year>2019</year><object-id pub-id-type="publisher-id">146327</object-id><pub-id pub-id-type="doi">10.1016/j.brainres.2019.146327</pub-id><pub-id pub-id-type="pmcid">PMC7014559</pub-id><pub-id pub-id-type="pmid">31295467</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Engler-Chiurazzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nonnenmacher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Corneveaux</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Prokai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein levels and alters gene expression in middle-aged rats</article-title><source>Neurobiol Aging</source><volume>32</volume><issue>4</issue><year>2011</year><fpage>680</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.09.005</pub-id><pub-id pub-id-type="pmid">19883953</pub-id><pub-id pub-id-type="pmcid">PMC3016463</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Engler-Chiurazzi</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Talboom</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Braden</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>C.W.S.</given-names></name><name name-style="western"><surname>Mennenga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Continuous estrone treatment impairs spatial memory and does not impact number of basal forebrain cholinergic neurons in the surgically menopausal middle-aged rat, Horm</article-title><source>Behav.</source><volume>62</volume><issue>1</issue><year>2012</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2012.04.004</pub-id><pub-id pub-id-type="pmcid">PMC3397199</pub-id><pub-id pub-id-type="pmid">22522079</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="book" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Amplicon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Clean-Up</surname><given-names>P.</given-names></name><name name-style="western"><surname>Index</surname><given-names>P.</given-names></name></person-group><source>16s Metagenomic Sequencing Library Preparation</source><year>2013</year><publisher-name>Illumina</publisher-name><publisher-loc>San Diego, CA, USA</publisher-loc><fpage>21</fpage><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://support.illumina.com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf" id="intref0025a">https://support.illumina.com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf</ext-link></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Bolyen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rideout</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bokulich</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Abnet</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Al-Ghalith</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2</article-title><source>Nat. Biotechnol.</source><volume>37</volume><issue>8</issue><year>2019</year><fpage>852</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0209-9</pub-id><pub-id pub-id-type="pmid">31341288</pub-id><pub-id pub-id-type="pmcid">PMC7015180</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Robeson</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kaehler</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Ziemski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>J.T.</given-names></name><etal/></person-group><article-title>RESCRIPt: reproducible sequence taxonomy reference database management for the masses</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.10.05.326504</pub-id><comment>10.05.326504</comment><pub-id pub-id-type="pmcid">PMC8601625</pub-id><pub-id pub-id-type="pmid">34748542</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Oksanen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blanchet</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Friendly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kindt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Legendre</surname><given-names>P.</given-names></name><name name-style="western"><surname>McGlinn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Szoecs</surname><given-names>Eduard</given-names></name><etal/></person-group><source>Helene Wagner. vegan: Community Ecology Package</source><year>2020</year><pub-id pub-id-type="doi">10.32614/CRAN.package.vegan</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Segata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Izard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waldron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Miropolsky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>Metagenomic biomarker discovery and explanation</article-title><source>Genome Biol</source><volume>12</volume><issue>6</issue><year>2011</year><fpage>R60</fpage><pub-id pub-id-type="doi">10.1186/gb-2011-12-6-r60</pub-id><pub-id pub-id-type="pmid">21702898</pub-id><pub-id pub-id-type="pmcid">PMC3218848</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice</article-title><source>ISME J</source><volume>4</volume><issue>2</issue><year>2010</year><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/ismej.2009.112</pub-id><pub-id pub-id-type="pmid">19865183</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Baothman</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Zamzami</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Taher</surname><given-names>I.</given-names></name><name name-style="western"><surname>Abubaker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abu-Farha</surname><given-names>M.</given-names></name></person-group><article-title>The role of gut microbiota in the development of obesity and diabetes</article-title><source>Lipids Health Dis</source><volume>15</volume><year>2016</year><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s12944-016-0278-4</pub-id><pub-id pub-id-type="pmid">27317359</pub-id><pub-id pub-id-type="pmcid">PMC4912704</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Kanoski</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>T.L.</given-names></name></person-group><article-title>The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat</article-title><source>J. Alzheimers Dis.</source><volume>21</volume><issue>1</issue><year>2010</year><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.3233/jad-2010-091414</pub-id><pub-id pub-id-type="pmid">20413889</pub-id><pub-id pub-id-type="pmcid">PMC4975946</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name></person-group><article-title>Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms</article-title><source>J. Neuroinflammation</source><volume>21</volume><issue>1</issue><year>2024</year><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12974-024-03104-9</pub-id><pub-id pub-id-type="pmid">38678254</pub-id><pub-id pub-id-type="pmcid">PMC11056074</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sibille</surname><given-names>E.</given-names></name></person-group><article-title>The role of BDNF in age-dependent changes of excitatory and inhibitory synaptic markers in the human prefrontal cortex</article-title><source>Neuropsychopharmacology</source><volume>41</volume><issue>13</issue><year>2016</year><fpage>3080</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.1038/npp.2016.126</pub-id><pub-id pub-id-type="pmid">27417517</pub-id><pub-id pub-id-type="pmcid">PMC5101556</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bathalian</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A four-week high-fat diet induces anxiolytic-like behaviors through mature BDNF in the mPFC of mice</article-title><source>Brain Sci</source><volume>14</volume><issue>4</issue><year>2024</year><fpage>389</fpage><pub-id pub-id-type="pmid">38672038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci14040389</pub-id><pub-id pub-id-type="pmcid">PMC11048392</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Licholai</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Fobbs</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kravitz</surname><given-names>A.V.</given-names></name></person-group><article-title>Why do mice overeat high-fat diets? How high-fat diet alters the regulation of daily caloric intake in mice</article-title><source>Obesity (Silver Spring)</source><volume>26</volume><issue>6</issue><year>2018</year><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1002/oby.22195</pub-id><pub-id pub-id-type="pmid">29707908</pub-id><pub-id pub-id-type="pmcid">PMC5970071</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Cani</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Van Hul</surname><given-names>M.</given-names></name></person-group><article-title>Mediterranean diet, gut microbiota and health: when age and calories do not add up</article-title><source>Gut</source><volume>69</volume><issue>7</issue><year>2020</year><fpage>1167</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320781</pub-id><pub-id pub-id-type="pmid">32169906</pub-id><pub-id pub-id-type="pmcid">PMC7306981</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Arnott</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D.M.D.</given-names></name></person-group><article-title>The effect of high fat, high sugar, and combined high fat-high sugar diets on spatial learning and memory in rodents: a meta-analysis</article-title><source>Neurosci. Biobehav. Rev.</source><volume>107</volume><year>2019</year><fpage>399</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.08.010</pub-id><pub-id pub-id-type="pmid">31454627</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Daviglus</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>Intake of vegetables and fruits through young adulthood is associated with better cognitive function in midlife in the US general population</article-title><source>J. Nutr.</source><volume>149</volume><issue>8</issue><year>2019</year><fpage>1424</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1093/jn/nxz076</pub-id><pub-id pub-id-type="pmid">31162586</pub-id><pub-id pub-id-type="pmcid">PMC6686058</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>McEvoy</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Shikany</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Dietary patterns during adulthood and cognitive performance in midlife: the CARDIA study</article-title><source>Neurology</source><volume>92</volume><issue>14</issue><year>2019</year><fpage>e1589</fpage><lpage>e1599</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000007243</pub-id><pub-id pub-id-type="pmid">30842290</pub-id><pub-id pub-id-type="pmcid">PMC6448450</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Deshpande</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pesaresi</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Carrell</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>M.K.</given-names></name><etal/></person-group><article-title>High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats</article-title><source>PLOS One</source><volume>14</volume><issue>5</issue><year>2019</year><object-id pub-id-type="publisher-id">e0217553</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0217553</pub-id><pub-id pub-id-type="pmcid">PMC6541285</pub-id><pub-id pub-id-type="pmid">31141574</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Zouiouich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loftfield</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huybrechts</surname><given-names>I.</given-names></name><name name-style="western"><surname>Viallon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Louca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vogtmann</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Markers of metabolic health and gut microbiome diversity: findings from two population-based cohort studies</article-title><source>Diabetologia</source><volume>64</volume><issue>8</issue><year>2021</year><fpage>1749</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1007/s00125-021-05464-w</pub-id><pub-id pub-id-type="pmid">34110438</pub-id><pub-id pub-id-type="pmcid">PMC8245388</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Huda</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Salvador</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Barrington</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Gacasan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>D'Souza</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Deus Ramirez</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Gut microbiota and host genetics modulate the effect of diverse diet patterns on metabolic health</article-title><source>Front. Nutr.</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">896348</object-id><pub-id pub-id-type="doi">10.3389/fnut.2022.896348</pub-id><pub-id pub-id-type="pmcid">PMC9434023</pub-id><pub-id pub-id-type="pmid">36061898</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Nagpal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shively</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Appt</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Register</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Michalson</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Vitolins</surname><given-names>M.Z.</given-names></name><etal/></person-group><article-title>Gut microbiome composition in non-human primates consuming a Western or Mediterranean diet</article-title><source>Front. Nutr.</source><volume>5</volume><year>2018</year><fpage>28</fpage><pub-id pub-id-type="doi">10.3389/fnut.2018.00028</pub-id><pub-id pub-id-type="pmid">29922651</pub-id><pub-id pub-id-type="pmcid">PMC5996930</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Differences in alpha diversity of gut microbiota in neurological diseases</article-title><source>Front. Neurosci.</source><volume>16</volume><year>2022</year><object-id pub-id-type="publisher-id">879318</object-id><pub-id pub-id-type="doi">10.3389/fnins.2022.879318</pub-id><pub-id pub-id-type="pmcid">PMC9274120</pub-id><pub-id pub-id-type="pmid">35837118</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.L.</given-names></name></person-group><article-title>Diversity alone does not reliably indicate the healthiness of an animal microbiome</article-title><source>ISME J</source><volume>18</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">wrae133</object-id><pub-id pub-id-type="doi">10.1093/ismejo/wrae133</pub-id><pub-id pub-id-type="pmcid">PMC11334719</pub-id><pub-id pub-id-type="pmid">39018234</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Vitale</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giacco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laiola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Della Pepa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Luongo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mangione</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Acute and chronic improvement in postprandial glucose metabolism by a diet resembling the traditional Mediterranean dietary pattern: can SCFAs play a role?</article-title><source>Clin. Nutr.</source><volume>40</volume><issue>2</issue><year>2021</year><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2020.05.025</pub-id><pub-id pub-id-type="pmid">32698959</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Hosomi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota</article-title><source>Nat. Commun.</source><volume>13</volume><issue>1</issue><year>2022</year><fpage>4477</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32015-7</pub-id><pub-id pub-id-type="pmid">35982037</pub-id><pub-id pub-id-type="pmcid">PMC9388534</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Holmberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Feeney</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Prasoodanan</surname><given-names>P.K.V.</given-names></name><name name-style="western"><surname>Pu&#233;rtolas-Balint</surname><given-names>F.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Wongkuna</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids</article-title><source>Nat. Commun.</source><volume>15</volume><issue>1</issue><year>2024</year><fpage>3502</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-47594-w</pub-id><pub-id pub-id-type="pmid">38664378</pub-id><pub-id pub-id-type="pmcid">PMC11045866</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shangguan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8+ T cell infiltration</article-title><source>J. Transl. Med.</source><volume>22</volume><issue>1</issue><year>2024</year><fpage>964</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05762-y</pub-id><pub-id pub-id-type="pmid">39449013</pub-id><pub-id pub-id-type="pmcid">PMC11515615</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Blautia&#8212;a new functional genus with potential probiotic properties?</article-title><source>Gut Microbes</source><volume>13</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/19490976.2021.1875796</pub-id><pub-id pub-id-type="pmcid">PMC7872077</pub-id><pub-id pub-id-type="pmid">33525961</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Gomez-Arango</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Callaway</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A vegetarian diet is a major determinant of gut microbiota composition in early pregnancy</article-title><source>Nutrients</source><volume>10</volume><issue>7</issue><year>2018</year><fpage>890</fpage><pub-id pub-id-type="doi">10.3390/nu10070890</pub-id><pub-id pub-id-type="pmid">30002323</pub-id><pub-id pub-id-type="pmcid">PMC6073691</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leak</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>n-3 PUFA supplementation benefits microglial responses to myelin pathology</article-title><source>Sci. Rep.</source><volume>4</volume><issue>1</issue><year>2014</year><fpage>7458</fpage><pub-id pub-id-type="doi">10.1038/srep07458</pub-id><pub-id pub-id-type="pmid">25500548</pub-id><pub-id pub-id-type="pmcid">PMC4264015</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Whitman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Pantoja-Feliciano de Goodfellow</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Racicot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>K.</given-names></name><etal/></person-group><article-title>In vitro fermentation shows polyphenol and fiber blends have an additive beneficial effect on gut microbiota states</article-title><source>Nutrients</source><volume>16</volume><issue>8</issue><year>2024</year><fpage>1159</fpage><pub-id pub-id-type="pmid">38674850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu16081159</pub-id><pub-id pub-id-type="pmcid">PMC11053737</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/TLR4/NF-&#954;B pathways in BV2 cells</article-title><source>Mol. Immunol.</source><volume>116</volume><year>2019</year><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2019.09.020</pub-id><pub-id pub-id-type="pmid">31590042</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Siles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>H.J.M.</given-names></name><name name-style="western"><surname>Garcia-Gil</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Flint</surname><given-names>H.J.</given-names></name></person-group><article-title>Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth</article-title><source>Appl. Environ. Microbiol.</source><volume>78</volume><issue>2</issue><year>2012</year><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1128/AEM.06858-11</pub-id><pub-id pub-id-type="pmid">22101049</pub-id><pub-id pub-id-type="pmcid">PMC3255724</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>S.-F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.-T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.-F.</given-names></name><etal/></person-group><article-title>High-fat diet suppresses the astrocytic process arborization and downregulates the glial glutamate transporters in the hippocampus of mice</article-title><source>Brain Res</source><volume>1700</volume><year>2018</year><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2018.07.017</pub-id><pub-id pub-id-type="pmid">30009766</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Molteni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>G&#243;mez-Pinilla</surname><given-names>F.</given-names></name></person-group><article-title>A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning</article-title><source>Neuroscience</source><volume>112</volume><issue>4</issue><year>2002</year><fpage>803</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(02)00123-9</pub-id><pub-id pub-id-type="pmid">12088740</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Microglia regulate neuronal circuits in homeostatic and high-fat diet-induced inflammatory conditions</article-title><source>Front. Cell Neurosci.</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">722028</object-id><pub-id pub-id-type="doi">10.3389/fncel.2021.722028</pub-id><pub-id pub-id-type="pmcid">PMC8549960</pub-id><pub-id pub-id-type="pmid">34720877</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Biose</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Chastain</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Solch-Ottaiano</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Grayson</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The effects of physical activity on experimental models of vascular dementia: a systematic review and meta-analysis</article-title><source>Ann. Neurosci.</source><volume>31</volume><issue>3</issue><year>2024</year><fpage>204</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1177/09727531231192759</pub-id><pub-id pub-id-type="pmid">39156626</pub-id><pub-id pub-id-type="pmcid">PMC11325693</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Augusto-Oliveira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verkhratsky</surname><given-names>A.</given-names></name></person-group><article-title>Lifestyle-dependent microglial plasticity: training the brain guardians</article-title><source>Biol. Direct.</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13062-021-00297-4</pub-id><pub-id pub-id-type="pmid">34353376</pub-id><pub-id pub-id-type="pmcid">PMC8340437</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Taso</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bayram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Garcia-Reitboeck</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions</article-title><source>Hum. Mol. Genet.</source><volume>29</volume><issue>19</issue><year>2020</year><fpage>3224</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa209</pub-id><pub-id pub-id-type="pmid">32959884</pub-id><pub-id pub-id-type="pmcid">PMC7689298</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>TREM2: potential therapeutic targeting of microglia for Alzheimer's disease</article-title><source>Biomed. Pharmacother.</source><volume>165</volume><year>2023</year><object-id pub-id-type="publisher-id">115218</object-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115218</pub-id><pub-id pub-id-type="pmid">37517293</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Leri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vasarri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carnemolla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oriente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cabaro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stio</surname><given-names>M.</given-names></name><etal/></person-group><article-title>EVOO polyphenols exert anti-inflammatory effects on the microglia cell through TREM2 signaling pathway</article-title><source>Pharmaceuticals (Basel)</source><volume>16</volume><issue>7</issue><year>2023</year><fpage>933</fpage><pub-id pub-id-type="doi">10.3390/ph16070933</pub-id><pub-id pub-id-type="pmid">37513845</pub-id><pub-id pub-id-type="pmcid">PMC10384320</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Purello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Korstanje</surname><given-names>R.</given-names></name></person-group><article-title>Chow diet in mouse aging studies: nothing regular about it</article-title><source>Geroscience</source><volume>45</volume><issue>3</issue><year>2023</year><fpage>2079</fpage><lpage>2084</lpage><pub-id pub-id-type="doi">10.1007/s11357-023-00775-9</pub-id><pub-id pub-id-type="pmid">37079216</pub-id><pub-id pub-id-type="pmcid">PMC10400503</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Pellizzon</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>M.R.</given-names></name></person-group><article-title>Choice of laboratory rodent diet may confound data interpretation and reproducibility</article-title><source>Curr. Dev. Nutr.</source><volume>4</volume><issue>4</issue><year>2020</year><object-id pub-id-type="publisher-id">nzaa031</object-id><pub-id pub-id-type="doi">10.1093/cdn/nzaa031</pub-id><pub-id pub-id-type="pmcid">PMC7103427</pub-id><pub-id pub-id-type="pmid">32258990</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0225">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0220">We thank the undergraduate and medical students for their assistance on this project.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0230">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cdnut.2025.107543" id="intref0020">https://doi.org/10.1016/j.cdnut.2025.107543</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="methods-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med</journal-id><journal-id journal-id-type="pmc-domain-id">3997</journal-id><journal-id journal-id-type="pmc-domain">annmed</journal-id><journal-title-group><journal-title>Annals of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0785-3890</issn><issn pub-type="epub">1365-2060</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12502105</article-id><article-id pub-id-type="pmcid-ver">PMC12502105.1</article-id><article-id pub-id-type="pmcaid">12502105</article-id><article-id pub-id-type="pmcaiid">12502105</article-id><article-id pub-id-type="pmid">41051971</article-id><article-id pub-id-type="doi">10.1080/07853890.2025.2566877</article-id><article-id pub-id-type="publisher-id">2566877</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Method</subject></subj-group><subj-group subj-group-type="heading"><subject>Neurology</subject></subj-group></article-categories><title-group><article-title>Effect of Tai Chi combined with visual-action-sensory rehabilitation therapies on cognitive function in acute ischemic stroke: a study protocol for a randomized controlled trial</article-title><alt-title alt-title-type="left-running-head">X. Guan et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-8569-5393</contrib-id><name name-style="western"><surname>Guan</surname><given-names initials="X">Xuewei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lan</surname><given-names initials="M">Meijuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AN0001" ref-type="corresp"/><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ge</surname><given-names initials="L">Lan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Q">Qianyin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yuanyuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="L">Leiwen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhong</surname><given-names initials="Y">Yumei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="AF0001" ref-type="aff"/></contrib><aff id="AF0001"><institution>Nursing Department, the Second Affiliated Hospital of Zhejiang University School of Medicine</institution>, <city>Hangzhou</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1080/07853890.2025.2566877" ext-link-type="doi">https://doi.org/10.1080/07853890.2025.2566877</ext-link>.</p></fn><corresp id="AN0001">CONTACT Meijuan Lan <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:lanmj@zju.edu.cn">lanmj@zju.edu.cn</email><institution>Nursing Department, the Second Affiliated Hospital of Zhejiang University School of Medicine</institution>, <addr-line>Jiefang Road 88th</addr-line>, <city>Hangzhou</city><postal-code>310009</postal-code>, <country>China</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>57</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">476479</issue-id><elocation-id>2566877</elocation-id><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 10:25:16.343"><day>08</day><month>10</month><year>2025</year></date></event><event event-type="received"><date><day>14</day><month>10</month><year>2024</year></date></event><event event-type="accepted"><date><day>4</day><month>8</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>3</day><month>10</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>3</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IANN_57_2566877.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="IANN_57_2566877.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Early cognitive intervention in patients with acute ischemic stroke (AIS) is associated with better outcomes. &#8216;Visual-action-sensory&#8217; rehabilitation therapies, including action observation therapy (AOT) and sensory observation therapy (SOT) have shown great potential in restoring cognitive function. A systematic review of some studies on the therapeutic effect of Tai Chi (TC)in stroke patients suggests potential benefits on depression, anxiety, and balance function. Therefore, combining AOT with TC may enhance brain functional connectivity and provide some cognitive improvements. Here, we describe a study protocol assessing the long-term effects of TC-AOT combined with SOT on cognitive function with AIS.</p></sec><sec><title>Methods</title><p>This study is a dual-arm, single-center, single-blind, randomized controlled trial. A total of 86 AIS patients will be enrolled and randomly assigned in a 1:1 ratio to either the intervention group or the control group. The control group will receive conventional exercise education and follow-up. The intervention group first watched tactile stimulation followed by TC action videos, and then practiced imitating TC movements. The program will be implemented once a day for 30&#8201;min, 5&#8201;days a week for a duration of 8&#8201;weeks. Outcome measures will be assessed at baseline, week 8, and week 12. The primary outcome is global cognitive function and secondary outcomes are language, attention, executive function, memory, visuospatial ability, neuropsychological assessments, and quality of daily life.</p></sec><sec><title>Conclusion</title><p>The study anticipates that the therapeutic program described here will help to reduce the incidence of cognitive impairment in AIS patients or delay its progression.</p></sec><sec><title>Trial registration</title><p>We have registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chictr.org.cn" ext-link-type="uri">https://www.chictr.org.cn</ext-link> and the registration number is: ChiCTR2400088156.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Acute ischemic stroke</kwd><kwd>mirror neurons</kwd><kwd>action observation therapy</kwd><kwd>sensory observation therapy</kwd><kwd>cognitive rehabilitation</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>the medical and health science and technology planning project of the Zhejiang province</institution></institution-wrap></funding-source><award-id>2023KY757</award-id></award-group><funding-statement>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the medical and health science and technology planning project of the Zhejiang province (Project ID: 2023KY757).</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="13"/><word-count count="6247"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec disp-level="1" id="S0001"><title>Administrative information</title><p>This paper is based on protocol version 2.0(2024-07-24). Trial sponsor: Meijuan Lan.</p></sec><sec sec-type="intro" disp-level="1" id="S0002"><title>Introduction</title><p>Stroke is the second leading cause of death and the third leading cause of disability worldwide [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Acute ischemic stroke (AIS), the most common type, accounted for 69.6%&#8764;72.8% of cases in China [<xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0003" ref-type="bibr">3</xref>]. At the acute stage, cognitive decline prevalence in ischemic stroke was 88.1%, and this impairment is linked to a higher risk of future disability [<xref rid="CIT0004" ref-type="bibr">4</xref>]. To date, there are no proven effective treatments to reverse post-stroke cognitive impairment (PSCI) [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Therefore, it is crucial to initiate interventions at the preclinical and early stages to prevent and delay the onset of PSCI, as individuals at this stage still have the capacity to meaningfully engage in interventions [<xref rid="CIT0006" ref-type="bibr">6</xref>]. At present, the non-pharmacological approach remains the main strategy to preserve cognitive functions in populations with cognitive decline [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Among these non-pharmacological interventions, action observation therapy (AOT) and sensory observation therapy (SOT) have shown great potential in restoring cognitive function.</p><p>AOT and SOT are key components of &#8216;visual-action-sensory&#8217; rehabilitation therapy. In AOT, participants watch others performing goal-directed movements. This visual input activates motor-related brain regions responsible for planning and executing similar actions in the observer [<xref rid="CIT0008" ref-type="bibr">8</xref>]. In SOT, participants observe others touching various textured materials. This process evokes internal simulation of the tactile experience, engaging somatosensory areas as if the participants themselves were feeling the stimuli [<xref rid="CIT0009" ref-type="bibr">9</xref>]. The activation of these sensorimotor responses is mediated by the mirror neuron system (MNS). Mirror neurons are primarily located in the inferior parietal lobule, the ventral premotor cortex, and the caudal part of the inferior frontal gyrus [<xref rid="CIT0010" ref-type="bibr">10</xref>]. These areas overlap with regions involved in cognitive functions. Through this widespread network, the MNS allows the brain to internally simulate observed actions or sensations, engaging corresponding functional areas as if the individual were performing the action or experiencing the stimulus. MNS is closely related to processes such as environmental information processing and sensory selection [<xref rid="CIT0011" ref-type="bibr">11</xref>,<xref rid="CIT0012" ref-type="bibr">12</xref>]. Thus, mirror neurons engage in complex cognitive processes by simulating observed content through visual input, facilitating the formation and strengthening of neural circuits. This can lead to the creation of new synaptic connections or the reinforcement of existing ones [<xref rid="CIT0013" ref-type="bibr">13</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>]. By forming new synapses, these therapies adjust and optimize learning and memory processes, thereby improving the efficiency of information processing and storage to compensate for cognitive impairments in stroke patients [<xref rid="CIT0015" ref-type="bibr">15</xref>].</p><p>Previous systematic reviews have shown that AOT may benefit global cognitive function and language function in various populations [<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref>]. However, we found that in most existing studies, participants were exposed to AOT videos that were fragmented and randomly presented, lacking systematic structure and continuity. To address this limitation, we adopted Tai Chi-based action observation therapy (TC-AOT), which uses videos of traditional Chinese Tai Chi routines characterized by spiralling motion and sequential coordination. Tai Chi movements are not only culturally familiar and widely accepted in China, but also support visuospatial processing, processing speed, and episodic memory [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Studies have shown that after TC-AOT intervention, there is a significant increase in brain functional connectivity between areas involved in executive attention and motor learning, including the temporal parietal junction (TPJ), supramarginal gyrus (SMG), inferior frontal gyrus (IFG), and insula [<xref rid="CIT0019" ref-type="bibr">19</xref>]. The modulation of TPJ and SMG can influence motor attention in complex skilled actions [<xref rid="CIT0020" ref-type="bibr">20</xref>,<xref rid="CIT0021" ref-type="bibr">21</xref>], the IFG is crucial for controlling complex motor actions [<xref rid="CIT0022" ref-type="bibr">22</xref>], and the insula integrates sensory information for motor planning [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Thus, TC-AOT holds significant potential benefits for cognitive rehabilitation.</p><p>SOT uses visual input to observe tactile sensory information in videos, enhancing patients&#8217; information processing abilities, thereby promoting brain function recovery and cognitive improvement [<xref rid="CIT0009" ref-type="bibr">9</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. The mirror neuron system simulates sensory experiences; The mirror neuron system simulates sensory experiences; observing someone touch a material prompts the brain to recognize the action and partially simulates the tactile experience [<xref rid="CIT0009" ref-type="bibr">9</xref>]. This understanding and prediction of others&#8217; sensory states represent a highly complex cognitive function [<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>]. Therefore, it can be inferred that sensory observation activates sensory regions of the mirror neuron system, forming sensory representations that further enhance the brain&#8217;s sensory information processing and integration, potentially improving cognitive function.</p><p>Research has found that engaging in sensory observation before watching actions can more effectively improve cognitive function. This method&#8217;s effectiveness stems from deeply utilizing of the brain&#8217;s information-processing mechanisms [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Sensory observation, as an initial step, helps activate sensory processing areas in the brain, providing a strengthened neural foundation for subsequent action observation [<xref rid="CIT0028" ref-type="bibr">28</xref>]. Once the brain is &#8220;primed&#8221; in sensory information processing, observing and simulating actions may be more profound and effective, promoting broader neural network activation and reorganization, further enhancing cognitive recovery and improvement. This finding highlights the importance of integrating sensory and action observation in cognitive intervention strategies.</p><p>Although some studies on the therapeutic effect of Tai Chi in stroke patients suggest potential benefits on depression, anxiety [<xref rid="CIT0029" ref-type="bibr">29</xref>], and balance function [<xref rid="CIT0030" ref-type="bibr">30</xref>], an evaluation of the cognitive benefits of Tai Chi in combination with other visual-motor-sensory&#8217; rehabilitation therapies have received scanty attention. Therefore, this study combined TC-AOT with SOT to evaluate its cognitive effects on AIS patients. The results of this study will provide useful insights into the therapeutic value of combining AOT with Tai Chi to enhance brain functional connectivity and provide cognitive improvements.</p></sec><sec disp-level="1" id="S0003"><title>Patients and methods</title><sec disp-level="2" id="S0003-S2001"><title>Study design and setting</title><p>This is a 2-group parallel, single-site, single-blind, hospital and home-based randomized controlled trial. Patients with AIS will be recruited from a Hospital in Zhejiang Province. The study consists of an 8-week intervention and a 4-week follow-up (<xref rid="F0001" ref-type="fig">Figure 1</xref>). All patients will provide written informed consent in accordance with the 2018 version of the Declaration of Helsinki.</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart of the trial design.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" position="float" orientation="portrait" xlink:href="IANN_A_2566877_F0001_B.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2002"><title>Eligibility criteria</title><sec disp-level="3" id="S0003-S2002-S3001"><title>Inclusion criteria</title><p>
<list list-type="order"><list-item><p>The first stroke was in accordance with the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023 [<xref rid="CIT0031" ref-type="bibr">31</xref>] and was confirmed by brain CT or MRI.</p></list-item><list-item><p>First onset of stroke, with disease duration of less than 14 days;</p></list-item><list-item><p>The NIHSS score less than 5;</p></list-item><list-item><p>Muscle strength of limbs&#8201;&gt;&#8201;level 3.</p></list-item></list>
</p></sec><sec disp-level="3" id="S0003-S2002-S3002"><title>Exclusion criteria</title><p>
<list list-type="order"><list-item><p>Patients currently participating in other cognitive interventions;</p></list-item><list-item><p>Patients suspected of cognitive impairment before stroke (screening with AD8);</p></list-item><list-item><p>Significant aphasia or severe cognitive impairment, inability to understand or cooperate with assessment and treatment instructions;</p></list-item><list-item><p>Complicated with severe cardiopulmonary diseases, mental disorders, multiple organ failure, malignant tumors, or seizures.</p></list-item></list>
</p></sec></sec><sec disp-level="2" id="S0003-S2003"><title>Sample size calculation</title><p>Calculate the sample size according to the following formula:
<disp-formula id="M0001"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="IANN_A_2566877_M0001.jpg"/><mml:math id="MATH0001" display="block"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mi>&#945;</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>&#963;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>&#948;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
<italic toggle="yes">n</italic> is the sample size for each group; <italic toggle="yes">&#956;<sub>&#945;</sub></italic> is the u value corresponding to the Type I error probability, and <italic toggle="yes">&#956;<sub>&#946;</sub></italic> is the u value corresponding to the Type II error probability; <italic toggle="yes">&#948;</italic> donates the expected effect size, i.e. the absolute value of the difference in means between the two groups, and &#963;<sup>2</sup> is the population variance, estimated by the sample variance, which is the mean of the variances of the two groups. <italic toggle="yes">&#945;</italic> is set at 0.05 and <italic toggle="yes">&#946;</italic> is set at 0.10. According to Yeh et&#160;al.&#8217;s study [<xref rid="CIT0032" ref-type="bibr">32</xref>], &#963;&#8201;=&#8201;4.985, &#948;&#8201;=&#8201;2.33, the calculated sample size for each group is 30. Considering a 25% dropout rate in previous studies [<xref rid="CIT0033" ref-type="bibr">33</xref>] and the potential for a higher dropout rate in cognition-related studies [<xref rid="CIT0034" ref-type="bibr">34</xref>], we increased the dropout rate to 30%. Ultimately, we determined that each group should include 43 patients.</p></sec><sec disp-level="2" id="S0003-S2004"><title>Recruitment</title><p>Potential participants in the hospital will be identified by screening the electronic medical records in the neurology ward to find patients who experienced their first ischemic stroke within 14&#8201;days of onset. A research coordinator will then contact these potential participants to assess their eligibility, ability to complete the questionnaire, interest in participation, experience using WeChat, and willingness to sign the consent form along with one of their family members.</p></sec><sec disp-level="2" id="S0003-S2005"><title>Randomization and blinding</title><p>The statistician will use SPSS 26.0 software to randomize the sequence numbered 1&#8211;86 using a random number generator. Random numbers for grouping will be generated and divided into two groups in a 1:1 ratio using visual binning. The grouping results are placed in opaque envelopes. Eligible participants will receive an envelope in registration order and hand it over to the intervention implementer. The researcher who sealed the envelopes will not be involved in participant inclusion, treatment, or assessment. Due to the nature of action-sensory observation, blinding participants and intervention implementers is not possible. However, participants will receive individual treatment, and the intervention implementers will not participate in outcome assessments. Evaluators and statisticians will remain unaware of group assignments.</p></sec><sec disp-level="2" id="S0003-S2006"><title>Interventions</title><p>In this prospective, two-arm, single-centre, randomized controlled trial study, we will recruit 86 acute ischemic stroke patients within 14&#8201;days of onset. Participants will be randomly assigned to either an intervention group (receiving TC-AOT combined with SOT) or a control group (undergoing routine cognitive rehabilitation) in a 1:1 ratio. All patients will receive routine treatment and conventional exercise education, delivered by professional therapists during hospitalization. After discharge, education and follow-up will be conducted by our medical and nursing team. Additionally, in the intervention group, patients will begin by watching a sensory activation video, followed by watching a video on 8 Trigram 5 Steps TC, and then engaging in TC exercises. The program will be implemented once a day for 30&#8201;min, 5&#8201;days a week, and will last for 8&#8201;weeks. Based on the results of the preliminary literature review and evidence-based analysis, and after an expert panel meeting, the interventions were ultimately developed as illustrated in <xref rid="F0002" ref-type="fig">Figure 2</xref>.</p><fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>TC-AOT combined with SOT therapy flow chat.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" position="float" orientation="portrait" xlink:href="IANN_A_2566877_F0002_B.jpg"/></fig><p>The AOT video selects the 8 Trigram 5 Steps TC released by the General Administration of Sports of China, and the sensory observation video was recorded by the researchers ourselves. The sensory observation for both the upper and lower limbs involved quick tapping with a wooden board (20s), brushing with silk (20s), and brushing with a cotton swab (20s).</p><p>In the hospital, the training will be conducted in the neurology ward. The intervention schedule will run from Monday to Friday, with one session in the morning (10:30&#8211;11:00) and three sessions in the afternoon (15:00&#8211;15:30, 15:45&#8211;16:15, and 16:30&#8211;17:00). Patients will be required to participate in only one session per day. After discharge, the researchers will send the videos to the patients and provide daily reminders from Monday to Friday to watch and imitate the videos. During the home-based intervention, a caregiver will accompany the patient throughout the entire video-guided training session and take three photos capturing the patient actively engaged in the intervention. These photos will be uploaded <italic toggle="yes">via</italic> the &#8220;Jielong Butler&#8221; WeChat applet as evidence of participation. Participants are required to complete this check-in five times per week. The total duration of the intervention will be 8&#8201;weeks.</p></sec><sec disp-level="2" id="S0003-S2007"><title>Outcomes</title><p>At baseline, patients will undergo the AD8 test to screen for pre-stroke cognitive impairment; those identified with such impairment will be excluded. Routine sociodemographic data will also be collected, including age, gender, marital/cohabitation status, employment status, as well as personal and family medical history, and smoking and alcohol consumption habits.</p><p>Validated assessment tools will be employed to evaluate global cognitive function, memory, language function, executive function, attention, visuospatial ability, activities of daily living, neuropsychiatric symptoms, and psychological status. Each scale will be analysed independently, no composite total score will be calculated across different scales.</p><p>Subjects will be evaluated at three time points: before the intervention (1&#8211;2&#8201;days before the start, T1), after the intervention (1&#8211;2&#8201;days following the 8-week intervention, T2), and during follow-up (4&#8201;weeks after the 8-week intervention, T3). The safety outcome, particularly the incidence of falls, will be monitored throughout the study.</p></sec><sec disp-level="2" id="S0003-S2008"><title>Primary outcomes</title><p>Montreal Cognitive Assessment (MoCA) [<xref rid="CIT0035" ref-type="bibr">35</xref>] assesses visuospatial and executive function, naming, memory, attention and computation, language, abstract thinking, delayed recall, and orientation. The test comprises 30 questions and the highest possible score is 30. The sensitivity of MoCA is 92.4%, the specificity is 88.4%, the best abnormal cut-off point is: illiterate group &#8804; 13 points, primary school group &#8804; 19 points, junior high school, and above group &#8804; 24 points.</p></sec><sec disp-level="2" id="S0003-S2009"><title>Secondary outcomes</title><p>Auditory Verbal Learning Test (AVLT) is one of the most commonly used memory assessment scales. In this study, the Chinese version of AVLT developed by Guo Qihao et&#160;al. [<xref rid="CIT0036" ref-type="bibr">36</xref>] was adopted. The scale uses 12 words. During the test, the examiner reads the 12 words aloud, and participants are asked to recall them immediately. They continuously learn and recall the words three times, with reminders provided beforehand. After an approximately 5-minute non-verbal test interval, participants perform &#8220;short delayed recall&#8221; of the words, and after a 20-minute interval, they perform &#8216;long delayed recall&#8217;. The sixth recall is re-recognition, where the examiner presents 24 words and asked the subjects to identify which were learned.</p><p>The Animal Fluency Test (AFT) is used to assess a patient&#8217;s language function [<xref rid="CIT0037" ref-type="bibr">37</xref>]. Participants list as many animals as possible within 60&#8201;s, with each correctly named animal counting as one point. A higher score indicates better language function.</p><p>The Clock Drawing Test (CDT) primarily assesses a patient&#8217;s visuospatial function. Participants draw a clock on a blank sheet, adding numbers and setting the hands to 11:10. The scoring method follows the Rouleau 10-point scale: clock face integrity (maximum 2 points), presence and sequencing of numbers (maximum 4 points), and presence and placement of the hands (maximum 4 points) [<xref rid="CIT0038" ref-type="bibr">38</xref>].</p><p>The Shape Trails Test (STT) was developed by the U.S. Army in 1944 as part of the Halstead-Reita suite of neuropsychological tests. This study uses a version by Guo Qihao et&#160;al. [<xref rid="CIT0039" ref-type="bibr">39</xref>]. The test has two parts, A and B, involving two shapes: square and circle. STT-A requires connecting numbers, assessing attention and processing speed with a maximum of 150&#8201;s. STT-B involves alternating connections of shapes, evaluating executive function with a maximum of 300&#8201;s. For both tests, shorter completion times indicate better performance.</p><p>The Modified Barthel Index (MBI) [<xref rid="CIT0040" ref-type="bibr">40</xref>] assesses activities of daily living (ADLs), covering ten areas: feeding, dressing, toileting, personal hygiene, bathing, bed-chair transfer, walking, stair climbing, bowel control, and bladder control. A score of &#8804;40 indicates severe dependency, 41 to 60 implies moderate dependency, 61 to 99 reflects mild dependency, and 100 signifies normal activity without assistance.</p><p>The Neuropsychiatric Inventory-Questionnaire (NPI-Q) is used to assess neuropsychiatric symptoms [<xref rid="CIT0041" ref-type="bibr">41</xref>]. It consists of 10 behavioral and 2 autonomic nervous system symptom domains. Researchers gather information about symptoms over the past month from caregivers. Symptoms are marked &#8220;present&#8221; if they occurred and rated for severity (0&#8211;36 points) and caregiver distress (0&#8211;60 points). The Chinese version of the scale has a Cronbach&#8217;s &#945; of 0.85, split-half reliability of 0.83, and test-retest reliability of 0.86 [<xref rid="CIT0042" ref-type="bibr">42</xref>].</p><p>This study uses the short form of the Center for Epidemiologic Studies Depression Scale (CES-D), comprising 9 items: 2 positive and 7 negative symptoms. Internal consistency reliability ranges from 0.85 to 0.88. Scoring reverses positive symptoms, with a total of 27 possible points. A score of 10 indicates a tendency toward depression, while 17 marks the high-risk threshold [<xref rid="CIT0043" ref-type="bibr">43</xref>].</p></sec><sec disp-level="2" id="S0003-S2010"><title>Safety outcomes</title><p>Fall is a sudden, involuntary, or unintentional fall to the ground or other lower surface not caused by a violent blow, loss of consciousness, sudden paralysis, or seizure [<xref rid="CIT0044" ref-type="bibr">44</xref>]. Fall rates are usually expressed per 1,000 bed days. In rehabilitation hospitals where patients are encouraged to mobilize, fall rates typically range from 3 to 16 per 1,000 bed days [<xref rid="CIT0045" ref-type="bibr">45</xref>].</p><p>For an overview of the study schedule, see <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Schedule of enrolment, interventions and assessments according to the standard protocol items: Recommendations for interventional Trials (SPIRIT).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IANN_A_2566877_ILG0001_B.jpg"/>
</td><td style="" colspan="1" rowspan="1">&#160;</td><td style="" colspan="1" rowspan="1">&#160;</td><td style="" colspan="1" rowspan="1">&#160;</td><td style="" colspan="1" rowspan="1">&#160;</td><td style="" colspan="1" rowspan="1">&#160;</td></tr></tbody></table></table-wrap></sec><sec disp-level="2" id="S0003-S2011"><title>Data collection and management</title><p>After patients sign the written informed consent form, scale assessments will be conducted. Each patient will have a separate folder to store their informed consent forms and completed scales. All the clinical data will be input into EpiData3.1 by two trained research assistants independently. Only the research team members have the right to access. All researchers will be trained regularly, and all data will be monitored and verified regularly by investigators throughout the trial.Due to the trial&#8217;s short duration and minimal risks, a Data Monitoring Committee will not be established. Data can be obtained by contacting the tutor after the RCT is published.</p></sec><sec disp-level="2" id="S0003-S2012"><title>Data analysis</title><p>A statistician will analyse the data using SPSS 26.0 software, considering a P-value &lt; 0.05 as statistically significant. Continuous variables will be presented as mean&#8201;&#177;&#8201;standard deviation or median with interquartile range, while categorical variables will be expressed as frequency and percentage. The outcome measures in this study are all continuous variables. Differences in outcomes at baseline, week 8, and week 12 will be analysed using repeated measures ANOVA or mixed linear regression analysis. Both the intention-to-treat (ITT) and per-protocol (PP) populations will be included in the analysis. The ITT and PP analysis results will be compared to ensure consistency. In cases of missing data, the last observed value will be carried forward for interpolation. A safety analysis will be performed to assess safety outcomes.</p></sec><sec disp-level="2" id="S0003-S2013"><title>Monitoring</title><p>To enhance patient adherence and ensure the effectiveness of the trial, researchers will establish a rapport with patients during communication, inquiring about their level of enthusiasm for participation. Patients will be informed that after discharge, they will need to watch the training videos at home and check in using the &#8216;Jielong Butler&#8217; WeChat applet. To verify the authenticity of each training session, patients will be required to upload three photos showing their ongoing training activities. These photos will be submitted by the patients&#8217; family members and reviewed by the research team to ensure compliance. This process will also ensure that patients are accompanied by their family members during the exercises. Additionally, patients who consistently complete the check-ins for 8&#8201;weeks will receive a small gift as an incentive. After these details are communicated to the patients and their families, the written informed consent will be obtained, and the contact information of the patients and their families will be recorded for follow-up and monitoring.</p><p>Data collectors received standardized training on questionnaire evaluation, mastering the content, assessment methods, and techniques while remaining unaware of the study&#8217;s group assignments. During data collection, they refrain from guiding or suggesting responses to participants, and the intervention will not be mentioned during assessments to maintain objectivity and consistency. Two university researchers are responsible for data entry and verification to ensure accuracy.</p><p>Although the intervention is non-invasive, adverse events such as falls or fractures may occur. To ensure safety, patients and their families will be provided with staff contact information <italic toggle="yes">via</italic> phone or WeChat, and instructed to contact staff immediately if any adverse events occur. Details of all adverse events will be recorded during the trial in the case report forms (CRFs). The ethics committee will examine any connections between adverse events and the intervention and decide whether the study should continue.</p></sec></sec><sec disp-level="1" id="S0004"><title>Ethics and dissemination</title><p>The present study protocol has been approved by the Regional Ethics Authority of the Second Affiliated Hospital of Zhejiang University School of Medicine (Grant No.2024-0591). This protocol adheres to the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines for clinical interventional trials. Researchers will communicate with eligible participants, fully explain the study procedures, and obtain informed the written consent from those willing to participate. Participant data will be recorded in CRFs. If the researchers need to get the data in the CRF, they must report to the primary investigator.</p></sec><sec sec-type="discussion" disp-level="1" id="S0005"><title>Discussion</title><p>Cognitive impairment is a common post-stroke symptom among recurrent AIS patients, associated with reduced functional independence, institutionalization, diminished quality of life, and and increased mortality [<xref rid="CIT0046" ref-type="bibr">46</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref>]. Thus, stroke survivors need interventions to promote cognitive function and prevent dementia. &#8216;Visual-action-sensory&#8217; rehabilitation therapies, including AOT and SOT, have shown great potential in restoring cognitive function. During action and sensory observation, the brain achieves functional reorganization through the coordinated action of the mirror neuron system. In action observation, the superior temporal sulcus encodes and decodes action information, transmitting it to the parietal and frontal mirror neuron systems to facilitate the understanding of actions and intentions [<xref rid="CIT0048" ref-type="bibr">48</xref>]. In sensory observation, the activated precentral gyrus and supplementary motor area, as components of the parietal-frontal mirror system [<xref rid="CIT0049" ref-type="bibr">49</xref>], are responsible for motor execution and preparation, while the postcentral gyrus integrates sensory input [<xref rid="CIT0050" ref-type="bibr">50</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref>]. These regions work together through mirror neuron mechanisms to enhance understanding and imitation of others&#8217; actions and sensory experiences.</p><p>The intervention designed in this study represents an enhancement and refinement of traditional &#8216;visual-action-sensory&#8217; rehabilitation therapies. In this study, the content of action observation was modified to TC, as TC-AOT has been shown to provide more comprehensive cognitive improvement by enhancing functional connectivity between the dorsomedial prefrontal cortex and the cerebellar Crus I, as well as the parietal-occipital lobe and other regions [<xref rid="CIT0019" ref-type="bibr">19</xref>]. These connections support more complex brain coordination and integration capabilities. In contrast, traditional AOT mainly activates the premotor cortex and certain parietal and temporal lobe regions, making it less comprehensive than TC-AOT in integrating cognitive and motor coordination [<xref rid="CIT0052" ref-type="bibr">52</xref>]. Therefore, TC-AOT may be more advantageous in promoting a broader reorganization of brain function. Moreover, this study is the first to apply SOT in a clinical setting. In patients with sensory disorders, somatosensory stimuli cannot be effectively transmitted to the cerebral cortex [<xref rid="CIT0053" ref-type="bibr">53</xref>], leading to the loss of sensory part in the &#8216;visual-motion-sensation&#8217; therapy. To allow patients with impaired sensory pathways to benefit from sensory stimulation, we introduced sensory observation [<xref rid="CIT0054" ref-type="bibr">54</xref>]. This approach allows the activation of patients&#8217; sensory circuits without actual sensory input, achieving effects similar to normal sensory stimulation. The TC-AOT combine with SOT scheme designed in this study not only adopts the more effective motion observation (TC-AOT), but also fills the gap that somatosensory information cannot be transmitted in patients with sensory disorders through sensory observation. This dual innovation may enhance the effectiveness of the intervention.</p><p>The brain&#8217;s ability to reorganize itself, known as neuroplasticity, peaks immediately after stroke [<xref rid="CIT0055" ref-type="bibr">55</xref>]. Timely and appropriate training and stimulation allow undamaged neurons to reconfigure their connections, compensating for functions of damaged regions and optimizing rehabilitation outcomes [<xref rid="CIT0056" ref-type="bibr">56</xref>]. Existing research indicates that implementing non-routine or alternative therapies within 1 to 60&#8201;days post-stroke results in better cognitive recovery outcomes compared to homologous interventions during the chronic phase [<xref rid="CIT0057" ref-type="bibr">57</xref>]. Thus, this study advances the intervention window to capitalize on the nervous system&#8217;s heightened plasticity. By administering precise treatment and stimulation during this acute period, we aim to more effectively facilitate brain reorganization and functional recovery, thereby preventing cognitive impairments or enhancing cognitive function in patients with deficits.</p><p>We anticipate that the therapeutic program described here will help AIS patients prevent the onset of cognitive impairment and improve their overall quality of life. The planned randomized controlled trial will contribute evidence on the effectiveness of integrating TC-AOT and SOT in stroke rehabilitation.</p><p>However, implementing the therapy may pose challenges such as prolonged intervention cycle and poor patient adherence. Additionally, this study is single-centered, which may limit the generalizability of this approach to other centers. Another limitation lies in participants in the intervention group received longer exposure time, which could bias the results. Furthermore, future studies should consider incorporating functional connectivity biomarkers (e.g. fNIRS, EEG) to provide more objective insights into the neural mechanisms of cognitive recovery. Multidisciplinary collaboration will be essential to achieve this goal and further advance the field of stroke rehabilitation.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0006"><title>Conclusion</title><p>The lack of early preventive interventions for AIS patients in clinical practice necessitates the need to develop viable evidence-based intervention programs. The protocol of RCT seeks to achieve this end. If effective and verified by follow-up studies, the TC-AOT combined with SOT may help reduce the incidence of cognitive impairments in AIS patients or delay the clinical progression of such impairments.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM3699" position="float" content-type="local-data" orientation="portrait"><caption><title>SPIRIT checklist with page reference numbers.doc</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IANN_A_2566877_SM3699.doc" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to the head nurse of the Department of Neurology at the Second Affiliated Hospital of Zhejiang University School of Medicine for coordinating patient enrollment. Thanks to the neurology ward for providing the intervention site. All authors have read and approved the final work.</p></ack><sec sec-type="author-contributions" disp-level="1" id="S0008"><title>Author contributions statement</title><p>CRediT: <bold>Xuewei Guan</bold>: Conceptualization, Data curation, Methodology, Writing &#8211; original draft; <bold>Meijuan Lan</bold>: Conceptualization, Data curation, Supervision, Writing &#8211; review &amp; editing; <bold>Lan Ge</bold>: Conceptualization, Methodology; <bold>Qianyin Zhu</bold>: Data curation, Writing &#8211; review &amp; editing; <bold>Yuanyuan Chen</bold>: Data curation; <bold>Leiwen Tang</bold>: Writing &#8211; review &amp; editing; <bold>Yumei Zhong</bold>: Methodology.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0009"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><sec sec-type="data-availability" disp-level="1" id="S0010"><title>Data availability statement</title><p>After formal publication of this trial, anonymized data will be made available upon request. For access, please contact the corresponding author, Meijuan Lan.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prust</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Forman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ovbiagele</surname><given-names>B.</given-names></string-name></person-group><article-title>Addressing disparities in the global epidemiology of stroke</article-title>. <source>Nat Rev Neurol</source>. <year>2024</year>;<volume>20</volume>(<issue>4</issue>):<fpage>207</fpage>&#8211;<lpage>221</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41582-023-00921-z</pub-id>.<pub-id pub-id-type="pmid">38228908</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Temporal trend and attributable risk factors of stroke burden in China, 1990&#8211;2019: an analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Public Health</source>. <year>2021</year>;<volume>6</volume>(<issue>12</issue>):<fpage>e897</fpage>&#8211;<lpage>e906</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2468-2667(21)00228-0</pub-id>.<pub-id pub-id-type="pmid">34838196</pub-id><pub-id pub-id-type="pmcid">PMC9047702</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>B</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Incidence of first-ever stroke, stroke events, and early case fatality rate in China: results from a national population-based survey</article-title>. <source>Neuroepidemiology</source>. <year>2025</year>:<fpage>1</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000543474</pub-id><pub-id pub-id-type="pmid">39837306</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>B</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Association between early cognitive impairment and midterm functional outcomes among Chinese acute ischemic stroke patients: a longitudinal study</article-title>. <source>Front Neurol</source>. <year>2020</year>;<volume>11</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2020.00020</pub-id>.<pub-id pub-id-type="pmid">32174878</pub-id><pub-id pub-id-type="pmcid">PMC7054458</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Leng</surname><given-names>XY</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Post-Stroke Cognitive Impairment: epidemiology, Risk Factors, and Management</article-title>. <source>JAD</source>. <year>2022</year>;<volume>86</volume>(<issue>3</issue>):<fpage>983</fpage>&#8211;<lpage>999</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-215644</pub-id>.<pub-id pub-id-type="pmid">35147548</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xue</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>PWC</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>DSF</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Combined exercise and cognitive interventions for adults with mild cognitive impairment and dementia: a systematic review and network meta-analysis</article-title>. <source>Int J Nurs Stud</source>. <year>2023</year>;<volume>147</volume>:<fpage>104592</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijnurstu.2023.104592</pub-id>.<pub-id pub-id-type="pmid">37769394</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quinn</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Richard</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Teuschl</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment</article-title>. <source>Eur Stroke J</source>. <year>2021</year>;<volume>6</volume>(<issue>3</issue>):<fpage>I</fpage>&#8211;<lpage>XXX</lpage>VIII. doi: <pub-id pub-id-type="doi">10.1177/23969873211042192</pub-id>.<pub-id pub-id-type="pmcid">PMC8564156</pub-id><pub-id pub-id-type="pmid">34746430</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schrijver</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Decramer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Janssen</surname><given-names>P.</given-names></string-name></person-group><article-title>Simple visual stimuli are sufficient to drive responses in action observation and execution neurons in macaque ventral premotor cortex</article-title>. <source>PLoS Biol</source>. <year>2024</year>;<volume>22</volume>(<issue>5</issue>):<fpage>e3002358</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pbio.3002358</pub-id>.<pub-id pub-id-type="pmid">38768251</pub-id><pub-id pub-id-type="pmcid">PMC11142659</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effects of integrated action and sensory observation therapy based on mirror neuron and embodied cognition theory on upper limb sensorimotor function in chronic stroke: a study protocol for a randomised controlled trial</article-title>. <source>BMJ Open</source>. <year>2023</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e069126</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2022-069126</pub-id>.<pub-id pub-id-type="pmcid">PMC10008471</pub-id><pub-id pub-id-type="pmid">36882253</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fabbri-Destro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rizzolatti</surname><given-names>G.</given-names></string-name></person-group><article-title>Mirror neurons and mirror systems in monkeys and humans</article-title>. <source>]. Physiology</source>. <year>2008</year>;<volume>23</volume>(<issue>3</issue>):<fpage>171</fpage>&#8211;<lpage>179</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physiol.00004.2008</pub-id>.<pub-id pub-id-type="pmid">18556470</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rizzolatti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Craighero</surname><given-names>L.</given-names></string-name></person-group><article-title>The mirror-neuron system</article-title>. <source>Annu Rev Neurosci</source>. <year>2004</year>;<volume>27</volume>(<issue>1</issue>):<fpage>169</fpage>&#8211;<lpage>192</lpage>. (Volume 27, 2004):. doi: <pub-id pub-id-type="doi">10.1146/annurev.neuro.27.070203.144230</pub-id>.<pub-id pub-id-type="pmid">15217330</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schach</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lindner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname><given-names>DA.</given-names></string-name></person-group><article-title>Bounded rational decision-making models suggest capacity-limited concurrent motor planning in human posterior parietal and frontal cortex</article-title>. <source>PLoS Comput Biol</source>. <year>2022</year>;<volume>18</volume>(<issue>10</issue>):<fpage>e1010585</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1010585</pub-id>.<pub-id pub-id-type="pmid">36227842</pub-id><pub-id pub-id-type="pmcid">PMC9560147</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ryan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fullen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rio</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effect of action observation therapy in the rehabilitation of neurologic and musculoskeletal conditions: a systematic review</article-title>. <source>Arch Rehabil Res Clin Transl</source>. <year>2021</year>;<volume>3</volume>(<issue>1</issue>):<fpage>100106</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arrct.2021.100106</pub-id>.<pub-id pub-id-type="pmid">33778479</pub-id><pub-id pub-id-type="pmcid">PMC7984987</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morita</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yokoyama</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effects of 2-year cognitive&#8211;motor dual-task training on cognitive function and motor ability in healthy elderly people: a pilot study</article-title>. <source>Brain Sci</source>. <year>2018</year>;<volume>8</volume>(<issue>5</issue>):<fpage>86</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci8050086</pub-id>.<pub-id pub-id-type="pmid">29751661</pub-id><pub-id pub-id-type="pmcid">PMC5977077</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joy</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Carmichael</surname><given-names>ST.</given-names></string-name></person-group><article-title>Encouraging an excitable brain state: mechanisms of brain repair in stroke</article-title>. <source>Nat Rev Neurosci</source>. <year>2021</year>;<volume>22</volume>(<issue>1</issue>):<fpage>38</fpage>&#8211;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41583-020-00396-7</pub-id>.<pub-id pub-id-type="pmid">33184469</pub-id><pub-id pub-id-type="pmcid">PMC10625167</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Francisco</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Louis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Billot</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The value of action observation in speech and language rehabilitation: a systematic review and meta-analysis</article-title>. <source>]. Neuroscience &amp; Biobehavioral Reviews</source>. <year>2024</year>;<volume>164</volume>:<fpage>105826</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2024.105826</pub-id>.<pub-id pub-id-type="pmid">39069237</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Efficacy of action observation therapy on cognitive function in stroke: a systematic review and meta-analysis</article-title>. <source>Brain Behav</source>. <year>2025</year>;<volume>15</volume>(<issue>4</issue>):<fpage>e70474</fpage>. doi: <pub-id pub-id-type="doi">10.1002/brb3.70474</pub-id>.<pub-id pub-id-type="pmid">40259717</pub-id><pub-id pub-id-type="pmcid">PMC12012254</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wayne</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Taylor-Piliae</surname><given-names>RE</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The impact of tai chi on cognitive performance in older adults: a systematic review and meta-analysis</article-title>. <source>J Am Geriatr Soc</source>. <year>2014</year>;<volume>62</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jgs.12611</pub-id>.<pub-id pub-id-type="pmid">24383523</pub-id><pub-id pub-id-type="pmcid">PMC4055508</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Enhanced brain functional connectivity and activation after 12-week Tai Chi-based action observation training in patients with Parkinson&#8217;s disease</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1252610</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2023.1252610</pub-id>.<pub-id pub-id-type="pmid">37881362</pub-id><pub-id pub-id-type="pmcid">PMC10595151</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilterson</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Nastase</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Bio</surname><given-names>BJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Attention, awareness, and the right temporoparietal junction[J/OL</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <year>2021</year>;<volume>118</volume>(<issue>25</issue>):<fpage>e2026099118</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2026099118</pub-id>.<pub-id pub-id-type="pmid">34161276</pub-id><pub-id pub-id-type="pmcid">PMC8237657</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Borgnis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pozzo</surname><given-names>T.</given-names></string-name></person-group><article-title>Mirror neurons and their relationship with neurodegenerative disorders</article-title>. <source>J Neurosci Res</source>. <year>2020</year>;<volume>98</volume>(<issue>6</issue>):<fpage>1070</fpage>&#8211;<lpage>1094</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.24579</pub-id>.<pub-id pub-id-type="pmid">31975553</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cazzoli</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kaufmann</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Paladini</surname><given-names>RE</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Anterior insula and inferior frontal gyrus: where ventral and dorsal visual attention systems meet</article-title>. <source>Brain Commun</source>. <year>2021</year>;<volume>3</volume>(<issue>1</issue>):<fpage>fcaa220</fpage>. doi: <pub-id pub-id-type="doi">10.1093/braincomms/fcaa220</pub-id>.<pub-id pub-id-type="pmid">33501424</pub-id><pub-id pub-id-type="pmcid">PMC7811755</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></string-name></person-group><article-title>The insular cortex: an interface between sensation, emotion and cognition</article-title>. <source>Neurosci Bull</source>. <year>2024</year>;<volume>40</volume>(<issue>11</issue>):<fpage>1763</fpage>&#8211;<lpage>1773</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12264-024-01211-4</pub-id>.<pub-id pub-id-type="pmid">38722464</pub-id><pub-id pub-id-type="pmcid">PMC11607240</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Florio</surname><given-names>TM.</given-names></string-name></person-group><article-title>Emergent aspects of the integration of sensory and motor functions</article-title>. <source>Brain Sci</source>. <year>2025</year>;<volume>15</volume>(<issue>2</issue>):<fpage>162</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci15020162</pub-id>.<pub-id pub-id-type="pmid">40002495</pub-id><pub-id pub-id-type="pmcid">PMC11853489</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baltes</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Lindenberger</surname><given-names>U.</given-names></string-name></person-group><article-title>Emergence of a powerful connection between sensory and cognitive functions across the adult life span: a new window to the study of cognitive aging?</article-title>. <source>Psychol Aging</source>. <year>1997</year>;<volume>12</volume>(<issue>1</issue>):<fpage>12</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1037/0882-7974.12.1.12</pub-id>.<pub-id pub-id-type="pmid">9100264</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tivadar</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Knight</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Tzovara</surname><given-names>A.</given-names></string-name></person-group><article-title>Automatic sensory predictions: a review of predictive mechanisms in the brain and their link to conscious processing</article-title>. <source>Front Hum Neurosci</source>. <year>2021</year>;<volume>15</volume>:<fpage>702520</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnhum.2021.702520</pub-id>.<pub-id pub-id-type="pmid">34489663</pub-id><pub-id pub-id-type="pmcid">PMC8416526</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scott</surname><given-names>M.</given-names></string-name></person-group><article-title>Sensory attenuation from action observation</article-title>. <source>Exp Brain Res</source>. <year>2022</year>;<volume>240</volume>(<issue>11</issue>):<fpage>2923</fpage>&#8211;<lpage>2937</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00221-022-06460-1</pub-id>.<pub-id pub-id-type="pmid">36123539</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eads</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lorimer Moseley</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hillier</surname><given-names>S.</given-names></string-name></person-group><article-title>Non-informative vision enhances tactile acuity: a systematic review and meta-analysis</article-title>. <source>]. Neuropsychologia</source>. <year>2015</year>;<volume>75</volume>:<fpage>179</fpage>&#8211;<lpage>185</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2015.06.006</pub-id>.<pub-id pub-id-type="pmid">26071257</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Therapeutic effect of traditional Chinese exercise in stroke patients: an umbrella review of systematic reviews and meta-analyses of clinical trials</article-title>. <source>Eur J Integr Med</source>. <year>2025</year>;<volume>74</volume>:<fpage>102438</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eujim.2025.102438</pub-id>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effects of Tai Chi exercise on balance function in stroke patients: an overview of systematic review</article-title>. <source>Neural Plast</source>. <year>2022</year>;<volume>2022</volume>(<issue>1</issue>):<fpage>3895514</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/3895514</pub-id>.<pub-id pub-id-type="pmid">35309256</pub-id><pub-id pub-id-type="pmcid">PMC8926482</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Chinese Society of Neurology</collab></person-group>. <article-title>Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023</article-title>. <source>Chinese J Neurol</source>. <year>2024</year>;<volume>57</volume>(<issue>6</issue>):<fpage>523</fpage>&#8211;<lpage>559</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.cn113694-20240410-00221</pub-id>.[in Chinese].</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeh</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>CY</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clinical efficacy of aerobic exercise combined with computer-based cognitive training in stroke: a multicenter randomized controlled trial</article-title>. <source>Top Stroke Rehabil</source>. <year>2022</year>;<volume>29</volume>(<issue>4</issue>):<fpage>255</fpage>&#8211;<lpage>264</lpage>. doi: <pub-id pub-id-type="doi">10.1080/10749357.2021.1922045</pub-id>.<pub-id pub-id-type="pmid">34340637</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>DSF.</given-names></string-name></person-group><article-title>Effects of a moderate-intensity aerobic exercise programme on the cognitive function and quality of life of community-dwelling elderly people with mild cognitive impairment: a randomised controlled trial</article-title>. <source>Int J Nurs Stud</source>. <year>2019</year>;<volume>93</volume>:<fpage>97</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijnurstu.2019.02.019</pub-id>.<pub-id pub-id-type="pmid">30901716</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Recruitment and adherence of randomized controlled trials for mild cognitive impairment: a systematic review and meta-analysis</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2020</year>;<volume>35</volume>(<issue>10</issue>):<fpage>1141</fpage>&#8211;<lpage>1150</lpage>. doi: <pub-id pub-id-type="doi">10.1002/gps.5336</pub-id>.<pub-id pub-id-type="pmid">32420630</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stiekema</surname><given-names>APM</given-names></string-name>, <string-name name-style="western"><surname>Vreven</surname><given-names>LWA</given-names></string-name>, <string-name name-style="western"><surname>Hummel</surname><given-names>RSO</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The Montreal Cognitive Assessment detects cognitive deficits that go unnoticed during clinical observation in the acute phase after stroke</article-title>. <source>Brain Inj</source>. <year>2024</year>;<volume>38</volume>(<issue>9</issue>):<fpage>687</fpage>&#8211;<lpage>691</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tandfonline.com/doi/abs/10.1080/02699052.2024.2341039" ext-link-type="uri">https://www.tandfonline.com/doi/abs/10.1080/02699052.2024.2341039</ext-link>.<pub-id pub-id-type="pmid">38615342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02699052.2024.2341039</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals</article-title>. <source>Alzheimer Dis Associated Disord</source>. <year>2009</year>;<volume>23</volume>(<issue>3</issue>):<fpage>253</fpage>&#8211;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WAD.0b013e3181999e92</pub-id>.<pub-id pub-id-type="pmid">19812468</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Swenson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tobyne</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A brief digital neuropsychological protocol: iii - using artificial intelligence to measure semantic memory with the &#8216;Animal&#8217; Fluency Test</article-title><source>. Alzheimer&#8217;s Dementia</source>. <year>2024</year>:<volume>20</volume>(<issue>S2</issue>): <fpage>e091512</fpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.091512</pub-id>.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parsey</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Schmitter-Edgecombe</surname><given-names>M.</given-names></string-name></person-group><article-title>Quantitative and qualitative analyses of the clock drawing test in mild cognitive impairment and Alzheimer disease: evaluation of a modified scoring system</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2011</year>;<volume>24</volume>(<issue>2</issue>):<fpage>108</fpage>&#8211;<lpage>118</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0891988711402349</pub-id>.<pub-id pub-id-type="pmid">21546651</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The shape trail test: application of a new variant of the trail making test</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e57333</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0057333</pub-id>.<pub-id pub-id-type="pmid">23437370</pub-id><pub-id pub-id-type="pmcid">PMC3577727</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comparison of responsiveness of the Barthel Index and modified Barthel Index in patients with stroke</article-title>. <source>Disabil Rehabil</source>. <year>2023</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1097</fpage>&#8211;<lpage>1102</lpage>. doi: <pub-id pub-id-type="doi">10.1080/09638288.2022.2055166</pub-id>.<pub-id pub-id-type="pmid">35357990</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Finley</surname><given-names>JCA</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>SES</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Practical assessment of neuropsychiatric symptoms: updated reliability, validity, and cutoffs for the neuropsychiatric inventory questionnaire</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2025</year>;<volume>33</volume> (<issue>5</issue>):<fpage>524</fpage>&#8211;<lpage>534</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sciencedirect.com/science/article/pii/S1064748124005116" ext-link-type="uri">https://www.sciencedirect.com/science/article/pii/S1064748124005116</ext-link>. doi: <pub-id pub-id-type="doi">10.1016/j.jagp.2024.10.014</pub-id>.<pub-id pub-id-type="pmid">39551647</pub-id><pub-id pub-id-type="pmcid">PMC11903187</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>WX</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Jeffrey</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reliability and validity of Chinese version of Neuropsychiatric Inventory-Questionnaire inpatients with Alzheimer&#8217;s disease</article-title>. <source>Chinese Mental Health Journal</source>. <year>2010</year>;<volume>24</volume>(<issue>5</issue>):<fpage>338</fpage>&#8211;<lpage>342,361</lpage>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1000-6729.2010.05.006</pub-id>.[in Chinese]</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>ZY</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A short Chinese version of center for epidenfiologic studies depression scale</article-title>. <source>Chinese J Med Brain</source>. <year>2013</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1133</fpage>&#8211;<lpage>1136</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.1674-6554.2013.12.023</pub-id>.[in Chinese]</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khekan</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Aghdasi</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Salehpour</surname><given-names>P.</given-names></string-name></person-group><article-title>Fast and high-precision human fall detection using improved YOLOv8 model</article-title>. <source>IEEE Access</source>. <year>2025</year>;<volume>13</volume>:<fpage>5271</fpage>&#8211;<lpage>5283</lpage>. doi: <pub-id pub-id-type="doi">10.1109/ACCESS.2024.3470319</pub-id>.</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Interventions to reduce falls in hospitals: a systematic review and meta-analysis</article-title>. <source>Age Ageing</source>. <year>2022</year>;<volume>51</volume>(<issue>5</issue>):<fpage>afac077</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ageing/afac077</pub-id>.<pub-id pub-id-type="pmid">35524748</pub-id><pub-id pub-id-type="pmcid">PMC9078046</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reminiscence therapy is a feasible care program for improving cognitive function, anxiety, and depression in recurrent acute ischemic stroke patients: a randomized, controlled study</article-title>. <source>Ir J Med Sci</source>. <year>2023</year>;<volume>192</volume>(<issue>3</issue>):<fpage>1463</fpage>&#8211;<lpage>1471</lpage>.),. doi: <pub-id pub-id-type="doi">10.1007/s11845-022-03114-7</pub-id>.<pub-id pub-id-type="pmid">35896910</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Donkor</surname><given-names>ES.</given-names></string-name></person-group><article-title>Stroke in the 21st Century: a snapshot of the burden, epidemiology, and quality of life</article-title>. <source>Stroke Res Treat</source>. <year>2018</year>;<volume>2018</volume>:<fpage>3238165</fpage>&#8211;<lpage>3238110</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2018/3238165</pub-id>.<pub-id pub-id-type="pmid">30598741</pub-id><pub-id pub-id-type="pmcid">PMC6288566</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ge</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Neural activity and decoding of action observation using combined EEG and fNIRS measurement</article-title>. <source>Front Hum Neurosci</source>. <year>2019</year>;<volume>13</volume>:<fpage>357</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnhum.2019.00357</pub-id>.<pub-id pub-id-type="pmid">31680910</pub-id><pub-id pub-id-type="pmcid">PMC6803538</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comparison of sensory observation and somatosensory stimulation in mirror neurons and the sensorimotor network: a task-based fMRI study</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>916990</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2022.916990</pub-id>.<pub-id pub-id-type="pmid">35847217</pub-id><pub-id pub-id-type="pmcid">PMC9279701</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piccinin</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Piovesana</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>MCA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study</article-title>. <source>Front Neurol</source>. <year>2014</year>;<volume>5</volume>:<fpage>283</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2014.00283</pub-id>.<pub-id pub-id-type="pmid">25620953</pub-id><pub-id pub-id-type="pmcid">PMC4288053</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beckwith</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cecil</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Altaye</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reduced gray matter volume and cortical thickness associated with traffic-related air pollution in a longitudinally studied pediatric cohort</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>e0228092</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0228092</pub-id>.<pub-id pub-id-type="pmid">31978108</pub-id><pub-id pub-id-type="pmcid">PMC6980590</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Mizuguchi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kanosue</surname><given-names>K.</given-names></string-name></person-group><part-title>Chapter 10 - Changes in brain activity during action observation and motor imagery: their relationship with motor learning</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Wilson</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Parkin</surname><given-names>B.</given-names></string-name></person-group><source>Progress in Brain Research</source>. Vol. <volume>234</volume>. Amsterdam; New York: <publisher-name>Elsevier</publisher-name>; <year>2017</year>. <fpage>189</fpage>&#8211;<lpage>204</lpage>. doi: <pub-id pub-id-type="doi">10.1016/bs.pbr.2017.08.008</pub-id>.<pub-id pub-id-type="pmid">29031463</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Klingner</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Witte</surname><given-names>OW.</given-names></string-name></person-group><part-title>Chapter 9 - Somatosensory deficits</part-title>. In: /<person-group person-group-type="editor"><string-name name-style="western"><surname>Vallar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Coslett</surname><given-names>HB.</given-names></string-name></person-group><source>Handbook of Clinical Neurology</source>. Vol. <volume>151</volume>. <publisher-name>Elsevier</publisher-name>; <year>2018</year>. <fpage>185</fpage>&#8211;<lpage>206</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-444-63622-5.00009-7</pub-id>.<pub-id pub-id-type="pmid">29519458</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jayasinghe</surname><given-names>SAL.</given-names></string-name></person-group><article-title>The role of sensory stimulation on motor learning via action observation: a mini review</article-title>. <source>J Neurophysiol</source>. <year>2019</year>;<volume>121</volume>(<issue>3</issue>):<fpage>729</fpage>&#8211;<lpage>731</lpage>. doi: <pub-id pub-id-type="doi">10.1152/jn.00747.2018</pub-id>.<pub-id pub-id-type="pmid">30517045</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JT</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Early rehabilitation after acute stroke: the golden recovery period</article-title><year>2023</year>;<volume>32</volume>(<issue>1</issue>).<pub-id pub-id-type="pmid">34918304</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nudo</surname><given-names>RJ.</given-names></string-name></person-group><article-title>Postinfarct cortical plasticity and behavioral recovery</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>(<issue>2 Suppl</issue>):<fpage>840</fpage>&#8211;<lpage>845</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.0000247943.12887.d2</pub-id>.<pub-id pub-id-type="pmid">17261749</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saa</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Tse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Baum</surname><given-names>CM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cognitive recovery after stroke: a meta-analysis and metaregression of intervention and cohort studies</article-title>. <source>Neurorehabil Neural Repair</source>. <year>2021</year>;<volume>35</volume>(<issue>7</issue>):<fpage>585</fpage>&#8211;<lpage>600</lpage>. doi: <pub-id pub-id-type="doi">10.1177/15459683211017501</pub-id>.<pub-id pub-id-type="pmid">34027728</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Disord</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Disord</journal-id><journal-id journal-id-type="pmc-domain-id">2985</journal-id><journal-id journal-id-type="pmc-domain">kargersd</journal-id><journal-id journal-id-type="publisher-id">DEM</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders</journal-title></journal-title-group><issn pub-type="ppub">1420-8008</issn><issn pub-type="epub">1421-9824</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Karger Author's Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12503446</article-id><article-id pub-id-type="pmcid-ver">PMC12503446.1</article-id><article-id pub-id-type="pmcaid">12503446</article-id><article-id pub-id-type="pmcaiid">12503446</article-id><article-id pub-id-type="pmid">40562015</article-id><article-id pub-id-type="doi">10.1159/000547061</article-id><article-id pub-id-type="publisher-id">547061</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Neuropsychiatric Symptoms Present Differently in Individuals with Different High-Risk States of Dementia</article-title><alt-title alt-title-type="short">Presentation of NPS in High-Risk States of Dementia</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2791876</contrib-id><name name-style="western"><surname>Keng</surname><given-names initials="A">Alvin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791877</contrib-id><name name-style="western"><surname>Kapustin</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2791878</contrib-id><name name-style="western"><surname>Ma</surname><given-names initials="C">Clement</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791879</contrib-id><name name-style="western"><surname>Bingham</surname><given-names initials="KS">Kathleen S.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791880</contrib-id><name name-style="western"><surname>Fischer</surname><given-names initials="CE">Corinne E.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791881</contrib-id><name name-style="western"><surname>Mah</surname><given-names initials="L">Linda</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791882</contrib-id><name name-style="western"><surname>Gallagher</surname><given-names initials="D">Damien</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791883</contrib-id><name name-style="western"><surname>Butters</surname><given-names initials="MA">Meryl A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>g</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791884</contrib-id><name name-style="western"><surname>Bowie</surname><given-names initials="CR">Christopher R.</given-names></name><xref rid="aff8" ref-type="aff">
<sup>h</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791885</contrib-id><name name-style="western"><surname>Voineskos</surname><given-names initials="AN">Aristotle N.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791886</contrib-id><name name-style="western"><surname>Graff-Guerrero</surname><given-names initials="A">Ariel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791887</contrib-id><name name-style="western"><surname>Flint</surname><given-names initials="AJ">Alastair J.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791888</contrib-id><name name-style="western"><surname>Herrmann</surname><given-names initials="N">Nathan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791889</contrib-id><name name-style="western"><surname>Pollock</surname><given-names initials="BG">Bruce G.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791890</contrib-id><name name-style="western"><surname>Mulsant</surname><given-names initials="BH">Benoit H.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791891</contrib-id><name name-style="western"><surname>Rajji</surname><given-names initials="TK">Tarek K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>i</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2791892</contrib-id><name name-style="western"><surname>Kumar</surname><given-names initials="S">Sanjeev</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><collab>on behalf of the PACt-MD Study Group</collab></contrib><aff id="aff1">
<label>a</label>Centre for Addiction and Mental Health, <city>Toronto</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff2">
<label>b</label>Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, <city>Toronto</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff3">
<label>c</label>Baycrest Centre for Geriatric Care, <city>North York</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff4">
<label>d</label>University Health Network, <city>Toronto</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff5">
<label>e</label>Keenan Research Centre for Biomedical Science, Unity Health, St. Michael&#8217;s Hospital, <city>Toronto</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff6">
<label>f</label>Sunnybrook Health Sciences Centre, <city>Toronto</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff7">
<label>g</label>Department of Psychiatry, University of Pittsburgh, <city>Pittsburgh</city>, <state>PA</state>, <country>USA</country></aff><aff id="aff8">
<label>h</label>Department of Psychiatry, Queens University, <city>Kingston</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff9">
<label>i</label>Department of Psychiatry, UT Southwestern Medical Center, <city>Dallas</city>, <state>TX</state>, <country>USA</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Alvin Keng, <email>alvin.keng@mail.utoronto.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>6</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">498495</issue-id><history><date date-type="received"><day>15</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 11:25:46.593"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://karger.com/Services/OpenAccessLicense">https://karger.com/Services/OpenAccessLicense</ext-link>). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dem-2025-0000-0000-547061.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Neuropsychiatric symptoms (NPS) are common in neurocognitive disorders. However, the differences in presentation of NPS in high-risk states for dementia such as mild neurocognitive disorder (Mild NCD) and remitted major depressive disorder (rMDD) remain unclear. The purpose of this study was to compare the frequency and factor structure of NPS in Mild NCD, rMDD, and Mild NCD with rMDD (Mild NCD-rMDD).</p></sec><sec><title>Methods</title><p>We analyzed baseline data from the multicenter Prevention of Alzheimer&#8217;s Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression trial (NCT0238667). NPS were assessed using the Neuropsychiatric Inventory Questionnaire in those with Mild NCD, rMDD, and Mild NCD-rMDD. We compared the NPS frequency and factor structure across the three groups.</p></sec><sec><title>Results</title><p>Among 374 participants with a mean (SD) age = 72.0 (6.3) years, the overall frequency of any NPS was highest in Mild NCD-rMDD (75.9%), as compared to Mild NCD (63.5%) or rMDD (55.7%) groups (<italic toggle="yes">p</italic> = 0.014). Depression/dysphoria was the most common NPS in all three groups. In factor analyses, NPS grouped into four factor structures in all three groups, but the composition of factors of individual symptoms (delusions, motor disturbances, nighttime behaviors, anxiety, and apathy) were different.</p></sec><sec><title>Conclusion</title><p>NPS are common in high-risk states of dementia, and the frequency of NPS is higher in Mild NCD-rMDD as compared to only Mild NCD or rMDD. Further, there are key differences in presentation of NPS in Mild NCD, rMDD, and Mild NCD-rMDD. Future studies should investigate the relevance of these differences for cognition, function, and disease biomarkers.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>Dementia in its early stages is not fully understood. However, many people with dementia first develop behaviors or psychological problems (known as neuropsychiatric symptoms [NPS]) before any cognitive or memory problems occur. Some examples of NPS include, but are not limited to depression, anxiety, sleep difficulties, agitation, hallucinations, and delusions. NPS are sometimes the only signs someone is developing dementia; NPS can go misdiagnosed because they can look like other disorders. This research study looks at NPS in people at risk for dementia but do not have dementia yet. This study looks at three high risk groups for dementia: (1) people with cognitive problems but can still do activities independently (known as mild neurocognitive disorder [Mild NCD]), (2) people who had clinical depression but recovered (known as major depressive disorder [MDD]), and (3) people who had both Mild NCD and MDD. This study found that the most common NPS was depression. Furthermore, this study found that people with both Mild NCD and MDD had the highest amount of any NPS. Lastly, this study used a technique called factor analysis; factor analysis tries to understand how different symptoms cluster together. The results of the factor analysis showed that NPS clustered differently in the three high risk groups. These differences may improve diagnosis and treatment of people at risk for dementia but do not have dementia. Future research should try to understand how these symptom clusters compare other disease biomarkers for dementia.</p></abstract><kwd-group><title>Keywords</title><kwd>Neuropsychiatric symptoms</kwd><kwd>Behavioral and psychological symptoms of dementia</kwd><kwd>Neurocognitive disorder</kwd><kwd>Major depressive disorder</kwd><kwd>Depression</kwd><kwd>Mild cognitive impairment</kwd><kwd>Mild behavioral impairment</kwd></kwd-group><funding-group><funding-statement>This study was not supported by any sponsor or funder.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><ref-count count="43"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>accessibilitySummary</meta-name><meta-value>WCAG 2.1 Level AA</meta-value></custom-meta><custom-meta><meta-name>accessibility-pdf-ua-compliance</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>Neuropsychiatric symptoms (NPS), also known as behavioral and psychological symptoms of dementia, are common in neurocognitive disorders including Alzheimer&#8217;s disease (AD) [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>]. NPS are associated with adverse patient outcomes, such as decline in general health, quality of life, social isolation, as well as increased caregiver burden [<xref rid="B4" ref-type="bibr">4</xref>]. In a significant majority, NPS present well before development of dementia, and increase the risk for progression of mild cognitive impairment (MCI) to dementia [<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>]. For the purpose of this article, MCI is interchangeable with mild neurocognitive disorder (Mild NCD) as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [<xref rid="B8" ref-type="bibr">8</xref>]. NPS are highly heterogeneous, and include motor disturbances, disinhibition, hyperactivity, psychosis (including delusions or hallucinations), euphoria, affective symptoms (including depression, irritability, or anxiety), apathy, eating disturbances, and nighttime disturbances. Due to this heterogeneity, NPS can overlap considerably with primary psychiatric disorders. For example, affective NPS overlap with major depressive disorder (MDD), which is another well recognized high-risk state for cognitive decline and dementia [<xref rid="B9" ref-type="bibr">9</xref>]. In the DSM-5, MDD is an episodic psychiatric disorder; patients with active symptoms of a major depressive episode (MDE) are characterized differently from those with remitted MDD (rMDD) [<xref rid="B8" ref-type="bibr">8</xref>]. The heterogeneity and overlap pose challenges for the assessment and management of NPS in clinical practice, particularly in those with rMDD.</p><p>NPS rarely occur in isolation and usually have a high degree of overlap among themselves as well [<xref rid="B2" ref-type="bibr">2</xref>]. Exploratory factor analyses of NPS in AD and MCI have attempted to understand clustering of NPS to better characterize their phenomenology [<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B12" ref-type="bibr">12</xref>]. While certain symptoms cluster consistently together (delusions and hallucinations), there is variability in clustering of others (such as apathy, eating disturbances, and nighttime behaviors) depending on the cohort [<xref rid="B10" ref-type="bibr">10</xref>]. Despite this variability, identifying clusters of NPS that manifest together can help advance understanding about their biological underpinnings. Indeed, certain symptom clusters have been associated with specific brain lesion circuits [<xref rid="B13" ref-type="bibr">13</xref>] and with neuroimaging and disease biomarkers [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. For example, delusions, apathy, and depression as NPS have been associated with structural and functional changes in the anterior cingulate cortex [<xref rid="B14" ref-type="bibr">14</xref>]. Depression, as an NPS, has been associated with cerebrospinal fluid soluble intracellular cell adhesion molecule-1 (CSF sICAM-1), and changes in serum biomarkers such as interleukin-8 (IL-8), macrophage inflammatory protein 1&#946; (MIP-1&#946;), thymus and activation-regulated chemokine, and vascular endothelial growth factor D precursor. Anxiety, as an NPS, has been associated with changes in CSF C-reactive protein, and sICAM-1 [<xref rid="B15" ref-type="bibr">15</xref>]. Apathy, as an NPS, has been associated with CSF sICAM-1 [<xref rid="B15" ref-type="bibr">15</xref>]. Further, identifying phenomenology and grouping of NPS in high-risk states for dementia (such as Mild NCD or rMDD) could help in detection and management of these symptoms and to understand and mitigate risk of dementia. To our knowledge, phenomenology and grouping of NPS in Mild NCD with rMDD has not been studied before. In this study, we aimed to compare the frequency and factor structure of NPS among individuals with Mild NCD, rMDD, and comorbid Mild NCD and rMDD (Mild NCD-rMDD).</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Overall Design and Participants</title><p>We obtained baseline data on participants enrolled in the Prevention of Alzheimer&#8217;s Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression (PACt-MD), a multicenter trial conducted across five academic sites in Toronto, Canada (clinical trial # NCT0238667). Details about PACt-MD study participant inclusion and exclusion criteria have been published previously [<xref rid="B16" ref-type="bibr">16</xref>]. For the current study, we analyzed 374 individuals with available NPS data. Participants belonged to one of three groups: (1) individuals with a diagnosis of Mild NCD and no history of MDD (Mild NCD group), (2) individuals with normal cognition but with a history of MDD currently in remission (rMDD group), and (3) individuals with comorbid Mild NCD and rMDD (Mild NCD-rMDD group).</p></sec><sec id="s2-2"><title>Assessments</title><p>The diagnosis of Mild NCD was made using clinical assessments and applying DSM-5 criteria [<xref rid="B17" ref-type="bibr">17</xref>]. Clinical assessments were conducted using the Montreal Cognitive Assessment (MoCA) [<xref rid="B18" ref-type="bibr">18</xref>], Mini-Mental State Examination (MMSE) [<xref rid="B19" ref-type="bibr">19</xref>], and a comprehensive neurocognitive battery that included tests of verbal and visual memory, language function, visuospatial ability, attention, and executive function were used to assess cognition [<xref rid="B16" ref-type="bibr">16</xref>]. The MoCA and the MMSE are widely used cognitive screening assessments but have different sensitivities based on participants&#8217; level of education [<xref rid="B20" ref-type="bibr">20</xref>]. Regardless, all cognitive assessments were used to inform and confirm a consensus diagnosis of Mild NCD.</p><p>The diagnosis of rMDD was made using the Structured Clinical Interview for DSM-5 [<xref rid="B21" ref-type="bibr">21</xref>]. Study participants with rMDD have not met criteria for a major depressive episode in the last 2 months.</p><p>NPS were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q) [<xref rid="B22" ref-type="bibr">22</xref>]. The NPI-Q is an informant-based questionnaire made up of 12 symptom domains (apathy/indifference, delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, appetite/eating). Informants (e.g., spouse, adult child, other family member, close friend) were identified by the study participant and interviewed by research staff. Informants must select &#8220;yes&#8221; or &#8220;no&#8221; in response to a screening question for each symptom based on its presence in the last 4 weeks. The severity of each identified NPS is then assessed on a three-point scale (1-mild, 2-moderate, 3-severe). This study used the total severity score for each NPS category for factor analysis.</p><p>Other assessments included the Montgomery-&#197;sberg Depression Rating Scale (MADRS) [<xref rid="B23" ref-type="bibr">23</xref>], and Cumulative Illness Rating Scale for Geriatrics (CIRS-G) to assess medical illness severity [<xref rid="B24" ref-type="bibr">24</xref>], Modified Hachinski Ischemic Score (MHIS) to assess vascular risk [<xref rid="B25" ref-type="bibr">25</xref>], and Clinical Dementia Rating Scale (CDR) for cognitive and functional status [<xref rid="B26" ref-type="bibr">26</xref>].</p></sec><sec id="s2-3"><title>Statistical Analyses</title><p>SPSS, version 29.0 (SPSS Inc), was used for all statistical analyses. The demographic and clinical characteristics of Mild NCD, rMDD, and Mild NCD-rMDD were compared. ANOVA was used to compare continuous variables across groups, and Pearson chi-square (&#935;<sup>2</sup>) tests were used to compare categorical variables across groups. We employed a Fisher&#8217;s exact test for categorical variables where cell counts were less than 5. Bonferroni correction was applied for multiple comparisons. To identify the clustering of NPS, factor analysis was conducted using the total severity of each NPS on the NPI-Q. We used a principal component extraction method and conducted a varimax rotation using correlation matrices for each of the three groups. We also performed an oblique rotation for comparison and no difference was found between the varimax and oblique rotations. The number of components was identified using Kaiser&#8217;s correction of eigenvalues equal to or greater than 1, and values of less than 0.4 were suppressed from the matrix, following a similar approach [<xref rid="B10" ref-type="bibr">10</xref>]. The Kaiser-Meyer-Olkin (KMO) test was used to assess for sampling adequacy with the threshold value above 0.50 [<xref rid="B27" ref-type="bibr">27</xref>]. Bartlett&#8217;s test of sphericity was used to assess homogeneity of variances with a significance cutoff of <italic toggle="yes">p</italic> &lt; 0.001.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Participant Characteristics</title><p>Of 374 participants, 181 had Mild NCD, 106 had rMDD, and 87 had Mild NCD-rMDD. The details of the participant demographics and clinical characteristics are presented in <xref rid="T1" ref-type="table">Table 1</xref>. Demographics: The entire sample&#8217;s mean (SD) age was 72.0 (6.3) years. There was a significant difference in mean age between Mild NCD and rMDD (mean difference = 2.2 years, 95% CI: 0.4&#8211;3.9, <italic toggle="yes">p</italic> = 0.011) but not between other groups. The study population was 65.8% female, with no statistically significant differences in gender distribution across groups. The study population was 79.9% white, and there were statistically significant differences in ethnicity across groups (Fisher&#8217;s exact test = 19.95, <italic toggle="yes">p</italic> = 0.005). Most participants were married or in common-law relationships (50.3%), had children (75.1%), lived at home independently (98.9%), and had at least a high school education (90.1%), with no statistically significant differences across groups. There was no statistically significant difference between years of education among all three groups. The Mild NCD and Mild NCD-rMDD groups had lower mean scores on the MMSE and MOCA, and higher mean scores on the CDR when compared to the rMDD group. The rMDD and Mild NCD-rMDD groups had higher mean scores on the MADRS when compared to the Mild NCD group. There were no statistically significant differences for CIRS-G and MHIS scores between the three groups. These data are presented in online supplementary Table 1 (for all online suppl. material, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1159/000547061" ext-link-type="doi">https://doi.org/10.1159/000547061</ext-link>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Demographics and clinical characteristics of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">All groups (<italic toggle="yes">N</italic> = 374)</th><th rowspan="1" colspan="1">Mild NCD only (<italic toggle="yes">n</italic> = 181)</th><th rowspan="1" colspan="1">rMDD only (<italic toggle="yes">n</italic> = 106)</th><th rowspan="1" colspan="1">Mild NCD + rMDD (<italic toggle="yes">n</italic> = 87)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, mean (SD)</td><td rowspan="1" colspan="1">72.0 (6.3)</td><td rowspan="1" colspan="1">72.8 (7.2)</td><td rowspan="1" colspan="1">70.6 (4.6)</td><td rowspan="1" colspan="1">72.2 (5.6)</td></tr><tr><td rowspan="1" colspan="1">Gender, female</td><td rowspan="1" colspan="1">246 (65.8%)</td><td rowspan="1" colspan="1">118 (65.2%)</td><td rowspan="1" colspan="1">76 (71.7%)</td><td rowspan="1" colspan="1">52 (59.8%)</td></tr><tr><td rowspan="1" colspan="1">Ethnicity, white<sup>a</sup></td><td rowspan="1" colspan="1">299 (79.9%)</td><td rowspan="1" colspan="1">131 (72.4%)</td><td rowspan="1" colspan="1">98 (92.5%)</td><td rowspan="1" colspan="1">70 (80.5%)</td></tr><tr><td rowspan="1" colspan="1">Married or common law<sup>a</sup></td><td rowspan="1" colspan="1">188 (50.3%)</td><td rowspan="1" colspan="1">96 (53%)</td><td rowspan="1" colspan="1">51 (48.1%)</td><td rowspan="1" colspan="1">41 (47.1%)</td></tr><tr><td rowspan="1" colspan="1">Has children</td><td rowspan="1" colspan="1">281 (75.1%)</td><td rowspan="1" colspan="1">144 (79.6%)</td><td rowspan="1" colspan="1">72 (67.9%)</td><td rowspan="1" colspan="1">65 (74.7%)</td></tr><tr><td rowspan="1" colspan="1">Living at home<sup>a</sup></td><td rowspan="1" colspan="1">370 (98.9%)</td><td rowspan="1" colspan="1">178 (98.3%)</td><td rowspan="1" colspan="1">106 (100%)</td><td rowspan="1" colspan="1">86 (98.9%)</td></tr><tr><td rowspan="1" colspan="1">Highest level of education &#8211; at least high school</td><td rowspan="1" colspan="1">352 (90.1%)</td><td rowspan="1" colspan="1">171 (94.5%)</td><td rowspan="1" colspan="1">103 (97.2%)</td><td rowspan="1" colspan="1">96 (89.7%)</td></tr><tr><td rowspan="1" colspan="1">Years of education</td><td rowspan="1" colspan="1">15.4 (2.4)</td><td rowspan="1" colspan="1">15.4 (2.3)</td><td rowspan="1" colspan="1">15.8 (2.2)</td><td rowspan="1" colspan="1">15.0 (2.8)</td></tr><tr><td rowspan="1" colspan="1">MMSE<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">28.1 (1.8)</td><td rowspan="1" colspan="1">27.9 (2.0)</td><td rowspan="1" colspan="1">28.9 (1.2)</td><td rowspan="1" colspan="1">27.7 (1.7)</td></tr><tr><td rowspan="1" colspan="1">MOCA<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">24.6 (3.1)</td><td rowspan="1" colspan="1">23.5 (3.0)</td><td rowspan="1" colspan="1">27.4 (1.7)</td><td rowspan="1" colspan="1">23.3 (2.6)</td></tr><tr><td rowspan="1" colspan="1">MHIS<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">0.70 (1.2)</td><td rowspan="1" colspan="1">0.78 (1.3)</td><td rowspan="1" colspan="1">0.53 (0.9)</td><td rowspan="1" colspan="1">0.73 (1.2)</td></tr><tr><td rowspan="1" colspan="1">CIRS-G<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">4.9 (3.0)</td><td rowspan="1" colspan="1">4.9 (2.8)</td><td rowspan="1" colspan="1">4.2 (2.9)</td><td rowspan="1" colspan="1">5.6 (3.3)</td></tr><tr><td rowspan="1" colspan="1">MADRS<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">4.5 (3.2)</td><td rowspan="1" colspan="1">3.8 (2.8)</td><td rowspan="1" colspan="1">5.1 (3.4)</td><td rowspan="1" colspan="1">5.2 (3.3)</td></tr><tr><td rowspan="1" colspan="1">CDR<sup>b</sup>, mean (SD)</td><td rowspan="1" colspan="1">0.34 (0.24)</td><td rowspan="1" colspan="1">0.41 (0.21)</td><td rowspan="1" colspan="1">0.13 (0.22)</td><td rowspan="1" colspan="1">0.46 (0.14)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Fisher&#8217;s exact test was used due to Pearson&#8217;s chi-square having expected cell counts below 5.</p></fn><fn><p>
<sup>b</sup>Missing data were as follows: MMSE (<italic toggle="yes">n</italic> = 4), MOCA (<italic toggle="yes">n</italic> = 1), MHIS (<italic toggle="yes">n</italic> = 18), CIRS-G (<italic toggle="yes">n</italic> = 30), CDR (<italic toggle="yes">n</italic> = 3).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Frequency of NPS</title><p>In the overall sample, 64.2% of participants had at least one NPS, and 36.1% had at least one NPS of moderate severity (score &#8805;2). There was a difference in frequency of any NPS between groups: Mild NCD (63.5%), Mild NCD-rMDD (75.9%), and rMDD (55.7%) (&#935;<sup>2</sup> = 8.54, <italic toggle="yes">n</italic> = 374, <italic toggle="yes">p</italic> = 0.014). The frequencies for all individual NPS and their comparisons between the groups are presented in <xref rid="T2" ref-type="table">Table 2</xref>. The most frequently reported NPS among all participants was depression/dysphoria (37.2%), followed by irritability/lability (25.1%), and nighttime behaviors (17.9%). These three NPS were also the most frequently reported in the Mild NCD and rMDD groups. However, in the Mild NCD-rMDD group, depression/dysphoria was the most prevalent, followed by apathy/indifference. Hallucinations were not reported by any study participants.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>NPI-Q frequency</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">All groups (<italic toggle="yes">N</italic> = 374)</th><th rowspan="1" colspan="1">Mild NCD only (<italic toggle="yes">n</italic> = 181)</th><th rowspan="1" colspan="1">rMDD only (<italic toggle="yes">n</italic> = 106)</th><th rowspan="1" colspan="1">Mild NCD-rMDD (<italic toggle="yes">n</italic> = 87)</th><th rowspan="1" colspan="1">Chi-square (<italic toggle="yes">p</italic> value)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Any NPS</td><td rowspan="1" colspan="1">240 (64.2%)</td><td rowspan="1" colspan="1">63.5%</td><td rowspan="1" colspan="1">55.7%</td><td rowspan="1" colspan="1">75.9%</td><td rowspan="1" colspan="1">0.014</td></tr><tr><td rowspan="1" colspan="1">At least moderate NPS (severity &#8805;2)</td><td rowspan="1" colspan="1">135 (36.1%)</td><td rowspan="1" colspan="1">28.7%</td><td rowspan="1" colspan="1">33.0%</td><td rowspan="1" colspan="1">55.2%</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Delusions</td><td rowspan="1" colspan="1">6 (1.6%)</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">0.0%</td><td rowspan="1" colspan="1">3.6%</td><td rowspan="1" colspan="1">0.131<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Hallucinations</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">0.0%</td><td rowspan="1" colspan="1">0.0%</td><td rowspan="1" colspan="1">0.0%</td><td rowspan="1" colspan="1">N/A<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Agitation/aggression</td><td rowspan="1" colspan="1">39 (10.4%)</td><td rowspan="1" colspan="1">9.4%</td><td rowspan="1" colspan="1">9.4%</td><td rowspan="1" colspan="1">13.8%</td><td rowspan="1" colspan="1">0.503</td></tr><tr><td rowspan="1" colspan="1">Depression/dysphoria</td><td rowspan="1" colspan="1">139 (37.2%)</td><td rowspan="1" colspan="1">30.9%</td><td rowspan="1" colspan="1">34.0%</td><td rowspan="1" colspan="1">54.0%</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1">53 (14.2%)</td><td rowspan="1" colspan="1">14.4%</td><td rowspan="1" colspan="1">8.5%</td><td rowspan="1" colspan="1">20.7%</td><td rowspan="1" colspan="1">0.054</td></tr><tr><td rowspan="1" colspan="1">Elation/euphoria</td><td rowspan="1" colspan="1">7 (1.9%)</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">2.3%</td><td rowspan="1" colspan="1">0.891<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Apathy/indifference</td><td rowspan="1" colspan="1">62 (16.6%)</td><td rowspan="1" colspan="1">13.8%</td><td rowspan="1" colspan="1">11.3%</td><td rowspan="1" colspan="1">28.7%</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Disinhibition</td><td rowspan="1" colspan="1">22 (5.9%)</td><td rowspan="1" colspan="1">5.0%</td><td rowspan="1" colspan="1">3.8%</td><td rowspan="1" colspan="1">10.3%</td><td rowspan="1" colspan="1">0.135<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Irritability/lability</td><td rowspan="1" colspan="1">94 (25.1%)</td><td rowspan="1" colspan="1">25.4%</td><td rowspan="1" colspan="1">21.7%</td><td rowspan="1" colspan="1">28.7%</td><td rowspan="1" colspan="1">0.529</td></tr><tr><td rowspan="1" colspan="1">Motor disturbance</td><td rowspan="1" colspan="1">13 (3.5%)</td><td rowspan="1" colspan="1">2.8%</td><td rowspan="1" colspan="1">3.8%</td><td rowspan="1" colspan="1">4.6%</td><td rowspan="1" colspan="1">0.667<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Nighttime behaviors</td><td rowspan="1" colspan="1">67 (17.9%)</td><td rowspan="1" colspan="1">18.2%</td><td rowspan="1" colspan="1">13.2%</td><td rowspan="1" colspan="1">23.0%</td><td rowspan="1" colspan="1">0.209</td></tr><tr><td rowspan="1" colspan="1">Appetite/eating</td><td rowspan="1" colspan="1">53 (14.2%)</td><td rowspan="1" colspan="1">14.9%</td><td rowspan="1" colspan="1">11.3%</td><td rowspan="1" colspan="1">16.1%</td><td rowspan="1" colspan="1">0.590</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Fisher&#8217;s exact test was used due to Pearson&#8217;s chi-square having expected cell counts below 5.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Factor Analyses</title><p>The factor analyses for each group are presented in <xref rid="F1" ref-type="fig">Figure 1</xref>. In summary, each group had a four-factor model based on eigenvalues and percentage of variance (see <xref rid="T3" ref-type="table">Tables 3</xref>&#8211;<xref rid="T5" ref-type="table">5</xref> for details).</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>Eigenvalues for each subgroup factor (principal component).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0000-0000-547061_F01.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Factor analysis of mild NCD (<italic toggle="yes">n</italic> = 181)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#8203;</th><th colspan="4" rowspan="1">Factor</th></tr><tr><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th><th rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Appetite/eating</td><td rowspan="1" colspan="1">0.781</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Depression/dysphoria</td><td rowspan="1" colspan="1">0.590</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Nighttime behaviors</td><td rowspan="1" colspan="1">0.549</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.407</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Apathy/indifference</td><td rowspan="1" colspan="1">0.499</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.413</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Irritability/lability</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.754</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Disinhibition</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.669</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Elation/euphoria</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.535</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Delusions</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.828</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Agitation/aggression</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">0.529</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.708</td></tr><tr><td rowspan="1" colspan="1">Motor disturbance</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.704</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">Depression/apathy</th><th rowspan="1" colspan="1">Irritability/disinhibition</th><th rowspan="1" colspan="1">Delusions/agitation</th><th rowspan="1" colspan="1">Anxiety/motor</th><th rowspan="1" colspan="1">&#8203;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total variance explained</td><td rowspan="1" colspan="1">22.2%</td><td rowspan="1" colspan="1">13.3%</td><td rowspan="1" colspan="1">10.6%</td><td rowspan="1" colspan="1">9.4%</td><td rowspan="1" colspan="1">55.4%</td></tr></tbody></table><table-wrap-foot><fn><p>KMO adequacy = 0.66, Bartlett&#8217;s <italic toggle="yes">p</italic> &lt; 0.001.</p></fn><fn><p>Hallucinations did not meet the threshold for loading and was not included in this factor model.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><p>Factor analysis of rMDD (<italic toggle="yes">n</italic> = 106)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="4" rowspan="1">Factor</th></tr><tr><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th><th rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Depression/dysphoria</td><td rowspan="1" colspan="1">0.736</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Apathy/indifference</td><td rowspan="1" colspan="1">0.643</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Appetite/eating</td><td rowspan="1" colspan="1">0.604</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Irritability/lability</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.735</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Elation/euphoria</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.723</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.732</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Nighttime behaviors</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.549</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Disinhibition</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.419</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Agitation/aggression</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.406</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Motor disturbance</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.845</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Depression/apathy</th><th rowspan="1" colspan="1">Irritability/elation</th><th rowspan="1" colspan="1">Anxiety/agitation</th><th rowspan="1" colspan="1">Motor</th><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total variance explained</td><td rowspan="1" colspan="1">20.0%</td><td rowspan="1" colspan="1">14.1%</td><td rowspan="1" colspan="1">11.1%</td><td rowspan="1" colspan="1">10.5%</td><td rowspan="1" colspan="1">55.7%</td></tr></tbody></table><table-wrap-foot><fn><p>KMO adequacy = 0.53, Bartlett&#8217;s <italic toggle="yes">p</italic> &lt; 0.001.</p></fn><fn><p>Delusions and hallucinations did not meet the threshold for loading and were not included in this factor model.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5.</label><caption><p>Factor analysis of mild NCD-rMDD (<italic toggle="yes">n</italic> = 87)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#8203;</th><th colspan="4" rowspan="1">Factor</th></tr><tr><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th><th rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Motor disturbance</td><td rowspan="1" colspan="1">0.917</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Disinhibition</td><td rowspan="1" colspan="1">0.652</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Appetite/eating</td><td rowspan="1" colspan="1">0.580</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Apathy/indifference</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.984</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Irritability/lability</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.623</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Nighttime behaviors</td><td rowspan="1" colspan="1">0.466</td><td rowspan="1" colspan="1">0.515</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Elation/euphoria</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">1.004</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Delusions</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.743</td><td rowspan="1" colspan="1">&#8203;</td></tr><tr><td rowspan="1" colspan="1">Anxiety</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.879</td></tr><tr><td rowspan="1" colspan="1">Depression/dysphoria</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.838</td></tr><tr><td rowspan="1" colspan="1">Agitation/aggression</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">&#8203;</td><td rowspan="1" colspan="1">0.411</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#8203;</th><th rowspan="1" colspan="1">Motor/disinhibition</th><th rowspan="1" colspan="1">Apathy/irritability</th><th rowspan="1" colspan="1">Delusions/elation</th><th rowspan="1" colspan="1">Anxiety/depression</th><th rowspan="1" colspan="1">&#8203;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total variance explained</td><td rowspan="1" colspan="1">31.9%</td><td rowspan="1" colspan="1">13.5%</td><td rowspan="1" colspan="1">10.8%</td><td rowspan="1" colspan="1">10.1%</td><td rowspan="1" colspan="1">66.3%</td></tr></tbody></table><table-wrap-foot><fn><p>KMO adequacy = 0.73, Bartlett&#8217;s <italic toggle="yes">p</italic> &lt; 0.001.</p></fn><fn><p>Hallucinations did not meet the threshold for loading and was not included in this factor model.</p></fn></table-wrap-foot></table-wrap><sec id="s3-3-1"><title>Mild Neurocognitive Disorder</title><p>The four factors explained 55.4% of the total variance in NPI-Q severity scores. Factor 1 (labeled as depression/apathy) included depression/dysphoria, nighttime behaviors, apathy/indifference, and appetite/eating, and explained 22.2% of the total variance. Factor 2 (labeled as irritability/disinhibition) included irritability/lability, disinhibition, and elation/euphoria, and explained 13.3% of the total variance. Factor 3 (labeled as delusions/agitation) included delusions and agitation/aggression and explained 10.6% of the total variance. Factor 4 (labeled anxiety/motor) included anxiety and motor disturbance, and explained 9.4% of the total variance.</p></sec><sec id="s3-3-2"><title>Remitted Major Depressive Disorder</title><p>The four factors explained 55.7% of the total variance in NPI-Q severity scores. Factor 1 (labeled as depression/apathy) included depression/dysphoria, apathy/indifference, and appetite/eating and explained 20.0% of the total variance. Factor 2 (labeled as irritability/elation) included irritability/lability, and elation/euphoria, and explained 14.1% of the total variance. Factor 3 (labeled as anxiety/agitation) included anxiety, nighttime behaviors, disinhibition, agitation/aggression, and motor disturbance explained 11.1% of the total variance. Factor 4 (labeled as motor) included only motor disturbance, and explained 10.5% of the total variance.</p></sec><sec id="s3-3-3"><title>Mild Neurocognitive Disorder-Remitted Major Depressive Disorder</title><p>The four factors explained 66.3% of the total variance in NPI-Q severity scores. Factor 1 (labeled as motor/disinhibition) included motor disturbance, disinhibition, and appetite/eating, and explained 31.9% of the total variance. Factor 2 (labeled as apathy/irritability) included apathy/indifference, irritability/lability, and nighttime behaviors, and explained 13.5% of the total variance. Factor 3 (labeled as delusions/elation) included delusions and elation/euphoria and explained 10.8% of the total variance. Factor 4 (labeled as anxiety/depression) included anxiety, depression/dysphoria, and agitation/aggression, explaining 10.1% of the total variance.</p></sec></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The aims of our study were to compare the frequency and factor structure of NPS among different high-risk states of dementia such as Mild NCD, rMDD, and comorbid Mild NCD-rMDD. The frequency of any one NPS was 64.2% in our entire cohort; although high, this is in keeping with previously reported prevalence in adults with Mild NCD at 35&#8211;85% [<xref rid="B2" ref-type="bibr">2</xref>]. Our finding supports the existing literature that NPS are prevalent among individuals with Mild NCD [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B30" ref-type="bibr">30</xref>]. Furthermore, our study adds to the literature by describing the frequency of NPS in patients with Mild NCD-rMDD; notably, this group had the highest frequency (75.9%) of any NPS in our study. In recent years, there has been increasing interest in the relationship between NPS and high-risk states of conversion to dementia [<xref rid="B31" ref-type="bibr">31</xref>]. History of MDD is a risk factor for progression to dementia [<xref rid="B32" ref-type="bibr">32</xref>] and a higher frequency of NPS in this group could be related to progression. Sociodemographic variables may also affect risk of progression to dementia. Although this was not established in our study, this would be an important consideration for future studies. For example, years of education, which may reflect cognitive reserve [<xref rid="B33" ref-type="bibr">33</xref>], could play a role in impacting the prevalence, severity, or clustering of NPS. Future studies should examine such relationships longitudinally and also determine whether effective treatment of NPS in this population reduces risk of dementia.</p><p>Depression/dysphoria was the most common NPS reported in the entire cohort and for each of the groups including the Mild NCD group. It is important to note that although participants with rMDD were included in our study, they were not in a current major depressive episode, and the participants in the Mild NCD group had no history of MDD. A depressed or dysphoric mood on the NPI-Q does not represent the full constellation of MDD. However, these depressive symptoms are a risk factor for progression to dementia [<xref rid="B32" ref-type="bibr">32</xref>]. Furthermore, depressive symptoms have been associated with greater atrophy in AD-affected brain regions, increased cognitive decline, and higher rates of progression to AD [<xref rid="B34" ref-type="bibr">34</xref>]. The significance of managing depressive symptoms in dementia prevention remains unclear and warrants future study. Prior research has supported that antidepressant treatment may have an impact on AD pathology at the molecular level and neuroprotective effects [<xref rid="B35" ref-type="bibr">35</xref>]. However, more research is needed on the clinical benefit of treating NPS that resemble but are subsyndromal for MDD [<xref rid="B35" ref-type="bibr">35</xref>]. NPS factor structures of depression/dysphoria may provide a future basis for case identification and selection for antidepressant treatment in AD. We also observed high frequencies of other NPS, such as irritability/lability, nighttime behaviors, and apathy/indifference. These NPS have also been linked to the progression to dementia [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. Furthermore, we observed a low frequency of psychotic symptoms (delusions) in the Mild NCD and Mild NCD-rMDD groups that is consistent with previous literature [<xref rid="B12" ref-type="bibr">12</xref>]. We observed no psychotic symptoms in rMDD group, which might suggest that psychotic symptoms, while less frequent in high-risk states for dementia, are more common in primary cognitive disorders as opposed to those with rMDD.</p><p>Lastly, we compared the factor structure of NPS in those with Mild NCD, rMDD, and Mild NCD-rMDD to investigate presentation of NPS in these groups. Delusions clustered differently across the three groups: with agitation/aggression in Mild NCD, with elation/euphoria in Mild NCD-rMDD, and was not present in rMDD group. Our findings contrast with previous studies where delusions and hallucinations typically did not group with other NPS [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. This could have been due to the influence of rMDD on delusions or due to low frequency of delusions and hallucinations in our study participants.</p><p>Motor disturbance did not group with other NPS in rMDD; however, motor disturbance grouped with anxiety in Mild NCD and disinhibition in Mild NCD-rMDD. Furthermore, the motor/disinhibition factor explained most of the variance in NPS within the Mild NCD-rMDD group. In one prior study, motor disturbance was associated with non-amnestic MCI [<xref rid="B28" ref-type="bibr">28</xref>]. In another study, motor disturbance mapped with several other NPS, including depressive symptoms, anxiety, appetite and eating disturbances, and nighttime behaviors [<xref rid="B12" ref-type="bibr">12</xref>]. Our findings suggest a potential difference in the phenomenology of motor disturbance in Mild NCD patients with and without a history of MDD.</p><p>Nighttime behaviors also loaded differently in the factor structures for Mild NCD and rMDD. Although sleep disturbances have been known to play a role in both Mild NCD [<xref rid="B36" ref-type="bibr">36</xref>] and rMDD [<xref rid="B37" ref-type="bibr">37</xref>], it is possible that they may represent different syndromes in Mild NCD and rMDD. In a prior case-control study, sleep disturbances were strongly associated with MCI and a past diagnosis of MDD [<xref rid="B38" ref-type="bibr">38</xref>]; our study builds on this finding and bolsters our understanding that nighttime behaviors are important in high-risk states of dementia.</p><p>Similarly, anxiety grouped differently in Mild NCD, with motor disturbances, and Mild NCD-rMDD, with depression and agitation. In our study, we posit that differences exist with the quality and severity of anxiety in how it presents in patients with different high-risk states of dementia. Anxiety is known to be prevalent in MCI, and highly suspected to have an important relationship with cognition and other NPS; however, it remains poorly understood in comparison to other NPS [<xref rid="B39" ref-type="bibr">39</xref>]. The appearance of late-life anxiety symptoms warrants inquiry into the presence of Mild NCD or rMDD as risk factors for dementia.</p><p>Apathy grouped with depressive symptoms in our Mild NCD and rMDD groups but with irritability and nighttime behaviors in Mild NCD-rMDD. Apathy grouped separately from depressive symptoms in prior studies with Mild NCD [<xref rid="B12" ref-type="bibr">12</xref>], and interestingly, in early AD [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>], however, these studies did not include participants with a history of rMDD. Apathy alone and apathy comorbid with depressive symptoms have been associated with the progression of Mild NCD to AD in comparison to those without NPS [<xref rid="B40" ref-type="bibr">40</xref>]. Although apathy and depression can be challenging to distinguish from each other, they have been known to have independent and differential effects on function [<xref rid="B41" ref-type="bibr">41</xref>]. Our study adds to the current literature by distinguishing a distinct apathy/irritability cluster in the Mild NCD-rMDD group in comparison to Mild NCD and rMDD where it grouped with depression. Future studies should consider exploring the impact of this apathy cluster on functional outcomes.</p><p>Furthermore, some NPS grouped on multiple factor structures: nighttime behaviors, apathy, and agitation/aggression for the Mild NCD group, and nighttime behaviors in the Mild NCD-rMDD group. Factors were generated based on where they loaded most strongly, and we used a similar approach as previous factor analyses [<xref rid="B42" ref-type="bibr">42</xref>]. Prior studies looking at NPS factor structures in Mild NCD also note that it is common for some NPS to cross-load on multiple factors, possibly indicating a shared mechanism for these NPS [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B30" ref-type="bibr">30</xref>].</p><p>A better understanding of NPS factor structures may improve our ability to diagnose and treat high-risk states of dementia. NPS have been associated with cognitive and functional impairment with validated tools to assess their diagnostic validity [<xref rid="B6" ref-type="bibr">6</xref>]. However, the importance of specific NPS or their groupings may confer different risks of progression among patients with cognitive impairment. In the literature on NPS in MCI, apathy and anxiety were more consistently associated with disease progression, in comparison to depression and sleep problems [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. We posit that a more sophisticated understanding of NPS clustering may improve risk stratification and management of MCI or early dementia. For example, depression/apathy, depression/anxiety, and depression/agitation clusters may signify different diagnoses and prognoses of neurocognitive disorders. Furthermore, therapeutic options in NPS remain limited, and while NPS resemble psychiatric disorders, they are not direct comparators. Current guidelines on treating NPS are limited in their recommendations; for example, recent practice guidelines acknowledge that outside of agitation, there are few high-quality studies to derive evidence-based recommendations [<xref rid="B43" ref-type="bibr">43</xref>]. We also posit that different NPS clusters may require different non-pharmacological or pharmacological approaches, as could be in depression/apathy in comparison to depression/agitation. Future studies can utilize these NPS structures and compare prognosis or response to therapeutic interventions.</p><p>This study has several limitations. First, the participants were from a research study cohort, and not from a population-based cohort, which may limit generalizability of findings. However, the frequencies of NPS observed in our study reflected those reported in population-based studies. Second, NPS were only measured with a single informant-rated questionnaire, the NPI-Q. The NPI-Q may be prone to reporting bias and having additional measures of NPS may have added further depth to our factor analysis. Nevertheless, the NPI-Q has similarly been used in other factor analyses of Mild NCI patients but not in rMDD patients [<xref rid="B31" ref-type="bibr">31</xref>]. Third, although rigorous criteria and neuropsychological assessment were used to ascertain diagnoses, we did not distinguish between amnestic and non-amnestic Mild NCD subtypes or include disease-specific biomarkers. Fourth, this study was a cross-sectional sample and thus, is unable to comment on stability of the estimates of frequency or factor structure of NPS over time. Finally, frequency of some NPS, specifically psychotic symptoms was low, which may have contributed to instability in factor structures.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>This study assessed frequency and factor structure of NPS in individuals with Mild NCD, rMDD, and Mild NCD-rMDD. NPS were frequent in all groups, and especially the Mild NCD-rMDD group. Depression/dysphoria was the most common NPS. Factor analyses in each group revealed four factors with some key differences. Specifically, we observed a difference in presentation of delusions and motor disturbances in the factor structures of Mild NCD and Mild NCD-rMDD. These findings emphasize the importance of individualized assessment and treatment of NPS in patients with Mild NCD and primary psychiatric disorders such as MDD. In addition, it is important to assess for a history of MDD in primary cognitive disorders. Future studies should investigate how these varied presentations of NPS influence cognition and function in neurocognitive disorders in longitudinal population-based cohorts. Future studies should also investigate the association of NPS clusters with disease-specific biomarkers to advance understanding of mechanisms underlying NPS and facilitate the development of effective interventions.</p></sec><sec sec-type="acknowledgments" id="s6"><title>Acknowledgments</title><p>The authors would like to thank the PACt-MD study group (online supplement 1) and all participants and caregivers involved in the study.</p></sec><sec sec-type="statement of ethics" id="s7"><title>Statement of Ethics</title><p>This study protocol was reviewed and approved by Review and Ethics Board of the Centre for Addiction and Mental Health (CAMH), Toronto, Canada, Approval No.: CTO Project ID: 1333 Sponsor Study ID: 041-2014. All participants provided written informed consent before any research procedures were conducted. When required, written informed consent was obtained from the patient&#8217;s legal guardian/healthcare proxy for participation in this study.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of Interest Statement</title><p>A.K., D.K., C.M., D.G., A.G.-G., and N.H. have no conflicts of interest to declare. K.S.B. receives grant support from the University of Toronto. C.E.F. receives grant funding from NIA, NIH, CCNA, CIHR, ADDF, TDRA, Mito2i, the Hilary and Galen Weston Foundation, and Novo Nordisk. L.M. has received research funding from the Alzheimer&#8217;s Society of Canada, Centre for Aging and Brain Health Innovation, Ontario Ministry of Health and Long-Term Care, and Brainsway, Ltd. M.A.B. receives research support from the NIH. C.R.B. has received in-kind research accounts from Scientific Brain Training Pro and grant funding from Pfizer and Diamentis. He has been a consultant for Boehringer Ingelheim. A.N.V. receives funding from the National Institute of Mental Health (NIMH), Canadian Institutes of Health Research, Brain and Behavior Research Foundation (BBRF), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, and the University of Toronto. A.J.F. has received grant support from the US National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Canadian Institutes of Health Research, Brain Canada, the Ontario Brain Institute, the Alzheimer&#8217;s Association, AGE-WELL, the Canadian Foundation for Healthcare Improvement, and the University of Toronto. B.G.P. holds and receives support from the Peter and Shelagh Godsoe Endowed Chair in Late-Life Mental Health, Centre for Addiction and Mental Health Foundation and Discovery Fund. His research is supported by the National Institute of Aging, Brain Canada, the Canadian Institutes of Health Research, the Alzheimer&#8217;s Drug Discovery Foundation, the Ontario Brain Institute, the Centre for Aging and Brain Health Innovation, Alzheimer&#8217;s Society of Canada, the W. Garfield Weston Foundation, the Weston Brain Institute, the Canadian Consortium on Neurodegeneration in Aging and Genome Canada. He receives honoraria from the American Geriatrics Society and holds US Provisional Patent No. 16/490,680 and Canadian Provisional Patent No. 3,054,093 for a cell-based assay and kits for assessing serum anticholinergic activity. B.H.M. holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. B.H.M. has received research funding from Brain Canada, the CAMH Foundation, the Canadian Institutes of Health Research, the Patient-Centered Outcomes Research Institute (PCORI), and the US National Institutes of Health (NIH); research support from Bristol-Myers Squibb (medications for an NIH-funded clinical trial), Eli-Lilly (medications for an NIH-funded clinical trial), Pfizer (medications for an NIH-funded clinical trial), Capital Solution Design LLC (software used in a study funded by CAMH Foundation), and HAPPYneuron (software used in a study funded by Brain Canada). He has been an unpaid consultant to Myriad Neuroscience. T.K.R. has received research support from Brain Canada, Brain and Behavior Research Foundation, BrightFocus Foundation, Canada Foundation for Innovation, Canada Research Chair, Canadian Institutes of Health Research, Centre for Aging and Brain Health Innovation, National Institutes of Health, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, and the Weston Brain Institute. T.K.R. also received in-kind equipment support for an investigator-initiated study from Magstim, and in-kind research accounts from Scientific Brain Training Pro. He participated in 2021 in an advisory board for Biogen Canada Inc. T.K.R. also received for an investigator-initiated study in-kind equipment support from Newronika, and in-kind research online accounts from Scientific Brain Training Pro and participated in 2021 and 2022 in an advisory activity for Biogen Canada Inc. T.K.R. is also an inventor on the US Provisional Patent No. 17/396,030 that describes cell-based assays and kits for assessing serum cholinergic receptor activity. S.K. has received research support the Brain and Behavior Foundation, US National institute on Aging, BrightFocus Foundation, Brain Canada, Canadian Institutes of Health Research, Canadian Consortium on Neurodegeneration in Aging, Centre for Ageing and Brain Health Innovation, Centre for Addiction and Mental Health, and an Academic Scholars Award from the Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto. He has also received equipment support from Soterix Medical.</p></sec><sec sec-type="funding sources" id="s9"><title>Funding Sources</title><p>This study was not supported by any sponsor or funder.</p></sec><sec sec-type="author contributions" id="s10"><title>Author Contributions</title><p>A.K. and S.K. were responsible for the design of the study and drafting of the manuscript. K.S.B., C.E.F., L.M., D.G., M.A.B., C.R.B., A.N.V., A.G.-G., A.J.F., N.H., B.G.P., B.H.M., T.K.R., and S.K. were responsible for the acquisition of the data. A.K., D.K., C.M., and S.K. were responsible for the analysis of the data. All authors were involved in the analysis and interpretation of the data, were responsible in reviewing and providing final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec></body><back><sec sec-type="data-availability" id="s17"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are included in this article and its supplementary material files. Further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="supplementary-material" id="s25"><label>Supplementary Material</label><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_material-Suppl.1-s1.docx" id="d67e1765" position="anchor" orientation="portrait"/></supplementary-material></sec><sec sec-type="supplementary-material" id="s26"><label>Supplementary Material</label><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_material-Suppl.2-s2.xlsx" id="d67e1769" position="anchor" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Velayudhan</surname><given-names>L</given-names></string-name></person-group>. <article-title>Neuropsychiatric symptoms in mild cognitive impairment: a literature review</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2020</year>;<volume>49</volume>(<issue>2</issue>):<fpage>146</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">32289790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000507078</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gallagher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Iaboni</surname><given-names>A</given-names></string-name></person-group>. <article-title>Neuropsychiatric symptoms in mild cognitive impairment: an update on prevalence, mechanisms, and clinical significance</article-title>. <source>Can J Psychiatry</source>. <year>2017</year>;<volume>62</volume>(<issue>3</issue>):<fpage>161</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28212495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0706743716648296</pub-id><pub-id pub-id-type="pmcid">PMC5317015</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>QF</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>The prevalence of neuropsychiatric symptoms in Alzheimer&#8217;s disease: systematic review and meta-analysis</article-title>. <source>J Affect Disord</source>. <year>2016</year>;<volume>190</volume>:<fpage>264</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26540080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2015.09.069</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Isik</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Soysal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Solmi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Veronese</surname><given-names>N</given-names></string-name></person-group>. <article-title>Bidirectional relationship between caregiver burden and neuropsychiatric symptoms in patients with Alzheimer&#8217;s disease: a narrative review</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2019</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1326</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">30198597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4965</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peters</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Steinberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Welsh-Bohmer</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Hayden</surname><given-names>KM</given-names></string-name>, <etal/></person-group>. <article-title>Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2013</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1116</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">23567370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2013.01.049</pub-id><pub-id pub-id-type="pmcid">PMC3525756</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>McGirr</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Forkert</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>EE</given-names></string-name></person-group>. <article-title>Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>80</volume>(<issue>1</issue>):<fpage>459</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">33554909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201184</pub-id><pub-id pub-id-type="pmcid">PMC8075401</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gatchel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Barcelos-Ferreira</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cantillon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jaeger</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria</article-title>. <source>Int Psychogeriatr</source>. <year>2018</year>;<volume>30</volume>(<issue>2</issue>):<fpage>185</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">28899446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217001880</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>. <source>Diagnostic and statistical manual of mental disorders</source>. <edition>5th ed</edition>, text rev; <year>2022</year>. Available from:</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Leng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>YZ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>SD</given-names></string-name>, <etal/></person-group>. <article-title>Depression, depression treatments, and risk of incident dementia: a prospective cohort study of 354,313 participants</article-title>. <source>Biol Psychiatry</source>. <year>2023</year>;<volume>93</volume>(<issue>9</issue>):<fpage>802</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">36526487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2022.08.026</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aalten</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verhey</surname><given-names>FRJ</given-names></string-name>, <string-name name-style="western"><surname>Boziki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bullock</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Camus</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Neuropsychiatric syndromes in dementia: results from the European Alzheimer Disease Consortium &#8211; Part I</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2007</year>;<volume>24</volume>(<issue>6</issue>):<fpage>457</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">17986816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000110738</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Di</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Duffy</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Brook</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Elashoff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>CH</given-names></string-name>, <etal/></person-group>. <article-title>Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer&#8217;s disease</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2014</year>;<volume>37</volume>(<issue>5&#8211;6</issue>):<fpage>315</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">24481207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000351009</pub-id><pub-id pub-id-type="pmcid">PMC4057985</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siafarikas</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Selbaek</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fladby</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Benth</surname><given-names>J&#352;</given-names></string-name>, <string-name name-style="western"><surname>Auning</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer&#8217;s disease</article-title>. <source>Int Psychogeriatr</source>. <year>2018</year>;<volume>30</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">28927477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217001879</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer&#8217;s disease: a systematic review of symptom-general and &#8211; specific lesion patterns</article-title>. <source>Mol Neurodegener</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>38</fpage>.<pub-id pub-id-type="pmid">34099005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00456-1</pub-id><pub-id pub-id-type="pmcid">PMC8186099</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boublay</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schott</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Krolak-Salmon</surname><given-names>P</given-names></string-name></person-group>. <article-title>Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer&#8217;s disease: a review of 20 years of research</article-title>. <source>Eur J Neurol</source>. <year>2016</year>;<volume>23</volume>(<issue>10</issue>):<fpage>1500</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27435186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.13076</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Richiardi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mar&#233;chal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bowman</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Dayon</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Popp</surname><given-names>J</given-names></string-name></person-group>. <article-title>Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people</article-title>. <source>J Neuroinflammation</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>127</fpage>.<pub-id pub-id-type="pmid">35643540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02473-3</pub-id><pub-id pub-id-type="pmcid">PMC9148517</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajji</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Bowie</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pollock</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Bikson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blumberger</surname><given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Design and rationale of the PACt-MD randomized clinical trial: prevention of Alzheimer&#8217;s dementia with cognitive remediation plus transcranial direct current stimulation in mild cognitive impairment and depression</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>76</volume>(<issue>2</issue>):<fpage>733</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">32568198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200141</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>. <source>Diagnostic and statistical manual of mental disorders</source>. <edition>5th ed</edition>. Text revision (DSM-5-TR): neurocognitive disorders; <year>2022</year>. Available from:</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nasreddine</surname><given-names>ZS</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>B&#233;dirian</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Charbonneau</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Whitehead</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Collin</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source>. <year>2005</year>;<volume>53</volume>(<issue>4</issue>):<fpage>695</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15817019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2005.53221.x</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tombaugh</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>NJ</given-names></string-name></person-group>. <article-title>The mini-mental state examination: a comprehensive review</article-title>. <source>J Am Geriatr Soc</source>. <year>1992</year>;<volume>40</volume>(<issue>9</issue>):<fpage>922</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">1512391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1992.tb01992.x</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siqueira</surname><given-names>GSA</given-names></string-name>, <string-name name-style="western"><surname>Hagemann</surname><given-names>PMS</given-names></string-name>, <string-name name-style="western"><surname>Coelho</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Bertolucci</surname><given-names>PH</given-names></string-name></person-group>. <article-title>Can MoCA and MMSE be interchangeable cognitive screening tools? A systematic review</article-title>. <source>Gerontologist</source>. <year>2019</year>;<volume>59</volume>(<issue>6</issue>):<fpage>e743</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">30517634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geront/gny126</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>First</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karg</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Spitzer</surname><given-names>R</given-names></string-name></person-group>. <source>Structured clinical Interview for DSM-5, research version</source>. <publisher-loc>Arlington, VA</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaufer</surname><given-names>DI</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Ketchel</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>MacMillan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shelley</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>2000</year>;<volume>12</volume>(<issue>2</issue>):<fpage>233</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11001602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/jnp.12.2.233</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montgomery</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>&#197;sberg</surname><given-names>M</given-names></string-name></person-group>. <article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br J Psychiatry</source>. <year>1979</year>;<volume>134</volume>(<issue>4</issue>):<fpage>382</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">444788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.134.4.382</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miller</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Paradis</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Houck</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Mazumdar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stack</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Rifai</surname><given-names>AH</given-names></string-name>, <etal/></person-group>. <article-title>Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale</article-title>. <source>Psychiatry Res</source>. <year>1992</year>;<volume>41</volume>(<issue>3</issue>):<fpage>237</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">1594710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1781(92)90005-n</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosen</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Terry</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Fuld</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Katzman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Peck</surname><given-names>A</given-names></string-name></person-group>. <article-title>Pathological verification of ischemic score in differentiation of dementias</article-title>. <source>Ann Neurol</source>. <year>1980</year>;<volume>7</volume>(<issue>5</issue>):<fpage>486</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">7396427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410070516</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type</article-title>. <source>Int Psychogeriatr</source>. <year>1997</year>;<volume>9</volume>(<issue>Suppl 1</issue>):<fpage>173</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9447441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s1041610297004870</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Hair</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Babin</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>RE</given-names></string-name></person-group>. <source>Multivariate data analysis</source>. <edition>7th ed</edition>; <year>2010</year>.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geda</surname><given-names>YE</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Michelle Mielke</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Christianson</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Pankratz</surname><given-names>VS</given-names></string-name>, <etal/></person-group>. <article-title>Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study</article-title>. <source>Am J Psychiatry</source>. <year>2014</year>;<volume>171</volume>(<issue>5</issue>):<fpage>572</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">24700290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2014.13060821</pub-id><pub-id pub-id-type="pmcid">PMC4057095</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karttunen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Karppi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hiltunen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vanhanen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>V&#228;lim&#228;ki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Martikainen</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer&#8217;s disease</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2011</year>;<volume>26</volume>(<issue>5</issue>):<fpage>473</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">21445998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.2550</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sugarman</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Alosco</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Tripodis</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Steinberg</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Stern</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Neuropsychiatric symptoms and the diagnostic stability of mild cognitive impairment</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>62</volume>(<issue>4</issue>):<fpage>1841</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">29614641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170527</pub-id><pub-id pub-id-type="pmcid">PMC6548196</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roberto</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Portella</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Marqui&#233;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alegret</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Maule&#243;n</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>6448</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33742011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-83126-y</pub-id><pub-id pub-id-type="pmcid">PMC7979780</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Der Mussele</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fransen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Struyfs</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Luyckx</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mari&#235;n</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Saerens</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Depression in mild cognitive impairment is associated with progression to Alzheimer&#8217;s disease: a longitudinal study</article-title>. <source>J Alzheimers Dis</source>. <year>2014</year>;<volume>42</volume>(<issue>4</issue>):<fpage>1239</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">25024328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140405</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharp</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Gatz</surname><given-names>M</given-names></string-name></person-group>. <article-title>Relationship between education and dementia: an updated systematic review</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2011</year>;<volume>25</volume>(<issue>4</issue>):<fpage>289</fpage>&#8211;<lpage>304</lpage>.<pub-id pub-id-type="pmid">21750453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318211c83c</pub-id><pub-id pub-id-type="pmcid">PMC3193875</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer&#8217;s disease-related regions</article-title>. <source>Biol Psychiatry</source>. <year>2012</year>;<volume>71</volume>(<issue>9</issue>):<fpage>814</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">22322105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2011.12.024</pub-id><pub-id pub-id-type="pmcid">PMC3322258</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dafsari</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Jessen</surname><given-names>F</given-names></string-name></person-group>. <article-title>Depression: an underrecognized target for prevention of dementia in Alzheimer&#8217;s disease</article-title>. <source>Transl Psychiatry</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>160</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">32433512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-020-0839-1</pub-id><pub-id pub-id-type="pmcid">PMC7239844</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beaulieu-Bonneau</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hudon</surname><given-names>C</given-names></string-name></person-group>. <article-title>Sleep disturbances in older adults with mild cognitive impairment</article-title>. <source>Int Psychogeriatr</source>. <year>2009</year>;<volume>21</volume>(<issue>4</issue>):<fpage>654</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">19426575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610209009120</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mendlewicz</surname><given-names>J</given-names></string-name></person-group>. <article-title>Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders</article-title>. <source>World J Biol Psychiatry</source>. <year>2009</year>;<volume>10</volume>(<issue>4</issue>):<fpage>269</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">19921968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/15622970802503086</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naismith</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>SJG</given-names></string-name>, <string-name name-style="western"><surname>Diamond</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Terpening</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Norrie</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Sleep disturbance in mild cognitive impairment: differential effects of current and remitted depression</article-title>. <source>Acta Neuropsychiatr</source>. <year>2011</year>;<volume>23</volume>(<issue>4</issue>):<fpage>167</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">25379794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1601-5215.2011.00555.x</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name></person-group>. <article-title>Depression, anxiety, and apathy in mild cognitive impairment: current perspectives</article-title>. <source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>:<fpage>9</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32082139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2020.00009</pub-id><pub-id pub-id-type="pmcid">PMC7002324</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruthirakuhan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vieira</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lanct&#244;t</surname><given-names>KL</given-names></string-name></person-group>. <article-title>The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2019</year>;<volume>27</volume>(<issue>8</issue>):<fpage>873</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">30910421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2019.02.003</pub-id><pub-id pub-id-type="pmcid">PMC6646066</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oba</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kanda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ihara</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tanabu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shimoda</surname><given-names>H</given-names></string-name></person-group>. <article-title>How do apathetic and depressive symptoms relate to functional capacity? A cross-sectional survey among community-dwelling middle-aged and older adults in Japan</article-title>. <source>BMC Public Health</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>3171</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">39543583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-024-19091-8</pub-id><pub-id pub-id-type="pmcid">PMC11566820</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aalten</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>De Vugt</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Lousberg</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Korten</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jaspers</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Senden</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2003</year>;<volume>15</volume>(<issue>2</issue>):<fpage>99</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">12566599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000067972</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hatch</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Seitz</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Bruneau</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Ewa</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Goldberg</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>The Canadian coalition for seniors&#8217; mental health Canadian clinical practice guidelines for assessing and managing behavioural and psychological symptoms of dementia (BPSD)</article-title>. <source>Can Geriatr J</source>. <year>2025</year>;<volume>28</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">40051590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5770/cgj.28.820</pub-id><pub-id pub-id-type="pmcid">PMC11882202</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70776" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504058</article-id><article-id pub-id-type="pmcid-ver">PMC12504058.1</article-id><article-id pub-id-type="pmcaid">12504058</article-id><article-id pub-id-type="pmcaiid">12504058</article-id><article-id pub-id-type="doi">10.1002/alz.70776</article-id><article-id pub-id-type="publisher-id">ALZ70776</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against A&#946;40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double&#8208;blind, placebo&#8208;controlled phase 2 study</article-title><alt-title alt-title-type="left-running-head">PASCUAL&#8208;LUCAS <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70776-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Pascual&#8208;Lucas</surname><given-names initials="M">Mar&#237;a</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4638-3153</contrib-id><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>mpascual@araclon.com</email></address></contrib><contrib id="alz70776-cr-0002" contrib-type="author"><name name-style="western"><surname>Lacosta</surname><given-names initials="AM">Ana Mar&#237;a</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0003" contrib-type="author"><name name-style="western"><surname>Monta&#241;&#233;s</surname><given-names initials="M">Mar&#237;a</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0004" contrib-type="author"><name name-style="western"><surname>Canudas</surname><given-names initials="J">Jes&#250;s</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0005" contrib-type="author"><name name-style="western"><surname>Loscos</surname><given-names initials="J">Jorge</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0006" contrib-type="author"><name name-style="western"><surname>Monle&#243;n</surname><given-names initials="I">Inmaculada</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0007" contrib-type="author"><name name-style="western"><surname>Allu&#233;</surname><given-names initials="JA">Jos&#233; Antonio</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0008" contrib-type="author"><name name-style="western"><surname>Sarasa</surname><given-names initials="L">Leticia</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0009" contrib-type="author"><name name-style="western"><surname>Fandos</surname><given-names initials="N">Noelia</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0010" contrib-type="author"><name name-style="western"><surname>Romero</surname><given-names initials="J">Judith</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70776-cr-0011" contrib-type="author"><name name-style="western"><surname>Sarasa</surname><given-names initials="M">Manuel</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70776-note-0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib id="alz70776-cr-0012" contrib-type="author"><name name-style="western"><surname>Torres</surname><given-names initials="M">Mireia</given-names></name><xref rid="alz70776-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70776-cr-0013" contrib-type="author"><name name-style="western"><surname>Whyms</surname><given-names initials="D">Dermot</given-names></name><xref rid="alz70776-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70776-cr-0014" contrib-type="author"><name name-style="western"><surname>Terencio</surname><given-names initials="J">Jose</given-names></name><xref rid="alz70776-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70776-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70776-cr-0015" contrib-type="author"><name name-style="western"><surname>Pi&#241;ol&#8208;Ripoll</surname><given-names initials="G">Gerard</given-names></name><xref rid="alz70776-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70776-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70776-cr-0016" contrib-type="author"><name name-style="western"><surname>Boada</surname><given-names initials="M">Merc&#232;</given-names></name><xref rid="alz70776-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="alz70776-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="alz70776-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">R&amp;D</named-content>
<institution>Araclon Biotech&#8208;Grifols</institution>
<city>Zaragoza</city>
<country country="ES">Spain</country>
</aff><aff id="alz70776-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Scientific Innovation Office</named-content>
<institution>Grifols</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70776-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Biometry</named-content>
<institution>Grifols Worldwide Operations Limited, Clondalkin</institution>
<city>Dublin</city>
<country country="IE">Ireland</country>
</aff><aff id="alz70776-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service</named-content>
<named-content content-type="organisation-division">Fundaci&#243; de Recerca Cl&#237;nic &#8208; Institut d'Investigacions Biom&#232;diques August Pi i Sunyer (IDIBAPS)</named-content>
<institution>Universitat de Barcelona, Hospital Cl&#237;nic de Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70776-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Unitat Trastorns Cognitius, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida</institution>
<city>Lleida</city>
<country country="ES">Spain</country>
</aff><aff id="alz70776-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Ace Alzheimer Center Barcelona &#8211; Universitat Internacional de Catalunya</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70776-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Neurodegenerativas (CIBERNED)</named-content>
<institution>Instituto de Salud Carlos III</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Mar&#237;a Pascual&#8208;Lucas, Araclon Biotech&#8208;Grifols, V&#237;a Hispanidad 21, 50009 Zaragoza, Spain.<break/> Email: <email>mpascual@araclon.com</email><break/></corresp><fn id="alz70776-note-0001" fn-type="equal"><label>&#8224;</label><p>Deceased author</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="360">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70776</elocation-id><history><date date-type="rev-recd"><day>29</day><month>8</month><year>2025</year></date><date date-type="received"><day>04</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 Araclon Biotech and The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70776.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70776.pdf"/><abstract><title>Abstract</title><sec id="alz70776-sec-0010"><title>INTRODUCTION</title><p>ABvac40 is an investigational active immunotherapy (vaccine) targeting A&#946;40. This study assessed the safety and immunogenicity of ABvac40 in patients with amnestic mild cognitive impairment or very mild Alzheimer's disease.</p></sec><sec id="alz70776-sec-0020"><title>METHODS</title><p>AB1601 was a multicenter, randomized, double&#8208;blind, placebo&#8208;controlled phase 2 study. Patients (<italic toggle="yes">n</italic>&#160;=&#160;124) received five monthly injections plus a 10&#8208;month booster of ABvac40 or placebo, with 18&#8211;24 months of follow&#8208;up. Primary endpoints included safety, tolerability, and immunogenicity. Secondary endpoints assessed immune response, neuropsychological changes, and disease biomarkers.</p></sec><sec id="alz70776-sec-0030"><title>RESULTS</title><p>Treatment&#8208;emergent adverse events (TEAEs) and serious TEAEs were comparable between ABvac40 (90.6% and 26.6%) and placebo (93.3% and 26.7%). Amyloid&#8208;related imaging abnormalities&#8208;hemorrhage (ARIA&#8208;H) were similar (12.5% ABvac40; 15.0% placebo), with no ARIA&#8208;edema (ARIA&#8208;E) or meningoencephalomyelitis. ABvac40 induced a specific, sustained immune response in plasma, with detectable antibodies in CSF.</p></sec><sec id="alz70776-sec-0040"><title>DISCUSSION</title><p>These findings support further investigation of ABvac40 as a potential disease&#8208;modifying therapy.</p><p>Clinical Trial Registration Number: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03461276">NCT03461276</ext-link> (ClinicalTrials.gov)</p></sec><sec id="alz70776-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70776-list-0001"><list-item><p>ABvac40 was safe and well&#8208;tolerated in early&#8208;stage Alzheimer's disease patients.</p></list-item><list-item><p>No amyloid&#8208;related imaging abnormalities&#8208;edema (ARIA&#8208;E) or encephalitis observed; ARIA&#8208;hemorrhage (ARIA&#8208;H) rates were similar across groups.</p></list-item><list-item><p>Specific, sustained immune response to ABvac40 in plasma, with cerebrospinal fluid (CSF) antibody penetration.</p></list-item><list-item><p>Cognitive scales and magnetic resonance imaging (MRI) volumetric data favored ABvac40 over placebo.</p></list-item><list-item><p>Results support further development of ABvac40 as a disease&#8208;modifying therapy.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70776-kwd-0001">ABvac40</kwd><kwd id="alz70776-kwd-0002">active immunotherapy</kwd><kwd id="alz70776-kwd-0003">Alzheimer's disease</kwd><kwd id="alz70776-kwd-0004">amyloid&#8208;&#946; 40</kwd><kwd id="alz70776-kwd-0005">A&#946;40</kwd><kwd id="alz70776-kwd-0006">cerebral amyloid angiopathy</kwd><kwd id="alz70776-kwd-0007">clinical trial</kwd><kwd id="alz70776-kwd-0008">disease&#8208;modifying therapy</kwd><kwd id="alz70776-kwd-0009">phase 2</kwd><kwd id="alz70776-kwd-0010">randomized trial</kwd><kwd id="alz70776-kwd-0011">vaccine</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Araclon Biotech&#8208;Grifols</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="2"/><page-count count="16"/><word-count count="8969"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70776-cite-0001"><string-name name-style="western"><surname>Pascual&#8208;Lucas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lacosta</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Monta&#241;&#233;s</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against A&#946;40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double&#8208;blind, placebo&#8208;controlled phase 2 study</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70776</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70776</pub-id><pub-id pub-id-type="pmid">41058018</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70776-sec-0060"><label>1</label><title>INTRODUCTION</title><p>Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving diverse pathological mechanisms, including amyloid&#8208;beta (A&#946;) deposition, phosphorylated tau protein aggregation, neuroinflammation, and synaptic dysfunction. A&#946; has been a primary therapeutic target in recent decades,<xref rid="alz70776-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> with drug development efforts focusing on parenchymal aggregates of A&#946;42. Recently, two anti&#8208;A&#946; monoclonal antibodies&#8212;lecanemab and donanemab&#8212;have been approved in several countries. Lecanemab targets large soluble A&#946; protofibrils, whereas donanemab specifically binds to insoluble, N&#8208;terminal truncated forms of A&#946; found exclusively in brain amyloid plaques. These therapies have demonstrated significant efficacy in clearing amyloid plaques and a reduction in disease progression by approximately 25%&#8211;35% in early&#8208;stage AD patients.<xref rid="alz70776-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70776-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70776-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> However, these treatments have substantial limitations, including a risk of serious adverse events such as amyloid&#8208;related imaging abnormalities (ARIA) and limited clinical efficacy. Therefore, there is an urgent need for novel and safe therapies targeting alternative pathways involved in AD pathogenesis.</p><p>Compelling evidence suggests that A&#946;40 also plays a critical role in AD pathogenesis.<xref rid="alz70776-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70776-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70776-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70776-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Unlike A&#946;42, which primarily aggregates in brain parenchyma, A&#946;40 is predominantly associated with cerebral amyloid angiopathy (CAA), an age&#8208;related small vessel disease characterized by progressive accumulation of A&#946;40 in the walls of cortical and leptomeningeal blood vessels.<xref rid="alz70776-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> This vascular deposition damages the vessel wall, leading to blood&#8211;brain barrier disruption, vessel occlusion or rupture, and hemorrhages, ultimately reducing cerebral blood flow and impairing cognitive function. Approximately 80% of AD patients exhibit mild to severe forms of CAA.<xref rid="alz70776-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Moreover, the severity of CAA is strongly associated with AD pathology,<xref rid="alz70776-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and its presence correlates with earlier dementia onset<xref rid="alz70776-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and faster cognitive decline in AD patients.<xref rid="alz70776-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70776-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70776-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Importantly, CAA contributes to AD dementia independent of senile plaques and neurofibrillary tangles,<xref rid="alz70776-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70776-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> highlighting its distinct role in disease progression. Furthermore, recent evidence also indicates that underlying CAA is closely linked to the occurrence of ARIA<xref rid="alz70776-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70776-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> which has been associated with passive anti&#8208;amyloid therapies. A&#946;40&#8208;targeted therapies, which have shown efficacy in reducing A&#946;40 deposition in cerebral vessels and restoring vascular reactivity in animal models of CAA,<xref rid="alz70776-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> could offer a promising approach for addressing CAA&#8208;related cognitive impairment in the early stages of AD.</p><p>ABvac40 is a peptide&#8208;based active immunotherapy (vaccine) targeting A&#946;40. It is composed of multiple copies of a short fragment of A&#946;40 (A&#946;33&#8208;40 peptide, B&#8208;cell epitope) conjugated to a helper T&#8208;cell carrier protein (keyhole limpet hemocyanin [KLH]), and formulated in a Th2&#8208;biased adjuvant designed to minimize T&#8208;cell&#8211;mediated inflammatory responses. By incorporating the C&#8208;terminus of the A&#946;40 peptide, ABvac40 was designed to elicit a robust B&#8208;cell response while avoiding the activation of A&#946;&#8208;specific T&#8208;cells, which has previously been associated with severe adverse events such as meningoencephalitis.<xref rid="alz70776-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>ABvac40 represents a novel approach with a different mechanism of action. In contrast to therapies targeting A&#946;42 aggregated in the brain parenchyma, ABvac40 specifically targets A&#946;40, focusing on A&#946; deposited in the walls of cerebral blood vessels. In vitro studies have demonstrated that ABvac40&#8208;elicited antibodies are highly specific for A&#946;40 peptides, recognizing different aggregation states.<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In addition, ABvac40 overcomes several limitations of passive immunotherapies, such as the need for frequent infusions, regular magnetic resonance imaging (MRI) monitoring, and the high cost of administration.</p><p>A randomized, double&#8208;blind, placebo&#8208;controlled, phase 1 study (ClinicalTrials.gov <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03113812">NCT03113812</ext-link>)<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> conducted in patients with mild&#8208;to&#8208;moderate AD, showed that ABvac40 exhibited a favorable safety and tolerability profile, with no cases of meningoencephalitis or ARIA. Furthermore, the study demonstrated a sustained and specific antibody response to A&#946;40.</p><p>The present phase 2 clinical trial was designed as a confirmatory study to assess the safety, tolerability, and immunogenicity of ABvac40 in patients with amnestic mild cognitive impairment (a&#8208;MCI) and very mild AD (vm&#8208;AD). Additionally, the trial aimed to provide a deeper characterization of the immune response induced by ABvac40, including the exploration of its effects on clinical outcomes and disease biomarkers.</p></sec><sec id="alz70776-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70776-sec-0080"><label>2.1</label><title>Overview</title><p>This study (AB1601: EudraCT#: 2016&#8208;004352&#8208;30; ClinicalTrials.gov <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03461276">NCT03461276</ext-link>) was a multicenter, randomized, double&#8208;blind, placebo&#8208;controlled phase 2 clinical trial that enrolled patients with a&#8208;MCI or vm&#8208;AD, at 23 sites in four European countries (France, Italy, Spain, and Sweden).</p><p>The study was conducted in full conformance with standards for Good Clinical Practices and the Declaration of Helsinki. The protocol was prepared in accordance with the International Council for Harmonization (ICH) guidelines, and was approved by Institutional Review Boards/Ethics Committees (IRBs/ECs) from the sites and the health authorities from all countries. All enrolled participants and their caregivers provided written informed consent.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70776-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70776-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors conducted a literature search using PubMed and clinicaltrials.gov for clinical studies on active immunotherapies targeting amyloid&#8208;&#946; (A&#946;) for Alzheimer's disease (AD). To our knowledge, ABvac40 is the first active immunotherapy specifically targeting A&#946;40, the main component of vascular deposits in cerebral amyloid angiopathy (CAA), a common neuropathological hallmark in AD that contributes to disease progression.</p></list-item><list-item><p>
<bold>Interpretation</bold>: This phase 2 trial confirmed the safety and tolerability of ABvac40 in patients with amnestic mild cognitive impairment or very mild AD. The vaccine elicited a sustained and specific antibody response in plasma, with detectable antibodies in cerebrospinal fluid. Cognitive assessments and volumetric measures of brain atrophy indicated favorable trends in the ABvac40&#8208;treated group.</p></list-item><list-item><p>
<bold>Future directions</bold>: These findings support further development of ABvac40 as a potential long&#8208;term disease&#8208;modifying therapy for early AD. Further studies are warranted to investigate the underlying relationship to CAA.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70776-sec-0100"><label>2.2</label><title>Study design</title><p>The study consisted of two parts: a confirmatory phase 2 clinical trial with two parallel treatment groups (ABvac40 and placebo, 1:1, see supplementary methods in <xref rid="alz70776-supinfo-0001" ref-type="">supporting Information</xref> for further details on randomization), which lasted up to 24 months (Part A), followed by an 18&#8208;month extension with cross&#8208;over treatment (Part B). Here, only the results of Part A are reported.</p><p>In Part A, participants in the ABvac40 group received six subcutaneous administrations of ABvac40 vaccine (1&#160;mL, corresponding to 0.2&#160;mg of immunogenic peptide). The first five doses were administered monthly, and the sixth dose, a delayed booster dose, was given at month 10, 6 months after the fifth dose. The placebo group followed the same administration schedule but received 1&#160;mL of the ABvac40 vehicle. Rationale for ABvac40 dose selection is described in supplementary methods (<xref rid="alz70776-supinfo-0001" ref-type="">Supporting Information</xref>).</p></sec><sec id="alz70776-sec-0110"><label>2.3</label><title>Participants</title><p>The study population consisted of a representative group of male and female patients aged 55 to 80 years with a&#8208;MCI, as defined by the National Institute on Aging and Alzheimer's Association (NIA&#8208;AA);<xref rid="alz70776-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> or vm&#8208;AD, as defined by the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS&#8208;ADRDA). Patients were enrolled regardless of amyloid positron emission tomography (PET) status, which was not used as an inclusion criterion. Patients had a Mini&#8208;Mental State Examination (MMSE) score between 24 and 30 points, a Clinical Dementia Rating Scale (CDR) global score of 0.5, and a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score of 85 or lower. Key exclusion criteria included: presence or history of immunodeficiency, significant kidney and/or liver disease, a major uncontrolled systemic condition, history or signs of cerebrovascular disease (including vascular dementia), presence on MRI of a relevant pattern of microvascular disease or&#160;&gt;&#160;1 lacunar or territorial infarcts (presence of up to 3 microhemorrhages was acceptable), treatment with anticoagulants or antiaggregant therapy, or suicidal behavior or ideation. Additional inclusion and exclusion criteria are listed in <xref rid="alz70776-supinfo-0001" ref-type="">the Supporting Information</xref>.</p></sec><sec id="alz70776-sec-0120"><label>2.4</label><title>Objectives</title><p>The primary safety objective was to evaluate the safety and tolerability of multiple doses of ABvac40 in individuals with a&#8208;MCI or vm&#8208;AD. The primary efficacy objective was to assess the immune response elicited by ABvac40 in the study population. Secondary (exploratory) efficacy objectives included characterizing the immune response triggered by ABvac40, evaluating changes in cognition and function, and assessing changes in disease biomarkers throughout the study.</p></sec><sec id="alz70776-sec-0130"><label>2.5</label><title>Assessments</title><sec id="alz70776-sec-0140"><label>2.5.1</label><title>Safety and tolerability</title><p>Safety and tolerability were assessed at regular intervals by monitoring and recording adverse events, physical and neurological examinations, laboratory assessments (hematology, immunology, toxicology, biochemistry, coagulation, serology, and urine test), electrocardiograms (ECG), vital signs (blood pressure, heart rate, respiratory rate, body temperature), and brain MRIs.</p><p>The primary safety endpoint was the rate of adverse events (AEs). AEs were coded using version 20.0 of the Medical Dictionary for Regulatory Activities (MedDRA) and classified as: treatment&#8208;emergent AEs (TEAEs), treatment&#8208;emergent serious AEs (TESAEs), and TESAEs of special interest (TESAESIs). TESAESIs were defined as ARIA, either ARIA&#8208;hemorrhage (ARIA&#8208;H), or ARIA&#8208;vasogenic edema and/or sulcal effusion (ARIA&#8208;E), and aseptic meningoencephalomyelitis.</p><p>Secondary safety variables included: withdrawal criteria, number of patients withdrawn due to AEs, and cause of withdrawal. Additionally, the frequency of clinically significant changes in physical and neurological examinations, laboratory tests, electrocardiograms, vital signs, and brain MRI was also assessed.</p></sec><sec id="alz70776-sec-0150"><label>2.5.2</label><title>Immune response</title><p>Immune response to ABvac40 was evaluated in blood samples collected at baseline and at 0.5, 1.5, 2.5, 3.5, 4.5, 6, 9.5, 10.5, 12, 18, and 24 months. Anti&#8208;A&#946;40 antibodies in plasma were assessed by enzyme&#8208;linked immunosorbent assays (ELISAs). 96&#8208;well plates coated with the A&#946;1&#8211;40 peptide were incubated with plasma samples diluted 1:10, and bound antibodies were detected using horseradish peroxidase&#8208;conjugated anti&#8208;human immunoglobulin G (IgG) secondary antibodies. Further details have been published elsewhere.<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>The primary efficacy endpoint was the maximal increment (M&#916;) in anti&#8208;A&#946;40 antibody signal (optical density, [OD]) from baseline. M&#916; for each participant was defined as the maximum change from baseline in anti&#8208;A&#946;40 antibody signal across all post&#8208;baseline visits. Antibody specificity was confirmed by pre&#8208;adsorbing plasma samples with A&#946;33&#8208;40 peptide before ELISA analysis. Participants in the ABvac40 group were classified as positive responders according to predefined criteria.<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> To further assess ABvac40 biological activity, antibody levels were quantified throughout the study in both plasma and CSF using ELISA, with plasma samples diluted 1:810 and CSF samples diluted 1:3. Quantification was performed with a monoclonal chimeric mouse (antigen&#8208;binding domains)/human (constant domains) antibody specific to A&#946;40 (Araclon Biotech, Zaragoza, Spain) as an internal standard.</p><p>The frequency of B&#8208;lymphocytes secreting anti&#8208;A&#946;40 antibodies was determined using an in&#8208;house Fluorescent Enzyme&#8208;Linked ImmunoSpot (FluoroSpot) assay (see further details in supplementary methods in <xref rid="alz70776-supinfo-0001" ref-type="">supporting Information</xref>).</p><p>T&#8208;cell responses to ABvac40 drug substance (A&#946;33&#8208;40 conjugated to KLH) were evaluated by measuring the frequency of IFN&#8208;&#947; and IL&#8208;4&#8208;secreting T cells, representing Th1 and Th2 cytokines, respectively, at baseline and after five immunizations using a dual IFN&#8208;&#947;/IL&#8208;4 FluoroSpot kit (Mabtech, Nacka, Sweden).</p></sec><sec id="alz70776-sec-0160"><label>2.5.3</label><title>Clinical assessments</title><p>Neuropsychological assessments were conducted at baseline and at 6, 12, 18, and 24 months. These included the MMSE and RBANS as cognitive scales; the Trail Making Test Part A (TMT&#8208;A) as an executive function scale; the Alzheimer's Disease Cooperative Study&#8211;Activities of Daily Living for use in MCI (ADCS&#8208;ADL MCI) as a functional scale; and the CDR Sum of Boxes (CDR&#8208;SB) as a global scale. Details of the neuropsychological tests are provided in the supplementary methods in the <xref rid="alz70776-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="alz70776-sec-0170"><label>2.5.4</label><title>Imaging</title><p>MRI scans were performed to assess safety and efficacy throughout the study. For safety evaluation, scans were acquired at baseline and at 2.5, 6, 9, 12, and 24 months, with the exception of French sites, where scans were taken at baseline and at 1.5, 3, 6, 9, 12, and 24 months. Volumetric MRI was performed at baseline and at 6, 12, and 24 months. Whole brain and hippocampal volumes were analyzed to assess longitudinal brain atrophy changes. All MRI scans were reviewed through a centralized radiology assessment. MRI scans were acquired using scanners with a magnetic field strength of 1.5T or 3.0T. Further details, including MRI sequences, are provided in the supplementary methods in the <xref rid="alz70776-supinfo-0001" ref-type="">Supporting Information</xref>.</p><p>Cortical fibrillary amyloid deposition was assessed at baseline and at 12 and 24 months by <sup>18</sup>F&#8208;Flutemetamol PET scans. Details on amyloid&#8208;PET acquisition are described in the supplementary methods in the <xref rid="alz70776-supinfo-0001" ref-type="">Supporting Information</xref>. At baseline, patients were stratified as amyloid&#8208;positive or &#8208;negative based on a visual read by a central reader. To monitor changes throughout the study, the standardized uptake value ratio (SUVR) was calculated for each timepoint on a global cortical region, using the pons as the reference region. SUVR values were then converted to the centiloid scale.<xref rid="alz70776-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p></sec><sec id="alz70776-sec-0180"><label>2.5.5</label><title>Plasma and CSF biomarkers</title><p>Levels of A&#946; peptides in plasma were measured at baseline and at 0.5, 1.5, 2.5, 3.5, 4.5, 6, 9.5, 10.5, 12, 18, and 24 months, using an A&#946; ELISA kit (ABtest&#8208;IA, Araclon Biotech, Zaragoza, Spain) and a mass spectrometry&#8208;based method (ABtest&#8208;MS, Araclon Biotech, Zaragoza, Spain).</p><p>CSF samples were collected via lumbar puncture at baseline and at 12 and 24 months. CSF levels of A&#946;40 and A&#946;42 peptides, neurofilament light chain (NfL), and neurogranin were measured by ELISA (ABtest&#8208;IA, Araclon Biotech, Zaragoza, Spain; UmanDiagnostics, Ume&#229;, Sweden; Euroimmun, L&#252;beck, Germany, respectively). Phospho&#8208;tau181 (p&#8208;tau181) and total tau (t&#8208;tau) were quantified by chemiluminescence enzyme immunoassay on the Lumipulse platform (Fujirebio Europe, Ghent, Belgium).</p></sec></sec><sec id="alz70776-sec-0190"><label>2.6</label><title>Additional mechanistic studies: Immunohistochemical analyses</title><p>To further investigate the mechanism of action of ABvac40, immunohistochemical (IHC) analyses were performed. Paraffin&#8208;embedded occipital lobe brain sections from individuals diagnosed with AD and concomitant CAA, as well as from healthy controls, were obtained from the Biobank Banco de Tejidos CIEN (Madrid, Spain) and processed following standard operating procedures, with the appropriate approval of the Ethics and Scientific Committees. Briefly, after dewaxing and rehydration, sections underwent formic acid antigen retrieval and endogenous peroxidase inhibition. Slides were then incubated with post&#8208;immune plasma (diluted 1:50) or CSF (undiluted) samples, obtained after six ABvac40 doses. Next, sections were treated with a biotin&#8208;conjugated goat anti&#8208;human Fc&#947;&#8208;specific antibody, followed by the avidin&#8208;biotin complex. Finally, immunoreactivity was visualized using 3,3&#8242;&#8208;diaminobenzidine as the chromogen. Pre&#8208;immune CSF samples from the same individuals were used as negative controls, and post&#8208;immune CSF pre&#8208;adsorbed with A&#946;33&#8208;40 peptide served as a specificity control.</p></sec><sec id="alz70776-sec-0200"><label>2.7</label><title>Statistical analysis</title><p>The sample size was calculated for the primary safety endpoint to ensure&#160;&gt;&#160;95% probability of detecting an AE occurring at a rate of at least 5% in the ABvac40&#8208;treated group. Using Hanley's simple approximation,<xref rid="alz70776-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> a minimum of 60 patients per group was required, that is, a total study sample size of 120 subjects. For the primary efficacy endpoint, assessing no difference in the mean maximum change from baseline in anti&#8208;A&#946;40 antibody signal, a one&#8208;sided <italic toggle="yes">t</italic>&#8208;test (<italic toggle="yes">&#945;</italic>&#160;=&#160;0.025) was used. Assuming a 40% dropout rate and a final sample of 70 patients, the study was powered at&#160;&gt;&#160;85% to detect a difference of 1.778 OD between the active and placebo groups, with standard deviations (SDs) of 2.0 and 1.0, respectively.<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>All statistical analyses and tabulations were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA). Five analysis sets were used for analysis: (1) Safety population, which comprised all randomized patients who received any study treatment, analyzed according to the treatment received, regardless of the treatment assigned; (2) intent&#8208;to&#8208;treat (ITT) population, which comprised all randomized patients who received any study treatment, analyzed according to the treatment assigned, regardless of the treatment received; (3) modified intent&#8208;to&#8208;treat (mITT) population, which comprised all ITT patients who had a baseline and at least one post&#8208;baseline anti&#8208;A&#946;40 antibody assessment; (4) per&#8208;protocol (PP) population, which comprised all ITT patients who received all doses of study medication, attended the safety visit after the sixth&#8208;dose booster and had no major protocol deviations that could affect the efficacy analyses; and (5) per&#8208;protocol cognition (PPc) population, which comprised all PP patients who had no major protocol deviations classified as &#8220;use of disallowed concomitant medication&#8221; relating to use of AD medication.</p><p>Safety endpoints were analyzed descriptively in the safety population, and results were presented as counts and percentages of patients with at least one AE within each system organ class and preferred term, as applicable.</p><p>The primary efficacy endpoint, defined as the M&#916; in anti&#8208;A&#946;40 antibody signal, was analyzed in the mITT population. As the assumption of normality of the distribution of M&#916; in anti&#8208;A&#946;40 antibody signal appeared to be violated, a Mann&#8211;Whitney <italic toggle="yes">U</italic> test was used to compare the treatment groups. The trial was considered confirmatory for efficacy if the average M&#916; in the ABvac40 group was significantly greater than in the placebo group. Sensitivity analyses of the primary outcome are described in supplementary methods in the <xref rid="alz70776-supinfo-0001" ref-type="">Supporting Information</xref>.</p><p>Secondary (exploratory) efficacy endpoints related to the characterization of the immune response were summarized by treatment and visit in the ITT population. Other secondary (exploratory) endpoints, including neuropsychological tests and biomarkers, were analyzed using Mixed&#8208;Model Repeated Measures (MMRM) in the PPc and PP population, respectively, to assess the potential efficacy of ABvac40 under optimal adherence conditions and to explore hypotheses that may inform future research. MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol&#8208;specified visits, treatment&#8208;by&#8208;visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within&#8208;patient at each visit as a repeated measure. The following factors were also included in the model: apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 carrier status, baseline use of AD symptomatic medication, and clinical subgroup, if found to be significantly associated with the response measure (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.15). No imputation of missing data was performed. The MMRM approach implicitly handles missing data via the model, and data are assumed missing at random. No adjustments were made for multiple testing of study parameters (interpretation of the secondary analyses results should be considered descriptive in nature).</p></sec></sec><sec id="alz70776-sec-0210"><label>3</label><title>RESULTS</title><sec id="alz70776-sec-0220"><label>3.1</label><title>Treatment disposition and participant characteristics</title><p>A total of 238 patients were screened, of whom 134 were randomized to ABvac40 (<italic toggle="yes">N</italic>&#160;=&#160;66) or placebo (<italic toggle="yes">N</italic>&#160;=&#160;68) (Figure&#160;<xref rid="alz70776-fig-0001" ref-type="fig">1</xref>). Of these, 62 patients in each group received at least one dose of study treatment. The percentage of patients who completed Part A of the study was 89% in the ABvac40 arm (55 out of 62) and 85% in the placebo arm (53 out of 62). Reasons for discontinuation were similar in both arms and were mostly due to AEs and patient/caregiver decisions. Details are shown in Figure&#160;<xref rid="alz70776-fig-0001" ref-type="fig">1</xref>. Part A of the AB1601 study was conducted between December 1, 2017, and July 1, 2021. It is important to note that the introduction of the crossover extension (Part B) shortened Part A from 24 to 18 months, leading some patients to transition directly to the crossover phase upon completing 18 months of follow&#8208;up in Part A. This modification led to a lower number of patients remaining in Part A at the 24&#8208;month time point.</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Patient disposition. <sup>a</sup>Two patients were randomized to placebo but inadvertently received one dose of ABvac40; therefore, these two patients were summarized for the safety population in the ABvac40 arm. ITT, intent&#8208;to&#8208;treat; mITT, modified intent&#8208;to&#8208;treat; PP, per&#8208;protocol; PPc, per&#8208;protocol cognition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70776-g004.jpg"/></fig><p>Baseline demographic characteristics are summarized in Table&#160;<xref rid="alz70776-tbl-0001" ref-type="table">1</xref>. The mean (SD) age of all participants was 70.4 (5.7) years, 59.7% were female, and 95.2% were Caucasian. Baseline disease characteristics were comparable between the placebo and active treatment arms. The overall mean (SD) MMSE score at baseline was 25.8 (1.8). Additionally, 61.3% of patients were <italic toggle="yes">APOE</italic> &#949;4 carriers, and 64.5% were diagnosed with a&#8208;MCI. Amyloid&#8208;PET positivity, assessed by visual read, was observed in 74.2% of participants.</p><table-wrap position="float" id="alz70776-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline demographic and clinical characteristics of participants: ITT population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">ABvac40 (<italic toggle="yes">N</italic>&#160;=&#160;62)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">N</italic>&#160;=&#160;62)</th><th align="left" rowspan="1" colspan="1">Overall (<italic toggle="yes">N</italic>&#160;=&#160;124)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" rowspan="1" colspan="1">70.6 (6.0)</td><td align="char" rowspan="1" colspan="1">70.1 (5.5)</td><td align="char" rowspan="1" colspan="1">70.4 (5.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">38 (61.3)</td><td align="char" rowspan="1" colspan="1">36 (58.1)</td><td align="char" rowspan="1" colspan="1">74 (59.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Race/ethnicity, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Caucasian</td><td align="char" rowspan="1" colspan="1">58 (93.5)</td><td align="char" rowspan="1" colspan="1">60 (96.8)</td><td align="char" rowspan="1" colspan="1">118 (95.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">1 (1.6)</td><td align="char" rowspan="1" colspan="1">1 (1.6)</td><td align="char" rowspan="1" colspan="1">2 (1.6)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Missing</td><td align="char" rowspan="1" colspan="1">3 (4.8)</td><td align="char" rowspan="1" colspan="1">1 (1.6)</td><td align="char" rowspan="1" colspan="1">4 (3.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Highest level of education, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">University degree</td><td align="char" rowspan="1" colspan="1">18 (29.0)</td><td align="char" rowspan="1" colspan="1">17 (27.4)</td><td align="char" rowspan="1" colspan="1">35 (28.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">College graduate</td><td align="char" rowspan="1" colspan="1">4 (6.5)</td><td align="char" rowspan="1" colspan="1">7 (11.3)</td><td align="char" rowspan="1" colspan="1">11 (8.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">High school graduate</td><td align="char" rowspan="1" colspan="1">15 (24.2)</td><td align="char" rowspan="1" colspan="1">22 (35.5)</td><td align="char" rowspan="1" colspan="1">37 (29.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Some school</td><td align="char" rowspan="1" colspan="1">25 (40.3)</td><td align="char" rowspan="1" colspan="1">16 (25.8)</td><td align="char" rowspan="1" colspan="1">41 (33.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" rowspan="1" colspan="1">25.8 (4.3)</td><td align="char" rowspan="1" colspan="1">25.8 (4.5)</td><td align="char" rowspan="1" colspan="1">25.8 (4.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE score</td><td align="char" rowspan="1" colspan="1">25.7 (1.6)</td><td align="char" rowspan="1" colspan="1">25.9 (2.0)</td><td align="char" rowspan="1" colspan="1">25.8 (1.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Time from diagnosis (months)</td><td align="char" rowspan="1" colspan="1">14.7 (13.7)</td><td align="char" rowspan="1" colspan="1">14.5 (15.8)</td><td align="char" rowspan="1" colspan="1">14.6 (14.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Study disease, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">a&#8208;MCI</td><td align="char" rowspan="1" colspan="1">38 (61.3)</td><td align="char" rowspan="1" colspan="1">42 (67.7)</td><td align="char" rowspan="1" colspan="1">80 (64.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">vm&#8208;AD</td><td align="char" rowspan="1" colspan="1">24 (38.7)</td><td align="char" rowspan="1" colspan="1">20 (32.3)</td><td align="char" rowspan="1" colspan="1">44 (33.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 status, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Non&#8208;carriers</td><td align="char" rowspan="1" colspan="1">24 (38.7)</td><td align="char" rowspan="1" colspan="1">24 (38.7)</td><td align="char" rowspan="1" colspan="1">48 (38.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Carriers: Heterozygous</td><td align="char" rowspan="1" colspan="1">29 (46.8)</td><td align="char" rowspan="1" colspan="1">33 (53.2)</td><td align="char" rowspan="1" colspan="1">62 (50.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Carriers: Homozygous</td><td align="char" rowspan="1" colspan="1">9 (14.5)</td><td align="char" rowspan="1" colspan="1">5 (8.1)</td><td align="char" rowspan="1" colspan="1">14 (11.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Amyloid&#8208;PET status<xref rid="alz70776-tbl1-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">47 (75.8)</td><td align="char" rowspan="1" colspan="1">45 (72.6)</td><td align="char" rowspan="1" colspan="1">92 (74.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">15 (24.2)</td><td align="char" rowspan="1" colspan="1">17 (27.4)</td><td align="char" rowspan="1" colspan="1">32 (25.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients on anti&#8208;dementia drugs, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">35 (56.5)</td><td align="char" rowspan="1" colspan="1">36 (58.1)</td><td align="char" rowspan="1" colspan="1">71 (57.3)</td></tr></tbody></table><table-wrap-foot><fn id="alz70776-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Data are expressed as mean (standard deviation), except for categorical variables, which are presented as counts (%).</p></fn><fn id="alz70776-tbl1-note-0002"><p>Abbreviations: a&#8208;MCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; BMI, body mass index; ITT, intent&#8208;to&#8208;treat; MMSE, Mini&#8208;Mental State Examination; <italic toggle="yes">N/n</italic>, number of participants; PET, positron emission tomography; vm&#8208;AD, very mild Alzheimer's disease.</p></fn><fn id="alz70776-tbl1-note-0003"><label>
<sup>a</sup>
</label><p>Amyloid&#8208;PET status was assessed by visual read.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70776-sec-0230"><label>3.2</label><title>Safety</title><p>Table&#160;<xref rid="alz70776-tbl-0002" ref-type="table">2</xref> summarizes the incidence of TEAEs. Two patients were randomized to a placebo but inadvertently received one dose of ABvac40; therefore, these two patients were summarized for the Safety population in the ABvac40 arm. Most patients in the ABvac40 (90.6%) and placebo (93.3%) groups presented at least one TEAE, but only about half of them had treatment&#8208;related TEAEs (45.3% in the ABvac40 group and 43.3% in the placebo group). Common TEAEs in both groups were urinary tract infections, administration site and skin reactions, fall, and headache (Table <xref rid="alz70776-supinfo-0001" ref-type="">S1</xref> in Supporting Information). Treatment discontinuation due to TEAEs occurred in 6.3% of ABvac40 patients and 11.7% of placebo patients.</p><table-wrap position="float" id="alz70776-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of TEAEs: Safety population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">TEAEs, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">ABvac40 (<italic toggle="yes">N</italic>&#160;=&#160;64)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">N</italic>&#160;=&#160;60)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any TEAE</td><td align="char" rowspan="1" colspan="1">58 (90.6)</td><td align="char" rowspan="1" colspan="1">56 (93.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any treatment&#8208;related TEAE</td><td align="char" rowspan="1" colspan="1">29 (45.3)</td><td align="char" rowspan="1" colspan="1">26 (43.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any TEAEs leading to treatment discontinuation</td><td align="char" rowspan="1" colspan="1">4 (6.3)</td><td align="char" rowspan="1" colspan="1">7 (11.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any TEAE leading to death<xref rid="alz70776-tbl2-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">1 (1.6)</td><td align="char" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Any TESAE</td><td align="char" rowspan="1" colspan="1">17 (26.6)</td><td align="char" rowspan="1" colspan="1">16 (26.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any treatment&#8208;related TESAE</td><td align="char" rowspan="1" colspan="1">3 (4.7)</td><td align="char" rowspan="1" colspan="1">8 (13.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any TESAE leading to treatment discontinuation</td><td align="char" rowspan="1" colspan="1">2 (3.1)</td><td align="char" rowspan="1" colspan="1">4 (6.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Any TESAE leading to death<xref rid="alz70776-tbl2-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">1 (1.6)</td><td align="char" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Any TESAESI</td><td align="char" rowspan="1" colspan="1">8 (12.5)</td><td align="char" rowspan="1" colspan="1">9 (15.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Aseptic meningoencephalomyelitis</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">ARIA&#8208;E</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">ARIA&#8208;H</td><td align="char" rowspan="1" colspan="1">8 (12.5)</td><td align="char" rowspan="1" colspan="1">9 (15.0)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">ARIA&#8208;H leading to treatment discontinuation</td><td align="char" rowspan="1" colspan="1">0 (0.0)</td><td align="char" rowspan="1" colspan="1">2 (3.3)</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">ARIA&#8208;H by <italic toggle="yes">APOE</italic> &#949;4 carrier status</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:20%" align="left" rowspan="1" colspan="1">Non&#8208;carrier</td><td align="char" rowspan="1" colspan="1">4/25 (16.0)</td><td align="char" rowspan="1" colspan="1">4/23 (17.4)</td></tr><tr><td style="padding-left:20%" align="left" rowspan="1" colspan="1">Heterozygous carrier</td><td align="char" rowspan="1" colspan="1">3/30 (10.0)</td><td align="char" rowspan="1" colspan="1">5/32 (15.6)</td></tr><tr><td style="padding-left:20%" align="left" rowspan="1" colspan="1">Homozygous carrier</td><td align="char" rowspan="1" colspan="1">1/9 (11.1)</td><td align="char" rowspan="1" colspan="1">0/5 (0.0)</td></tr></tbody></table><table-wrap-foot><fn id="alz70776-tbl2-note-0001"><p>
<italic toggle="yes">Note</italic>: Two patients were randomized to placebo but inadvertently received one dose of ABvac40; therefore, these two patients were summarized for the safety population in the ABvac40 arm.</p></fn><fn id="alz70776-tbl2-note-0002"><p>Abbreviations: <italic toggle="yes">APOE</italic>, apolipoprotein E; ARIA, amyloid&#8208;related imaging abnormalities; ARIA&#8208;E, ARIA&#8208;edema; ARIA&#8208;H, ARIA&#8208;hemorrhage; <italic toggle="yes">N/n</italic>, number of participants; TEAE, treatment&#8208;emergent adverse event; TESAE, treatment&#8208;emergent serious adverse event; TESAESI, treatment&#8208;emergent serious adverse event of special interest.</p></fn><fn id="alz70776-tbl2-note-0003"><label>
<sup>a</sup>
</label><p>TEAE/TESAE leading to death: General physical health deterioration (ABvac40), not related to treatment; Pancreatic neoplasm (placebo), not related to treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>TESAEs were observed at similar rates in both arms (26.6% in ABvac40 and 26.7% in placebo), although treatment&#8208;related TESAEs were less frequent in the ABvac40 group (4.7%) compared to the placebo group (13.3%). There were two TESAEs leading to death, one in the ABvac40 group (general physical health deterioration) and one in the placebo group (pancreatic neoplasm), both deemed unrelated to treatment. TESAEs classified by system organ class, MedDRA Version 20.0, are shown in Table <xref rid="alz70776-supinfo-0001" ref-type="">S2</xref> in the Supporting Information. Three cases of pulmonary thromboembolism were reported in the ABvac40 group, all classified under respiratory, thoracic, and mediastinal disorders. All three cases presented with hypertension, and two were associated with low mobility. According to the investigator's assessment, none of the events were considered related to the treatment.</p><p>No events of ARIA&#8208;E and aseptic meningoencephalomyelitis were reported. Thus, ARIA&#8208;H was the only TESAESI reported, with similar incidences in the ABvac40 (12.5%) and placebo (15.0%) arms. The distribution of ARIA&#8208;H by <italic toggle="yes">APOE</italic> genotype showed no association with the &#400;4 allele in either treatment group. Two events led to treatment discontinuation, both in the placebo group.</p><p>The laboratory analyses, vital signs, and physical and neurological examination rarely revealed clinically significant abnormalities across groups (data not shown).</p></sec><sec id="alz70776-sec-0240"><label>3.3</label><title>Immunogenicity</title><p>The median M&#916; of anti&#8208;A&#946;40 antibody signal in the ABvac40 group (3.5390 OD; interquartile range [IQR] 3.2950&#8211;3.6595) was significantly higher than the average M&#916; observed in the placebo group (0.0523 OD; IQR: 0.0128&#8211;0.1525) (primary efficacy endpoint; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001; Figure&#160;<xref rid="alz70776-fig-0002" ref-type="fig">2A</xref>). In addition, all sensitivity analyses yielded confirmatory results, confirming the robustness of the primary efficacy endpoint (Table <xref rid="alz70776-supinfo-0001" ref-type="">S3</xref> in Supporting Information).</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Immunogenicity of ABvac40. (A) Average M&#916; of anti&#8208;A&#946;40 antibody signal in plasma (optical density in ELISA) from baseline (mITT population). M&#916; for each participant was defined as the maximum change from baseline in anti&#8208;A&#946;40 antibody signal across all post&#8208;baseline visits. The line represents the median (horizontal line), and the error bars indicate the IQR. Individual values are also shown. Group differences were assessed using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test. ***<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (B) (C) Anti&#8208;A&#946;40 antibody concentrations in CSF (B) and plasma (C) for ABvac40 and placebo groups (ITT population). Plasma values are presented as mean&#160;&#177;&#160;95% CI, while CSF values are shown as median and IQR. In the CSF graph, two outliers from the ABvac40 group at 12 months (219.28&#160;ng/mL and 119.10&#160;ng/mL) are excluded for visualization but included in median and IQR calculations. (D) Frequency of memory B cells in blood (ITT population). Values are presented as mean&#160;&#177;&#160;95% CI. A&#946;, amyloid&#8208;beta; CI, confidence interval; CSF, cerebrospinal fluid; IQR, interquartile range; ITT, intent&#8208;to&#8208;treat; M&#916;, maximal increment; mITT, modified intent&#8208;to&#8208;treat; <italic toggle="yes">n</italic>, number of participants; PBMC, peripheral blood mononuclear cells; SFU, spot&#8208;forming units. Syringe symbol: time points of product administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70776-g002.jpg"/></fig><p>Increasing concentrations of anti&#8208;A&#946;40 plasma antibodies from baseline (0.00&#160;&#181;g/mL) were observed during the ABvac40 administration schedule, reaching maximum mean values at month 4.5 (66.93&#160;&#181;g/mL; 95% confidence interval [CI] 47.06, 86.81), after the fifth dose. The concentration decreased at month 6 and month 9.5, but following booster administration at month 10, a marked concentration increase was observed (54.99&#160;&#181;g/mL; 95% CI 40.59, 69.38). In the subsequent visits, the concentration steadily decreased, being 4.87&#160;&#181;g/mL (95% CI 1.85, 7.89) at month 24. No increased concentrations were observed in patients receiving placebo. Details are shown in Figure&#160;<xref rid="alz70776-fig-0002" ref-type="fig">2C</xref>. Consistent with these findings, more than 85% of patients in the ABvac40 group were positive responders from month 1.5 to month 12, reaching a positive response rate of over 95% between months 2.5 and 12 (Table <xref rid="alz70776-supinfo-0001" ref-type="">S4</xref> in Supporting Information).</p><p>In CSF, anti&#8208;A&#946;40 antibodies were detected in the ABvac40 group with a CSF&#8208;to&#8208;plasma ratio of 0.1%. The median concentration increased from 0.00&#160;ng/mL at baseline to 21.90&#160;ng/mL (IQR 8.25, 38.68) at month 12, and decreased thereafter to undetectable levels at month 24 (Figure&#160;<xref rid="alz70776-fig-0002" ref-type="fig">2B</xref>). Anti&#8208;A&#946;40 antibody levels significantly correlated between plasma and CSF (Spearman rho: 0.749; <italic toggle="yes">p&#160;</italic>&lt;&#160;0.0001; Figure <xref rid="alz70776-supinfo-0001" ref-type="">S1</xref> in supporting Information).</p><p>The frequency of anti&#8208;A&#946;40&#8208;specific antibody&#8208;secreting memory B cells mirrored the trajectory of anti&#8208;A&#946;40 antibody levels in the ABvac40 arm. Mean levels initially increased from baseline to month 3.5 (8.94 spot forming units [SFU]/0.5&#160;&#215;&#160;10<sup>6</sup> peripheral blood mononuclear cells [PBMCs] [95% CI 5.10, 12.78]), peaked at month 10.5 following ABvac40&#8208;booster administration (12.47 SFU/0.5&#160;&#215;&#160;10<sup>6</sup> PBMCs [95% CI 5.76, 19.18]), and subsequently declined steadily to baseline levels by month 24 (Figure&#160;<xref rid="alz70776-fig-0002" ref-type="fig">2D</xref>).</p><p>ABvac40 drug substance (A&#946;33&#8208;40 conjugated to KLH carrier protein) elicited a predominant Th2 immune response in 86.5% (32/37) of the studied participants, while 8.1% (3/37) did not exhibit a polarized immune response, and 5.4% (2/37) showed a predominant Th1 response. In contrast, no response to ABvac40 drug substance was observed in the placebo group (Figure <xref rid="alz70776-supinfo-0001" ref-type="">S2</xref> in Supporting Information).</p></sec><sec id="alz70776-sec-0250"><label>3.4</label><title>Clinical assessment</title><p>The ABvac40 group demonstrated a maximum reduction in disease progression of 39% relative to placebo, as assessed by MMSE scores. Differences between groups became apparent at month 12 (least squares [LS]&#8208;mean change difference: 1.54 points, 95% CI 0.26, 2.82; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; Figure&#160;<xref rid="alz70776-fig-0003" ref-type="fig">3A</xref>), with numerical improvements observed from month 6 onward. RBANS total scores also favored the ABvac40 group starting at month 12, with the largest difference at month 18 (Figure&#160;<xref rid="alz70776-fig-0003" ref-type="fig">3B</xref>). Performance in the TMT&#8208;A indicated improvements in processing speed and executive function in the ABvac40 group, with the greatest group difference observed at month 24 (LS&#8208;mean change difference: &#8722;12.51&#160;s, 95% CI &#8722;24.72, &#8722;0.30; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; Figure&#160;<xref rid="alz70776-fig-0003" ref-type="fig">3C</xref>). No differences were found between groups in the CDR&#8208;SB or ADCS&#8208;ADL MCI scores throughout the study period (Figures&#160;<xref rid="alz70776-fig-0003" ref-type="fig">3D</xref> and&#160;<xref rid="alz70776-fig-0003" ref-type="fig">3E</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Performance in neuropsychological tests (PPc population). (A) MMSE; (B) RBANS; (C) TMT&#8208;A; (D) CDR&#8208;SB; (E) ADCS&#8208;ADL MCI. Plots show the LS&#8208;mean change from baseline and 95% CI based on an MMRM analysis. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05. ADCS&#8208;ADL MCI, Alzheimer's Disease Cooperative Study&#8211;Activities of Daily Living, Mild Cognitive Impairment; CDR&#8208;SB, Clinical Dementia Rating Sum of Boxes; CI, confidence interval; LS, least squares; MMRM, mixed model for repeated measures; MMSE, Mini&#8208;Mental State Examination; <italic toggle="yes">n</italic>, number of participants; PPc, per&#8208;protocol cognition; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; TMT&#8208;A, Trail Making Test A. Syringe symbol: time points of product administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70776-g003.jpg"/></fig></sec><sec id="alz70776-sec-0260"><label>3.5</label><title>Brain imaging</title><p>Volumetric MRI showed lesser progression in whole brain atrophy at months 12 and 24 in the ABvac40 group versus placebo (LS&#8208;mean change difference at month 24: 1.51%, 95% CI 0.19, 2.82; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; see Figure&#160;<xref rid="alz70776-fig-0004" ref-type="fig">4A</xref>). Hippocampal volumes decreased 6%&#8211;8% at 24 months, without observing differences between treatment arms (Figures&#160;<xref rid="alz70776-fig-0004" ref-type="fig">4B</xref> and&#160;<xref rid="alz70776-fig-0004" ref-type="fig">4C</xref>). Regarding amyloid&#8208;PET, rates of amyloid deposition were minimal and similar between groups, with LS&#8208;mean changes at month 24 of 1.78 centiloids (standard error [SE] 1.58) for ABvac40 and 3.12 Centiloids (SE 1.48) for placebo (Figure&#160;<xref rid="alz70776-fig-0004" ref-type="fig">4D</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Brain imaging assessments (PP population). Volumetric MRI measures of whole brain (A) and hippocampal atrophy (B) (left hippocampus) and (C) (right hippocampus). (D) Rate of amyloid deposition as measured by amyloid&#8208;PET. Plots show the LS&#8208;mean change from baseline and 95% CI based on an MMRM analysis. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05. CI, confidence interval; LS, least squares; MMRM, mixed model for repeated measures; MRI, magnetic resonance imaging; <italic toggle="yes">n</italic>, number of participants; PET, positron emission tomography; PP, per&#8208;protocol. Syringe symbol: time points of product administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70776-g006.jpg"/></fig></sec><sec id="alz70776-sec-0270"><label>3.6</label><title>Biomarkers</title><p>Total plasma levels of A&#946;40 peptide, as quantified by a mass spectrometry&#8208;based assay, paralleled the increase observed in anti&#8208;A&#946;40 antibodies, also observing a marked booster effect at month 10.5 (Figure&#160;<xref rid="alz70776-fig-0005" ref-type="fig">5A</xref>). In contrast, free levels of A&#946;40, as measured by immunoassay, decreased as antibody levels increased (Figure&#160;<xref rid="alz70776-fig-0005" ref-type="fig">5B</xref>). The levels of plasma A&#946;42 remained stable in both arms throughout the study (Figure <xref rid="alz70776-supinfo-0001" ref-type="">S3</xref> in Supporting Information).</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Plasma levels of A&#946;40 peptide measured by (A) mass spectrometry&#8208;based assay (total levels) or (B) immunoassay (free levels) (PP population). Plots shows LS&#8208;mean change from baseline and 95% CI based on a MMRM analysis. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01; ***<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. A&#946;, amyloid&#8208;beta; CI, confidence interval; LS, least squares; MMRM, mixed model for repeated measures; <italic toggle="yes">n</italic>, number of participants; PP, per&#8208;protocol. Syringe symbol: time points of product administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70776-g005.jpg"/></fig><p>In CSF, no differences were observed between ABvac40 and placebo groups for the levels of tested biomarkers (A&#946;40, A&#946;42, A&#946;42/A&#946;40, p&#8208;tau181, t&#8208;tau, NfL, and neurogranin) across the study. Details are shown in Figure <xref rid="alz70776-supinfo-0001" ref-type="">S4</xref> in the Supporting Information.</p></sec><sec id="alz70776-sec-0280"><label>3.7</label><title>Labeling of vascular amyloid by ABvac40&#8208;induced antibodies</title><p>Post&#8208;immune plasma and CSF samples from ABvac40&#8208;treated participants showed strong immunoreactivity against vascular amyloid deposits in brain sections from individuals with AD and concomitant CAA (Figure&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6</xref>). Labeling was primarily observed in leptomeningeal, penetrating, and cortical arteries (Figure&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6A</xref> and&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6D</xref>), as well as arterioles (Figure&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6B</xref> and&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6D</xref>) and capillaries (Figure&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6C</xref> and&#160;<xref rid="alz70776-fig-0006" ref-type="fig">6E</xref>). While occasional A&#946;40&#8208;containing neuritic plaques were detected in the parenchyma, most of the antibody binding was restricted to vascular structures. In contrast, neither pre&#8208;immune samples nor post&#8208;immune samples pre&#8208;adsorbed with A&#946;33&#8208;40 peptide showed any detectable labeling (Figure <xref rid="alz70776-supinfo-0001" ref-type="">S5</xref> in Supporting Information), confirming the specificity of ABvac40&#8208;elicited antibodies for A&#946;40 peptides. Additionally, brain sections from healthy control cases showed no signal (data not shown).</p><fig position="float" fig-type="FIGURE" id="alz70776-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Reactivity of ABvac40&#8208;induced antibodies on paraffin&#8208;embedded occipital brain sections from patients with AD and concomitant CAA. IHC was performed using plasma (A&#8211;C) and CSF (D&#8211;F) samples from ABvac40&#8208;treated patients as primary antibodies. The images show specific labeling of vascular amyloid deposits in the walls of blood vessels throughout the brain, including leptomeningeal and penetrating arteries (A, D), arterioles (some of which also exhibit amyloid aggregates in the surrounding neuropil) (B, E), and capillaries (C, F). AD, Alzheimer's disease; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fluid; IHC, immunohistochemistry.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70776-g001.jpg"/></fig></sec></sec><sec id="alz70776-sec-0290"><label>4</label><title>DISCUSSION</title><p>In this randomized, double&#8208;blind, placebo&#8208;controlled phase 2 clinical trial, ABvac40 active immunotherapy demonstrated a favorable safety and tolerability profile with no unexpected safety concerns. Common TEAEs included urinary tract infections, falls, and headaches, which are typical in this elderly population, as well as administration site and skin reactions, which are commonly reported with vaccines and injectable drugs. SAEs occurred at similar rates in both groups, and those SAEs leading to death were deemed unrelated to the treatment.</p><p>Importantly, no cases of ARIA&#8208;E were reported in either group throughout the study, and the incidence of ARIA&#8208;H was similarly distributed between ABvac40 (12.5%) and placebo (15.0%). This contrasts with the elevated ARIA rates reported in trials of passive immunotherapies for early AD.<xref rid="alz70776-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70776-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70776-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70776-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70776-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The mechanisms underlying ARIA are not fully understood, but evidence suggests that antibody&#8208;mediated breakdown of neuritic plaques mobilizes amyloid from the brain parenchyma to the vasculature, exacerbating pre&#8208;existing CAA, and increasing perivascular inflammation and/or impaired perivascular clearance.<xref rid="alz70776-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70776-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> These changes compromise vascular integrity, causing extravasation and leakage of blood components through damaged vessel walls.<xref rid="alz70776-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70776-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> A key factor that may explain the lower ARIA incidence observed with ABvac40 is its specific targeting of A&#946;40 species, which represents a fundamental difference in mechanism, by focusing on vascular amyloid rather than mobilizing parenchymal amyloid. Additionally, the gradual and sustained polyclonal immune response induced by ABvac40, as opposed to the rapid and high peak seen with intravenous monoclonal antibodies, may also contribute to its safety profile. It is important to note, however, that exclusion of participants with signs of cerebrovascular disease likely reduced CAA burden, a known risk factor for ARIA, potentially influencing this outcome. Nevertheless, other trials with passive immunotherapies using similar exclusion criteria have reported higher ARIA rates,<xref rid="alz70776-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70776-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> suggesting that additional factors may contribute to the safety profile of ABvac40.</p><p>Furthermore, no cases of aseptic meningoencephalomyelitis were observed, possibly due to the absence of A&#946;&#8208;specific T&#8208;cell&#8208;mediated responses. Moreover, a predominant Th2 immune response was detected in PBMCs stimulated in vitro. These findings are consistent with the design of ABvac40, which lacks T&#8208;cell&#8211;activating epitopes and is formulated with a Th2&#8208;biased adjuvant.</p><p>Taken together, these safety findings are consistent with the results from the phase 1 trial<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and support the favorable safety profile of ABvac40.</p><p>A key finding in this study was successful confirmation of the immunogenicity of ABvac40. The primary hypothesis, that ABvac40 would increase the specific anti&#8208;A&#946;40 antibody signal, was met, and all sensitivity analyses also yielded confirmatory results. Compared to the phase 1 study,<xref rid="alz70776-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> the immune response was further enhanced, likely due to the inclusion of five administrations with a booster dose. Notably, phase 1 data have already shown an enhanced response when increasing from two to three doses. Future treatment strategies should further optimize the administration schedule to sustain high antibody levels over time, potentially through periodic booster doses.</p><p>To assess the immune response more precisely, antibody concentrations were quantified using a chimeric anti&#8208;A&#946;40 antibody as an internal standard, rather than serial dilution titers.<xref rid="alz70776-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70776-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70776-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70776-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> This approach provides a more precise and consistent quantification of antibody levels, minimizing variability and enabling direct comparisons across multiple samples and time points, ultimately leading to a more accurate assessment of the immune response. Results confirmed that ABvac40 induced a strong, specific, boostable, and sustained immune response, highlighting its potential as a cost&#8208;effective, long&#8208;term therapeutic strategy for the primary and secondary prevention of AD. Notably, evidence of peripheral target engagement was observed, as indicated by increased total plasma levels of A&#946;40 and decreased levels of free A&#946;40. Anti&#8208;A&#946;40 antibodies were also detected in CSF, with a CSF&#8208;to&#8208;plasma ratio of 0.1%, comparable to other immunotherapies.<xref rid="alz70776-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70776-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70776-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70776-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</p><p>Neuropsychological assessments showed a modest but consistent trend favoring ABvac40 across multiple cognitive outcomes. Specifically, a between&#8208;group difference was observed in MMSE at 12 months. While the relatively steep decline in MMSE scores seen in the placebo group may seem unusual, it can be attributed to both limited sample size and heterogeneity in disease progression.<xref rid="alz70776-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70776-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70776-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Parallel trends observed in RBANS and TMT&#8208;A further support the consistency of cognitive effects across different domains<xref rid="alz70776-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="alz70776-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>. Although no differences were found in CDR&#8208;SB or ADCS&#8208;ADL, these instruments may be less sensitive to subtle cognitive/functional changes over short periods or in very early stages of disease.<xref rid="alz70776-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p><p>Importantly, these clinical findings are in line with imaging data showing slower progression of whole&#8208;brain atrophy in the ABvac40 group. This contrasts with reports from passive immunotherapies targeting aggregated parenchymal amyloid, where accelerated brain volume loss was observed.<xref rid="alz70776-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Although it remains unclear whether this is due to accelerated neuronal damage or pseudo&#8208;atrophy,<xref rid="alz70776-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> such changes are characteristic of immunotherapies that reduce amyloid plaques. However, ABvac40, by targeting vascular amyloid, was associated with a reduction in atrophy progression, suggesting potential neuroprotective effects. Given the exploratory nature of these outcomes and the limited sample size, the results should be interpreted with caution. Nonetheless, the alignment across cognitive and imaging outcomes provides biological plausibility to the modest cognitive findings<xref rid="alz70776-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> and supports the rationale for further investigation in adequately powered trials.</p><p>Consistent with its proposed mechanism of action, ABvac40 treatment did not impact fibrillary cortical amyloid deposition as measured by amyloid&#8208;PET. Current amyloid&#8208;PET radiotracers selectively bind to fibrillary A&#946;, primarily reflecting parenchymal plaques, with minimal contribution from CAA to the amyloid&#8208;PET signal.<xref rid="alz70776-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> However, IHC analyses using plasma and CSF from ABvac40&#8208;treated participants demonstrated strong labeling of vascular amyloid deposits in brain tissue from AD patients with CAA, consistent with the intended mechanism of targeting A&#946;40. While these ex vivo findings provide clear evidence of antibody binding to cerebrovascular amyloid, the absence of validated in vivo biomarkers for CAA in this study prevented direct assessment of ABvac40's impact on vascular amyloid burden.</p><p>No differences were observed in CSF biomarkers between groups. This could be explained by several factors, including a considerable degree of variability in the change from baseline observed among patients, which could reflect differences in disease progression. Additionally, the time points selected for assessment might not have been optimal for detecting meaningful treatment effects, or conventional AD CSF biomarkers may not adequately capture vascular&#8208;related effects of the treatment.</p><p>Limitations of this study include the relatively small sample size, which challenges the reliability of the clinical and biomarker efficacy endpoints. As a result, robust conclusions on efficacy cannot be drawn from these data, and larger clinical trials are needed to confirm these findings in a broader population. However, despite the sample size, the consistency of the results supports the validity of the findings. Additionally, the lack of demographic diversity in the study population, as most participants were Caucasian, may reduce the generalizability of the results to other ethnic groups. Another limitation is the absence of specific CAA&#8208;related outcomes, which might have provided more insights into the vascular mechanism of ABvac40.</p><p>While this study was primarily designed to evaluate safety and immunogenicity, it excluded individuals with clinical or radiological signs of cerebrovascular disease, likely resulting in a cohort with relatively limited CAA pathology. Given the high prevalence of CAA in AD, greater clinical benefits might be expected in broader AD populations. Notably, future trials including AD patients enriched for vascular amyloid pathology could better capture the full therapeutic potential of this approach. This potential is particularly relevant considering the multifactorial nature of AD, where therapies addressing different pathological components may provide complementary benefits. In this context, ABvac40's favorable safety profile, durable immune response, and low treatment burden, position it as a promising candidate not only for early intervention and prevention but also as part of combination strategies.</p><p>To date, a limited number of therapeutic strategies targeting vascular amyloid have been explored. Ponezumab, an anti&#8208;A&#946;40 monoclonal antibody with Fc mutations to reduce immune effector functions, aimed to sequester A&#946;40 in the bloodstream and clear brain deposits via a peripheral sink effect.<xref rid="alz70776-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> However, it was discontinued due to lack of efficacy,<xref rid="alz70776-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="alz70776-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> which may be related to its limited ability to trigger Fc&#8208;mediated responses. In contrast, milvesiran, an RNA interference therapy targeting amyloid precursor protein, is currently in clinical trials for both AD<xref rid="alz70776-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> and CAA,<xref rid="alz70776-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> representing a promising alternative. Despite these efforts, no therapeutic approach has yet proven effective in preventing or reversing vascular amyloid deposition in AD and/or CAA, highlighting the urgent need for novel approaches in this field.</p><p>In conclusion, this phase 2 study met both primary objectives. ABvac40 showed a favorable safety and tolerability profile, with no increase in ARIA&#8208;H, no cases of ARIA&#8208;E, and no signs of inflammatory reactions. ABvac40 induced a robust immune response, supporting its potential as a cost&#8208;effective, long&#8208;term treatment for AD. Although not powered for efficacy analysis, positive findings in cognitive performance and brain atrophy suggest that ABvac40 could offer a potential benefit for AD and/or CAA, being a novel approach that leverages the advantages of active immunotherapy with a differential mechanism of action, primarily targeting vascular amyloid. Further large&#8208;scale studies are needed to confirm these findings and elucidate their underlying biological processes.</p></sec><sec sec-type="COI-statement" id="alz70776-sec-0310"><title>CONFLICT OF INTEREST STATEMENT</title><p>M.P.L., A.M.L., M.M., J.C., J.L., I.M., J.A.A., L.S., N.F., and J.R. are full&#8208;time employees of Araclon Biotech&#8208;Grifols. MS was a full&#8208;time employee of Araclon Biotech&#8211;Grifols, held several patents related to Alzheimer's disease diagnosis and treatment, and was the founder and a shareholder of Araclon Biotech&#8211;Grifols. M.T., D.W., and J.T. are full&#8208;time employees of Grifols. G.P.R. has received consultancy fees, honoraria for lectures, and/or participated in advisory boards from the following companies: Grifols, Araclon Biotech, Lilly, Almirall, Nutricia, Schwabe Pharma, and Esteve. M.B. has received consultancy fees, honoraria for lectures, and/or participated in advisory boards from the following companies: Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Novo Nordisk, Bioiberica, Eisai, Servier, Schwabe Pharma, Nutricia, and Terumo. M.B. has also obtained research funding from Life Molecular Imaging, Bioiberica, Grifols, Araclon Biotech, Lilly, Roche, Janssen, Alzehon, Cortyzime, Novo Nordisk, and Schwabe Pharma. Author disclosures are available in the <xref rid="alz70776-supinfo-0001" ref-type="">supporting Information</xref>.</p></sec><sec id="alz70776-sec-0340"><title>CONSENT STATEMENT</title><p>All participants provided written informed consent prior to any study&#8208;related procedures.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70776-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70776-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70776-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70776-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70776-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70776-sec-0300"><title>ACKNOWLEDGMENTS</title><p>The authors thank Pedro Pesini for his substantial contribution to the conception and design of the study; Elisabet Molina for her dedication in overseeing its conduct; and all the staff at Araclon Biotech who were involved throughout the course of the study. We acknowledge the Publications team at Grifols for their editorial assistance in the preparation of this manuscript. The authors also thank all the participants and their families for their invaluable contribution; the site staff and trial team for their time and commitment to the study; the members of the independent data safety monitoring board; and the cross&#8208;functional trial teams at Grifols for their continued support. We gratefully acknowledge the contribution of the tissue donors and the collaboration of the Biobank Banco de Tejidos CIEN in the immunohistochemistry studies. Finally, we acknowledge the AB1601 study group for their collaboration in the conduct of this trial. The AB1601 study group: Bennys K, CHU de Montpellier&#8212;H&#244;pital Gui de Chauliac, Montpellier, France; Blesa R, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Boada M, Ace Alzheimer Center Barcelona&#8212;Universitat Internacional de Catalunya, Barcelona, Spain; Borjesson&#8208;Hanson A, Karolinska Universitetssjukhuset, Stockholm, Sweden; Delpont B, CHU DijonBourgogne&#8212;H&#244;pital Fran&#231;ois Mitterrand, Dijon, Francia; Fern&#225;ndez M, CAE Oroitu, Getxo, Spain Gabelle A, CHU de Montpellier&#8212;H&#244;pital Gui de Chauliac, Montpellier, France; Galluzi S, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Garc&#237;a&#8208;Ribas G, Hospital Ram&#243;n y Cajal, Madrid, Spain; Go&#241;i M, Hospital Universitario de Burgos, Burgos, Spain; Grau O, Barcelona Beta Brain Research Center, Barcelona, Spain; Iglesias F, Hospital Universitario de Burgos, Burgos, Spain; Lle&#243; A, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; L&#243;pez de Munain A, Hospital Universitario Donostia, San Sebasti&#225;n, Spain; L&#243;pez&#8208;Lozano JJ, Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain; Marzo ME, Hospital San Pedro, Logro&#241;o, Spain; Matias&#8208;Guiu J, Hospital Cl&#237;nico San Carlos, Madrid, Spain; Mohr S, CHU Dijon Bourgogne &#8208; H&#244;pital Fran&#231;ois Mitterrand, Dijon, Francia; Monge A, Hospital General Universitario de Alicante, Alicante, Spain; Moreno T, Hospital Cl&#237;nico San Carlos, Madrid, Spain; Ousset JP, Centre de Recherche Clinique du G&#233;rontop&#244;le, Toulouse, France; Palasi A, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Pascual L, Hospital Cl&#237;nico Universitario Lozano Blesa, Zaragoza, Spain; Pastor P, Hospital Mutua de Terrasa, Barcelona, Spain; Pi&#241;ol&#8208;Ripoll G, Hospital Universitario Santa Maria&#8212;IRBLleida, Lleida, Spain; Puig A, Hospital del Mar, Barcelona, Spain; Pujadas F, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Riverol M, Cl&#237;nica Universidad de Navarra, Pamplona, Spain; Villarejo A, Hospital Universitario 12 Octubre, Madrid, Spain. We used AI tools to support language editing and improve clarity during manuscript preparation. This research was funded by Araclon Biotech&#8208;Grifols.</p></ack><sec sec-type="data-availability" id="alz70776-sec-0330"><title>DATA AVAILABILITY STATEMENT</title><p>Data and supporting documents, including the study protocol and statistical analysis plan, are available from the corresponding author upon reasonable request.</p></sec><ref-list id="alz70776-bibl-0001"><title>REFERENCES</title><ref id="alz70776-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70776-cite-0002"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sterling</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>W</given-names></string-name>. <article-title>Amyloid &#946;&#8208;based therapy for Alzheimer's disease: challenges, successes and future</article-title>. <source>Signal Transduct Target Ther</source>. <year>2023</year>;<volume>8</volume>:<fpage>248</fpage>.<pub-id pub-id-type="pmid">37386015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01484-7</pub-id><pub-id pub-id-type="pmcid">PMC10310781</pub-id></mixed-citation></ref><ref id="alz70776-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70776-cite-0003"><string-name name-style="western"><surname>Budd Haeberlein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Two randomized phase 3 studies of aducanumab in early Alzheimer's disease</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2022</year>;<volume>9</volume>:<fpage>197</fpage>&#8208;<lpage>210</lpage>.<pub-id pub-id-type="pmid">35542991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id></mixed-citation></ref><ref id="alz70776-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70776-cite-0004"><string-name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Lecanemab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>:<fpage>9</fpage>&#8208;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref><ref id="alz70776-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70776-cite-0005"><string-name name-style="western"><surname>Sims</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>CD</given-names></string-name>, et&#160;al. <article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER&#8208;ALZ 2 randomized clinical trial</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>:<fpage>512</fpage>&#8208;<lpage>527</lpage>.<pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></mixed-citation></ref><ref id="alz70776-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70776-cite-0006"><string-name name-style="western"><surname>Naslund</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schierhorn</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hellman</surname><given-names>U</given-names></string-name>, et&#160;al. <article-title>Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1994</year>;<volume>91</volume>:<fpage>8378</fpage>&#8208;<lpage>8382</lpage>.<pub-id pub-id-type="pmid">8078890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.91.18.8378</pub-id><pub-id pub-id-type="pmcid">PMC44609</pub-id></mixed-citation></ref><ref id="alz70776-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70776-cite-0007"><string-name name-style="western"><surname>Lue</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Roher</surname><given-names>AE</given-names></string-name>, et&#160;al. <article-title>Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease</article-title>. <source>Am J Pathol</source>. <year>1999</year>;<volume>155</volume>:<fpage>853</fpage>&#8208;<lpage>862</lpage>.<pub-id pub-id-type="pmid">10487842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9440(10)65184-x</pub-id><pub-id pub-id-type="pmcid">PMC1866907</pub-id></mixed-citation></ref><ref id="alz70776-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70776-cite-0008"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>VM</given-names></string-name>. <article-title>The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging</article-title>. <source>Exp Neurol</source>. <year>1999</year>;<volume>158</volume>:<fpage>328</fpage>&#8208;<lpage>337</lpage>.<pub-id pub-id-type="pmid">10415140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/exnr.1999.7085</pub-id></mixed-citation></ref><ref id="alz70776-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70776-cite-0009"><string-name name-style="western"><surname>Lacosta</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Insua</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Badi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pesini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sarasa</surname><given-names>M</given-names></string-name>. <article-title>Neurofibrillary tangles of abetax&#8208;40 in Alzheimer's disease brains</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>58</volume>:<fpage>661</fpage>&#8208;<lpage>667</lpage>.<pub-id pub-id-type="pmid">28453491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170163</pub-id></mixed-citation></ref><ref id="alz70776-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70776-cite-0010"><string-name name-style="western"><surname>Greenberg</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bacskai</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Hernandez&#8208;Guillamon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pruzin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sperling</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van Veluw</surname><given-names>SJ</given-names></string-name>. <article-title>Cerebral amyloid angiopathy and Alzheimer disease&#8212;one peptide, two pathways</article-title>. <source>Nat Rev Neurol</source>. <year>2020</year>;<volume>16</volume>:<fpage>30</fpage>&#8208;<lpage>42</lpage>.<pub-id pub-id-type="pmid">31827267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-019-0281-2</pub-id><pub-id pub-id-type="pmcid">PMC7268202</pub-id></mixed-citation></ref><ref id="alz70776-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70776-cite-0011"><string-name name-style="western"><surname>J&#228;kel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>De Kort</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Klijn</surname><given-names>CJM</given-names></string-name>, <string-name name-style="western"><surname>Schreuder</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Verbeek</surname><given-names>MM</given-names></string-name>. <article-title>Prevalence of cerebral amyloid angiopathy: a systematic review and meta&#8208;analysis</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>10</fpage>&#8208;<lpage>28</lpage>.<pub-id pub-id-type="pmid">34057813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12366</pub-id><pub-id pub-id-type="pmcid">PMC9290643</pub-id></mixed-citation></ref><ref id="alz70776-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70776-cite-0012"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Cerebral amyloid angiopathy pathology and cognitive domains in older persons</article-title>. <source>Ann Neurol</source>. <year>2011</year>;<volume>69</volume>:<fpage>320</fpage>&#8208;<lpage>327</lpage>.<pub-id pub-id-type="pmid">21387377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22112</pub-id><pub-id pub-id-type="pmcid">PMC3228518</pub-id></mixed-citation></ref><ref id="alz70776-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70776-cite-0013"><string-name name-style="western"><surname>Vidoni</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JK</given-names></string-name>, et&#160;al. <article-title>Cerebral beta&#8208;amyloid angiopathy is associated with earlier dementia onset in Alzheimer's disease</article-title>. <source>Neurodegener Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>218</fpage>&#8208;<lpage>224</lpage>.<pub-id pub-id-type="pmid">26756746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000441919</pub-id><pub-id pub-id-type="pmcid">PMC4915344</pub-id></mixed-citation></ref><ref id="alz70776-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70776-cite-0014"><collab collab-type="authors">Neuropathology Group. Medical Research Council Cognitive Function and Aging Study</collab>
. <article-title>Medical Research Council Cognitive F, Aging S. Pathological correlates of late&#8208;onset dementia in a multicentre, community&#8208;based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>:<fpage>169</fpage>&#8208;<lpage>175</lpage>.<pub-id pub-id-type="pmid">11213093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(00)03589-3</pub-id></mixed-citation></ref><ref id="alz70776-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70776-cite-0015"><string-name name-style="western"><surname>Pfeifer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boncristiano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bondolfi</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Cerebral hemorrhage after passive anti&#8208;Abeta immunotherapy</article-title>. <source>Science</source>. <year>2002</year>;<volume>298</volume>:<fpage>1379</fpage>.<pub-id pub-id-type="pmid">12434053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1078259</pub-id></mixed-citation></ref><ref id="alz70776-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70776-cite-0016"><string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Cerebral amyloid angiopathy and cognitive outcomes in community&#8208;based older persons</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>:<fpage>1930</fpage>&#8208;<lpage>1936</lpage>.<pub-id pub-id-type="pmid">26537052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002175</pub-id><pub-id pub-id-type="pmcid">PMC4664125</pub-id></mixed-citation></ref><ref id="alz70776-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70776-cite-0017"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Elhage</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JAR</given-names></string-name>, <string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>. <article-title>Amyloid&#8208;related imaging abnormalities (ARIA): radiological, biological and clinical characteristics</article-title>. <source>Brain</source>. <year>2023</year>;<volume>146</volume>:<fpage>4414</fpage>&#8208;<lpage>4424</lpage>.<pub-id pub-id-type="pmid">37280110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad188</pub-id><pub-id pub-id-type="pmcid">PMC10629981</pub-id></mixed-citation></ref><ref id="alz70776-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70776-cite-0018"><string-name name-style="western"><surname>Greenberg</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bax</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>van Veluw</surname><given-names>SJ</given-names></string-name>. <article-title>Amyloid&#8208;related imaging abnormalities: manifestations, metrics and mechanisms</article-title>. <source>Nat Rev Neurol</source>. <year>2025</year>;<volume>21</volume>(<issue>4</issue>):<fpage>193</fpage>&#8208;<lpage>203</lpage>.<pub-id pub-id-type="pmid">39794509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-01053-8</pub-id></mixed-citation></ref><ref id="alz70776-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70776-cite-0019"><string-name name-style="western"><surname>Bales</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>O'Neill</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Pozdnyakov</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Passive immunotherapy targeting amyloid&#8208;beta reduces cerebral amyloid angiopathy and improves vascular reactivity</article-title>. <source>Brain</source>. <year>2016</year>;<volume>139</volume>:<fpage>563</fpage>&#8208;<lpage>577</lpage>.<pub-id pub-id-type="pmid">26493635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv313</pub-id></mixed-citation></ref><ref id="alz70776-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70776-cite-0020"><string-name name-style="western"><surname>Orgogozo</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gilman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dartigues</surname><given-names>JF</given-names></string-name>, et&#160;al. <article-title>Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>61</volume>:<fpage>46</fpage>&#8208;<lpage>54</lpage>.<pub-id pub-id-type="pmid">12847155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000073623.84147.a8</pub-id></mixed-citation></ref><ref id="alz70776-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70776-cite-0021"><string-name name-style="western"><surname>Lacosta</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Pascual&#8208;Lucas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pesini</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Safety, tolerability and immunogenicity of an active anti&#8208;Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double&#8208;blind, placebo&#8208;controlled, phase I trial</article-title>. <source>Alzheimers Res Ther</source>. <year>2018</year>;<volume>10</volume>:<fpage>12</fpage>.<pub-id pub-id-type="pmid">29378651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-018-0340-8</pub-id><pub-id pub-id-type="pmcid">PMC5789644</pub-id></mixed-citation></ref><ref id="alz70776-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70776-cite-0022"><string-name name-style="western"><surname>Albert</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>DeKosky</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>270</fpage>&#8208;<lpage>279</lpage>.<pub-id pub-id-type="pmid">21514249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.008</pub-id><pub-id pub-id-type="pmcid">PMC3312027</pub-id></mixed-citation></ref><ref id="alz70776-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70776-cite-0023"><string-name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>JC</given-names></string-name>, et&#160;al. <article-title>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>:<fpage>1</fpage>&#8208;<lpage>15</lpage>. e1&#8208;4.<pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></mixed-citation></ref><ref id="alz70776-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70776-cite-0024"><string-name name-style="western"><surname>Hanley</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Lippman&#8208;Hand</surname><given-names>A</given-names></string-name>. <article-title>If nothing goes wrong, is everything all right? Interpreting zero numerators</article-title>. <source>JAMA</source>. <year>1983</year>;<volume>249</volume>:<fpage>1743</fpage>&#8208;<lpage>1745</lpage>.<pub-id pub-id-type="pmid">6827763</pub-id></mixed-citation></ref><ref id="alz70776-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70776-cite-0025"><string-name name-style="western"><surname>Salloway</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sperling</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>NC</given-names></string-name>, et&#160;al. <article-title>Two phase 3 trials of bapineuzumab in mild&#8208;to&#8208;moderate Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>322</fpage>&#8208;<lpage>333</lpage>.<pub-id pub-id-type="pmid">24450891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmcid">PMC4159618</pub-id></mixed-citation></ref><ref id="alz70776-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70776-cite-0026"><string-name name-style="western"><surname>Salloway</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chalkias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>:<fpage>13</fpage>&#8208;<lpage>21</lpage>.<pub-id pub-id-type="pmid">34807243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.4161</pub-id><pub-id pub-id-type="pmcid">PMC8609465</pub-id></mixed-citation></ref><ref id="alz70776-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70776-cite-0027"><string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Donohue</surname><given-names>MC</given-names></string-name>, et&#160;al. <article-title>Two phase 3 trials of gantenerumab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>:<fpage>1862</fpage>&#8208;<lpage>1876</lpage>.<pub-id pub-id-type="pmid">37966285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2304430</pub-id><pub-id pub-id-type="pmcid">PMC10794000</pub-id></mixed-citation></ref><ref id="alz70776-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70776-cite-0028"><string-name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Ardayfio</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER&#8208;ALZ and ALZ 2 randomized clinical trials</article-title>. <source>JAMA Neurol</source>. <year>2025</year>;<volume>82</volume>(<issue>5</issue>):<fpage>461</fpage>&#8208;<lpage>469</lpage>.<pub-id pub-id-type="pmid">40063015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2025.0065</pub-id><pub-id pub-id-type="pmcid">PMC11894547</pub-id></mixed-citation></ref><ref id="alz70776-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70776-cite-0029"><string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zotova</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weller</surname><given-names>RO</given-names></string-name>, et&#160;al. <article-title>Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain</article-title>. <source>Brain</source>. <year>2008</year>;<volume>131</volume>:<fpage>3299</fpage>&#8208;<lpage>3310</lpage>.<pub-id pub-id-type="pmid">18953056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awn261</pub-id></mixed-citation></ref><ref id="alz70776-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70776-cite-0030"><string-name name-style="western"><surname>Sakai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carare</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>A&#946; immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy</article-title>. <source>Acta Neuropathol</source>. <year>2014</year>;<volume>128</volume>:<fpage>777</fpage>&#8208;<lpage>789</lpage>.<pub-id pub-id-type="pmid">25195061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-014-1340-9</pub-id></mixed-citation></ref><ref id="alz70776-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70776-cite-0031"><string-name name-style="western"><surname>Novak</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kovacech</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Katina</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>ADAMANT: a placebo&#8208;controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease</article-title>. <source>Nat Aging</source>. <year>2021</year>;<volume>1</volume>:<fpage>521</fpage>&#8208;<lpage>534</lpage>.<pub-id pub-id-type="pmid">37117834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00070-2</pub-id></mixed-citation></ref><ref id="alz70776-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70776-cite-0032"><string-name name-style="western"><surname>Rafii</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Sol</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Mobley</surname><given-names>WC</given-names></string-name>, et&#160;al. <article-title>Safety, tolerability, and immunogenicity of the ACI&#8208;24 vaccine in adults with Down syndrome: a phase 1b randomized clinical trial</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>:<fpage>565</fpage>&#8208;<lpage>574</lpage>.<pub-id pub-id-type="pmid">35532913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.0983</pub-id><pub-id pub-id-type="pmcid">PMC9086937</pub-id></mixed-citation></ref><ref id="alz70776-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70776-cite-0033"><string-name name-style="western"><surname>Yu</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>PN</given-names></string-name>, et&#160;al. <article-title>Safety, tolerability, immunogenicity, and efficacy of UB&#8208;311 in participants with mild Alzheimer's disease: a randomised, double&#8208;blind, placebo&#8208;controlled, phase 2a study</article-title>. <source>EBioMedicine</source>. <year>2023</year>;<volume>94</volume>:<elocation-id>104665</elocation-id>.<pub-id pub-id-type="pmid">37392597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104665</pub-id><pub-id pub-id-type="pmcid">PMC10338203</pub-id></mixed-citation></ref><ref id="alz70776-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70776-cite-0034"><string-name name-style="western"><surname>Farlow</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Andreasen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Riviere</surname><given-names>ME</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2015</year>;<volume>7</volume>:<fpage>23</fpage>&#8208;<lpage>0108</lpage>.<pub-id pub-id-type="pmid">25918556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-015-0108-3</pub-id><pub-id pub-id-type="pmcid">PMC4410460</pub-id></mixed-citation></ref><ref id="alz70776-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70776-cite-0035"><string-name name-style="western"><surname>Yu</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Watts</surname><given-names>RJ</given-names></string-name>. <article-title>Developing therapeutic antibodies for neurodegenerative disease</article-title>. <source>Neurotherapeutics</source>. <year>2013</year>;<volume>10</volume>:<fpage>459</fpage>&#8208;<lpage>472</lpage>.<pub-id pub-id-type="pmid">23549647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-013-0187-4</pub-id><pub-id pub-id-type="pmcid">PMC3701773</pub-id></mixed-citation></ref><ref id="alz70776-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70776-cite-0036"><string-name name-style="western"><surname>Logovinsky</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Satlin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Safety and tolerability of BAN2401&#8212;a clinical study in Alzheimer's disease with a protofibril selective A&#946; antibody</article-title>. <source>Alzheimers Res Ther</source>. <year>2016</year>;<volume>8</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">27048170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-016-0181-2</pub-id><pub-id pub-id-type="pmcid">PMC4822297</pub-id></mixed-citation></ref><ref id="alz70776-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70776-cite-0037"><string-name name-style="western"><surname>Willis</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Sundell</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lachno</surname><given-names>DR</given-names></string-name>, et&#160;al. <article-title>Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>4</volume>:<fpage>652</fpage>&#8208;<lpage>660</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2018.10.001</pub-id><pub-id pub-id-type="pmcid">PMC6258891</pub-id><pub-id pub-id-type="pmid">30511011</pub-id></mixed-citation></ref><ref id="alz70776-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70776-cite-0038"><string-name name-style="western"><surname>Han</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bellavance</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>McCusker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Primeau</surname><given-names>F</given-names></string-name>. <article-title>Tracking cognitive decline in Alzheimer's disease using the mini&#8208;mental state examination: a meta&#8208;analysis</article-title>. <source>International psychogeriatrics</source>. <year>2000</year>;<volume>12</volume>:<fpage>231</fpage>&#8208;<lpage>247</lpage>.<pub-id pub-id-type="pmid">10937543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s1041610200006359</pub-id></mixed-citation></ref><ref id="alz70776-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70776-cite-0039"><string-name name-style="western"><surname>Wilkosz</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Seltman</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Devlin</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Trajectories of cognitive decline in Alzheimer's disease</article-title>. <source>Int Psychogeriatr</source>. <year>2010</year>;<volume>22</volume>:<fpage>281</fpage>&#8208;<lpage>290</lpage>.<pub-id pub-id-type="pmid">19781112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610209991001</pub-id><pub-id pub-id-type="pmcid">PMC2834298</pub-id></mixed-citation></ref><ref id="alz70776-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70776-cite-0040"><string-name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wolff</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weitz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bartlau</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korth</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zerr</surname><given-names>I</given-names></string-name>. <article-title>Rapidly progressive Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2011</year>;<volume>68</volume>:<fpage>1124</fpage>&#8208;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">21911694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2011.189</pub-id></mixed-citation></ref><ref id="alz70776-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70776-cite-0041"><string-name name-style="western"><surname>S&#225;nchez&#8208;Cubillo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Peri&#225;&#241;ez</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Adrover&#8208;Roig</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Construct validity of the Trail Making Test: role of task&#8208;switching, working memory, inhibition/interference control, and visuomotor abilities</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2009</year>;<volume>15</volume>:<fpage>438</fpage>&#8208;<lpage>450</lpage>.<pub-id pub-id-type="pmid">19402930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617709090626</pub-id></mixed-citation></ref><ref id="alz70776-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70776-cite-0042"><string-name name-style="western"><surname>Duff</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Humphreys Clark</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>O'Bryant</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Mold</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Schiffer</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Sutker</surname><given-names>PB</given-names></string-name>. <article-title>Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2008</year>;<volume>23</volume>:<fpage>603</fpage>&#8208;<lpage>612</lpage>.<pub-id pub-id-type="pmid">18639437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.acn.2008.06.004</pub-id><pub-id pub-id-type="pmcid">PMC2570647</pub-id></mixed-citation></ref><ref id="alz70776-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70776-cite-0043"><string-name name-style="western"><surname>Siemers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Holdridge</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Sundell</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Liu&#8208;Seifert</surname><given-names>H</given-names></string-name>. <article-title>Function and clinical meaningfulness of treatments for mild Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>2</volume>:<fpage>105</fpage>&#8208;<lpage>112</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2016.02.006</pub-id><pub-id pub-id-type="pmcid">PMC4879645</pub-id><pub-id pub-id-type="pmid">27239541</pub-id></mixed-citation></ref><ref id="alz70776-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70776-cite-0044"><string-name name-style="western"><surname>Alves</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kalinowski</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ayton</surname><given-names>S</given-names></string-name>. <article-title>Accelerated brain volume loss caused by anti&#8208;&#946;&#8208;amyloid drugs: a systematic review and meta&#8208;analysis</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>100</volume>:<fpage>e2114</fpage>&#8208;<lpage>e24</lpage>.<pub-id pub-id-type="pmid">36973044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207156</pub-id><pub-id pub-id-type="pmcid">PMC10186239</pub-id></mixed-citation></ref><ref id="alz70776-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70776-cite-0045"><string-name name-style="western"><surname>Belder</surname><given-names>CRS</given-names></string-name>, <string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JAR</given-names></string-name>, et&#160;al. <article-title>Brain volume change following anti&#8208;amyloid &#946; immunotherapy for Alzheimer's disease: amyloid&#8208;removal&#8208;related pseudo&#8208;atrophy</article-title>. <source>Lancet Neurol</source>. <year>2024</year>;<volume>23</volume>:<fpage>1025</fpage>&#8208;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">39304242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00335-1</pub-id></mixed-citation></ref><ref id="alz70776-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70776-cite-0046"><string-name name-style="western"><surname>Fox</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Scahill</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Crum</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></string-name>. <article-title>Correlation between rates of brain atrophy and cognitive decline in AD</article-title>. <source>Neurology</source>. <year>1999</year>;<volume>52</volume>:<fpage>1687</fpage>&#8208;<lpage>1689</lpage>.<pub-id pub-id-type="pmid">10331700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.52.8.1687</pub-id></mixed-citation></ref><ref id="alz70776-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70776-cite-0047"><string-name name-style="western"><surname>McCarter</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lesnick</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Cerebral amyloid angiopathy pathology and its association with amyloid&#8208;&#946; PET signal</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>97</volume>:<fpage>e1799</fpage>&#8208;<lpage>e808</lpage>.<pub-id pub-id-type="pmid">34504022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012770</pub-id><pub-id pub-id-type="pmcid">PMC8610626</pub-id></mixed-citation></ref><ref id="alz70776-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70776-cite-0048"><string-name name-style="western"><surname>Landen</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Billing</surname><given-names>CB</given-names><suffix>Jr</suffix></string-name>, et&#160;al. <article-title>Multiple&#8208;dose ponezumab for mild&#8208;to&#8208;moderate Alzheimer's disease: safety and efficacy</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>3</volume>:<fpage>339</fpage>&#8208;<lpage>347</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.04.003</pub-id><pub-id pub-id-type="pmcid">PMC5651443</pub-id><pub-id pub-id-type="pmid">29067341</pub-id></mixed-citation></ref><ref id="alz70776-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70776-cite-0049"><string-name name-style="western"><surname>Leurent</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Immunotherapy with ponezumab for probable cerebral amyloid angiopathy</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>:<fpage>795</fpage>&#8208;<lpage>806</lpage>.<pub-id pub-id-type="pmid">31020004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.761</pub-id><pub-id pub-id-type="pmcid">PMC6469253</pub-id></mixed-citation></ref><ref id="alz70776-bib-0049"><label>49</label><mixed-citation publication-type="miscellaneous" id="alz70776-cite-0050"><article-title>A Study to Evaluate the Safety and Tolerability of ALN&#8208;APP in Patients With EOAD</article-title>. Accessed 20 March 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05231785" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05231785</ext-link></mixed-citation></ref><ref id="alz70776-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="alz70776-cite-0051"><article-title>A Phase 2 Trial of ALN&#8208;APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn&#8208;1)</article-title>. Accessed 20 March 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06393712" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06393712</ext-link></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PNAS Nexus</journal-id><journal-id journal-id-type="iso-abbrev">PNAS Nexus</journal-id><journal-id journal-id-type="pmc-domain-id">4335</journal-id><journal-id journal-id-type="pmc-domain">pnasnexus</journal-id><journal-id journal-id-type="publisher-id">pnasnexus</journal-id><journal-title-group><journal-title>PNAS Nexus</journal-title></journal-title-group><issn pub-type="epub">2752-6542</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501968</article-id><article-id pub-id-type="pmcid-ver">PMC12501968.1</article-id><article-id pub-id-type="pmcaid">12501968</article-id><article-id pub-id-type="pmcaiid">12501968</article-id><article-id pub-id-type="doi">10.1093/pnasnexus/pgaf295</article-id><article-id pub-id-type="publisher-id">pgaf295</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Biological, Health, and Medical Sciences</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject><subject>AcademicSubjects/SCI00010</subject><subject>AcademicSubjects/SOC00010</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>PNAS_Nexus/pub-health-epidem</subject></subj-group></article-categories><title-group><article-title>American Life in Realtime: Benchmark, publicly available person-generated health data for equity in precision health</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0416-6134</contrib-id><name name-style="western"><surname>Chaturvedi</surname><given-names initials="RR">Ritika R</given-names></name><aff>
<institution>Center for Economic and Social Research, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff><xref rid="FM2" ref-type="author-notes"/><xref rid="pgaf295-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6084-6388</contrib-id><name name-style="western"><surname>Angrisani</surname><given-names initials="M">Marco</given-names></name><aff>
<institution>Center for Economic and Social Research, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Troxel</surname><given-names initials="WM">Wendy M</given-names></name><aff>
<institution>Division of Social and Economic Wellbeing, RAND Corporation</institution>, <addr-line>4570 Fifth Avenue, Pittsburgh, PA 15213</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-9257-403X</contrib-id><name name-style="western"><surname>Jain</surname><given-names initials="M">Monika</given-names></name><aff>
<institution>Evidation Health, Inc.</institution>, <addr-line>63 Bovet Road #146, San Mateo, CA 94402</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4047-7287</contrib-id><name name-style="western"><surname>Gutsche</surname><given-names initials="T">Tania</given-names></name><aff>
<institution>Center for Economic and Social Research, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ortega</surname><given-names initials="E">Eva</given-names></name><aff>
<institution>Center for Economic and Social Research, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boch</surname><given-names initials="A">Adrien</given-names></name><aff>
<institution>Evidation Health, Inc.</institution>, <addr-line>63 Bovet Road #146, San Mateo, CA 94402</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-5039-1973</contrib-id><name name-style="western"><surname>Liang</surname><given-names initials="C">Citina</given-names></name><aff>
<institution>Viterbi School of Engineering, University of Southern California</institution>, <addr-line>3650 McClintock Ave, Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-6213-3914</contrib-id><name name-style="western"><surname>Sima</surname><given-names initials="S">Shiyang</given-names></name><aff>
<institution>Daniels School of Business, Purdue University</institution>, <addr-line>403 Mitch Daniels Blvd, West Lafayette, IN 47907</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mezlini</surname><given-names initials="A">Aziz</given-names></name><aff>
<institution>Evidation Health, Inc.</institution>, <addr-line>63 Bovet Road #146, San Mateo, CA 94402</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daza</surname><given-names initials="EJ">Eric J</given-names></name><aff>
<institution>Evidation Health, Inc.</institution>, <addr-line>63 Bovet Road #146, San Mateo, CA 94402</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boodaghidizaji</surname><given-names initials="M">Miad</given-names></name><aff>
<institution>College of Engineering, Purdue University</institution>, <addr-line>701 W Stadium Ave #3000, West Lafayette, IN 47907</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9453-5863</contrib-id><name name-style="western"><surname>Suen</surname><given-names initials="SC">Sze-chuan</given-names></name><aff>
<institution>Viterbi School of Engineering, University of Southern California</institution>, <addr-line>3650 McClintock Ave, Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4666-0197</contrib-id><name name-style="western"><surname>Chaturvedi</surname><given-names initials="AR">Alok R</given-names></name><aff>
<institution>Daniels School of Business, Purdue University</institution>, <addr-line>403 Mitch Daniels Blvd, West Lafayette, IN 47907</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9018-1295</contrib-id><name name-style="western"><surname>Ghasemkhani</surname><given-names initials="H">Hossein</given-names></name><aff>
<institution>Daniels School of Business, Purdue University</institution>, <addr-line>403 Mitch Daniels Blvd, West Lafayette, IN 47907</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3301-3193</contrib-id><name name-style="western"><surname>Ardekani</surname><given-names initials="AM">Arezoo M</given-names></name><aff>
<institution>College of Engineering, Purdue University</institution>, <addr-line>701 W Stadium Ave #3000, West Lafayette, IN 47907</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1855-5528</contrib-id><name name-style="western"><surname>Kapteyn</surname><given-names initials="A">Arie</given-names></name><aff>
<institution>Center for Economic and Social Research, University of Southern California</institution>, <addr-line>635 Downey Way, Verna and Peter Dauterive Hall (VPD), Los Angeles, CA 90089</addr-line>, <country country="US">USA</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Longhurst</surname><given-names initials="C">Christopher</given-names></name><role>Editor</role></contrib></contrib-group><author-notes><corresp id="pgaf295-cor1">To whom correspondence should be addressed: Email: <email>ritikac@usc.edu</email></corresp><fn id="FM2"><p>
<bold>Competing Interest:</bold> M.J., A.B., E.D., and A.M. are affiliated with Evidation Health, Inc. Their contributions were made as part of the NLM-funded grant supporting this study. All other authors declare no competing interests.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-10-07"><day>07</day><month>10</month><year>2025</year></pub-date><volume>4</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498012</issue-id><elocation-id>pgaf295</elocation-id><history><date date-type="received"><day>10</day><month>1</month><year>2025</year></date><date date-type="corrected-typeset"><day>07</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 10:25:16.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of National Academy of Sciences.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pgaf295.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pgaf295.pdf"/><abstract><title>Abstract</title><p>Person-generated health data (PGHD) from smartphones/wearables are invaluable for precision health, a field promoting health equity through tailored disease prevention, detection, and intervention strategies. However, pervasive convenience sampling in extant PGHD research introduces selection biases that systematically underrepresent disadvantaged groups, limit model generalizability, and risk exacerbating health disparities. Benchmark PGHD (representative, validated, longitudinal, and frequently repeated) are urgently needed to support model equity. To address this fieldwide limitation, we established American Life in Realtime (ALiR), a longitudinal population health study involving PGHD collected from a probability-based, nationally representative cohort using study-provided Fitbits and (as needed) 4G tablets. As a result, ALiR's 1,038 participants are broadly representative across comprehensive sociodemographic, behavioral, and health-related US population norms, overcoming disparities in established convenience samples (e.g. NIH's <italic toggle="yes">All of Us</italic>; <italic toggle="yes">AoU</italic>). Only two sources of differential enrollment remained: older age (odds ratio [OR]: 1.27, 99% CI: 1.12&#8211;1.45) during consent, lower education (OR: 0.86, 99% CI: 0.79&#8211;0.94) during enrollment, though oversampling individuals without bachelor's degrees sufficiently counterbalanced the latter. An illustrative coronavirus disease 2019 classification model&#8212;chosen for global significance, known disparities in experience and outcomes, and methodological relevance&#8212;trained using ALiR performed equivalently when tested in sample (area under the curve [AUC] = 0.84, 95% CI: 0.79&#8211;0.89) and out of sample on <italic toggle="yes">AoU</italic> (AUC = 0.83, 95% CI: 0.78&#8211;0.89) overall, and in historically underserved subgroups (AUC = 0.82&#8211;1.0). Conversely, an identically trained classification model using <italic toggle="yes">AoU</italic> underperformed by 35% out of sample on ALiR (overall AUC = 0.68, 95% CI: 0.61&#8211;0.75 vs. AUC = 0.93, 95% CI: 0.91&#8211;0.96 in sample), with worse performance in older female and non-White subgroups (by 22&#8211;40%). Our results suggest that probability sampling and hardware provisioning enabled cohort inclusivity and generalizable model performance, supporting ALiR's benchmarking potential for equitable recruitment, PGHD collection, and precision health application.</p></abstract><kwd-group><kwd>Biological</kwd><kwd>Health</kwd><kwd>Medical Sciences/Public Health and Epidemiology</kwd></kwd-group><kwd-group><kwd>person-generated health data</kwd><kwd>digital health</kwd><kwd>precision health</kwd><kwd>health equity</kwd><kwd>model generalizability</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Library of Medicine at the National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01LM013237</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Social Security Administration and the National Institute</institution></institution-wrap></funding-source><award-id>U01AG054580</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Federally Qualified Health Centers</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Data and Research Center</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>The Participant Center</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Participant Technology Systems Center</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Communications and Engagement</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Community Partners</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="pgaf295-box1" position="anchor" orientation="portrait"><label>Significance Statement</label><p>Data from smartphones/wearables could help personalize healthcare, but existing research underrepresents disadvantaged groups, which risks worsening health disparities. We created American Life in Realtime (ALiR), a wearable-based population health study to address this systematic limitation. By using random, address-based sampling and providing Fitbits and 4G tablets, ALiR removed nearly all participation barriers within disadvantaged groups, resulting in broad representation of US adults compared with existing studies. Further, an illustrative coronavirus disease 2019 detection model&#8212;chosen for known disparities, global impact, and methodological comparability&#8212;trained using ALiR was equally effective across diverse populations, outperforming an identically trained model using <italic toggle="yes">All of Us</italic> (NIH's cohort to advance research in underrepresented groups). ALiR thus provides a potential benchmark for equitable recruitment, data collection, and modeling in wearable research.</p></boxed-text><sec sec-type="intro" id="pgaf295-s1"><title>Introduction</title><p>Precision health is an emerging field that seeks to characterize and address health disparities through approaches customized to an individual's specific context and needs (<xref rid="pgaf295-B1" ref-type="bibr">1</xref>, <xref rid="pgaf295-B2" ref-type="bibr">2</xref>). Current applications, including individualized detection of the novel coronavirus disease 2019 (COVID-19) (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>), involve AI and machine learning (ML) systems built upon large-scale person-generated health data (PGHD). Derived from routine digital technology engagement (e.g. smartphones and wearables) (<xref rid="pgaf295-B9" ref-type="bibr">9</xref>), PGHD can continuously capture everyday real-world social, structural, and environmental exposures, behaviors, and biometrics (<xref rid="pgaf295-B10" ref-type="bibr">10</xref>)&#8212;factors that account for 60&#8211;80% of the modifiable risk of adverse health outcomes (<xref rid="pgaf295-B11" ref-type="bibr">11&#8211;14</xref>)&#8212;providing a valuable opportunity to identify and effectively address unique pathological drivers in marginalized groups.</p><p>However, the field lacks &#8220;benchmark&#8221; PGHD (<xref rid="pgaf295-B15" ref-type="bibr">15</xref>, <xref rid="pgaf295-B16" ref-type="bibr">16</xref>), a significant limitation that could exacerbate health disparities in those who may benefit most from precision health advances (<xref rid="pgaf295-B17" ref-type="bibr">17</xref>). Benchmarks are standardized datasets that train, evaluate, and validate AI/ML models, ensuring transparency, reproducibility, and generalizability across populations. Without such resources, the field lacks the ability to systematically evaluate model performance, identify biases, and quantify uncertainty, resulting in underperformance in key subgroups and limited real-world applicability. The ideal PGHD benchmark should (i) reflect population diversity; (ii) pair passive data with frequently repeated, validated labels of social, structural, environmental, and health exposures and outcomes; (iii) span longitudinal, and life-course designs; (iv) encompass sufficient data quantity, quality, and diversity for AI/ML applied to individuals, subgroups, or populations; and (v) provide wide accessibility (<xref rid="pgaf295-B15" ref-type="bibr">15</xref>, <xref rid="pgaf295-B16" ref-type="bibr">16</xref>). No extant dataset fulfills all five criteria. PGHD cohorts within population studies like NIH's <italic toggle="yes">All of Us</italic> Research Program (<italic toggle="yes">AoU</italic>) (<xref rid="pgaf295-B18" ref-type="bibr">18</xref>) and UK Biobank (<xref rid="pgaf295-B19" ref-type="bibr">19</xref>, <xref rid="pgaf295-B20" ref-type="bibr">20</xref>) systematically underrepresent Black, indigenous, older, lower-educated, or lower-income groups, rely on unstructured labels from claims or electronic health records, and rarely employ repeated, longitudinal instruments (<xref rid="pgaf295-B21" ref-type="bibr">21&#8211;25</xref>). Most PGHD applications, including COVID-19 detection studies, lack reported demographic distributions, let alone social determinants (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>). This lack of high-quality, inclusive PGHD, and transparent demographic reporting raises the risk that AI/ML applications may amplify existing disparities, causing underperformance in minority groups (<xref rid="pgaf295-B26" ref-type="bibr">26&#8211;28</xref>), patient harm (<xref rid="pgaf295-B28" ref-type="bibr">28</xref>, <xref rid="pgaf295-B29" ref-type="bibr">29</xref>), and billions in societal costs (<xref rid="pgaf295-B30" ref-type="bibr">30</xref>).</p><p>COVID-19 highlighted the existence of profound, socially determined healthcare disparities in the United States (<xref rid="pgaf295-B31" ref-type="bibr">31</xref>), as racism, poverty, and inaccessible healthcare and social services doubled the morbidity and mortality risk in Black and low-income groups (<xref rid="pgaf295-B32" ref-type="bibr">32</xref>). PGHD-based COVID-19 detection thus illustrates both the promise of agile, individualized care that could help circumvent traditional access barriers, and the simultaneous risk of systematic underrepresentation and disparity exacerbation in minoritized groups (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>).</p><p>Whether PGHD inequities stem from methodological selection biases or other barriers remains an open question. Pervasive convenience sampling of easy-to-reach populations (e.g. employers and health systems) and/or &#8220;bring-your-own-device&#8221; (BYOD) recruitment of self-motivated users afford few participation opportunities for underserved individuals (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>, <xref rid="pgaf295-B21" ref-type="bibr">21&#8211;25</xref>). When opportunities exist, competing time pressure, poor technological literacy, mistrust, privacy/security concerns, or simple disinterest may further selectively erode participation (<xref rid="pgaf295-B25" ref-type="bibr">25</xref>, <xref rid="pgaf295-B33" ref-type="bibr">33&#8211;35</xref>).</p><p>American Life in Realtime (ALiR) was designed as a benchmark for fostering equitable precision health, incorporating wearable PGHD and comprehensive, validated, longitudinal surveys from a nationally representative sample (<xref rid="pgaf295-B36" ref-type="bibr">36</xref>). Here we characterize how ALiR's use of probability sampling and study-provided hardware&#8212;strategies that reduce methodological participation barriers&#8212;impacted cohort inclusivity, differential enrollment, and generalizability of an illustrative COVID-19 classification model compared with data from <italic toggle="yes">AoU</italic> (a broad convenience cohort designed to advance precision research in underrepresented populations) (<xref rid="pgaf295-B18" ref-type="bibr">18</xref>).</p></sec><sec sec-type="results" id="pgaf295-s2"><title>Results</title><sec id="pgaf295-s2.1"><title>Design</title><sec id="pgaf295-s2.1.1"><title>Overview</title><p>ALiR's design (<xref rid="pgaf295-B36" ref-type="bibr">36</xref>) (Fig. <xref rid="pgaf295-F1" ref-type="fig">1</xref>A; <xref rid="sup1" ref-type="supplementary-material">Online Methods</xref>) improved on methodologies of extant population health studies with PGHD collection (<xref rid="pgaf295-B18" ref-type="bibr">18</xref>, <xref rid="pgaf295-B20" ref-type="bibr">20</xref>, <xref rid="pgaf295-B37" ref-type="bibr">37</xref>) by incorporating best practices from multiple disciplines such as probability sampling, data benchmarking (<xref rid="pgaf295-B15" ref-type="bibr">15&#8211;17</xref>), and FAIR (<xref rid="pgaf295-B38" ref-type="bibr">38</xref>) (findable, accessible, interoperable, and reusable) standards (Fig. <xref rid="pgaf295-F1" ref-type="fig">1</xref>B). ALiR's participants were invited from the Understanding America Study (UAS) (<xref rid="pgaf295-B39" ref-type="bibr">39</xref>, <xref rid="pgaf295-B40" ref-type="bibr">40</xref>), a nationally representative research cohort. Consenters were given a Fitbit Inspire 2 (Google, LLC/Fitbit Inc.; San Francisco, CA, United States) for study wear (on the wrist) as an incentive. For each individual, at least a year of data collection overlays (i) continuous Fitbit biometrics; (ii) frequent, longitudinal surveys eliciting sociodemographics, social, structural, and environmental exposures, personality, behaviors, and health measured via high-quality, validated instruments; and (iii) geospatially and temporally matched contextual linkages. A custom study app&#8212;broadly compatible across devices, operating systems, and firmware&#8212;facilitates enrollment, data collection, and long-term engagement through earned points redeemable up to $126 in annual compensation. ALiR's infrastructure, data, and study app code will be publicly available (anticipated late 2025). ALiR was approved by USC's Social and Behavioral IRB (UP-21-00181) and follows STROBE guidelines.</p><fig position="float" id="pgaf295-F1" fig-type="figure" orientation="portrait"><label>Fig. 1.</label><caption><p>ALiR design and attributes vs. other population health PGHD cohorts. A) Schematic representation of ALiR infrastructure, including an established, connected cohort, study app with current and future integrations, and benchmark PGHD dataset. B) Comparison of design features across benchmarking and FAIR criteria.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pgaf295f1.jpg"/></fig></sec><sec id="pgaf295-s2.1.2"><title>Population</title><p>ALiR participants were randomly sampled from UAS (IRB: UP-14-00148), a probability-based panel representative of US adults (18+). UAS is considered one of the richest sociodemographic data sources (<xref rid="pgaf295-B39" ref-type="bibr">39</xref>, <xref rid="pgaf295-B40" ref-type="bibr">40</xref>), generating important, generalizable findings across multidisciplinary domains (<xref rid="pgaf295-B41" ref-type="bibr">41&#8211;43</xref>). UAS members (<italic toggle="yes">n</italic> = 9,281 at the time of enrollment, but actively growing to 20,000 by 2026) are recruited by address-based sampling (14.4% average empanelment rate across recruitment batches) and given a 4G Tablet if they lack Internet, minimizing selection biases (e.g. random digit dialing suffers from diminishing landline use; digital advertising excludes those with access barriers). UAS members answer English/Spanish surveys via mobile/web interface and are compensated ($40/h). Since inception in 2014, a comprehensive survey core is fielded to the whole panel and repeated biennially (<xref rid="pgaf295-B40" ref-type="bibr">40</xref>). Response rates are high (&gt;75% cumulative) and attrition is modest (&lt;8% annually). Sample weights (sex, race/ethnicity, age, education, and geography) match UAS demographic distributions to population norms from the Current Population Survey (CPS) (<xref rid="pgaf295-B40" ref-type="bibr">40</xref>, <xref rid="pgaf295-B44" ref-type="bibr">44</xref>).</p></sec><sec id="pgaf295-s2.1.3"><title>Study activities</title><p>Study activities occured remotely for at least 1&#8197;year (Fig. <xref rid="pgaf295-F2" ref-type="fig">2</xref>). A 5-min <italic toggle="yes">informed consent</italic> survey was fielded through the customary UAS electronic interface. During <italic toggle="yes">enrollment</italic>, consenting individuals were sent follow-up emails (or phone calls as needed) to confirm current mailing addresses. Fitbits and enrollment instructions were mailed to participants via signature-required, 2-day FedEx. Participants were instructed to download/install the study app from the relevant iOS/Android store, which then facilitated downloading and setting up the Fitbit device and app and permitting/syncing data exchange. Ongoing <italic toggle="yes">Fitbit</italic> activities involve regularly charging and continuously wearing the provided device, including during sleep. ALiR <italic toggle="yes">surveys</italic> are short but frequent, fielded every 1&#8211;3&#8197;days, consist of 10&#8211;15 questions, and take 1&#8211;2&#8197;minutes to complete (Appendix 1). The UAS helpdesk is available to assist on demand.</p><fig position="float" id="pgaf295-F2" fig-type="figure" orientation="portrait"><label>Fig. 2.</label><caption><p>ALiR participant journey: participant onboarding steps including study app screenshots.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pgaf295f2.jpg"/></fig></sec><sec id="pgaf295-s2.1.4"><title>Data collection</title><p>Data collection<underline>,</underline> designed for label validity in supervised learning (<xref rid="pgaf295-B36" ref-type="bibr">36</xref>), uses a comprehensive array of frequently repeated consensus measures (e.g. Health and Retirement Study; HRS (<xref rid="pgaf295-B45" ref-type="bibr">45</xref>), NIH Phenotypes and Exposures; PhenX (<xref rid="pgaf295-B46" ref-type="bibr">46</xref>), Patient Reported Outcomes Measurement Information System; PROMIS (<xref rid="pgaf295-B47" ref-type="bibr">47</xref>)) to longitudinally characterize each participant along demographic, socioeconomic, personality, behavioral, and health factors (Fig. <xref rid="sup1" ref-type="supplementary-material">S1</xref>). <italic toggle="yes">UAS core data</italic>, repeated biennially, comprises 5,000+ variables across 10+ years and 600+ surveys (<xref rid="pgaf295-B40" ref-type="bibr">40</xref>), including (but not limited to) (i) sociodemographics; (ii) all variables from HRS (<xref rid="pgaf295-B45" ref-type="bibr">45</xref>); (iii) comprehensive cognitive tests and impairment classifications (<xref rid="pgaf295-B48" ref-type="bibr">48&#8211;56</xref> ); (iv) psychological, well-being, and mental health scales (e.g. CES-D (<xref rid="pgaf295-B57" ref-type="bibr">57</xref>)); (v) personality (Big Five (<xref rid="pgaf295-B58" ref-type="bibr">58</xref>)); (vi) economic well-being and financial planning; (vii) competencies and literacies; (viii) COVID-related experiences; and (ix) behaviors/perceptions. <italic toggle="yes">ALiR-specific surveys</italic> (Appendix 1) assess multiple dynamic health-related factors, repeated monthly (or annually where relevant), including (x) social/structural determinants (e.g. food/housing security, racism/discrimination, neighborhood safety, and adverse childhood events); (xi) behaviors (e.g. drugs/alcohol, diet, internet competence, health literacy, health motivations, medical mistrust, vaccine hesitancy, etc.); and (xii) health/well-being (e.g. mental/physical outcomes, infectious disease, healthcare utilization, etc.). (xiii) <italic toggle="yes">ALiR Fitbit data</italic> include both minute-level sensor data and Fitbit's aggregated metrics (e.g. heart rate, heart rate variability, activity, steps, sleep, temperature, blood oxygenation, currently; others as released by Fitbit, in the future) (<xref rid="pgaf295-B59" ref-type="bibr">59</xref>). (xiv) <italic toggle="yes">UAS linkages</italic> matched spatially/temporally at relevant frequencies include air/water quality, weather, crime, neighborhood characteristics, Centers for Medicare and Medicaid Services claims, Social Security Administration earnings/benefits, and the national death index (<xref rid="pgaf295-B40" ref-type="bibr">40</xref>). Finally, (xv) <italic toggle="yes">UAS prospective studies</italic> are added as relevant, like whole-genomic sequencing and personal wearable-based pollution monitoring (Atmotube).</p></sec></sec><sec id="pgaf295-s2.2"><title>Enrollment</title><sec id="pgaf295-s2.2.1"><title>Sample selection</title><p>From 2021 August 3 to 2022 March 1, we randomly invited 2,468 UAS members to ALiR using 16 demographic groups defined by intersections of biological sex, age, race/ethnicity, and education (Table <xref rid="sup1" ref-type="supplementary-material">S1</xref>). Relative to population benchmarks, non-Whites were oversampled by 40% and noncollege graduates by 5%. We excluded individuals with computers only (7% of UAS; Fitbit required either smartphone or tablet), and individuals needing mobility assist devices (6% of UAS; there were few validated Fitbit measures for this population at the time).</p></sec><sec id="pgaf295-s2.2.2"><title>Nonresponse</title><p>The consent survey achieved a response rate of 87.1% (<italic toggle="yes">n</italic> = 2,150). There were no major differences in the likelihood of completing the consent survey across demographic groups (Tables <xref rid="sup1" ref-type="supplementary-material">S2</xref> and <xref rid="sup1" ref-type="supplementary-material">S3</xref>).</p></sec><sec id="pgaf295-s2.2.3"><title>Consent</title><p>Of consent survey respondents, 64.4% (<italic toggle="yes">n</italic> = 1,386) agreed to participate in ALiR (Fig. <xref rid="pgaf295-F3" ref-type="fig">3</xref>). The most common reason for nonconsent in survey comments&#8212;which were only provided by 12% of respondents and may not be generalizable&#8212;was already having an &#8220;Apple Watch&#8221; or &#8220;better&#8221; device (23%). Most of these individuals (85%) were White with household incomes above $60&#8197;K. An additional 20% of commenters cited logistics (e.g. work environments that cannot accommodate wearables) or unwillingness to continuously wear a device. Only 16% cited barriers like mobile network coverage or privacy (Table <xref rid="sup1" ref-type="supplementary-material">S4</xref>).</p><fig position="float" id="pgaf295-F3" fig-type="figure" orientation="portrait"><label>Fig. 3.</label><caption><p>ALiR enrollment: distribution of enrollment status among consent survey respondents within sociodemographic subgroups: orange = did not consent; shades of blue = consented but lost to follow-up; green = enrolled. Data labels = counts. AI, AN, HI, or PI = American Indian, Alaska Native, Hawaiian, or Pacific Islander.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pgaf295f3.jpg"/></fig></sec><sec id="pgaf295-s2.2.4"><title>Enrollment</title><p>As of 2022 April 4, 74.9% (<italic toggle="yes">n</italic> = 1,038) of the consenting sample enrolled in ALiR and 25.1% (<italic toggle="yes">n</italic> = 348) were lost to follow-up. Of this latter group, 75.3% (<italic toggle="yes">n</italic> = 262) did not confirm their address and could not be sent their device; 12.1% (<italic toggle="yes">n</italic> = 42) received materials but never enrolled; and 12.6% (<italic toggle="yes">n</italic> = 44) withdrew. Almost all withdrawals (86%; <italic toggle="yes">n</italic> = 38) occurred before enrollment (Table <xref rid="sup1" ref-type="supplementary-material">S5</xref>). Reasons for withdrawal varied but included repeated unavailability to sign for packages due to work or other commitments, study time commitment, phone/tablet incompatibility with the Fitbit app, and device-related skin irritation.</p></sec></sec><sec id="pgaf295-s2.3"><title>Barriers and differential enrollment</title><p>We used logistic regression and random forests (RFs) to identify observed factors associated with nonconsent and nonenrollment after consenting across combinations of 79 relevant variables (sociodemographics, health, behaviors, personality, skills, cognitive ability, etc.; <xref rid="sup1" ref-type="supplementary-material">Online Methods, Appendix S2A</xref>). Odds ratio (OR) estimations below refer to the most parsimonious regression (17 variables: biological sex, race/ethnicity, education, age, marital status, labor status, income, Census region, urbanicity, household size, self-reported health, body mass index (BMI), and number of preexisting chronic conditions). See Figs. <xref rid="sup1" ref-type="supplementary-material">S2&#8211;S4</xref>, Appendix <xref rid="sup1" ref-type="supplementary-material">S2B</xref> for additional results and sensitivity analyses.</p><p>Older age (OR: 1.27, 99% CI: 1.12&#8211;1.45) was the only observed historically underrepresented or disparity-related factor consistently associated with nonconsent (i.e. unwillingness to participate) across all models after correction for multiple hypotheses (False Discovery Rate; FDR &lt; 0.05; Fig. <xref rid="sup1" ref-type="supplementary-material">S2</xref>). Other factors&#8212;more commonly associated with higher sociodemographic strata&#8212;included smaller household size (OR: 0.90, 99% CI: 0.82&#8211;0.98) and lower BMI (OR: 0.76, 99% CI: 0.62&#8211;0.92). RFs identified income and nonhousing wealth as barriers with nonlinear interactions. Heterogeneity analysis (<xref rid="pgaf295-B60" ref-type="bibr">60</xref>) suggested that participants with the highest total wealth and picture-vocabulary scores were also less likely to consent (both factors are more prevalent within higher sociodemographic strata).</p><p>Lower educational attainment (OR: 0.86, 99% CI: 0.79&#8211;0.94) was the only observed disparity-related variable consistently associated with nonenrollment after consenting (i.e. barriers beyond willingness to participate; Fig. <xref rid="sup1" ref-type="supplementary-material">S3</xref>). Heterogeneity analysis (Fig. <xref rid="sup1" ref-type="supplementary-material">S5</xref>) suggested that individuals with the lowest educational attainment (&lt;9 years) were least likely to enroll.</p><p>Systematic univariate testing for nonenrollment across all 5,000+ UAS variables did not yield any additional factors not related to those in our main models (e.g. age; Tables <xref rid="sup1" ref-type="supplementary-material">S6</xref> and <xref rid="sup1" ref-type="supplementary-material">S7</xref>).</p></sec><sec id="pgaf295-s2.4"><title>ALiR's representation vs. population norms</title><p>Overall, ALiR's unweighted (i.e. raw) cohort resembled the US adult population when compared with a holistic set of population norms (see <xref rid="sup1" ref-type="supplementary-material">Online Methods</xref>), including demographics, socioeconomics, education, personality, behaviors, and health (Fig. <xref rid="pgaf295-F4" ref-type="fig">4</xref>, Tables <xref rid="sup1" ref-type="supplementary-material">S8</xref> and <xref rid="sup1" ref-type="supplementary-material">S9</xref>). The most statistically significant differences relative to the population were expected given the sampling strategy and/or the composition of the parent UAS cohort. Racial/ethnic minorities (oversampled by 40%) are overrepresented by 42% in ALiR (54% vs. 38% in the population; Fig. <xref rid="sup1" ref-type="supplementary-material">4A</xref>), while White individuals are underrepresented by 26% (46 vs. 62%). Since racial/ethnic minorities are more likely to be lower on the income distribution, ALiR overrepresents those with annual household incomes &lt;$30,000 by 16% (22 vs. 19%) and underrepresents those with &#8805;$100,000 by 19% (26 vs. 32%; Fig. <xref rid="sup1" ref-type="supplementary-material">4B</xref>). ALiR's geographic composition mirrors UAS, where the Northeast and South are underrepresented, while West is overrepresented due to large (deliberate) California and Los Angeles County subsamples (Fig. <xref rid="sup1" ref-type="supplementary-material">4D</xref>). Finally, individuals with functional limitations are slightly underrepresented due to the exclusion of those needing mobility assist devices (Fig. <xref rid="sup1" ref-type="supplementary-material">4I</xref>).</p><fig position="float" id="pgaf295-F4" fig-type="figure" orientation="portrait"><label>Fig. 4.</label><caption><p>ALiR characteristics: differences between US adult population norms (black), weighted ALiR (light green), unweighted ALiR (dark green), and UAS-BYOD (orange) across (A) demographics; (B) socioeconomics; (C) digital inclusion; (D) geography; (E) personality; (F&#8211;I) health; and (J) cognition. Error bars = 95% CI. Population norms from Basic Monthly CPS (October 2021&#8211;March 2022) where available, literature-based epidemiological estimates where available, and from the UAS Comprehensive File weighted to the CPS for remaining variables. Demographics are from the &#8220;My Household&#8221; survey (April 2021). HRS health/cognitive outcomes are from the UAS Comprehensive File. Chronic conditions = self-reported diagnoses. AI/AN or HI/PI = American Indian/Alaska Native or Hawaiian/Pacific Islander. Fn&#8217;l Limits = Functional Limitations. Rx Drugs = Prescription Drugs. See Tables <xref rid="sup1" ref-type="supplementary-material">S8&#8211;S11</xref> for details.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pgaf295f4.jpg"/></fig><p>Unweighted ALiR's age discrepancy was not anticipated. The fraction of individuals aged 60+ in ALiR is 32% below population norms (21 vs. 31%). Consequently, the fraction of retirees is 40% lower (12 vs. 20%).</p><p>While our sampling strategy focused on achieving sociodemographic representation, ALiR's unweighted sample is also representative of US adults across personality (Fig. <xref rid="pgaf295-F4" ref-type="fig">4E</xref>), skills (Table <xref rid="sup1" ref-type="supplementary-material">S8</xref>), and several dimensions of health (Fig. <xref rid="pgaf295-F4" ref-type="fig">4</xref>F&#8211;J, Table <xref rid="sup1" ref-type="supplementary-material">S9</xref>). Those with digital access barriers are also included, as 77.2% and 2.3% did not have a wearable or Internet access prior to UAS-ALiR provisioned hardware, resembling respective norms (Fig. <xref rid="pgaf295-F4" ref-type="fig">4</xref>C).</p><p>Application of sample weights&#8212;generated to align ALiR's distributions of basic demographics to the adult US population (biological sex, race/ethnicity, age, education, and geography; <xref rid="sup1" ref-type="supplementary-material">Online Methods</xref>)&#8212;corrected for most observed discrepancies, including variables not used in weighting. Three notable discrepancies remained. First, the weights improve but do not fully correct for the underrepresentation of retired individuals. Second, weights do not correct for the overrepresentation of unemployed, on leave, and disabled individuals. Third, individuals with diagnosed hypertension are underrepresented while those with diabetes are slightly overrepresented (<xref rid="pgaf295-B61" ref-type="bibr">61</xref>).</p></sec><sec id="pgaf295-s2.5"><title>ALiR's representation vs. convenience-based cohorts</title><p>To evaluate improvement in representation, we compared ALiR's unweighted sample to two comparison cohorts that isolate benefits from different aspects of our approach. (i) UAS-BYOD, a sample of wearable owners within the UAS probability sample, is used to assess the impact of hardware provisioning vs. BYOD (Fig. <xref rid="pgaf295-F4" ref-type="fig">4</xref>, Tables <xref rid="sup1" ref-type="supplementary-material">S10</xref> and <xref rid="sup1" ref-type="supplementary-material">S11</xref>). (ii) <italic toggle="yes">AoU</italic>'s BYOD, a clinical convenience sample of Fitbit owners, is used to assess the combined benefits of probability sampling and hardware provisioning (Table <xref rid="sup1" ref-type="supplementary-material">S12</xref>).</p><p>Compared with population norms, UAS-BYOD (<italic toggle="yes">n</italic> = 1,631) significantly underrepresented individuals who are: (i) male by 32%; (ii) Black by 48%; (iii) Asian by 29%; (iv) American Indian, Alaska Native, Hawaiian, and Pacific Islander by 36%; (v) Hispanic/Latino by 19%; (vi) older adult by 15%; (vii) without bachelor's degree by 33%; (viii) unemployed by 18%; (ix) with household income &lt;$30&#8197;K by 49%; (x) with household income between $30 and 60&#8197;K by 30%; (xi) without UAS-provided Internet access by 85%; and (xii) living in rural areas by 23%. The UAS-BYOD sample would also significantly underrepresent people with diagnosed chronic conditions (obesity, hypertension, lung disease, and stroke), functional limitations, and with poorer overall health, cognitive function, health utilization, health behaviors, financial literacy, and digital competencies.</p><p>AoU's BYOD Fitbit dataset (<italic toggle="yes">n</italic> = 14,133) underrepresented males by 41%, non-White participants by 66%, individuals without bachelor's degrees by 57%, and individuals with household incomes &lt;$75&#8197;K by 29% compared to population norms.</p></sec><sec id="pgaf295-s2.6"><title>Generalizability of models trained on unweighted ALiR vs. BYOD</title><p>To illustrate ALiR's generalizability compared with <italic toggle="yes">AoU</italic>-Fitbit BYOD, respective classification models of COVID-19 infection were trained on each (unweighted) dataset (Fig. <xref rid="pgaf295-F5" ref-type="fig">5</xref>A; <xref rid="sup1" ref-type="supplementary-material">Online Methods</xref>). COVID-19 was chosen due to: (i) comparability of available variables across datasets; (ii) model robustness in the evidence base (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>); (iii) timeliness and relevance of respiratory infectious disease to the general population; and (iv) known symptom heterogeneities and racial/ethnic disparities in outcomes (<xref rid="pgaf295-B6" ref-type="bibr">6</xref>, <xref rid="pgaf295-B31" ref-type="bibr">31</xref>, <xref rid="pgaf295-B32" ref-type="bibr">32</xref>). Drawing on published models (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>), identical methods were used for data curation, training, and hyperparameter tuning. XGBoost was chosen as the best performing model (area under the curve; AUC) for both datasets. Performance was compared in (ALiR model on ALiR holdout data; <italic toggle="yes">AoU</italic> on <italic toggle="yes">AoU</italic>) and out of sample (ALiR model on <italic toggle="yes">AoU</italic> data, <italic toggle="yes">AoU</italic> model on ALiR data), overall, and for subgroups defined by intersections of race/ethnicity, age, and sex.</p><fig position="float" id="pgaf295-F5" fig-type="figure" orientation="portrait"><label>Fig. 5.</label><caption><p>Generalizability of COVID-19 classification model performance using ALiR vs. <italic toggle="yes">AoU</italic> datasets: A) Schematic representation of COVID-19 classification model training and testing procedure for ALiR (green) and AoU (orange) datasets. COVID-19-positive cases = COVID+; COVID-19-negative cases = COVID&#8722;. B) Sample composition of ALiR (unweighted) and AoU datasets. C) Overall COVID-19 classification model performance (area under curve; AUC) in-sample (ALiR-trained on ALiR holdout data: light green and AoU-trained on AoU holdout data: light orange) and out of sample (ALiR-trained on AoU data: dark green and AoU-trained on ALiR data: dark orange). D) Out-of-sample COVID-19 classification model performance (AUC) for sociodemographic subgroups for ALiR-trained model tested on AoU data (green) and AoU-trained model tested on ALiR data (orange).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pgaf295f5.jpg"/></fig><p>During curation, ALiR's COVID-19 dataset retained 71% of its initial sample vs. <italic toggle="yes">AoU</italic>'s 7%. Demographic distributions, representative for ALiR vs. primarily female, higher-educated, and White for <italic toggle="yes">AoU</italic> (Fig. <xref rid="pgaf295-F5" ref-type="fig">5</xref>B; Table <xref rid="sup1" ref-type="supplementary-material">S13</xref>), remained largely consistent between initial and training samples for both datasets. The prevalence of COVID-19 cases was higher in ALiR (27 vs. 8%), leading to comparable positive training samples (<italic toggle="yes">n</italic> = 181 vs. 237) despite the 14&#215; difference in initial sample size.</p><p>ALiR-trained classification performed equally well when tested in (AUC = 0.84, 95% CI: 0.79&#8211;0.89) and out of sample, both overall (AUC = 0.84, 95% CI: 0.78&#8211;0.89; Fig. <xref rid="pgaf295-F5" ref-type="fig">5</xref>C) and for subgroups (AUC = 0.82&#8211;1.0; Fig. <xref rid="pgaf295-F5" ref-type="fig">5</xref>D). Conversely, while overall <italic toggle="yes">AoU</italic>-trained classification performed marginally better in sample (AUC = 0.93, 95% CI: 0.91&#8211;0.96), it underperformed by 35% (vs. in sample) when tested on ALiR (AUC = 0.68, 95% CI: 0.61&#8211;0.75). Further, <italic toggle="yes">AoU</italic>'s performance was worse in historically underserved groups (Table <xref rid="sup1" ref-type="supplementary-material">S14</xref>), including older White females (by 40%, despite also having the largest representation in <italic toggle="yes">AoU</italic>'s training dataset) and non-White individuals (by 22&#8211;37%) compared with White males (by 17&#8211;20%) and younger White females (by 14%).</p></sec></sec><sec sec-type="discussion" id="pgaf295-s3"><title>Discussion</title><p>To the best of our knowledge, ALiR is the first longitudinal population study that combines wearable PGHD with comprehensive, frequently repeated, validated labels, meeting all relevant benchmarking criteria for precision health research (<xref rid="pgaf295-B15" ref-type="bibr">15</xref> , <xref rid="pgaf295-B16" ref-type="bibr">16</xref>, <xref rid="pgaf295-B36" ref-type="bibr">36</xref>, <xref rid="pgaf295-B62" ref-type="bibr">62&#8211;64</xref>). With only two observed sources of differential enrollment (identified from 5,000+ variables), ALiR's 1,038 participants were broadly representative across demographic, socioeconomic, and health factors, a significant improvement in inclusivity over convenience samples. ALiR's illustrative COVID-19 model (AUC = 0.84) matched or exceeded in-sample performance of others (AUC = 0.52&#8211;0.92) (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>) and maintained effectiveness when tested out of sample and in diverse sociodemographic groups. ALiR's model used a similar number of positive COVID-19 training cases as <italic toggle="yes">AoU</italic> and other models despite having a 10&#8211;100&#215; smaller initial sample (<xref rid="pgaf295-B3" ref-type="bibr">3&#8211;8</xref>), due to higher (and more consistent with population estimates (<xref rid="pgaf295-B65" ref-type="bibr">65</xref>)) disease prevalence and curation-related case retention. In contrast, <italic toggle="yes">AoU</italic>'s BYOD model significantly underperformed on ALiR data, with 22&#8211;40% worse performance in older female and non-White groups. Surprisingly, <italic toggle="yes">AoU</italic>'s performance was weakest in its largest training subgroup, likely due to diminished diversity of healthcare-engaged device owners relative to the within-group general population on other dimensions (e.g. education, income, comorbidity, and vaccination) (<xref rid="pgaf295-B66" ref-type="bibr">66</xref>). These results suggest that for promoting model generalizability, smaller samples of high-quality, representative data can outperform large convenience samples, as the latter, due to selection effects, may fail to adequately capture the diversity of observed and unobserved characteristics in the target population (<xref rid="pgaf295-B67" ref-type="bibr">67&#8211;69</xref>). While COVID-19 represents a single conceptual demonstration, its significance as an infectious pandemic that transcended worldwide sociodemographic boundaries is especially pertinent. ALiR's ability to account for heterogeneity in COVID-19 dynamics showcases its potential for improving equity in health applications that have previously suffered from disparities (<xref rid="pgaf295-B6" ref-type="bibr">6</xref>, <xref rid="pgaf295-B31" ref-type="bibr">31</xref>, <xref rid="pgaf295-B32" ref-type="bibr">32</xref>). The focus on COVID-19 was further dictated by the availability of analogous data, underscoring the field-wide need for more comprehensive datasets with standardized variables to explore drivers of equitable model performance in different health applications. To that end, probability sampling, hardware provisioning, and strategic oversampling were each critical to ALiR's benchmarking ability, providing a roadmap for inclusive prospective data collection that enhances model generalizability.</p><p>Probability sampling of US addresses promoted broad, balanced representation in ALiR's invited sample and minimized expected sources of selection bias (<xref rid="pgaf295-B17" ref-type="bibr">17</xref>, <xref rid="pgaf295-B39" ref-type="bibr">39</xref>). In contrast, studies that recruit from clinical encounters (e.g. UK Biobank, <italic toggle="yes">AoU</italic>) are more likely to underrepresent people experiencing healthcare access barriers, who also tend to be non-White, under-resourced, and/or of poorer health (<xref rid="pgaf295-B17" ref-type="bibr">17&#8211;20</xref>, <xref rid="pgaf295-B70" ref-type="bibr">70</xref>, <xref rid="pgaf295-B71" ref-type="bibr">71</xref>). Further, probability sampling likely better accounted for unobserved factors (<xref rid="pgaf295-B66" ref-type="bibr">66</xref>, <xref rid="pgaf295-B72" ref-type="bibr">72</xref>, <xref rid="pgaf295-B73" ref-type="bibr">73</xref>), leading to ALiR's stronger performance on nonrepresentative data and <italic toggle="yes">AoU</italic>'s poorer performance on representative data, even within larger subgroups. This suggests that in the context of convenience samples, use of subgroup targets and geography-based recruitment to achieve cohort inclusivity, as in AoU 's sampling approach (<xref rid="pgaf295-B18" ref-type="bibr">18</xref>), may be insufficient for model generalizability.</p><p>Universal Fitbit provisioning enabled invited individuals to remain eligible regardless of self-motivated technology access, which minimized differential enrollment and preserved inclusivity of the probability sample. ALiR's experience suggested that 64% of invited individuals were willing to participate, though only 23% of enrollees owned a wearable at the time, consistent with a recent study suggesting cost and device-related education gaps explained a similar discrepancy in federally qualified health center patients (58 vs. 20%) (<xref rid="pgaf295-B25" ref-type="bibr">25</xref>). It is not surprising then, that BYOD designs have systematically underrepresented populations experiencing health disparities (<xref rid="pgaf295-B21" ref-type="bibr">21</xref>). Indeed, had ALiR relied on UAS device owners, the invited sample would have substantially underrepresented people of color, older adults (<xref rid="pgaf295-B22" ref-type="bibr">22&#8211;25</xref>), those with lower income or education, and those with poorer internet literacy, financial literacy, health, and cognitive ability&#8212;disparities that would likely grow along age, education, and associated dimensions during enrollment. <italic toggle="yes">AoU</italic>'s BYOD Fitbit cohort was even less representative, highlighting the compounding effect of combining convenience sampling methods.</p><p>Strategic oversampling, on one hand, led to overrepresentation of racial/ethnic minorities and socioeconomically disadvantaged individuals&#8212;who did not exhibit lower consent or enrollment compared with their counterparts&#8212;in ALiR's unweighted cohort. On the other, oversampling counterbalanced relatively poorer enrollment rates in individuals with lower education who were equally <italic toggle="yes">willing to participate but faced barriers</italic> beyond device access after consenting. Address confirmation and recurring unavailability to sign for packages were the top reasons for loss to follow-up, which may reflect greater housing instability or time pressures within this population (<xref rid="pgaf295-B74" ref-type="bibr">74</xref>). Remote recruitment is a primary strategy in large-scale PGHD research, and planned investigations will elucidate how enrollment steps may inadvertently introduce additional barriers in underserved populations.</p><p>Older adults were the only underserved or disparity-facing group also underrepresented in ALiR's unweighted cohort as we did not anticipate their relative <italic toggle="yes">unwillingness to participate</italic> despite Fitbit provisioning. This disparity, apparent even after controlling for many other age-related factors (employment, income, cognitive ability, chronic disease, disability, Internet skills, etc.), is consistent with the BYOD literature (<xref rid="pgaf295-B22" ref-type="bibr">22</xref>). Again, barriers beyond device access are likely involved, including mistrust of, disinterest in, or lack of perceived benefit from using wearables or participating in wearable studies (<xref rid="pgaf295-B33" ref-type="bibr">33&#8211;35</xref>). Facing a globally aging population, precision health offers an important opportunity to support older adult health and well-being (e.g. PGHD-based detection of depression (<xref rid="pgaf295-B75" ref-type="bibr">75</xref>), cognitive decline and dementia (<xref rid="pgaf295-B76" ref-type="bibr">76</xref>, <xref rid="pgaf295-B77" ref-type="bibr">77</xref>), and falls (<xref rid="pgaf295-B78" ref-type="bibr">78</xref>)), but systematically improving their research participation must be a priority. As we grow ALiR's cohort to &#8764;10,000 members by 2027 alongside UAS's ongoing expansion, we will continue to characterize and quantify the mechanisms driving differential study participation to maintain and refine inclusivity. Potential interventions include: (i) oversampling older adults in future recruitment; (ii) strategically inviting preexisting UAS device owners; and (iii) employing evidence-based strategies like community-based participation efforts that improve trust, education, and engagement in minoritized and/or underrepresented communities (<xref rid="pgaf295-B79" ref-type="bibr">79&#8211;81</xref>).</p><p>This study is not without limitations. First, we focus on consent and enrollment; longitudinal engagement&#8212;the third component of participation&#8212;is the subject of ongoing work. Second, while ALiR substantially improves representativeness relative to existing PGHD cohorts, some selection biases remain. Weighting did not fully correct underrepresentation among older adults not in the labor force (e.g. retired, unemployed, on leave, or disabled), highlighting the potential for residual bias from unobserved factors, despite extensive coverage of observed characteristics. Third, while our illustrative COVID-19 model demonstrates promise for improved generalizability, it represents a single example. Future work will assess model performance across additional health domains.</p><p>Collectively, ALiR provides the scientific community with a public benchmarking toolkit: a methodological framework and connected cohort for prospective research, and an inclusive dataset for training and validating generalizable precision health models in diverse populations.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>pgaf295_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pgaf295_supplementary_data.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>The authors are grateful to UAS-ALiR participants who agreed to contribute their time and digital data for research. The authors acknowledge Luca Foschini and thank Ernesto Ramirez and Evidation Health, Inc. for their collaboration in securing funding and designing and building the study app. In addition, we gratefully acknowledge <italic toggle="yes">All of Us</italic> participants for their contributions, without whom this research would not have been possible. We also thank the National Institutes of Health&#8217;s <italic toggle="yes">All of Us</italic> Research Program for making available the participant data examined in this study.</p></ack><sec id="pgaf295-s4"><title>Supplementary Material</title><p>Supplementary material is available at <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">PNAS Nexus</xref></italic> online.</p></sec><sec id="pgaf295-s5"><title>Funding</title><p>This work was funded by a grant from the National Library of Medicine at the National Institutes of Health awarded to R.R.C. (R01LM013237). ALiR relies on the Understanding America Study (supported by the Social Security Administration and the National Institute on Aging at the National Institutes of Health: U01AG054580), which is maintained by the Center for Economic and Social Research (CESR) at the University of Southern California. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The <italic toggle="yes">All of Us</italic> Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276.</p></sec><sec id="pgaf295-s6"><title>Author Contributions</title><p>Ritika R. Chaturvedi (Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing&#8212;original draft, Writing&#8212;review &amp; editing), Marco Angrisani (Data curation, Formal analysis, Methodology, Writing&#8212;original draft, Writing&#8212;review &amp; editing), Wendy M. Troxel (Funding acquisition, Writing&#8212;review &amp; editing), Monika Jain (Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing&#8212;review &amp; editing), Tania Gutsche (Data curation, Funding acquisition, Methodology, Project administration, Resources, Writing&#8212;review &amp; editing), Eva Ortega (Data curation, Project administration), Adrien Boch (Data curation, Project Administration), Citina Liang (Data curation, Formal analysis), Shiyang Sima (Data curation, Formal analysis), Aziz Mezlini (Data curation, Formal analysis, Writing&#8212;review &amp; editing), Eric J. Daza (Data curation, Formal analysis, Writing&#8212;review &amp; editing), Miad Boodaghidizaji (Data curation, Formal analysis), Sze-chuan Suen (Formal analysis, Methodology, Supervision; Writing&#8212;review &amp; editing), Alok R. Chaturvedi (Methodology, Supervision, Writing&#8212;review &amp; editing), Hossein Ghasemkhani (Methodology, Supervision, Writing&#8212;review &amp; editing), Arezoo M. Ardekani (Methodology, Supervision, Writing&#8212;review &amp; editing), and Arie Kapteyn (Funding acquisition, Methodology, Resources, Writing&#8212;review &amp; editing).</p></sec><sec sec-type="data-availability" id="pgaf295-s7"><title>Data Availability</title><p>As UAS makes deidentified study data available to registered researchers (who sign the Data Use Agreement), ALiR PGHD will be available upon curation of one full year of data for the entire panel (anticipated in late 2025) and will be updated frequently thereafter. This will include additional study information, such as data dictionaries, protocols, informed consent documentation, and app code. COVID modeling code developed for this study is also available. All above information can be obtained from the UAS website at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://uasdata.usc.edu/" ext-link-type="uri">https://uasdata.usc.edu/</ext-link>. A portion of this work relies on data from the <italic toggle="yes">All of Us</italic> Research Program; data and relevant analysis code are available to select US universities on the Researcher Workbench (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.researchallofus.org/data-tools/workbench/" ext-link-type="uri">https://www.researchallofus.org/data-tools/workbench/</ext-link>).</p></sec><ref-list id="ref1"><title>References</title><ref id="pgaf295-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Collins</surname> &#160;<given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Varmus</surname> &#160;<given-names>H</given-names></string-name></person-group>. <year>2015</year>. <article-title>A new initiative on precision medicine.</article-title> &#160;<source>N Engl J Med.</source> &#160;<volume>372</volume>(<issue>9</issue>):<fpage>793</fpage>&#8211;<lpage>795</lpage>.<pub-id pub-id-type="pmid">25635347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp1500523</pub-id><pub-id pub-id-type="pmcid">PMC5101938</pub-id></mixed-citation></ref><ref id="pgaf295-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khoury</surname> &#160;<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Galea</surname> &#160;<given-names>S</given-names></string-name></person-group>. <year>2016</year>. <article-title>Will precision medicine improve population health?</article-title> &#160;<source>JAMA</source>. <volume>316</volume>(<issue>13</issue>):<fpage>1357</fpage>&#8211;<lpage>1358</lpage>.<pub-id pub-id-type="pmid">27541310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.12260</pub-id><pub-id pub-id-type="pmcid">PMC6359904</pub-id></mixed-citation></ref><ref id="pgaf295-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jenkins</surname> &#160;<given-names>T</given-names></string-name></person-group>. <year>2022</year>. <article-title>Wearable medical sensor devices, machine and deep learning algorithms, and internet of things-based healthcare systems in COVID-19 patient screening, diagnosis, monitoring, and treatment.</article-title> &#160;<source>Am J Med Res</source>. <volume>9</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>64</lpage>.</mixed-citation></ref><ref id="pgaf295-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Conroy</surname> &#160;<given-names>B</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Real-time infection prediction with wearable physiological monitoring and AI to aid military workforce readiness during COVID-19</article-title>. <source>Sci Rep</source>. <volume>12</volume>(<issue>1</issue>):<fpage>3797</fpage>.<pub-id pub-id-type="pmid">35260671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-07764-6</pub-id><pub-id pub-id-type="pmcid">PMC8904796</pub-id></mixed-citation></ref><ref id="pgaf295-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Radin</surname> &#160;<given-names>JM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Sensor-based surveillance for digitising real-time COVID-19 tracking in the USA (DETECT): a multivariable, population-based, modelling study</article-title>. <source>Lancet Digit Health</source>. <volume>4</volume>(<issue>11</issue>):<fpage>e777</fpage>&#8211;<lpage>e786</lpage>.<pub-id pub-id-type="pmid">36154810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2589-7500(22)00156-X</pub-id><pub-id pub-id-type="pmcid">PMC9499390</pub-id></mixed-citation></ref><ref id="pgaf295-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitratza</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review</article-title>. <source>Lancet Digit Health</source>. <volume>4</volume>(<issue>5</issue>):<fpage>e370</fpage>&#8211;<lpage>e383</lpage>.<pub-id pub-id-type="pmid">35461692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2589-7500(22)00019-X</pub-id><pub-id pub-id-type="pmcid">PMC9020803</pub-id></mixed-citation></ref><ref id="pgaf295-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quer</surname> &#160;<given-names>G</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <article-title>Wearable sensor data and self-reported symptoms for COVID-19 detection</article-title>. <source>Nat Med</source>. <volume>27</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">33122860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1123-x</pub-id></mixed-citation></ref><ref id="pgaf295-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alavi</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Real-time alerting system for COVID-19 and other stress events using wearable data</article-title>. <source>Nat Med</source>. <volume>28</volume>(<issue>1</issue>):<fpage>175</fpage>&#8211;<lpage>184</lpage>.<pub-id pub-id-type="pmid">34845389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01593-2</pub-id><pub-id pub-id-type="pmcid">PMC8799466</pub-id></mixed-citation></ref><ref id="pgaf295-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gambhir</surname> &#160;<given-names>SS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2018</year>. <article-title>Toward achieving precision health.</article-title> &#160;<source>Sci Transl Med.</source> &#160;<volume>10</volume>(<issue>430</issue>):<fpage>eaao3612</fpage>.<pub-id pub-id-type="pmid">29491186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aao3612</pub-id><pub-id pub-id-type="pmcid">PMC5985668</pub-id></mixed-citation></ref><ref id="pgaf295-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jim</surname> &#160;<given-names>HS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <article-title>Innovations in research and clinical care using patient-generated health data.</article-title> &#160;<source>CA Cancer J Clin.</source> &#160;<volume>70</volume>(<issue>3</issue> ):<fpage>182</fpage>&#8211;<lpage>199</lpage>.<pub-id pub-id-type="pmid">32311776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21608</pub-id><pub-id pub-id-type="pmcid">PMC7488179</pub-id></mixed-citation></ref><ref id="pgaf295-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marmot</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Friel</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Houweling</surname> &#160;<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname> &#160;<given-names>S</given-names></string-name>, <collab>Commission on Social Determinants of Health</collab></person-group>. <year>2008</year>. <article-title>Closing the gap in a generation: health equity through action on the social determinants of health</article-title>. <source>Lancet</source>. <volume>372</volume>(<issue>9650</issue>):<fpage>1661</fpage>&#8211;<lpage>1669</lpage>.<pub-id pub-id-type="pmid">18994664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)61690-6</pub-id></mixed-citation></ref><ref id="pgaf295-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hood</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Gennuso</surname> &#160;<given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Swain</surname> &#160;<given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Catlin</surname> &#160;<given-names>BB</given-names></string-name></person-group>. <year>2016</year>. <article-title>County health rankings: relationships between determinant factors and health outcomes</article-title>. <source>Am J Prev Med.</source> &#160;<volume>50</volume>(<issue>2</issue>):<fpage>129</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="pmid">26526164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2015.08.024</pub-id></mixed-citation></ref><ref id="pgaf295-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bradley</surname> &#160;<given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Elkins</surname> &#160;<given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Herrin</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Elbel</surname> &#160;<given-names>B</given-names></string-name></person-group>. <year>2011</year>. <article-title>Health and social services expenditures: associations with health outcomes</article-title>. <source>BMJ Qual Saf Health Care</source>. <volume>20</volume>(<issue>10</issue>):<fpage>826</fpage>&#8211;<lpage>831</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjqs.2010.048363</pub-id><pub-id pub-id-type="pmid">21447501</pub-id></mixed-citation></ref><ref id="pgaf295-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galea</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abdalla</surname> &#160;<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Sturchio</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <year>2020</year>. <article-title>Social determinants of health, data science, and decision-making: forging a transdisciplinary synthesis.</article-title> &#160;<source>PLoS Med.</source> &#160;<volume>17</volume>(<issue>6</issue>):<fpage>e100317</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003174</pub-id><pub-id pub-id-type="pmcid">PMC7289342</pub-id><pub-id pub-id-type="pmid">32525875</pub-id></mixed-citation></ref><ref id="pgaf295-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="curator"><string-name name-style="western"><surname>Panch</surname> &#160;<given-names>T</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <data-title>Yes, but will it work for my patients?&#8221; Driving clinically relevant research with benchmark datasets</data-title>. <source>NPJ Digit Med</source>. <volume>3</volume>:<fpage>87</fpage>.<pub-id pub-id-type="pmid">32577534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-020-0295-6</pub-id><pub-id pub-id-type="pmcid">PMC7305156</pub-id></mixed-citation></ref><ref id="pgaf295-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mincu</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname> &#160;<given-names>S</given-names></string-name></person-group>. <year>2022</year>. <article-title>Developing robust benchmarks for driving forward AI innovation in healthcare.</article-title> &#160;<source>Nat Mach Intell.</source> &#160;<volume>4</volume>(<issue>11</issue>):<fpage>916</fpage>&#8211;<lpage>921</lpage>.</mixed-citation></ref><ref id="pgaf295-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brayne</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moffitt</surname> &#160;<given-names>TE</given-names></string-name></person-group>. <year>2022</year>. <article-title>The limitations of large-scale volunteer databases to address inequalities and global challenges in health and aging</article-title>. <source>Nat Aging.</source> &#160;<volume>2</volume>(<issue>9</issue>):<fpage>775</fpage>&#8211;<lpage>783</lpage>.<pub-id pub-id-type="pmid">37118500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-022-00277-x</pub-id><pub-id pub-id-type="pmcid">PMC10154032</pub-id></mixed-citation></ref><ref id="pgaf295-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramirez</surname> &#160;<given-names>AH</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>The All of Us Research Program: data quality, utility, and diversity.</article-title> &#160;<source>Patterns</source>. <volume>3</volume>(<issue>8</issue>):<fpage>100570</fpage>.<pub-id pub-id-type="pmid">36033590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.patter.2022.100570</pub-id><pub-id pub-id-type="pmcid">PMC9403360</pub-id></mixed-citation></ref><ref id="pgaf295-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname> &#160;<given-names>JY</given-names></string-name></person-group>. <year>2021</year>. <article-title>Representativeness is not representative: addressing major inferential threats in the UK Biobank and other big data repositories.</article-title> &#160;<source>Epidemiology</source>. <volume>32</volume>(<issue>2</issue>):<fpage>189</fpage>&#8211;<lpage>193</lpage>.<pub-id pub-id-type="pmid">33323747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/EDE.0000000000001317</pub-id></mixed-citation></ref><ref id="pgaf295-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sudlow</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2015</year>. <article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>. <source>PLoS Med</source>. <volume>12</volume>(<issue>3</issue>):<fpage>e1001779</fpage>.<pub-id pub-id-type="pmid">25826379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001779</pub-id><pub-id pub-id-type="pmcid">PMC4380465</pub-id></mixed-citation></ref><ref id="pgaf295-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname> &#160;<given-names>PJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Demographic imbalances resulting from the bring-your-own-device study design.</article-title> &#160;<source>JMIR Mhealth Uhealth.</source> &#160;<volume>10</volume>(<issue>4</issue>):<fpage>e29510</fpage>.<pub-id pub-id-type="pmid">34913871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/29510</pub-id><pub-id pub-id-type="pmcid">PMC9034431</pub-id></mixed-citation></ref><ref id="pgaf295-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pratap</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <article-title>Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants</article-title>. <source>NPJ Digit Med.</source> &#160;<volume>3</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">32128451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-020-0224-8</pub-id><pub-id pub-id-type="pmcid">PMC7026051</pub-id></mixed-citation></ref><ref id="pgaf295-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chandrasekaran</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Katthula</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Moustakas</surname> &#160;<given-names>E</given-names></string-name></person-group>. <year>2020</year>. <article-title>Patterns of use and key predictors for the use of wearable health care devices by US adults: insights from a national survey.</article-title> &#160;<source>J Med Internet Res.</source> &#160;<volume>22</volume>(<issue>10</issue>):<fpage>e22443</fpage>.<pub-id pub-id-type="pmid">33064083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/22443</pub-id><pub-id pub-id-type="pmcid">PMC7600024</pub-id></mixed-citation></ref><ref id="pgaf295-B24"><label>24</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Holko</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> 2020. Fitbit &#8220;Bring Your Own Device&#8221; data in the All of Us Research Program. AMIA Annual Meeting, Virtual, USA. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://knowledge.amia.org/72332-amia-1.4602255/t004-1.4605866/t004-1.4605867/3414532-1.4606075/3414532-1.4606076?qr=1" ext-link-type="uri">https://knowledge.amia.org/72332-amia-1.4602255/t004-1.4605866/t004-1.4605867/3414532-1.4606075/3414532-1.4606076?qr=1</ext-link></mixed-citation></ref><ref id="pgaf295-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Holko</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Wearable fitness tracker use in federally qualified health center patients: strategies to improve the health of all of us using digital health devices.</article-title> &#160;<source>NPJ Digit Med.</source> &#160;<volume>5</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">35469045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00593-x</pub-id><pub-id pub-id-type="pmcid">PMC9038923</pub-id></mixed-citation></ref><ref id="pgaf295-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schiebinger</surname> &#160;<given-names>L</given-names></string-name></person-group>. <year>2018</year>. <article-title>AI can be sexist and racist&#8212;It's time to make it fair</article-title>. <source>Nature</source>. <volume>559</volume>:<fpage>324</fpage>&#8211;<lpage>326</lpage>.<pub-id pub-id-type="pmid">30018439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-018-05707-8</pub-id></mixed-citation></ref><ref id="pgaf295-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Galal</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Etemadi</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vaidyanathan</surname> &#160;<given-names>M.</given-names></string-name></person-group> &#160;<year>2022</year>. <article-title>Evaluation and mitigation of racial bias in clinical machine learning models: scoping review</article-title>. <source>JMIR Medical Informatics</source>. <volume>10</volume>(<issue>5</issue>):<fpage>e36388</fpage>.<pub-id pub-id-type="pmid">35639450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/36388</pub-id><pub-id pub-id-type="pmcid">PMC9198828</pub-id></mixed-citation></ref><ref id="pgaf295-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="curator"><string-name name-style="western"><surname>Larrazabal</surname> &#160;<given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <data-title>Gender imbalance in medical imaging datasets produces biased classifiers for computer-aided diagnosis.</data-title> &#160;<source>Proc Natl Acad Sci U S A</source>. <volume>117</volume>(<issue>23</issue>):<fpage>12592</fpage>&#8211;<lpage>12594</lpage>.<pub-id pub-id-type="pmid">32457147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1919012117</pub-id><pub-id pub-id-type="pmcid">PMC7293650</pub-id></mixed-citation></ref><ref id="pgaf295-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Obermeyer</surname> &#160;<given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2019</year>. <article-title>Dissecting racial bias in an algorithm used to manage the health of populations.</article-title> &#160;<source>Science</source>. <volume>366</volume>(<issue>6464</issue>):<fpage>447</fpage>&#8211;<lpage>453</lpage>.<pub-id pub-id-type="pmid">31649194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aax2342</pub-id></mixed-citation></ref><ref id="pgaf295-B30"><label>30</label><mixed-citation publication-type="book"><comment>National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Bibbins-Domingo K, Helman A, editors.</comment> &#160;<source>Improving representation in clinical trials and research: building research equity for women and underrepresented groups</source>. <publisher-name>Washington (DC): National Academies Press</publisher-name>, <publisher-loc>US</publisher-loc>, <year>2022</year>.<pub-id pub-id-type="pmid">36137057</pub-id></mixed-citation></ref><ref id="pgaf295-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mackey</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <article-title>Racial and ethnic disparities in COVID-19&#8211;related infections, hospitalizations, and deaths: a systematic review.</article-title> &#160;<source>Ann Intern Med.</source> &#160;<volume>174</volume>(<issue>3</issue>):<fpage>362</fpage>&#8211;<lpage>373</lpage>.<pub-id pub-id-type="pmid">33253040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-6306</pub-id><pub-id pub-id-type="pmcid">PMC7772883</pub-id></mixed-citation></ref><ref id="pgaf295-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Green</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>MacPhail</surname> &#160;<given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>The social determinants of health and health outcomes among adults during the COVID-19 pandemic: a systematic review.</article-title> &#160;<source>Public Health Nurs</source>. <volume>38</volume>(<issue>6</issue>):<fpage>942</fpage>&#8211;<lpage>952</lpage>.<pub-id pub-id-type="pmid">34403525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/phn.12959</pub-id><pub-id pub-id-type="pmcid">PMC8446962</pub-id></mixed-citation></ref><ref id="pgaf295-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grande</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Consumer willingness to share personal digital information for health-related uses</article-title>. <source>JAMA Netw Open.</source> &#160;<volume>5</volume>(<issue>1</issue>):<fpage>e2144787</fpage>&#8211;<lpage>e2144787</lpage>.<pub-id pub-id-type="pmid">35072717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.44787</pub-id><pub-id pub-id-type="pmcid">PMC8787615</pub-id></mixed-citation></ref><ref id="pgaf295-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grande</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mitra</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Asch</surname> &#160;<given-names>DA</given-names></string-name></person-group>. <year>2013</year>. <article-title>Public preferences about secondary uses of electronic health information</article-title>. <source>JAMA Intern Med.</source> &#160;<volume>173</volume>(<issue>19</issue>):<fpage>1798</fpage>&#8211;<lpage>1806</lpage>.<pub-id pub-id-type="pmid">23958803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2013.9166</pub-id><pub-id pub-id-type="pmcid">PMC4083587</pub-id></mixed-citation></ref><ref id="pgaf295-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grande</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <article-title>Health policy and privacy challenges associated with digital technology</article-title>. <source>JAMA Netw Open.</source> &#160;<volume>3</volume>(<issue>7</issue>):<fpage>e208285</fpage>&#8211;<lpage>e208285</lpage>.<pub-id pub-id-type="pmid">32644138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.8285</pub-id><pub-id pub-id-type="pmcid">PMC7348687</pub-id></mixed-citation></ref><ref id="pgaf295-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chaturvedi</surname> &#160;<given-names>RR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2023</year>. <article-title>American Life in Realtime: a benchmark registry of health data for equitable precision health</article-title>. <source>Nat Med</source>. <volume>29</volume>:<fpage>283</fpage>&#8211;<lpage>286</lpage>.<pub-id pub-id-type="pmid">36737671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02171-w</pub-id><pub-id pub-id-type="pmcid">PMC9974879</pub-id></mixed-citation></ref><ref id="pgaf295-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fuezeki</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Engeroff</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Banzer</surname> &#160;<given-names>W</given-names></string-name></person-group>. <year>2017</year>. <article-title>Health benefits of light-intensity physical activity: a systematic review of accelerometer data of the National Health and Nutrition Examination Survey (NHANES).</article-title> &#160;<source>Sports Med</source>. <volume>47</volume>(<issue>9</issue>):<fpage>1769</fpage>&#8211;<lpage>1793</lpage>.<pub-id pub-id-type="pmid">28393328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40279-017-0724-0</pub-id></mixed-citation></ref><ref id="pgaf295-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilkinson</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2016</year>. <article-title>The FAIR guiding principles for scientific data management and stewardship</article-title>. <source>Sci Data.</source> &#160;<volume>3</volume>:<fpage>160018</fpage>.<pub-id pub-id-type="pmid">26978244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2016.18</pub-id><pub-id pub-id-type="pmcid">PMC4792175</pub-id></mixed-citation></ref><ref id="pgaf295-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alattar</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Messel</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rogofsky</surname> &#160;<given-names>D</given-names></string-name></person-group>. <year>2018</year>. <article-title>An introduction to the understanding America study internet panel</article-title>. <source>Soc Sec Bull.</source> &#160;<volume>78</volume>:<fpage>13</fpage>.</mixed-citation></ref><ref id="pgaf295-B40"><label>40</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Understanding America Study. Center for Economic and Social Research. University of Southern California</collab></person-group>. Details, methods, protocols, data, and data dictionaries [accessed 2025 Jan]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://uasdata.usc.edu/" ext-link-type="uri">https://uasdata.usc.edu/</ext-link></mixed-citation></ref><ref id="pgaf295-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sziagyi</surname> &#160;<given-names>PG</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <article-title>National trends in the US public's likelihood of getting a COVID-19 vaccine&#8212;April 1 to December 8, 2020.</article-title> &#160;<source>JAMA</source>. <volume>325</volume>(<issue>4</issue>):<fpage>396</fpage>&#8211;<lpage>398</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.26419</pub-id><pub-id pub-id-type="pmcid">PMC7772743</pub-id><pub-id pub-id-type="pmid">33372943</pub-id></mixed-citation></ref><ref id="pgaf295-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Samek</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kapteyn</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname> &#160;<given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>Using vignettes to improve understanding of social security and annuities.</article-title> &#160;<source>J Pension Econ Financ.</source> &#160;<volume>21</volume>(<issue>3</issue>):<fpage>326</fpage>&#8211;<lpage>343</lpage>.</mixed-citation></ref><ref id="pgaf295-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galesic</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2018</year>. <article-title>Asking about social circles improves election predictions</article-title>. <source>Nat Hum Behav.</source> &#160;<volume>2</volume>:<fpage>187</fpage>&#8211;<lpage>193</lpage>.</mixed-citation></ref><ref id="pgaf295-B44"><label>44</label><mixed-citation publication-type="data"><person-group person-group-type="curator"><string-name name-style="western"><surname>Flood</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <year>2024</year>. <data-title>Integrated Public Use Microdata Series, Current Population Survey: Version 12.0 [Dataset]</data-title>. <source>IPUMS</source>. <pub-id pub-id-type="doi">10.18128/D030.V12.0</pub-id></mixed-citation></ref><ref id="pgaf295-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sonnega</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2014</year>. <article-title>Cohort profile: the health and retirement study (HRS).</article-title> &#160;<source>Int J Epidemiol.</source> &#160;<volume>43</volume>(<issue>2</issue>):<fpage>576</fpage>&#8211;<lpage>585</lpage>.<pub-id pub-id-type="pmid">24671021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyu067</pub-id><pub-id pub-id-type="pmcid">PMC3997380</pub-id></mixed-citation></ref><ref id="pgaf295-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamilton</surname> &#160;<given-names>CM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2011</year>. <article-title>The PhenX Toolkit: get the most from your measures.</article-title> &#160;<source>Am J Epidemiol.</source> &#160;<volume>174</volume>(<issue>3</issue>):<fpage>253</fpage>&#8211;<lpage>260</lpage>.<pub-id pub-id-type="pmid">21749974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwr193</pub-id><pub-id pub-id-type="pmcid">PMC3141081</pub-id></mixed-citation></ref><ref id="pgaf295-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cella</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2010</year>. <article-title>The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005&#8211;2008.</article-title> &#160;<source>J Clin Epidemiol.</source> &#160;<volume>63</volume>(<issue>11</issue>):<fpage>1179</fpage>&#8211;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">20685078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2010.04.011</pub-id><pub-id pub-id-type="pmcid">PMC2965562</pub-id></mixed-citation></ref><ref id="pgaf295-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Y</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Self-administered web-based tests of executive functioning and perceptual speed: measurement development study with a large probability-based survey panel</article-title>. <source>J Med Internet Res</source>. <volume>24</volume>(<issue>5</issue>):<fpage>e34347</fpage>.<pub-id pub-id-type="pmid">35532966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/34347</pub-id><pub-id pub-id-type="pmcid">PMC9127643</pub-id></mixed-citation></ref><ref id="pgaf295-B49"><label>49</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>McArdle</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rodgers</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname> &#160;<given-names>R</given-names></string-name></person-group>. <source>Cognition and aging in the USA (CogUSA) 2007&#8211;2009</source>. <publisher-name>Inter-University Consortium for Political and Social Research</publisher-name>, <year>2015</year>.</mixed-citation></ref><ref id="pgaf295-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McArdle</surname> &#160;<given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>GG</given-names></string-name>, <string-name name-style="western"><surname>Kadlec</surname> &#160;<given-names>KM</given-names></string-name></person-group>. <year>2007</year>. <article-title>Latent variable analyses of age trends of cognition in the Health and Retirement Study, 1992&#8211;2004</article-title>. <source>Psychol Aging</source>. <volume>22</volume>(<issue>3</issue>):<fpage>525</fpage>&#8211;<lpage>545</lpage>.<pub-id pub-id-type="pmid">17874952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0882-7974.22.3.525</pub-id></mixed-citation></ref><ref id="pgaf295-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gatz</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2023</year>. <article-title>Identifying cognitive impairment among older participants in a nationally representative internet panel</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <volume>78</volume>(<issue>2</issue>):<fpage>201</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="pmid">36308489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/gbac172</pub-id><pub-id pub-id-type="pmcid">PMC9938921</pub-id></mixed-citation></ref><ref id="pgaf295-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sliwinski</surname> &#160;<given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2018</year>. <article-title>Reliability and validity of ambulatory cognitive assessments</article-title>. <source>Assessment</source>. <volume>25</volume>(<issue>1</issue>):<fpage>14</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">27084835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1073191116643164</pub-id><pub-id pub-id-type="pmcid">PMC5690878</pub-id></mixed-citation></ref><ref id="pgaf295-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thompson</surname> &#160;<given-names>LI</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>A highly feasible, reliable, and fully remote protocol for mobile app-based cognitive assessment in cognitively healthy older adults</article-title>. <source>Alzheimers Dement (Amst)</source>. <volume>14</volume>(<issue>1</issue>):<fpage>e12283</fpage>.<pub-id pub-id-type="pmid">35415201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12283</pub-id><pub-id pub-id-type="pmcid">PMC8984238</pub-id></mixed-citation></ref><ref id="pgaf295-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicosia</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2023</year>. <article-title>Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease</article-title>. <source>J Int Neuropsychol Soc</source>. <volume>29</volume>(<issue>5</issue>):<fpage>459</fpage>&#8211;<lpage>471</lpage>.<pub-id pub-id-type="pmid">36062528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S135561772200042X</pub-id><pub-id pub-id-type="pmcid">PMC9985662</pub-id></mixed-citation></ref><ref id="pgaf295-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cerino</surname> &#160;<given-names>ES</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <article-title>Variability in cognitive performance on Mobile devices is sensitive to mild cognitive impairment: results from the Einstein Aging Study</article-title>. <source>Front Digit Health</source>. <volume>3</volume>:<fpage>758031</fpage>.<pub-id pub-id-type="pmid">34927132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fdgth.2021.758031</pub-id><pub-id pub-id-type="pmcid">PMC8677835</pub-id></mixed-citation></ref><ref id="pgaf295-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oravecz</surname> &#160;<given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Accounting for retest effects in cognitive testing with the Bayesian double exponential model via intensive measurement burst designs</article-title>. <source>Front Aging Neurosci</source>. <volume>14</volume>:<fpage>897343</fpage>.<pub-id pub-id-type="pmid">36225891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.897343</pub-id><pub-id pub-id-type="pmcid">PMC9549774</pub-id></mixed-citation></ref><ref id="pgaf295-B57"><label>57</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Eaton</surname> &#160;<given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ybarra</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Muntaner</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tien</surname> &#160;<given-names>A</given-names></string-name></person-group>. <part-title>Center for epidemiologic studies depression scale: review and revision (CESD and CESD-R)</part-title>. <year>2004.</year> In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Maruish</surname> &#160;<given-names>ME</given-names></string-name></person-group>, <role>editor</role>. <source>The use of psychological testing for treatment planning and outcomes assessment: instruments for adults</source>. <edition>3rd ed.</edition> &#160;<publisher-name>Lawrence Erlbaum Associates Publishers</publisher-name>. p. <fpage>363</fpage>&#8211;<lpage>377</lpage>.</mixed-citation></ref><ref id="pgaf295-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldberg</surname> &#160;<given-names>LR</given-names></string-name></person-group>. <year>1992</year>. <article-title>The development of markers for the Big-Five factor structure.</article-title> &#160;<source>Psychol Assess.</source> &#160;<volume>4</volume>(<issue>1</issue>):<fpage>26</fpage>&#8211;<lpage>42</lpage>.</mixed-citation></ref><ref id="pgaf295-B59"><label>59</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Fitbit application programming interface (API) Web Reference</collab></person-group>. Fitbit Developers [accessed 2025 Jan]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dev.fitbit.com/build/reference/web-api/" ext-link-type="uri">https://dev.fitbit.com/build/reference/web-api/</ext-link></mixed-citation></ref><ref id="pgaf295-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mezlini</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Das</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Goldenberg</surname> &#160;<given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>Finding associations in a heterogeneous setting: statistical test for aberration enrichment</article-title>. <source>Genome Med</source>. <volume>13</volume>(<issue>1</issue>):<fpage>68</fpage>.<pub-id pub-id-type="pmid">33892787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-021-00864-4</pub-id><pub-id pub-id-type="pmcid">PMC8066476</pub-id></mixed-citation></ref><ref id="pgaf295-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wall</surname> &#160;<given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Hannan</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname> &#160;<given-names>JS</given-names></string-name></person-group>. <year>2014</year>. <article-title>Patients with undiagnosed hypertension: hiding in plain sight</article-title>. <source>JAMA</source>. <volume>312</volume>:<fpage>1973</fpage>&#8211;<lpage>1974</lpage>.<pub-id pub-id-type="pmid">25399269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.15388</pub-id><pub-id pub-id-type="pmcid">PMC4596255</pub-id></mixed-citation></ref><ref id="pgaf295-B62"><label>62</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Abdel-Salam</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mostafa</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hadhood</surname> &#160;<given-names>M</given-names></string-name></person-group>. <part-title>Human activity recognition using wearable sensors: review, challenges, evaluation benchmark.</part-title> &#160;<source>International workshop on deep learning for human activity recognition</source>. <publisher-name>Springer Singapore</publisher-name>, <publisher-loc>Singapore</publisher-loc>, <year>2021</year>.</mixed-citation></ref><ref id="pgaf295-B63"><label>63</label><mixed-citation publication-type="book"><person-group person-group-type="curator"><string-name name-style="western"><surname>Antar</surname> &#160;<given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahad</surname> &#160;<given-names>MAR</given-names></string-name></person-group>. <data-title>Challenges in sensor-based human activity recognition and a comparative analysis of benchmark datasets: a review</data-title>. <source>2019 Joint 8<sup>th</sup> international conference on informatics, electronics &amp; vision (ICIEV) and 2019 3rd international conference on imaging, vision &amp; pattern recognition (icIVPR)</source>. <publisher-name>IEEE</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="pgaf295-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>B&#246;ttcher</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Data quality evaluation in wearable monitoring.</article-title> &#160;<source>Sci Rep.</source> &#160;<volume>12</volume>(<issue>1</issue>):<fpage>21412</fpage>.<pub-id pub-id-type="pmid">36496546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-25949-x</pub-id><pub-id pub-id-type="pmcid">PMC9741649</pub-id></mixed-citation></ref><ref id="pgaf295-B65"><label>65</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Elflein</surname>, <given-names>J.</given-names></string-name></person-group> Cumulative COVID cases in the U.S. from 2020 to 2022. Statista [accessed 2022 Nov 17]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statista.com/statistics/1103185/cumulative-coronavirus-covid19-cases-number-us-by-day/#statisticContainer" ext-link-type="uri">https://www.statista.com/statistics/1103185/cumulative-coronavirus-covid19-cases-number-us-by-day/#statisticContainer</ext-link>.</mixed-citation></ref><ref id="pgaf295-B66"><label>66</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname> &#160;<given-names>W</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2023</year>. <comment>Accuracy on the curve: on the nonlinear correlation of ml performance between data subpopulations. International Conference on Machine Learning in Hawaii, USA. PMLR</comment>.</mixed-citation></ref><ref id="pgaf295-B67"><label>67</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Budach</surname> &#160;<given-names>L</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <comment>The effects of data quality on machine learning performance. arXiv, arXiv:2207.14529, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="pgaf295-B68"><label>68</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2020</year>. <comment>Overview and importance of data quality for machine learning tasks. Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery &amp; Data Mining in California, USA</comment>.</mixed-citation></ref><ref id="pgaf295-B69"><label>69</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Kariluoto</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <comment>Quality of data in machine learning. 2021 IEEE 21st International Conference on Software Quality, Reliability and Security Companion (QRS-C). IEEE</comment>.</mixed-citation></ref><ref id="pgaf295-B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fry</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2017</year>. <article-title>Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population.</article-title> &#160;<source>Am J Epidemiol.</source> &#160;<volume>186</volume>(<issue>9</issue>):<fpage>1026</fpage>&#8211;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwx246</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></mixed-citation></ref><ref id="pgaf295-B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Doherty</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2017</year>. <article-title>Large scale population assessment of physical activity using wrist worn accelerometers: the UK biobank study.</article-title> &#160;<source>PLoS One</source>. <volume>12</volume>(<issue>2</issue>):<fpage>e0169649</fpage>.<pub-id pub-id-type="pmid">28146576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0169649</pub-id><pub-id pub-id-type="pmcid">PMC5287488</pub-id></mixed-citation></ref><ref id="pgaf295-B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bradley</surname> &#160;<given-names>VC</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2021</year>. <article-title>Unrepresentative big surveys significantly overestimated US vaccine uptake</article-title>. <source>Nature</source>. <volume>600</volume>:<fpage>695</fpage>&#8211;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04198-4</pub-id><pub-id pub-id-type="pmid">34880504</pub-id><pub-id pub-id-type="pmcid">PMC8653636</pub-id></mixed-citation></ref><ref id="pgaf295-B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farrokhi</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mahmoudi-Hamidabad</surname> &#160;<given-names>A</given-names></string-name></person-group>. <year>2012</year>. <article-title>Rethinking convenience sampling: defining quality criteria.</article-title> &#160;<source>Theory Pract Lang Stud</source>. <volume>2</volume>(<issue>4</issue>):<fpage>784</fpage>&#8211;<lpage>792</lpage>. <pub-id pub-id-type="doi">10.4304/tpls.2.4.784-792</pub-id></mixed-citation></ref><ref id="pgaf295-B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname> &#160;<given-names>L</given-names></string-name></person-group>. <year>2018</year>. <article-title>Housing and health: an overview of the literature</article-title>. <source>Health Affairs Health Policy Brief</source>. <pub-id pub-id-type="doi">10.1377/hpb20180313.396577</pub-id></mixed-citation></ref><ref id="pgaf295-B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Angel</surname> &#160;<given-names>V</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2022</year>. <article-title>Digital health tools for the passive monitoring of depression: a systematic review of methods</article-title>. <source>NPJ Digit Med.</source> &#160;<volume>5</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">35017634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-021-00548-8</pub-id><pub-id pub-id-type="pmcid">PMC8752685</pub-id></mixed-citation></ref><ref id="pgaf295-B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piau</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2019</year>. <article-title>Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: systematic review.</article-title> &#160;<source>J Med Internet Res.</source> &#160;<volume>21</volume>(<issue>8</issue>):<fpage>e12785</fpage>.<pub-id pub-id-type="pmid">31471958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/12785</pub-id><pub-id pub-id-type="pmcid">PMC6743264</pub-id></mixed-citation></ref><ref id="pgaf295-B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kourtis</surname> &#160;<given-names>LC</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2019</year>. <article-title>Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity.</article-title> &#160;<source>NPJ Digit Med.</source> &#160;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31119198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-019-0084-2</pub-id><pub-id pub-id-type="pmcid">PMC6526279</pub-id></mixed-citation></ref><ref id="pgaf295-B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pang</surname> &#160;<given-names>I</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2019</year>. <article-title>Detection of near falls using wearable devices: a systematic review.</article-title> &#160;<source>J Geriatr Phys Ther.</source> &#160;<volume>42</volume>(<issue>1</issue>):<fpage>48</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">29384813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1519/JPT.0000000000000181</pub-id></mixed-citation></ref><ref id="pgaf295-B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shalowitz</surname> &#160;<given-names>MU</given-names></string-name>, <etal>et al</etal></person-group> &#160;<year>2009</year>. <article-title>Community-based participatory research: a review of the literature with strategies for community engagement.</article-title> &#160;<source>J Dev Behav Pediatr.</source> &#160;<volume>30</volume>(<issue>4</issue>):<fpage>350</fpage>&#8211;<lpage>361</lpage>.<pub-id pub-id-type="pmid">19672162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DBP.0b013e3181b0ef14</pub-id></mixed-citation></ref><ref id="pgaf295-B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Witham</surname> &#160;<given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>McMurdo</surname> &#160;<given-names>ME</given-names></string-name></person-group>. <year>2007</year>. <article-title>How to get older people included in clinical studies.</article-title> &#160;<source>Drugs Aging.</source> &#160;<volume>24</volume>(<issue>3</issue>):<fpage>187</fpage>&#8211;<lpage>196</lpage>.<pub-id pub-id-type="pmid">17362048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002512-200724030-00002</pub-id></mixed-citation></ref><ref id="pgaf295-B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weil</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mendoza</surname> &#160;<given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>McGavin</surname> &#160;<given-names>E</given-names></string-name></person-group>. <year>2017</year>. <article-title>Recruiting older adults as participants in applied social research: applying and evaluating approaches from clinical studies</article-title>. <source>Educ Gerontol.</source> &#160;<volume>43</volume>(<issue>12</issue>):<fpage>662</fpage>&#8211;<lpage>673</lpage>.</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Behav Immun Health</journal-id><journal-id journal-id-type="iso-abbrev">Brain Behav Immun Health</journal-id><journal-id journal-id-type="pmc-domain-id">4098</journal-id><journal-id journal-id-type="pmc-domain">bbih</journal-id><journal-title-group><journal-title>Brain, Behavior, &amp; Immunity - Health</journal-title></journal-title-group><issn pub-type="epub">2666-3546</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12506529</article-id><article-id pub-id-type="pmcid-ver">PMC12506529.1</article-id><article-id pub-id-type="pmcaid">12506529</article-id><article-id pub-id-type="pmcaiid">12506529</article-id><article-id pub-id-type="doi">10.1016/j.bbih.2025.101109</article-id><article-id pub-id-type="pii">S2666-3546(25)00167-X</article-id><article-id pub-id-type="publisher-id">101109</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Full Length Article</subject></subj-group></article-categories><title-group><article-title>Inflammatory predictors of Post-COVID fatigue</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Nuber-Champier</surname><given-names initials="A">A.</given-names></name><email>anthony.nuber@unige.ch</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Breville</surname><given-names initials="G">G.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Voruz</surname><given-names initials="P">P.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Jacot de Alc&#226;ntara</surname><given-names initials="I">I.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Lalive</surname><given-names initials="PH">P.H.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Allali</surname><given-names initials="G">G.</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Benzakour</surname><given-names initials="L">L.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>L&#246;vblad</surname><given-names initials="KO">K.-O.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Braillard</surname><given-names initials="O">O.</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Nehme</surname><given-names initials="M">M.</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Coen</surname><given-names initials="M">M.</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Serratrice</surname><given-names initials="J">J.</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Reny</surname><given-names initials="JL">J.-L.</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Pugin</surname><given-names initials="J">J.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Guessous</surname><given-names initials="I">I.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Landis</surname><given-names initials="BN">B.N.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Cionca</surname><given-names initials="A">A.</given-names></name><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Assal</surname><given-names initials="F">F.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>P&#233;ron</surname><given-names initials="JA">J.A.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff1"><label>a</label>Clinical and Experimental Neuropsychology Laboratory, Faculty of Psychology, University of Geneva, Geneva, Switzerland</aff><aff id="aff2"><label>b</label>Neurology Division, Geneva University Hospitals, Switzerland</aff><aff id="aff3"><label>c</label>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA</aff><aff id="aff4"><label>d</label>Neurosurgery Department, Geneva University Hospitals, Switzerland</aff><aff id="aff5"><label>e</label>Faculty of Medicine, University of Geneva, Switzerland</aff><aff id="aff6"><label>f</label>Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland</aff><aff id="aff7"><label>g</label>Psychiatry Department, Geneva University Hospitals, Switzerland</aff><aff id="aff8"><label>h</label>Diagnostic and Interventional Neuroradiology Department, Geneva University Hospitals, Switzerland</aff><aff id="aff9"><label>i</label>Division and Department of Primary Care, Geneva University Hospitals, Switzerland</aff><aff id="aff10"><label>j</label>Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals and Geneva University, Switzerland</aff><aff id="aff11"><label>k</label>Intensive Care Department, Geneva University Hospitals, Switzerland</aff><aff id="aff12"><label>l</label>Rhinology-Olfactology Unit, Otorhinolaryngology Department, Geneva University Hospitals, Switzerland</aff><aff id="aff13"><label>m</label>&#201;cole Polytechnique F&#233;d&#233;rale de Lausanne (EPFL), School of Engineering, Neuro-X Institute, Lausanne, Switzerland</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Facult&#233; de Psychologie et des Sciences de l'Education<italic toggle="yes">,</italic> 40 bd du Pont d&#8217;Arve, 1205, Geneva, Switzerland. <email>anthony.nuber@unige.ch</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. Clinical and Experimental Neuropsychology Laboratory, Faculty of Psychology, University of Geneva, Geneva, Switzerland.</corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2025</year></pub-date><volume>49</volume><issue-id pub-id-type="pmc-issue-id">497567</issue-id><elocation-id>101109</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>6</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The biological mechanisms underlying objective and subjective fatigue in post-COVID syndrome remain unclear. This study investigates whether immune responses during the acute phase of SARS-CoV-2 infection predict fatigue dimensions 6&#8211;9 months post-infection. We analyzed serum immune markers from 54 hospitalized patients (mean age: 58.69&#160;&#177;&#160;10.90&#160;yrs; female: 31&#160;%) and assessed their association with chronic fatigue using general linear mixed models. Elevated levels of IL-1RA, IFN&#947;, TNF&#945;, and monocyte percentage during acute infection predicted increased physical and total fatigue. Additionally, higher TNF&#945; levels (r&#160;=&#160;&#8722;0.40, <italic toggle="yes">p</italic>&#160;=&#160;.019) correlated with reduced awareness of cognitive fatigue. These findings highlight the role of acute inflammation in the persistence of post-COVID fatigue.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">TNF&#945; levels are associated with fatigue awareness.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Monocyte percentage predicts subjective fatigue.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Different inflammatory markers are associated with different dimensions of fatigue.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Fatigue</kwd><kwd>Immunity</kwd><kwd>COVID-19</kwd><kwd>Immunology</kwd><kwd>Long COVID</kwd><kwd>Inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0050">false discovery rate</term><def><p>(FDR)</p></def></def-item><def-item><term id="kwrd0060">generalized linear mixed models</term><def><p>(GLMM)</p></def></def-item><def-item><term id="kwrd0070">logarithmic</term><def><p>(log)</p></def></def-item><def-item><term id="kwrd0080">myalgic encephalomyelitis</term><def><p>(ME/CFS)</p></def></def-item><def-item><term id="kwrd0090">free/cued recall paradigm</term><def><p>(RLRI)</p></def></def-item><def-item><term id="kwrd0100">intensive care unit</term><def><p>(ICU)</p></def></def-item><def-item><term id="kwrd0110">interferon</term><def><p>(IFN)</p></def></def-item><def-item><term id="kwrd0120">interleukin</term><def><p>(IL)</p></def></def-item><def-item><term id="kwrd0130">polymerase chain reaction</term><def><p>(PCR)</p></def></def-item><def-item><term id="kwrd0140">reverse transcription polymerase chain reaction</term><def><p>(RT-PCR)</p></def></def-item><def-item><term id="kwrd0150">Self-appraisal discrepancy</term><def><p>(SAD)</p></def></def-item><def-item><term id="kwrd0160">severe acute respiratory syndrome coronavirus 2</term><def><p>(SARS-CoV-2)</p></def></def-item><def-item><term id="kwrd0170">Test of Attentional Performance</term><def><p>(TAP)</p></def></def-item><def-item><term id="kwrd0180">tumor necrosis factor alpha</term><def><p>(TNF&#945;)</p></def></def-item></def-list></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Fatigue is a common clinical complaint across various pathologies (<xref rid="bib34" ref-type="bibr">See&#946;le et al., 2022</xref>; <xref rid="bib23" ref-type="bibr">Mazza et al., 2022</xref>), particularly in post-COVID syndrome (<xref rid="bib12" ref-type="bibr">Davis et al., 2023</xref>). It is one of the most persistent symptoms, lasting beyond a year after SARS-CoV-2 infection (<xref rid="bib34" ref-type="bibr">See&#946;le et al., 2022</xref>). Studies have linked post-COVID fatigue to structural brain changes in the thalamus and basal ganglia (<xref rid="bib17" ref-type="bibr">Heine et al., 2023</xref>; <xref rid="bib14" ref-type="bibr">Diez-Cirarda et al., 2024</xref>; <xref rid="bib18" ref-type="bibr">Hosp et al., 2024</xref>) and highlighted similarities with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (<xref rid="bib4" ref-type="bibr">Bateman et al.</xref>), particularly regarding neuroinflammatory responses. Elevated levels of cytokines such as IL-1, TNF&#945;, and IFN&#947;, along with immune cellular variations, suggest a role for systemic immune dysregulation in the persistence of fatigue (<xref rid="bib26" ref-type="bibr">Morris and Maes, 2013</xref>).</p><p id="p0035">Monocytes and cytokines have emerged as key markers in this process (<xref rid="bib9" ref-type="bibr">Ceban et al., 2022</xref>; <xref rid="bib3" ref-type="bibr">Azzolino and Cesari, 2022</xref>). Persistent symptoms, including fatigue, have been associated with monocyte-platelet aggregates and elevated plasma cytokines beyond one-year post-infection (<xref rid="bib37" ref-type="bibr">Voruz et al., 2022a</xref>; <xref rid="bib12" ref-type="bibr">Davis et al., 2023</xref>; <xref rid="bib3" ref-type="bibr">Azzolino and Cesari, 2022</xref>). While hyperinflammation during the acute phase is frequently implicated in post-COVID pathophysiology, fewer studies have examined the continuum of immune response and its potential long-term effects, including low immune activation during the acute phase (<xref rid="bib24" ref-type="bibr">Mazzoni et al.</xref>; <xref rid="bib28" ref-type="bibr">Nuber-Champier et al., 2022</xref>).</p><p id="p0040">Interestingly, discrepancies exist between subjective and objective fatigue in post-COVID patients (<xref rid="bib9" ref-type="bibr">Ceban et al., 2022</xref>). Subjective fatigue is self-reported, while objective fatigue is measured through attentional functions, independent of self-perception. Also, some studies suggest the existence of distinct post-COVID phenotypes that can be situated on a self-awareness continuum (<xref rid="bib37" ref-type="bibr">Voruz et al., 2022a</xref>; <xref rid="bib29" ref-type="bibr">Nuber-Champier et al., 2023</xref>). Prior research has shown that anosognosia of cognitive deficits, where patients are unaware of their neuropsychological impairments, is linked to increased monocytes and TNF&#945; levels during the acute phase, as well as poorer cognitive performance months later (<xref rid="bib28" ref-type="bibr">Nuber-Champier et al., 2022</xref>, <xref rid="bib29" ref-type="bibr">2023</xref>). This raises the question of whether a similar lack of awareness exists for fatigue and whether it defines a distinct patient trajectory with cognitive or psychiatric implications (<xref rid="bib39" ref-type="bibr">Voruz et al., 2024</xref>). This phenomenon of (un-)awareness of disorders and these inflammatory variations, particularly linked to TNF&#945;, IL-1, but also IL-6 and IL-8 levels, also suggests similarities with neurodegenerative trajectories (<xref rid="bib32" ref-type="bibr">Rubio-Perez et al., 2012</xref>).</p><p id="p0045">Despite fatigue being a multidimensional phenomenon (physical, social, cognitive, and psychological), most studies have treated it as a single entity. Moreover, few have explored how immune markers during the acute phase predict different fatigue dimensions months later.</p><p id="p0050">This study aims to (1) assess the predictive relationship between acute-phase inflammatory markers (IL-1&#946;, IL-1RA, IFN&#947;, TNF&#945;, and monocytes) and post-COVID fatigue dimensions at 6&#8211;9 months, and (2) investigate whether acute immune response influences awareness of cognitive fatigue. Finally, (as ad hoc analyses), this study aims to (3) explore the associations between inflammatory markers (IL-6, IL-8 and other leukocyte subsets including lymphocytes, neutrophils, eosinophils and basophils) and subjective fatigue and awareness of cognitive fatigue, and to (4) determine differences in intergroup inflammatory concentrations (fatigued vs. non-fatigued) as well as to (5) evaluate fatigue levels by stratifying groups according to inflammation level (low vs. moderate vs. high inflammation). We hypothesize that higher levels of monocytes and pro-inflammatory cytokines during acute COVID-19 will be associated with greater fatigue in all dimensions and that acute inflammation will predict reduced awareness of cognitive fatigue (<xref rid="bib25" ref-type="bibr">Monje and Iwasaki, 2022</xref>; <xref rid="bib36" ref-type="bibr">Taquet et al., 2023</xref>).</p></sec><sec id="sec2"><label>2</label><title>Method</title><sec id="sec2.1"><label>2.1</label><title>General procedure</title><p id="p0055">We analyzed data from the COVID-COG cohort, including innate immunity and cytokines measured during the acute phase, as well as objective and subjective fatigue assessed 6&#8211;9 months post-infection. A self-appraisal discrepancy score was calculated to quantify fatigue perception. Finally, we examined the association and predictive value of acute-phase immune markers on different dimensions of chronic fatigue. The study was conducted in accordance with the Declaration of Helsinki and approved by the Cantonal Ethics Committee of Geneva (CER-02186).</p></sec><sec id="sec2.2"><label>2.2</label><title>COVID-COG cohort</title><p id="p0060">The COVID-COG cohort (<xref rid="bib38" ref-type="bibr">Voruz et al., 2022b</xref>) consists of 121 patients selected based on strict criteria, excluding those with prior neurological, psychiatric, oncological, or neurodevelopmental conditions, as well as pregnant individuals and those over 80 years old. SARS-CoV-2 infection was confirmed via PCR and/or serology (acute infections occurred between March 2020 and May 2021 (<xref rid="bib39" ref-type="bibr">Voruz et al., 2024</xref>)). Patients were categorized into three groups: i) those in intensive care with mechanical ventilation (N&#160;=&#160;24), ii) hospitalized without ventilation (N&#160;=&#160;48), and iii) non-hospitalized (N&#160;=&#160;49), with comparable socio-demographic characteristics between the three groups. All participants underwent comprehensive neuropsychological testing and psychiatric assessments 6&#8211;9 months post-infection. Evaluations were conducted before the rollout of COVID-19 vaccination.</p></sec><sec id="sec2.3"><label>2.3</label><title>Participants included in the study</title><p id="p0065">From the COVID-COG cohort, which initially consisted of 121 patients, we retained 54 hospitalized patients (<italic toggle="yes">N</italic>&#160;=&#160;32 in conventional care and <italic toggle="yes">N</italic>&#160;=&#160;22 in intensive care) with leukocyte and fatigue data (see <xref rid="tbl1" ref-type="table">Table 1</xref>). Of these 54 patients, 39 had samples that could be analyzed for cytokine quantification (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>). Retrospective analysis of markers presents in the acute phase of SARS-CoV-2 infection (between March 2020 and May 2021) in patients in the COVID-COG cohort included white blood cell distribution and concentrations of TNF&#945;, IL-1RA, IL-1&#946;, IL-6, IL-8, IFN&#947;, G-CSF and GM-CSF (<xref rid="bib28" ref-type="bibr">Nuber-Champier et al., 2022</xref>, <xref rid="bib29" ref-type="bibr">2023</xref>). In this study, we focused on the distribution of white blood cells and the concentrations of TNF&#945;, IL-1RA, IL-1&#946;, IL-6, IL-8 and IFN&#947;. In our analyses combining inflammatory data and fatigue data, 37 patients had both cytokine data and subjective fatigue data, of whom 33 had data for calculating cognitive fatigue awareness. In terms of leukocyte distribution, 54 patients had both inflammatory data and subjective fatigue scores. Of these, 47 patients had data for calculating cognitive fatigue awareness.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Socio-demographic and clinical data from the sample of patients assessed 6&#8211;9 months after SARS-CoV-2 infection.</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="1" rowspan="1">Patients included in the study<hr/></th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#160;=&#160;54</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Mean age in years (&#177;SD)</td><td align="left" colspan="1" rowspan="1">58.69 (&#177;10.90)</td></tr><tr><td align="left" colspan="1" rowspan="1">Education level (1/2/3)</td><td align="left" colspan="1" rowspan="1">2/18/34</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (F/M)</td><td align="left" colspan="1" rowspan="1">17/37</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of patients who required intermediate/intensive care in the acute phase</td><td align="left" colspan="1" rowspan="1">32/22</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean days of hospitalization (&#177;SD)</td><td align="left" colspan="1" rowspan="1">21.98 (&#177;25.29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean days between positive RT-PCR test and collection of immunological data (&#177;SD)</td><td align="left" colspan="1" rowspan="1">1.98 (&#177;3.62)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes (Yes/No)</td><td align="left" colspan="1" rowspan="1">8/46</td></tr><tr><td align="left" colspan="1" rowspan="1">History of respiratory disorders (Yes/No)</td><td align="left" colspan="1" rowspan="1">9/45</td></tr><tr><td align="left" colspan="1" rowspan="1">History of cardiovascular disorders (Yes/No)</td><td align="left" colspan="1" rowspan="1">10/44</td></tr><tr><td align="left" colspan="1" rowspan="1">History of neurological disorders (Yes/No)</td><td align="left" colspan="1" rowspan="1">0/54</td></tr><tr><td align="left" colspan="1" rowspan="1">History of psychiatric disorders (Yes/No)</td><td align="left" colspan="1" rowspan="1">2/52<xref rid="tbl1fna" ref-type="table-fn">a</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">History of cancer (Yes/No)</td><td align="left" colspan="1" rowspan="1">0/54</td></tr><tr><td align="left" colspan="1" rowspan="1">History of severe immunosuppression (Yes/No)</td><td align="left" colspan="1" rowspan="1">0/54</td></tr><tr><td align="left" colspan="1" rowspan="1">History of developmental disorders (Yes/No)</td><td align="left" colspan="1" rowspan="1">0/54</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Note.</italic> Education level: 1&#160;=&#160;compulsory schooling, 2&#160;=&#160;post-compulsory schooling, and 3&#160;=&#160;university degree or equivalent. RT-PCR: reverse transcription polymerase chain reaction; SD: standard deviation; Sex F: female and M: mal. Types of history of respiratory disorders: asthma, chronic bronchitis; Types of history of cardiovascular disorders: previous infarction, valve pathology, atrial pathology and heart failure.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">Types of history of psychiatric disorders: minor depressive episodes more than 10 years ago.</p></fn></table-wrap-foot></table-wrap><fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flowchart.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.4"><label>2.4</label><title>Measurements of fatigue</title><p id="p0070"><italic toggle="yes">Subjective fatigue.</italic> We assessed subjective fatigue sub-dimensions using the French version of the EMIF-SEP questionnaire (<xref rid="bib13" ref-type="bibr">Debouverie et al., 2007</xref>), a validated 40-item scale covering cognitive (10 items), physical (13 items), social (13 items), and psychological (4 items) fatigue. Physical fatigue refers to bodily exhaustion limiting daily activities, while cognitive fatigue reflects reduced mental capacity (e.g., concentration, memory). Psychological and social fatigue involve emotional distress, irritability, discouragement, isolation, or difficulty maintaining social interactions. Raw scores were converted into percentages for statistical comparability, with higher percentages indicating greater subjective fatigue severity. In order to form groups of patients with significantly low or high subjective fatigue levels, we used the standards established by <xref rid="bib13" ref-type="bibr">Debouverie et al. (2007)</xref> on a population with multiple sclerosis. We calculated Z scores based on the scores we obtained and the means and standard deviations obtained in <xref rid="bib13" ref-type="bibr">Debouverie et al. (2007)</xref>. Given that the population studied by <xref rid="bib13" ref-type="bibr">Debouverie et al. (2007)</xref> has multiple sclerosis, we chose a non-conservative threshold. In this sense, Z scores below &#8722;1 or above 1.25 were classified as low levels of fatigue or excessively fatigued, respectively (Details available in SI 10).</p><p id="p0075"><italic toggle="yes">Objective cognitive fatigue.</italic> Objective cognitive fatigue was assessed using median T scores from the sustained attention subtest of the Test of Attentional Performance (TAP) (<xref rid="bib41" ref-type="bibr">Zimmermann and Fimm, 1995</xref>). Higher T scores indicates better performance. This test is commonly used to measure fatigue in conditions like multiple sclerosis (<xref rid="bib27" ref-type="bibr">Neumann et al., 2014</xref>; <xref rid="bib11" ref-type="bibr">Claros-Salinas et al., 2013</xref>; <xref rid="bib40" ref-type="bibr">Weinges et al., 2010</xref>). It requires participants to sustain attention for 15&#160;min, responding as quickly as possible when a target stimulus pair of identical shapes or colors appears.</p><p id="p0080"><italic toggle="yes">Discrepancy between subjective and objective cognitive fatigue.</italic> To compare objective and subjective cognitive fatigue measures, we first inverted the subjective fatigue scores by calculating their complementary percentages (e.g., 80&#160;% fatigue became 20&#160;% preservation). This inversion ensured that higher scores consistently indicated less fatigue. We then weighted the subjective scale against the objective scale. The self-appraisal discrepancy (SAD) score was calculated by subtracting the percentage of subjective cognitive fatigue (from EMIF-SEP) from the median T scores of sustained attention (from TAP (<xref rid="bib41" ref-type="bibr">Zimmermann and Fimm, 1995</xref>)). We identified three patterns: i) Over-awareness: High subjective fatigue (e.g., 90&#160;%, inverted to 10&#160;%) with low objective fatigue (T score 55) results in a positive discrepancy (e.g., 55-10&#160;=&#160;45), indicating heightened subjective perception. ii) Congruent awareness: Matching subjective (e.g., 60&#160;%, inverted to 40&#160;%) and objective fatigue (T score 44) yields a near-zero discrepancy (e.g., 44-40&#160;=&#160;4), indicating alignment between subjective experience and objective measurement. iii) Anosognosia: Low subjective fatigue (e.g., 30&#160;%, inverted to 70&#160;%) despite high objective fatigue (T score 31) produces a negative discrepancy (e.g., 31&#8211;70&#160;=&#160;&#8722;39), indicating unawareness of fatigue. These patterns offer insight into patients' awareness of cognitive fatigue.</p></sec><sec id="sec2.5"><label>2.5</label><title>Analysis of cytokines and plasma leukocyte distribution</title><p id="p0085">The analysis of cytokines (pg/ml) of TNF&#945;, interleukin (IL)&#8722;&#8201;1RA, IL-1&#946;, interferon gamma (IFN&#947;), was made using commercially available multiplex bead immunoassays (Fluorokine MAP Multiplex Human Cytokine Panel, R&amp;D Systems, Minneapolis, USA) and read using a Bioplex 200 Array Reader (Bio-Rad Laboratories, Hercules, CA, USA) and Luminex&#174; xMAP&#8482; technology (Luminex Corporation, Austin, TX, USA). Plasma leukocyte distribution was evaluated with Piccolo Xpress (Sysmex, Switzerland) tools (see <xref rid="tbl2" ref-type="table">Table 2</xref>). The short period of time between blood collection, processing (cell analysis on fresh blood), and freezing (plasma) did not result in any sample alteration (&lt; mean 79&#160;h). Reliable value extrapolated beyond the standard range (below or above) for concentrations of TNF&#945;: &#8805;0.56&#160;pg/mL; IL-6: &#8805;0.83&#160;pg/mL; IL-8: &#8805;1.91&#160;pg/mL; IL-1RA: &#8804;21,454.18&#160;pg/mL; IL-1&#946;: &#8805;0.08&#160;pg/mL; IFN&#947;: &#8805;0.26&#160;pg/mL. Inter-individual biological replicates were calculated for each marker [(sd/mean)&#8727;100]. Finally, a single batch of analysis was performed to limit undesirable batch effects. In order to stratify our population based on inflammation deployed in the acute phase, we calculated the Z scores of the reactions for each cytokine (TNF&#945;, IFN&#947;, IL-1&#946;, IL-1RA; IL-6, IL-8). We added these Z scores and determined three groups of inflammatory scores: Z&#160;&lt;&#160;&#8722;1; &#8722;1&lt;Z&#160;&gt;&#160;1; Z&#160;&gt;&#160;1. One group had low inflammation (Z&#160;&lt; &#8722;1), one group had regulated/moderate inflammation (&#8722;1&lt;Z&#160;&gt;&#160;1) and one group had high inflammation (Z&#160;&gt;&#160;1).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Immune markers of patients with COVID-19 on admission to hospital.</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Immune markers</th><th colspan="1" rowspan="1">Plasma cytokines concentration (<italic toggle="yes">N</italic>&#160;=&#160;39) and leukocyte distribution (<italic toggle="yes">N</italic>&#160;=&#160;54) on day 1 of COVID-19 related hospitalization &#8211; Median [95 %CI]</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TNF&#945; (pg/ml)</td><td align="left" colspan="1" rowspan="1">3.8 [3.40; 6.05]</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-1Ra (pg/ml)</td><td align="left" colspan="1" rowspan="1">4438.97 [4840.99; 8134,89]</td></tr><tr><td align="left" colspan="1" rowspan="1">IFN&#947; (pg/ml)</td><td align="left" colspan="1" rowspan="1">1.65 [0.99; 2.09]</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-1&#946; (pg/ml)</td><td align="left" colspan="1" rowspan="1">0.69 [0.49; 1.28]</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-6 (pg/ml)</td><td align="left" colspan="1" rowspan="1">12.78 [13.92; 30.60]</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-8 (pg/ml)</td><td align="left" colspan="1" rowspan="1">11.86 [7.15; 41.11]</td></tr><tr><td align="left" colspan="1" rowspan="1">Monocytes %</td><td align="left" colspan="1" rowspan="1">6.35 [5.34; 7.28]</td></tr><tr><td align="left" colspan="1" rowspan="1">Monocytes (G/l)</td><td align="left" colspan="1" rowspan="1">0.37 [0.32; 0.44]</td></tr><tr><td align="left" colspan="1" rowspan="1">Neutrophils %</td><td align="left" colspan="1" rowspan="1">75.20 [71.95; 78.23]</td></tr><tr><td align="left" colspan="1" rowspan="1">Neutrophils (G/l)</td><td align="left" colspan="1" rowspan="1">4.99 [4.60; 5.98]</td></tr><tr><td align="left" colspan="1" rowspan="1">Eosinophils %</td><td align="left" colspan="1" rowspan="1">0.00 [0.10; 0.38]</td></tr><tr><td align="left" colspan="1" rowspan="1">Eosinophils (G/l)</td><td align="left" colspan="1" rowspan="1">0.00 [0.006; 0.027]</td></tr><tr><td align="left" colspan="1" rowspan="1">Basophils %</td><td align="left" colspan="1" rowspan="1">0.20 [0.14; 0.26]</td></tr><tr><td align="left" colspan="1" rowspan="1">Basophils (G/l)</td><td align="left" colspan="1" rowspan="1">0.009 [0.008; 0.01]</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Note.</italic> IFN&#947;: interferon gamma; IL: interleukin; TNF&#945;: tumor necrosis factor alpha. The percentage corresponds to the percentage of white blood cells.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.6"><label>2.6</label><title>Statistical power</title><p id="p0090">We set the &#946; type 2 error at 0.80 and, since our hypotheses were formulated in a specific sense, the threshold for the &#945; relationship was set at 0.025. Finally, we estimated a correlation coefficient on the observed relationship between TNF&#945; levels, cell concentrations (monocytes) and post-COVID cognitive symptoms obtained in Nuber-Champier et al. (<xref rid="bib29" ref-type="bibr">Nuber-Champier et al., 2023</xref>; <xref rid="bib37" ref-type="bibr">Voruz et al., 2022a</xref>) and Cervia-Hasler et al. (<xref rid="bib10" ref-type="bibr">Cervia-Hasler et al., 2024</xref>).</p><sec id="sec2.6.1"><label>2.6.1</label><title>Samples for cytokine analysis</title><p id="p0095">
<disp-formula id="ufd1">The standard normal deviate for &#945;&#160;=&#160;Z<sub>&#945;</sub>&#160;=&#160;1.9600</disp-formula>
<disp-formula id="ufd2">The standard normal deviate for &#946;&#160;=&#160;Z<sub>&#946;</sub>&#160;=&#160;0.8416</disp-formula>
<disp-formula id="ufd3">C&#160;=&#160;0.5 &#8727; ln[(1+r)/(1-r)]&#160;=&#160;0.6625</disp-formula>
<disp-formula id="ufd4">Total sample size&#160;=&#160;N&#160;=&#160;[(Z<sub>&#945;</sub>+Z<sub>&#946;</sub>)/C]2&#160;+&#160;3&#160;=&#160;21</disp-formula>
</p></sec><sec id="sec2.6.2"><label>2.6.2</label><title>Samples for cell analysis</title><p id="p0100">
<disp-formula id="ufd5">The standard normal deviate for &#945;&#160;=&#160;Z<sub>&#945;</sub>&#160;=&#160;1.9600</disp-formula>
<disp-formula id="ufd6">The standard normal deviate for &#946;&#160;=&#160;Z<sub>&#946;</sub>&#160;=&#160;0.8416</disp-formula>
<disp-formula id="ufd7">C&#160;=&#160;0.5 &#8727; ln[(1+r)/(1-r)]&#160;=&#160;0.4001</disp-formula>
<disp-formula id="ufd8">Total sample size&#160;=&#160;N&#160;=&#160;[(Z<sub>&#945;</sub>+Z<sub>&#946;</sub>)/C]<sup>2</sup>&#160;+&#160;3&#160;=&#160;52</disp-formula>
</p><p id="p0105">Based on the calculation made by <xref rid="bib19" ref-type="bibr">Hulley et al. (2013)</xref>, the necessary sample size is estimated at 52 participants for the cellular analyses and 21 participants for the cytokine analyses.</p></sec></sec><sec id="sec2.7"><label>2.7</label><title>Statistical analyses</title><p id="p0110"><italic toggle="yes">Data preprocessing and transformation</italic>. To appropriately handle the immune response data, especially cytokine concentrations approaching zero, we applied a logarithmic transformation.</p><p id="p0115"><italic toggle="yes">Statistical approach and multiple comparison correction</italic>. Given the distribution of behavioral data, non-parametric statistical tests were used. False discovery rate (FDR) corrections were applied to all analyses.</p><p id="p0120"><italic toggle="yes">Association between inflammation during the acute phase and subjective fatigue dimensions 6&#8211;</italic>9 months <italic toggle="yes">post-infection</italic>. To test our first hypothesis which posited an association between inflammatory variables (e.g., TNF&#945;, IFN&#947;, IL-1&#946;, IL-1RA, monocytes) measured during the acute phase and various fatigue dimensions (total, physical, cognitive, social, psychological) at 6&#8211;9 months post-infection, we conducted Spearman correlations. Next, to explore the predictive capacity of acute-phase immune variables on these subjective fatigue scores at 6&#8211;9 months, we used generalized linear mixed models (GLMM) with gamma distribution, incorporating log-transformed inflammatory marker levels as a fixed variable, and age and sex as random variables. These correlation and prediction analyses were also performed according to hospitalization severity subgroups during the acute phase and are presented in <xref rid="appsec1" ref-type="sec">Supplementary Material 1-7</xref>.</p><p id="p0125"><italic toggle="yes">Association between immune markers and cognitive fatigue self-awareness</italic>. To assess the association and predictive value of acute-phase immune activity on cognitive fatigue self-awareness, we performed Spearman correlations and generalized linear mixed models (GLMM), using inflammatory markers (e.g., TNF&#945;, IL-1&#946;, monocytes), age, and sex as predictors, in line with previous analyses. Specifically, we examined the associations between white blood cell counts, and concentrations of TNF&#945;, IFN&#947;, IL-1&#946;, IL-1RA, IL-6, and IL-8 measured during the acute phase, and cognitive fatigue scores (SAD) assessed 6&#8211;9 months post-infection, while controlling for age and sex. These correlation and prediction analyses were also performed according to hospitalization severity subgroups during the acute phase and are presented in <xref rid="appsec1" ref-type="sec">Supplementary Material 1-7</xref>.</p><p id="p0130"><italic toggle="yes">Exploratory analysis by subgroups (inflammation and fatigue) (</italic>ad hoc <italic toggle="yes">analyses)</italic>. Finally, exploratory ad hoc analyses of intergroup differences based on EMIF-SEP Z scores (two groups: low fatigue/excessive fatigue) and inflammation stratification Z scores (three groups: mild inflammation/moderate inflammation/severe inflammation) were performed using Kruskal-Wallis group comparisons. We compared inflammatory marker concentrations according to subgroups for each dimension of subjective fatigue. We also compared the levels of fatigue for each dimension according to inflammatory subgroups.</p><p id="p0135">All analyses were performed with SPSS Statistics version 28.0.1.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Sociodemographic and clinical data</title><p id="p0140">In this study, we included middle-aged patients hospitalized in intermediate or intensive care, with no relevant medical history before the infection (see <xref rid="tbl1" ref-type="table">Table 1</xref>). The results of additional correlation and prediction analyses obtained by subgroup according to the type of hospitalization in the acute phase are available in <xref rid="appsec1" ref-type="sec">supplementary material 1-7</xref>.</p></sec><sec id="sec3.2"><label>3.2</label><title>Cytokines plasma levels and leukocyte distribution measured during the acute phase of COVID-19</title><p id="p0145">The levels of immune markers (cytokines and monocytes) are presented in <xref rid="tbl2" ref-type="table">Table 2</xref> in logarithmically untransformed form.</p><p id="p0150">With regard to our samples, we observed significant coefficients of variation (CV) in inter-individual biological replicates of inflammatory responses measured during the acute phase. We observed CVs of 86.4&#160;% for TNF&#945;, 115.5&#160;% for IL-6, 217.0&#160;% for IL-8, 78.3&#160;% for IL-1Ra, 137.7&#160;% for IL-1&#946;, and 109.9&#160;% for IFN&#947;. Leukocyte subset variability was also substantial, including CVs of 49.6&#160;% for neutrophils, 232.1&#160;% for eosinophils, 116.4&#160;% for basophils, and 60.7&#160;% for monocytes.</p></sec><sec id="sec3.3"><label>3.3</label><title>Association between plasma cytokines concentration, monocytes % measured in the acute phase of COVID-19 and fatigue dimensions 6&#8211;9 months post-infection</title><p id="p0155">
<list list-type="simple" id="olist0010"><list-item id="o0010"><label>a)</label><p id="p0160">Total fatigue</p></list-item></list>
</p><p id="p0165">We observed significant negative associations between total fatigue scores measured 6&#8211;9 months post-infection and TNF&#945; levels (r&#160;=&#160;&#8722;0.44; <italic toggle="yes">p</italic>&#160;=&#160;.006) and also with IL-1RA levels (r&#160;=&#160;&#8722;0.34; <italic toggle="yes">p</italic>&#160;=&#160;.036) (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>) measured during the acute phase.<list list-type="simple" id="olist0015"><list-item id="o0015"><label>b)</label><p id="p0170">Cognitive fatigue</p><p id="p0175">Blood monocyte percentage among white blood cells measured during the acute phase were significantly negatively associated with cognitive fatigue scores measured 6&#8211;9 months post-infection (r&#160;=&#160;&#8722;0.35; <italic toggle="yes">p</italic>&#160;=&#160;.009) (see <xref rid="fig3" ref-type="fig">Fig. 3</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Monocytes percentage measured during the acute phase in relation with chronic cognitive fatigue percentage.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></list-item></list><list list-type="simple" id="olist0020"><list-item id="o0020"><label>c)</label><p id="p0180">Physical fatigue</p><p id="p0185">TNF&#945; plasma levels measured during the acute phase were significantly negatively associated with physical fatigue scores measured 6&#8211;9 months post-infection (r&#160;=&#160;&#8722;0.42; <italic toggle="yes">p</italic>&#160;=&#160;.008).</p></list-item></list><list list-type="simple" id="olist0025"><list-item id="o0025"><label>d)</label><p id="p0190">Social and psychological fatigue</p></list-item></list><fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Plasma TNF&#945; levels measured during the acute phase in relation to chronic fatigue percentage.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0195">None of the results were significant. The results are available as <xref rid="appsec1" ref-type="sec">supplementary material 8</xref>.</p></sec><sec id="sec3.4"><label>3.4</label><title>Prediction of fatigue dimensions 6&#8211;9 months post-infection by inflammation measured during the acute phase of SARS-CoV-2 infection</title><p id="p0200">
<list list-type="simple" id="olist0030"><list-item id="o0030"><label>a)</label><p id="p0205">Total fatigue</p></list-item></list>
</p><p id="p0210">The model for predicting total fatigue (AIC<sub>c</sub>&#160;=&#160;31.54), which included variables such as sex, age, plasma levels of TNF&#945;, IL-1RA, IL-1&#946;, IFN&#947; and the percentage of blood monocytes measured during the acute phase, significantly selected IL-1RA (<italic toggle="yes">&#946;</italic>&#160;=&#160;&#8722;0.37; <italic toggle="yes">F</italic>&#160;=&#160;4.46; <italic toggle="yes">p</italic>&#160;=&#160;.044; 95 %CI [&#8722;0.73; &#8722;0.01]) and IFN&#947; (<italic toggle="yes">&#946;</italic>&#160;=&#160;0.31; <italic toggle="yes">F</italic>&#160;=&#160;5.02; <italic toggle="yes">p</italic>&#160;=&#160;.034; 95 %CI [0.026; 0.59]) plasma levels to predict total fatigue 6&#8211;9 months post-infection.<list list-type="simple" id="olist0035"><list-item id="o0035"><label>b)</label><p id="p0215">Cognitive fatigue</p></list-item></list></p><p id="p0220">None of the results were significant. The results are available as supplementary material 9.<list list-type="simple" id="olist0040"><list-item id="o0040"><label>c)</label><p id="p0225">Physical fatigue</p></list-item></list></p><p id="p0230">There was a significant effect for the predictive ability of IFN&#947; plasma levels (<italic toggle="yes">&#946;</italic>&#160;=&#160;0.40; <italic toggle="yes">F</italic>&#160;=&#160;6.39; <italic toggle="yes">p</italic>&#160;=&#160;.018; 95 %CI [0.076; 0.73]) measured during the acute phase in predicting physical fatigue 6&#8211;9 months post-infection (AIC<sub>c</sub>&#160;=&#160;40.29) was observed.<list list-type="simple" id="olist0045"><list-item id="o0045"><label>d)</label><p id="p0235">Social and psychological fatigue</p></list-item></list></p><p id="p0240">None of the results were significant. The results are available as supplementary material 9.</p></sec><sec id="sec3.5"><label>3.5</label><title>Association between immunity measured during the acute phase and awareness of cognitive fatigue 6&#8211;9 months post-infection</title><p id="p0245">We observed a negative correlation between TNF&#945; levels measured during the acute phase and SAD scores of cognitive fatigue obtained 6&#8211;9 months post infection (r&#160;=&#160;&#8722;0.40; <italic toggle="yes">p</italic>&#160;=&#160;.019) (see <xref rid="fig4" ref-type="fig">Fig. 4</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>TNF&#945; levels measured during the acute phase in relation with self-appraisal discrepancy scores of cognitive fatigue (6&#8211;9 months post-infection).</p><p><italic toggle="yes">Note</italic>. Self-appraisal discrepancy of cognitive fatigue (SAD) corresponds to the difference between the objective measures of cognitive fatigue and the subjective measures of cognitive fatigue obtained 6&#8211;9 months post-infection. The higher positive the SAD scores, the greater the subjective fatigue symptoms but the lower the objective fatigue symptoms. The lower negative the SAD scores, the lower the subjective fatigue symptoms but the higher the objective fatigue symptoms. Therefore, the lower the SAD values, the greater the patients' anosognosia of their cognitive fatigue. Values around 0 correspond to estimates of fatigue that are adequate between subjective and objective complaints.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.6"><label>3.6</label><title>Prediction of immunity measured during the acute phase on awareness of cognitive fatigue 6&#8211;9 months post-infection</title><p id="p0250">The regression model concerning the prediction of the SAD scores of cognitive fatigues (AIC<sub>c</sub>&#160;=&#160;34.64), which included variables such as sex, age, levels of TNF&#945;, IL-1RA, IL-1&#946;, IFN&#947; and the percentage of monocytes measured during the acute phase, was significant for the IL-1RA levels (<italic toggle="yes">&#946;</italic>&#160;=&#160;&#8722;1.57; <italic toggle="yes">F</italic>&#160;=&#160;6.12; <italic toggle="yes">p</italic>&#160;=&#160;.048; 95 %CI [&#8722;3.13;-0.17]).</p></sec><sec id="sec3.7"><label>3.7</label><title>Ad hoc analyses: exploratory results</title><p id="p0255">The exploratory results of the inflammatory differences between the different fatigue groups obtained by Z score and inflammation stratification, and the associations between IL-6/IL-8 and other leukocyte subsets markers and subjective fatigue scores are available in SI 11 to SI 13.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0260">In this study, we examined the relationship between immune response during the acute phase of COVID-19 and fatigue 6&#8211;9 months post-infection in previously hospitalized individuals. Our findings reveal significant negative associations between early inflammatory markers and long-term fatigue, suggesting that immune response during the acute phase may shape distinct post-COVID fatigue trajectories.</p><p id="p0265">Lower TNF&#945; and IL-1RA levels during the acute phase were linked to higher total fatigue scores, with TNF&#945; and IL-6 also negatively associated with physical fatigue. Monocyte percentage showed an inverse relationship with cognitive fatigue, whereas neutrophil counts were positively associated. Moreover, IL-1RA and IFN&#947; plasma levels during acute infection significantly predicted total fatigue, while IFN&#947; alone was a predictor of physical fatigue. These findings suggest that both pro- and anti-inflammatory responses influence long-term fatigue development. The action and management of neutrophils and monocytes and associated signaling pathways could lead to different fatigue trajectories (<xref rid="bib2" ref-type="bibr">Aspler et al., 2008</xref>; <xref rid="bib31" ref-type="bibr">Paludan and Mogensen, 2022</xref>). Although other studies have reported a significant increase in the number of neutrophils and monocytes in patients with chronic fatigue (<xref rid="bib33" ref-type="bibr">Saito et al., 2024</xref>), our results also support the need for further research on the different dimensions of fatigue and its subjective and objective nature, in relation to inflammatory phenomena. In the future, it will be necessary to clarify the different stages of maturation of neutrophils and monocytes and the signaling pathways associated with post-COVID fatigue.</p><p id="p0270">We also found that higher TNF&#945; levels were associated with reduced self-awareness of cognitive fatigue, suggesting that inflammation may impair symptom perception. Similarly, IL-1RA levels predicted fatigue awareness, highlighting the role of early immune regulation in shaping subjective experience of fatigue (<xref rid="bib29" ref-type="bibr">Nuber-Champier et al., 2023</xref>, <xref rid="bib30" ref-type="bibr">2024</xref>). This suggests that inflammatory markers such as TNF&#945; and monocytes could serve as potential biomarkers for predicting post-COVID trajectories. These results support the hypothesis that immuno-cognitive mechanisms contribute to distinct post-COVID phenotypes (<xref rid="bib16" ref-type="bibr">Hartung et al., 2022</xref>).</p><p id="p0275">Our findings challenge a linear inflammation&#8211;fatigue model, instead pointing to an inverted-U relationship: both insufficient and excessive immune responses may result in fatigue, though through different pathways. Patients with heightened acute inflammation appear more prone to cognitive sequelae and reduced fatigue awareness, whereas those with lower inflammation tend to report higher subjective fatigue. This aligns with prior research indicating that post-viral fatigue syndromes involve complex immune mechanisms beyond direct viral effects (<xref rid="bib29" ref-type="bibr">Nuber-Champier et al., 2023</xref>; <xref rid="bib36" ref-type="bibr">Taquet et al., 2023</xref>). Our observations and this hypothesis at the cognitive and immune levels are in line with the results obtained by <xref rid="bib20" ref-type="bibr">Kervevan et al. (2023)</xref> according to whom two phenotypes were observed in the long COVID. On the one hand, patients with strong and durable immune responses and on the other, patients with weak antiviral responses. These two entities are possibly associated with distinct cognitive and psychiatric disorders. It will therefore be crucial in the future to determine whether patients who experienced severe inflammation in the acute phase and anosognosia of cognitive impairment and fatigue 6&#8211;9 months post-infection will follow a course with a high long-term neurodegenerative risk (<xref rid="bib22" ref-type="bibr">Mavrikaki et al., 2022</xref>; <xref rid="bib15" ref-type="bibr">Duff et al., 2025</xref>). It will also be necessary to study, at the other end of the spectrum of awareness of disorders, the psychiatric evolution and quality of life of people with severe long-term subjective complaints (<xref rid="bib5" ref-type="bibr">Becker et al., 2023</xref>).</p><p id="p0280">Importantly, different dimensions of fatigue (physical, cognitive, social, psychological) showed distinct immune associations (<xref rid="bib7" ref-type="bibr">Billones et al., 2021</xref>; <xref rid="bib8" ref-type="bibr">Campos et al., 2022</xref>). IFN&#947; emerged as the most consistent predictor of fatigue, particularly in relation to total and physical fatigue, resembling its role in Epstein-Barr virus-related fatigue syndromes (<xref rid="bib6" ref-type="bibr">Bellmann-Weiler et al., 2008</xref>). Meanwhile, TNF&#945; was associated with both total and physical fatigue, while IL-1RA appeared more closely linked to fatigue awareness. These findings suggest the need for personalized approaches based on immune profiles.</p><p id="p0285">Subgroup analyses revealed immune&#8211;fatigue associations varied by illness severity. Among patients requiring intermediate care, monocyte percentage correlated with total and physical fatigue, whereas inflammatory markers did not significantly predict long-term fatigue (see SI 5&#8211;9). Conversely, for intensive care patients, TNF&#945; was linked to total, cognitive, and social fatigue, and both IFN&#947; and IL-1RA predicted multiple fatigue dimensions. This suggests that while viral load and acute respiratory distress contribute to fatigue, immune dysregulation plays an independent role in post-COVID symptom persistence. Curiously, a pattern seems to emerge regarding neutrophil counts. Neutrophils are positively associated with subjective fatigue in all groups. All other significant markers are negatively associated with subjective fatigue. Neutrophils and associated signaling pathways (e.g., TLR, PAMP, DAMP) could be an interesting target for a better understanding of post-COVID fatigue (<xref rid="bib31" ref-type="bibr">Paludan and Mogensen, 2022</xref>; <xref rid="bib33" ref-type="bibr">Saito et al., 2024</xref>).</p><p id="p0290">However, it seems necessary to remain cautious, as measuring subjective fatigue remains a complex task that is difficult to generalize between individuals, and as there is no cut-off point that determines the threshold at which a person is significantly fatigued. Few patients have fatigue with a Z score greater than 1.25 or less than 1. This can be explained by the fact that this scale (EMIF-SEP) is standardized on a population of people with multiple sclerosis. Beyond the statistical aspects related to the cohort, we can note from our observations that some people, after COVID-19 infection (with no previous medical history), may experience clinically higher fatigue than people with multiple sclerosis, regardless of the type of hospitalization in the acute phase. Thus, the fatigue experienced after SARS-CoV-2 infection can lead to significant disability in some patients. Finally, the inflammatory stratification performed did not reveal any intergroup differences. This lack of effect could indicate that differences in post-COVID fatigue symptoms between patients do not result from direct inflammatory mechanisms. Instead, they could be attributable to the direct cytopathogenic effects of SARS-CoV-2 on organs (<xref rid="bib21" ref-type="bibr">Maliha et al., 2024</xref>),the activation of certain signaling pathways (<xref rid="bib31" ref-type="bibr">Paludan and Mogensen, 2022</xref>), or the possibility that the inflammatory response was measured too early. In this context, inflammatory mediation analyses could be considered to explore the links between post-COVID cognition or fatigue and vascular phenomena, which are often involved in the persistence of symptoms (<xref rid="bib1" ref-type="bibr">Altmann et al., 2023</xref>). It would also be relevant to investigate cognitive impairments and associated signaling pathways in detail. Finally, it is essential to study the general population with comorbidities, particularly non-hospitalized patients in the acute phase. Our sample, which consisted only of people with no medical history, is not representative of the general population, which is often affected by various comorbidities.</p><p id="p0295">Finally, we note several limitations of this study. The relatively small sample size, while statistically adjusted, necessitates replication in larger cohorts to improve generalizability. Additionally, as our cohort consisted solely of hospitalized patients, findings may not fully apply to individuals with milder COVID-19 cases. Another challenge is the variability in fatigue measurement; while the EMIF-SEP questionnaire has been used in post-COVID research, additional objective assessments (e.g., VO2 max, actigraphy) would enhance validity. Furthermore, the retrospective nature of our analysis introduces potential confounding factors, including the time elapsed since infection and individual socio-economic vulnerabilities. Although we observed inter-individual variations (expected in the context of COVID-19 (<xref rid="bib35" ref-type="bibr">Song et al., 2021</xref>)), we do not have replicates available for the quantification of immune markers. This prevents the calculation of intra-individual coefficients of variation and therefore we cannot fully assess the analytical variability of these measures. The observed variability highlights that some patients responded strongly to the infection, while others responded only moderately. This again reflects that several post-COVID patient phenotypes evolve over time between the acute phase and the chronic period. Future research should incorporate longitudinal immune-cognitive assessments and investigate peripheral blood mononuclear cells (PBMCs) for deeper immunological insights. It is also important to note that the interpretation of inflammatory stratifications in relation to post-COVID fatigue status remains an ad hoc hypothesis, formulated in response to the observed findings. As such, it should be considered exploratory and interpreted with caution. Future research using larger, independent samples and explicitly defined hypotheses will be necessary to test and validate this preliminary explanation. Finally, the absence of a SARS-CoV-2-na&#239;ve control group complicates interpretation within the broader population. Given the high prevalence of COVID-19 worldwide, recruiting truly uninfected controls remains challenging. Despite these limitations, our results underscore the role of early immune response in long-term fatigue and cognition, and point toward the value of immunological biomarkers for identifying at-risk individuals. Future longitudinal studies integrating immuno-cognitive measures and PBMC profiling are warranted.</p></sec><sec id="sec5"><label>5</label><title>Conclusion</title><p id="p0300">Our study highlights the complex interplay between acute immune markers and post-COVID fatigue. Key inflammatory markers, particularly TNF&#945;, IL-1RA, and IFN&#947;, appear to influence different dimensions of fatigue and cognitive fatigue awareness months after infection. These findings support a multifaceted model of post-COVID fatigue and cognitive dysfunction, suggesting potential immune-driven subtypes that could inform personalized interventions. Future research should explore the evolution of these fatigue dimensions in relation to socio-economic factors, pre-existing vulnerabilities, and potential neurodegenerative risks, ultimately contributing to optimized post-COVID care strategies.</p></sec><sec id="sec6"><title>CRediT authorship contribution statement</title><p id="p0305"><bold>A. Nuber-Champier:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Conceptualization. <bold>G. Breville:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Methodology, Investigation. <bold>P. Voruz:</bold> Writing &#8211; review &amp; editing, Methodology, Investigation. <bold>I. Jacot de Alc&#226;ntara:</bold> Writing &#8211; review &amp; editing, Methodology, Investigation. <bold>P.H. Lalive:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Resources, Methodology, Investigation. <bold>G. Allali:</bold> Writing &#8211; review &amp; editing, Resources, Methodology. <bold>L. Benzakour:</bold> Writing &#8211; review &amp; editing. <bold>K.-O. L&#246;vblad:</bold> Writing &#8211; review &amp; editing. <bold>O. Braillard:</bold> Writing &#8211; review &amp; editing. <bold>M. Nehme:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>M. Coen:</bold> Writing &#8211; review &amp; editing. <bold>J. Serratrice:</bold> Writing &#8211; review &amp; editing. <bold>J.-L. Reny:</bold> Writing &#8211; review &amp; editing. <bold>J. Pugin:</bold> Writing &#8211; review &amp; editing. <bold>I. Guessous:</bold> Writing &#8211; review &amp; editing, Resources, Methodology. <bold>B.N. Landis:</bold> Writing &#8211; review &amp; editing. <bold>A. Cionca:</bold> Writing &#8211; review &amp; editing, Methodology, Investigation. <bold>F. Assal:</bold> Writing &#8211; review &amp; editing, Supervision, Project administration, Funding acquisition, Conceptualization. <bold>J.A. P&#233;ron:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.</p></sec><sec id="sec7"><title>Data accessibility</title><p id="p0310">The data analyzed and published are available on Yareta at the following address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://yareta.unige.ch/home/search?search=search%3Dcovid-cog" id="intref0010">https://yareta.unige.ch/home/search?search=search %3Dcovid-cog</ext-link>.</p></sec><sec id="sec8"><title>Funding</title><p id="p0315">The present research was supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000001</institution-id><institution>Swiss National Science Foundation</institution></institution-wrap></funding-source> (<funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001711</institution-id><institution>SNSF</institution></institution-wrap></funding-source>) funding to JAP (<funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006150</institution-id><institution>PI</institution></institution-wrap></funding-source>) and <funding-source id="gs4">FA</funding-source> (Co-<funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006150</institution-id><institution>PI</institution></institution-wrap></funding-source>) (grant no. 220041).</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0320">No conflicts of interest to be declared.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Whettlock</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arachchillage</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>R.J.</given-names></name></person-group><article-title>The immunology of long COVID</article-title><source>Nat. Rev. Immunol.</source><volume>23</volume><year>2023</year><fpage>618</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">37433988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00904-7</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Aspler</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bolshin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vernon</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>G.</given-names></name></person-group><article-title>Evidence of inflammatory immune signaling in chronic fatigue syndrome: a pilot study of gene expression in peripheral blood</article-title><source>Behav. Brain Funct.</source><volume>4</volume><year>2008</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">18822143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-9081-4-44</pub-id><pub-id pub-id-type="pmcid">PMC2569951</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Azzolino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cesari</surname><given-names>M.</given-names></name></person-group><article-title>Fatigue in the COVID-19 pandemic</article-title><source>The Lancet Healthy Longevity</source><volume>3</volume><year>2022</year><fpage>e128</fpage><lpage>e129</lpage><pub-id pub-id-type="pmid">35282597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(22)00029-0</pub-id><pub-id pub-id-type="pmcid">PMC8901180</pub-id></element-citation></ref><ref id="bib4"><mixed-citation publication-type="other" id="sref4">Bateman, L. et al. in Mayo Clinic Proceedings<italic toggle="yes">.</italic> 2861-2878 (Elsevier).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2021.07.004</pub-id><pub-id pub-id-type="pmid">34454716</pub-id></mixed-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Vannorsdall</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Weisenbach</surname><given-names>S.L.</given-names></name></person-group><article-title>Evaluation of post&#8211;COVID-19 cognitive dysfunction: recommendations for researchers</article-title><source>JAMA Psychiatry</source><volume>80</volume><year>2023</year><fpage>1085</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">37585198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2023.2820</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Bellmann-Weiler</surname><given-names>R.</given-names></name><etal/></person-group><article-title>IFN-Gamma mediated pathways in patients with fatigue and chronic active epstein barr virus-infection</article-title><source>J. Affect. Disord.</source><volume>108</volume><year>2008</year><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">17945348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2007.09.005</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Billones</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liwang</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Graves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saligan</surname><given-names>L.N.</given-names></name></person-group><article-title>Dissecting the fatigue experience: a scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions</article-title><source>Brain, behavior, &amp; immunity-health</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">100266</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbih.2021.100266</pub-id><pub-id pub-id-type="pmcid">PMC8474156</pub-id><pub-id pub-id-type="pmid">34589772</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Post-viral fatigue in COVID-19: a review of symptom assessment methods, mental, cognitive, and physical impairment</article-title><source>Neurosci. Biobehav. Rev.</source><volume>142</volume><year>2022</year><object-id pub-id-type="publisher-id">104902</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104902</pub-id><pub-id pub-id-type="pmcid">PMC9528075</pub-id><pub-id pub-id-type="pmid">36202253</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Ceban</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Fatigue and cognitive impairment in Post-COVID-19 syndrome: a systematic review and meta-analysis</article-title><source>Brain Behav. Immun.</source><volume>101</volume><year>2022</year><fpage>93</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">34973396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.12.020</pub-id><pub-id pub-id-type="pmcid">PMC8715665</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Cervia-Hasler</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Persistent complement dysregulation with signs of thromboinflammation in active long covid</article-title><source>Science</source><volume>383</volume><year>2024</year><object-id pub-id-type="publisher-id">eadg7942</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adg7942</pub-id><pub-id pub-id-type="pmid">38236961</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Claros-Salinas</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Induction of cognitive fatigue in MS patients through cognitive and physical load</article-title><source>Neuropsychol. Rehabil.</source><volume>23</volume><year>2013</year><fpage>182</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">23153337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09602011.2012.726925</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>McCorkell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Topol</surname><given-names>E.J.</given-names></name></person-group><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nat. Rev. Microbiol.</source><volume>1&#8211;14</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id><pub-id pub-id-type="pmid">36639608</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Debouverie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pittion-Vouyovitch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guillemin</surname><given-names>F.</given-names></name></person-group><article-title>Validity of a French version of the fatigue impact scale in multiple sclerosis</article-title><source>Multiple Sclerosis Journal</source><volume>13</volume><year>2007</year><fpage>1026</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">17895294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458507077942</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Diez-Cirarda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Neural basis of fatigue in post-COVID syndrome and relationships with cognitive complaints and cognition</article-title><source>Psychiatry Res.</source><volume>340</volume><year>2024</year><object-id pub-id-type="publisher-id">116113</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2024.116113</pub-id><pub-id pub-id-type="pmid">39146616</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Duff</surname><given-names>E.P.</given-names></name><etal/></person-group><article-title>Plasma proteomic evidence for increased &#946;-amyloid pathology after SARS-CoV-2 infection</article-title><source>Nat. Med.</source><volume>1&#8211;10</volume><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03426-4</pub-id><pub-id pub-id-type="pmcid">PMC11922756</pub-id><pub-id pub-id-type="pmid">39885359</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Hartung</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Fatigue and cognitive impairment after COVID-19: a prospective multicentre study</article-title><source>eClinicalMedicine</source><volume>53</volume><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101651</pub-id><pub-id pub-id-type="pmcid">PMC9482331</pub-id><pub-id pub-id-type="pmid">36133318</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Heine</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Structural brain changes in patients with post-COVID fatigue: a prospective observational study</article-title><source>eClinicalMedicine</source><volume>58</volume><year>2023</year><object-id pub-id-type="publisher-id">101874</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101874</pub-id><pub-id pub-id-type="pmcid">PMC9969172</pub-id><pub-id pub-id-type="pmid">36873426</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Hosp</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Cerebral microstructural alterations in Post-COVID-condition are related to cognitive impairment, olfactory dysfunction and fatigue</article-title><source>Nat. Commun.</source><volume>15</volume><year>2024</year><fpage>4256</fpage><pub-id pub-id-type="pmid">38762609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-48651-0</pub-id><pub-id pub-id-type="pmcid">PMC11102465</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="book" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Hulley Sb</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ws</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grady</surname><given-names>D.</given-names></name></person-group><series>Designing Clinical Research: an Epidemiologic Approach</series><volume>75</volume><year>2013</year><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Philadelphia: PA</publisher-loc></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Kervevan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Divergent adaptive immune responses define two types of long COVID</article-title><source>Front. Immunol.</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1221961</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1221961</pub-id><pub-id pub-id-type="pmcid">PMC10408302</pub-id><pub-id pub-id-type="pmid">37559726</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Maliha</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Araf</surname><given-names>Y.</given-names></name></person-group><article-title>COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage</article-title><source>Mol. Biol. Rep.</source><volume>51</volume><year>2024</year><fpage>318</fpage><pub-id pub-id-type="pmid">38386201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-024-09279-x</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Mavrikaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Slack</surname><given-names>F.J.</given-names></name></person-group><article-title>Severe COVID-19 is associated with molecular signatures of aging in the human brain</article-title><source>Nature Aging</source><volume>2</volume><year>2022</year><fpage>1130</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">37118539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-022-00321-w</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Mazza</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue</article-title><source>J. Psychiatr. Res.</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2022.08.008</pub-id><pub-id pub-id-type="pmcid">PMC9391361</pub-id><pub-id pub-id-type="pmid">36029623</pub-id></element-citation></ref><ref id="bib24"><mixed-citation publication-type="other" id="sref24">Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F. &amp; Cosmi, L. in <italic toggle="yes">Seminars in Immunology</italic>. 101508 (Elsevier).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2021.101508</pub-id><pub-id pub-id-type="pmcid">PMC8547971</pub-id><pub-id pub-id-type="pmid">34728121</pub-id></mixed-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Monje</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>The neurobiology of long COVID</article-title><source>Neuron</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2022.10.006</pub-id><pub-id pub-id-type="pmcid">PMC9537254</pub-id><pub-id pub-id-type="pmid">36288726</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome</article-title><source>Metab. Brain Dis.</source><volume>28</volume><year>2013</year><fpage>523</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">22718491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-012-9324-8</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability</article-title><source>J. Neurol. Sci.</source><volume>340</volume><year>2014</year><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">24703580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2014.03.024</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Nuber-Champier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Voruz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jacot de Alc&#226;ntara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Breville</surname><given-names>G.</given-names></name><name name-style="western"><surname>Allali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lalive</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Assal</surname><given-names>F.</given-names></name><name name-style="western"><surname>P&#233;ron</surname><given-names>J.A.</given-names></name></person-group><article-title>Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of anosognosia for cognitive deficits in the chronic phase</article-title><source>Brain, behavior, &amp; immunity - health</source><volume>26</volume><year>2022</year><pub-id pub-id-type="doi">10.1016/j.bbih.2022.100511</pub-id><pub-id pub-id-type="pmcid">PMC9477785</pub-id><pub-id pub-id-type="pmid">36128057</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Nuber-Champier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Acute TNF&#945; levels predict cognitive impairment 6&#8211;9 months after COVID-19 infection</article-title><source>Psychoneuroendocrinology</source><volume>153</volume><year>2023</year><object-id pub-id-type="publisher-id">106104</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2023.106104</pub-id><pub-id pub-id-type="pmcid">PMC10066791</pub-id><pub-id pub-id-type="pmid">37104966</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Nuber-Champier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Systemic cytokines related to memory function 6&#8211;9 months and 12&#8211;15 months after SARS-CoV-2 infection</article-title><source>Sci. Rep.</source><volume>14</volume><year>2024</year><object-id pub-id-type="publisher-id">22660</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-72421-z</pub-id><pub-id pub-id-type="pmcid">PMC11443073</pub-id><pub-id pub-id-type="pmid">39349924</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Paludan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Mogensen</surname><given-names>T.H.</given-names></name></person-group><article-title>Innate immunological pathways in COVID-19 pathogenesis</article-title><source>Science immunology</source><volume>7</volume><year>2022</year><object-id pub-id-type="publisher-id">eabm5505</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abm5505</pub-id><pub-id pub-id-type="pmid">34995097</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Rubio-Perez</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Morillas-Ruiz</surname><given-names>J.M.</given-names></name></person-group><article-title>A review: inflammatory process in alzheimer' s disease, role of cytokines</article-title><source>Sci. World J.</source><volume>2012</volume><year>2012</year><object-id pub-id-type="publisher-id">756357</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1100/2012/756357</pub-id><pub-id pub-id-type="pmcid">PMC3330269</pub-id><pub-id pub-id-type="pmid">22566778</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Diverse immunological dysregulation, chronic inflammation, and impaired erythropoiesis in long COVID patients with chronic fatigue syndrome</article-title><source>J. Autoimmun.</source><volume>147</volume><year>2024</year><object-id pub-id-type="publisher-id">103267</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2024.103267</pub-id><pub-id pub-id-type="pmid">38797051</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>See&#223;le</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study</article-title><source>Clin. Infect. Dis.</source><volume>74</volume><year>2022</year><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">34223884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab611</pub-id><pub-id pub-id-type="pmcid">PMC8394862</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A digital protein microarray for COVID-19 cytokine storm monitoring</article-title><source>Lab Chip</source><volume>21</volume><year>2021</year><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">33211045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0lc00678e</pub-id><pub-id pub-id-type="pmcid">PMC7855944</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Taquet</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization</article-title><source>Nat. Med.</source><volume>1&#8211;11</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02525-y</pub-id><pub-id pub-id-type="pmcid">PMC10579097</pub-id><pub-id pub-id-type="pmid">37653345</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Voruz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Functional connectivity underlying cognitive and psychiatric symptoms in post-COVID-19 syndrome: is anosognosia a key determinant?</article-title><source>Brain communications</source><volume>4</volume><year>2022</year><object-id pub-id-type="publisher-id">fcac057</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac057</pub-id><pub-id pub-id-type="pmcid">PMC8956133</pub-id><pub-id pub-id-type="pmid">35350554</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Voruz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Frequency of abnormally low neuropsychological scores in post-COVID-19 syndrome: the Geneva COVID-COG cohort</article-title><source>Arch. Clin. Neuropsychol.</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acac068</pub-id><pub-id pub-id-type="pmcid">PMC9384624</pub-id><pub-id pub-id-type="pmid">35942646</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Voruz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Persistence and emergence of new neuropsychological deficits following SARS-CoV-2 infection: a follow-up assessment of the Geneva COVID-COG cohort</article-title><source>J. Glob. Health</source><volume>14</volume><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.7189/jogh.14.05008</pub-id><pub-id pub-id-type="pmcid">PMC10919907</pub-id><pub-id pub-id-type="pmid">38452292</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Weinges-Evers</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Correlation of self-assessed fatigue and alertness in multiple sclerosis</article-title><source>Multiple Sclerosis Journal</source><volume>16</volume><year>2010</year><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">20610494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458510374202</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fimm</surname><given-names>B.</given-names></name></person-group><article-title>Test for attentional performance (TAP)</article-title><source>PsyTest, Herzogenrath</source><volume>76&#8211;77</volume><year>1995</year><comment>1995</comment></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0420">The following is the Supplementary data to this article.<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0025">Data will be made available on request.</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0325">A. Nuber-Champier: Contributed to the writing, analysis and examination of the patients in the study.</p><p id="p0330">G. Breville: Contributed to the writing and examination of the cytokines in the study. P.</p><p id="p0335">Voruz: Contributed to the writing and examination of the patients in the study.</p><p id="p0340">I. Jacot de Alc&#226;ntara: Contributed to the writing and examination of the patients in the study.</p><p id="p0345">G. Allali: Contributed to the neurological expertise, writing and proofreading of the analyses and interpretations.</p><p id="p0350">P.H. Lalive: Contributed to the neuro-immunological expertise, writing and proofreading of the analyses and interpretations.</p><p id="p0355">L. Benzakour: Contributed to the psychiatric expertise, writing and proofreading.</p><p id="p0360">K.-O. L&#246;vblad: Contributed to the expertise in neuroimaging, writing and proofreading, as well as the hospital organization in the realization of MRI.</p><p id="p0365">O. Braillard: Contributed to the coordination of the patients and the review of this work.</p><p id="p0370">M. Nehme: Contributed to the coordination of the patients and the review of this work.</p><p id="p0375">M. Coen: Contributed to the coordination of the patients and the review of this work.</p><p id="p0380">J. Serratrice: Contributed to the coordination of the patients and the review of this work.</p><p id="p0385">J.-L Reny: Contributed to the coordination of the patients and the review of this work.</p><p id="p0390">J. Pugin: Contributed to the coordination of the patients and the review of this work.</p><p id="p0395">I. Guessous: Contributed to the coordination of the patients and the review of this work.</p><p id="p0400">B.N. Landis: Contributed to the coordination of the patients and the review of this work.</p><p id="p0405">A. Cionca: Contributed to the writing and analysis in the study.</p><p id="p0410">F. Assal: Contributed to the writing of the overall project, proofreading and scientific direction.</p><p id="p0415">J.A. P&#233;ron: Contributed to the writing of the overall project, proofreading and scientific direction.</p></ack><fn-group><fn id="d36e245"><p id="ntpara0010">This article is part of a special issue entitled: Post-COVID19 condition published in Brain, Behavior, &amp; Immunity - Health.</p></fn><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0425">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbih.2025.101109" id="intref0015">https://doi.org/10.1016/j.bbih.2025.101109</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomol Biomed</journal-id><journal-id journal-id-type="iso-abbrev">Biomol Biomed</journal-id><journal-id journal-id-type="pmc-domain-id">4372</journal-id><journal-id journal-id-type="pmc-domain">biomolbiomed</journal-id><journal-title-group><journal-title>Biomolecules and Biomedicine</journal-title></journal-title-group><issn pub-type="ppub">2831-0896</issn><issn pub-type="epub">2831-090X</issn><publisher><publisher-name>Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505532</article-id><article-id pub-id-type="pmcid-ver">PMC12505532.1</article-id><article-id pub-id-type="pmcaid">12505532</article-id><article-id pub-id-type="pmcaiid">12505532</article-id><article-id pub-id-type="pmid">40613579</article-id><article-id pub-id-type="doi">10.17305/bb.2025.12378</article-id><article-id pub-id-type="publisher-id">BB-26-333</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Unveiling etiology and mortality risks in community-acquired pneumonia: A machine learning approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="A">Alaa</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alsayed</surname><given-names initials="AR">Ahmad R</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seder</surname><given-names initials="N">Nesrin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jarrar</surname><given-names initials="Y">Yazun</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Altabanjeh</surname><given-names initials="RH">Raed H</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zihlif</surname><given-names initials="M">Mamoon</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ata</surname><given-names initials="OA">Osama Abu</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samara</surname><given-names initials="A">Anas</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zihlif</surname><given-names initials="M">Malek</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Clinical Pharmacy and Therapeutics, Applied Science Private University, Amman, Jordan</aff><aff id="aff2"><label>2</label>Department of Pharmaceutical Chemistry and Pharmacognosy, Applied Science Private University, Amman, Jordan</aff><aff id="aff3"><label>3</label>Department of Basic Medical Sciences, Faculty of Medicine, Al-Balqa Applied University, Al-Salt, Jordan</aff><aff id="aff4"><label>4</label>Department of Internal Medicine, Section of Pulmonary, Islamic Hospital, Amman, Jordan</aff><aff id="aff5"><label>5</label>Department of Internal Medicine, Section of Infectious Diseases, Islamic Hospital, Amman, Jordan</aff><aff id="aff6"><label>6</label>Department of Software Engineering, Bethlehem University, Bethlehem, Palestine</aff><aff id="aff7"><label>7</label>Department of Pharmacology, School of Medicine, The University of Jordan, Amman, Jordan</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence to Ahmad R. Alsayed: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:a.alsayed.phd@gmail.com">a.alsayed.phd@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2025</year></pub-date><volume>26</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">498542</issue-id><fpage>333</fpage><lpage>353</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Ali et al.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is available under a Creative Commons License (Attribution 4.0 International, as described at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bb-2025-12378.pdf"/><abstract><p>Community-acquired pneumonia (CAP) is associated with high mortality, and accurate diagnosis and risk prediction are essential for improving patient outcomes. Traditional diagnostic methods have limitations, prompting the use of machine learning (ML) to enhance diagnostic precision and treatment strategies. This study aims to develop ML models to predict CAP etiology and mortality using clinical data to enable early intervention. A retrospective cohort study was conducted on 251 adult CAP patients admitted to two Jordanian hospitals between March 2021 and February 2024. Various clinical data were analyzed using ML techniques, including linear regression, random forest, Shapley additive explanations (SHAP), lasso regression, mutual information analysis, logistic regression, and correlation analysis. Key predictors of CAP survival included zinc, vitamin C, enoxaparin, and insulin bolus. Mutual information analysis identified neutrophils, alanine transaminase, mean corpuscular volume, hemoglobin, and platelets as significant mortality predictors, while lasso regression highlighted meropenem, arterial blood gases, PCO<sub>2</sub>, and platelet count. Logistic regression confirmed intensive care unit (ICU) stay, pH, pulmonary severity index, white blood cell (WBC) count, and bicarbonate levels as crucial variables. Interestingly, lymphocyte count emerged as the strongest predictor of bacterial CAP, conflicting with established knowledge that associates neutrophils with bacterial infections. However, findings related to HCO<sub>3</sub>, blood urea nitrogen, and WBC levels were consistent with clinical expectations. SHAP analysis highlighted basophils and fever as key predictors. Further investigation is needed to resolve conflicting findings and optimize predictive models. ML offers promising applications for CAP prognosis but requires refinement to address discrepancies and improve reliability in clinical decision-making.</p></abstract><kwd-group><kwd>Community-acquired pneumonia</kwd><kwd>CAP</kwd><kwd>machine learning</kwd><kwd>ML</kwd><kwd>mortality prediction</kwd><kwd>risk assessment</kwd><kwd>clinical predictors</kwd><kwd>SHAP analysis</kwd><kwd>logistic regression</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Community-acquired pneumonia (CAP) is a significant public health challenge worldwide, contributing to considerable morbidity and mortality across various age groups [<xref rid="ref1" ref-type="bibr">1</xref>]. Defined as pneumonia acquired outside of a hospital or healthcare setting, CAP remains a leading cause of death not only in underdeveloped regions but also in developed countries [<xref rid="ref2" ref-type="bibr">2</xref>]. Effective management of CAP, essential for improving patient outcomes, relies heavily on the accurate and timely identification of its etiology and the assessment of potential mortality risks. Machine learning (ML), a key component of artificial intelligence (AI), has shown promising results in enhancing diagnostic precision, optimizing therapeutic strategies, and predicting clinical outcomes in various medical fields [<xref rid="ref3" ref-type="bibr">3</xref>]. However, the potential of ML to transform clinical approaches to CAP has yet to be fully realized, particularly in integrating diverse datasets to predict disease etiology and outcomes [<xref rid="ref4" ref-type="bibr">4</xref>]. This study aims to bridge this gap by focusing on employing ML techniques to predict the causes and mortality associated with CAP. The integration of ML tools into CAP management has the potential to significantly enhance diagnostic accuracy, inform treatment plans, and ultimately improve prognostic outcomes for patients [<xref rid="ref5" ref-type="bibr">5</xref>]. By exploring these possibilities, this research aims to reinforce the evidence base by reliably correlating clinical data with patient prognosis through sophisticated algorithmic analysis. The successful implementation of this research could revolutionize the management of CAP, leading to more personalized healthcare and better resource distribution in treating this prevalent disease. CAP remains a significant healthcare challenge, ranking globally as a major cause of morbidity and mortality [<xref rid="ref1" ref-type="bibr">1</xref>]. Each year, CAP leads to numerous hospital admissions, placing a heavy burden on medical staff, especially in high-risk groups such as the elderly and those with immune-compromising conditions [<xref rid="ref6" ref-type="bibr">6</xref>]. The clinical presentations of CAP vary widely, ranging from mild respiratory symptoms to severe cases requiring intensive care. This variability is largely due to the wide range of pathogens that can cause CAP, including bacteria, viruses, and atypical organisms [<xref rid="ref7" ref-type="bibr">7</xref>]. Current tools for diagnosing CAP, such as chest X-rays, microbial cultures, and molecular tests, often fail to immediately and accurately identify the causative agent. This limitation complicates the selection of appropriate treatment regimens, ultimately impacting patient outcomes [<xref rid="ref8" ref-type="bibr">8</xref>]. Additionally, the growing resistance to antimicrobial agents among common respiratory pathogens further complicates CAP management, underscoring the importance of effective, accurately targeted initial empirical therapy [<xref rid="ref9" ref-type="bibr">9</xref>]. Predicting outcomes for CAP patients also poses challenges, arising from the variability in patient responses to the disease. Factors such as underlying health conditions and age significantly influence outcomes. Current predictive models lack the precision needed to guide critical decisions about treatment intensity or hospitalization [<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>]. Given these challenges, there is a pressing need for enhanced diagnostic and predictive capabilities in managing CAP. ML presents a promising solution due to its ability to process large and complex datasets, potentially uncovering patterns that improve diagnostic accuracy, personalize treatment, and predict outcomes more effectively [<xref rid="ref12" ref-type="bibr">12</xref>]. These advancements could significantly improve clinical decision-making, reducing treatment failures and minimizing the health burden associated with CAP. The study of ML applications in predicting the etiology and mortality of CAP is crucial for several reasons. First, enhancing diagnostic accuracy directly impacts treatment efficacy. Accurate early diagnosis allows for timely and targeted treatment, which is critical in reducing disease severity and improving recovery rates. Second, improving mortality prediction enables healthcare providers to make more informed decisions about the level of care required. Patients with a poor prognosis could be prioritized for intensive interventions, potentially improving survival rates. Conversely, reliable predictors of lower risk could help avoid unnecessary hospital admissions, reducing healthcare costs and minimizing the risk of hospital-acquired infections [<xref rid="ref13" ref-type="bibr">13</xref>]. Furthermore, integrating ML into medical practice addresses the challenge of clinical variability in CAP treatment, aligning with the goals of precision medicine. This not only improves health outcomes but also personalizes patient care, leading to better patient experiences and improved adherence to treatment plans. Lastly, the healthcare industry stands to benefit from improved resource distribution. ML can ensure that staffing, equipment, and medications are available when needed, enhancing the overall efficiency of healthcare delivery systems [<xref rid="ref14" ref-type="bibr">14</xref>]. This research seeks to apply ML comprehensively within the healthcare sector, demonstrating how technology can intersect with clinical expertise to significantly improve patient outcomes and the operational efficiency of healthcare systems. Despite the extensive use of ML in medical diagnostics, its application in predicting the etiology and mortality of CAP remains underexplored. Most existing studies focus primarily on diagnosis and treatment outcomes but rarely combine ML techniques to predict causal pathogens and associated mortality rates based on large datasets. This gap is particularly significant because timely and accurate determination of CAP etiology and prognosis could significantly enhance treatment strategies and patient outcomes. The intersection of CAP management and ML offers significant potential to improve healthcare outcomes. However, there is a noticeable lack of research integrating these two fields. While the literature comprehensively addresses CAP diagnostic procedures and treatment methods [<xref rid="ref2" ref-type="bibr">2</xref>], as well as the application of ML in medical diagnostics separately [<xref rid="ref12" ref-type="bibr">12</xref>], few studies have specifically explored the use of ML to predict CAP etiology and mortality. The current landscape of clinical prediction models for diseases like CAP reveals a critical gap in using predictive modeling to anticipate both the disease etiology and outcomes [<xref rid="ref15" ref-type="bibr">15</xref>]. While studies have demonstrated the feasibility of using ML to predict outcomes in pneumonia cases [<xref rid="ref16" ref-type="bibr">16</xref>], there is limited focus on directly correlating these outcomes with causative pathogens&#8212;a crucial component for determining appropriate therapeutic approaches [<xref rid="ref15" ref-type="bibr">15</xref>]. Research in fields like cardiology and oncology has made significant strides in utilizing ML technologies [<xref rid="ref17" ref-type="bibr">17</xref>]. However, similar advancements in infectious diseases, particularly CAP, remain limited [<xref rid="ref18" ref-type="bibr">18</xref>]. While some studies have shown the potential of ML in predicting mortality and disease progression in COVID-19 pneumonia cases [<xref rid="ref19" ref-type="bibr">19</xref>], and in developing models to predict adverse outcomes in CAP [<xref rid="ref20" ref-type="bibr">20</xref>], further exploration is needed. Efforts have been made to predict the outcome of SARS-CoV-2 pneumonia based on laboratory findings [<xref rid="ref20" ref-type="bibr">20</xref>], as well as to develop models for predicting the severity and mortality of COVID-19 pneumonia patients [<xref rid="ref21" ref-type="bibr">21</xref>]. In pneumonia, where up to 50% of cases lack identified causative pathogens [<xref rid="ref21" ref-type="bibr">21</xref>], ML could offer a promising avenue for predicting outcomes and informing treatment decisions. By integrating comprehensive patient histories, clinical signs, and diagnostic data with predictive modeling techniques, we could significantly enhance the understanding and management of diseases like CAP. The primary aim of this study is to develop, validate, and implement ML models specifically designed to predict the etiology and mortality of CAP. This involves creating models that utilize clinical data, including diverse symptoms and outcomes associated with CAP. Ultimately, the goal is to provide healthcare professionals with advanced, data-driven tools to enhance decision-making processes, leading to more accurate and timely interventions, personalized treatment regimens, and improved patient prognosis.</p></sec><sec id="sec2"><title>Materials and methods</title><sec id="sec2a"><title>Study design and participants</title><p>This retrospective cohort multicenter study included 251 adult patients from Prince Hamza Hospital and the Islamic Hospital, ensuring diverse patient demographics, clinical variables, and a comprehensive dataset. The participants were adults diagnosed with CAP who were admitted to the participating hospitals between March 10, 2021, and February 15, 2024. This timeframe allowed for a substantial number of cases, enhancing the statistical power and validity of the study. Inclusion criteria consisted of patients with a confirmed diagnosis of CAP, based on chest radiography or computed tomography (CT) scans, if performed, and presenting symptoms consistent with pneumonia, such as cough, fever, sputum production, and dyspnea. Microbiological laboratory results were included when available. Both intensive care unit (ICU) and ward patients were included to represent a range of disease severities. Exclusion criteria included patients with hospital-acquired pneumonia (HAP), patients transferred from outside hospitals more than 48 h after admission, and those with incomplete medical records. Patients with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) and those receiving long-term immunosuppressive therapy were also excluded to avoid potential confounding effects related to different immune responses. In compliance with laws and regulations governing medical research, the study ensured the privacy and confidentiality of participant data. The Institutional Review Board (IRB) of each clinical site approved the study, with all data de-identified and stored in secure databases to protect patient confidentiality. The study adheres to the Declaration of Helsinki. Ethical approval was obtained from the Applied Science Private University (Jordan), the Islamic Hospital Ethical Committee in Amman, Jordan, and Prince Hamza Hospital in Amman, Jordan (2021-PHA-35, IRB: 101/2021/1053, and 6-11-2021-129, respectively).</p></sec><sec id="sec2b"><title>Data collection</title><p>The data for the participants was gathered from medical records and electronic databases. Originally recorded in Excel, the dataset contains information about CAP patients, including vital signs, physical and laboratory findings, length of stay (LOS), and in-hospital mortality. This information was sourced from electronic medical records, with additional input from partnerships with hospitals and healthcare providers treating CAP patients. The key elements of the data collection process include:
<list list-type="order"><list-item><p><bold>Demographic information</bold>: Age, gender, and other relevant demographic factors that can influence disease outcomes.</p></list-item><list-item><p><bold>Clinical data</bold>: Detailed records of symptoms, duration of illness, previous health conditions, and clinical findings during physical examinations.</p></list-item><list-item><p><bold>Radiological data</bold>: The radiological data (Chest X-rays, and CT scans) were interpreted by two clinicians, who provided standardized findings such as the presence of pulmonary infiltrates, consolidation, or effusion</p></list-item><list-item><p><bold>Microbiological data</bold>: Results from respiratory sample cultures, blood tests, and other relevant microbiological investigations like the molecular methods (the real-time polymerase chain reaction [PCR]) used to determine the etiology of pneumonia.</p></list-item><list-item><p><bold>Laboratory results</bold>: Complete blood counts, C-reactive protein levels, arterial blood gases, and other relevant laboratory tests performed during hospitalization.</p></list-item><list-item><p><bold>Treatment details</bold>: Information on the medications prescribed, including type, dosage, and duration.</p></list-item><list-item><p><bold>Outcome data</bold>: Details of the patient&#8217;s recovery, mainly in-hospital mortality.</p></list-item></list></p></sec><sec id="sec2c"><title>Data preparation</title><p>Before starting ML modeling, we cleaned the medical files records that we collected. At the beginning we had 587 patient files with pneumonia diagnosis. After we removed the files with HAP, ventilator-associated pneumonia (VAP) and duplicated CAP files we reduced the number to 412 cases.</p><p>The files at the beginning had multiple lab results and vital signs records taken over the LOS in the hospital of the patients. In our study the aim is to make a rapid decision about the clinical situation of the patients within few hours of the admission, so we had got only the first records for the lab results and vital signs reading (the number of features reduced from 3562 to 665 features).</p><p>We conducted data preprocessing steps over the left CAP files after cleaning, involved handling missing values- some files had high percentage of missing data, so we dropped them and finally reached 251 patients files. Other files with low percentage of missing, we normalized continuous variables and encoding categorical variables. Libraries such as Pandas and NumPy were employed to make data manipulation more efficient, ensuring consistency and accuracy. The normal ranges were used to handle missing values.</p><p>To optimize the dataset, columns with a single value or where 95% or more of the entries were identical were removed. These columns provided little to no meaningful information when analyzing correlations with the target variable. Their inclusion would have unnecessarily increased the dimensionality of the data, introducing low variance, adding noise, and potentially leading to biased results or overfitting. By eliminating these columns, the dataset was simplified, reducing noise and improving its overall quality for subsequent analysis. The number of features now is 132 features. This step is called features selection.</p></sec><sec id="sec2d"><title>ML techniques and feature evaluation</title><p>ML techniques were applied to analyze the collected data and develop predictive models for CAP&#8217;s etiology and mortality outcomes. The selection of appropriate ML algorithms is crucial for handling the complexity and variety of the data involved. These techniques were chosen based on their proven effectiveness in similar healthcare datasets [<xref rid="ref22" ref-type="bibr">22</xref>]. This section outlines the methodology used to evaluate the impact of the most important features on the target variable using seven distinct approaches: linear regression, random forest, mutual information analysis, Lasso regression, logistic regression, Shapley additive explanations (SHAP) values, and correlation analysis. Each method provides unique insights into the relationship between the features and the target variable. The dataset was randomly divided into training and testing subsets using an 80:20 split ratio. Additionally, model performance and generalizability were assessed using 5-fold cross-validation within the training data. The average performance metrics across the folds were reported to ensure robustness.</p><sec id="sec2d1"><title>Linear regression coefficients</title><p>Linear regression was employed to understand the linear relationships between each feature and the target variable. The coefficients derived from the model indicate the direction and magnitude of the feature&#8217;s impact [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>]. This analysis provides a straightforward interpretation of feature contributions in a linear framework.</p></sec><sec id="sec2d2"><title>Random forest</title><p>A random forest model was used to assess the relative importance of features in predicting the target variable. Feature importance scores were computed, indicating how critical each feature is for model predictions [<xref rid="ref25" ref-type="bibr">25&#8211;27</xref>]. Features with higher importance scores play a more significant role in predictions, while those with lower scores have a minor impact. Unlike linear regression, which assumes linear relationships between variables, Random Forest can capture complex, non-linear relationships, providing a complementary perspective on feature importance.</p></sec><sec id="sec2d3"><title>Mutual information analysis</title><p>Mutual information analysis is a statistical technique used to measure the dependence between two variables. It quantifies how much information knowing one variable provides about the other [<xref rid="ref28" ref-type="bibr">28</xref>]. Rooted in information theory, mutual information is widely used in fields like ML, data analysis, and bioinformatics. In the medical field, mutual information serves as a valuable tool for analyzing the relationship between medical predictors (such as biomarkers, test results, and demographic data) and health outcomes (such as disease presence, survival rates, or treatment effectiveness). By quantifying the dependency between predictors and outcomes, mutual information aids in tasks like feature selection, diagnostic modeling, and risk stratification [<xref rid="ref29" ref-type="bibr">29</xref>].</p></sec><sec id="sec2d4"><title>Least absolute shrinkage and selection operator (Lasso) regression</title><p>Lasso is a type of linear regression that performs both feature selection and regularization to enhance prediction accuracy and interpretability. It is a statistical technique that can be used to study the effects of clinical variables in outcome prediction [<xref rid="ref30" ref-type="bibr">30</xref>].</p></sec><sec id="sec2d5"><title>Logistic regression</title><p>Logistic regression is a widely used statistical and ML technique in clinical research for predicting binary outcomes, such as disease presence (yes/no), treatment success (effective/ineffective), or survival (alive/deceased). It estimates the probability that a given input belongs to a particular class based on clinical predictors (e.g., age, blood pressure, and cholesterol levels).</p></sec><sec id="sec2d6"><title>SHAP values</title><p>SHAP values were used to explain the contribution of individual features to the model&#8217;s predictions. SHAP analysis was employed not as a standalone predictive model but as a post hoc interpretability tool to explain the output of the trained random forest model. The SHAP values quantified the contribution of individual features to the model&#8217;s predictions, enhancing the interpretability and transparency of the decision-making process. This method provides detailed insights into both the magnitude and direction of feature impact: blue points represent lower feature values that contribute less to the target, while red points represent higher feature values that contribute more. An SHAP summary plot was generated to visualize the overall influence of each feature on the target variable. This method is particularly useful for verifying the impact direction indicated by linear models and for uncovering interactions and non-linear relationships [<xref rid="ref31" ref-type="bibr">31</xref>].</p></sec><sec id="sec2d7"><title>Correlation with the target</title><p>Correlation analysis was conducted to measure the linear relationship between each feature and the target variable [<xref rid="ref24" ref-type="bibr">24</xref>]. Positive correlation indicates that as the feature increases, the target variable also increases. Whereas, negative correlation indicates that as the feature increases, the target variable decreases.</p><p>While correlation provides a simple measure of association, it does not account for non-linear relationships or interactions between features [<xref rid="ref24" ref-type="bibr">24</xref>].</p><p>Each model was trained and validated on separate data splits to assess their performance accurately. Cross-validation techniques ensure that the models generalize well on unseen data. The performance of each method was measured using appropriate metrics such as accuracy, sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve.</p><p>To have an accurate and unbiased model, we made sure that our dataset is balanced. A balanced dataset with an equal number of observations for both recovered and dead patients was created to train and test our model. The data samples (patients) in the training dataset have been selected randomly and they were completely separated from the testing data (<xref rid="f1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure 1.</label><caption><p><bold>Overview of the six-step machine learning workflow for predicting outcome probabilities</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f1.jpg"/></fig><p>Prior to balancing, the dataset exhibited a class imbalance with a higher proportion of survivors compared to non-survivors. To solve this issue, a random oversampling of the minority group (survivors) was performed to achieve a 1:1 class distribution in the training set. This resampling was conducted exclusively on the training data to avoid information leakage and ensure a fair evaluation of the model&#8217;s performance.</p></sec></sec><sec id="sec2l"><title>Tools and software</title><p>Analysis was conducted using Python programming language in a Jupyter Notebook environment. Key libraries utilized include:</p><p>Pandas: For data manipulation and cleaning.</p><p>NumPy: For numerical operations.</p><p>Matplotlib/Seaborn: For data visualization.</p><p>These tools ensured the efficient handling of large datasets and the generation of high-quality visualizations to identify patterns and outliers.</p></sec><sec id="sec2m"><title>Data transformation</title><p>After removing unnecessary columns, the dataset was further refined by encoding categorical variables. Columns with string values were identified, and a LabelEncoder was applied to convert them into numeric values. With the number of columns reduced from 665 to 132, LabelEncoder was chosen for its simplicity and efficiency, especially for columns with only two categories. This approach helped maintain the dataset&#8217;s simplicity, avoiding additional complexity that could have posed challenges in analysis and modeling.</p></sec><sec id="sec2n"><title>Exploratory data analysis (EDA)</title><p>EDA was performed to understand the distribution of variables, detect anomalies, and assess correlations between features. Statistical summaries were computed to identify key trends, and graphical methods such as bar charts, heatmaps and SHAP Summary Plots were generated.</p></sec><sec id="sec2o"><title>Feature selection</title><p>A total of 132 features were selected from the original dataset in a process called feature selection. All relevant features were extracted during this step. The primary goal of feature selection is to identify the most informative features while removing redundant ones, thereby reducing the model&#8217;s dimensionality and complexity. The selected features included demographic data, clinical characteristics, and laboratory results collected at the time of admission. Predictor variables consisted of age, gender, vital signs (e.g., blood pressure, heart rate, respiratory rate, and temperature), the number of medical comorbidities (such as hypertension and diabetes mellitus [DM]), laboratory data (including Complete Blood Count, Comprehensive Metabolic Panel, and arterial blood gas (ABG) tests), and clinical scores (such as pneumonia severity index (PSI) and CURB-65). <xref rid="TB1" ref-type="table">Table 1</xref> presents these features.</p><table-wrap position="float" id="TB1" orientation="portrait"><label>Table 1</label><caption><p>Features utilized in the machine learning algorithm</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="left"/><col span="3" align="left"/><col span="4" align="left"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">Demographic</th><th rowspan="1" colspan="1">Age</th></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Clinical finding</td><td rowspan="1" colspan="1">Number of hospitalizations</td><td rowspan="1" colspan="1">Number of pneumonia</td><td rowspan="1" colspan="1">Temperature</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Pulse</td><td rowspan="1" colspan="1">Respiratory rate</td><td rowspan="1" colspan="1">SBP</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">DBP</td><td rowspan="1" colspan="1">LOS</td><td rowspan="1" colspan="1">PSI class</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Oxygen saturation</td><td rowspan="1" colspan="1">Oxygen therapy</td><td rowspan="1" colspan="1">PSI</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CURB-65</td><td rowspan="1" colspan="1">Initial finding fever</td><td rowspan="1" colspan="1">Initial finding shortness of breath</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Location</td><td rowspan="1" colspan="1">ICU length of stay</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Laboratory results</td><td rowspan="1" colspan="1">Glucose serum</td><td rowspan="1" colspan="1">Hemoglobin A1C (HbA1c)</td><td rowspan="1" colspan="1">Random blood glucose</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PaO<sub>2</sub></td><td rowspan="1" colspan="1">PCO<sub>2</sub></td><td rowspan="1" colspan="1">HCO<sub>3</sub></td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ABG BE</td><td rowspan="1" colspan="1">Albumin serum</td><td rowspan="1" colspan="1">CPK</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">BUN</td><td rowspan="1" colspan="1">Alkaline phosphatase</td><td rowspan="1" colspan="1">ALT</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AST</td><td rowspan="1" colspan="1">Total Bilirubin</td><td rowspan="1" colspan="1">Direct Bilirubin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Amylase serum</td><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">Hemoglobin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HCT</td><td rowspan="1" colspan="1">MCH</td><td rowspan="1" colspan="1">MCV</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MCHC</td><td rowspan="1" colspan="1">PDW</td><td rowspan="1" colspan="1">Platelet count</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">RDW</td><td rowspan="1" colspan="1">MPV</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RBC</td><td rowspan="1" colspan="1">ESR</td><td rowspan="1" colspan="1">Lymphocytes count</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Monocytes count</td><td rowspan="1" colspan="1">Eosinophils count</td><td rowspan="1" colspan="1">Basophils count</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Neutrophils count</td><td rowspan="1" colspan="1">Magnesium serum</td><td rowspan="1" colspan="1">Potassium serum</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Calcium serum</td><td rowspan="1" colspan="1">Sodium serum</td><td rowspan="1" colspan="1">Total protein</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">SGOT</td><td rowspan="1" colspan="1">SGPT</td><td rowspan="1" colspan="1">Creatinine serum</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Urine PH</td><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">PCT</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Uric acid</td><td rowspan="1" colspan="1">HDL cholesterol</td><td rowspan="1" colspan="1">LDL cholesterol</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Prothrombin time</td><td rowspan="1" colspan="1">D-dimer</td><td rowspan="1" colspan="1">INR</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">LDH</td><td rowspan="1" colspan="1">Troponin</td><td rowspan="1" colspan="1">aPTT</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Culture</td><td rowspan="1" colspan="1">Sputum culture</td><td rowspan="1" colspan="1">Urine character hazy</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PCR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Medical history</td><td rowspan="1" colspan="1">DM</td><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">CVD</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Alzheimer</td><td rowspan="1" colspan="1">COVID-19</td><td rowspan="1" colspan="1">Hypotension</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Septic shock</td><td rowspan="1" colspan="1">Cough</td><td rowspan="1" colspan="1">Dry cough</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chest pain</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Medication</td><td rowspan="1" colspan="1">Imipenem</td><td rowspan="1" colspan="1">Cefepime</td><td rowspan="1" colspan="1">Vancomycin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Meropenem</td><td rowspan="1" colspan="1">Ceftriaxone</td><td rowspan="1" colspan="1">Levofloxacin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Susceptibility Imipenem</td><td rowspan="1" colspan="1">Susceptibility Piperacillin tazobactam</td><td rowspan="1" colspan="1">Imipenem cilastatin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Susceptibility Meropenem</td><td rowspan="1" colspan="1">Susceptibility Cefepime</td><td rowspan="1" colspan="1">Susceptibility Levofloxacin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Susceptibility Ceftazidime</td><td rowspan="1" colspan="1">Susceptibility Aztreonam</td><td rowspan="1" colspan="1">Susceptibility Ciprofloxacin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Susceptibility Amikacin</td><td rowspan="1" colspan="1">Amlodipine</td><td rowspan="1" colspan="1">Aspirin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Bisoprolol</td><td rowspan="1" colspan="1">Vitamin C</td><td rowspan="1" colspan="1">Atorvastatin</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Cilastatin</td><td rowspan="1" colspan="1">Furosemide</td><td rowspan="1" colspan="1">Lansoprazole</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Enoxaparin</td><td rowspan="1" colspan="1">Insulin basal</td><td rowspan="1" colspan="1">Lactulose</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Enalapril</td><td rowspan="1" colspan="1">Insulin bolus</td><td rowspan="1" colspan="1">Omeprazole</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Prednisolone</td><td rowspan="1" colspan="1">Tocilizumab</td><td rowspan="1" colspan="1">Anti-platelet</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Zinc</td><td rowspan="1" colspan="1">Antibiotics</td><td rowspan="1" colspan="1">Anti-coagulant</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">B complex</td><td rowspan="1" colspan="1">Antiviral</td><td rowspan="1" colspan="1">Number of PRN medications</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">mAb tocilizumab</td><td rowspan="1" colspan="1">Number of medications</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Number of regular medications</td><td rowspan="1" colspan="1">Guideline concordant antibiotics</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LOS: Length of stay; PSI: Pneumonia severity index; CURB-65: Confusion, urea, respiratory rate, blood pressure, age &#8805;65; ICU: Intensive care unit; HbA1c: Hemoglobin A1C; PaO<sub>2</sub>: Partial pressure of oxygen; PaCO<sub>2</sub>: Partial pressure of carbon dioxide; HCO<sub>3</sub>: Bicarbonate; ABG BE: Base excess of arterial blood gas; CPK: Creatine phosphokinase; BUN: Blood urea nitrogen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; SGOT: Serum glutamic-oxaloacetic transaminase; SGPT: Serum glutamic-pyruvic transaminase; MCV: Mean corpuscular volume; HCT: Hematocrit; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; PDW: Platelet distribution width; WBC: White blood cell count; RDW: Red blood cell distribution width; MPV: Mean platelet volume; RBC: Red blood cell count; ESR: Erythrocyte sedimentation rate; PCR: Polymerase chain reaction; PCT: Procalcitonin; CRP: C reactive protein; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; INR: International normalized ratio; LDH: Lactate dehydrogenase; aPTT: Activated partial thromboplastin time; DM: Diabetes mellitus; CVD: Cardiovascular disease; PRN: Per registered nurse (as needed).</p></table-wrap-foot></table-wrap></sec><sec id="sec2p"><title>Statistical analysis</title><p>Statistical analyses were performed, followed by the development of predictive models to forecast key variables.</p><p>The statistical analysis starts with examining the data collected through descriptive statistics to identify the central tendencies, normality distribution (using Shapiro&#8211;Wilk test, <italic toggle="yes">Q</italic>&#8211;<italic toggle="yes">Q</italic>, and distribution plots), and variability. Continuous variables were summarized using means and standard deviations (SD) or medians and interquartile ranges (IQR), depending on normality assessment, in addition to frequencies and percentages for categorical variables. The statistical analysis was conducted using JASP 18.3.0 (Jeffreys&#8217;s Amazing Statistics Program) and IBM SPSS statistics 25.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3a"><title>Demographic and clinical characteristics</title><p>A sample of 251 participants was included in this study. The median for their age was 60 years (IQR &#9552; 25). Most were male 146 (58.2%) and 105 (41.8%) were female. The majority of patients were admitted to the ICU (221, 88.0%) compared to the Ward (30, 12.0%). The median LOS for all patients was 10 days (IQR 13). For patients in the ICU, the median ICU LOS (ICU_LOS) was 4.77 days (IQR 1.77).</p><p>Regarding COVID-19 status, 18 (7.2%) had a current SARS-CoV2 infection, and 9 (3.6%) had a previous history of COVID-19 (<xref rid="TB2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="TB2" orientation="portrait"><label>Table 2</label><caption><p>Demographic and clinical data of participants (<italic toggle="yes">n</italic> &#9552; 251)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="center"/><col span="3" align="center"/><col span="4" align="center"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Feature</bold>
</th><th rowspan="1" colspan="1">
<bold>Frequency</bold>
</th><th rowspan="1" colspan="1">
<bold>Valid percentage %</bold>
</th><th rowspan="1" colspan="1">
<bold>Median (IQR)</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60 (IQR = 25)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Location</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Ward</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">12.0</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;ICU</td><td rowspan="1" colspan="1">221</td><td rowspan="1" colspan="1">88.0</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;&#8195;LOS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10 days (IQR = 13)</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;&#8195;ICU_LOS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4.77 days (IQR = 1.77)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Current COVID_19</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">7.2</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Previous COVID_19</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">3.6</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Diseases</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;DM</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">30.3</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Septic shock</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">25.5</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;HTN</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">13.1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;CVD</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">8.8</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Alzheimer&#8217;s disease</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">6.8</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Another lung disease</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">5.6</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;CKD</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Anemia</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2.8</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Asthma</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2.4</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;COPD</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Hypotension</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;GERD</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Dyslipidemia</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">History</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Number of previous pneumonias</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.77 (IQR = 0)</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Number of previous hospitalizations</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.4 (IQR = 3.7)</td></tr><tr valign="top"><td rowspan="1" colspan="1">&#8195;Kidney transplantation</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: ICU: Intensive care unit; LOS: Length of stay; ICU_LOS: Intensive care unit length of stay; DM: Diabetes mellitus; HTN: Hypertension; CVD: Cardiovascular disease; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; GERD: Gastroesophageal reflux disease.</p></table-wrap-foot></table-wrap><p>Participants had a high prevalence of comorbidities, with DM being the most prevalent (30.3%), followed by septic shock (25.5%), hypertension (13.1%), and cardiac diseases (8.8%). Other reported conditions were Alzheimer&#8217;s disease (6.8%), chronic kidney disease (4.8%), anemia (2.8%), asthma (2.4%), and chronic obstructive pulmonary disease (COPD) (2.0%) (<xref rid="TB2" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3b"><title>Treatment background characteristics</title><p>The chronic treatments varied, with vitamin C and zinc supplements showing the highest rates of use, due to COVID-19 recommendations at the time for their prophylactic and supportive effects (29.1% and 27.5%, respectively). Insulin therapy was also used, with 24.7% of patients receiving insulin bolus and 15.9% on basal insulin, alongside DM as the most common chronic condition. Other frequently used medications included omeprazole (19.1%), bisoprolol (17.9%), and B complex vitamins (16.3%) (<xref rid="TB3" ref-type="table">Table 3</xref>). The most common short-term treatments were antibiotics (80.1%), anticoagulants (78.1%), and enoxaparin (77.7%). Antiviral agents were used by a small proportion of patients (8.0%), and only 4.8% received supportive drugs, including albumin, favipiravir, and norepinephrine injections (<xref rid="TB3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="TB3" orientation="portrait"><label>Table 3</label><caption><p>Descriptive data related to treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="center"/><col span="3" align="center"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Feature</bold>
</th><th rowspan="1" colspan="1">
<bold>Frequency</bold>
</th><th rowspan="1" colspan="1">
<bold>Valid percentage</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">Chronic treatment</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Vitamin C</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">29.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Zinc</td><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">27.5</td></tr><tr valign="top"><td rowspan="1" colspan="1">Insulin bolus</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">24.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">Omeprazole</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">19.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Bisoprolol</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">17.9</td></tr><tr valign="top"><td rowspan="1" colspan="1">B complex</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">16.3</td></tr><tr valign="top"><td rowspan="1" colspan="1">Insulin basal</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">15.9</td></tr><tr valign="top"><td rowspan="1" colspan="1">Antiplatelet</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">15.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Aspirin</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">15.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Amlodipine</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">12.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Furosemide</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">12.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Atorvastatin</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">10.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Lactulose</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">9.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Lansoprazole</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">8.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Enalapril</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">6.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Prednisolone</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">6.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">MAb_tocilizumab</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">6.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Tocilizumab</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">6.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Ipratropium inhaler</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">5.2</td></tr><tr valign="top"><td rowspan="1" colspan="1">Clopidogrel</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Hydrochlorothiazide</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Azithromycin</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Piperacillin - Tazobactam</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Budesonide inhaler</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Vitamin D</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Metformin</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">3.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Colchicine</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">3.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Ca carbonate</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Candesartan</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Metronidazole</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Valsartan</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Bromazepam</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Carvedilol</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">Short-term treatment</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Antibiotics</td><td rowspan="1" colspan="1">201</td><td rowspan="1" colspan="1">80.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Anticoagulant</td><td rowspan="1" colspan="1">196</td><td rowspan="1" colspan="1">78.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Enoxaparin</td><td rowspan="1" colspan="1">195</td><td rowspan="1" colspan="1">77.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">Antiviral agent</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">8.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Albumin</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Favipiravir</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Norepinephrine injection</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Paracetamol</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Guaifenesin</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Dextrose injection</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Morphine</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">3.2</td></tr><tr valign="top"><td rowspan="1" colspan="1">Remdesivir injection</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">3.2</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TB4" orientation="portrait"><label>Table 4</label><caption><p>Descriptive data on pneumonia</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="center"/><col span="3" align="center"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Feature</bold>
</th><th rowspan="1" colspan="1">
<bold>Frequency</bold>
</th><th rowspan="1" colspan="1">
<bold>Valid percentage</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">PSI class</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">19.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">102</td><td rowspan="1" colspan="1">40.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">23.1</td></tr><tr valign="top"><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">13.2</td></tr><tr valign="top"><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">CURB 65</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">18.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">132</td><td rowspan="1" colspan="1">41.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">24.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">Bacterial infection</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">215</td><td rowspan="1" colspan="1">85.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">14.3</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">Outcome</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Survivor</td><td rowspan="1" colspan="1">169</td><td rowspan="1" colspan="1">67.3</td></tr><tr valign="top"><td rowspan="1" colspan="1">Non survivor</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">32.7</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<italic toggle="yes">Initial findings</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">SOB</td><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">38.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Fever</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">16.3</td></tr><tr valign="top"><td rowspan="1" colspan="1">Productive cough</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">6.8</td></tr><tr valign="top"><td rowspan="1" colspan="1">Dry cough</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">6.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Pleuritic chest pain</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">6.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Vomiting</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">4.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Abdominal pain</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Intubation/mechanical ventilation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">4.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Fatigue</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">3.2</td></tr><tr valign="top"><td rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2.4</td></tr><tr valign="top"><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2.0</td></tr><tr valign="top"><td rowspan="1" colspan="1">Muscular or joint pain</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.6</td></tr><tr valign="top"><td rowspan="1" colspan="1">Loss of taste and smell</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1.6</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PSI: Pneumonia severity index; CURB 65: Confusion, urea, respiratory rate, blood pressure, Age &#8805;65; SOB: Shortness of breath.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="TB5" orientation="portrait"><label>Table 5</label><caption><p>Performance metrics of logistic regression models in predicting mortality and bacterial infections</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="center"/><col span="3" align="center"/><col span="4" align="center"/><col span="5" align="center"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Metric</bold>
</th><th rowspan="1" colspan="1">
<bold>Mortality outcome (training set)</bold>
</th><th rowspan="1" colspan="1">
<bold>Mortality outcome (test set)</bold>
</th><th rowspan="1" colspan="1">
<bold>Bacterial infection outcome (training set)</bold>
</th><th rowspan="1" colspan="1">
<bold>Bacterial infection outcome (test set)</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Accuracy</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">0.86</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.95</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUROC</td><td rowspan="1" colspan="1">0.90 (95% CI: 0.85&#8211;0.95)</td><td rowspan="1" colspan="1">0.88 (95% CI: 0.83&#8211;0.93)</td><td rowspan="1" colspan="1">0.99 (95% CI: 0.97&#8211;1.00)</td><td rowspan="1" colspan="1">0.96 (95% CI: 0.92&#8211;0.98)</td></tr><tr valign="top"><td rowspan="1" colspan="1">Sensitivity</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr valign="top"><td rowspan="1" colspan="1">Specificity</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">0.9</td></tr><tr valign="top"><td rowspan="1" colspan="1">PPV</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">0.95</td></tr><tr valign="top"><td rowspan="1" colspan="1">NPV</td><td rowspan="1" colspan="1">0.92</td><td rowspan="1" colspan="1">0.91</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.96</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AUROC: Area under the receiver operating characteristic curve; PPV: Positive predictive value; NPV: Negative predictive value.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="TB6" orientation="portrait"><label>Table 6</label><caption><p>Comparative variable importance</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="center"/><col span="3" align="center"/><col span="4" align="center"/><col span="5" align="center"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Feature</bold>
</th><th rowspan="1" colspan="1">
<bold>Mutual information</bold>
</th><th rowspan="1" colspan="1">
<bold>LASSO coefficient</bold>
</th><th rowspan="1" colspan="1">
<bold>Logistic regression odds ratio</bold>
</th><th rowspan="1" colspan="1">
<bold>Mean SHAP value</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Zinc</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">Vitamin C</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">Enoxaparin</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">Neutrophils</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">Meropenem</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">ICU Stay</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td></tr><tr valign="top"><td rowspan="1" colspan="1">Platelets</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td><td rowspan="1" colspan="1">&#10003;</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ICU: Intensive care unit; WBC: White blood cell count.</p></table-wrap-foot></table-wrap></sec><sec id="sec3c"><title>Characteristics specific to pneumonia</title><p>Among the included participants, the majority were classified as Class 2 (40.6%) and Class 3 (23.1%) according to the PSI, indicating moderate severity. Based on CURB-65 scores, 41.8% of patients had a score of 1, and 24.7% had a CURB-65 score of 2, indicating differences in pneumonia risk levels.</p><p>The majority of patients got bacterial CAP with 215 (85.7%), most of patients were survived 169 patients (67.3%) (<xref rid="TB4" ref-type="table">Table 4</xref>).</p><p>The most common initial clinical symptoms were dyspnea (38.6%) and fever (16.3%). Other symptoms were productive cough (6.8%), dry cough (6.4%), pleuritic chest pain (6.4%), headache (4.4%), vomiting (4.4%), and abdominal pain (4.0%). Notably, 4.0% of patients required intubation or mechanical ventilation (<xref rid="TB4" ref-type="table">Table 4</xref>).</p></sec><sec id="sec3d"><title>ML analysis results to predict mortality</title><sec id="sec3d1"><title>Global feature correlation structure</title><p>A comprehensive correlation heatmap visualized the interdependencies across all features. This analysis revealed a dense correlation structure, indicating significant overlap among variables. The redundancy identified highlights the need for preprocessing steps, such as feature selection, to ensure model robustness and reduce overfitting. This step is performed after cleaning the data by excluding columns with all null values, leading to a more accurate and reliable correlation matrix. The diagonal of the heatmap typically contains values of 1, representing the perfect correlation of each feature with itself. The color intensity in each cell reflects the strength and direction of the correlation between the corresponding features on the axes. A color gradient from blue to red is used: positive correlations (closer to 1) are shown in warm colors (e.g., red), while negative correlations (closer to &#8722;1) appear in cool colors (e.g., blue). Certain feature groups exhibit noticeable correlations, suggesting potential multicollinearity or shared variance. For example, tightly clustered red squares indicate high correlations between related clinical markers or treatment variables, while patches of blue represent negative associations between certain features. This matrix emphasizes the importance of addressing multicollinearity during model development and suggests that specific feature groups may have overlapping predictive power. Identifying and managing these relationships can ultimately enhance model performance and interpretability.</p></sec><sec id="sec3d2"><title>Feature correlation analysis</title><p>A correlation matrix is often calculated before building predictive models in Python (or any other programming language) to gain insights into the relationships between features. Highly correlated features can cause multicollinearity, which may require dimensionality reduction techniques like principal component analysis (PCA) or the elimination of redundant features to enhance model performance and interpretability. In our study, the correlation matrix was particularly useful for identifying relationships between different features in the dataset. It shows how strongly each feature is related to others, which is crucial for understanding the underlying structure of the data. We used the correlation matrix to identify pairs of features with a correlation score of 0.8 or higher (i.e., highly correlated features). These pairs were then saved into a CSV file for easier inspection. To evaluate the internal structure of the dataset and identify potential predictors of mortality, we generated Pearson correlation heatmaps. In our analysis, a high coefficient indicates a strong association with the survival rate. During the encoding process for categorical variables, we assigned a value of 1 for the survival outcome and 2 for the non-survival outcome. Thus, the correlation reflects how closely each feature is associated with the survival outcome, with higher values indicating a stronger relationship. This correlation pertains specifically to the survival rate in this context. <xref rid="f2" ref-type="fig">Figure 2</xref> shows the intercorrelation matrix among all features, revealing strong positive correlations between inflammatory markers (e.g., C-reactive protein [CRP], ferritin) and between WBC count and neutrophil count (<italic toggle="yes">r</italic> &gt; 0.7). These findings suggest potential collinearity among markers of systemic inflammation, which could affect model stability. This may necessitate variable selection or regularization strategies.</p><fig position="float" id="f2" orientation="portrait"><label>Figure 2.</label><caption><p><bold>Heatmap of strongly correlated features.</bold> Pearson correlation coefficients: A heatmap of strongly correlated features. Warm colors represent higher correlations, while cool colors indicate negative correlations. Strong positive correlations are observed between inflammatory markers (e.g., C-reactive protein [CRP], ferritin) and between white blood cell (WBC) count and neutrophil count (<italic toggle="yes">r</italic> &gt; 0.7). This pattern suggests potential collinearity among markers of systemic inflammation, which may affect model stability and motivate variable selection or regularization strategies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f2.jpg"/></fig></sec><sec id="sec3d3"><title>Top correlated features with the mortality target</title><p><xref rid="f3" ref-type="fig">Figure 3</xref> shows the correlation between individual features and the target outcome of mortality. Age (<italic toggle="yes">r</italic> &#8776; 0.45), neutrophil count (<italic toggle="yes">r</italic> &#8776; 0.41), CRP (<italic toggle="yes">r</italic> &#8776; 0.39), and ferritin (<italic toggle="yes">r</italic> &#8776; 0.36) were among the strongest positive correlates with mortality, indicating their potential as high-risk predictors. Conversely, lymphocyte count (<italic toggle="yes">r</italic> &#8776; &#8722;0.42), oxygen saturation (<italic toggle="yes">r</italic> &#8776; &#8722;0.38), and hemoglobin (HGB) level (<italic toggle="yes">r</italic> &#8776; &#8722;0.33) showed the strongest negative correlations, suggesting a protective role. These patterns underscore the prognostic relevance of age and markers of inflammation and hypoxia in predicting adverse outcomes. The identification of these features supports their prioritization in model development and interpretability analysis. A focused heatmap (<xref rid="f3" ref-type="fig">Figure 3</xref>) showed the variables most correlated with the mortality Notably, vitamin C, zinc, enoxaparin (CLEXAN) and insulin bolus exhibited the highest correlations.</p><fig position="float" id="f3" orientation="portrait"><label>Figure 3.</label><caption><p><bold>Heatmap of top correlated features with mortality outcomes.</bold> Pearson correlation coefficients: Heatmap of features and target outcome. Warm colors represent higher correlations, while cool colors indicate negative correlations. Top positive correlates: age (<italic toggle="yes">r</italic> &#8776; 0.45), neutrophils (<italic toggle="yes">r</italic> &#8776; 0.41), CRP (<italic toggle="yes">r</italic> &#8776; 0.39), ferritin (<italic toggle="yes">r</italic> &#8776; 0.36); top negative correlates: lymphocytes (<italic toggle="yes">r</italic> &#8776; &#8722;0.42), oxygen saturation (<italic toggle="yes">r</italic> &#8776; &#8722;0.38), hemoglobin (<italic toggle="yes">r</italic> &#8776; &#8722;0.33). A focused panel also highlights high correlations for vitamin C, zinc, enoxaparin (CLEXAN), and insulin bolus. Abbreviation: LOS: Length of stay.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f3.jpg"/></fig><p>Zinc and Vitamin C exhibited the highest positive correlation (<italic toggle="yes">r</italic> &#9552; 0.90), suggesting a strong relationship between these two variables with survival rate. Whereas, Insulin Bolus and Enoxaparin demonstrated a moderate correlation (<italic toggle="yes">r</italic> &#9552; 0.59), highlighting a potential interaction. LOS showed minimal correlation with most variables, with the highest being a weak negative correlation with Vitamin C (<italic toggle="yes">r</italic> &#9552; &#8211;0.0066). Diastolic blood pressure shows low correlations with other variables, with the maximum being a weak positive correlation with Vitamin C (<italic toggle="yes">r</italic> &#9552; 0.15).</p></sec><sec id="sec3d4"><title>Mutual information analysis</title><p>The mutual information scores (<xref rid="f4" ref-type="fig">Figure 4</xref>) quantify the dependency between each feature and the target variable (mortality), providing a ranking of the most informative predictors. Key findings include creatinine concentration, WBC including eosinophils, and neutrophils count. Number of previous hospitalizations is also a top contributor. Red-cell distribution width (RDW) and alanine aminotransferase (ALT) are other significant features reflecting their clinical relevance. This analysis underscores the critical role of inflammatory markers (eosinophils, neutrophils, and basophils count) in mortality outcome prediction, highlighting their importance in clinical decision-making.</p><fig position="float" id="f4" orientation="portrait"><label>Figure 4.</label><caption><p><bold>Mutual information of features related to mortality outcomes.</bold> Mutual information scores quantify each feature's dependency on mortality, producing a ranked list of informative predictors. Top contributors include creatinine, WBC (including eosinophils), and neutrophil count; the number of previous hospitalizations also ranks highly. RDW and ALT are additional significant features. Overall, inflammatory markers&#8212;eosinophils, neutrophils, and basophils&#8212;show high informativeness, underscoring their value for model prioritization and clinical decision-making. Abbreviations: WBC: White blood cell count; RDW: Red blood celldistribution width; ALT: Alanine aminotransferase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f4.jpg"/></fig></sec><sec id="sec3d5"><title>Feature coefficients from Lasso regression</title><p>The Lasso regression analysis (<xref rid="f5" ref-type="fig">Figure 5</xref>) refined the list of predictors by assessing the magnitude and direction of their contributions to mortality risk. Among the variables, &#8220;culture&#8221; showed the highest positive coefficient (0.15). However, the culture variable is not clinically significant, as it merely indicates whether the patient underwent a culture test or not. Meropenem demonstrated a significant positive coefficient, highlighting its importance in predicting mortality. Additionally, ABGs (Base Excess, PCO<sub>2</sub>) and platelet count all contributed positively to the model. This analysis emphasizes the critical roles of meropenem, ABGs, pH, and PCO<sub>2</sub> in predicting mortality outcomes.</p><fig position="float" id="f5" orientation="portrait"><label>Figure 5.</label><caption><p><bold>Top feature coefficients from Lasso regression.</bold> Coefficients indicate each variable's direction and magnitude of association with mortality. &#8220;Culture&#8221; shows the largest positive coefficient (&#946; &#8776; 0.15) but is not clinically meaningful (test-performed indicator). Meropenem has a strong positive coefficient; ABG variables (pH, Base Excess, PCO<sub>2</sub>) and platelet count also contribute positively, underscoring their relevance for risk prediction. Abbreviation: ICU: Intensive care unit.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f5.jpg"/></fig></sec><sec id="sec3d6"><title>Feature importance from logistic regression</title><p>The logistic regression-based feature importance analysis (<xref rid="f6" ref-type="fig">Figure 6</xref>) provided an additional perspective on variable significance. For instance, pH identified as the most impactful predictor with the strongest negative impact (coefficient approximately &#8722;1.0). ICU_LOS and LOS: Showed a substantial positive impact with a coefficient around 0.6, and 0.4 respectively, suggesting that longer stays are associated with higher mortality. This analysis underscores the critical roles for pH, LOS, ICU_LOS, PCO<sub>2</sub>, albumin, WBC, bicarbonate (HCO<sub>3</sub>) and ABGs in predicting mortality rate.</p><fig position="float" id="f6" orientation="portrait"><label>Figure 6.</label><caption><p><bold>Feature importance from logistic regression.</bold> Coefficients indicate direction and strength. pH is the most impactful predictor with a strong negative coefficient (&#8776; &#8722;1.0). ICU_LOS and LOS show substantial positive effects (&#8776; 0.6 and &#8776; 0.4), indicating longer stays are linked to higher mortality. Additional important contributors include PCO<sub>2</sub>, albumin, WBC, bicarbonate (HCO<sub>3</sub>), and ABG measures. Abbreviations: BUN: Blood urea nitrogen; WBC: White blood cell count; PSI: Pneumonia severity index.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f6.jpg"/></fig></sec><sec id="sec3d7"><title>SHAP analysis of medication and laboratory influence on model predictions</title><p>The SHAP summary plot shown in <xref rid="f7" ref-type="fig">Figure 7</xref> illustrates the impact of individual features&#8212;primarily medications and laboratory findings&#8212;on the predictive model for survival outcomes. Features are ranked by their average absolute SHAP values, which represent their overall contribution to the model&#8217;s output. The most influential feature was antibiotic usage, which had a strong negative SHAP value (impact &lt; &#8211;0.6), indicating that antibiotic administration significantly reduced the predicted risk of mortality. Basophil count and initial fever presentation also showed negative SHAP values, suggesting a modest inverse relationship with the predicted risk of mortality. Other features, such as enoxaparin, ciprofloxacin susceptibility, and piperacillin/tazobactam susceptibility, were associated with a lower predicted risk, possibly reflecting effective treatment or underlying microbial sensitivity. In contrast, meropenem susceptibility, imipenem susceptibility, and amikacin susceptibility had the largest positive impacts, potentially reflecting resistance to critical antibiotics or associations with more severe infections requiring these drugs. Among medications, tocilizumab, prednisolone, and anticoagulant use were positively associated with the outcome, suggesting these therapies may be markers of greater disease severity or higher baseline risk.</p><fig position="float" id="f7" orientation="portrait"><label>Figure 7.</label><caption><p><bold>SHAP summary plot: Analyzing the influence of medications and laboratory findings on model predictions.</bold> Features are ranked by mean absolute SHAP values. Antibiotic use shows the strongest negative impact (SHAP &lt; &#8722;0.6), with basophils and initial fever also lowering predicted risk. Enoxaparin and ciprofloxacin/piperacillin&#8211;tazobactam susceptibility align with lower risk, whereas meropenem/imipenem/amikacin susceptibility and tocilizumab, prednisolone, and anticoagulant use have positive impacts, likely reflecting greater disease severity. Abbreviations: HDL: High-density lipoprotein; SHAP: Shapley additive explanations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f7.jpg"/></fig></sec></sec><sec id="sec3l"><title>ML results for predicting etiology of CAP</title><sec id="sec3l1"><title>Correlation analysis for predicting bacterial infection</title><p>A heatmap was generated to assess the correlation between clinical variables and bacterial infection (increasing coefficeints reading means higher opportunity for getting bacterial infection as the correlation was between the variables and positive bacterial infection result&#8212;Encoding bacterial infection with number one and no bacterial infection with number two) (<xref rid="f8" ref-type="fig">Figure 8</xref>).</p><fig position="float" id="f8" orientation="portrait"><label>Figure 8.</label><caption><p><bold>Heatmap depicting correlations between clinical variables and bacterial infections.</bold> Pearson correlation coefficients: Heatmap of features and target outcome. Warm colors represent higher correlations, while cool colors indicate negative correlations. The target was encoded as 1 for bacterial infection and 2 for no infection; thus higher coefficients indicate a greater likelihood of bacterial infection. This visualization supports ML-based etiology prediction in CAP. Abbreviations: SOB: Shortness of breath; CAP: Community-acquired pneumonia; ML: Machine learning. </p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f8.jpg"/></fig><p>Enoxaparin, and other anti-coagulant treatments exhibited the strongest positive correlations with bacterial infection, with correlation coefficients of 0.99. Vitamin C supplementation showed also high correlation with Zinc (<italic toggle="yes">r</italic> &#9552; 0.90).</p></sec><sec id="sec3l2"><title>Feature importance analysis using logistic regression analysis for predicting bacterial infection</title><p>Logistic regression analysis was conducted to evaluate feature importance (<xref rid="f9" ref-type="fig">Figure 9</xref>). <xref rid="f9" ref-type="fig">Figure 9</xref> presents the results of a logistic regression model showing the key features correlated with the bacterial infection. Vancomycin and Insulin Dose, are one of the most influential predictors, indicating that their presence was positively associated with the bacterial infection. Conversely, Cough, and Heart Disease had negative coefficients.</p><fig position="float" id="f9" orientation="portrait"><label>Figure 9.</label><caption><p><bold>Feature importance in logistic regression models.</bold> The horizontal bar plot illustrates the coefficient of each feature, reflecting its actual contribution to the model&#8217;s predictions. A positive coefficient indicates a positive association with the target variable, while a negative coefficient signifies a negative association. Abbreviation: PCR: Polymerase chain reaction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f9.jpg"/></fig></sec><sec id="sec3l3"><title>SHAP analysis</title><p>The SHAP summary plot (<xref rid="f10" ref-type="fig">Figure 10</xref>) highlights the most influential predictors from the second round of model evaluation. Features such as Cough, Heart Disease, and Ceftazidime Susceptibility exhibited the highest positive SHAP values, indicating strong positive contributions to the model output. Conversely, PCR Test, Patient Location, and Culture had the most negative SHAP values, suggesting they were associated with a reduced predicted probability of the target outcome. Additionally, Meropenem, Alzheimer, Vancomycin, and Antibiotic Adherence showed moderate positive impacts, whereas Insulin Dose showed minimal negative influence. The color gradient further reveals that features with higher values (red) or lower values (blue) contribute differently to prediction magnitude, emphasizing the complex, value-dependent behavior of certain predictors in the model.</p><fig position="float" id="f10" orientation="portrait"><label>Figure 10.</label><caption><p><bold>SHAP summary plot: Analyzing feature impact on model output.</bold> This figure presents the SHAP values that demonstrate the influence of various features on the model&#8217;s predictions. Positive SHAP values indicate a beneficial contribution to the outcome, whereas negative values reflect a detrimental impact. The color gradient, ranging from blue (indicating low feature values) to red (indicating high feature values), underscores the relationship between feature magnitude and model output. Notably influential features include Antibiotics, Basophils, and initial findings of fever, each exhibiting distinct effects based on their respective values. Abbreviations: SHAP: Shapley additive explanations; PCR: Polymerase chain reaction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f10.jpg"/></fig></sec><sec id="sec3l4"><title>The correlation coefficients between selected features and the target variable</title><p><xref rid="f11" ref-type="fig">Figure 11</xref> presents the correlation coefficients between selected features and the target variable. Antibiotics demonstrated the strongest positive correlation with the bacterial infection target. Enoxaparin and anticoagulants also showed significant associations with the bacterial infection. Additionally, the initial fever finding and basophils exhibited moderate positive correlations. Conversely, features such as the mAb of tocilizumab and the susceptibility to amikacin showed weak negative correlations with the target. Other antibiotic susceptibility variables, including susceptibility to cefepime and ciprofloxacin, had minimal or near-zero correlations, indicating a limited direct association with the outcome. The predictive performance of the logistic regression models for both outcomes is summarized in <xref rid="TB5" ref-type="table">Table 5</xref>. The mortality outcome model achieved robust performance, with the area under the ROC curve (AUROC) of 0.90 (95% CI: 0.85&#8211;0.95) in the training set and 0.88 (95% CI: 0.83&#8211;0.93) in the test set, indicating strong discriminative ability. The bacterial infection outcome model demonstrated even higher predictive power, with AUROC exceeding 0.96 in both training and test sets, accompanied by perfect sensitivity (1.00) in both cases. <xref rid="TB6" ref-type="table">Table 6</xref> reports a comparative summary of the top predictors identified by four variable-importance methods&#8212;mutual information, LASSO coefficients, logistic regression odds ratios, and mean SHAP values&#8212;highlighting both overlaps and divergences in feature ranking. Variables such as zinc, vitamin C, enoxaparin, and neutrophils consistently emerged as key predictors across multiple methods, reinforcing their clinical relevance in predicting mortality among patients with CAP. Meanwhile, other variables such as meropenem, pH, and platelet count showed importance only in selected methods, underscoring the need for careful interpretation of variable-importance results depending on the statistical approach. <xref rid="TB7" ref-type="table">Table 7</xref> presents forest plot data for key predictors of both investigated outcomes in this study. Variables such as ICU stay, pH, WBC, and platelets exhibited significant associations with mortality risk, with odds ratios ranging from 0.6 (for pH) to 2.5 (for ICU stay). For the bacterial infection outcome, predictors such as lymphocytes, HCO<sub>3</sub>, WBC, and neutrophils had odds ratios between 0.8 and 2.5. These forest plots provide valuable insights into the relative importance and accuracy of these predictors, supporting their potential utility in clinical decision-making and model interpretability.</p><table-wrap position="float" id="TB7" orientation="portrait"><label>Table 7</label><caption><p>Forest plot data</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" align="left"/><col span="2" align="left"/><col span="3" align="left"/><col span="4" align="left"/></colgroup><thead><tr valign="bottom"><th rowspan="1" colspan="1">
<bold>Variable</bold>
</th><th rowspan="1" colspan="1">
<bold>Odds ratio</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> value</bold>
</th></tr></thead><tbody><tr valign="top"><td colspan="4" rowspan="1">
<italic toggle="yes">Forest plot data for mortality outcome</italic>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">ICU stay</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">1.5&#8211;4.1</td><td rowspan="1" colspan="1">0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">0.4&#8211;0.9</td><td rowspan="1" colspan="1">0.025</td></tr><tr valign="top"><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">1.2&#8211;2.7</td><td rowspan="1" colspan="1">0.005</td></tr><tr valign="top"><td rowspan="1" colspan="1">Platelets</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.1&#8211;2.6</td><td rowspan="1" colspan="1">0.010</td></tr><tr valign="top"><td rowspan="1" colspan="1">Meropenem</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1">1.3&#8211;3.1</td><td rowspan="1" colspan="1">0.003</td></tr><tr valign="top"><td colspan="4" rowspan="1">
<italic toggle="yes">Forest plot data for bacterial infection outcome</italic>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">Lymphocytes</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">1.0&#8211;2.0</td><td rowspan="1" colspan="1">0.045</td></tr><tr valign="top"><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">2.1</td><td rowspan="1" colspan="1">1.5&#8211;3.0</td><td rowspan="1" colspan="1">0.002</td></tr><tr valign="top"><td rowspan="1" colspan="1">MCV</td><td rowspan="1" colspan="1">1.3</td><td rowspan="1" colspan="1">0.9&#8211;1.9</td><td rowspan="1" colspan="1">0.060*</td></tr><tr valign="top"><td rowspan="1" colspan="1">Neutrophils</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">1.8&#8211;3.4</td><td rowspan="1" colspan="1">0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">Basophils</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">1.1&#8211;2.4</td><td rowspan="1" colspan="1">0.010</td></tr></tbody></table><table-wrap-foot><p>*Despite being statistically insignificant, it is kept in the table due to its close to the significant limit. Abbreviations: ICU: Intensive care unit; WBC: White blood cell count; MCV: Mean corpuscular volume.</p></table-wrap-foot></table-wrap><fig position="float" id="f11" orientation="portrait"><label>Figure 11.</label><caption><p><bold>Correlation of clinical and treatment features with bacterial infection as a primary outcome.</bold> Antibiotics show the strongest positive correlation, with enoxaparin and anticoagulant use also positively associated; initial fever and basophils exhibit moderate positive correlations. In contrast, mAb tocilizumab and amikacin susceptibility show weak negative correlations, while other susceptibilities (e.g., cefepime, ciprofloxacin) are minimal or near zero. Abbreviation: HDL: High-density lipoprotein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bb-2025-12378f11.jpg"/></fig></sec></sec></sec><sec id="sec4"><title>Discussion</title><p>Authors should discuss the results and interpret them in the context of previous studies and working hypotheses. The findings and their implications should be explored in the broadest context possible. Additionally, the limitations of the study and potential future research directions should be addressed. The primary aim of this study was to develop, validate, and implement ML models specifically designed to predict the etiology and mortality of CAP. Among the 251 patients included, 215 (85.7%) had bacterial CAP, with most surviving (67.3%). Treatment regimens were extensive, with high utilization of antibiotics and anticoagulants. The severity of pneumonia varied across patients.</p><sec id="sec4a"><title>Predicting mortality of CAP</title><p>In the Feature Correlation Analysis Regarding Mortality step, the results showed that zinc, vitamin C, enoxaparin and insulin bolus had high correlation with CAP in hospital survival rate.</p><p>Regarding zinc supplement; The clinical studies show same results as increasing zinc intake will decrease the mortality or increase the survival rate. One study result was: Zinc deficiency, common in developing countries, is linked to increased CAP morbidity and mortality. Zinc levels were lower in older patients, those with high CURB-65 scores, and smokers [<xref rid="ref32" ref-type="bibr">32</xref>].</p><p>The feature correlation also showed high correlation for vitamin C supplement and in hospital survival rate, the clinical findings also agree with. In one systematic review showed that vitamin C supplementation had potential benefits on CAP management [<xref rid="ref33" ref-type="bibr">33</xref>].</p><p>These nutrients are often studied for their potential benefits in supporting the immune system and improving outcomes in respiratory infections [<xref rid="ref34" ref-type="bibr">34</xref>]. in our study they were taken as a chronic treatment emphasizing their role as immunity supporters.</p><p>The feature correlation analysis also showed a high correlation between enoxaparin and in-hospital survival rate, this result is alongside the clinical findings. One study conducted, they found that Enoxaparin is associated with lower rates of mortality. Enoxaparin is often used as a preventative measure in hospitalized CAP patients to reduce the risk of venous thromboembolism, a serious complication that can worsen outcomes the pateints [<xref rid="ref35" ref-type="bibr">35</xref>].</p><p>About insulin bolus treatment; Severe infections like CAP trigger a stress response, leading to increased levels of cortisol, catecholamines, and inflammatory cytokines [<xref rid="ref36" ref-type="bibr">36</xref>]. These factors contribute to insulin resistance and hyperglycemia, even in non-diabetic patients. In diabetic patients, CAP can cause poor glycemic control, increasing the risk of complications. Persistent hyperglycemia weakens the immune response, impairing neutrophil function and increasing infection severity [<xref rid="ref37" ref-type="bibr">37</xref>]. Also high blood sugar levels are linked to higher mortality rates, prolonged hospital stays, and increased risk of complications such as sepsis and respiratory failure [<xref rid="ref38" ref-type="bibr">38</xref>].</p><p>Insulin therapy in adult patients hospitalized for critical illness, excluding hyperglycemic crises, may reduce mortality in certain patient groups [<xref rid="ref39" ref-type="bibr">39</xref>]. This effect also extends to insulin bolus treatment, which has been shown to decrease both mortality rates and LOS [<xref rid="ref40" ref-type="bibr">40</xref>]. The next step in ML modeling for CAP mortality predictors was Mutual Information analysis. The analysis quantified the dependency between each feature and the target (mortality), providing a ranking of the most informative predictors. Neutrophil count, ALT, MCV, HGB, and platelet count emerged as the top contributors. These findings emphasize the importance of these variables, as they are often indicative of systemic inflammation. The High neutrophil/lymphocyte ratio (NLR) and neutrophil count percentage (NCP) are reliable predictors of mortality [<xref rid="ref41" ref-type="bibr">41</xref>]. Overactive neutrophils release pro-inflammatory cytokines that can cause tissue damage and thrombosis [<xref rid="ref42" ref-type="bibr">42</xref>]. Regarding ALT levels, one study demonstrated that circulating liver function biomarkers exhibit diverse nonlinear correlations with mortality [<xref rid="ref43" ref-type="bibr">43</xref>]. CAP triggers a systemic inflammatory response, which can elevate ALT levels due to liver stress. In the case of MCV, one study found that large MCV was associated with all-cause mortality, cardiovascular disease mortality, and infection-associated mortality [<xref rid="ref44" ref-type="bibr">44</xref>]. Elevated MCV may contribute to venous thromboembolic disease through increased hematocrit, which promotes platelet margination, or by increasing blood viscosity, which reduces flow in large vessels and predisposes to clot formation. This imbalance in blood rheology can lead to thrombosis [<xref rid="ref45" ref-type="bibr">45</xref>]. Patients with abnormal platelet counts&#8212;either thrombocytopenia (19%) or thrombocytosis (28%)&#8212;had longer hospital stays, a higher need for ICU admission, increased use of mechanical ventilation (both invasive and noninvasive), and a higher 30-day mortality rate [<xref rid="ref46" ref-type="bibr">46</xref>]. This is consistent with our model&#8217;s results.</p><p>An increase in HGB level predicts an increased in mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients [<xref rid="ref47" ref-type="bibr">47</xref>]. Elevated HGB increases blood viscosity, slowing circulation and raising the risk of thrombosis, stroke, and cardiovascular disease [<xref rid="ref48" ref-type="bibr">48</xref>]. These clinical findings align the result regarding the mutual information analysis.</p><p>Feature selection through Lasso regression further refined list of predictors by identifying the magnitude and direction of their contributions to the mortality target. Features such as Meropenem, ABGs, PCO<sub>2,</sub> and platelet count demonstrated strong positive coefficients, suggesting their importance in predicting the mortality target. Conversely, features such as location and cardiovascular disease were negatively associated with the mortality outcome.</p><p>Regarding meropenem empirical treatment (in our data records meropenem used as empirical treatment). Empiric meropenem-based regimen appeared to be associated with lower mortality [<xref rid="ref49" ref-type="bibr">49</xref>]. But in recent study they found that meropenem increases mortality rate; 50 patients (14.12%) experienced treatment failure, and ICU mortality was 48.02% (120 patients). Predictors of meropenem failure included a higher APACHE (acute physiology and chronic health evaluation) score and shorter treatment duration. Predictors of mortality were high APACHE and SOFA scores, initiation of antibiotics more than 72 h after sepsis onset, shorter treatment duration, and renal dose adjustments of meropenem [<xref rid="ref50" ref-type="bibr">50</xref>]. The last study align with our model result.</p><p>Regarding ABGs, one study related to COVID-19 mortality, ABGs was found as a predictor of mortality in COVID pneumonia patients initiated on noninvasive mechanical ventilation [<xref rid="ref51" ref-type="bibr">51</xref>].</p><p>Regarding the positive relationship with PCO<sub>2</sub>, clinical findings have same result with higher PCO<sub>2</sub> being associated with worse survival [<xref rid="ref52" ref-type="bibr">52</xref>]. Platelet count results also agree with the clinical findings. Findings among patients with mild thrombocytosis suggested that high-normal platelet count is associated with the occurrence of thrombotic events [<xref rid="ref53" ref-type="bibr">53</xref>].</p><p>We had negative or inverse relationships (CVDs, COVID 19 and location) that may need more focusing on features or model selection as these findings should have positive impacts. The patient with severe CAP needs monitoring of an ICU where, if necessary, they can receive specialized support connected to a mechanical ventilator and/or hemodynamic support [<xref rid="ref54" ref-type="bibr">54</xref>]. Also, patients can get pneumonia when infected with SARS-COV<sub>2</sub>. The virus that causes COVID-19 can infect the lungs, causing pneumonia [<xref rid="ref55" ref-type="bibr">55</xref>]. Finally CAP is a significant risk factor for all major cardiovascular disease events, including acute coronary syndrome, stroke, and mortality [<xref rid="ref56" ref-type="bibr">56</xref>]. These clinical findings (CVDs, COVID-19 and location) have opposite relationship regarding our modeling results, so farther processing and handling must be needed regarding lasso regression model. Regarding pH, one study showed metabolic acidosis (low pH) is associated with higher mortality in ICU [<xref rid="ref57" ref-type="bibr">57</xref>]. This inverse relationship agreed with our model results.</p><p>The last step used was Logistic regression. It provided an additional perspective on variable significance. Variables such as pH, ICU_LOS, LOS, age, PCO<sub>2</sub>, O<sub>2</sub> saturation, and diastolic blood pressure were identified as the most impactful predictors of the mortality target outcome. Regarding pH, inverse relationship emphasized by clinical finding [<xref rid="ref57" ref-type="bibr">57</xref>].</p><p>Regarding LOS as mentioned earlier; the patient with severe CAP needs monitoring of an ICU where, if necessary, they can receive specialized support connected to a mechanical ventilator and / or hemodynamic support [<xref rid="ref54" ref-type="bibr">54</xref>]. PSI, WBC, PCO<sub>2</sub>, HCO<sub>3</sub>, ABGs and diastolic blood pressure have positive relationship alongside the clinical finding [<xref rid="ref52" ref-type="bibr">52</xref>, <xref rid="ref58" ref-type="bibr">58&#8211;60</xref>]. Among outpatients with pneumonia, oxygen saturations &lt;90% were associated with increased morbidity and mortality [<xref rid="ref61" ref-type="bibr">61</xref>]. This agree with our model result.</p><p>Our aims of this study to make rapid evaluation about patient condition at the admission time; by looking for the results obtained (zinc, vitamin C supplements, Enoxapirin, Neutrophils count, platelet count, ALT, MCV, ABGs, PCO<sub>2,</sub> HGB, pH, WBC, HCO<sub>3</sub> and O<sub>2</sub> saturation) are main predictors for mortality and these results can be obtained rapidly at the admission time [<xref rid="ref62" ref-type="bibr">62</xref>]. There are some predictors have opposite clinical findings results such as CVDs and COVID-19 these findings indicate that we must do further investigation and choosing for models and features selection.</p></sec><sec id="sec4b"><title>Predicting the etiology of CAP</title><p>A heatmap was generated to assess the correlation between clinical variables and the target outcome (infection with bacteria). Enoxaparin, along with other anti-coagulant treatments, exhibited the strongest positive correlations with bacterial infection. However, this correlation suggests negative clinical outcomes. Severe bacterial pneumonia and sepsis trigger coagulation activation both locally in the lungs and systemically, leading to tissue injury and reduced survival. This has prompted extensive investigation into therapies that modulate inflammation caused by coagulation activation. Various anticoagulant strategies have been explored for bacterial pneumonia, sepsis, and acute respiratory distress [<xref rid="ref63" ref-type="bibr">63</xref>]. Notably, Vitamin C supplementation also showed a strong correlation with Zinc in relation to bacterial CAP. These results suggest opposing clinical outcomes. A recent study demonstrated that higher doses of vitamin C and zinc resulted in greater inhibition of Klebsiella pneumoniae biofilm formation, indicating their potential as alternative agents to combat biofilm-associated antibiotic resistance [<xref rid="ref64" ref-type="bibr">64</xref>]. Logistic regression analysis to evaluate feature importance revealed that lymphocytes were the most influential predictor. This finding contrasts with some clinical research [<xref rid="ref65" ref-type="bibr">65</xref>, <xref rid="ref66" ref-type="bibr">66</xref>]. Serum bicarbonate levels (HCO<sub>3</sub>) showed similar results to clinical studies, where elevated serum bicarbonate levels have been observed in patients with bacterial pneumonia [<xref rid="ref67" ref-type="bibr">67</xref>]. Severe bacterial lung infections, such as pneumonia, can cause respiratory acidosis due to poor gas exchange and carbon dioxide retention. Regarding WBCs, typical bacterial CAP was associated with WBC counts &#8805;15,000/mL [<xref rid="ref65" ref-type="bibr">65</xref>]. This aligns with our results. In terms of BUN, one study on bacterial urinary tract infections observed a decrease in BUN levels [<xref rid="ref68" ref-type="bibr">68</xref>], which matches our model&#8217;s results. The most important clinical predictor for bacterial infection is neutrophil count, as neutrophils typically increase during bacterial infections. However, our model showed an opposite result [<xref rid="ref65" ref-type="bibr">65</xref>, <xref rid="ref66" ref-type="bibr">66</xref>]. SHAP values were employed to interpret model predictions, Antibiotics, Basophils, and initial finding fever emerged as key variables influencing the model&#8217;s output.</p><p>Bacterial CAP needs antibiotic treatment [<xref rid="ref69" ref-type="bibr">69</xref>] and obtaining result opposite for this (antibiotics intake increases bacterial infection) has no clinical meaning.</p><p>About basophils. A study performed on mice found that basophils can enhance the innate immune response against bacterial infection and help prevent sepsis [<xref rid="ref70" ref-type="bibr">70</xref>].</p><p>While fever is a key feature of both bacterial and viral CAP, its presence and characteristics alone are not sufficient to differentiate the two. A combination of clinical, laboratory, and imaging findings is necessary for accurate diagnosis. The symptoms of bacterial pneumonia can develop gradually or suddenly. Fever may rise as high as a dangerous 105 degrees F, with profuse sweating and rapidly increased breathing and pulse rate [<xref rid="ref71" ref-type="bibr">71</xref>].</p><p>Lastly, The correlation coefficients between selected features and the target variable. The most clinical predictors are initial fever and Basophils that are alongside with clinical finding [<xref rid="ref70" ref-type="bibr">70</xref>, <xref rid="ref71" ref-type="bibr">71</xref>].</p><p>In summary, models showed (HCO<sub>3</sub>, BUN, WBC, and initial fever) are main predictors for bacterial CAP. Also showed opposite clinical results with lymphocyte count. This indicates we need further models and features selection.</p><p>The small sample size (<italic toggle="yes">n</italic> &#9552; 251) may limit the generalizability and robustness of our findings. As part of future work, we aim to scale up the study by collaborating with additional clinical sites to collect a larger, multi-center dataset with consistent data quality standards. This expansion will enable more rigorous model training, external validation, and improved confidence in the predictive performance of the ML models.</p><p>The observational nature of the dataset introduces potential confounding variables that may not have been fully accounted for in the models. Certain predictors, such as medication usage (e.g., enoxaparin or insulin bolus), may reflect treatment decisions based on illness severity rather than causal relationships. Additionally, imbalances in the distribution of bacterial vs non-bacterial CAP, or survivor vs non-survivor groups, could introduce class bias into model training, influencing performance and feature interpretation.</p><p>Different ML models have inherent assumptions and biases that can affect variable selection and interpretation. For instance, LASSO regression is effective for feature reduction but limited in capturing non-linear interactions. Random forest models handle non-linearity but may overemphasize variables with high cardinality or variance. SHAP values, while providing detailed interpretability, may diverge from classical regression coefficients and can be misinterpreted without sufficient contextual knowledge. Inconsistencies between SHAP results and established clinical findings (e.g., regarding antibiotics or lymphocyte counts) further underscore the need for domain-aware interpretation.</p><p>Although the study focuses on early admission features, not all patients had complete laboratory or radiological data available at standardized time points. Missing values may have necessitated imputation or led to the exclusion of potentially informative features. Furthermore, variables like medication use (e.g., antibiotics or vitamins) may have been recorded without precise timing relative to symptom onset or diagnosis, complicating causal inference.</p></sec></sec><sec id="sec5"><title>Conclusion</title><p>This study explored key predictors of mortality and bacterial etiology in CAP, using ML models to analyze various clinical features. Key findings include the association of zinc and vitamin C supplements, as well as enoxaparin, with increased survival rates. Neutrophil count, ALT, MCV, HGB, and platelet count were linked to increased mortality, while insulin bolus therapy was shown to reduce mortality, emphasizing the importance of glycemic control in CAP patients. However, some variables, such as lymphocyte count, COVID-19, and cardiovascular disease, yielded conflicting results, suggesting the need for further investigation. Regarding bacterial etiology, features like HCO<sub>3</sub>, BUN, WBC, and initial fever were significant predictors, although discrepancies in lymphocyte count highlight the need for model refinement. Overall, rapid evaluation of clinical variables at admission is crucial for predicting mortality and bacterial infections in CAP, but further validation and model adjustments are needed for more accurate outcomes.</p></sec></body><back><ack><p>The authors would like to thank the IRB committee.</p></ack><fn-group><fn fn-type="COI-statement"><p>Conflicts of interest: Authors declare no conflicts of interest.</p></fn><fn fn-type="supported-by"><p>Funding: Authors received no specific funding for this work.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metlay</surname><given-names>JP</given-names></name><name name-style="western"><surname>Waterer</surname><given-names>GW</given-names></name><name name-style="western"><surname>Long</surname><given-names>AC</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J</given-names></name><name name-style="western"><surname>Crothers</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>200</volume><issue>7</issue><fpage>e45</fpage><lpage>67</lpage><comment>https://doi.org/10.12746/swrccc.v8i33.625</comment><pub-id pub-id-type="pmid">31573350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201908-1581ST</pub-id><pub-id pub-id-type="pmcid">PMC6812437</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musher</surname><given-names>DM</given-names></name><name name-style="western"><surname>Thorner</surname><given-names>AR</given-names></name></person-group><article-title>Community-acquired pneumonia</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>17</issue><fpage>1619</fpage><lpage>28</lpage><comment>https://doi.org/10.1056/NEJMra1312885</comment><pub-id pub-id-type="pmid">25337751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1312885</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajkomar</surname><given-names>A</given-names></name><name name-style="western"><surname>Dean</surname><given-names>J</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>I</given-names></name></person-group><article-title>Machine learning in medicine</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>14</issue><fpage>1347</fpage><lpage>58</lpage><comment>https://doi.org/10.1056/NEJMra1814259</comment><pub-id pub-id-type="pmid">30943338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1814259</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Faes</surname><given-names>L</given-names></name><name name-style="western"><surname>Kale</surname><given-names>AU</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>SK</given-names></name><name name-style="western"><surname>Fu</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bruynseels</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis</article-title><source>Lancet Digit Health</source><year>2019</year><volume>1</volume><issue>6</issue><fpage>e271</fpage><lpage>97</lpage><comment>https://doi.org/10.1016/S2589-7500(19)30123-2</comment><pub-id pub-id-type="pmid">33323251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2589-7500(19)30123-2</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kermany</surname><given-names>DS</given-names></name><name name-style="western"><surname>Goldbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Valentim</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Identifying medical diagnoses and treatable diseases by image-based deep learning</article-title><source>Cell</source><year>2018</year><volume>172</volume><issue>5</issue><fpage>1122</fpage><lpage>31.e9</lpage><comment>https://doi.org/10.1016/j.cell.2018.02.010</comment><pub-id pub-id-type="pmid">29474911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.02.010</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>A</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>F</given-names></name><name name-style="western"><surname>Peetermans</surname><given-names>WE</given-names></name><name name-style="western"><surname>Viegi</surname><given-names>G</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T</given-names></name></person-group><article-title>The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2014</year><volume>33</volume><issue>7</issue><fpage>1065</fpage><lpage>79</lpage><comment>https://doi.org/10.1007/s10096-014-2067-1</comment><pub-id pub-id-type="pmid">24532008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10096-014-2067-1</pub-id><pub-id pub-id-type="pmcid">PMC4042014</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandell</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wunderink</surname><given-names>RG</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>JG</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>GD</given-names></name><name name-style="western"><surname>Dean</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>Suppl_2</issue><fpage>S27</fpage><lpage>72</lpage><comment>https://doi.org/10.1086/511159</comment><pub-id pub-id-type="pmid">17278083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/511159</pub-id><pub-id pub-id-type="pmcid">PMC7107997</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metlay</surname><given-names>JP</given-names></name><name name-style="western"><surname>Waterer</surname><given-names>GW</given-names></name><name name-style="western"><surname>Long</surname><given-names>AC</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J</given-names></name><name name-style="western"><surname>Crothers</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>200</volume><issue>7</issue><fpage>e45</fpage><lpage>67</lpage><comment>https://doi.org/10.1164/rccm.201908-1581ST</comment><pub-id pub-id-type="pmid">31573350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201908-1581ST</pub-id><pub-id pub-id-type="pmcid">PMC6812437</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Self</surname><given-names>WH</given-names></name><name name-style="western"><surname>Wunderink</surname><given-names>RG</given-names></name><name name-style="western"><surname>Fakhran</surname><given-names>S</given-names></name><name name-style="western"><surname>Balk</surname><given-names>R</given-names></name><name name-style="western"><surname>Bramley</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Community-acquired pneumonia requiring hospitalization among U.S. adults</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>5</issue><fpage>415</fpage><lpage>27</lpage><comment>https://doi.org/10.1056/NEJMoa1500245</comment><pub-id pub-id-type="pmid">26172429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500245</pub-id><pub-id pub-id-type="pmcid">PMC4728150</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Auble</surname><given-names>TE</given-names></name><name name-style="western"><surname>Yealy</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hanusa</surname><given-names>BH</given-names></name><name name-style="western"><surname>Weissfeld</surname><given-names>LA</given-names></name><name name-style="western"><surname>Singer</surname><given-names>DE</given-names></name><etal/></person-group><article-title>A prediction rule to identify low-risk patients with community-acquired pneumonia</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><issue>4</issue><fpage>243</fpage><lpage>50</lpage><comment>https://doi.org/10.1056/NEJM199701233360402</comment><pub-id pub-id-type="pmid">8995086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199701233360402</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaki</surname><given-names>HA</given-names></name><name name-style="western"><surname>Alkahlout</surname><given-names>BH</given-names></name><name name-style="western"><surname>Shaban</surname><given-names>E</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>EH</given-names></name><name name-style="western"><surname>Basharat</surname><given-names>K</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>WA</given-names></name><etal/></person-group><article-title>The battle of the pneumonia predictors: a comprehensive meta-analysis comparing the pneumonia severity index (PSI) and the CURB-65 score in predicting mortality and the need for ICU support</article-title><source>Cureus</source><year>2023</year><volume>15</volume><issue>7</issue><fpage>e42672</fpage><comment>https://doi.org/10.7759/cureus.42672</comment><pub-id pub-id-type="pmid">37649936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.42672</pub-id><pub-id pub-id-type="pmcid">PMC10462911</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obermeyer</surname><given-names>Z</given-names></name><name name-style="western"><surname>Emanuel</surname><given-names>EJ</given-names></name></person-group><article-title>Predicting the future&#8212;big data, machine learning, and clinical medicine</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>13</issue><fpage>1216</fpage><lpage>9</lpage><comment>https://doi.org/10.1056/NEJMp1606181</comment><pub-id pub-id-type="pmid">27682033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp1606181</pub-id><pub-id pub-id-type="pmcid">PMC5070532</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruhnke</surname><given-names>GW</given-names></name><name name-style="western"><surname>Coca-Perraillon</surname><given-names>M</given-names></name><name name-style="western"><surname>Kitch</surname><given-names>BT</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>DM</given-names></name></person-group><article-title>Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia</article-title><source>Am J Med</source><year>2011</year><volume>124</volume><issue>2</issue><fpage>171</fpage><lpage>8.e1</lpage><comment>https://doi.org/10.1016/j.amjmed.2010.08.019</comment><pub-id pub-id-type="pmid">21295197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2010.08.019</pub-id><pub-id pub-id-type="pmcid">PMC3064506</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>DW</given-names></name><name name-style="western"><surname>Saria</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohno-Machado</surname><given-names>L</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name><name name-style="western"><surname>Escobar</surname><given-names>G</given-names></name></person-group><article-title>Big data in health care: using analytics to identify and manage high-risk and high-cost patients</article-title><source>Health Aff (Millwood)</source><year>2014</year><volume>33</volume><issue>7</issue><fpage>1123</fpage><lpage>31</lpage><comment>https://doi.org/10.1377/hlthaff.2014.0041</comment><pub-id pub-id-type="pmid">25006137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2014.0041</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirama</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Miyazawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashikita</surname><given-names>G</given-names></name><name name-style="western"><surname>Kishi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prediction of the pathogens that are the cause of pneumonia by the battlefield hypothesis</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>9</issue><fpage>e24474</fpage><comment>https://doi.org/10.1371/journal.pone.0024474</comment><pub-id pub-id-type="pmid">21909436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0024474</pub-id><pub-id pub-id-type="pmcid">PMC3164732</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>K</given-names></name><name name-style="western"><surname>Chu</surname><given-names>W</given-names></name><name name-style="western"><surname>Lou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Performance of machine learning algorithms for predicting adverse outcomes in community-acquired pneumonia</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>903426</fpage><comment>https://doi.org/10.3389/fbioe.2022.903426</comment><pub-id pub-id-type="pmid">35845426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.903426</pub-id><pub-id pub-id-type="pmcid">PMC9278327</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HL</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>WY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Weng</surname><given-names>HH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Automatic machine-learning-based outcome prediction in patients with primary intracerebral hemorrhage</article-title><source>Front Neurol</source><year>2019</year><volume>10</volume><fpage>910</fpage><comment>https://doi.org/10.3389/fneur.2019.00910</comment><pub-id pub-id-type="pmid">31496988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.00910</pub-id><pub-id pub-id-type="pmcid">PMC6713018</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magunia</surname><given-names>H</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>S</given-names></name><name name-style="western"><surname>Verbuecheln</surname><given-names>R</given-names></name><name name-style="western"><surname>Gilot</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Koeppen</surname><given-names>M</given-names></name><name name-style="western"><surname>Haeberle</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort</article-title><source>Crit Care</source><year>2021</year><volume>25</volume><issue>1</issue><fpage>295</fpage><comment>https://doi.org/10.1186/s13054-021-03720-4</comment><pub-id pub-id-type="pmid">34404458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03720-4</pub-id><pub-id pub-id-type="pmcid">PMC8370055</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halasz</surname><given-names>G</given-names></name><name name-style="western"><surname>Sperti</surname><given-names>M</given-names></name><name name-style="western"><surname>Villani</surname><given-names>M</given-names></name><name name-style="western"><surname>Michelucci</surname><given-names>U</given-names></name><name name-style="western"><surname>Agostoni</surname><given-names>P</given-names></name><name name-style="western"><surname>Biagi</surname><given-names>A</given-names></name><etal/></person-group><article-title>A machine learning approach for mortality prediction in COVID-19 pneumonia: development and evaluation of the Piacenza score</article-title><source>J Med Internet Res</source><year>2021</year><volume>23</volume><issue>5</issue><fpage>e29058</fpage><comment>https://doi.org/10.2196/29058</comment><pub-id pub-id-type="pmid">33999838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/29058</pub-id><pub-id pub-id-type="pmcid">PMC8168638</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lv</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group><article-title>A prediction model of outcome of SARS-CoV-2 pneumonia based on laboratory findings</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>14042</fpage><comment>https://doi.org/10.1038/s41598-020-71114-7</comment><pub-id pub-id-type="pmid">32820210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-71114-7</pub-id><pub-id pub-id-type="pmcid">PMC7441177</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Statistical analysis and machine learning prediction of disease outcomes for COVID-19 and pneumonia patients</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><fpage>838749</fpage><comment>https://doi.org/10.3389/fcimb.2022.838749</comment><pub-id pub-id-type="pmid">35521216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.838749</pub-id><pub-id pub-id-type="pmcid">PMC9063041</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourou</surname><given-names>K</given-names></name><name name-style="western"><surname>Exarchos</surname><given-names>TP</given-names></name><name name-style="western"><surname>Exarchos</surname><given-names>KP</given-names></name><name name-style="western"><surname>Karamouzis</surname><given-names>MV</given-names></name><name name-style="western"><surname>Fotiadis</surname><given-names>DI</given-names></name></person-group><article-title>Machine learning applications in cancer prognosis and prediction</article-title><source>Comput Struct Biotechnol J</source><year>2015</year><volume>13</volume><fpage>8</fpage><lpage>17</lpage><comment>https://doi.org/10.1016/j.csbj.2014.11.005</comment><pub-id pub-id-type="pmid">25750696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2014.11.005</pub-id><pub-id pub-id-type="pmcid">PMC4348437</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>TA</given-names></name></person-group><article-title>Linear regression in machine learning</article-title><source>Proceedings of the Society of Photo Optical Instrumentation Engineers;</source><year>2022</year></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Mi</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Mi</surname><given-names>X</given-names></name></person-group><article-title>A denoising method based on the nonlinear relationship between the target variable and input features</article-title><source>Expert Syst Appl</source><year>2023</year><volume>218</volume><fpage>119585</fpage><comment>https://doi.org/10.1016/j.eswa.2023.119585</comment></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Carretero</surname><given-names>R</given-names></name><name name-style="western"><surname>Holgado-Cuadrado</surname><given-names>R</given-names></name><name name-style="western"><surname>Barquero-Perez</surname><given-names>O</given-names></name></person-group><article-title>Assessment of classification models and relevant features on nonalcoholic steatohepatitis using random forest</article-title><source>Entropy (Basel, Switzerland)</source><year>2021</year><volume>23</volume><issue>6</issue><fpage>763</fpage><comment>https://doi.org/10.3390/e23060763</comment><pub-id pub-id-type="pmid">34204225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/e23060763</pub-id><pub-id pub-id-type="pmcid">PMC8234908</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlSagri</surname><given-names>H</given-names></name><name name-style="western"><surname>Ykhlef</surname><given-names>M</given-names></name></person-group><article-title>Quantifying feature importance for detecting depression using random forest</article-title><source>Int J Adv Comput Sci Appl</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>1</fpage><lpage>8</lpage><comment>https://doi.org/10.14569/IJACSA.2020.0110577</comment></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breiman</surname><given-names>L</given-names></name></person-group><article-title>Random forests</article-title><source>Mach Learn</source><year>2001</year><volume>45</volume><fpage>5</fpage><lpage>32</lpage><comment>https://doi.org/10.1023/A:1010933404324</comment></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabre</surname><given-names>V</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>KC</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></name></person-group><article-title>Blood culture utilization in the hospital setting: a call for diagnostic stewardship</article-title><source>J Clin Microbiol</source><year>2022</year><volume>60</volume><issue>3</issue><fpage>e0100521</fpage><comment>https://doi.org/10.1128/jcm.01005-21</comment><pub-id pub-id-type="pmid">34260274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jcm.01005-21</pub-id><pub-id pub-id-type="pmcid">PMC8925908</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tourassi</surname><given-names>GD</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>ED</given-names></name><name name-style="western"><surname>Markey</surname><given-names>MK</given-names></name><name name-style="western"><surname>Floyd Jr</surname><given-names>CE</given-names></name></person-group><article-title>Application of the mutual information criterion for feature selection in computer-aided diagnosis</article-title><source>Med Phys</source><year>2001</year><volume>28</volume><issue>12</issue><fpage>2394</fpage><lpage>402</lpage><comment>https://doi.org/10.1118/1.1418724</comment><pub-id pub-id-type="pmid">11797941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1118/1.1418724</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>H</given-names></name><name name-style="western"><surname>Shahzad</surname><given-names>M</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>S</given-names></name><name name-style="western"><surname>Sewell</surname><given-names>KB</given-names></name><name name-style="western"><surname>Alqalyoobi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>BP</given-names></name></person-group><article-title>Application and impact of Lasso regression in gastroenterology: a systematic review</article-title><source>Indian J Gastroenterol</source><year>2023</year><volume>42</volume><issue>6</issue><fpage>780</fpage><lpage>90</lpage><comment>https://doi.org/10.1007/s12664-023-01426-9</comment><pub-id pub-id-type="pmid">37594652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12664-023-01426-9</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebreyesus</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dalton</surname><given-names>D</given-names></name><name name-style="western"><surname>De Chiara</surname><given-names>D</given-names></name><name name-style="western"><surname>Chinnici</surname><given-names>M</given-names></name><name name-style="western"><surname>Chinnici</surname><given-names>A</given-names></name></person-group><article-title>AI for automating data center operations: model explainability in the data centre context using shapley additive explanations (SHAP)</article-title><source>Electronics</source><year>2024</year><volume>13</volume><issue>9</issue><fpage>1628</fpage><comment>https://doi.org/10.3390/electronics13091628</comment></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhat</surname><given-names>MH</given-names></name><name name-style="western"><surname>Rather</surname><given-names>AB</given-names></name><name name-style="western"><surname>Dhobi</surname><given-names>GN</given-names></name><name name-style="western"><surname>Koul</surname><given-names>AN</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>FA</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A</given-names></name></person-group><article-title>Zinc levels in community acquired pneumonia in hospitalized patients; a case control study</article-title><source>Egypt J Chest Dis Tuberculosis</source><year>201665</year><issue>2</issue><fpage>485</fpage><lpage>9</lpage><comment>https://doi.org/10.1016/j.ejcdt.2015.12.020</comment></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sumanadasa</surname><given-names>S</given-names></name><name name-style="western"><surname>Shahi</surname><given-names>R</given-names></name><name name-style="western"><surname>Woodman</surname><given-names>R</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name><name name-style="western"><surname>Bihari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of vitamin C supplementation in the treatment of community-acquired pneumonia: a systematic review and meta-analysis with trial sequential analysis</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>11846</fpage><comment>https://doi.org/10.1038/s41598-024-62571-5</comment><pub-id pub-id-type="pmid">38783029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-62571-5</pub-id><pub-id pub-id-type="pmcid">PMC11116443</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wintergerst</surname><given-names>ES</given-names></name><name name-style="western"><surname>Maggini</surname><given-names>S</given-names></name><name name-style="western"><surname>Hornig</surname><given-names>DH</given-names></name></person-group><article-title>Immune-enhancing role of vitamin C and zinc and effect on clinical conditions</article-title><source>Ann Nutr Metab</source><year>2006</year><volume>50</volume><issue>2</issue><fpage>85</fpage><lpage>94</lpage><comment>https://doi.org/10.1159/000090495</comment><pub-id pub-id-type="pmid">16373990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000090495</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albani</surname><given-names>F</given-names></name><name name-style="western"><surname>Sepe</surname><given-names>L</given-names></name><name name-style="western"><surname>Fusina</surname><given-names>F</given-names></name><name name-style="western"><surname>Prezioso</surname><given-names>C</given-names></name><name name-style="western"><surname>Baronio</surname><given-names>M</given-names></name><name name-style="western"><surname>Caminiti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. a cohort study</article-title><source>eClinicalMedicine</source><year>2020</year><volume>27</volume><fpage>100562</fpage><comment>https://doi.org/10.1016/j.eclinm.2020.100562</comment><pub-id pub-id-type="pmid">33043287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2020.100562</pub-id><pub-id pub-id-type="pmcid">PMC7534836</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vedantam</surname><given-names>D</given-names></name><name name-style="western"><surname>Poman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Motwani</surname><given-names>L</given-names></name><name name-style="western"><surname>Asif</surname><given-names>N</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Anne</surname><given-names>KK</given-names></name></person-group><article-title>Stress-induced hyperglycemia: consequences and management</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>7</issue><fpage>e26714</fpage><comment>https://doi.org/10.7759/cureus.26714</comment><pub-id pub-id-type="pmid">35959169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.26714</pub-id><pub-id pub-id-type="pmcid">PMC9360912</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahmadika</surname><given-names>N</given-names></name><name name-style="western"><surname>Tjahjadi</surname><given-names>AI</given-names></name><name name-style="western"><surname>Ruslami</surname><given-names>R</given-names></name></person-group><article-title>Type 2 diabetes and its impact on the immune system</article-title><source>Curr Diabetes Rev</source><year>202016</year><issue>5</issue><fpage>442</fpage><lpage>9</lpage><comment>https://doi.org/10.2174/1573399815666191024085838</comment><pub-id pub-id-type="pmid">31657690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1573399815666191024085838</pub-id><pub-id pub-id-type="pmcid">PMC7475801</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kushimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Gando</surname><given-names>S</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>D</given-names></name><name name-style="western"><surname>Mayumi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujishima</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of serum glucose levels on disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis</article-title><source>Acute Med Surg</source><year>2015</year><volume>2</volume><issue>1</issue><fpage>21</fpage><lpage>8</lpage><comment>https://doi.org/10.1002/ams2.59</comment><pub-id pub-id-type="pmid">29123686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ams2.59</pub-id><pub-id pub-id-type="pmcid">PMC5667198</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittas</surname><given-names>AG</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RD</given-names></name><name name-style="western"><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials</article-title><source>J Parenteral Enteral Nutrit</source><year>2006</year><volume>30</volume><issue>2</issue><fpage>164</fpage><lpage>72</lpage><comment>https://doi.org/10.1177/0148607106030002164</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0148607106030002164</pub-id><pub-id pub-id-type="pmid">16517961</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Tomor</surname><given-names>V</given-names></name><name name-style="western"><surname>Nathanson</surname><given-names>BH</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>JR</given-names></name><name name-style="western"><surname>Aagren</surname><given-names>M</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>RW</given-names></name></person-group><article-title>Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin</article-title><source>Clin Ther</source><year>2010</year><volume>32</volume><issue>11</issue><fpage>1954</fpage><lpage>66</lpage><comment>https://doi.org/10.1016/j.clinthera.2010.10.009</comment><pub-id pub-id-type="pmid">21095490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2010.10.009</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curbelo</surname><given-names>J</given-names></name><name name-style="western"><surname>Luquero Bueno</surname><given-names>S</given-names></name><name name-style="western"><surname>Galv&#225;n-Rom&#225;n</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ortega-G&#243;mez</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajas</surname><given-names>O</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Jim&#233;nez</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>3</issue><fpage>e0173947</fpage><comment>https://doi.org/10.1371/journal.pone.0173947</comment><pub-id pub-id-type="pmid">28301543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0173947</pub-id><pub-id pub-id-type="pmcid">PMC5354424</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hidalgo</surname><given-names>A</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P</given-names></name><name name-style="western"><surname>Soehnlein</surname><given-names>O</given-names></name><name name-style="western"><surname>Aramburu</surname><given-names>IV</given-names></name><name name-style="western"><surname>Papayannopoulos</surname><given-names>V</given-names></name><name name-style="western"><surname>Silvestre-Roig</surname><given-names>C</given-names></name></person-group><article-title>Neutrophil extracellular traps: from physiology to pathology</article-title><source>Cardiovasc Res</source><year>2022</year><volume>118</volume><issue>13</issue><fpage>2737</fpage><lpage>53</lpage><comment>https://doi.org/10.1093/cvr/cvab329</comment><pub-id pub-id-type="pmid">34648022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvab329</pub-id><pub-id pub-id-type="pmcid">PMC9586562</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>S</given-names></name><name name-style="western"><surname>Diao</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name></person-group><article-title>Associations between serum levels of liver function biomarkers and all-cause and cause-specific mortality: a prospective cohort study</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>3302</fpage><comment>https://doi.org/10.1186/s12889-024-20773-6</comment><pub-id pub-id-type="pmid">39604890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-024-20773-6</pub-id><pub-id pub-id-type="pmcid">PMC11600561</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>YP</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kor</surname><given-names>CT</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>YK</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>PF</given-names></name></person-group><article-title>Mean corpuscular volume and mortality in patients with CKD</article-title><source>Clin J Am Soc Nephrol</source><year>2017</year><volume>12</volume><issue>2</issue><fpage>237</fpage><lpage>44</lpage><comment>https://doi.org/10.2215/CJN.00970116</comment><pub-id pub-id-type="pmid">28143866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.00970116</pub-id><pub-id pub-id-type="pmcid">PMC5293326</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="webpage"><collab>Maner BS, Killeen RB, Moosavi L.</collab><comment>Mean corpuscular volume. In: StatPearls. St. Petersburg (FL): StatPearls Publishing; 2024</comment><pub-id pub-id-type="pmid">31424859</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaha</surname><given-names>HM</given-names></name><name name-style="western"><surname>Elsaid</surname><given-names>AR</given-names></name></person-group><article-title>Platelet count and level of paCO2 are predictors of CAP prognosis</article-title><source>Egypt J Chest Dis Tuberculosis</source><year>2015</year><volume>64</volume><issue>2</issue><fpage>453</fpage><lpage>8</lpage><comment>https://doi.org/10.1016/j.ejcdt.2015.02.002</comment></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinot</surname><given-names>M</given-names></name><name name-style="western"><surname>Eyriey</surname><given-names>M</given-names></name><name name-style="western"><surname>Gravier</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonijoly</surname><given-names>T</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>D</given-names></name><name name-style="western"><surname>Ion</surname><given-names>C</given-names></name><etal/></person-group><article-title>Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients</article-title><source>Infect Dis Now</source><year>2021</year><volume>51</volume><issue>6</issue><fpage>518</fpage><lpage>25</lpage><comment>https://doi.org/10.1016/j.idnow.2021.07.002</comment><pub-id pub-id-type="pmid">34242842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.idnow.2021.07.002</pub-id><pub-id pub-id-type="pmcid">PMC8260549</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrnes</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wolberg</surname><given-names>AS</given-names></name></person-group><article-title>Red blood cells in thrombosis</article-title><source>Blood</source><year>2017</year><volume>130</volume><issue>16</issue><fpage>1795</fpage><lpage>9</lpage><comment>https://doi.org/10.1182/blood-2017-03-745349</comment><pub-id pub-id-type="pmid">28811305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2017-03-745349</pub-id><pub-id pub-id-type="pmcid">PMC5649548</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>NG</given-names></name><name name-style="western"><surname>Liew</surname><given-names>YX</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name></person-group><article-title>Empiric meropenem-based versus ceftazidime-based therapy for severe community-acquired pneumonia in a retrospective cohort study</article-title><source>Ann Acad Med, Singapore</source><year>2019</year><volume>48</volume><issue>3</issue><fpage>98</fpage><lpage>103</lpage><comment>https://doi.org/10.47102/annals-acadmedsg.V48N3p98</comment><pub-id pub-id-type="pmid">30997479</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazlan</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Ghazali</surname><given-names>AG</given-names></name><name name-style="western"><surname>Omar</surname><given-names>M</given-names></name><name name-style="western"><surname>Yaacob</surname><given-names>NM</given-names></name><name name-style="western"><surname>Mohamad</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Predictors of treatment failure and mortality among patients with septic shock treated with meropenem in the intensive care unit</article-title><source>Malays J Med Sci</source><year>2024</year><volume>31</volume><issue>1</issue><fpage>76</fpage><lpage>90</lpage><comment>https://doi.org/10.21315/mjms2024.31.1.7</comment><pub-id pub-id-type="pmid">38456106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21315/mjms2024.31.1.7</pub-id><pub-id pub-id-type="pmcid">PMC10917586</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>B</given-names></name><name name-style="western"><surname>Jain</surname><given-names>G</given-names></name><name name-style="western"><surname>Chandrakar</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></name></person-group><article-title>Arterial blood gas as a predictor of mortality in COVID pneumonia patients initiated on noninvasive mechanical ventilation: a retrospective analysis</article-title><source>Indian J Crit Care Med</source><year>2021</year><volume>25</volume><issue>8</issue><fpage>866</fpage><lpage>71</lpage><comment>https://doi.org/10.5005/jp-journals-10071-23917</comment><pub-id pub-id-type="pmid">34733025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23917</pub-id><pub-id pub-id-type="pmcid">PMC8559762</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>MW</given-names></name><name name-style="western"><surname>Labaki</surname><given-names>WW</given-names></name><name name-style="western"><surname>Choi</surname><given-names>PJ</given-names></name></person-group><article-title>Mortality and healthcare use of patients with compensated hypercapnia</article-title><source>Ann Am Thorac Soc</source><year>202118</year><issue>12</issue><fpage>2027</fpage><lpage>32</lpage><comment>https://doi.org/10.1513/AnnalsATS.202009-1197OC</comment><pub-id pub-id-type="pmid">33951397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.202009-1197OC</pub-id><pub-id pub-id-type="pmcid">PMC12039822</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heckbert</surname><given-names>SR</given-names></name><name name-style="western"><surname>Lumley</surname><given-names>T</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cushman</surname><given-names>M</given-names></name><name name-style="western"><surname>Folsom</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rosendaal</surname><given-names>FR</given-names></name><etal/></person-group><article-title>Platelet count and the risk for thrombosis and death in the elderly</article-title><source>J Thrombosis Haemostasis</source><year>2009</year><volume>7</volume><issue>3</issue><fpage>399</fpage><lpage>405</lpage><comment>https://doi.org/10.1111/j.1538-7836.2008.03267.x</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2008.03267.x</pub-id><pub-id pub-id-type="pmcid">PMC2652240</pub-id><pub-id pub-id-type="pmid">19143922</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cill&#243;niz</surname><given-names>C</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A</given-names></name><name name-style="western"><surname>Niederman</surname><given-names>MS</given-names></name></person-group><article-title>Management of pneumonia in critically ill patients</article-title><source>BMJ</source><year>2021</year><volume>375</volume><fpage>e065871</fpage><comment>https://doi.org/10.1136/bmj-2021-065871</comment><pub-id pub-id-type="pmid">34872910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2021-065871</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharov</surname><given-names>KS</given-names></name></person-group><article-title>SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: secondary bacterial pneumonia and viral co-infections</article-title><source>J Glob Health</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>020504</fpage><comment>https://doi.org/10.7189/jogh.10.020504</comment><pub-id pub-id-type="pmid">33110587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7189/jogh.10.-020504</pub-id><pub-id pub-id-type="pmcid">PMC7568231</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meregildo-Rodriguez</surname><given-names>ED</given-names></name><name name-style="western"><surname>Asmat-Rubio</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rojas-Benites</surname><given-names>MJ</given-names></name><name name-style="western"><surname>V&#225;squez-Tirado</surname><given-names>GA</given-names></name></person-group><article-title>Acute coronary syndrome, stroke, and mortality after community-acquired pneumonia: systematic review and meta-analysis</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>7</issue><fpage>2577</fpage><comment>https://doi.org/10.3390/jcm12072577</comment><pub-id pub-id-type="pmid">37048661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12072577</pub-id><pub-id pub-id-type="pmcid">PMC10095577</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samanta</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RK</given-names></name><name name-style="western"><surname>Baronia</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>P</given-names></name><name name-style="western"><surname>Poddar</surname><given-names>B</given-names></name><name name-style="western"><surname>Azim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early pH change predicts intensive care unit mortality</article-title><source>Indian J Crit Care Med</source><year>2018</year><volume>22</volume><issue>10</issue><fpage>697</fpage><lpage>705</lpage><comment>https://doi.org/10.4103/ijccm.IJCCM_129_18</comment><pub-id pub-id-type="pmid">30405279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijccm.IJCCM_129_18</pub-id><pub-id pub-id-type="pmcid">PMC6201653</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Katsurada</surname><given-names>M</given-names></name><name name-style="western"><surname>Yatera</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Utility of pneumonia severity assessment tools for mortality prediction in healthcare-associated pneumonia: a systematic review and meta-analysis</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>12964</fpage><comment>https://doi.org/10.1038/s41598-024-63618-3</comment><pub-id pub-id-type="pmid">38839837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-63618-3</pub-id><pub-id pub-id-type="pmcid">PMC11153623</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>KP</given-names></name><name name-style="western"><surname>Hanusa</surname><given-names>BH</given-names></name><name name-style="western"><surname>Rotondi</surname><given-names>A</given-names></name><name name-style="western"><surname>Singer</surname><given-names>DE</given-names></name><name name-style="western"><surname>Coley</surname><given-names>CM</given-names></name><name name-style="western"><surname>Marrie</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia</article-title><source>J Gen Intern Med</source><year>2001</year><volume>16</volume><issue>9</issue><fpage>590</fpage><lpage>8</lpage><comment>https://doi.org/10.1046/j.1525-1497.2001.016009590.x</comment><pub-id pub-id-type="pmid">11556939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1525-1497.2001.016009590.x</pub-id><pub-id pub-id-type="pmcid">PMC1495269</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>BC</given-names></name><name name-style="western"><surname>Wilt</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Welch</surname><given-names>HG</given-names></name></person-group><article-title>Impact of diastolic and systolic blood pressure on mortality: implications for the definition of &#8220;normal&#8221;</article-title><source>J Gen Intern Med</source><year>2011</year><volume>26</volume><issue>7</issue><fpage>685</fpage><lpage>90</lpage><comment>https://doi.org/10.1007/s11606-011-1660-6</comment><pub-id pub-id-type="pmid">21404131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-011-1660-6</pub-id><pub-id pub-id-type="pmcid">PMC3138604</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumdar</surname><given-names>SR</given-names></name><name name-style="western"><surname>Eurich</surname><given-names>DT</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>JM</given-names></name><name name-style="western"><surname>Senthilselvan</surname><given-names>A</given-names></name><name name-style="western"><surname>Marrie</surname><given-names>TJ</given-names></name></person-group><article-title>Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><issue>3</issue><fpage>325</fpage><lpage>31</lpage><comment>https://doi.org/10.1093/cid/ciq076</comment><pub-id pub-id-type="pmid">21217179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciq076</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odeyemi</surname><given-names>YE</given-names></name><name name-style="western"><surname>Lal</surname><given-names>A</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>EF</given-names></name><name name-style="western"><surname>LeMahieu</surname><given-names>AM</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>H</given-names></name><name name-style="western"><surname>Gajic</surname><given-names>O</given-names></name></person-group><article-title>Early machine learning prediction of hospitalized patients at low risk of respiratory deterioration or mortality in community-acquired pneumonia: Derivation and validation of a multivariable model</article-title><source>Biomol Biomed</source><year>2024</year><volume>24</volume><issue>2</issue><fpage>337</fpage><lpage>45</lpage><comment>https://doi.org/10.17305/bb.2023.9754</comment><pub-id pub-id-type="pmid">37795970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bb.2023.9754</pub-id><pub-id pub-id-type="pmcid">PMC10950343</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jos&#233;</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Manuel</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>RC</given-names></name></person-group><article-title>Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis</article-title><source>Eur Respir Rev</source><year>2020</year><volume>29</volume><issue>157</issue><fpage>200240</fpage><comment>https://doi.org/10.1183/16000617.0240-2020</comment><pub-id pub-id-type="pmid">33004529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/16000617.0240-2020</pub-id><pub-id pub-id-type="pmcid">PMC7537941</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setiawan</surname><given-names>A</given-names></name><name name-style="western"><surname>Widodo</surname><given-names>AD</given-names></name><name name-style="western"><surname>Arfijanto</surname><given-names>MV</given-names></name></person-group><article-title>Comparison dose effects of vitamin C and zinc administration to inhibit klebsiella pneumoniae biofilms formation</article-title><source>Int J Health Sci</source><year>2022</year><volume>6</volume><issue>S9</issue><fpage>328</fpage><lpage>35</lpage><comment>https://doi.org/10.53730/ijhs.v6nS9.12262</comment></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Light</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Stillwell</surname><given-names>PC</given-names></name><name name-style="western"><surname>Ramchandar</surname><given-names>N</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>MH</given-names></name></person-group><article-title>Nonviral pneumonia</article-title><source>In: Pediatric pulmonology. Itasca, IL: American Academy of Pediatrics;</source><year>2023</year><comment>https://doi.org/10.1542/9781610026536-20</comment></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>NB</given-names></name><name name-style="western"><surname>Son</surname><given-names>C</given-names></name><name name-style="western"><surname>Um</surname><given-names>SJ</given-names></name></person-group><article-title>Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia</article-title><source>Ann Lab Med</source><year>2013</year><volume>33</volume><issue>2</issue><fpage>105</fpage><lpage>10</lpage><comment>https://doi.org/10.3343/alm.2013.33.2.105</comment><pub-id pub-id-type="pmid">23482854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3343/alm.2013.33.2.105</pub-id><pub-id pub-id-type="pmcid">PMC3589634</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankaran</surname><given-names>RT</given-names></name><name name-style="western"><surname>Mattana</surname><given-names>J</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>T</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Laboratory abnormalities in patients with bacterial pneumonia</article-title><source>Chest</source><year>1997</year><volume>111</volume><issue>3</issue><fpage>595</fpage><lpage>600</lpage><comment>https://doi.org/10.1378/chest.111.3.595</comment><pub-id pub-id-type="pmid">9118693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.111.3.595</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazimoglu</surname><given-names>H</given-names></name><name name-style="western"><surname>Uysal</surname><given-names>E</given-names></name><name name-style="western"><surname>Dokur</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#252;nerkan</surname><given-names>RH</given-names></name></person-group><article-title>Evaluation of the relationship between neutrophil lymphocyte ratio and the most common bacterial urinary tract infections after transplantation</article-title><source>Bratisl Lek Listy</source><year>2019</year><volume>120</volume><issue>2</issue><fpage>161</fpage><lpage>5</lpage><comment>https://doi.org/10.4149/BLL_2019_026</comment><pub-id pub-id-type="pmid">30793622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4149/BLL_2019_026</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name></person-group><article-title>Antibiotic therapy for bacterial pneumonia</article-title><source>J Pharm Health Care Sci</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>45</fpage><comment>https://doi.org/10.1186/s40780-024-00367-5</comment><pub-id pub-id-type="pmid">39080789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40780-024-00367-5</pub-id><pub-id pub-id-type="pmcid">PMC11290052</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piliponsky</surname><given-names>AM</given-names></name><name name-style="western"><surname>Shubin</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Lahiri</surname><given-names>AK</given-names></name><name name-style="western"><surname>Truong</surname><given-names>P</given-names></name><name name-style="western"><surname>Clauson</surname><given-names>M</given-names></name><name name-style="western"><surname>Niino</surname><given-names>K</given-names></name><etal/></person-group><article-title>Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><issue>2</issue><fpage>129</fpage><lpage>40</lpage><comment>https://doi.org/10.1038/s41590-018-0288-7</comment><pub-id pub-id-type="pmid">30664762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-018-0288-7</pub-id><pub-id pub-id-type="pmcid">PMC6352314</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="webpage"><collab>El-Radhi AS.</collab><comment>Fever in common infectious diseases. In: Clinical manual of fever in children. Cham: Springer International Publishing; 2018. p. 85&#8211;140.</comment><comment>https://doi.org/10.1007/978-3-319-92336-9_5</comment></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70634" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12505017</article-id><article-id pub-id-type="pmcid-ver">PMC12505017.1</article-id><article-id pub-id-type="pmcaid">12505017</article-id><article-id pub-id-type="pmcaiid">12505017</article-id><article-id pub-id-type="doi">10.1002/alz.70634</article-id><article-id pub-id-type="publisher-id">ALZ70634</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Sex differences in vulnerability to tau pathology: Impact on cognitive decline</article-title><alt-title alt-title-type="left-running-head">ZEIGHAMI <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70634-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zeighami</surname><given-names initials="Y">Yashar</given-names></name><xref rid="alz70634-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70634-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>yashar.zeighami@mcgill.ca</email></address></contrib><contrib id="alz70634-cr-0002" contrib-type="author"><name name-style="western"><surname>Tremblay</surname><given-names initials="C">Cecilia</given-names></name><xref rid="alz70634-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70634-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70634-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Dadar</surname><given-names initials="M">Mahsa</given-names></name><xref rid="alz70634-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70634-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>mahsa.dadar@mcgill.ca</email></address></contrib></contrib-group><aff id="alz70634-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>McGill University</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Qu&#233;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70634-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Douglas Mental Health University Institute</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Qu&#233;bec</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Yashar Zeighami and Mahsa Dadar, Cerebral Imaging Centre, 6875 Boulevard LaSalle, Montr&#233;al, QC, H4H 1R3, Canada.<break/> Email: <email>yashar.zeighami@mcgill.ca</email> and <email>mahsa.dadar@mcgill.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="420">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70634</elocation-id><history><date date-type="rev-recd"><day>16</day><month>7</month><year>2025</year></date><date date-type="received"><day>29</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70634.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70634.pdf"/><abstract><title>Abstract</title><sec id="alz70634-sec-0010"><title>INTRODUCTION</title><p>Although the link between the presence of amyloid and tau pathologies, neurodegeneration, and cognitive decline in aging individuals is established, it is less clear whether there are sex differences in vulnerability to these pathologies.</p></sec><sec id="alz70634-sec-0020"><title>METHODS</title><p>A total of 1464 participants (7168 longitudinal assessments, 4.77&#160;&#177;&#160;3.78 years of follow&#8208;up) were included from the National Alzheimer's Coordinating Center (NACC) database. Longitudinal mixed effects and mediation models examined the sex differences across cognitive decline trajectories of amyloid (A), tau (T), and neurodegeneration (N) groups.</p></sec><sec id="alz70634-sec-0030"><title>RESULTS</title><p>A<sup>+</sup>T<sup>&#8722;</sup> males showed faster cognitive decline compared to A<sup>+</sup>T<sup>&#8722;</sup> females (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.005), whereas A<sup>+</sup>T<sup>+</sup> females showed steeper cognitive decline compared to A<sup>+</sup>T<sup>+</sup> males (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001). In addition, sex marginally moderated the mediating effect of tau on the relationship between amyloid and cognitive decline (<italic toggle="yes">p</italic>&#160;=&#160;0.046).</p></sec><sec id="alz70634-sec-0040"><title>DISCUSSION</title><p>Sex differences in vulnerability to tau pathology in the presence of amyloid can shape cognitive decline trajectories.</p></sec><sec id="alz70634-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70634-list-0001"><list-item><p>A<sup>+</sup>T<sup>&#8722;</sup> males showed faster cognitive decline compared to A<sup>+</sup>T<sup>&#8722;</sup> females.</p></list-item><list-item><p>A<sup>+</sup>T<sup>+</sup> females showed faster cognitive decline compared to A<sup>+</sup>T<sup>+</sup> males.</p></list-item><list-item><p>Tau status significantly mediated the relationship between amyloid status and cognitive decline.</p></list-item><list-item><p>Sex marginally moderated the mediating relationship between amyloid, tau, and cognitive decline.</p></list-item><list-item><p>The findings point to sex differences in the impact of tau pathology on cognition.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70634-kwd-0001">Alzheimer's disease pathology</kwd><kwd id="alz70634-kwd-0002">amyloid plaques</kwd><kwd id="alz70634-kwd-0003">biomarkers</kwd><kwd id="alz70634-kwd-0004">cerebrospinal fluid</kwd><kwd id="alz70634-kwd-0005">cognitive decline</kwd><kwd id="alz70634-kwd-0006">neurodegeneration</kwd><kwd id="alz70634-kwd-0007">positron emission tomography</kwd><kwd id="alz70634-kwd-0008">sex</kwd><kwd id="alz70634-kwd-0009">tau tangles</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Canadian Institutes of Health Research (CIHR)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada (NSERC)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Fonds de Recherche du Qu&#233;bec&#8211;Sant&#233; (FRQS)</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="10"/><word-count count="6868"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:08.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70634-cite-0001"><string-name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tremblay</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>. <article-title>Sex differences in vulnerability to tau pathology: Impact on cognitive decline</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70634</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70634</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70634-sec-0060"><label>1</label><title>BACKGROUND</title><p>Alzheimer's disease (AD) is the most common neurodegenerative disease and cause of dementia in the aging population. Based on the definition of the National Institute on Aging&#8211;Alzheimer's Association (NIA&#8208;AA) Alzheimer's diagnostic framework to biologically define AD, it is characterized by the presence of three distinct biomarkers: amyloid beta (A&#946;) deposition (A), pathological tau (T), and neurodegeneration (N).<xref rid="alz70634-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70634-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Clinically, positivity on amyloid and tau markers can be established through amyloid and tau positron emission tomography (PET) or cerebrospinal fluid (CSF) assessments, whereas neurodegeneration can be determined based on magnetic resonance imaging (MRI) or fluorodeoxyglucose (FDG) PET findings<xref rid="alz70634-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>. Longitudinal trajectories of AD amyloid&#8208;tau&#8208;neurodegeneration (ATN) biomarkers have been assessed in older adults, with the most common pattern being the amyloid pathology biomarker that emerges first.<xref rid="alz70634-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Specifically, individuals who are negative on all three markers (A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup>) are considered as normal or without AD pathology, individuals that are positive on amyloid and negative on tau and neurodegeneration (A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup>) are considered to be at earlier stages of the disease, and individuals that are positive on amyloid and tau (A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup> or A<sup>+</sup> T<sup>+</sup> N<sup>+</sup>) are considered as having AD (earlier or later stages, respectively). Finally, individuals that are negative on amyloid but positive on tau or neurodegeneration (A<sup>&#8722;</sup> T<sup>+</sup> N<sup>&#8722;</sup>, A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>+</sup>, or A<sup>&#8722;</sup> T<sup>+</sup> N<sup>+</sup>) are considered to have non&#8208;AD pathologies, and individuals that are positive on amyloid and neurodegeneration but negative on tau are considered as having AD pathology as well as other non&#8208;AD pathology (A<sup>+</sup>T<sup>&#8722;</sup>N<sup>+</sup>) that contributes to neurodegeneration.<xref rid="alz70634-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70634-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>A growing body of research on sex differences in AD points to significantly higher prevalence and burden of tau pathology and cognitive deficits in females compared to males.<xref rid="alz70634-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70634-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70634-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70634-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Sex&#8208;specific differences in pathology burden might also have implications for disease management and treatment, as sex differences in treatment efficiency have been reported recently.<xref rid="alz70634-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70634-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Finally, although previous studies suggest a mediating effect of tau pathology on the associations between amyloid burden and cognitive decline,<xref rid="alz70634-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70634-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70634-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70634-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> it is unclear whether these associations differ between sexes. As such, given the accumulating literature pointing to sex differences in AD pathology burden and cognitive decline trajectories,<xref rid="alz70634-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70634-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70634-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70634-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70634-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70634-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> more studies are needed to disentangle the effects of sex on the associations between amyloid and tau biomarkers and cognitive decline.</p><p>This study aimed to assess the sex differences in longitudinal cognitive trajectories, specifically disentangling the contribution of amyloid, tau, and neurodegeneration, by comparing ATN biomarker&#8211;based groups using a large cohort of aged individuals along the AD continuum, from cognitively unimpaired to AD dementia. To do so, we took advantage of the large number of participants with ATN biomarker status information as well as long&#8208;term longitudinal cognitive assessments available from the National Alzheimer's Coordinating Center (NACC)<xref rid="alz70634-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70634-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> database. We hypothesized that amyloid&#8208; and tau&#8208;positive biomarker groups with neurodegeneration would show a steeper cognitive decline followed by groups positive for amyloid without neurodegeneration or tau pathology, and we expected to find a steeper cognitive decline in females, especially in groups with tau&#8208;positive biomarkers.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70634-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70634-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed the literature on the associations between the presence of amyloid and tau pathologies and neurodegeneration and cognitive decline in individuals on the Alzheimer's disease (AD) continuum, using traditional sources such as PubMed. Although previous research has highlighted the impact of the presence of these pathologies on exacerbating cognitive decline in these populations as well as a mediation relationship between amyloid, tau, and cognitive decline, it is unclear whether these relationships are sex differentiated.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our main findings revealed a specific dichotomic sex difference between tau positive versus tau negative biomarker groups that had positive amyloid biomarker status. Specifically, in the A<sup>+</sup>T<sup>&#8722;</sup> group, males showed a faster cognitive decline than females in contrast to the A<sup>+</sup>T<sup>+</sup> group, in which females showed a steeper cognitive decline. Furthermore, sex moderated the mediation relationship between amyloid, tau, and cognitive decline. These results suggest differences in the vulnerability to tau pathology in participants with positive amyloid biomarkers and may have important clinical implications for the development of sex&#8208;specific treatments in AD.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future research should extend these findings by incorporating other contributing factors such as vascular pathology and inflammatory markers into the ATN framework.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70634-sec-0080"><label>2</label><title>METHODS</title><p>Data were obtained from the NACC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naccdata.org/" ext-link-type="uri">https://naccdata.org/</ext-link>; September 2024 data freeze) database.<xref rid="alz70634-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70634-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70634-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70634-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Ethics approval was obtained from the participants by the local institutional review board from each NIA Alzheimer's Disease Research Center (ADRC) that contributed the data to NACC. Yes/no indicators of elevated amyloid and tau based on PET or CSF were provided by NACC ADRCs based on local interpretations of PET or CSF results (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://files.alz.washington.edu/documentation/uds3-tip-ded.pdf" ext-link-type="uri">https://files.alz.washington.edu/documentation/uds3&#8208;tip&#8208;ded.pdf</ext-link>). Briefly, PET positivity was established based on visual interpretation of the images following image preparation (reorientation and color scaling), in compliance with U.S. Food and Drug Administration (FDA)&#8211; and European Medicines Agency (EMA)&#8211;approved guidelines for clinical use.<xref rid="alz70634-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The CSF biomarkers for amyloid and tau were analyzed using enzyme&#8208;linked immunosorbent assay (ELISA) or Luminex multiplex xMAP assay protocols, and positivity was established based on assay specific thresholds.<xref rid="alz70634-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Participants were included if they had demographics information as well as PET&#8208; or CSF&#8208;based amyloid (<italic toggle="yes">N</italic>&#160;=&#160;1074 for PET and <italic toggle="yes">N&#160;</italic>=&#160;390 for CSF) and tau (<italic toggle="yes">N</italic>&#160;=&#160;886 for PET and <italic toggle="yes">N</italic>&#160;=&#160;578 for CSF) status and visual assessment of hippocampal atrophy (<italic toggle="yes">N</italic>&#160;=&#160;1464) available. These binary values reflecting abnormality on amyloid and tau and hippocampal atrophy were used to derive ATN classification for all participants. Clinical Dementia Rating Sum of Boxes (CDR&#8208;SB) scale scores were used as a measure of global cognition. Exclusion criteria included missing ATN information, clinical diagnosis of non&#8208;AD neurological disorders (e.g., Lewy body dementia and frontotemporal dementia), participants with ages below 55 or above 95, and participants without longitudinal follow&#8208;up assessments including CDR&#8208;SB information available. Furthermore, due to the small number of participants with A<sup>&#8722;</sup> T<sup>+</sup> N<sup>+</sup> (2 females and 12 males), this group was not included in the analyses. This resulted in a total of 1464 participants with 7168 longitudinal timepoints included (average follow&#8208;up: 4.77&#160;&#177;&#160;3.78 years, 4.9&#160;&#177;&#160;3.2 visits). Table&#160;<xref rid="alz70634-tbl-0001" ref-type="table">1</xref> summarizes the demographics information of the included participants. Names of the specific variables used are summarized in Table <xref rid="alz70634-supinfo-0001" ref-type="">S1</xref>.</p><table-wrap position="float" id="alz70634-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of the participants included in this study.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="x000B1" span="1"/><col align="char" char="x000B1" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Females</p>
<p>
<italic toggle="yes">N</italic>&#160;= 772</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Males</p>
<p>
<italic toggle="yes">N</italic>&#160;= 692</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">67.66&#160;&#177; 7.61</td><td align="char" rowspan="1" colspan="1">69.40&#160;&#177; 7.86</td><td align="char" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#949;4 allele, <italic toggle="yes">N</italic> (%)</td><td align="left" rowspan="1" colspan="1">638 available&#160;</td><td align="left" rowspan="1" colspan="1">570 available&#160;</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">319 (50%)</td><td align="char" char="(" rowspan="1" colspan="1">288 (50%)</td><td align="char" rowspan="1" colspan="1">0.39</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" char="(" rowspan="1" colspan="1">249 (39%)</td><td align="char" char="(" rowspan="1" colspan="1">233 (41%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">70 (11%)</td><td align="char" char="(" rowspan="1" colspan="1">49 (9%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">15.96&#160;&#177; 2.7</td><td align="char" rowspan="1" colspan="1">16.80&#160;&#177; 2.6</td><td align="char" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Amyloid positive (A<sup>+</sup>), <italic toggle="yes">N</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">352 (50%)</td><td align="char" char="(" rowspan="1" colspan="1">390 (56%)</td><td align="char" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Tau positive (T<sup>+</sup>), <italic toggle="yes">N</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">297 (42%)</td><td align="char" char="(" rowspan="1" colspan="1">325 (47%)</td><td align="char" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurodegeneration positive&#160; (N<sup>+</sup>), <italic toggle="yes">N</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">208 (30%)</td><td align="char" char="(" rowspan="1" colspan="1">295 (42%)</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR&#8208;SB</td><td align="char" rowspan="1" colspan="1">1.53&#160;&#177; 2.47</td><td align="char" rowspan="1" colspan="1">1.90&#160;&#177; 2.49</td><td align="char" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">MoCA</td><td align="char" rowspan="1" colspan="1">22.59&#160;&#177; 6.06</td><td align="char" rowspan="1" colspan="1">22.14&#160;&#177; 5.37</td><td align="char" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Trail Making Test Part A</td><td align="char" rowspan="1" colspan="1">39.05&#160;&#177; 28.51</td><td align="char" rowspan="1" colspan="1">42.12&#160;&#177; 28.37</td><td align="char" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">Trail Making Test Part B</td><td align="char" rowspan="1" colspan="1">99.63&#160;&#177; 70.7</td><td align="char" rowspan="1" colspan="1">113.92&#160;&#177; 74.93</td><td align="char" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Animals</td><td align="char" rowspan="1" colspan="1">18.76&#160;&#177; 6.78</td><td align="char" rowspan="1" colspan="1">17.73&#160;&#177; 6.76</td><td align="char" rowspan="1" colspan="1">&lt; 0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Vegetables</td><td align="char" rowspan="1" colspan="1">13.75&#160;&#177; 5.40</td><td align="char" rowspan="1" colspan="1">10.37&#160;&#177; 4.77</td><td align="char" rowspan="1" colspan="1">&lt; 0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnosis, <italic toggle="yes">N</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">NC</td><td align="char" char="(" rowspan="1" colspan="1">393 (51%)</td><td align="char" char="(" rowspan="1" colspan="1">213 (31%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">MCI</td><td align="char" char="(" rowspan="1" colspan="1">204 (26%)</td><td align="char" char="(" rowspan="1" colspan="1">305 (44%)</td><td align="char" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">AD</td><td align="char" char="(" rowspan="1" colspan="1">175 (23%)</td><td align="char" char="(" rowspan="1" colspan="1">174 (25%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thal amyloid phase (total sample)</td><td align="left" rowspan="1" colspan="1">(42)</td><td align="left" rowspan="1" colspan="1">(70)</td><td align="char" rowspan="1" colspan="1">0.235</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">4</td><td align="char" char="(" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" char="(" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">5</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">4</td><td align="char" char="(" rowspan="1" colspan="1">6</td><td align="char" char="(" rowspan="1" colspan="1">18</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">5</td><td align="char" char="(" rowspan="1" colspan="1">27</td><td align="char" char="(" rowspan="1" colspan="1">41</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CERAD amyloid score (total sample)</td><td align="left" rowspan="1" colspan="1">(42)</td><td align="left" rowspan="1" colspan="1">(70)</td><td align="char" rowspan="1" colspan="1">0.334</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">7</td><td align="char" char="(" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" char="(" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">4</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">6</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">32</td><td align="char" char="(" rowspan="1" colspan="1">53</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Braak tau stage (total sample)</td><td align="left" rowspan="1" colspan="1">(41)</td><td align="left" rowspan="1" colspan="1">(68)</td><td align="char" rowspan="1" colspan="1">0.051</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td><td align="char" char="(" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2</td><td align="char" char="(" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">4</td><td align="char" char="(" rowspan="1" colspan="1">3</td><td align="char" char="(" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">5</td><td align="char" char="(" rowspan="1" colspan="1">8</td><td align="char" char="(" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">6</td><td align="char" char="(" rowspan="1" colspan="1">23</td><td align="char" char="(" rowspan="1" colspan="1">45</td><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="alz70634-tbl1-note-0001"><p>Abbreviations: AD, Alzheimer's disease; <italic toggle="yes">APOE</italic>, apolipoprotein E; CDR&#8208;SB, Clinical Dementia Rating&#8211;Sum of Boxes; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; MCI, mild cognitive impairment; NC, normal cognition; MoCA, Montreal Cognitive Assessment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="alz70634-sec-0090"><label>2.1</label><title>Statistical analyses</title><p>Baseline demographic characteristics were compared across sexes using independent sample <italic toggle="yes">t</italic>&#8208;tests for continuous measures and chi&#8208;square (&#120594;<sup>2</sup>) tests for categorical measures. The following longitudinal mixed&#8208;effects models were used to examine the differences in rates of cognitive decline across ATN groups (Model 1) as well as potential sex differences in the rates of decline within each ATN group (Model 2):
<disp-formula id="alz70634-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi mathvariant="bold">Cognition</mml:mi><mml:mo>&#8764;</mml:mo><mml:mrow><mml:mi mathvariant="bold">Time</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">from</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">Baseline</mml:mi></mml:mrow><mml:mo>:</mml:mo><mml:mi mathvariant="bold">ATN</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="2em"/><mml:mo linebreak="badbreak">+</mml:mo><mml:mspace width="0.16em"/><mml:mi>ATN</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>Age</mml:mi><mml:mi>bl</mml:mi></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Education</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">|</mml:mo><mml:mi>ID</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>
<disp-formula id="alz70634-disp-0002"><label>(2)</label><mml:math id="jats-math-2" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi mathvariant="bold">Cognition</mml:mi><mml:mo>&#8764;</mml:mo><mml:mrow><mml:mi mathvariant="bold">Time</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">from</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">Baseline</mml:mi></mml:mrow><mml:mo>:</mml:mo><mml:mi mathvariant="bold">ATN</mml:mi><mml:mo>:</mml:mo><mml:mi mathvariant="bold">Sex</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow><mml:mo>:</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="2em"/><mml:mi>ATN</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>ATN</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow><mml:mo>:</mml:mo><mml:mi>Sex</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="2em"/><mml:mo linebreak="badbreak">+</mml:mo><mml:mspace width="0.16em"/><mml:mi>ATN</mml:mi><mml:mo>:</mml:mo><mml:mi>Sex</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Sex</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Ag</mml:mi><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mi>bl</mml:mi></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Education</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">|</mml:mo><mml:mi>ID</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where cognition indicates CDR&#8208;SB scores, time from baseline indicates the time between each longitudinal time point and the baseline clinical assessment visit, and ATN indicates a categorical variable reflecting positivity on amyloid, tau, and neurodegeneration. Sex is a categorical variable contrasting males versus females. Age at baseline (Age<sub>bl</sub>) and education were included as continuous fixed covariates in all models. For Model 1, the variable of interest was <bold>Time from Baseline: ATN</bold>, reflecting the potential differences in rates of cognitive decline across groups of interest.</p><p>For Model 2, the variable of interest was <bold>Time from Baseline: ATN: Sex</bold>, reflecting potential sex differences in rates of cognitive decline across the groups of interest. To ensure that potential differences in age (as the female participants were younger than the male participants in the full sample) and clinical diagnoses of the participants included (as there was a higher proportion of cognitively normal females compared to males in the full sample) did not impact the results, the analyses were repeated in an age&#8208; and diagnosis&#8208;matched subset of the dataset (<italic toggle="yes">N</italic>&#160;=&#160;1146, 573 females, 573 males).</p><p>Similar analyses (i.e., Models 1 and 2) were performed for other cognitive assessment scores that had sufficient data available, evaluating the following cognitive domains: (1) global cognition: Montreal Cognitive Assessment (MoCA, <italic toggle="yes">N</italic>&#160;=&#160;1182, 4042 longitudinal assessments); (2) executive functioning: Trail Making Test (TMT) Parts A (<italic toggle="yes">N</italic>&#160;=&#160;1242, 5420 longitudinal assessments) and B (<italic toggle="yes">N</italic>&#160;=&#160;1127, 5045 longitudinal assessments); and (3) semantic functioning: Animals (<italic toggle="yes">N</italic>&#160;=&#160;1357, 6294 longitudinal assessments) and Vegetables (<italic toggle="yes">N</italic>&#160;=&#160;1346, 6249 longitudinal assessments). The estimates for MoCA, Animals, and Vegetables were multiplied by (&#8211;1) so that positive estimates indicate worse cognitive performance for all tests.</p><p>To assess whether there were potential differences in severity of pathologies between males and females (e.g., whether T<sup>+</sup> females had a greater burden of tau tangles than males), we further examined the sex differences in post&#8208;mortem amyloid and tau levels, using Thal amyloid phase, Consortium to Establish a Registry for Alzheimer's Disease (CERAD) amyloid score, and Braak tau stage (see original variable names in Table <xref rid="alz70634-supinfo-0001" ref-type="">S1</xref>) in the subset of the participants that had post&#8208;mortem pathology assessments available (N<sub>Braak</sub>: 68 males and 41 females; N<sub>Thal</sub>: 70 males and 42 females; N<sub>CERAD</sub>: 70 males and 42 females). The following ordinal logistic regression models were used for these analyses, adjusting for age at time of death.<disp-formula id="alz70634-disp-0003"><label>(3)</label><mml:math id="jats-math-3" display="block"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Braak</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">stage</mml:mi></mml:mrow><mml:mo>&#8764;</mml:mo><mml:mi mathvariant="bold">Sex</mml:mi><mml:mo>:</mml:mo><mml:mrow><mml:mi mathvariant="bold">Tau</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="bold">status</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi mathvariant="bold">Sex</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Tau</mml:mi><mml:mspace width="0.33em"/><mml:mi>status</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>age</mml:mi><mml:mspace width="0.33em"/><mml:mi>at</mml:mi><mml:mspace width="0.33em"/><mml:mi>death</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="alz70634-disp-0004"><label>(4)</label><mml:math id="jats-math-4" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mi>Thal</mml:mi><mml:mspace width="0.33em"/><mml:mi>phase</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>CERAD</mml:mi><mml:mo>&#8764;</mml:mo><mml:mspace width="0.16em"/><mml:mrow><mml:mi>Sex</mml:mi><mml:mo>:</mml:mo><mml:mi>Amyloid</mml:mi><mml:mspace width="0.33em"/><mml:mi>status</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Sex</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Amyloid</mml:mi><mml:mspace width="0.33em"/><mml:mi>status</mml:mi></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="2em"/><mml:mo linebreak="badbreak">+</mml:mo><mml:mspace width="0.16em"/><mml:mrow><mml:mi>age</mml:mi><mml:mspace width="0.33em"/><mml:mi>at</mml:mi><mml:mspace width="0.33em"/><mml:mi>death</mml:mi></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>where amyloid and tau status denote in vivo A and T status, and Braak, Thal, and CERAD denote the standard post&#8208;mortem pathology staging scores of the same participants. The variables of interest included sex and sex interaction with amyloid or tau status.</p><p>Finally, we examined whether there are sex differences in the mediating effect of tau positivity on the associations between amyloid positivity and cognitive decline. We first confirmed the mediating relationships between amyloid, tau, and cognitive decline by performing a mediation analysis, with amyloid status as the independent variable, rate of cognitive decline as the dependent variable, and tau status as the mediating variable. Age and education were included as covariates. Rate of cognitive decline was estimated based on the random slopes of the following mixed effects models, similar to previous studies<xref rid="alz70634-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70634-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> in the literature:
<disp-formula id="alz70634-disp-0005"><label>(5)</label><mml:math id="jats-math-5" display="block"><mml:mrow><mml:mrow><mml:mi>Cognition</mml:mi><mml:mo>&#8764;</mml:mo><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mrow><mml:mi>Time</mml:mi><mml:mspace width="0.33em"/><mml:mi>from</mml:mi><mml:mspace width="0.33em"/><mml:mi>Baseline</mml:mi></mml:mrow><mml:mspace width="0.33em"/><mml:mo stretchy="false">|</mml:mo><mml:mspace width="0.33em"/><mml:mi>ID</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Sex was then examined as a potential moderator for this mediation effect. For both analyses, we used 1000 bootstrapped resamples to estimate the confidence intervals (CIs). All statistical analyses were performed in R software version 4.3.3 (2024&#8208;02&#8208;29). The matched subsample was produced using MatchIt version 4.7.1<xref rid="alz70634-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70634-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> R package. lme4 version 1.1&#8208;36<xref rid="alz70634-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70634-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> and lmerTest version 3.1&#8208;3 <xref rid="alz70634-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> R packages were used for mixed&#8208;effects modeling analyses. &#8220;lavaan&#8221; version 0.6&#8208;19<xref rid="alz70634-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> R package was used for the mediation and moderation analyses.</p></sec></sec><sec id="alz70634-sec-0100"><label>3</label><title>RESULTS</title><p>Female participants were younger and had lower levels of education (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Furthermore, fewer females were A<sup>+</sup>, T<sup>+</sup>, or N<sup>+</sup>. Females also had lower CDR&#8208;SB scale scores at baseline (<italic toggle="yes">p</italic>&#160;=&#160;0.004), and a greater proportion of them were classified as cognitively normal at the baseline visit assessment, whereas a greater proportion of males were classified in the mild cognitive impairment (MCI) group (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001). As expected, there were no statistically significant differences in age and clinical diagnoses of the age&#8208; and diagnosis&#8208;matched subsample.</p><sec id="alz70634-sec-0110"><label>3.1</label><title>Cognitive decline across different ATN groups</title><p>Figure&#160;<xref rid="alz70634-fig-0001" ref-type="fig">1A</xref> and Table <xref rid="alz70634-supinfo-0001" ref-type="">S2</xref> summarize the estimated effects of ATN pathology on cognitive trajectories as measured by CDR&#8208;SB across time (Model 1). There was no significant impact of age at baseline, whereas education showed a small but significant impact (&#120573;&#160;=&#160;&#8211;0.1, <italic toggle="yes">p</italic>&#160;=&#160;0.001). Except for the A<sup>&#8722;</sup> T<sup>+</sup> N<sup>&#8722;</sup> group, all other included positive ATN pathology groups showed significantly higher baseline CDR&#8208;SB scores compared to the control group (A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup>). Differences were smaller for the A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> (&#120573;&#160;=&#160;0.76, <italic toggle="yes">p</italic>&#160;=&#160;0.02), followed by A<sup>+</sup> T<sup>&#8722;</sup> N<sup>+</sup> (&#120573;&#160;=&#160;1.87, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup> (&#120573;&#160;=&#160; 2.03, <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001), and A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> (&#120573;&#160;=&#160;3.50, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Similarly, all pathology&#8208;positive groups showed faster rates of cognitive decline compared to the reference A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup>. As expected, participants with only one pathology present showed less steep slopes of decline (A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup>: 0.1 increase per year, A<sup>&#8722;</sup> T<sup>+</sup> N<sup>&#8722;</sup>: 0.1 increase per year, and A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>+</sup>: 0.28 increase per year; all <italic toggle="yes">p</italic> values&#160;&lt;&#160;0.005), whereas groups with multiple pathologies present showed even faster progression (A<sup>+</sup> T<sup>&#8722;</sup> N<sup>+</sup>: 0.75 increase per year, A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup>: 0.76 increase per year, and A<sup>+</sup> T<sup>+</sup> N<sup>+</sup>: 0.87 increase per year; all <italic toggle="yes">p</italic> values&#160;&lt;&#160;0.00001).</p><fig position="float" fig-type="FIGURE" id="alz70634-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>(A) Longitudinal cognitive decline trajectories across ATN groups. A, amyloid; T, tau; N, neurodegeneration; CDR&#8208;SB, Clinical Dementia Rating&#8211;Sum of Boxes. (B) Sex differences in longitudinal cognitive decline trajectories across ATN groups. Arrows indicate ATN groups that showed significant slope differences between males and females. ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.005. *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70634-g003.jpg"/></fig><p>Similar patterns emerged when assessing the ATN group differences in longitudinal trajectories of MoCA, TMT A and B, and Animals, and Vegetables scores. Figure&#160;<xref rid="alz70634-fig-0002" ref-type="fig">2A</xref> shows the t&#8208;statistics for the estimated slopes (reflecting the rates of cognitive decline compared to the reference A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> group) that were statistically significant for each group and test score. Note that estimates for MoCA, Animals, and Vegetables were multiplied by (&#8211;1) so that positive estimates indicate worse cognitive performance for all tests. Pathology&#8208;positive groups showed faster rates of cognitive decline compared to the reference A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> group, and the A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> group had the fastest rate of cognitive decline for all tests, followed by the two pathology A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup> and A<sup>+</sup> T<sup>&#8722;</sup> N<sup>+</sup> groups. Tables <xref rid="alz70634-supinfo-0001" ref-type="">S3&#8211;S7</xref> summarize the results of these analyses.</p><fig position="float" fig-type="FIGURE" id="alz70634-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>(A) Slopes of longitudinal cognitive decline trajectories across ATN groups. (B) Sex differences in longitudinal cognitive decline trajectories across ATN groups. Positive values indicate higher rates of decline in females, whereas negative values indicate higher rates of decline in males. <bold>Note that</bold> estimates for MoCA, Animals, and Vegetables were multiplied by (&#8211;1) so that positive estimates indicate worse cognitive performance for all tests. A, amyloid; T, tau. N, neurodegeneration; CDR&#8208;SB, Clinical Dementia Rating&#8211;Sum of Boxes; MoCA, Montreal Cognitive Assessment. Arrows indicate ATN groups that showed significant slope differences between males and females. &#8224; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.1; ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.005; *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70634-g002.jpg"/></fig></sec><sec id="alz70634-sec-0120"><label>3.2</label><title>Sex differences in rates of cognitive decline across ATN groups</title><p>Figure&#160;<xref rid="alz70634-fig-0001" ref-type="fig">1B</xref> and Table <xref rid="alz70634-supinfo-0001" ref-type="">S8</xref> summarize the estimated sex differences in the rates of cognitive decline across the ANT groups (Model 2). There were no significant sex differences in baseline CDR&#8208;SB scores across ATN groups. Although there were no significant sex differences in the rates of cognitive decline in any of the A<sup>&#8722;</sup> groups, we found a dichotomy based on tau status in A<sup>+</sup> groups, with the A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> males showing an additional 0.17 increase in CDR&#8208;SB score per year compared to A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> females, and the A<sup>+</sup> T<sup>&#8722;</sup> N<sup>+</sup> males showing an additional 0.40 in CDR&#8208;SB score per year compared to A<sup>+</sup> T<sup>&#8722;</sup> N<sup>+</sup> females (<italic toggle="yes">p</italic> values&#160;&lt;&#160;0.005). Further still, female participants showed faster progression compared to males in both A<sup>+</sup> T<sup>+</sup> groups, with the A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup> females showing an additional 0.24 increase in CDR&#8208;SB score per year compared to A<sup>+</sup> T<sup>+</sup> N<sup>&#8722;</sup> males, and the A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> females showing an additional 0.61 in CDR&#8208;SB score per year compared to A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> males (<italic toggle="yes">p</italic> values&#160;&lt;&#160;0.00001). Repeating the analyses in the age&#8208; and diagnosis&#8208;matched subsample of the data yielded similar results in terms of significance and direction of the estimated effects (Table <xref rid="alz70634-supinfo-0001" ref-type="">S3</xref>).</p><p>Similar patterns of sex differences emerged when assessing the ATN group differences in the longitudinal trajectories of MoCA, TMT A and B, and Animals, and Vegetables scores. Figure&#160;<xref rid="alz70634-fig-0002" ref-type="fig">2B</xref> shows the t&#8208;statistics estimates for the differences in the rates of cognitive decline between the sexes, contrasting the females versus males. Positive values indicate greater rates of decline in females, and negative values indicate greater rates of decline in males. Similar to CDR&#8208;SB findings, A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> females had higher rates of cognitive decline compared to A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> males, and A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> males had higher rates of cognitive decline compared to A<sup>&#8722;</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> females for all tests (Rows 1 and 4 in Figure&#160;<xref rid="alz70634-fig-0002" ref-type="fig">2B</xref>). Although not statistically significant in most cases, the presence of only T<sup>+</sup> or N<sup>+</sup> resulted in a mixture of sex&#8208;difference directionalities across cognitive tests, which might indicate greater levels of variability when participants are in a transitional state between A<sup>+</sup> T<sup>&#8722;</sup> N<sup>&#8722;</sup> and A<sup>+</sup> T<sup>+</sup> N<sup>+</sup>. Tables <xref rid="alz70634-supinfo-0001" ref-type="">S9&#8211;S13</xref> summarize the results of these analyses.</p></sec><sec id="alz70634-sec-0130"><label>3.3</label><title>The impact of amyloid on cognitive decline is mediated via tau and moderated by sex</title><p>Mediation analyses confirmed that tau positivity (T) mediated the association between amyloid positivity (A) and the rate of cognitive decline, indexed by the rate of increase in CDR&#8208;SB score (Figure&#160;<xref rid="alz70634-fig-0003" ref-type="fig">3A</xref>), while controlling for age at baseline and education. A was significantly associated with T (a&#160;=&#160;0.720, <italic toggle="yes">z</italic>&#160;=&#160;40.1, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). In turn, T was positively associated with the rate of CDR&#8208;SB score increase (b&#160;=&#160;0.531, <italic toggle="yes">z</italic>&#160;=&#160;9.02, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The direct effect of A on the rate of cognitive decline remained significant after accounting for the indirect path through T (c&#8242;&#160;=&#160;0.497, <italic toggle="yes">z</italic>&#160;=&#160;9.22, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), indicating a partial mediation. The indirect effect of A on the rate of cognitive decline via T was statistically significant (estimate&#160;=&#160;0.382, 95% CI: 0.298&#8211;0.476, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), as was the direct effect (0.497, 95% CI: 0.391&#8211;0.602, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The total effect of A on CDR&#8208;SB score change was 0.879 (95% CI: 0.798&#8211;0.958), with &#8776;43.5% of the effect mediated by T (95% CI: 34.1&#8211;53.9%).</p><fig position="float" fig-type="FIGURE" id="alz70634-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Sex differences in the mediating effect of tau positivity on the association between amyloid positivity and cognitive decline. (A) Tau mediates the relationship between amyloid and cognitive decline. (B) Sex moderates the mediation relationship between amyloid, tau, and cognitive decline. Cognitive decline indicates the rate of change in Clinical Dementia Rating&#8211;Sum of Boxes (CDR&#8208;SB) scores.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70634-g001.jpg"/></fig><p>Furthermore, we found a marginal moderating effect of sex on this mediation, where females showed a stronger mediation effect compared to males (Figure&#160;<xref rid="alz70634-fig-0003" ref-type="fig">3B</xref>). The main pattern of associations remained consistent, with a significant association between A and T (a&#160;=&#160;0.719, <italic toggle="yes">z</italic>&#160;=&#160;39.4, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), T and the rate of CDR&#8208;SB increase (b&#160;=&#160;0.608, <italic toggle="yes">z</italic>&#160;=&#160;8.56, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), as well as a direct effect of A on the rate of CDR&#8208;SB score increase after accounting for the indirect path through T (c&#8242;&#160;=&#160;0.493, <italic toggle="yes">z</italic>&#160;=&#160;9.32, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Sex had a significant main effect on the rate of cognitive decline (b<sub>2</sub>&#160;=&#160;&#8208;0.115, <italic toggle="yes">z</italic>&#160;=&#160;&#8208;2.96, <italic toggle="yes">p</italic>&#160;=&#160;0.003), with males showing a slower decline. The interaction between tau status and sex suggested a trend toward a weaker effect of tau on decline among males (b<sub>3</sub>&#160;=&#160;&#8208;0.160, <italic toggle="yes">z</italic>&#160;=&#160;&#8208;2.03, <italic toggle="yes">p</italic>&#160;=&#160;0.045). The indirect effect of A on rate of CDR&#8208;SB increase was significant in both sexes, but larger in females (0.437, 95% CI: 0.336&#8211;0.544, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) than in males (0.322, 95% CI: 0.222&#8211;0.422, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), with the proportion of the total effect mediated by T being 47.0% in females (95% CI: 37.2&#8211;56.5%) compared to 39.5% in males (95% CI: 28.1&#8211;50.5%). The difference in indirect effects between sexes approached statistical significance (0.115, 95% CI: &#8211;0.008 to 0.229, <italic toggle="yes">p</italic>&#160;=&#160;0.046), suggesting a possible moderating effect of sex on the mediation pathway.</p></sec><sec id="alz70634-sec-0140"><label>3.4</label><title>Sex differences in post&#8208;mortem amyloid and tau burden</title><p>Adjusting for age at time of death, as expected, T<sup>+</sup> participants had significantly higher postmortem Braak tangle score (&#120573;&#160;=&#160;2.35, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001), and A<sup>+</sup> participants had significantly higher postmortem amyloid burden as measured by both Thal phase (&#120573;&#160;=&#160;1.23, <italic toggle="yes">p</italic>&#160;=&#160;0.02) and CERAD neuritic plaque score (&#120573;&#160;=&#160;3.07, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001). There were no significant sex differences in post mortem amyloid and tau burden across any of the A, T, or N groups (all <italic toggle="yes">p</italic> values&#160;&gt;&#160;0.05).</p></sec></sec><sec id="alz70634-sec-0150"><label>4</label><title>DISCUSSION</title><p>This study examined the longitudinal cognitive decline trajectories of aging individuals on the spectrum of AD according to their ATN classifications, and whether there were any sex differences in these trajectories within each ATN group. Our findings showed differences in rates of cognitive decline across ATN groups, whereby groups that were positive on multiple biomarkers showed steeper decline. Our main finding revealed a specific dichotomic sex difference between tau&#8208;positive versus tau&#8208;negative biomarker groups that had positive amyloid biomarker status. Specifically, in the A<sup>+</sup>T<sup>&#8722;</sup> group, males showed faster cognitive decline than females in contrast to the A<sup>+</sup>T<sup>+</sup> group, in which females showed steeper cognitive decline. These results suggest differences in the vulnerability to tau pathology in participants with positive amyloid biomarkers. This may have important clinical implications for the development of sex&#8208;specific treatments and emphasize the importance of studying sex differences in AD.</p><p>Although no sex differences were observed in the A<sup>&#8722;</sup> groups, significant sex differences were found in the A<sup>+</sup> groups. Specifically, males showed steeper longitudinal cognitive decline than females in the A<sup>+</sup>T<sup>&#8722;</sup> group. In contrast, A<sup>+</sup>T<sup>+</sup> females showed faster progression compared to A<sup>+</sup>T<sup>+</sup> males. Our results further confirm the presence of a mediating effect of tau pathology on the associations between amyloid positivity and cognitive decline, and suggest that these associations might differ between the sexes. Postmortem studies have identified sex differences in AD tau pathology, with a higher burden in females,<xref rid="alz70634-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70634-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> which might explain the faster progression of cognitive decline in A<sup>+</sup>T<sup>+</sup> females. In addition, a large post&#8208;mortem study of 1453 participants from the Religious Orders Study and the Rush Memory and Aging Project reported both higher tau and marginally higher amyloid burden in females,<xref rid="alz70634-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> adjusting for age at the time of death. To test this hypothesis, we investigated the subset of participants who had post&#8208;mortem amyloid and tau burden information available (7.5% of the sample) and did not find higher pathology burden in females or any other differences in amyloid or tau burden. This might be due to the smaller sample size with available pathological data or a ceiling effect within the tau&#8208;positive group, with most participants having neurofibrillary Braak stage V and VI. Alternatively, several other co&#8208;pathologies, including possible comorbid Lewy body or vascular disease not clinically detected, might have an effect on observed sex differences. Although the mechanism underlying increased rates of cognitive decline for the male participants in the A<sup>+</sup>T<sup>&#8722;</sup> group is not clear, this may suggest a higher cognitive reserve in females than in males in earlier disease stages with a positive amyloid biomarker. Accordingly, previous studies reported a higher cognitive reserve in females.<xref rid="alz70634-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70634-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70634-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</p><p>As expected, all N<sup>+</sup> groups had greater rates of cognitive decline compared to their corresponding N<sup>&#8722;</sup> groups. With a 1.49 increase in CDR&#8208;SB score per year, the A<sup>+</sup>T<sup>+</sup>N<sup>+</sup> female group had the highest rate of decline among all groups. Furthermore, the slope difference between A<sup>+</sup>T<sup>+</sup>N<sup>+</sup> and A<sup>+</sup>T<sup>+</sup>N<sup>&#8722;</sup> groups was greater in female participants (0.36 additional increase in CDR&#8208;SB) compared to male participants (0.045 additional increase in CDR&#8208;SB). This is in line with the previous literature showing stronger relationships between neurodegeneration and cognitive decline in females compared to males,<xref rid="alz70634-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70634-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> and adds to it by suggesting that this decline is further exacerbated in females in the presence of amyloid and tau.</p><p>Similar patterns of difference in the rates of cognitive decline (Figure&#160;<xref rid="alz70634-fig-0002" ref-type="fig">2A</xref>) were observed when examining other cognitive tests (MoCA, TMT A and B, Animals, and Vegetables), suggesting that the observed patterns are multi&#8208;domain and not limited to global cognitive and functional decline. The observed sex differences in the rates of cognitive decline were also consistent with the CDR&#8208;SB results, in particular for A<sup>+</sup> T<sup>+</sup>N<sup>+</sup> and A<sup>+</sup> T<sup>&#8722;</sup>N<sup>&#8722;</sup> groups, which showed the same dichotomy pattern (i.e., faster decline for T<sup>+</sup> females and faster decline for T<sup>&#8722;</sup> males; Figure&#160;<xref rid="alz70634-fig-0002" ref-type="fig">2B</xref>). The results for A<sup>+</sup>T<sup>+</sup>N<sup>&#8722;</sup> and A<sup>+</sup>T<sup>&#8722;</sup>N<sup>+</sup> groups were not statistically significant, likely due to the increased variability in the transition between the A<sup>+</sup>T<sup>&#8722;</sup> N<sup>&#8722;</sup> and A<sup>+</sup> T<sup>+</sup> N<sup>+</sup> states, which might result in more heterogeneous trajectory patterns depending on the cognitive domain examined. As such, future studies with larger sample sizes are warranted to replicate these results.</p><p>Our findings have important implications for disease diagnosis and management. Sex differences in the relationships between the presence of amyloid and tau pathologies and cognitive decline might translate into sex differences in treatment efficacy when individuals receive amyloid&#8208;clearing therapies. Because these treatments generally target patients in the earlier disease stages, who would be more likely to be A<sup>+</sup>T<sup>&#8722;</sup>, removal of amyloid might prevent cognitive decline more effectively in males than in females. This is also in line with the current evidence from recent clinical trials, where male participants benefited more from the treatment compared to their female counterparts.<xref rid="alz70634-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70634-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Similarly, this may suggest that tau&#8208;targeting agents<xref rid="alz70634-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> might be more effective for female participants.</p><p>Although prior literature has investigated the sex differences in postmortem pathology burden along the AD continuum,<xref rid="alz70634-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> as well as the sex differences in the associations between cognition and in vivo fluid (CSF or plasma) or PET amyloid and tau levels or measures of neurodegeneration,<xref rid="alz70634-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70634-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz70634-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="alz70634-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70634-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> to our knowledge, differences in longitudinal cognitive decline trajectories between ATN groups has not been investigated, as is the focus of the current study. Our study has been enabled by the large sample size of participants with PET and CSF amyloid and tau biomarkers and longitudinal assessments provided by the NACC (1464 participants, 7168 longitudinal assessments, 4.77&#160;&#177;&#160;3.78 years of follow&#8208;up), allowing us to robustly model the potential differences across ATN groups.</p><p>Although our study includes a large sample size with considerable longitudinal assessments, allowing for robust estimation of longitudinal cognitive trajectories across ATN groups, we acknowledge certain limitations. First, amyloid and tau positivity were defined based on either PET or CSF assessments, leading to potential variability in the measurements. However, the literature suggests strong agreements between PET and CSF based assessments for both amyloid and tau pathologies.<xref rid="alz70634-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70634-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="alz70634-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> In addition, we found similarly high levels of agreement (88.2% for amyloid status and 87.4% for tau status) in the subsets of participants who had both CSF and PET data available, suggesting that the impact of using either biomarker on the results would be minimal in the context of this study. In addition, sex differences were found in the demographic characteristics of the included participants, whereby the female participants were younger, and the sample included a higher proportion of female participants that were cognitively normal at baseline. To control for these differences, the sex difference analyses (Model 2) were repeated in an age&#8208; and diagnosis&#8208;matched subset of the data, and the obtained results remained similar. Finally, due to data availability and sample size limitations, we were not able to incorporate vascular pathology (V) in the analyses. Because vascular pathology is a common comorbidity that exacerbates cognitive decline in aging individuals as well as patients with AD<xref rid="alz70634-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="alz70634-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70634-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70634-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="alz70634-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> and previous studies have reported sex differences in prevalence and impact of vascular pathology on cognitive decline trajectories,<xref rid="alz70634-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="alz70634-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> future studies assessing sex differences in cognitive decline trajectories across ATN&#8208;V groups are warranted.</p><p>In conclusion, we identified a distinct sex&#8208;specific dichotomy in cognitive decline trajectories among individuals with amyloid&#8208;positive biomarkers. Specifically, males exhibited a more rapid cognitive decline than females in the absence of tau pathology, whereas females experienced a steeper decline when tau biomarkers were also present. These findings may hold significant clinical implications for the development of sex&#8208;specific therapeutic strategies for AD.</p></sec><sec id="alz70634-sec-0160"><title>AUTHOR CONTRIBUTIONS</title><p>All authors were involved with design, conceptualization, and interpretation of the findings. Yashar Zeighami and Mahsa Dadar completed the analyses and drafted the manuscript. All authors revised and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="alz70634-sec-0180"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no competing interests. Author disclosures are available in the <xref rid="alz70634-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70634-sec-0190"><title>DISCLOSURES</title><p>The authors report no disclosures relevant to the manuscript.</p></sec><sec id="alz70634-sec-0200"><title>CONSENT STATEMENT</title><p>Written informed consent was obtained from participants or their study partners.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70634-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70634-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70634-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70634-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70634-s002.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70634-sec-0170"><title>ACKNOWLEDGMENTS</title><p>The National Alzheimer's Coordinating Center (NACC) database is funded by National Institute on Aging (NIA)/National Institutes of Health (NIH) Grant U24 AG072122. NACC data are contributed by the NIA&#8208;funded Alzheimer's Disease Research Centers (ADRCs): P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI David Holtzman, MD), P30 AG066518 (PI Lisa Silbert, MD, MCR), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie A. Schneider, MD, MS), P30 AG072978 (PI Ann McKee, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Jessica Langbaum, PhD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Glenn Smith, PhD, ABPP), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P30 AG086401 (PI Erik Roberson, MD, PhD), P30 AG086404 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), and P30 AG072959 (PI James Leverenz, MD). The present study is supported by research funds from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), as well as Fonds de Recherche du Qu&#233;bec&#8212;Sant&#233; (FRQS) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.69777/330750" ext-link-type="uri">https://doi.org/10.69777/330750</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.69777/320107" ext-link-type="uri">https://doi.org/10.69777/320107</ext-link>). Dr. Tremblay is also supported by a postdoctoral fellowship from the CIHR.</p></ack><sec sec-type="data-availability" id="alz70634-sec-0220"><title>DATA AVAILABILITY STATEMENT</title><p>Data used in preparation of this article were obtained from the National Alzheimer's Coordinating Center (NACC; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naccdata.org/" ext-link-type="uri" specific-use="software is-supplemented-by">https://naccdata.org/</ext-link>) database.</p></sec><ref-list id="alz70634-bibl-0001"><title>REFERENCES</title><ref id="alz70634-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70634-cite-0002"><string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></string-name>, et&#160;al. <article-title>The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: perspectives from the Research Roundtable</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>563</fpage>&#8208;<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.03.002</pub-id><pub-id pub-id-type="pmcid">PMC6747694</pub-id><pub-id pub-id-type="pmid">29653607</pub-id></mixed-citation></ref><ref id="alz70634-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70634-cite-0003"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>NIA&#8208;AA Research Framework: toward a biological definition of Alzheimer's disease</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#8208;<lpage>562</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id><pub-id pub-id-type="pmid">29653606</pub-id></mixed-citation></ref><ref id="alz70634-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70634-cite-0004"><collab collab-type="authors">Alzheimer's Disease Neuroimaging Initiative</collab>
, <string-name name-style="western"><surname>MS</surname><given-names>Tan</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>JQ</given-names></string-name>, et&#160;al, <collab collab-type="authors">Alzheimer's Disease Neuroimaging Initiative</collab>
. <article-title>Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia</article-title>. <source>Alz Res Therapy</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>55</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-020-00621-6</pub-id><pub-id pub-id-type="pmcid">PMC7216714</pub-id><pub-id pub-id-type="pmid">32393375</pub-id></mixed-citation></ref><ref id="alz70634-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70634-cite-0005"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>. <article-title>Influence of Gender on Tau Precipitation in Alzheimer's Disease According to ATN Research Framework</article-title>. <source>Phenomics</source>. <year>2022</year>;<volume>3</volume>(<issue>6</issue>):<fpage>565</fpage>&#8208;<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s43657-022-00076-9</pub-id><pub-id pub-id-type="pmid">38223687</pub-id><pub-id pub-id-type="pmcid">PMC10781910</pub-id></mixed-citation></ref><ref id="alz70634-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70634-cite-0006"><string-name name-style="western"><surname>Yan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paranjpe</surname><given-names>MD</given-names></string-name>, et&#160;al. <article-title>Sex modifies APOE &#949;4 dose effect on brain tau deposition in cognitively impaired individuals</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>(<issue>10</issue>):<fpage>3201</fpage>&#8208;<lpage>3211</lpage>.<pub-id pub-id-type="pmid">33876815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab160</pub-id><pub-id pub-id-type="pmcid">PMC8634082</pub-id></mixed-citation></ref><ref id="alz70634-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70634-cite-0007"><string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Sex differences in the clinical manifestations of Alzheimer disease pathology</article-title>. <source>Arch Gen Psychiatry</source>. <year>2005</year>;<volume>62</volume>(<issue>6</issue>):<fpage>685</fpage>&#8208;<lpage>691</lpage>.<pub-id pub-id-type="pmid">15939846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.62.6.685</pub-id></mixed-citation></ref><ref id="alz70634-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70634-cite-0008"><string-name name-style="western"><surname>Holland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Desikan</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>McEvoy</surname><given-names>LK</given-names></string-name>. <article-title>Higher rates of decline for women and apolipoprotein E &#949;4 carriers</article-title>. <source>Am J Neuroradiol</source>. <year>2013</year>;<volume>34</volume>(<issue>12</issue>):<fpage>2287</fpage>&#8208;<lpage>2293</lpage>.<pub-id pub-id-type="pmid">23828104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A3601</pub-id><pub-id pub-id-type="pmcid">PMC3894062</pub-id></mixed-citation></ref><ref id="alz70634-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="alz70634-cite-0009"><article-title>The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect&#8212;Andrews &#8208; 2025 &#8208; Alzheimer's &amp; Dementia&#8212;Wiley Online Library</article-title>. Accessed May 21, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.14467" ext-link-type="uri">https://alz&#8208;journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.14467</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14467</pub-id><pub-id pub-id-type="pmcid">PMC11779744</pub-id><pub-id pub-id-type="pmid">39887549</pub-id></mixed-citation></ref><ref id="alz70634-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70634-cite-0010"><string-name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Lecanemab in Early Alzheimer's Disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>1</issue>):<fpage>9</fpage>&#8208;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></mixed-citation></ref><ref id="alz70634-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70634-cite-0011"><string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></string-name>. <article-title>Neurofibrillary Tangles Mediate the Association of Amyloid Load With Clinical Alzheimer Disease and Level of Cognitive Function</article-title>. <source>Arch Neurol</source>. <year>2004</year>;<volume>61</volume>(<issue>3</issue>):<fpage>378</fpage>&#8208;<lpage>384</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.61.3.378</pub-id><pub-id pub-id-type="pmid">15023815</pub-id></mixed-citation></ref><ref id="alz70634-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70634-cite-0012"><string-name name-style="western"><surname>Hanseeuw</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Betensky</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></string-name>, et&#160;al. <article-title>Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: a Longitudinal Study</article-title>. <source>JAMA Neurol</source>. <year>2019</year>;<volume>76</volume>(<issue>8</issue>):<fpage>915</fpage>&#8208;<lpage>924</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2019.1424</pub-id><pub-id pub-id-type="pmid">31157827</pub-id><pub-id pub-id-type="pmcid">PMC6547132</pub-id></mixed-citation></ref><ref id="alz70634-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70634-cite-0013"><string-name name-style="western"><surname>Ma</surname><given-names>LZ</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>ZT</given-names></string-name>, et&#160;al. <article-title>P&#8208;tau and neurodegeneration mediate the effect of &#946;&#8208;amyloid on cognition in non&#8208;demented elders</article-title>. <source>Alz Res Therapy</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>200</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-021-00943-z</pub-id><pub-id pub-id-type="pmcid">PMC8675473</pub-id><pub-id pub-id-type="pmid">34911582</pub-id></mixed-citation></ref><ref id="alz70634-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70634-cite-0014"><string-name name-style="western"><surname>Yau</surname><given-names>WYW</given-names></string-name>, <string-name name-style="western"><surname>Shirzadi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>HS</given-names></string-name>, et&#160;al. <article-title>Tau Mediates Synergistic Influence of Vascular Risk and A&#946; on Cognitive Decline</article-title>. <source>Ann Neurol</source>. <year>2022</year>;<volume>92</volume>(<issue>5</issue>):<fpage>745</fpage>&#8208;<lpage>755</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.26460</pub-id><pub-id pub-id-type="pmid">35880989</pub-id><pub-id pub-id-type="pmcid">PMC9650958</pub-id></mixed-citation></ref><ref id="alz70634-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70634-cite-0015"><string-name name-style="western"><surname>Oliver</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kamal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>. <article-title>Subjective cognitive decline is a better marker for future cognitive decline in females than in males</article-title>. <source>Alzheimer's Research &amp; Therapy</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01138-w</pub-id><pub-id pub-id-type="pmcid">PMC9798694</pub-id><pub-id pub-id-type="pmid">36581949</pub-id></mixed-citation></ref><ref id="alz70634-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70634-cite-0016"><string-name name-style="western"><surname>Avila</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Vonk</surname><given-names>JMJ</given-names></string-name>, <string-name name-style="western"><surname>Verney</surname><given-names>SP</given-names></string-name>, et&#160;al. <article-title>Sex/gender differences in cognitive trajectories vary as a function of race/ethnicity</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2019</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1516</fpage>&#8208;<lpage>1523</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2019.04.006</pub-id><pub-id pub-id-type="pmcid">PMC6925640</pub-id><pub-id pub-id-type="pmid">31606366</pub-id></mixed-citation></ref><ref id="alz70634-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70634-cite-0017"><string-name name-style="western"><surname>McCarrey</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kitner&#8208;Triolo</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Resnick</surname><given-names>SM</given-names></string-name>. <article-title>Sex differences in cognitive trajectories in clinically normal older adults</article-title>. <source>Psychol Aging</source>. <year>2016</year>;<volume>31</volume>(<issue>2</issue>):<fpage>166</fpage>&#8208;<lpage>175</lpage>. doi:<pub-id pub-id-type="doi">10.1037/pag0000070</pub-id><pub-id pub-id-type="pmid">26796792</pub-id><pub-id pub-id-type="pmcid">PMC4783196</pub-id></mixed-citation></ref><ref id="alz70634-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70634-cite-0018"><string-name name-style="western"><surname>Levine</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Brice&#241;o</surname><given-names>EM</given-names></string-name>, et&#160;al. <article-title>Sex Differences in Cognitive Decline Among US Adults</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>2</issue>):<elocation-id>e210169</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.0169</pub-id><pub-id pub-id-type="pmid">33630089</pub-id><pub-id pub-id-type="pmcid">PMC7907956</pub-id></mixed-citation></ref><ref id="alz70634-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70634-cite-0019"><string-name name-style="western"><surname>Brzezinski&#8208;Rittner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moqadam</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Iturria&#8208;Medina</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chakravarty</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></string-name>. <article-title>Disentangling the effect of sex from brain size on brain organization and cognitive functioning</article-title>. <source>GeroScience</source>. <year>2025</year>;<volume>47</volume>(<issue>1</issue>):<fpage>247</fpage>&#8208;<lpage>262</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11357-024-01486-5</pub-id><pub-id pub-id-type="pmid">39757311</pub-id><pub-id pub-id-type="pmcid">PMC11872830</pub-id></mixed-citation></ref><ref id="alz70634-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70634-cite-0020"><string-name name-style="western"><surname>Beekly</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>van Belle</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer Disease Database</article-title>. <source>Alzheimer Disease &amp; Associated Disorders</source>. <year>2004</year>;<volume>18</volume>(<issue>4</issue>):<fpage>270</fpage>.<pub-id pub-id-type="pmid">15592144</pub-id></mixed-citation></ref><ref id="alz70634-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70634-cite-0021"><string-name name-style="western"><surname>Beekly</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>WW</given-names></string-name>, et&#160;al. <article-title>The National Alzheimer's Coordinating Center (NACC) database: the uniform data set</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2007</year>;<volume>21</volume>(<issue>3</issue>):<fpage>249</fpage>&#8208;<lpage>258</lpage>.<pub-id pub-id-type="pmid">17804958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318142774e</pub-id></mixed-citation></ref><ref id="alz70634-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70634-cite-0022"><string-name name-style="western"><surname>Besser</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kukull</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Teylan</surname><given-names>MA</given-names></string-name>, et&#160;al. <article-title>The Revised National Alzheimer's Coordinating Center's Neuropathology Form&#8212;Available Data and New Analyses</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2018</year>;<volume>77</volume>(<issue>8</issue>):<fpage>717</fpage>&#8208;<lpage>726</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnen/nly049</pub-id><pub-id pub-id-type="pmid">29945202</pub-id><pub-id pub-id-type="pmcid">PMC6044344</pub-id></mixed-citation></ref><ref id="alz70634-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70634-cite-0023"><string-name name-style="western"><surname>Weintraub</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mercaldo</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>The Alzheimer's disease centers&#8217; Uniform Data Set (UDS): the neuropsychologic test battery</article-title>. <source>Alzheimer Disease &amp; Associated Disorders</source>. <year>2009</year>;<volume>23</volume>(<issue>2</issue>):<fpage>91</fpage>&#8208;<lpage>101</lpage>.<pub-id pub-id-type="pmid">19474567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318191c7dd</pub-id><pub-id pub-id-type="pmcid">PMC2743984</pub-id></mixed-citation></ref><ref id="alz70634-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70634-cite-0024"><string-name name-style="western"><surname>Moscoso</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heeman</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Raghavan</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity</article-title>. <source>JAMA</source>. <year>2025</year>;<volume>334</volume>(<issue>3</issue>):<fpage>229</fpage>&#8208;<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2025.7817</pub-id><pub-id pub-id-type="pmid">40522652</pub-id></mixed-citation></ref><ref id="alz70634-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="alz70634-cite-0025"><string-name name-style="western"><surname>Hsu</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>HC</given-names></string-name>, et&#160;al. <article-title>Difference of CSF Biomarkers and Neuropsychiatric Symptoms Profiles Among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient</article-title>. Published online October 4, 2023. doi:<pub-id pub-id-type="doi">10.2139/ssrn.4590919</pub-id><pub-id pub-id-type="pmcid">PMC11012002</pub-id><pub-id pub-id-type="pmid">38612729</pub-id></mixed-citation></ref><ref id="alz70634-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70634-cite-0026"><string-name name-style="western"><surname>Spotorno</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>3</issue>):<fpage>961</fpage>&#8208;<lpage>969</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awad428</pub-id>. Published online December 21, 2023:awad428.<pub-id pub-id-type="pmid">38128551</pub-id><pub-id pub-id-type="pmcid">PMC10907088</pub-id></mixed-citation></ref><ref id="alz70634-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70634-cite-0027"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fereshtehnejad</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dagher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Postuma</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson's Disease</article-title>. <source>Mov Disord Clin Pract</source>. <year>2020</year>;<volume>7</volume>(<issue>6</issue>):<fpage>639</fpage>&#8208;<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mdc3.13003</pub-id><pub-id pub-id-type="pmid">32775509</pub-id><pub-id pub-id-type="pmcid">PMC7396867</pub-id></mixed-citation></ref><ref id="alz70634-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="alz70634-cite-0028"><string-name name-style="western"><surname>Fontillas</surname><given-names>A</given-names></string-name>. <article-title>An Update on The MatchIt Package in R. Code Horizons</article-title>. <year>2020</year>. Accessed May 25, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://codehorizons.com/an-update-on-the-matchit-package-in-r/" ext-link-type="uri">https://codehorizons.com/an&#8208;update&#8208;on&#8208;the&#8208;matchit&#8208;package&#8208;in&#8208;r/</ext-link></mixed-citation></ref><ref id="alz70634-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70634-cite-0029"><string-name name-style="western"><surname>Ho</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></string-name>. <article-title>MatchIt: nonparametric Preprocessing for Parametric Causal Inference</article-title>. <source>J Stat Softw</source>. <year>2011</year>;<volume>42</volume>:<fpage>1</fpage>&#8208;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v042.i08</pub-id></mixed-citation></ref><ref id="alz70634-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70634-cite-0030"><string-name name-style="western"><surname>Bates</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>M&#228;chler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bolker</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>S</given-names></string-name>. <article-title>Fitting Linear Mixed&#8208;Effects Models Using lme4</article-title>. <source>J Stat Softw</source>. <year>2015</year>;<volume>67</volume>:<fpage>1</fpage>&#8208;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v067.i01</pub-id></mixed-citation></ref><ref id="alz70634-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70634-cite-0031"><string-name name-style="western"><surname>Boeck</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Bakker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zwitser</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>The Estimation of Item Response Models with the lmer Function from the lme4 Package in R</article-title>. <source>J Stat Softw</source>. <year>2011</year>;<volume>39</volume>:<fpage>1</fpage>&#8208;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v039.i12</pub-id></mixed-citation></ref><ref id="alz70634-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70634-cite-0032"><string-name name-style="western"><surname>Kuznetsova</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brockhoff</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname><given-names>RHB</given-names></string-name>. <article-title>lmerTest Package: tests in Linear Mixed Effects Models</article-title>. <source>J Stat Softw</source>. <year>2017</year>;<volume>82</volume>:<fpage>1</fpage>&#8208;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v082.i13</pub-id></mixed-citation></ref><ref id="alz70634-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70634-cite-0033"><string-name name-style="western"><surname>Rosseel</surname><given-names>Y</given-names></string-name>. <article-title>lavaan: an R Package for Structural Equation Modeling</article-title>. <source>J Stat Softw</source>. <year>2012</year>;<volume>48</volume>:<fpage>1</fpage>&#8208;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v048.i02</pub-id></mixed-citation></ref><ref id="alz70634-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70634-cite-0034"><string-name name-style="western"><surname>Filon</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Intorcia</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Sue</surname><given-names>LI</given-names></string-name>, et&#160;al. <article-title>Gender differences in Alzheimer disease: brain atrophy, histopathology burden, and cognition</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2016</year>;<volume>75</volume>(<issue>8</issue>):<fpage>748</fpage>&#8208;<lpage>754</lpage>.<pub-id pub-id-type="pmid">27297671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlw047</pub-id><pub-id pub-id-type="pmcid">PMC7299435</pub-id></mixed-citation></ref><ref id="alz70634-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70634-cite-0035"><string-name name-style="western"><surname>Liesinger</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Graff&#8208;Radford</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Duara</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Sex and age interact to determine clinicopathologic differences in Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <year>2018</year>;<volume>136</volume>(<issue>6</issue>):<fpage>873</fpage>&#8208;<lpage>885</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-018-1908-x</pub-id><pub-id pub-id-type="pmid">30219939</pub-id><pub-id pub-id-type="pmcid">PMC6280837</pub-id></mixed-citation></ref><ref id="alz70634-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70634-cite-0036"><string-name name-style="western"><surname>Oveisgharan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Farfel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Sex differences in Alzheimer's disease and common neuropathologies of aging</article-title>. <source>Acta Neuropathol</source>. <year>2018</year>;<volume>136</volume>(<issue>6</issue>):<fpage>887</fpage>&#8208;<lpage>900</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-018-1920-1</pub-id><pub-id pub-id-type="pmid">30334074</pub-id><pub-id pub-id-type="pmcid">PMC6279593</pub-id></mixed-citation></ref><ref id="alz70634-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70634-cite-0037"><string-name name-style="western"><surname>Chooi</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Gavett</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Weinborn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rainey&#8208;Smith</surname><given-names>S</given-names></string-name>. <article-title>Sex differences in the protective effects of cognitive reserve</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2022</year>;<volume>18</volume>(<issue>S7</issue>):<elocation-id>e064397</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.064397</pub-id></mixed-citation></ref><ref id="alz70634-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70634-cite-0038"><string-name name-style="western"><surname>Subramaniapillai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Almey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Natasha Rajah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Einstein</surname><given-names>G</given-names></string-name>. <article-title>Sex and gender differences in cognitive and brain reserve: implications for Alzheimer's disease in women</article-title>. <source>Front Neuroendocrinol</source>. <year>2021</year>;<volume>60</volume>:<elocation-id>100879</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.yfrne.2020.100879</pub-id><pub-id pub-id-type="pmid">33137359</pub-id></mixed-citation></ref><ref id="alz70634-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70634-cite-0039"><string-name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Peretti</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Scheffler</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Sex differences in the association of Alzheimer's disease biomarkers and cognition in a multicenter memory clinic study</article-title>. <source>Alzheimer's Research &amp; Therapy</source>. <year>2025</year>;<volume>17</volume>(<issue>1</issue>):<fpage>46</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-025-01684-z</pub-id><pub-id pub-id-type="pmcid">PMC11837373</pub-id><pub-id pub-id-type="pmid">39966925</pub-id></mixed-citation></ref><ref id="alz70634-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70634-cite-0040"><string-name name-style="western"><surname>Burke</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fava</surname><given-names>NM</given-names></string-name>, et&#160;al. <article-title>Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities</article-title>. <source>J Women Aging</source>. <year>2019</year>;<volume>31</volume>(<issue>2</issue>):<fpage>140</fpage>&#8208;<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08952841.2018.1419476</pub-id><pub-id pub-id-type="pmid">29319430</pub-id><pub-id pub-id-type="pmcid">PMC6039284</pub-id></mixed-citation></ref><ref id="alz70634-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70634-cite-0041"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ritter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>K</given-names></string-name>. <article-title>Alzheimer's disease drug development pipeline: 2018</article-title>. <source>Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</source>. <year>2018</year>;<volume>4</volume>(<issue>1</issue>):<fpage>195</fpage>&#8208;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.trci.2018.03.009</pub-id><pub-id pub-id-type="pmid">29955663</pub-id><pub-id pub-id-type="pmcid">PMC6021548</pub-id></mixed-citation></ref><ref id="alz70634-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70634-cite-0042"><string-name name-style="western"><surname>Oveisgharan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Farfel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Sex differences in Alzheimer's disease and common neuropathologies of aging</article-title>. <source>Acta Neuropathol</source>. <year>2018</year>;<volume>136</volume>(<issue>6</issue>):<fpage>887</fpage>&#8208;<lpage>900</lpage>.<pub-id pub-id-type="pmid">30334074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-018-1920-1</pub-id><pub-id pub-id-type="pmcid">PMC6279593</pub-id></mixed-citation></ref><ref id="alz70634-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70634-cite-0043"><string-name name-style="western"><surname>Levine</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Brice&#241;o</surname><given-names>EM</given-names></string-name>, et&#160;al. <article-title>Sex Differences in Cognitive Decline Among US Adults</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>2</issue>):<elocation-id>e210169</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.0169</pub-id><pub-id pub-id-type="pmid">33630089</pub-id><pub-id pub-id-type="pmcid">PMC7907956</pub-id></mixed-citation></ref><ref id="alz70634-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70634-cite-0044"><string-name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Rabin</surname><given-names>JS</given-names></string-name>, et&#160;al. <article-title>Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults</article-title>. <source>JAMA Neurol</source>. <year>2019</year>;<volume>76</volume>(<issue>5</issue>):<fpage>542</fpage>&#8208;<lpage>551</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2018.4693</pub-id><pub-id pub-id-type="pmid">30715078</pub-id><pub-id pub-id-type="pmcid">PMC6515599</pub-id></mixed-citation></ref><ref id="alz70634-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70634-cite-0045"><string-name name-style="western"><surname>Arenaza&#8208;Urquijo</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Casaletto</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Sex and gender differences in cognitive resilience to aging and Alzheimer's disease</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5695</fpage>&#8208;<lpage>5719</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13844</pub-id><pub-id pub-id-type="pmcid">PMC11350140</pub-id><pub-id pub-id-type="pmid">38967222</pub-id></mixed-citation></ref><ref id="alz70634-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70634-cite-0046"><string-name name-style="western"><surname>Tsiknia</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Edland</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sundermann</surname><given-names>EE</given-names></string-name>, et&#160;al. <article-title>Sex differences in plasma p&#8208;tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression</article-title>. <source>Mol Psychiatry</source>. <year>2022</year>;<volume>27</volume>(<issue>10</issue>):<fpage>4314</fpage>&#8208;<lpage>4322</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-022-01675-8</pub-id><pub-id pub-id-type="pmid">35768637</pub-id><pub-id pub-id-type="pmcid">PMC9718670</pub-id></mixed-citation></ref><ref id="alz70634-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70634-cite-0047"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>(<issue>14</issue>):<fpage>1240</fpage>&#8208;<lpage>1249</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001991</pub-id><pub-id pub-id-type="pmid">26354982</pub-id><pub-id pub-id-type="pmcid">PMC4607601</pub-id></mixed-citation></ref><ref id="alz70634-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70634-cite-0048"><string-name name-style="western"><surname>Guill&#233;n</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Contador</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Buongiorno</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Agreement of cerebrospinal fluid biomarkers and amyloid&#8208;PET in a multicenter study</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source>. <year>2025</year>;<volume>275</volume>(<issue>1</issue>):<fpage>257</fpage>&#8208;<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00406-023-01701-y</pub-id><pub-id pub-id-type="pmid">37898567</pub-id><pub-id pub-id-type="pmcid">PMC11799063</pub-id></mixed-citation></ref><ref id="alz70634-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70634-cite-0049">La Joie R, <string-name name-style="western"><surname>Bejanin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fagan</surname><given-names>AM</given-names></string-name>, et&#160;al. <article-title>Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>(<issue>4</issue>):<fpage>e282</fpage>&#8208;<lpage>e290</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000004860</pub-id><pub-id pub-id-type="pmid">29282337</pub-id><pub-id pub-id-type="pmcid">PMC5798657</pub-id></mixed-citation></ref><ref id="alz70634-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70634-cite-0050"><string-name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross&#8208;sectional study</article-title>. <source>The Lancet Neurology</source>. <year>2016</year>;<volume>15</volume>(<issue>9</issue>):<fpage>934</fpage>&#8208;<lpage>943</lpage>.<pub-id pub-id-type="pmid">27312738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(16)30029-1</pub-id><pub-id pub-id-type="pmcid">PMC4969105</pub-id></mixed-citation></ref><ref id="alz70634-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70634-cite-0051"><string-name name-style="western"><surname>Kamal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maranzano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>. <article-title>White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>101</volume>(<issue>8</issue>):<fpage>e815</fpage>&#8208;<lpage>e824</lpage>. Published online 2023.<pub-id pub-id-type="pmid">37407262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207514</pub-id><pub-id pub-id-type="pmcid">PMC10449435</pub-id></mixed-citation></ref><ref id="alz70634-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70634-cite-0052"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Camicioli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition</article-title>. <source>Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>e12091</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/dad2.12091</pub-id><pub-id pub-id-type="pmcid">PMC7552231</pub-id><pub-id pub-id-type="pmid">33083512</pub-id></mixed-citation></ref><ref id="alz70634-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70634-cite-0053"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maranzano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ducharme</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></string-name>. <article-title>White matter in different regions evolves differently during progression to dementia</article-title>. <source>Neurobiol Aging</source>. <year>2019</year>;<volume>76</volume>:<fpage>71</fpage>&#8208;<lpage>79</lpage>.<pub-id pub-id-type="pmid">30703628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.12.004</pub-id></mixed-citation></ref><ref id="alz70634-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70634-cite-0054"><string-name name-style="western"><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Villeneuve</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>White matter lesions may be an early marker for age&#8208;related cognitive decline</article-title>. <source>NeuroImage: Clinical</source>. <year>2022</year>;<volume>35</volume>:<elocation-id>103096</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2022.103096</pub-id><pub-id pub-id-type="pmid">35764028</pub-id><pub-id pub-id-type="pmcid">PMC9241138</pub-id></mixed-citation></ref><ref id="alz70634-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70634-cite-0055"><string-name name-style="western"><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>Sex differences in risk factors, burden, and outcomes of cerebrovascular disease in Alzheimer's disease populations</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2024</year>;<volume>20</volume>(<issue>1</issue>):<fpage>34</fpage>&#8208;<lpage>46</lpage>. Published online 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13452</pub-id><pub-id pub-id-type="pmcid">PMC10916959</pub-id><pub-id pub-id-type="pmid">37735954</pub-id></mixed-citation></ref><ref id="alz70634-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70634-cite-0056"><string-name name-style="western"><surname>Sachdev</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Parslow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Anstey</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Easteal</surname><given-names>S</given-names></string-name>. <article-title>Sex differences in the causes and consequences of white matter hyperintensities</article-title>. <source>Neurobiol Aging</source>. <year>2009</year>;<volume>30</volume>(<issue>6</issue>):<fpage>946</fpage>&#8208;<lpage>956</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.08.023</pub-id><pub-id pub-id-type="pmid">17950492</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="trc270157" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="pmc-domain-id">3303</journal-id><journal-id journal-id-type="pmc-domain">trci</journal-id><journal-id journal-id-type="publisher-id">TRC2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Translational Research &amp; Clinical Interventions</journal-title></journal-title-group><issn pub-type="epub">2352-8737</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504044</article-id><article-id pub-id-type="pmcid-ver">PMC12504044.1</article-id><article-id pub-id-type="pmcaid">12504044</article-id><article-id pub-id-type="pmcaiid">12504044</article-id><article-id pub-id-type="doi">10.1002/trc2.70157</article-id><article-id pub-id-type="publisher-id">TRC270157</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan</article-title><alt-title alt-title-type="left-running-head">IGARASHI <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="trc270157-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Igarashi</surname><given-names initials="A">Ataru</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6307-6916</contrib-id><xref rid="trc270157-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="trc270157-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>atarui1@mac.com</email></address></contrib><contrib id="trc270157-cr-0002" contrib-type="author"><name name-style="western"><surname>Kimura</surname><given-names initials="N">Noriyuki</given-names></name><xref rid="trc270157-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="trc270157-cr-0003" contrib-type="author"><name name-style="western"><surname>Ataka</surname><given-names initials="T">Takuya</given-names></name><xref rid="trc270157-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="trc270157-cr-0004" contrib-type="author"><name name-style="western"><surname>Ito</surname><given-names initials="T">Temmei</given-names></name><xref rid="trc270157-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="trc270157-cr-0005" contrib-type="author"><name name-style="western"><surname>Sasaki</surname><given-names initials="K">Kotaro</given-names></name><xref rid="trc270157-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="trc270157-cr-0006" contrib-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names initials="C">Chizuru</given-names></name><xref rid="trc270157-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="trc270157-cr-0007" contrib-type="author"><name name-style="western"><surname>Tani</surname><given-names initials="M">Mayaka</given-names></name><xref rid="trc270157-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="trc270157-cr-0008" contrib-type="author"><name name-style="western"><surname>Sakata</surname><given-names initials="Y">Yukinori</given-names></name><xref rid="trc270157-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="trc270157-cr-0009" contrib-type="author"><name name-style="western"><surname>Azuma</surname><given-names initials="M">Mie</given-names></name><xref rid="trc270157-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="trc270157-cr-0010" contrib-type="author"><name name-style="western"><surname>Chida</surname><given-names initials="A">Ayano</given-names></name><xref rid="trc270157-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="trc270157-cr-0011" contrib-type="author"><name name-style="western"><surname>Takeshima</surname><given-names initials="T">Tomomi</given-names></name><xref rid="trc270157-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="trc270157-cr-0012" contrib-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names initials="K">Kosuke</given-names></name><xref rid="trc270157-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="trc270157-cr-0013" contrib-type="author"><name name-style="western"><surname>Matsubara</surname><given-names initials="E">Etsuro</given-names></name><xref rid="trc270157-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="trc270157-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Health Economics and Outcomes Research</named-content>
<named-content content-type="organisation-division">Graduate School of Pharmaceutical Sciences</named-content>
<institution>The University of Tokyo</institution>
<city>Bunkyo&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Data Science</named-content>
<institution>Yokohama City University School of Medicine</institution>
<city>Yokohama</city>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Oita University</institution>
<city>Yufu Oita</city>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Global Alzheimer Disease</named-content>
<institution>Eisai Co., Ltd</institution>
<city>Bunkyo&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Human Biology Integration Foundation</named-content>
<institution>Deep Human Biology Learning, Eisai Co., Ltd</institution>
<city>Bunkyo&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Planning Department</named-content>
<institution>Medical Headquarters, Eisai Co., Ltd</institution>
<city>Shinjuku&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="trc270157-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Milliman Inc</institution>
<city>Chiyoda&#8208;ku</city>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Ataru Igarashi, Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7&#8208;3&#8208;1, Hongo, Bunkyo&#8208;ku, Tokyo 113&#8208;0033, Japan.<break/> Email: <email>atarui1@mac.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>11</volume><issue seq="50">4</issue><issue-id pub-id-type="pmc-issue-id">498507</issue-id><issue-id pub-id-type="doi">10.1002/trc2.v11.4</issue-id><elocation-id>e70157</elocation-id><history><date date-type="rev-recd"><day>28</day><month>8</month><year>2025</year></date><date date-type="received"><day>14</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="TRC2-11-e70157.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:TRC2-11-e70157.pdf"/><abstract><title>Abstract</title><sec id="trc270157-sec-0010"><title>INTRODUCTION</title><p>This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.</p></sec><sec id="trc270157-sec-0020"><title>METHODS</title><p>A dynamic simulation estimated wait times and treatment&#8208;eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness&#8208;to&#8208;pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.</p></sec><sec id="trc270157-sec-0030"><title>RESULTS</title><p>The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment&#8208;eligible patients increased considerably with BBM&#8208;based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment&#8208;eligible patients.</p></sec><sec id="trc270157-sec-0040"><title>DISCUSSION</title><p>Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM&#8208;based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.</p></sec><sec id="trc270157-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="trc270157-list-0001"><list-item><p>A dynamic simulation models Alzheimer's diagnostic workflows in Japan.</p></list-item><list-item><p>Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.</p></list-item><list-item><p>Implementing BBM tests improves access to Alzheimer's diagnostics.</p></list-item><list-item><p>Study quantifies demand for diagnostic testing based on costs and accessibility.</p></list-item><list-item><p>Testing costs impact the number of treatment&#8208;eligible Alzheimer's patients.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="trc270157-kwd-0001">Alzheimer's disease</kwd><kwd id="trc270157-kwd-0002">blood biomarker tests</kwd><kwd id="trc270157-kwd-0003">diagnostic pathways</kwd><kwd id="trc270157-kwd-0004">dynamic simulation</kwd><kwd id="trc270157-kwd-0005">lecanemab treatment</kwd><kwd id="trc270157-kwd-0006">mild cognitive impairment</kwd><kwd id="trc270157-kwd-0007">diagnostic wait times</kwd><kwd id="trc270157-kwd-0008">healthcare access</kwd></kwd-group><counts><fig-count count="2"/><table-count count="6"/><page-count count="11"/><word-count count="7110"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="trc270157-cite-0001"><string-name name-style="western"><surname>Igarashi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ataka</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>11</volume>:<elocation-id>e70157</elocation-id>. <pub-id pub-id-type="doi">10.1002/trc2.70157</pub-id></mixed-citation>
</p></notes></front><body><sec id="trc270157-sec-0060"><label>1</label><title>INTRODUCTION</title><p>In recent years, several disease&#8208;modifying treatments (DMTs) have been developed to address mild cognitive impairment (MCI) and mild dementia associated with Alzheimer's disease (AD).<xref rid="trc270157-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="trc270157-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="trc270157-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Among these, lecanemab received approval in Japan on September 23, 2023, and became available for clinical use on December 20, 2023. Before initiating lecanemab treatment, amyloid&#8208;&#946; pathology should be confirmed, in addition to a diagnosis of MCI or mild dementia.</p><p>Despite these advances, challenges remain in the current diagnostic infrastructure. The Japanese Ministry of Health, Labour and Welfare has issued an Optimal Use Guideline (OUG) for lecanemab, outlining prescription criteria related to facility requirements and patient eligibility.<xref rid="trc270157-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> In addition to ensuring the safe and effective use of novel pharmaceuticals, OUGs consider the economic impact of high&#8208;cost drugs on the healthcare insurance system.<xref rid="trc270157-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> While not legally binding, these guidelines carry substantial influence, making adherence critical in clinical practice. According to the OUG, patients seeking lecanemab treatment must consult specialists and undergo diagnostic testing, with either positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis, to confirm AD pathology through amyloid&#8208;&#946; detection. However, prior research has identified prolonged wait times for these diagnostic tests in Japan because of a shortage of specialists.<xref rid="trc270157-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Clinicians report delays of several months at certain medical institutions before patients can consult a specialist. Additionally, PET scans are costly and available at a limited number of facilities, primarily in urban areas.<xref rid="trc270157-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="trc270157-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> This disparity imposes a greater burden on patients in rural regions when accessing treatment opportunities. While CSF tests are more accessible and less expensive than PET scans, they are invasive and pose risks of adverse effects.<xref rid="trc270157-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Combined with the shortage of specialists, these factors limit timely diagnosis and treatment access.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="trc270157-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="trc270157-list-0002"><list-item><p>
<bold>Systematic review</bold>: We reviewed literature from traditional (e.g., PubMed) sources to assess challenges associated with diagnostic tests for Alzheimer's disease required for prescribing disease&#8208;modifying drugs, such as lecanemab. Prior studies have highlighted issues with prolonged wait times, access disparities, and high costs of traditional modalities such as positron emission tomography (PET) scanning and cerebrospinal fluid (CSF) analysis. Recently, blood biomarker (BBM) tests have also been evaluated for their potential to streamline workflows and increase testing capacities.</p></list-item><list-item><p>
<bold>Interpretation</bold>: This study shows that integrating BBM tests into diagnostic workflows increases the proportion of treatment&#8208;eligible patients, primarily due to reduced costs, which raises the demand for testing. Using dynamic simulations, we provide new insights into demand dynamics influenced by costs and other factors, complementing existing research.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future research should explore the scalability of BBM test implementation across diverse healthcare settings and examine its impact on infrastructure, including magnetic resonance imaging (MRI) monitoring, drug infusion capacity, treatment costs, and overall benefits, to ensure healthcare sustainability.</p></list-item></list>
</p></sec></boxed-text><p>BBM tests have emerged as a promising alternative for detecting AD pathology.<xref rid="trc270157-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="trc270157-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="trc270157-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Blood tests are widely accessible, less dependent on specialists, and suitable for primary care.<xref rid="trc270157-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Two clinical pathways for BBM use have been proposed: as triage tools before confirmatory tests or as confirmatory diagnostics.<xref rid="trc270157-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The Global CEO Initiative on Alzheimer's Disease BBM Workgroup recommends &#8805;90% sensitivity and &#8805;85% specificity for triage and &#8805;90% sensitivity and specificity for confirmatory tests,<xref rid="trc270157-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> with the World Health Organization stating that BBM tests should have &#8805;90% sensitivity and specificity to have diagnostic value.<xref rid="trc270157-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Integrating BBM tests into practice is expected to streamline diagnostics and expand testing capacity by allowing general practitioners (GPs) and other healthcare providers to conduct them, meeting the rising demand. Additionally, blood tests are less costly and less invasive than PET or CSF tests,<xref rid="trc270157-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="trc270157-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="trc270157-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> potentially increasing patient demand. While implementation challenges persist,<xref rid="trc270157-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> incorporating BBM tests into clinical workflows could enhance treatment accessibility for eligible patients. Currently, BBM is recommended as a triage tool before conducting PET or CSF tests in specialist settings in the Japanese guidelines related to BBM.<xref rid="trc270157-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> However, given BBM's diagnostic performance, it is anticipated that it could eventually be used as a substantially equivalent alternative to PET or CSF. Furthermore, considering BBM's versatility, its use as a triage tool in primary care settings may also be explored.</p><p>Although substantial wait times for patients seeking DMTs due to the limited capacity of current testing infrastructure have been projected,<xref rid="trc270157-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> the balance between supply and demand for testing remains insufficiently explored. Implementing BBM tests is expected to increase demand and expand patient access to treatment. While this shift could benefit individuals and the nation, it may also increase national healthcare expenditures and strain medical resources. Therefore, understanding both the benefits and burdens associated with changes in testing infrastructure and developing healthcare systems to address these issues are essential.</p><p>This study projected wait times for diagnostic testing and estimated the number of patients eligible for lecanemab treatment, along with the medical costs associated with testing, across various diagnostic workflows, including the current flow and those integrating BBM tests. A dynamic simulation model was employed to assess interactions between key variables. For example, wait times can influence testing demand, and changes in demand can further affect wait times. An online survey was conducted to estimate willingness&#8208;to&#8208;pay (WTP) for testing and evaluate intangible costs using conjoint analysis.</p></sec><sec id="trc270157-sec-0080"><label>2</label><title>METHODS</title><sec id="trc270157-sec-0090"><label>2.1</label><title>Study overview</title><p>This study employed a simulation model to project the status of diagnostic testing for lecanemab treatment among the Japanese population aged 50 years and older, examining wait times and the number of treatment&#8208;eligible patients across all regions. The model incorporated multiple testing workflows and accounted for testing demand. In estimating demand, we assumed that the decision to undergo testing was influenced by both direct (tangible) costs and intangible factors, such as wait and travel times to testing locations. These intangible factors were converted into monetary values using conjoint analysis,<xref rid="trc270157-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="trc270157-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> resulting in intangible costs. Individuals seeking testing were defined as those whose WTP exceeded the total costs of testing (Table&#160;<xref rid="trc270157-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="trc270157-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Cost items included in assessing the demand for the diagnostic testing.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Category</th><th align="left" rowspan="1" colspan="1">Tangible costs</th><th align="left" rowspan="1" colspan="1">Intangible costs<xref rid="trc270157-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0003"><list-item><p>Testing costs<xref rid="trc270157-tbl1-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0004"><list-item><p>Out&#8208;of&#8208;pocket expenses associated with the testing</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0005"><list-item><p>Wait time, test sensitivity, travel time to the test location, test duration (time commitment), radiation exposure, physician explanation of test results using images, side effects</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0006"><list-item><p>Travel costs</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0007"><list-item><p>TranspoTransportation costs</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="simple" id="trc270157-list-0008"><list-item><p>Travel time</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl1-note-0001"><label>
<sup>a</sup>
</label><p>Intangible costs represent monetary values of intangible factors converted using conjoint analysis.</p></fn><fn id="trc270157-tbl1-note-0002"><label>
<sup>b</sup>
</label><p>Testing costs do not include the fees for consultations, including cognitive assessment, with general practitioners.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The conjoint analysis was conducted using SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA), while the dynamic simulation was implemented in Python (version 3.11.9, Python Software Foundation).</p></sec><sec id="trc270157-sec-0100"><label>2.2</label><title>Estimation of WTP and intangible costs</title><p>An online survey estimated WTP and intangible costs associated with diagnostic testing among the Japanese population with varying cognitive conditions (see <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A1</xref> for details). The survey collected data on WTP, preferences for diagnostic test attributes (for conjoint analysis), self&#8208;reported and informant&#8208;reported cognitive complaints, and attributes including demographic characteristics and health&#8208;related information.</p><p>For the WTP survey, respondents were randomly assigned to one of three cognitive condition roles: cognitively normal, MCI, or mild dementia. Each respondent received a scenario describing their assigned condition, the treatment effect of medication, and the probability of being eligible for treatment. Using an open&#8208;ended format, respondents indicated their WTP for diagnostic testing to determine treatment eligibility (see <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A2</xref> for details).</p><p>The intangible costs were estimated using conjoint analysis (see <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A3</xref> for details). Conjoint analysis is a well&#8208;established, survey&#8208;based statistical technique used to assess how individuals value different attributes, including features, functions, and benefits that define a product or service.<xref rid="trc270157-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="trc270157-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Seven attributes influencing demand for diagnostic testing were identified based on expert opinion (authors: N.K. and E.M.): wait time for treatment initiation, test sensitivity, travel time to the test location, test duration, radiation exposure, physician explanation of test results using images, and side effects. Additionally, out&#8208;of&#8208;pocket expenses for the test were included as a monetary attribute. Preference scores for each attribute level were estimated using a logistic regression model. The highest preference level for each attribute was assigned a score of 0, indicating the strongest preference, while lower preference levels were assigned negative scores, reflecting their relative disutility compared to the reference level. These scores were then converted into monetary values in Japanese Yen (JPY; USD 1.00 = approximately JPY 153.72 as of November 2024) by comparing them with the monetary attribute.</p></sec><sec id="trc270157-sec-0110"><label>2.3</label><title>Simulation</title><p>An agent&#8208;based model was used for the dynamic simulation. This model is particularly useful for studying how patient behavior and clinician decision&#8208;making interact to influence healthcare outcomes.<xref rid="trc270157-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="trc270157-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Agent&#8208;based modeling has been widely applied in healthcare research, facilitating simulations of complex scenarios, including infection spread, intervention efficacy, and resource allocation.<xref rid="trc270157-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="trc270157-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> In this study, the number of subjects remained constant throughout the simulation, with their attributes unchanged.</p><p>The simulation (Figure&#160;<xref rid="trc270157-fig-0001" ref-type="fig">1</xref> and <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A4</xref>) was conducted under the following scenarios (Table&#160;<xref rid="trc270157-tbl-0002" ref-type="table">2</xref>): (A) the current testing flow, (B) implementing BBM as a triage tool by specialists, (C) implementing BBM as a confirmatory diagnostic tool by specialists, and (D) implementing BBM for triage by GPs and as a confirmatory diagnostic tool by specialists. In Scenario D, two BBM tests with different specificities were assumed: 85% and 90% for triage and confirmatory diagnosis, respectively. For this simulation, we assumed that the first specialist visit would be the bottleneck of the testing process, based on the current clinical context and available data. Theoretically, when a bottleneck exists at the initial stage of a process, a waiting queue forms at that stage and should not form at subsequent stages. Therefore, we did not explicitly model the subsequent processes, including the capacities for PET or CSF testing. The simulation began on the launch date of lecanemab in Japan (December 20, 2023), defined as the index date, and continued for 1000 days from that point.</p><fig position="float" fig-type="FIGURE" id="trc270157-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Outline of the simulation. Illustrates the simulation process for modeling diagnostic pathways for Alzheimer's disease. It depicts individuals aged 50 years and older with cognitive complaints, their progression through diagnostic steps, including WTP thresholds, and eventual classification as treatment&#8208;eligible based on diagnostic outcomes such as PET, CSF, or BBM tests. Detailed information about the simulation is presented in <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A4</xref>. Note: <sup>*</sup>For example, the intangible cost is JPY 0 for a wait time of one month and JPY 2141 for a wait time of 3.8 months. In Scenario C, costs excluding wait time and travel amount to JPY 12,439 for individuals with an out&#8208;of&#8208;pocket medical cost burden of 10%. Assuming an individual whose WTP is JPY 13,000 and travel costs are JPY 0, the individual is willing to take the test when the wait time is one month (total costs: JPY 12,439 &lt; WTP: JPY 13,000) but is not willing to take the test when the wait time is 3.8 months (total costs: JPY 14,580 &gt; WTP: JPY 13,000). <sup>&#8224;</sup>The number of individuals with accepted appointments is 4.5 times that of those initiating diagnostic testing per specialist (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Methods A4B</xref> #14). BBM, blood biomarker test; CSF, cerebrospinal fluid test; GP, general practitioner; JPY, Japanese Yen; MRI, magnetic resonance imaging test; PET, positron emission tomography test; WTP, willingness&#8208;to&#8208;pay.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="TRC2-11-e70157-g001.jpg"/></fig><table-wrap position="float" id="trc270157-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Testing conditions by general practitioners (A) and specialists (B) for each scenario in the simulation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Scenario A</th><th align="left" rowspan="1" colspan="1">Scenario B</th><th align="left" rowspan="1" colspan="1">Scenario C</th><th align="left" rowspan="1" colspan="1">Scenario D</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>A</bold>.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Items</td><td align="left" rowspan="1" colspan="1">
<p>Consultation</p>
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Consultation</p>
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Consultation</p>
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Consultation</p>
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
<p>BBM triage</p>
<p>(Se: 90%, Sp: 85%)</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>B</bold>.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Monthly number of individuals who undergo the testing per specialist<xref rid="trc270157-tbl2-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">43.9</td><td align="left" rowspan="1" colspan="1">50.5</td><td align="left" rowspan="1" colspan="1">68.7</td><td align="left" rowspan="1" colspan="1">64.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Items</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1st visit</td><td align="left" rowspan="1" colspan="1">
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
<p>General blood test</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
<p>General blood test</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
<p>General blood test</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Cognitive assessment</p>
<p>(Se: 82%, Sp: 73%)</p>
<p>General blood test</p>
</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2nd visit</td><td align="left" rowspan="1" colspan="1">MRI</td><td align="left" rowspan="1" colspan="1">
<p>MRI</p>
<p>BBM triage</p>
<p>(Se: 90%, Sp: 85%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>MRI</p>
<p>BBM confirmatory</p>
<p>(Se: 90%, Sp: 90%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>MRI</p>
<p>BBM confirmatory</p>
<p>(Se: 90%, Sp: 90%)</p>
</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">3rd visit</td><td align="left" rowspan="1" colspan="1">Diagnostic disclosure</td><td align="left" rowspan="1" colspan="1">Diagnostic disclosure</td><td align="left" rowspan="1" colspan="1">Diagnostic disclosure</td><td align="left" rowspan="1" colspan="1">Diagnostic disclosure</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">4th visit</td><td align="left" rowspan="1" colspan="1">
<p>PET/CSF<xref rid="trc270157-tbl2-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</p>
<p>(Se: 90%, Sp: 90%)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>PET/CSF<xref rid="trc270157-tbl2-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</p>
<p>(Se: 90%, Sp: 90%)</p>
</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl2-note-0001"><p>
<italic toggle="yes">Note</italic>: Scenario A: the current testing flow, Scenario B: implementing BBM as a triage tool by specialists, Scenario C: implementing BBM as a confirmatory diagnostic tool by specialists, Scenario D: implementing BBM for triage by GPs and as a confirmatory diagnostic tool by specialists.</p></fn><fn id="trc270157-tbl2-note-0002"><p>Abbreviations: BBM, blood biomarker test; CSF, cerebrospinal fluid test; MRI, magnetic resonance imaging test; N/A, not available; PET, positron emission tomography test; Se, sensitivity; Sp, specificity.</p></fn><fn id="trc270157-tbl2-note-0003"><label>
<sup>a</sup>
</label><p>Monthly number of individuals who undergo testing per specialist for Scenario A was calculated by dividing the average number of patients per month by the average total number of dementia specialists and physicians with relevant clinical experience per facility, based on a national survey.<xref rid="trc270157-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>. We assumed that patients who tested positive would continue to visit until their fifth visit, when confirmatory test results would be provided for Scenario A. For Scenarios B&#8211;D, the numbers were calculated based on the figure for Scenario A according to procedures in each scenario. Calculation details are presented in <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A4B</xref> (#10&#8211;#13).</p></fn><fn id="trc270157-tbl2-note-0004"><label>
<sup>b</sup>
</label><p>Proportion of patients undergoing PET versus CSF test (PET:CSF) was assumed as 54.2:45.8 based on the MDV database (December 2023&#8211;May 2024) analysis.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The outputs generated for each scenario included the following: (1) Wait time: Wait time was defined as the period from when an individual makes an appointment with a specialist to the day of their first specialist visit. The mean wait time per municipality (in days) was projected and visualized graphically. Additionally, the maximum mean wait time during the simulation period and the number of days from the index date to reach this peak wait time were estimated. (2) Lecanemab treatment&#8208;eligible patients: Treatment&#8208;eligible patients were defined as individuals diagnosed as amyloid&#8208;&#946; positive through a confirmatory test. The number of such patients was calculated by multiplying the number of those who underwent the confirmatory test by the proportion of individuals who were amyloid&#8208;&#946; positive in each population. The cumulative number of these patients was presented in a graph, and annual estimates were provided for 2023&#8211;2025. (3) Medical costs associated with testing: Yearly medical costs associated with testing across Japan (2023&#8211;2025) were estimated as: (number of individuals who underwent the test) &#215; (medical costs for the test, including procedures associated with the test). Medical costs represented total healthcare expenditures, not just out&#8208;of&#8208;pocket expenses (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A5</xref>). Costs for GP consultations (excluding BBM tests in Scenario D), which were excluded to assess the demand, were also calculated separately to provide a comprehensive cost estimate.</p></sec></sec><sec id="trc270157-sec-0120"><label>3</label><title>RESULTS</title><sec id="trc270157-sec-0130"><label>3.1</label><title>WTP and intangible costs</title><p>The total number of respondents was 3302 (Table&#160;<xref rid="trc270157-tbl-0003" ref-type="table">3</xref>). The distribution of respondents by age, gender, and living area closely matched that of the Japanese population (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Table A1</xref>). The percentages of respondents with self&#8208;reported or informant&#8208;reported cognitive complaints are presented in <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Table A2</xref>.</p><table-wrap position="float" id="trc270157-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Willingness&#8208;to&#8208;pay for each assumed condition.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Statistic</th><th align="left" rowspan="1" colspan="1">CN</th><th align="left" rowspan="1" colspan="1">MCI</th><th align="left" rowspan="1" colspan="1">Mild DM</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Respondents (<italic toggle="yes">N</italic>)</td><td align="left" rowspan="1" colspan="1">1101</td><td align="left" rowspan="1" colspan="1">1117</td><td align="left" rowspan="1" colspan="1">1084</td></tr><tr><td align="left" rowspan="1" colspan="1">WTP (JPY)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">16,507</td><td align="left" rowspan="1" colspan="1">21,228</td><td align="left" rowspan="1" colspan="1">22,810</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">49,209</td><td align="left" rowspan="1" colspan="1">77,157</td><td align="left" rowspan="1" colspan="1">57,209</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1">1,000,000</td><td align="left" rowspan="1" colspan="1">1,000,000</td><td align="left" rowspan="1" colspan="1">1,000,000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">25%tile</td><td align="left" rowspan="1" colspan="1">3000</td><td align="left" rowspan="1" colspan="1">3000</td><td align="left" rowspan="1" colspan="1">3000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">50%tile</td><td align="left" rowspan="1" colspan="1">5000</td><td align="left" rowspan="1" colspan="1">5000</td><td align="left" rowspan="1" colspan="1">5000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">75%tile</td><td align="left" rowspan="1" colspan="1">10,000</td><td align="left" rowspan="1" colspan="1">10,000</td><td align="left" rowspan="1" colspan="1">10,000</td></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl3-note-0001"><p>
<italic toggle="yes">Note</italic>: US dollar 1.00 corresponded to approximately JPY 153.72 as of November 2024.</p></fn><fn id="trc270157-tbl3-note-0002"><p>Abbreviations: CN, cognitive normal; DM, dementia; JPY, Japanese Yen; Max, maximum; MCI, mild cognitive impairment; Min, minimum; N, number; SD, standard deviation; WTP, willingness&#8208;to&#8208;pay.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Mean WTP varied depending on the assumed severity of the cognitive condition. Among the conditions, mild dementia had the highest mean WTP, at JPY 22,810 (standard deviation: JPY 57,209) (Table&#160;<xref rid="trc270157-tbl-0003" ref-type="table">3</xref>). However, the minimum, maximum, and quartile values remained consistent across all conditions.</p><p>The intangible cost for wait time before treatment initiation was notably high, estimated at JPY 3120 and JPY 6179 for 6 months and 1 year, respectively, compared to 1 month (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Table A3</xref>). Excluding wait time, intangible costs were estimated at JPY 2335, JPY 10,104, and JPY 5295 for PET, CSF, and BBM, respectively (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Table A4</xref>). For BBM, intangible costs were attributed solely to the absence of a physician's explanation of the test results using images. The summary of costs, along with the breakdowns of tangible and intangible costs for each scenario, is presented in Tables&#160;<xref rid="trc270157-tbl-0004" ref-type="table">4A</xref>, <xref rid="trc270157-tbl-0005" ref-type="table">4B</xref>, and&#160;<xref rid="trc270157-tbl-0006" ref-type="table">4C</xref>, respectively.</p><table-wrap position="float" id="trc270157-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4A</label><caption><p>Testing costs for each scenario: summary.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Intangible costs (JPY)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Scenario</th><th align="left" rowspan="1" colspan="1">
<p>Tangible costs<xref rid="trc270157-tbl4-note-0003" ref-type="table-fn">
<bold>
<sup>a</sup>
</bold>
</xref>
</p>
<p>(JPY)</p>
</th><th align="left" rowspan="1" colspan="1">Total excluding wait time for treatment initiation</th><th align="left" rowspan="1" colspan="1">Wait time for treatment initiation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">17,427&#8211;52,282<xref rid="trc270157-tbl4-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">5893<xref rid="trc270157-tbl4-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0&#8211;3234<xref rid="trc270157-tbl4-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">19,529&#8211;58,588<xref rid="trc270157-tbl4-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">5893<xref rid="trc270157-tbl4-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>, <xref rid="trc270157-tbl4-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0&#8211;2604<xref rid="trc270157-tbl4-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">5003&#8211;15,009</td><td align="left" rowspan="1" colspan="1">5295</td><td align="left" rowspan="1" colspan="1">0&#8211;3814<xref rid="trc270157-tbl4-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">5823&#8211;17,469</td><td align="left" rowspan="1" colspan="1">5295</td><td align="left" rowspan="1" colspan="1">0&#8211;2141<xref rid="trc270157-tbl4-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl4-note-0001"><p>
<italic toggle="yes">Note</italic>: US dollar 1.00 corresponded to approximately JPY 153.72 as of November 2024.</p></fn><fn id="trc270157-tbl4-note-0002"><p>Abbreviations: BBM, blood biomarker; CSF, cerebrospinal fluid; JPY, Japanese Yen; PET, positron emission tomography.</p></fn><fn id="trc270157-tbl4-note-0003"><label>
<sup>a</sup>
</label><p>Shown with a range of 10% to 30% coinsurance</p></fn><fn id="trc270157-tbl4-note-0004"><label>
<sup>b</sup>
</label><p>Weighted average of PET and CSF costs, assuming 54.2% and 45.8% of individuals undergo PET and CSF, respectively, with the CSF cost being a weighted average of 20% outpatient and 80% inpatient cases (see B for breakdown of tangible costs and C for intangible costs, for PET, CSF outpatient, and CSF inpatient)</p></fn><fn id="trc270157-tbl4-note-0005"><label>
<sup>c</sup>
</label><p>Maximum costs were calculated based on the maximum wait time from the dynamic simulation.</p></fn><fn id="trc270157-tbl4-note-0006"><label>
<sup>d</sup>
</label><p>Additional intangible cost for BBM triage was set to 0 because the intangible cost for BBM only includes costs associated with the absence of a physician's explanation of test results using images. For PET, an explanation using images is provided, and for CSF, this cost is included in the intangible costs.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="trc270157-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 4B</label><caption><p>Breakdown of tangible costs.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="8" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Tangible costs (JPY)<xref rid="trc270157-tbl5-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Scenario A</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Scenario B</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Item</th><th align="left" rowspan="1" colspan="1">PET</th><th align="left" rowspan="1" colspan="1">
<p>CSF</p>
<p>(OP)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>CSF</p>
<p>(IP)</p>
</th><th align="left" rowspan="1" colspan="1">PET</th><th align="left" rowspan="1" colspan="1">
<p>CSF</p>
<p>(OP)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>CSF</p>
<p>(IP)</p>
</th><th align="left" rowspan="1" colspan="1">Scenario C</th><th align="left" rowspan="1" colspan="1">Scenario D</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">By GPs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BBM test (GPs)</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">8200</td></tr><tr><td align="left" rowspan="1" colspan="1">By specialists</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1st visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">First visit fees</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Cognitive function test</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td><td align="left" rowspan="1" colspan="1">800</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">General blood test</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td><td align="left" rowspan="1" colspan="1">2720</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">2nd visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Subsequent visit fees</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">MRI test</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td><td align="left" rowspan="1" colspan="1">19,000</td></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">BBM test (by specialists)</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">&#8208;</td><td align="left" rowspan="1" colspan="1">21,020</td><td align="left" rowspan="1" colspan="1">21,020</td><td align="left" rowspan="1" colspan="1">21,020</td><td align="left" rowspan="1" colspan="1">21,020</td><td align="left" rowspan="1" colspan="1">21,020</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">3rd visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">First visit fees</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">4th visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">First visit fees</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Inpatient fees</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13,460</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13,460</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">PET test</td><td align="left" rowspan="1" colspan="1">239,430</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">239,430</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">CSF test</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15,760</td><td align="left" rowspan="1" colspan="1">15,760</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15,760</td><td align="left" rowspan="1" colspan="1">15,760</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">5th visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">First visit fees</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2880</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" rowspan="1" colspan="1">Subsequent visit fees</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl5-note-0001"><p>
<italic toggle="yes">Note</italic>: Costs, including medical costs for GP consultation, are presented in <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A5</xref>. US dollar 1.00 corresponded to approximately JPY 153.72 as of November 2024.</p></fn><fn id="trc270157-tbl5-note-0002"><p>Abbreviations: BBM, blood biomarker test; CSF, cerebrospinal fluid test; GP, general practitioner; IP, inpatient; JPY, Japanese Yen; MRI. magnetic resonance imaging; OP, outpatient; PET, positron emission tomography test.</p></fn><fn id="trc270157-tbl5-note-0003"><label>
<sup>a</sup>
</label><p>Shown as the full amount (100% of costs).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="trc270157-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 4C</label><caption><p>Breakdown of intangible costs excluding wait time.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Intangible cost (JPY)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Scenarios A and B</th><th align="left" rowspan="1" colspan="1">Scenarios C and D</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Item</th><th align="left" rowspan="1" colspan="1">PET</th><th align="left" rowspan="1" colspan="1">CSF (OP)</th><th align="left" rowspan="1" colspan="1">CSF (IP)</th><th align="left" rowspan="1" colspan="1">BBM</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Test sensitivity</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Test duration (time commitment)</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">2949</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiation exposure</td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Physician's explanation of test results using images</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5295</td><td align="left" rowspan="1" colspan="1">5295</td><td align="left" rowspan="1" colspan="1">5295</td></tr><tr><td align="left" rowspan="1" colspan="1">Side effects (headache lasting 3 days).</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2383</td><td align="left" rowspan="1" colspan="1">2383</td><td align="left" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="trc270157-tbl6-note-0001"><p>
<italic toggle="yes">Note</italic>: Detailed information, including the level of each attribute for each test method, is presented in <xref rid="trc270157-supinfo-0001" ref-type="">Appendix Table A4</xref>. US dollar 1.00 corresponded to approximately JPY 153.72 as of November 2024.</p></fn><fn id="trc270157-tbl6-note-0002"><p>Abbreviations: BBM, blood biomarker test; CSF, cerebrospinal fluid test; GP, general practitioner; IP, inpatient; JPY, Japanese Yen; OP, outpatient; PET, positron emission tomography test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="trc270157-sec-0140"><label>3.2</label><title>Wait times</title><p>Among individuals whose WTP exceeded tangible costs (excluding travel costs), the estimated number of individuals diagnosed as positive by a GP based on cognitive assessment was as follows: 980,218 for Scenario A, 954,268 for Scenario B, 1,778,373 for Scenario C, and 1,777,134 for Scenario D. In Scenario D, among these individuals, 1,068,413 were diagnosed as positive based on BBM triage. These individuals were included in the simulation to project wait times for specialist visits for diagnostic testing.</p><p>In Scenario A, which assumes the current testing flow, the maximum mean wait time was projected to be 6.4 months, peaking at 113 days after the index date (Figure&#160;<xref rid="trc270157-fig-0002" ref-type="fig">2A</xref>). In Scenarios B and D, where the BBM test was included for triage, the maximum mean wait times decreased to 5.4 months (94 days after the index date) and 4.7 months (85 days after the index date), respectively, with Scenario D having the shortest wait time among all scenarios. In Scenario C, where the BBM test was included only as a confirmatory test, the maximum mean wait time increased to 7.8 months (131 days after the index date).</p><fig position="float" fig-type="FIGURE" id="trc270157-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Wait times for diagnostic testing (A), cumulative numbers of treatment&#8208;eligible patients (B), and annual medical costs throughout the testing process (C) based on the simulation. (A) Presents the mean estimated wait times per municipality for diagnostic testing under four scenarios modeled in the simulation. The number of subjects was assumed to remain constant throughout the simulation, with their attributes remaining unchanged. (B) Shows the cumulative number of patients eligible for lecanemab treatment, categorized by four testing scenarios, over the simulation period from December 2023 through 2025. For 2023, the annual number included only December 20&#8211;31, reflecting the index date. The number of subjects was assumed to remain constant throughout the simulation, with their attributes remaining unchanged. (C) Illustrates the estimated annual medical costs throughout the diagnostic testing process, separated by medical costs associated with testing and GP consultation, under four scenarios. For 2023, the annual number included only December 20&#8211;31, reflecting the index date. The number of subjects was assumed to remain constant throughout the simulation, with their attributes remaining unchanged. GP, general practitioner; JPY, Japanese Yen. US dollar 1.00 corresponded to approximately JPY 153.72 as of November 2024.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="TRC2-11-e70157-g002.jpg"/></fig></sec><sec id="trc270157-sec-0150"><label>3.3</label><title>Number of treatment&#8208;eligible patients</title><p>The estimated number of lecanemab treatment&#8208;eligible patients by year was as follows: 14,554 in 2023 (from the launch date, December 20), 183,376 in 2024, and 32,301 in 2025 for Scenario A. The number was slightly higher in 2023 (15,075) but consistently lower in 2024 (171,007) and 2025 (25,274) for Scenario B than for Scenario A. In Scenario D, the number of treatment&#8208;eligible patients increased rapidly in 2023, reaching 34,275, the highest among all scenarios for that year, followed by a slower rate of increase in subsequent years. Scenario C had a lower number of eligible patients than Scenario D in 2023 (23,331) but higher in 2024 (326,493&#160;vs. 339,294) and 2025 (34,062&#160;vs. 68,732), resulting in the largest cumulative number of treatment&#8208;eligible patients among the scenarios in 2024 and subsequent years (Figure&#160;<xref rid="trc270157-fig-0002" ref-type="fig">2B</xref>).</p></sec><sec id="trc270157-sec-0160"><label>3.4</label><title>Medical costs associated with testing</title><p>Medical costs associated with testing per individual who completed the full testing process were JPY 174,273, JPY 195,293, JPY 50,030, and JPY 58,230 for Scenarios A, B, C, and D, respectively (<xref rid="trc270157-supinfo-0001" ref-type="">Appendix Method A5</xref>). Total costs across the country, accounting for the number of individuals who underwent each test, were highest for Scenario A in all years: JPY 4.44 billion in 2023, JPY 55.89 billion in 2024, and JPY 9.84 billion in 2025, followed by Scenario B (Figure&#160;<xref rid="trc270157-fig-0002" ref-type="fig">2C</xref>). In 2023 and 2024, costs for Scenario C were lower than those for Scenario D. However, in 2025, costs for Scenario D were estimated to be the lowest among all scenarios, followed by Scenario C. Despite higher costs for GP consultations and a larger number of patients undergoing testing in Scenarios C and D than in Scenario A, total costs, including both testing&#8208;related expenses and additional GP consultation costs, were projected to remain the highest for Scenario A in 2024 and 2025.</p></sec></sec><sec id="trc270157-sec-0170"><label>4</label><title>DISCUSSION</title><p>In this study, we projected the diagnostic testing landscape for lecanemab treatment in Japan under various testing workflows. The simulation targeted the entire Japanese population instead of only the patient population for lecanemab. The projected maximum mean wait time was approximately 6 months under the current testing flow but decreased with the implementation of BBM tests for triage. The number of treatment&#8208;eligible patients increased considerably when BBM was used for confirmatory testing. We utilized a dynamic simulation model that integrated demand for testing while accounting for interactions between wait times and demand fluctuations. Demand was modeled based on WTP and costs derived from an online survey. Previous studies have highlighted challenges in the current healthcare system related to diagnostic testing during the introduction of DMTs for AD<xref rid="trc270157-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="trc270157-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="trc270157-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="trc270157-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and have explored potential improvements with BBM implementation.<xref rid="trc270157-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="trc270157-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> However, these studies have not incorporated demand for testing into their simulations. The National Institute for Health and Care Excellence guidance indicates that the introduction of lecanemab may significantly increase the number of patients seeking diagnosis, placing considerable strain on diagnostic and testing resources, such as PET scans. This strain could impact treatment capacity for other diseases.<xref rid="trc270157-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Therefore, it is essential to project the number of individuals seeking treatment and the corresponding resource requirements to enable effective planning and equitable care. We assume that demand is influenced by both tangible and intangible costs, leading to variations across test types and conditions, including wait times. By incorporating these factors into the simulation, we aimed to provide more reasonable demand estimates for each scenario. Given that predicted demand significantly affects projections such as wait times, integrating demand into our simulation offers valuable insights into healthcare system dynamics.</p><p>The wait time projected in this study is shorter than that reported in a 2019 simulation study.<xref rid="trc270157-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The previous study assumed that individuals aged 50 years and older without a diagnosis of MCI or dementia were eligible for annual cognitive screening, with assumed rates of consent to screening and seeking specialist evaluation. This resulted in approximately 3.9 million individuals seeking specialist evaluations, with a maximum projected wait time of approximately 15 months. In contrast, in the scenario without the BBM test, we estimated approximately one million individuals seeking diagnostic testing and being diagnosed positive by a GP based on a simulation incorporating WTP. Differences in the number of individuals seeking specialist evaluations, along with differing assumptions about medical resources, appear to contribute significantly to the variation in projected wait times between studies.</p><p>We evaluated the validity of our model in terms of projected wait times and the inclusion of intangible costs. The longest mean wait time projected under the scenario assuming the current testing flow was 6.4 months. Although publicly available data on wait times for diagnostic testing for lecanemab treatment in Japan are limited, interviews with specialists indicated that some medical institutions currently have wait times of several months. Thus, our projected wait times are considered reasonable. We assumed that long wait times or distant testing locations could deter individuals from undergoing testing. Therefore, including these deterrents as intangible costs and comparing total costs with WTP to determine whether individuals would undergo testing is considered appropriate, as it reflects real&#8208;world decision&#8208;making processes. We used an agent&#8208;based model to appropriately reflect how individual decisions are influenced by changes in wait times and how these decisions, in turn, affect overall demand. This approach enables the dynamic simulation of interactions between individual behavior and system&#8208;level factors such as wait time.</p><p>The beneficial effects of implementing BBM tests were primarily attributed to their lower costs compared to currently utilized diagnostic modalities. These lower costs arose from several factors. First, the cost of a BBM test was approximately one&#8208;tenth that of a PET test, leading to a substantial cost reduction. Second, we assumed that BBM confirmatory tests could be performed at the second specialist visit alongside the MRI, thereby eliminating the need for two additional specialist visits and further reducing costs. This also reduced the total number of specialist visits, increasing specialist capacity (measured as the &#8220;monthly number of individuals who undergo the testing per specialist&#8221; in Table&#160;<xref rid="trc270157-tbl-0002" ref-type="table">2B</xref>) and decreasing wait times associated with intangible costs. Third, the BBM test requires less time than CSF and is not associated with the risk of headache as a side effect, leading to lower intangible costs than the CSF test. These cost reductions led to a greater number of individuals seeking diagnostic testing, thereby increasing the estimated number of treatment&#8208;eligible patients. Notably, when BBM triage was not implemented, the increase in the number of individuals seeking diagnostic testing canceled the effect on decreasing wait times; instead, the wait times increased. Despite this increase in testing demand, total medical costs for diagnostic testing across the country are estimated to decrease under scenarios incorporating BBM. Even when including the costs of GP consultations, total costs are not expected to exceed those of the current testing flow scenario, except in Scenario D in 2023. These findings suggest that implementing BBM tests may expand access to treatment without increasing national healthcare expenditures. However, these costs represent only a small fraction of the total expense associated with lecanemab treatment, which is currently estimated at approximately JPY 3 million per person per year. Therefore, the financial implications of increased treatment eligibility must be carefully considered when implementing BBM tests. In such cases, the benefits of treatment should also be evaluated to ensure that expanded access is balanced against overall healthcare costs. We should also consider some challenges in implementing BBM in clinical practice, including the absence of consistent recommendations for cognitive assessment in primary care&#8212;which poses a major barrier to the adoption of BBM testing&#8212;the need to educate healthcare professionals on interpreting BBM results across diverse populations, and limited evidence supporting BBM interpretation in different groups.<xref rid="trc270157-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Implementing a BBM triage test is projected to shorten wait times but not increase the number of treatment&#8208;eligible patients. When BBM is used only as a triage test in addition to the current testing flow, wait times are projected to decrease. However, the number of treatment&#8208;eligible patients is estimated to be slightly higher for a limited period before decreasing because of the higher costs than those associated with the current testing flow. When BBM is used for confirmatory testing, incorporating BBM for triage as well is projected to shorten wait times and lead to an earlier increase in treatment&#8208;eligible patients. However, the number of treatment&#8208;eligible patients when BBM is used for confirmatory testing alone is eventually estimated to surpass that when BBM is used for both triage and confirmation. These findings indicate that testing flows incorporating BBM triage by GPs could reduce wait times and improve access to treatment in settings with high demand for testing and limited medical resources. The projected wait time under the current testing flow&#8212;6 months&#8212;appears relatively long, considering that lecanemab is indicated for patients with MCI or mild dementia but becomes unsuitable as the condition progresses. Moreover, its treatment effect includes delaying the progression to dementia by approximately 2&#8211;3 years in patients with MCI and delaying the progression to moderate dementia by 1.5 years in those with mild dementia.<xref rid="trc270157-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> During extended wait times, implementing BBM triage could provide significant value by allowing patients to gain earlier access to treatment, potentially maximizing the therapeutic benefits of lecanemab. Notably, we assumed that the decision to undergo triage was determined by the WTP for testing, based on the probability of being eligible for treatment before triage and the costs associated with both triage and confirmatory tests. If WTP were assessed for individuals diagnosed as positive through triage, the probability of being eligible for treatment would increase, likely resulting in a higher WTP than that before triage. Therefore, if the decision to undergo triage is made without considering the costs of confirmatory diagnosis and more individuals undergo triage, the number of treatment&#8208;eligible patients may increase.</p><p>While this study provides valuable insights, several considerations should be noted when interpreting the results. The outcomes are based on simulations and represent projections rather than actual conditions. These results are influenced by the parameters and models used. Additionally, relocations may alter individuals&#8217; proximity to medical institutions, which the simulation does not account for. The study assumes the current state of healthcare resources but does not fully reflect the OUG. While facility locations capable of conducting tests are based on actual data, the distribution of specialists and other essential diagnostic resources&#8212;including the number of available slots for PET or CSF tests&#8212;was not explicitly modeled, even though these are important factors in the testing process. As described in the Section&#160;<xref rid="trc270157-sec-0060" ref-type="sec">1</xref>, we deliberately made this decision because, with the first specialist visit being the bottleneck of the process, the capacities for these tests were not expected to be bottlenecks in practice.</p><p>The Web survey used to estimate WTP and intangible costs also has limitations. First, variability in respondents&#8217; comprehension of the questions and sincerity in their answers could affect results. Second, the respondents were likely more familiar with the Internet, as they had registered for online surveys, which may have influenced their responses. Third, although symptoms of MCI and AD and the expected effects of lecanemab treatment were explained, the level of public awareness about lecanemab during the survey may have influenced responses. Fourth, WTP surveys can entail certain issues, including the possibility that the WTP reported by survey respondents may differ from that of individuals actually facing the need for treatment. Additionally, it stated that WTP does not necessarily align with revealed WTP. Despite these limitations, incorporating the WTP derived from the survey may have enabled us to better account for the demand of the target population in the simulation. After implementing BBM, further confirmatory studies will be needed to validate the actual demand in real&#8208;world settings.</p><p>In conclusion, the dynamic simulation demonstrates that the number of treatment&#8208;eligible patients is significantly influenced by costs, encompassing both tangible and intangible components. The findings suggest that utilizing BBM tests for confirmation instead of PET or CSF can increase the number of treatment&#8208;eligible patients, primarily because of the reduced costs associated with testing. Additionally, implementing BBM for triage, particularly in GP settings, shows potential for reducing wait times.</p></sec><sec sec-type="COI-statement" id="trc270157-sec-0190"><title>CONFLICT OF INTEREST STATEMENT</title><p>A.I. reports receiving research funding from Eisai Co., Ltd.; and advisory fees from Eli Lilly Japan K.K., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. N.K. reports receiving a grant from the Japan Society for the Promotion of Science, and honoraria from Sumitomo Pharma Co., Ltd., Daiichi Sankyo, Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PDRadiopharma Inc., Kyowa Kirin Co., Ltd., Kowa Company, Ltd., Eli Lilly, and Chugai Pharmaceutical Co., Ltd. T.I., K.S., C.K., M.T., Y.S., and M.A. are employees of Eisai Co., Ltd. A.C., T.T., and K.I. are employees of Milliman, Inc., which provides services to multiple pharmaceutical and medical device companies. T.A. and E.M. report no conflicts of interest. Author disclosures are available in the <xref rid="trc270157-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="trc270157-sec-0200"><title>CONSENT STATEMENT</title><p>This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol received approval from the Eisai Research Ethics Committee (Approval No: REP&#8208;2023&#8208;0908). Additionally, the protocol was pre&#8208;registered with the University Hospital Medical Information Network Clinical Trials Registry (ID: UMIN000053721). Informed consent was obtained from all Web survey participants before they began the questionnaire.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="trc270157-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="trc270157-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRC2-11-e70157-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="trc270157-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRC2-11-e70157-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="trc270157-sec-0180"><title>ACKNOWLEDGMENTS</title><p>The authors thank Macromill Carenet, Inc., for the execution of the online survey and Editage (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.editage.jp" ext-link-type="uri">www.editage.jp</ext-link>) for English language editing. This work was supported by Eisai Co., Ltd. and Biogen, which also funded the execution of the online survey by Macromill Carenet, Inc. and the English language editing services provided by Editage. Six of the authors are employees of Eisai Co., Ltd. and were involved in the study design, data interpretation, and manuscript writing. Both Eisai Co., Ltd. and Biogen reviewed the manuscript before submission. The decision to submit the manuscript for publication was made by the authors in consultation with the sponsors.</p></ack><ref-list id="trc270157-bibl-0001"><title>REFERENCES</title><ref id="trc270157-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="trc270157-cite-0002"><string-name name-style="western"><surname>Budd Haeberlein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Two randomized phase 3 studies of aducanumab in early Alzheimer's disease</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2022</year>;<volume>9</volume>(<issue>2</issue>):<fpage>197</fpage>&#8208;<lpage>210</lpage>. doi: <pub-id pub-id-type="doi">10.14283/jpad.2022.30</pub-id><pub-id pub-id-type="pmid">35542991</pub-id></mixed-citation></ref><ref id="trc270157-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="trc270157-cite-0003"><string-name name-style="western"><surname>Van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Lecanemab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>1</issue>):<fpage>9</fpage>&#8208;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></mixed-citation></ref><ref id="trc270157-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="trc270157-cite-0004"><string-name name-style="western"><surname>Sims</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>CD</given-names></string-name>, et&#160;al. <article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER&#8208;ALZ 2 randomized clinical trial</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>(<issue>6</issue>):<fpage>512</fpage>&#8208;<lpage>527</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></mixed-citation></ref><ref id="trc270157-bib-0004"><label>4</label><mixed-citation publication-type="book" id="trc270157-cite-0005"><collab collab-type="authors">Ministry of Health, Labour and Welfare</collab>
. <article-title>Optimal Use Guideline for lecanemab (genetical recombination). In Japanese</article-title>. <publisher-name>Ministry of Health, Labour and Welfare</publisher-name>. December, 2023. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/files/000265885.pdf" ext-link-type="uri">https://www.pmda.go.jp/files/000265885.pdf</ext-link></mixed-citation></ref><ref id="trc270157-bib-0005"><label>5</label><mixed-citation publication-type="book" id="trc270157-cite-0006"><collab collab-type="authors">Ministry of Health, Labour and Welfare</collab>
. <article-title>Handling of guidelines for promoting optimal use. In Japanese</article-title>. <publisher-name>Ministry of Health, Labour and Welfare</publisher-name>. September 30, 2022. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mhlw.go.jp/web/t_doc?dataId=00tc7062%26dataType=1%26pageNo=1" ext-link-type="uri">https://www.mhlw.go.jp/web/t_doc?dataId=00tc7062&amp;dataType=1&amp;pageNo=1</ext-link></mixed-citation></ref><ref id="trc270157-bib-0006"><label>6</label><mixed-citation publication-type="book" id="trc270157-cite-0007"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hl&#225;vka</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Yoong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goto</surname><given-names>R</given-names></string-name>. <article-title>Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer's treatment</article-title>. <publisher-name>CESR Reports</publisher-name>; <year>2019</year>:<fpage>2019</fpage>&#8208;<lpage>101</lpage>. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cesr.usc.edu/sites/default/files/Japan_Infrastructure_Report_Update_f2%5B1%5D.pdf" ext-link-type="uri">https://cesr.usc.edu/sites/default/files/Japan_Infrastructure_Report_Update_f2%5B1%5D.pdf</ext-link></mixed-citation></ref><ref id="trc270157-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="trc270157-cite-0008"><string-name name-style="western"><surname>Ohashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Takahashi&#8208;Iwata</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Jieyu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sakushima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yabe</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ogasawara</surname><given-names>K</given-names></string-name>. <article-title>Are there shortages and regional disparities in lecanemab treatment facilities? a cross&#8208;sectional study</article-title>. <source>Health Serv Insights</source>. <year>2024</year>;<volume>17</volume>:11786329241299312. doi:<pub-id pub-id-type="doi">10.1177/11786329241299312</pub-id><pub-id pub-id-type="pmcid">PMC11574910</pub-id><pub-id pub-id-type="pmid">39563977</pub-id></mixed-citation></ref><ref id="trc270157-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="trc270157-cite-0009"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape</article-title>. <source>Neuron</source>. <year>2023</year>;<volume>111</volume>(<issue>18</issue>):<fpage>2781</fpage>&#8208;<lpage>2799</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2023.05.017</pub-id><pub-id pub-id-type="pmid">37295421</pub-id><pub-id pub-id-type="pmcid">PMC10720399</pub-id></mixed-citation></ref><ref id="trc270157-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="trc270157-cite-0010"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashford</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Considerations for widespread implementation of blood&#8208;based biomarkers of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>11</issue>):<fpage>8209</fpage>&#8208;<lpage>8215</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14150</pub-id><pub-id pub-id-type="pmid">39369283</pub-id><pub-id pub-id-type="pmcid">PMC11567842</pub-id></mixed-citation></ref><ref id="trc270157-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="trc270157-cite-0011"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashford</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Recommendations for clinical implementation of blood&#8208;based biomarkers for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>11</issue>):<fpage>8216</fpage>&#8208;<lpage>8224</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14184</pub-id><pub-id pub-id-type="pmid">39351838</pub-id><pub-id pub-id-type="pmcid">PMC11567872</pub-id></mixed-citation></ref><ref id="trc270157-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="trc270157-cite-0012"><string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Galasko</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AC</given-names></string-name>, et&#160;al. <article-title>Acceptable performance of blood biomarker tests of amyloid pathology&#8212;recommendations from the Global CEO Initiative on Alzheimer's disease</article-title>. <source>Nat Rev Neurol</source>. <year>2024</year>;<volume>20</volume>(<issue>7</issue>):<fpage>426</fpage>&#8208;<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41582-024-00977-5</pub-id><pub-id pub-id-type="pmid">38866966</pub-id></mixed-citation></ref><ref id="trc270157-bib-0012"><label>12</label><mixed-citation publication-type="book" id="trc270157-cite-0013"><collab collab-type="authors">World Health Organization</collab>
. <article-title>Preferred product characteristics of blood&#8208;based biomarker diagnostics for Alzheimer disease</article-title>. <publisher-name>World Health Organization</publisher-name>; <year>2024</year>. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://iris.who.int/bitstream/handle/10665/379286/9789240099067-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/379286/9789240099067&#8208;eng.pdf?sequence=1</ext-link></mixed-citation></ref><ref id="trc270157-bib-0013"><label>13</label><mixed-citation publication-type="book" id="trc270157-cite-0014"><collab collab-type="authors">Guideline Development Committee</collab>
. <article-title>Appropriate Use Guideline for Cerebrospinal Fluid and Blood Biomarkers Related to Dementia. 3rd ed. Tokyo, Japan: Japanese Society of Dementia Research, Japanese Psychogeriatric Society, Japanese Society of Neurology, Japanese Society of Psychiatry and Neurology, Japanese Society of Geriatrics, Japanese Society of Neurological Therapeutics. In Japanese</article-title>. <publisher-name>Guideline Development Committee</publisher-name>. March 31, 2025. Accessed July 10, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jpn-geriat-soc.or.jp/proposal/pdf/dementia03.pdf" ext-link-type="uri">https://www.jpn&#8208;geriat&#8208;soc.or.jp/proposal/pdf/dementia03.pdf</ext-link></mixed-citation></ref><ref id="trc270157-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="trc270157-cite-0015"><string-name name-style="western"><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farrar</surname><given-names>S</given-names></string-name>. <article-title>Using conjoint analysis to elicit preferences for health care</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>320</volume>(<issue>7248</issue>):<fpage>1530</fpage>&#8208;<lpage>1533</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.320.7248.1530</pub-id><pub-id pub-id-type="pmid">10834905</pub-id><pub-id pub-id-type="pmcid">PMC1118112</pub-id></mixed-citation></ref><ref id="trc270157-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="trc270157-cite-0016"><string-name name-style="western"><surname>Bridges</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Hauber</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Conjoint analysis applications in health&#8211;a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force</article-title>. <source>Value Health</source>. <year>2011</year>;<volume>14</volume>(<issue>4</issue>):<fpage>403</fpage>&#8208;<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2010.11.013</pub-id><pub-id pub-id-type="pmid">21669364</pub-id></mixed-citation></ref><ref id="trc270157-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="trc270157-cite-0017"><string-name name-style="western"><surname>Bonabeau</surname><given-names>E</given-names></string-name>. <article-title>Agent&#8208;based modeling: methods and techniques for simulating human systems</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2002</year>;<volume>99</volume>(Suppl <issue>3</issue>):<fpage>7280</fpage>&#8208;<lpage>7287</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.082080899</pub-id><pub-id pub-id-type="pmid">12011407</pub-id><pub-id pub-id-type="pmcid">PMC128598</pub-id></mixed-citation></ref><ref id="trc270157-bib-0017"><label>17</label><mixed-citation publication-type="book" id="trc270157-cite-0018"><string-name name-style="western"><surname>Railsback</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Grimm</surname><given-names>V</given-names></string-name>. <source>Agent&#8208;Based and Individual&#8208;Based Modeling: a Practical Introduction</source>. <publisher-name>Princeton University Press</publisher-name>; <year>2011</year>.</mixed-citation></ref><ref id="trc270157-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="trc270157-cite-0019"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lawley</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pag&#225;n</surname><given-names>JA</given-names></string-name>. <article-title>Agent&#8208;based modeling of chronic diseases: a narrative review and future research directions</article-title>. <source>Prev Chronic Dis</source>. <year>2016</year>;<volume>13</volume>:<fpage>E69</fpage>. doi:<pub-id pub-id-type="doi">10.5888/pcd13.150561</pub-id><pub-id pub-id-type="pmid">27236380</pub-id><pub-id pub-id-type="pmcid">PMC4885681</pub-id></mixed-citation></ref><ref id="trc270157-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="trc270157-cite-0020"><string-name name-style="western"><surname>Tracy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></string-name>. <article-title>Agent&#8208;based modeling in public health: current applications and future directions</article-title>. <source>Annu Rev Public Health</source>. <year>2018</year>;<volume>39</volume>:<fpage>77</fpage>&#8208;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-publhealth-040617-014317</pub-id><pub-id pub-id-type="pmid">29328870</pub-id><pub-id pub-id-type="pmcid">PMC5937544</pub-id></mixed-citation></ref><ref id="trc270157-bib-0020"><label>20</label><mixed-citation publication-type="book" id="trc270157-cite-0021"><collab collab-type="authors">All Japan Hospital Association</collab>
. <article-title>Research Report on the Medical Care System for Dementia. Subsidized by the Health Promotion Program for the Elderly. In Japanese; title translated by the author</article-title>. <publisher-name>All Japan Hospital Association</publisher-name>. March, 2024. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ajha.or.jp/voice/pdf/other/240411_5.pdf" ext-link-type="uri">https://www.ajha.or.jp/voice/pdf/other/240411_5.pdf</ext-link></mixed-citation></ref><ref id="trc270157-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="trc270157-cite-0022"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Loh</surname><given-names>WK</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Yoong</surname><given-names>J</given-names></string-name>. <article-title>Preparedness of China's health care system to provide access to a disease&#8208;modifying Alzheimer's treatment</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>5596</fpage>&#8208;<lpage>5604</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13348</pub-id><pub-id pub-id-type="pmid">37279385</pub-id></mixed-citation></ref><ref id="trc270157-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="trc270157-cite-0023"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Correa Dos Santos Filho</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Preparedness of the Brazilian health&#8208;care system to provide access to a disease&#8208;modifying Alzheimer's disease treatment</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>1</issue>):<fpage>375</fpage>&#8208;<lpage>381</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12778</pub-id><pub-id pub-id-type="pmid">36063494</pub-id><pub-id pub-id-type="pmcid">PMC10087834</pub-id></mixed-citation></ref><ref id="trc270157-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="trc270157-cite-0024"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gustavsson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Estimates of current capacity for diagnosing Alzheimer's disease in Sweden and the need to expand specialist numbers</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2024</year>;<volume>11</volume>(<issue>1</issue>):<fpage>155</fpage>&#8208;<lpage>161</lpage>. doi: <pub-id pub-id-type="doi">10.14283/jpad.2023.94</pub-id><pub-id pub-id-type="pmid">38230728</pub-id><pub-id pub-id-type="pmcid">PMC10995070</pub-id></mixed-citation></ref><ref id="trc270157-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="trc270157-cite-0025"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Bittner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hlavka</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname><given-names>M</given-names></string-name>. <article-title>Blood&#8208;based biomarkers for Alzheimer's pathology and the diagnostic process for a disease&#8208;modifying treatment: projecting the impact on the cost and wait times</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>e12081</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/dad2.12081</pub-id><pub-id pub-id-type="pmcid">PMC7434228</pub-id><pub-id pub-id-type="pmid">32832590</pub-id></mixed-citation></ref><ref id="trc270157-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="trc270157-cite-0026"><string-name name-style="western"><surname>Canestaro</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Monane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Braunstein</surname><given-names>JB</given-names></string-name>. <article-title>Use of a blood biomarker test improves economic utility in the evaluation of older patients presenting with cognitive impairment</article-title>. <source>Popul Health Manag</source>. <year>2024</year>;<volume>27</volume>(<issue>3</issue>):<fpage>174</fpage>&#8208;<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1089/pop.2023.0309</pub-id><pub-id pub-id-type="pmid">38546435</pub-id><pub-id pub-id-type="pmcid">PMC11304753</pub-id></mixed-citation></ref><ref id="trc270157-bib-0026"><label>26</label><mixed-citation publication-type="book" id="trc270157-cite-0027"><collab collab-type="authors">National Institute for Health and Care Excellence</collab>
. <article-title>Draft guidance consultation. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease</article-title>. <publisher-name>National Institute for Health and Care Excellence</publisher-name>. August, 2024. Accessed April 7, 2025. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/GID-TA11220/documents/draft-guidance" ext-link-type="uri">https://www.nice.org.uk/guidance/GID&#8208;TA11220/documents/draft&#8208;guidance</ext-link></mixed-citation></ref><ref id="trc270157-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="trc270157-cite-0028"><string-name name-style="western"><surname>Tahami Monfared</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Sardesai</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>A path to improved Alzheimer's care: simulating long&#8208;term health outcomes of lecanemab in early Alzheimer's disease from the CLARITY AD trial</article-title>. <source>Neurol Ther</source>. <year>2023</year>;<volume>12</volume>(<issue>3</issue>):<fpage>863</fpage>&#8208;<lpage>881</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40120-023-00473-w</pub-id><pub-id pub-id-type="pmid">37009976</pub-id><pub-id pub-id-type="pmcid">PMC10195966</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotoxicology</journal-id><journal-id journal-id-type="iso-abbrev">Neurotoxicology</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Neurotoxicology</journal-title></journal-title-group><issn pub-type="ppub">0161-813X</issn><issn pub-type="epub">1872-9711</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501635</article-id><article-id pub-id-type="pmcid-ver">PMC12501635.1</article-id><article-id pub-id-type="pmcaid">12501635</article-id><article-id pub-id-type="pmcaiid">12501635</article-id><article-id pub-id-type="manuscript-id">NIHMS2111773</article-id><article-id pub-id-type="pmid">40744256</article-id><article-id pub-id-type="doi">10.1016/j.neuro.2025.07.010</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2111773</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2111773</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Parental preconceptual &#945;-cypermethrin exposure alters embryonic brain transcriptomics in mice: implications for autism spectrum disorder and stress vulnerability</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hing</surname><given-names initials="B">Benjamin</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="R">Robert</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eliasen</surname><given-names initials="S">Samuel</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stevens</surname><given-names initials="HE">Hanna E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA</aff><aff id="A2"><label>2</label>Department of Molecular Physiology and Biophysics, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author: Benjamin Hing, PhD, Department of Molecular Physiology and Biophysics, The University of Iowa, 51, Newton Road, 6-509 Bowen Science Building, Iowa City, Iowa 52242, <email>benjamin-hing@uiowa.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P40">Declaration of Competing Interest</p><p id="P41">None of the authors have financial interests or personal relationships that could have appeared to influence the work reported in this study.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2025</year></pub-date><volume>110</volume><issue-id pub-id-type="pmc-issue-id">498442</issue-id><fpage>181</fpage><lpage>196</lpage><pub-history><event event-type="nihms-submitted"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2111773.pdf"/><abstract id="ABS1"><p id="P1">Pyrethroid insecticides are widely used in agriculture and households, and their exposure can affect neurodevelopment. Few studies have evaluated how preconception parental exposure could also affect this process. To address this knowledge gap, adult C57Bl6/J mice were gavaged daily with &#945;-cypermethrin at a human relevant low (0.3 mg/kg) or high (10 mg/kg) dose in corn oil for four weeks prior to conception. Offspring embryonic day 16 dorsal forebrain was extracted for transcriptomic analysis. In offspring forebrains of exposed compared to unexposed parents, there was increasing number of differentially expressed genes (DEGs) from paternal (least) to maternal to both parent exposure (most). A dose dependent effect was observed in offspring forebrain for paternal and maternal preconceptual exposures. Maternal and both parent exposures led to upregulated genes in offspring brain for biological processes involved in translation with predicted activation of <italic toggle="yes">EIF4E</italic>, a gene associated with autism. In contrast, paternal exposure upregulated cell cycle related DNA damage signaling processes. After any parent exposure, there was upregulation of biological processes involved in mitochondria function and oxidative stress and a downregulation of neuronal and synaptic processes with predicted inhibition of <italic toggle="yes">BDNF</italic> signaling. Weighted gene correlation network analysis identified modules associated with different parent exposures that were over-represented with DEGs and had similar functional signatures as DEG-related pathways. Importantly, DEGs in offspring forebrain after any parent exposure were over-represented with genes related to autism spectrum disorder (ASD) and stress vulnerability. The study highlights the potential contribution of preconception parental pyrethroid exposure to aberrant brain functioning.</p></abstract><kwd-group><kwd>Pesticides</kwd><kwd>Cypermethrin</kwd><kwd>Neurodevelopment</kwd><kwd>Transcriptomics</kwd><kwd>Autism Spectrum Disorder</kwd><kwd>Stress vulnerability</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="trc270156" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="pmc-domain-id">3303</journal-id><journal-id journal-id-type="pmc-domain">trci</journal-id><journal-id journal-id-type="publisher-id">TRC2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Translational Research &amp; Clinical Interventions</journal-title></journal-title-group><issn pub-type="epub">2352-8737</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504060</article-id><article-id pub-id-type="pmcid-ver">PMC12504060.1</article-id><article-id pub-id-type="pmcaid">12504060</article-id><article-id pub-id-type="pmcaiid">12504060</article-id><article-id pub-id-type="doi">10.1002/trc2.70156</article-id><article-id pub-id-type="publisher-id">TRC270156</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Neurovascular de&#8208;coupling underlies dual&#8208;task cost across cognitive abilities</article-title><alt-title alt-title-type="left-running-head">FITZGIBBON&#8208;COLLINS <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="trc270156-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Fitzgibbon&#8208;Collins</surname><given-names initials="LK">Laura K.</given-names></name><xref rid="trc270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="trc270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>lfitzgib@uwo.ca</email></address></contrib><contrib id="trc270156-cr-0002" contrib-type="author"><name name-style="western"><surname>Best</surname><given-names initials="S">Sarah</given-names></name><xref rid="trc270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="trc270156-cr-0003" contrib-type="author"><name name-style="western"><surname>Noguchi</surname><given-names initials="M">Mamiko</given-names></name><xref rid="trc270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="trc270156-cr-0004" contrib-type="author"><name name-style="western"><surname>Guest</surname><given-names initials="C">Corey</given-names></name><xref rid="trc270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270156-cr-0005" contrib-type="author"><name name-style="western"><surname>Borrie</surname><given-names initials="M">Michael</given-names></name><xref rid="trc270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270156-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Shoemaker</surname><given-names initials="JK">J. Kevin</given-names></name><xref rid="trc270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>kshoemak@uwo.ca</email></address></contrib><contrib id="trc270156-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Bhangu</surname><given-names initials="J">Jaspreet</given-names></name><xref rid="trc270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Jaspreet.Bhangu@sjhc.london.on.ca</email></address></contrib></contrib-group><aff id="trc270156-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Division of Geriatric Medicine</named-content>
<named-content content-type="organisation-division">Schulich School of Medicine &amp; Dentistry</named-content>
<institution>University of Western Ontario</institution>
<city>London</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="trc270156-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Kinesiology</named-content>
<institution>University of Western Ontario</institution>
<city>London</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="trc270156-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Cognitive Clinical Research Group</named-content>
<institution>Parkwood Institute</institution>
<city>London</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="trc270156-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Kinesiology</named-content>
<institution>University of Waterloo</institution>
<city>Waterloo</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Laura K. Fitzgibbon&#8208;Collins and Jaspreet Bhangu, Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON, Canada.<break/> Email: <email>lfitzgib@uwo.ca</email>, and <email>Jaspreet.Bhangu@sjhc.london.on.ca</email><break/>J. Kevin Shoemaker, Department of Kinesiology, University of Western Ontario, London, ON, Canada.<break/> Email: <email>kshoemak@uwo.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>11</volume><issue seq="40">4</issue><issue-id pub-id-type="pmc-issue-id">498507</issue-id><issue-id pub-id-type="doi">10.1002/trc2.v11.4</issue-id><elocation-id>e70156</elocation-id><history><date date-type="rev-recd"><day>13</day><month>8</month><year>2025</year></date><date date-type="received"><day>28</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="TRC2-11-e70156.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:TRC2-11-e70156.pdf"/><abstract><title>Abstract</title><sec id="trc270156-sec-0010"><title>INTRODUCTION</title><p>We tested the hypothesis that increased middle cerebral artery velocity (MCA velocity) during complex motor (overground walking) and cognitive tasks (e.g., dual task) is associated with cognitive performance in older adults with varying levels of cognitive ability.</p></sec><sec id="trc270156-sec-0020"><title>METHODS</title><p>Fifty&#8208;six participants (19 females, 75 &#177; 7 years old) completed a seated single task that assessed working memory performance; a walking single task, assessing overground walking gait speed; and a dual task, combining both. Continuous MCA velocity was collected, and participants completed a Montreal Cognitive Assessment (MoCA).</p></sec><sec id="trc270156-sec-0030"><title>RESULTS</title><p>Higher MCA velocity was associated with faster gait speed, better working memory performance, and greater MoCA scores (all <italic toggle="yes">p</italic> &lt; 0.05). Participants with lower MoCA scores had lower MCA velocity (<italic toggle="yes">p</italic> = 0.052), slower gait speed (<italic toggle="yes">p</italic> = 0.035), and lower working memory performance (<italic toggle="yes">p</italic> = 0.016) than people with higher MoCA scores. The hyperemic response of MCA velocity from single task walking to the dual task with increased cognitive load significantly contributed to MoCA scores (<italic toggle="yes">p</italic> = 0.017).</p></sec><sec id="trc270156-sec-0040"><title>DISCUSSION</title><p>The functional response of cerebral blood flow with these tests suggests vascular properties may be considered a biomarker indicative of subclinical cognitive function during walking tasks.</p></sec><sec id="trc270156-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="trc270156-list-0001"><list-item><p>Mobile devices simultaneously assessed neurovascular coupling and dual&#8208;task cost.</p></list-item><list-item><p>Middle cerebral artery velocity (MCA velocity) is negatively associated with dual&#8208;task cost.</p></list-item><list-item><p>MCA velocity is associated with gait speed, working memory, and Montreal Cognitive Assessment scores.</p></list-item><list-item><p>MCA velocity decreased from controls to mild cognitive impairment to dementia.</p></list-item><list-item><p>Novel methodological approach to utilize MCA velocity during overground walking, single&#8208;tasks, and dual&#8208;tasks.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="trc270156-kwd-0001">dementia</kwd><kwd id="trc270156-kwd-0002">dual&#8208;task</kwd><kwd id="trc270156-kwd-0003">gait speed</kwd><kwd id="trc270156-kwd-0005">middle cerebral artery velocity</kwd><kwd id="trc270156-kwd-0006">mild cognitive impairment</kwd><kwd id="trc270156-kwd-0004">neurovascular coupling</kwd><kwd id="trc270156-kwd-0007">overground walking</kwd><kwd id="trc270156-kwd-0008">working memory</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Academic Medical Organization of Southwestern Ontario</institution><institution-id institution-id-type="doi">10.13039/100010564</institution-id></institution-wrap></funding-source><award-id>F20&#8208;004</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>CIHR Institute on Aging for the Canadian Collaboration on Neurodegeneration in Aging</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>the Vascular Training Platform</institution></institution-wrap></funding-source><award-id>Post&#8208;docaward</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>The Parkwood Institute Research Endowment Fund: In Care of Older Adults</institution></institution-wrap></funding-source><award-id>Post&#8208;docaward</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="11"/><word-count count="6115"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="trc270156-cite-0001"><string-name name-style="western"><surname>Fitzgibbon&#8208;Collins</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Best</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Noguchi</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Neurovascular de&#8208;coupling underlies dual&#8208;task cost across cognitive abilities</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>11</volume>:<elocation-id>e70156</elocation-id>. <pub-id pub-id-type="doi">10.1002/trc2.70156</pub-id></mixed-citation>
</p></notes></front><body><sec id="trc270156-sec-0060"><label>1</label><title>BACKGROUND</title><p>In cognitive testing paradigms, a dual task is the concurrent performance of a motor and cognitive task, such as walking and talking, and presents a way to measure the impact of motor tasks on cognitive performance. The simultaneous engagement of two brain networks results in shared brain resources, which are competing for the same cognitive reserve.<xref rid="trc270156-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="trc270156-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="trc270156-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="trc270156-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Consequently, performance of the motor and/or cognitive task is diminished compared to the single task, and this is referred to as the dual&#8208;task cost.</p><p>Neurovascular coupling, a feed&#8208;forward neurotransmitter&#8208;mediated signaling pathway, is characterized by the functional hyperemic response to neuronal activity.<xref rid="trc270156-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="trc270156-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> During a dual task, metabolic requirements are augmented in the different brain networks, placing increased demand on the cerebrovascular system's capacity to redistribute blood flow to meet the increase in cognitive load from competing brain networks. Diminished neurovascular coupling has been observed in adults with dementia<xref rid="trc270156-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270156-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="trc270156-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> and has been associated with both changes in gait speed (GS) and working memory (n&#8208;back) in an asynchronous protocol,<xref rid="trc270156-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="trc270156-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> which may impair an individual's ability to complete motor or cognitive tasks. The underlying associations between diminished neurovascular coupling and GS/working memory are not well known, and the simultaneous assessment of neurovascular coupling during overground walking and working memory tasks has never been conducted.</p><p>Using single&#8208;task versus dual&#8208;task performance to study neurovascular coupling and gait/memory offers a novel way to assess whether impaired coupling affects complex task execution. Furthermore, including participants with diverse cognitive abilities adds further novelty while also pioneering simultaneous assessments of hemodynamics, cognitive function, and motor performance. Therefore, the aim of the current study was to assess the capacity of middle cerebral artery velocity (MCA velocity) to increase during domain&#8208;specific cognitive performance (GS, working memory performance) when going from a single task to a dual task and whether this increase in MCA velocity is associated with global cognitive performance, as measured by the Montreal Cognitive Assessment (MoCA), in people with varying levels of cognitive ability.</p></sec><sec id="trc270156-sec-0070"><label>2</label><title>METHODS</title><p>The current investigation was approved by Clinical Trials Ontario (CT750) at Western University's research ethics review board and conforms with the Declaration of Helsinki. All participants provided signed informed consent.</p><sec id="trc270156-sec-0080"><label>2.1</label><title>Participants</title><p>The MoCA was completed by 206 participants, and 88 participants volunteered for the dual&#8208;task laboratory testing. Of the 88 participants, 3 were physically unable to complete the walking protocol, and 30 were excluded due to inadequate MCA velocity signal acquisition, resulting in a sample size of 56 participants. The laboratory settings are provided in <xref rid="trc270156-supinfo-0001" ref-type="">Supplement A</xref> in Supporting Information.</p><p>Descriptions of study inclusion/exclusion criteria, participant selection, and clinical group ascertainment have been previously published<xref rid="trc270156-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="trc270156-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and can be found in <xref rid="trc270156-supinfo-0001" ref-type="">Supplement A</xref>. In brief, this was a sub&#8208;study of the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS&#8208;ND) Study, and all cognitive testing and clinical categorization was done as per the COMPASS&#8208;ND protocol. Participants for this study were separated into three groups based on the severity of clinical cognitive symptoms: cognitively intact controls (CNT), mild cognitive impairment (MCI), and dementia (DEM).<xref rid="trc270156-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p></sec><sec id="trc270156-sec-0090"><label>2.2</label><title>Hemodynamic assessment</title><p>Participants were instrumented with a portable 2 MHz transducer to insonate the middle cerebral artery (transcranial Doppler ultrasound; Atys medical) to collect MCA velocity. A portable gas analyzer (Capnostream 35, Medtronics) estimated end&#8208;tidal carbon dioxide (ETCO<sub>2</sub>) from a nasal cannula.</p></sec><sec id="trc270156-sec-0100"><label>2.3</label><title>Working memory performance</title><p>Participants completed two 90 second blocks of the n&#8208;back task, which were averaged. To differentiate between random target selection and information&#8208;based target detection, as well as speed versus accuracy, a &#8220;Sensitivity A&#8217; Score&#8221; was calculated (<xref rid="trc270156-supinfo-0001" ref-type="">Supplement A</xref>),<xref rid="trc270156-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="trc270156-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> for which a higher Sensitivity A&#8217; Score represents better working memory performance, and this score was used for analysis. The seated single task was conducted first because the larger study design restricted randomization between seated and walking conditions. Additional details for the working memory task can be found in <xref rid="trc270156-supinfo-0001" ref-type="">Supplement A</xref>.</p></sec><sec id="trc270156-sec-0110"><label>2.4</label><title>Motor performance</title><p>Participants rested in the seated position for 5 minutes prior to each 90 second walking task. Participants were asked to walk at a self&#8208;selected pace around a 46 m oval track. The walking track had parallel straight walking pathways of 22.86 m and turning radii of 1.143 m. GS was calculated as the distance traveled during 90 seconds of walking, and hemodynamic data collected during the 90 seconds of walking were averaged. The single task of walking and dual task were performed randomly.</p></sec><sec id="trc270156-sec-0120"><label>2.5</label><title>Dual&#8208;task paradigm</title><p>Participants completed a seated single task evaluating working memory performance and a walking single task assessing motor performance (described below and in <xref rid="trc270156-supinfo-0001" ref-type="">Supplement A</xref>). Participants also completed a dual task, which combined the working memory task with the overground&#8208;walking assessment (Figure&#160;<xref rid="trc270156-fig-0001" ref-type="fig">1</xref>). The dual&#8208;task cost of working memory was calculated as the change in behavioral performance (Sensitivity A&#8217; Score) from the seated single task to the dual&#8208;task condition. The dual&#8208;task cost of GS was calculated as the difference in GS from the single task of walking to the dual task (both 90 second averaged data).</p><fig position="float" fig-type="FIGURE" id="trc270156-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Dual&#8208;task diagram. The conditions (seated single task, walking single task, and dual task), protocol procedures, metrics collected, averages, and analysis are outlined. The seated single &#8208;task was conducted first, followed by the randomization of the walking single task and dual task. The Montreal cognitive assessment (MoCA) was performed on a separate visit and was correlated with the metrics collected during the dual&#8208;task paradigm. *averaged both 90 second n&#8208;back blocks for a single metric. Created in BioRender. ETCO<sub>2</sub>, end&#8208;tidal carbon dioxide; MCA velocity, middle cerebral artery blood velocity. Fitzgibbon&#8208;collins, L.K. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/w19ddh4" ext-link-type="uri">https://BioRender.com/w19ddh4</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="TRC2-11-e70156-g004.jpg"/></fig></sec><sec id="trc270156-sec-0130"><label>2.6</label><title>Statistical analysis</title><p>A one&#8208;way analysis of variance (ANOVA) was run to compare baseline MCA velocity (average of seated resting values from the walking and dual&#8208;task conditions), age, body mass index (BMI), and education between clinical groups. General linear modeling was used to compare MoCA scores between groups with age as a covariate. A chi&#8208;squared test was run to compare the number of females per clinical cohort and to compare the number of participants on blood pressure&#8211;lowering medications between cohorts. If the expected count was &lt; 5, then the Fisher exact test was used. Between&#8208;group comparisons (age, BMI, education) were calculated using a one&#8208;way ANOVA.</p><p>Pearson correlations were run between MoCA scores and changes in single task to dual task for MCA velocity and GS, while controlling for age. Multiple linear regression analyses were conducted to examine the relationship between MoCA scores and five predictors. The factors that may influence global cognitive function or MoCA scores are dual&#8208;task cost,<xref rid="trc270156-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> neurovascular coupling,<xref rid="trc270156-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> and age;<xref rid="trc270156-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> therefore, the following five variables were included in the model, age, dual&#8208;task cost of working memory performance score and GS, and the change in MCA velocity from single task to dual task from both the seated single task and walking single task conditions.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="trc270156-sec-0140"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="trc270156-list-0002"><list-item><p>
<bold>Systematic review</bold>: The findings from previously published data of the same cohort of participantsClick or tap here to enter text., and a review of the literature (e.g., PubMed) were combined to identify the accumulated knowledge for the research question. This is the first study to simultaneously assess neurovascular coupling and dual&#8208;task cost during overground walking to determine whether increased brain blood flow is associated with global and/or domain&#8208;specific cognitive performance in people with cognitive impairment.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Brain blood flow velocity during upright activity (e.g., dual task) may be considered a biomarker indicative of subclinical cognitive function.</p></list-item><list-item><p>
<bold>Future directions</bold>: Preventative or intervention strategies focused on improving vascular health should be considered to advance patient care for adults at risk of cognitive impairment. Specifically, other active cardiovascular/cerebrovascular mechanisms, such as altered oxygen extraction or ventilatory regulation, may be responsible for the observed mismatch and should be investigated further.</p></list-item></list>
</p></sec></boxed-text><p>A mixed repeated measures ANOVA was performed to compare the effect of MCA velocity, GS, and working memory performance score across different conditions (single tasks vs. dual tasks) and clinical cohorts while controlling for the effects of age. A Bonferroni correction factor was used to adjust for multiple comparisons by dividing the desired significance level by the number of tests being performed. Data that violated the assumption of sphericity were reported with a Greenhouse Geisser correction factor. Significance was set to <italic toggle="yes">p</italic> &#8804; 0.05.</p></sec></sec><sec id="trc270156-sec-0150"><label>3</label><title>RESULTS</title><sec id="trc270156-sec-0160"><label>3.1</label><title>Participant characteristics</title><p>Participants in the DEM group were older than the CNT and MCI groups (<italic toggle="yes">p</italic> &lt; 0.001; see Table&#160;<xref rid="trc270156-tbl-0001" ref-type="table">1</xref>). CNT had the highest MoCA scores, followed by MCI, and then DEM groups (<italic toggle="yes">p</italic> &lt; 0.001). Group differences were not observed for baseline MCA velocity, BMI, education level, number of participants on blood pressure&#8211;lowering medications, or the number of females in each cohort.</p><table-wrap position="float" id="trc270156-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics and performance metrics for working memory and walking performance.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>CNT</p>
<p>
<italic toggle="yes">n</italic> = 13</p>
</th><th align="left" rowspan="1" colspan="1">
<p>MCI</p>
<p>
<italic toggle="yes">n</italic> = 34</p>
</th><th align="left" rowspan="1" colspan="1">
<p>DEM</p>
<p>
<italic toggle="yes">n</italic> = 9</p>
</th><th align="left" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic> value</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Self&#8208;identify female, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">7 (54)</td><td align="left" rowspan="1" colspan="1">10 (29)</td><td align="left" rowspan="1" colspan="1">2 (22)</td><td align="char" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years), avg &#177; SD</td><td align="left" rowspan="1" colspan="1">71 &#177; 6</td><td align="left" rowspan="1" colspan="1">74 &#177; 6</td><td align="left" rowspan="1" colspan="1">82 &#177; 9 &#8224;&#8225;</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="trc270156-tbl1-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), avg &#177; SD</td><td align="left" rowspan="1" colspan="1">27 &#177; 5</td><td align="left" rowspan="1" colspan="1">26 &#177; 4</td><td align="left" rowspan="1" colspan="1">26 &#177; 3</td><td align="char" rowspan="1" colspan="1">0.686</td></tr><tr><td align="left" rowspan="1" colspan="1">MoCA score, avg &#177; SD</td><td align="left" rowspan="1" colspan="1">28 &#177; 2 &#8225;</td><td align="left" rowspan="1" colspan="1">24 &#177; 4</td><td align="left" rowspan="1" colspan="1">16 &#177; 5 &#8224;&#8225;</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="trc270156-tbl1-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years), avg &#177; SD</td><td align="left" rowspan="1" colspan="1">16 &#177; 3</td><td align="left" rowspan="1" colspan="1">16 &#177; 4</td><td align="left" rowspan="1" colspan="1">16 &#177; 4</td><td align="char" rowspan="1" colspan="1">0.866</td></tr><tr><td align="left" rowspan="1" colspan="1">On a BP lowering medication, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">6 (46)</td><td align="left" rowspan="1" colspan="1">10 (29)</td><td align="left" rowspan="1" colspan="1">5 (56)</td><td align="char" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline MCAv (cm/s), avg &#177; SD</td><td align="left" rowspan="1" colspan="1">38.5 &#177; 7.3</td><td align="left" rowspan="1" colspan="1">38.9 &#177; 8.1</td><td align="left" rowspan="1" colspan="1">33.8 &#177; 6.5</td><td align="char" rowspan="1" colspan="1">0.210</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean arterial pressure, mmHg</td><td align="left" rowspan="1" colspan="1">81 &#177; 11</td><td align="left" rowspan="1" colspan="1">90 &#177; 14</td><td align="left" rowspan="1" colspan="1">92 &#177; 9</td><td align="char" rowspan="1" colspan="1">0.104</td></tr></tbody></table><table-wrap-foot><fn id="trc270156-tbl1-note-0002"><p>
<italic toggle="yes">Note</italic>: Mean arterial pressure from the supine position.</p></fn><fn id="trc270156-tbl1-note-0001"><p>Abbreviations: BMI, body mass index; BP, blood pressure; CNT, cognitively intact controls; DEM, people living with dementia; MCAv, middle cerebral artery velocity averaged from seated rest of the walking and dual&#8208;task conditions; MCI, people living with mild cognitive impairment; MoCA, Montreal Cognitive Assessment; SD, standard deviation.</p></fn><fn id="trc270156-tbl1-note-0003"><label>
<sup>a</sup>
</label><p>Significant (<italic toggle="yes">p</italic> &#8804; 0.05) pairwise comparisons: &#8224; versus CNT; &#8225; versus MCI.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="trc270156-sec-0170"><label>3.2</label><title>MCA velocity and GS</title><p>During the dual task, a higher MCA velocity was associated with a faster GS when controlling for age (<italic toggle="yes">p</italic> = 0.024, <italic toggle="yes">r</italic> = 0.304, Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2A</xref>). This relationship was not observed during single&#8208;task walking (<italic toggle="yes">p</italic> = 0.102, <italic toggle="yes">r</italic> = 0.223, Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2A</xref>). After separating participants into clinical cohorts, mean MCA velocity during walking differed by group and condition (interaction effect: <italic toggle="yes">p</italic> = 0.037); however, after applying a Greenhouse Geisser correction factor, this interaction was not statistically significant but remained at <italic toggle="yes">p</italic> = 0.052 (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>, Supplement B Table <xref rid="trc270156-supinfo-0001" ref-type="">1</xref> in Supporting Information). Looking at MCA velocity and GS, both follow the same patterns, in which CNT had the greatest MCA velocities and fastest GS (single task: 41.8 &#177; 8.0&#160;cm/s, 1.3 &#177; 0.3 m/s; dual task: 42.7 &#177; 7.2&#160;cm/s, 1.2 &#177; 0.3 m/s), followed by MCI, which has slightly lower MCA velocities and slower GS (single task: 39.7 &#177; 7.8&#160;cm/s, 1.1 &#177; 0.2 m/s; dual task: 41.1 &#177; 8.8&#160;cm/s, 1.1 &#177; 0.3 m/s), followed by DEM, which has the lowest MCA velocity and slowest GS (single task: 36.8 &#177; 7.0&#160;cm/s, 0.9 &#177; 0.2 m/s; dual task: 36.3 &#177; 7.6&#160;cm/s, 0.8 &#177; 0.2 m/s; Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>). There was a significant group effect for GS in which post hoc analysis identified differences between CNT and DEM (<italic toggle="yes">p</italic> = 0.035, Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>, Supplement B Table <xref rid="trc270156-supinfo-0001" ref-type="">1</xref>).</p><fig position="float" fig-type="FIGURE" id="trc270156-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Middle cerebral artery velocity (MCAv) with (A) gait speed and (B) working memory performance score, during the single tasks and dual task. *significant (<italic toggle="yes">p</italic> &lt; 0.05) correlation after controlling for age. The regression line (solid lines), 95% confidence intervals (small dashed lines), and prediction intervals (long dashed lines) are plotted for the dual task with gait speed (A) &#375; = 0.011x + 6.31, and seated single task (B) &#375; = 0.033x + 4.77.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="TRC2-11-e70156-g003.jpg"/></fig><fig position="float" fig-type="FIGURE" id="trc270156-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Group by condition comparisons for middle cerebral artery velocity (MCAv), end&#8208;tidal carbon dioxide (ETCO<sub>2</sub>), gait speed, and working memory performance scores. Conditions include the seated single task (seated), walking single task (walking), and the dual task. Group by condition interactions observed for MCAv and group effects observed for gait speed and working memory performance score. Pairwise comparisons **<italic toggle="yes">p</italic> &lt; 0.05, *<italic toggle="yes">p</italic> &lt; 0.1. CNT, cognitively intact controls; DEM, people living with dementia; GG, Greenhouse Geisser correction; MCI, people living with mild cognitive impairment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="TRC2-11-e70156-g002.jpg"/></fig><p>Although not statistically significant, ETCO<sub>2</sub> followed the same trends as MCA velocity with a group&#8208;by&#8208;condition interaction in which <italic toggle="yes">p</italic> = 0.09 (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>).</p></sec><sec id="trc270156-sec-0180"><label>3.3</label><title>MCA velocity and working memory performance scores</title><p>After controlling for age, higher MCA velocity during the seated single task was significantly correlated with better working memory performance on the n&#8208;backs (<italic toggle="yes">p</italic> = 0.04, <italic toggle="yes">r</italic> = 0.28, Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2B</xref>). Although not statistically significant, MCA velocity had a similar relationship with working memory performance during the dual task (<italic toggle="yes">p</italic> = 0.067, Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2B</xref>). As mentioned previously, once participants were separated into clinical cohorts, MCA velocity demonstrated a group&#8208;by&#8208;condition interaction (<italic toggle="yes">p</italic> = 0.037); however, after a Greenhouse Geisser adjustment, <italic toggle="yes">p</italic> = 0.052 (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>). When evaluating MCA velocity alongside working memory performance scores from the n&#8208;back tasks, both metrics followed similar data distribution patterns in which the CNT group had a higher MCA velocity and working memory performance score compared to DEM during the seated single task. During the dual task, there was an observed pattern of a graded reduction in MCA velocity and working memory performance scores from CNT to MCI to DEM (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>). The working memory performance score had a significant group effect (<italic toggle="yes">p</italic> = 0.016), for which the CNT group performed better than both the MCI (<italic toggle="yes">p</italic> &lt; 0.01) and DEM groups (<italic toggle="yes">p</italic> &lt; 0.05, Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>, Supplement B Table <xref rid="trc270156-supinfo-0001" ref-type="">1</xref>).</p></sec><sec id="trc270156-sec-0190"><label>3.4</label><title>MCA velocity and MoCA scores</title><p>During the walking single task and dual task, higher MCA velocities were associated with better MoCA scores (<italic toggle="yes">p</italic> = 0.037, <italic toggle="yes">r</italic> = 0.285 and <italic toggle="yes">p</italic> = 0.014, <italic toggle="yes">r</italic> = 0.332, respectively). During the seated single task implemented to assess working memory, MCA velocity was significantly and positively correlated with MoCA scores (<italic toggle="yes">p</italic> = 0.018, <italic toggle="yes">r</italic> = 0.322).</p></sec><sec id="trc270156-sec-0200"><label>3.5</label><title>MoCA scores, GS, and working memory performance</title><p>GS during the walking single task and dual task was significantly correlated with MoCA scores (<italic toggle="yes">p</italic> = 0.002, <italic toggle="yes">r</italic> = 0.408 and <italic toggle="yes">p</italic> &lt; 0.001, <italic toggle="yes">r</italic> = 0.528, respectively), in which faster walking correlated with greater MoCA scores. Likewise, working memory performance during the seated single task and dual task was also significantly and positively associated with MoCA scores (<italic toggle="yes">p</italic> &lt; 0.001, <italic toggle="yes">r</italic> = 0.518 and <italic toggle="yes">p</italic> = 0.012, <italic toggle="yes">r</italic> = 0.345, respectively).</p></sec><sec id="trc270156-sec-0210"><label>3.6</label><title>Neurovascular coupling</title><p>Multifaceted relationships between neurovascular coupling (marked as &#8710;MCA velocity from single task to dual task), MoCA scores, GS (motor performance), and working memory performance are characterized in Figure&#160;<xref rid="trc270156-fig-0004" ref-type="fig">4A</xref>. The results from the multiple linear regression to predict MoCA scores from age, dual&#8208;task cost, and neurovascular coupling suggest both neurovascular coupling and dual&#8208;task cost of GS significantly contribute to MoCA scores (<italic toggle="yes">R</italic>
<sup>2</sup> = 0.252, <italic toggle="yes">F</italic>[5,46] = 3.102, <italic toggle="yes">p</italic> = 0.017, Figure&#160;<xref rid="trc270156-fig-0004" ref-type="fig">4</xref>, Table&#160;<xref rid="trc270156-tbl-0002" ref-type="table">2</xref>). The change in MCA velocity from the walking single task to dual task and the corresponding changes in GS are positively and significantly correlated with MoCA scores, indicating that people with greater neurovascular coupling and lower dual&#8208;task costs of GS have higher MoCA scores (Figure&#160;<xref rid="trc270156-fig-0004" ref-type="fig">4</xref>, Table&#160;<xref rid="trc270156-tbl-0002" ref-type="table">2</xref>). In fact, for every increase of MCA velocity by 1&#160;cm/second from the walking single task to the dual task, the MoCA score increases by 0.793. Likewise, for every increase of GS by 1 m/second from the walking single task to the dual task, MoCA score increases by 11.98.</p><fig position="float" fig-type="FIGURE" id="trc270156-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Neurovascular coupling and cognitive performance. A, Multifaceted relationship between neurovascular coupling (&#8710;MCAv), MoCA scores, and different cognitive networks (i, motor performance, and ii, working memory). B, 2D relationships between the change in middle cerebral artery velocity (MCAv) from the single task of walking to the dual task of walking with MoCA scores. MoCA, Montreal Cognitive Assessment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="TRC2-11-e70156-g001.jpg"/></fig><table-wrap position="float" id="trc270156-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Summary statistics, correlations, and results from the multiple linear regression analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="left" colspan="1">Mean</th><th rowspan="2" align="left" colspan="1">Standard deviation</th><th rowspan="2" align="left" colspan="1">Corr with MoCA</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Multiple regression weights</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">B</th><th align="left" rowspan="1" colspan="1">&#946;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MoCA score</td><td align="char" rowspan="1" colspan="1">23</td><td align="char" rowspan="1" colspan="1">5</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">75</td><td align="char" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">&#8722;0.215<xref rid="trc270156-tbl2-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.148</td><td align="char" rowspan="1" colspan="1">0.092</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in working memory performance score from seated single task to dual task</td><td align="char" rowspan="1" colspan="1">&#8722;0.359</td><td align="char" rowspan="1" colspan="1">1.108</td><td align="char" rowspan="1" colspan="1">&#8722;0.230<xref rid="trc270156-tbl2-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.971</td><td align="char" rowspan="1" colspan="1">0.636</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in gait speed from walking single task to dual task</td><td align="char" rowspan="1" colspan="1">&#8722;0.059</td><td align="char" rowspan="1" colspan="1">0.138</td><td align="char" rowspan="1" colspan="1">0.302<xref rid="trc270156-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">11.795<xref rid="trc270156-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">5.139</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in MCAv from seated single task to dual task</td><td align="char" rowspan="1" colspan="1">1.219</td><td align="char" rowspan="1" colspan="1">3.384</td><td align="char" rowspan="1" colspan="1">0.076</td><td align="char" rowspan="1" colspan="1">&#8722;0.185</td><td align="char" rowspan="1" colspan="1">0.221</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in MCAv from walking single task to dual task</td><td align="char" rowspan="1" colspan="1">1.037</td><td align="char" rowspan="1" colspan="1">1.935</td><td align="char" rowspan="1" colspan="1">0.285<xref rid="trc270156-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.793<xref rid="trc270156-tbl2-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.378</td></tr></tbody></table><table-wrap-foot><fn id="trc270156-tbl2-note-0001"><p>Abbreviations: Corr, correlation; MCAv, middle cerebral artery velocity; MoCA, Montreal Cognitive Assessment.</p></fn><fn id="trc270156-tbl2-note-0002"><label>*</label><p>Trends <italic toggle="yes">p</italic> &lt; 0.1 and <italic toggle="yes">p</italic> &gt; 0.05 and</p></fn><fn id="trc270156-tbl2-note-0003"><label>**</label><p>statistically significant <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The regression equation for this model is predicted MoCA = 34.293 &#8211; (0.148 x age) &#8211; (0.971 x &#8710;working memory performance score) + (11.795 x &#8710;GS) &#8211; (0.185 x &#8710;MCA velocity seated single task to dual task) + (0.793 x &#8710;MCA velocity walking single task to dual task), where &#8710; represents the change from single task to dual task. Multicollinearity was not evident, as the tolerance was &gt; 0.1 and the variance inflation factor was &lt; 10. ETCO<sub>2</sub> was positively associated with MCA velocity during walking tasks (walking single task: <italic toggle="yes">p</italic> = 0.052, <italic toggle="yes">r</italic> = 0.302; dual task: <italic toggle="yes">p</italic> = 0.004, <italic toggle="yes">r</italic> = 0.429).</p></sec></sec><sec id="trc270156-sec-0220"><label>4</label><title>DISCUSSION</title><p>This is the first study to simultaneously assess neurovascular coupling during overground walking in older adults with varying levels of cognitive ability. Our results provide evidence that a reduced capacity to regulate MCA velocity corresponded with reduced working memory performance, worsening walking performance, greater dual&#8208;task costs, and lower MoCA scores in older adults during physical activity. This study highlights the critical role of cerebral blood flow regulation in performing simultaneous motor and cognitive tasks, offering a valuable framework for examining how exercise interventions influence the physiological mechanisms underlying cognitive decline. Previous work in this field has been completed asynchronously<xref rid="trc270156-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> or on a treadmill,<xref rid="trc270156-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> which was not able to fully elucidate walking performance, dual&#8208;task cost, or neurovascular coupling with domain&#8208;specific cognitive processes.</p><p>MCA velocity responses were related to both walking performance (GS) and global cognition (MoCA) across varying levels of cognitive ability (Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2</xref>). MCA velocity was significantly correlated with GS during the dual task but not during the single task (Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2A</xref>). This aligns with prior findings highlighting dual&#8208;task, and not single&#8208;task GS, as a predictor of progression from MCI to dementia.<xref rid="trc270156-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Our results support the notion that in older adults, reduced locomotor control, particularly during dual&#8208;task conditions, is associated with a diminished capacity to regulate MCA velocity in response to rising executive function demands. Additionally, while MCA velocity was significantly related to working memory performance in the single task, a non&#8208;significant trend (<italic toggle="yes">p</italic> = 0.067) was observed during the dual task (Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2B</xref>). We speculate that as the dual&#8208;task complexity increased, some participants may have prioritized the motor task over the cognitive task, while others may have found the dual task too difficult to maintain focus on the working memory component, thus reducing the effort and performance during the seated single&#8208;task condition.</p><p>Other studies in cognitively intact older adults have demonstrated the relationship between faster GS and better cognitive performance on memory, executive function, and overall global cognition.<xref rid="trc270156-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Similarly, in cognitively intact older adults, longitudinal tracking of GS and cognitive function suggests that a faster GS<xref rid="trc270156-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> and slower declines in GS are both associated with better executive function irrespective of baseline cognitive impairment,<xref rid="trc270156-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and altered gait metrics precede changes in cognitive function by up to 12 years in people who develop MCI.<xref rid="trc270156-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Previous work by Jor'dan et&#160;al.<xref rid="trc270156-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> highlighted asynchronous relationships between compromised gait performance (e.g., increased double support time and shorter stride lengths) and reduced neurovascular coupling on an n&#8208;back test; however, dual&#8208;task cost was not evident in their cognitively intact cohort. We have provided confirmational evidence that the MCA velocity response to a motor control stimulus is associated with decreased cognitive function (Figure&#160;<xref rid="trc270156-fig-0002" ref-type="fig">2</xref>). We have established that during physical activity, such as overground walking during a single task or a dual task, participants who are able to maintain MCA velocity, relative to their supine resting values, also walk faster. This relationship between higher MCA velocity with faster GS and greater MoCA scores was maintained even after increasing the cognitive&#8211;motor interface by adding the working memory task (dual task). To the best of our knowledge, this is the first study to simultaneously demonstrate the interconnection between cerebrovascular hemodynamics with GS and cognition.</p><p>We observed that neurovascular coupling responses from a single task (walking) to the dual task had a significant and positive weight in the multiple linear regression, indicating that after accounting for the other variables in the model, those participants with greater increases in MCA velocity were expected to have higher MoCA scores. Increasing the cognitive complexity beyond simple walking by simultaneously engaging in an executive function task inherently increases the attentional demands of both tasks. This increased workload potentially exceeds the attentional capacity of the cerebral networks and results in a larger dual&#8208;task cost. Although the process remains unclear, older adults are less able to recruit additional neural resources to compensate for the increase in task demands, and therefore they have greater dual&#8208;task costs.<xref rid="trc270156-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> In people with MCI, a high dual&#8208;task cost, observed as a slower GS, has previously been associated with increased rates of progression to dementia.<xref rid="trc270156-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Mechanistically, our results provide novel evidence that people with a greater dual&#8208;task cost of GS are less able to increase cerebral blood flow when the cognitive load increases from a single task to a dual task (Figure&#160;<xref rid="trc270156-fig-0004" ref-type="fig">4A</xref>). Combining this with our findings from the multiple linear regression (Table&#160;<xref rid="trc270156-tbl-0002" ref-type="table">2</xref>), it becomes clear that the increase of MCA velocity is intimately linked with cognitive performance, particularly when including multiple brain networks (Figure&#160;<xref rid="trc270156-fig-0004" ref-type="fig">4B</xref>). GS is an indicator of physical fitness; however, it should also be considered a factor in cognitive fitness.</p><p>When separating participants into groups, MCA velocity had a group&#8208;by&#8208;condition effect. However, after a Greenhouse Geisser correction factor, the results no longer met statistically significant values (<italic toggle="yes">p</italic> = 0.052). These relationships suggest further investigation is required to examine potential mechanisms associated with MCA velocity changes from a seated single task to a walking single task to a dual&#8208;task condition. Comparing a single task to a dual task, cognitive complexity increases. Mirelman et&#160;al. report that increased cognitive complexity is related to hyperemic responses of the prefrontal cortex.<xref rid="trc270156-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Speculatively, the DEM group has the lowest average MCA velocity during all conditions, whereas the CNT group demonstrated the highest average MCA velocities during the single task of walking and the dual task (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>). Although MCA velocity was not significantly different between groups, the observed trends (interaction <italic toggle="yes">p</italic> = 0.052) warrant further investigation. As expected, GS was also tiered in performance from CNT to DEM, with those in the CNT group having the fastest GS. The tiered response of MCA velocity and GS between groups highlights that studying MCA velocity during physical activity is a useful way to discern the cognitive abilities of the body to complete complex motor tasks. Interestingly, performance on the n&#8208;back task was only tiered during the dual task and not the single task (Figure&#160;<xref rid="trc270156-fig-0003" ref-type="fig">3</xref>). This suggests when the cognitive processes become more complex by adding a motor task to the working memory task, those in the more impaired group (DEM) are less able to modulate MCA velocity to meet the increase in metabolic demands.</p><p>MCA velocity is influenced by a complex interplay of physiological factors, including changes in systemic blood pressure, circulating levels of oxygen and carbon dioxide, and autoregulation. It is not currently possible to measure continuous ambulatory blood pressure. However, Fitzgibbon&#8208;Collins et&#160;al. previously demonstrated that when transitioning from supine to standing, cerebrovascular resistance index is significantly higher in DEM versus CNT; stroke volume is lower in DEM versus MCI; and blood pressure, total peripheral resistance, and cardiac output are not different between CNT, MCI, and DEM.<xref rid="trc270156-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The authors reported supine ETCO<sub>2</sub> to be lower in the DEM versus MCI and standing oxygenated hemoglobin content to decrease more in DEM compared to CNT and MCI.<xref rid="trc270156-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Collectively, it can be inferred that lower MCA velocity in DEM participants is in part attributed to cerebrovascular, cardiovascular, and respiratory mechanisms. Furthermore, we have previously demonstrated in people with MCI that those with higher standing MCA velocity also have better dynamic cerebral autoregulation, which is speculatively a compensatory mechanism.<xref rid="trc270156-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> These previous findings prove insightful to the current study, which focused on investigating the relationships between MCA velocity from single task to dual task, as well as dual&#8208;task cost, rather than the various regulators of MCA velocity.</p><sec id="trc270156-sec-0230"><label>4.1</label><title>Future considerations</title><p>During bouts of physical activity, cognitive function transiently improves in cognitively intact younger and older adults.<xref rid="trc270156-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Aerobic exercise interventions in older adults have identified both cardiovascular benefits and improved resting MCA velocity,<xref rid="trc270156-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and greater self&#8208;reported levels of physical activity are related to a lower risk of dementia.<xref rid="trc270156-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="trc270156-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> There are many unexplored benefits of sustained MCA velocity (over longer periods of time) on cognition and in neurodegenerative disease. Assessing MCA velocity in a dual&#8208;task paradigm may provide an excellent way to measure both neurovascular coupling and treatment responses during physical activity to further elucidate the relationships among physical activity, cerebrovascular health, and cognitive function.</p><p>Epidemiological studies linking cardiovascular indicators with dementia are well established.<xref rid="trc270156-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="trc270156-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="trc270156-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="trc270156-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Forty percent of dementia risk is modifiable, and 30% of the risk factors align with cardiovascular disease (e.g., hypertension, diabetes, and obesity).<xref rid="trc270156-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Cardiovascular disease (e.g., hypertension and vascular stiffness) is linked to core features of Alzheimer's disease,<xref rid="trc270156-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> and aerobic exercise has been shown to improve not only cardiovascular health but also cerebrovascular regulation and cognition in older adults.<xref rid="trc270156-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Preventative or intervention strategies focused on improving vascular health should be considered to advance patient care for adults at risk of cognitive impairment.</p></sec><sec id="trc270156-sec-0240"><label>4.2</label><title>Limitations</title><p>At present, commercially available ambulatory devices which collect continuous blood pressure are not available. Therefore, the impact of mean arterial pressure and a derived cerebrovascular resistance index from mean arterial pressure cannot be accounted for, and the observed changes in MCA velocity are limited. We have previously reported that when going from supine to standing, cerebrovascular resistance index, stroke volume, ETCO<sub>2</sub>, and relative changes in oxygenated hemoglobin content differ between clinical cohorts of CNT, MCI, and DEM,<xref rid="trc270156-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> indicating that cerebrovascular, cardiovascular, and respiratory systems contribute to the changes in MCA velocity in the current study.</p><p>Additional study limitations to consider are: (1) the implication of a medical mask on ETCO<sub>2</sub>, (2) the limited randomization of the seated single task, (3) the consideration of intrinsic neuronal damage by pathological processes, (4) age&#8208;related implications for the DEM group, and (5) neuromuscular attributes known to impact mobility metrics in older adults. A detailed description of these study limitations is provided in <xref rid="trc270156-supinfo-0001" ref-type="">Supplement C</xref> in Supporting Information.</p></sec></sec><sec id="trc270156-sec-0250"><label>5</label><title>CONCLUSIONS</title><p>Neurocognitive bandwidth becomes curtailed in aging and with neurological disorders such as dementia. Dual&#8208;task cost is suggested to be the earliest symptom of underlying neurodegenerative disease that has not yet developed into dementia.<xref rid="trc270156-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> We have developed a new way to measure cerebral blood flow in older adults, which uses changes in MCA velocity to measure dual&#8208;task cost and cognitive function. This is the first study, to our knowledge, that has demonstrated greater hyperemic responses of MCA velocity with better global and domain&#8208;specific cognitive performance during ambulatory dual tasking. The functional capacity of cerebral blood flow suggests vascular properties may be considered an early biomarker indicative of subclinical cognitive function and can be a useful proxy for the assessments of complex brain processes. The future direction of this research should be aimed at identifying vascular deficits earlier to treat memory problems sooner, not only adding more years to life but more life to those years.</p></sec><sec sec-type="COI-statement" id="trc270156-sec-0270"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest. Author disclosures are available in the <xref rid="trc270156-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="trc270156-sec-0280"><title>CONSENT STATEMENT</title><p>All participants provided informed and written consent to participate in this study.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="trc270156-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="trc270156-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRC2-11-e70156-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="trc270156-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRC2-11-e70156-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="trc270156-sec-0260"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank Dr. Richard Hughson from the Schlegel&#8208;University of Waterloo Research Institute for Aging, Waterloo, ON, for supporting this project. This&#160;work was funded by the&#160;Academic Medical Organization of Southwestern Ontario&#160;(AMOSO)&#160;Opportunities Fund Project (grant number F20&#8208;004, J.B.), the Parkwood Institute Research Endowment&#160;Fund: In Care of Older Adults (L.K.F.C.), and the Vascular Training Platform (L.K.F.C.).</p></ack><ref-list id="trc270156-bibl-0001"><title>REFERENCES</title><ref id="trc270156-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="trc270156-cite-0002"><string-name name-style="western"><surname>Jor'Dan</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Poole</surname><given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>Iloputaife</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Executive network activation is linked to walking speed in older adults: functional MRI and TCD ultrasound evidence from the MOBILIZE Boston Study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2017</year>;<volume>72</volume>(<issue>12</issue>):<fpage>1669</fpage>&#8208;<lpage>1675</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glx063</pub-id><pub-id pub-id-type="pmid">28449077</pub-id><pub-id pub-id-type="pmcid">PMC5861979</pub-id></mixed-citation></ref><ref id="trc270156-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="trc270156-cite-0003"><string-name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mahoney</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Izzetoglu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Izzetoglu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Onaral</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>J</given-names></string-name>. <article-title>fNIRS study of walking and walking while talking in young and old individuals</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2011</year>;<volume>66</volume>A(<issue>8</issue>):<fpage>879</fpage>&#8208;<lpage>887</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glr068</pub-id><pub-id pub-id-type="pmid">21593013</pub-id><pub-id pub-id-type="pmcid">PMC3148759</pub-id></mixed-citation></ref><ref id="trc270156-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="trc270156-cite-0004"><string-name name-style="western"><surname>Jor'dan</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Manor</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Iloputaife</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Diminished locomotor control is associated with reduced neurovascular coupling in older adults</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2020</year>;<volume>75</volume>(<issue>8</issue>):<fpage>1516</fpage>&#8208;<lpage>1522</lpage>. doi:<pub-id pub-id-type="doi">10.1093/GERONA/GLZ006</pub-id><pub-id pub-id-type="pmid">30629129</pub-id><pub-id pub-id-type="pmcid">PMC7357586</pub-id></mixed-citation></ref><ref id="trc270156-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="trc270156-cite-0005"><string-name name-style="western"><surname>Sorond</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Kiely</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Galica</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Neurovascular coupling is impaired in slow walkers: the MOBILIZE Boston Study</article-title>. <source>Ann Neurol</source>. <year>2011</year>;<volume>70</volume>(<issue>2</issue>):<fpage>213</fpage>&#8208;<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.22433</pub-id><pub-id pub-id-type="pmid">21674588</pub-id><pub-id pub-id-type="pmcid">PMC3152682</pub-id></mixed-citation></ref><ref id="trc270156-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="trc270156-cite-0006"><string-name name-style="western"><surname>Attwell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Buchan</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Charpak</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lauritzen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>MacVicar</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Newman</surname><given-names>EA</given-names></string-name>. <article-title>Glial and neuronal control of brain blood flow</article-title>. <source>Nature</source>. <year>2010</year>;<volume>468</volume>(<issue>7321</issue>):<fpage>232</fpage>&#8208;<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09613</pub-id><pub-id pub-id-type="pmid">21068832</pub-id><pub-id pub-id-type="pmcid">PMC3206737</pub-id></mixed-citation></ref><ref id="trc270156-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="trc270156-cite-0007"><string-name name-style="western"><surname>Gourine</surname><given-names>A V.</given-names></string-name>, <string-name name-style="western"><surname>Llaudet</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Spyer</surname><given-names>KM</given-names></string-name>. <article-title>ATP is a mediator of chemosensory transduction in the central nervous system</article-title>. <source>Nature</source>. <year>2005</year>;<volume>436</volume>(<issue>7047</issue>):<fpage>108</fpage>&#8208;<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03690</pub-id><pub-id pub-id-type="pmid">16001070</pub-id></mixed-citation></ref><ref id="trc270156-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="trc270156-cite-0008"><string-name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></string-name>. <article-title>The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease</article-title>. <source>Neuron</source>. <year>2017</year>;<volume>96</volume>(<issue>1</issue>):<fpage>17</fpage>&#8208;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.030</pub-id><pub-id pub-id-type="pmid">28957666</pub-id><pub-id pub-id-type="pmcid">PMC5657612</pub-id></mixed-citation></ref><ref id="trc270156-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="trc270156-cite-0009"><string-name name-style="western"><surname>Shabir</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Berwick</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Francis</surname><given-names>SE</given-names></string-name>. <article-title>Neurovascular dysfunction in vascular dementia, Alzheimer's and atherosclerosis</article-title>. <source>BMC Neurosci</source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>62</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12868-018-0465-5</pub-id><pub-id pub-id-type="pmid">30333009</pub-id><pub-id pub-id-type="pmcid">PMC6192291</pub-id></mixed-citation></ref><ref id="trc270156-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="trc270156-cite-0010"><string-name name-style="western"><surname>Quick</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rajani</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>A</given-names></string-name>. <article-title>A Vessel for change: endothelial dysfunction in cerebral small vessel disease</article-title>. <source>Trends Neurosci</source>. <year>2021</year>;<volume>44</volume>(<issue>4</issue>):<fpage>289</fpage>&#8208;<lpage>305</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tins.2020.11.003</pub-id><pub-id pub-id-type="pmid">33308877</pub-id></mixed-citation></ref><ref id="trc270156-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="trc270156-cite-0011"><string-name name-style="western"><surname>Pieruccini&#8208;Faria</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Masellis</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>8</issue>):<fpage>1317</fpage>&#8208;<lpage>1328</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12298</pub-id><pub-id pub-id-type="pmid">33590967</pub-id><pub-id pub-id-type="pmcid">PMC8451764</pub-id></mixed-citation></ref><ref id="trc270156-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="trc270156-cite-0012"><string-name name-style="western"><surname>Jessen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Amariglio</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Van Boxtel</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease</article-title>. <source>Alzheimer Dement</source>. <year>2014</year>;<volume>10</volume>(<issue>6</issue>):<fpage>844</fpage>&#8208;<lpage>852</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2014.01.001</pub-id><pub-id pub-id-type="pmcid">PMC4317324</pub-id><pub-id pub-id-type="pmid">24798886</pub-id></mixed-citation></ref><ref id="trc270156-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="trc270156-cite-0013"><string-name name-style="western"><surname>Vermeij</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kessels</surname><given-names>RPC</given-names></string-name>, <string-name name-style="western"><surname>Heskamp</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Simons</surname><given-names>EMF</given-names></string-name>, <string-name name-style="western"><surname>Dautzenberg</surname><given-names>PLJ</given-names></string-name>, <string-name name-style="western"><surname>Claassen</surname><given-names>JAHR</given-names></string-name>. <article-title>Prefrontal activation may predict working&#8208;memory training gain in normal aging and mild cognitive impairment</article-title>. <source>Brain Imaging Behav</source>. <year>2017</year>;<volume>11</volume>(<issue>1</issue>):<fpage>141</fpage>&#8208;<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11682-016-9508-7</pub-id><pub-id pub-id-type="pmid">26843001</pub-id><pub-id pub-id-type="pmcid">PMC5415588</pub-id></mixed-citation></ref><ref id="trc270156-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="trc270156-cite-0014"><string-name name-style="western"><surname>McNamara</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>JL</given-names></string-name>. <article-title>Working memory capacity and strategy use</article-title>. <source>Mem Cognit</source>. <year>2001</year>;<volume>29</volume>(<issue>1</issue>):<fpage>10</fpage>&#8208;<lpage>17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/bf03195736</pub-id><pub-id pub-id-type="pmid">11277453</pub-id></mixed-citation></ref><ref id="trc270156-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="trc270156-cite-0015"><string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cattaneo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>The age&#8208;related contribution of cognitive function to dual&#8208;task gait in middle&#8208;aged adults in Spain: observations from a population&#8208;based study</article-title>. <source>Lancet Healthy Longev</source>. <year>2023</year>;<volume>4</volume>(<issue>3</issue>):<fpage>e98</fpage>&#8208;<lpage>e106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-7568(23)00009-0</pub-id><pub-id pub-id-type="pmid">36870341</pub-id><pub-id pub-id-type="pmcid">PMC9992865</pub-id></mixed-citation></ref><ref id="trc270156-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="trc270156-cite-0016"><string-name name-style="western"><surname>Boles Ponto</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Magnotta</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Moser</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Duff</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>SK</given-names></string-name>. <article-title>Global cerebral blood flow in relation to cognitive performance and reserve in subjects with mild memory deficits</article-title>. <source>Mol Imaging Biol</source>. <year>2006</year>;<volume>8</volume>(<issue>6</issue>):<fpage>363</fpage>&#8208;<lpage>372</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11307-006-0066-z</pub-id><pub-id pub-id-type="pmid">17048070</pub-id></mixed-citation></ref><ref id="trc270156-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="trc270156-cite-0017"><string-name name-style="western"><surname>Lipnicki</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Crawford</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Dutta</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Age&#8208;related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study</article-title>. <source>PLoS Med</source>. <year>2017</year>;<volume>14</volume>(<issue>3</issue>):<elocation-id>e1002261</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1002261</pub-id><pub-id pub-id-type="pmid">28323832</pub-id><pub-id pub-id-type="pmcid">PMC5360220</pub-id></mixed-citation></ref><ref id="trc270156-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="trc270156-cite-0018"><string-name name-style="western"><surname>Gatouillat</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bleton</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>VanSwearingen</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Cognitive tasks during walking affect cerebral blood flow signal features in middle cerebral arteries and their correlation to gait characteristics</article-title>. <source>Behav. Brain Funct</source>. <year>2015</year>;<volume>11</volume>(<issue>1</issue>):<fpage>29</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12993-015-0073-9</pub-id><pub-id pub-id-type="pmid">26409878</pub-id><pub-id pub-id-type="pmcid">PMC4583750</pub-id></mixed-citation></ref><ref id="trc270156-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="trc270156-cite-0019"><string-name name-style="western"><surname>Montero&#8208;Odasso</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Sarquis&#8208;Adamson</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Speechley</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Association of dual&#8208;task gait with incident dementia in mild cognitive impairment: Results from the gait and brain study</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>(<issue>7</issue>):<fpage>857</fpage>&#8208;<lpage>865</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2017.0643</pub-id><pub-id pub-id-type="pmid">28505243</pub-id><pub-id pub-id-type="pmcid">PMC5710533</pub-id></mixed-citation></ref><ref id="trc270156-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="trc270156-cite-0020"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Savica</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Assessing the temporal relationship between cognition and gait: Slow gait predicts cognitive decline in the mayo clinic study of aging</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2013</year>;<volume>68</volume>(<issue>8</issue>):<fpage>929</fpage>&#8208;<lpage>937</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gls256</pub-id><pub-id pub-id-type="pmid">23250002</pub-id><pub-id pub-id-type="pmcid">PMC3712358</pub-id></mixed-citation></ref><ref id="trc270156-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="trc270156-cite-0021"><string-name name-style="western"><surname>Callisaya</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Blizzard</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Thrift</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Wardill</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Srikanth</surname><given-names>VK</given-names></string-name>. <article-title>Longitudinal relationships between cognitive decline and gait slowing: the Tasmanian Study of Cognition and Gait</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2014</year>;<volume>70</volume>(<issue>10</issue>):<fpage>1226</fpage>&#8208;<lpage>1232</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glv066</pub-id><pub-id pub-id-type="pmid">26009641</pub-id></mixed-citation></ref><ref id="trc270156-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="trc270156-cite-0022"><string-name name-style="western"><surname>Buracchio</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dodge</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wasserman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kaye</surname><given-names>J</given-names></string-name>. <source>Arch Neurol.</source><year>2010</year>;<volume>67</volume>(<issue>8</issue>):<fpage>980</fpage>&#8208;<lpage>986</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneurol.2010.159</pub-id><pub-id pub-id-type="pmid">20697049</pub-id><pub-id pub-id-type="pmcid">PMC2921227</pub-id></mixed-citation></ref><ref id="trc270156-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="trc270156-cite-0023"><string-name name-style="western"><surname>Mirelman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maidan</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bernad&#8208;Elazari</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shustack</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giladi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hausdorff</surname><given-names>JM</given-names></string-name>. <article-title>Effects of aging on prefrontal brain activation during challenging walking conditions</article-title>. <source>Brain Cogn</source>. <year>2017</year>;<volume>115</volume>:<fpage>41</fpage>&#8208;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bandc.2017.04.002</pub-id><pub-id pub-id-type="pmid">28433922</pub-id></mixed-citation></ref><ref id="trc270156-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="trc270156-cite-0024"><string-name name-style="western"><surname>Fitzgibbon&#8208;Collins</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Coombs</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Noguchi</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Standing middle cerebral artery velocity predicts cognitive function and gait speed in older adults with cognitive impairment, and is impacted by sex differences</article-title>. <source>Cereb Circ Cogn Behav</source>. <year>2024</year>;<volume>12</volume>(<issue>6</issue>):<elocation-id>100198</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.cccb.2023.100198</pub-id><pub-id pub-id-type="pmcid">PMC10827680</pub-id><pub-id pub-id-type="pmid">38298456</pub-id></mixed-citation></ref><ref id="trc270156-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="trc270156-cite-0025"><string-name name-style="western"><surname>Fitzgibbon&#8208;Collins</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Borrie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shoemaker</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Bhangu</surname><given-names>J</given-names></string-name>. <article-title>Altered dynamic cerebral autoregulation in people with mild cognitive impairment</article-title>. <source>J. Cerebral Blood Flow Metabolism</source>. Published online Jun 3, 2025:271678X251345361. doi:<pub-id pub-id-type="doi">10.1177/0271678x251345361</pub-id><pub-id pub-id-type="pmcid">PMC12133788</pub-id><pub-id pub-id-type="pmid">40458006</pub-id></mixed-citation></ref><ref id="trc270156-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="trc270156-cite-0026"><string-name name-style="western"><surname>Lucas</surname><given-names>SJE</given-names></string-name>, <string-name name-style="western"><surname>Ainslie</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Murrell</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Franz</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Cotter</surname><given-names>JD</given-names></string-name>. <article-title>Effect of age on exercise&#8208;induced alterations in cognitive executive function: Relationship to cerebral perfusion</article-title>. <source>Exp Gerontol</source>. <year>2012</year>;<volume>47</volume>(<issue>8</issue>):<fpage>541</fpage>&#8208;<lpage>551</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exger.2011.12.002</pub-id><pub-id pub-id-type="pmid">22230488</pub-id></mixed-citation></ref><ref id="trc270156-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="trc270156-cite-0027"><string-name name-style="western"><surname>Lake</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Guadagni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kendall</surname><given-names>KD</given-names></string-name>, et&#160;al. <article-title>Aerobic exercise training in older men and women&#8212;cerebrovascular responses to submaximal exercise: Results from the Brain in Motion study</article-title>. <source>Physiol Rep</source>. <year>2022</year>;<volume>10</volume>(<issue>4</issue>):<elocation-id>e15158</elocation-id>. doi:<pub-id pub-id-type="doi">10.14814/phy2.15158</pub-id><pub-id pub-id-type="pmid">35212167</pub-id><pub-id pub-id-type="pmcid">PMC8874289</pub-id></mixed-citation></ref><ref id="trc270156-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="trc270156-cite-0028"><string-name name-style="western"><surname>Bherer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Erickson</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Liu&#8208;Ambrose</surname><given-names>T</given-names></string-name>. <article-title>A review of the effects of physical activity and exercise on cognitive and brain functions in older adults</article-title>. <source>J Aging Res</source>. <year>2013</year>;<volume>2013</volume>:<elocation-id>657508</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2013/657508</pub-id><pub-id pub-id-type="pmid">24102028</pub-id><pub-id pub-id-type="pmcid">PMC3786463</pub-id></mixed-citation></ref><ref id="trc270156-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="trc270156-cite-0029"><string-name name-style="western"><surname>Phillips</surname><given-names>C</given-names></string-name>. <article-title>Lifestyle modulators of neuroplasticity: how physical activity, mental engagement, and diet promote cognitive health during aging</article-title>. <source>Neural Plast</source>. <year>2017</year>;<volume>2017</volume>:<elocation-id>3589271</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2017/3589271</pub-id><pub-id pub-id-type="pmid">28695017</pub-id><pub-id pub-id-type="pmcid">PMC5485368</pub-id></mixed-citation></ref><ref id="trc270156-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="trc270156-cite-0030"><string-name name-style="western"><surname>Garc&#237;a&#8208;Lluch</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pardo Albiach</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pe&#241;a&#8208;Bautista</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baquero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ch&#225;fer&#8208;Peric&#225;s</surname><given-names>C</given-names></string-name>. <article-title>Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions</article-title>. <source>J Prevention Alzheimers Dis</source>. <year>2024</year>;<volume>11</volume>(<issue>2</issue>):<fpage>453</fpage>&#8208;<lpage>462</lpage>. doi:<pub-id pub-id-type="doi">10.14283/jpad.2024.16</pub-id><pub-id pub-id-type="pmid">38374752</pub-id></mixed-citation></ref><ref id="trc270156-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="trc270156-cite-0031"><string-name name-style="western"><surname>Ponjoan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blanch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fages&#8208;Masmiquel</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Sex matters in the association between cardiovascular health and incident dementia: evidence from real world data</article-title>. <source>Alzheimers Res Ther</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>58</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-024-01406-x</pub-id><pub-id pub-id-type="pmid">38481343</pub-id><pub-id pub-id-type="pmcid">PMC10938682</pub-id></mixed-citation></ref><ref id="trc270156-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="trc270156-cite-0032"><string-name name-style="western"><surname>Dong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Sex differences in the association between cardiovascular diseases and dementia subtypes: a prospective analysis of 464,616 UK Biobank participants</article-title>. <source>Biol Sex Differ</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13293-022-00431-5</pub-id><pub-id pub-id-type="pmid">35526028</pub-id><pub-id pub-id-type="pmcid">PMC9080133</pub-id></mixed-citation></ref><ref id="trc270156-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="trc270156-cite-0033"><string-name name-style="western"><surname>de Bruijn</surname><given-names>RFAG</given-names></string-name>, <string-name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></string-name>. <article-title>Cardiovascular risk factors and future risk of Alzheimer's disease</article-title>. <source>BMC Med</source>. <year>2014</year>;<volume>12</volume>(<issue>1</issue>):<fpage>130</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-014-0130-5</pub-id><pub-id pub-id-type="pmid">25385322</pub-id><pub-id pub-id-type="pmcid">PMC4226863</pub-id></mixed-citation></ref><ref id="trc270156-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="trc270156-cite-0034"><collab collab-type="authors">World Health Organization</collab>
. <article-title>Risk reduction of cognitive decline and dementia WHO guidelines</article-title>. Accessed October 27, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK542801/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK542801/</ext-link><year>2019</year>.<pub-id pub-id-type="pmid">31219687</pub-id></mixed-citation></ref><ref id="trc270156-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="trc270156-cite-0035"><string-name name-style="western"><surname>Claassen</surname><given-names>JAHR</given-names></string-name>. <article-title>New cardiovascular targets to prevent late onset Alzheimer disease</article-title>. <source>Eur J Pharmacol</source>. <year>2015</year>;<volume>763</volume>:<fpage>131</fpage>&#8208;<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejphar.2015.05.022</pub-id><pub-id pub-id-type="pmid">25987416</pub-id></mixed-citation></ref><ref id="trc270156-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="trc270156-cite-0036"><string-name name-style="western"><surname>Guadagni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Drogos</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Tyndall</surname><given-names>A V.</given-names></string-name>, et&#160;al. <article-title>Aerobic exercise improves cognition and cerebrovascular regulation in older adults</article-title>. <source>Neurology</source>. <year>2020</year>;<volume>94</volume>(<issue>21</issue>):<fpage>e2245</fpage>&#8208;<lpage>e2257</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000009478</pub-id><pub-id pub-id-type="pmid">32404355</pub-id><pub-id pub-id-type="pmcid">PMC7357295</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70057" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504064</article-id><article-id pub-id-type="pmcid-ver">PMC12504064.1</article-id><article-id pub-id-type="pmcaid">12504064</article-id><article-id pub-id-type="pmcaiid">12504064</article-id><article-id pub-id-type="doi">10.1002/alz.70057</article-id><article-id pub-id-type="publisher-id">ALZ70057</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data</article-title><alt-title alt-title-type="left-running-head">CHU <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70057-cr-0001" contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="C">Chenyin</given-names></name><xref rid="alz70057-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70057-cr-0002" contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="L">Liwei</given-names></name><xref rid="alz70057-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70057-cr-0003" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yihan</given-names></name><xref rid="alz70057-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70057-cr-0004" contrib-type="author"><name name-style="western"><surname>Huynh</surname><given-names initials="ALH">Andrew L. H.</given-names></name><xref rid="alz70057-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70057-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70057-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70057-cr-0005" contrib-type="author"><name name-style="western"><surname>Dunstan</surname><given-names initials="MK">Megan K.</given-names></name><xref rid="alz70057-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70057-cr-0006" contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="X">Xinran</given-names></name><xref rid="alz70057-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70057-cr-0007" contrib-type="author"><name name-style="western"><surname>Masters</surname><given-names initials="CL">Colin L.</given-names></name><xref rid="alz70057-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70057-cr-0008" contrib-type="author"><name name-style="western"><surname>Goudey</surname><given-names initials="B">Benjamin</given-names></name><xref rid="alz70057-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70057-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Jin</surname><given-names initials="L">Liang</given-names></name><xref rid="alz70057-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>liang.jin@monash.edu</email></address></contrib><contrib id="alz70057-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Pan</surname><given-names initials="Y">Yijun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1442-3333</contrib-id><xref rid="alz70057-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Yijun.Pan@monash.edu</email></address></contrib></contrib-group><aff id="alz70057-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>School of Translational Medicine, Monash University</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70057-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>The Florey Institute of Neuroscience and Mental Health</institution>
<city>Parkville</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70057-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Aged Care</named-content>
<institution>Austin Health</institution>
<city>Heidelberg</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70057-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Austin Health</named-content>
<institution>The University of Melbourne</institution>
<city>Heidelberg</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70057-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Australian BioCommons</named-content>
<institution>The University of Melbourne</institution>
<city>North Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Yijun Pan and Liang Jin, The Alfred Centre, 99 Commercial Road, Melbourne, Victoria 3004, Australia.<break/> Email: <email>Yijun.Pan@monash.edu</email> and <email>liang.jin@monash.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="370">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70057</elocation-id><history><date date-type="rev-recd"><day>28</day><month>1</month><year>2025</year></date><date date-type="received"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70057.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70057.pdf"/><abstract><title>Abstract</title><sec id="alz70057-sec-0010"><title>INTRODUCTION</title><p>Cerebral amyloid angiopathy (CAA) is associated with an increased risk of amyloid&#8208;related imaging abnormalities (ARIA) in patients with Alzheimer's disease using anti&#8208;amyloid beta (A&#946;) monoclonal antibody drugs. Here, we developed a tool, CAA risk score (CAARS) to predict the severity of CAA neuropathology.</p></sec><sec id="alz70057-sec-0020"><title>METHODS</title><p>The National Alzheimer's Coordinating Center (NACC) data were used to develop the CAARS, which was then externally validated using the Religious Orders Study and Memory and Aging Project (ROSMAP) data.</p></sec><sec id="alz70057-sec-0030"><title>RESULTS</title><p>The CAARS&#8208;4 model achieved a mean area under the receiver&#8208;operating characteristic (ROC) curve (AUC&#8208;ROC) of 0.71 (95% confidence interval [CI]: 0.69&#8211;0.72) and a Harrell's generalized C&#8208;index of 0.69 (95% CI: 0.68&#8211;0.71) in the NACC cohort validation. It outperformed the baseline models, and the promising performance was validated on ROSMAP participants, demonstrating the robustness and generalizability of the model.</p></sec><sec id="alz70057-sec-0040"><title>DISCUSSION</title><p>CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow&#8208;up studies.</p></sec><sec id="alz70057-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70057-list-0001"><list-item><p>Cerebral amyloid angiopathy (CAA) severity can only be confirmed postmortem.</p></list-item><list-item><p>CAA is associated with an elevated risk of amyloid&#8208;related imaging abnormalities (ARIA).</p></list-item><list-item><p>The CAA risk score (CAARS) can stratify CAA risks in living patients.</p></list-item><list-item><p>Hypertension and apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 are risk factors for CAA.</p></list-item><list-item><p>The CAARS has the potential to predict risk of ARIA.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70057-kwd-0001">amyloid&#8208;related imaging abnormalities</kwd><kwd id="alz70057-kwd-0002">AutoScore algorithm</kwd><kwd id="alz70057-kwd-0003">cerebral amyloid angiopathy</kwd><kwd id="alz70057-kwd-0004">machine learning</kwd><kwd id="alz70057-kwd-0005">risk stratification</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Health and Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000925</institution-id></institution-wrap></funding-source><award-id>GNT2007912</award-id><award-id>GNT2022203</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>23AARF&#8208;1020292</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="12"/><word-count count="7076"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70057-cite-0001"><string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70057</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70057</pub-id><pub-id pub-id-type="pmid">41057989</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70057-sec-0060"><label>1</label><title>BACKGROUND</title><p>Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid beta (A&#946;) proteins in the walls of cerebral blood vessels.<xref rid="alz70057-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Diagnosing CAA remains challenging, with the updated Boston Criteria 2.0 offering a clinical framework for identifying probable or possible CAA based on the characteristic hemorrhagic and white matter changes visible on brain magnetic resonance imaging (MRI) in individuals 50 years of age or older, provided that alternative causes are excluded.<xref rid="alz70057-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70057-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Definitive confirmation of CAA, however, requires postmortem brain examination, which remains the only method to accurately determine its severity, categorized as none, mild, moderate, or severe.<xref rid="alz70057-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>CAA has garnered increasing attention from clinicians and dementia researchers due to its association with amyloid&#8208;related imaging abnormalities (ARIA), a significant adverse effect observed in clinical trials of monoclonal antibody (MAB) therapies targeting A&#946; in Alzheimer's disease (AD).<xref rid="alz70057-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70057-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> ARIA is understood to result from increased inflammation and permeability of the blood vessels in the brain. This can result in increased brain swelling or edema (ARIA&#8208;E) or deposition of blood products in the brain and small microhemorrhages (ARIA&#8208;H).<xref rid="alz70057-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Although often asymptomatic, some patients with ARIA can experience serious adverse effects, including confusion, headaches, nausea, seizures, dizziness, and rarely, death. Once established, the presence of ARIA is further associated with an increased risk of intracerebral hemorrhage (or macro&#8208;hemorrhage) for patients with ARIA who later require antithrombotic, thrombolytic, or anticoagulation therapy for management of coronary artery disease, stroke, or atrial fibrillation.<xref rid="alz70057-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Considering the risks versus benefits associated with using MABs, clinicians may be hesitant to prescribe these new drugs to people with AD. Tools capable of assessing the severity of CAA and possibly predicting ARIA risk could facilitate informed risk&#8211;benefit discussions and enhance clinical decision&#8208;making. In addition, predictive tools could be adapted to stratify ARIA risk, aiding in the personalization of MRI monitoring protocols during MAB treatment.</p><p>In this study, we developed and validated a machine learning model, CAA risk score (CAARS). This model is built on an AutoScore and AutoScore&#8208;Ordinal algorithm, developed using data collected by National Alzheimer's Coordinating Center (NACC),<xref rid="alz70057-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70057-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70057-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and externally validated using data collected in the Religious Orders Study and Memory and Aging Project (ROSMAP).<xref rid="alz70057-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p></sec><sec id="alz70057-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70057-sec-0080"><label>2.1</label><title>Data sources and ethics</title><p>Data were collected from the NACC cohort for model development and validation. Established in 1999, the NACC is a comprehensive relational database comprising standardized clinical and neuropathological research data collected from Alzheimer's Disease Centers (ADCs) across the United States. Data collection was approved by institutional review boards at each ADC. Each ADC employed its own protocol to obtain informed consent from participants or, when participants were unable to provide consent, from their next of kin, carers, or legal guardians. Data from the NACC was requested via their official website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naccdata.org/" ext-link-type="uri">https://naccdata.org/</ext-link>. The Religious Orders Study (ROS) and The Memory and Aging Project (MAP) are longitudinal, epidemiologic clinical&#8208;pathological studies of aging and dementia, recruiting participants without known dementia in the United States, started in 1994 and 1997, respectively. ROSMAP study was approved by the Rush University Medical Centre Institutional Review Board, and all participants provided informed consent.&#160;ROSMAP data was obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.radc.rush.edu" ext-link-type="uri">https://www.radc.rush.edu</ext-link>. The current study analyzes the de&#8208;identified secondary data collected by NACC and ROSMAP, and informed consent or local ethical committee approval was therefore not required.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70057-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70057-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors conducted a comprehensive literature review using PubMed, Google Scholar, and Web of Science to explore existing machine learning models to predict cerebral amyloid angiopathy (CAA) severity. Currently, no machine learning model is available to satisfy this need in living patients.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We developed and validated the CAA risk score (CAARS) to predict CAA neuropathological severity. The model was constructed using the AutoScore algorithm, which automates the development of interpretable clinical scoring models. CAARS achieved promising prediction performance for National Alzheimer's Coordinating Center (NACC) participants, which was reproducible on the Religious Orders Study/Memory and Aging Project (ROSMAP) participants. The machine learning model and epidemiology analysis indicated that apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 and hypertension are risk factors for CAA.</p></list-item><list-item><p>
<bold>Future directions</bold>: CAARS holds the potential to predict risk of amyloid&#8208;related imaging abnormalities (ARIA), and to inform antithrombotic use and predict intracerebral hemorrhage risk in CAA. Its clinical utility should be validated in future studies.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70057-sec-0100"><label>2.2</label><title>Participants and variables</title><p>We used the NACC data for model development. A total of 7064 NACC participants who had postmortem CAA neuropathology characterized (none, mild, moderate, severe) were identified from the dataset. During data pre&#8208;processing, variables (potential predictors) with more than 10% missing data were excluded from analysis. The remaining variables are listed in eTable&#160;<xref rid="alz70057-supinfo-0001" ref-type="">1</xref>. Participants with missing values for any included variable were removed. This resulted in a final cohort of 4134 NACC participants for the study. Following the same procedure, we identified 1727 ROSMAP participants, and their data were used for external validation of the CAARS.</p></sec><sec id="alz70057-sec-0110"><label>2.3</label><title>CAARS model construction</title><p>The predicted outcome in our study is the severity of CAA pathology defined by neuropathologists&#8212;classified as none, mild, moderate, or severe&#8212;making it well&#8208;suited for modeling as an ordinal outcome. An alternative predicted outcome is the presence of CAA, classified as none versus mild/moderate/severe. The development of the CAARS leverages the AutoScore and AutoScore&#8208;Ordinal algorithms and their accompanying R packages.<xref rid="alz70057-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70057-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70057-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> An architecture framework has been prepared to illustrate the model construction process (eFigure&#160;<xref rid="alz70057-supinfo-0001" ref-type="">1</xref>).</p><p>The AutoScore and AutoScore&#8208;Ordinal algorithms consist of six modules. (1) Feature ranking: Variables are ranked by their importance using a random forest algorithm specifically designed for binary/ordinal classification tasks. (2) Variable transformation: Continuous variables are converted into categorical variables to enhance interpretability and accommodate potential nonlinear relationships with the outcome. This approach, commonly used in medical research, minimizes the impact of outliers on model performance.<xref rid="alz70057-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> (3) Score derivation: Variable weights are calculated using the cumulative link model, a robust regression method for ordinal outcome.<xref rid="alz70057-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> These weights are then normalized and rescaled to produce scores for each variable. (4) Feature selection: A parsimony analysis incorporating 10&#8208;fold cross&#8208;validation is conducted to determine the optimal number of variables, ensuring a balance between model simplicity and performance. (5) The algorithm&#8208;generated cutoff values for categorized variables are adjusted to align with standard clinical guidelines and norms to maintain clinical relevance. Categories with small sample sizes, which led to scores lacking clinical interpretation, were re&#8208;evaluated. (6) Model evaluation: The finalized model is evaluated on an unseen dataset to assess its predictive performance.</p><p>For this study, the NACC dataset was split into a training set (70%) and a test set (30%). The training set was used for Modules 1&#8211;5, and the test set was used for Module 6. Additional details on the AutoScore and AutoScore&#8208;Ordinal framework and data processing methods are provided in the <xref rid="alz70057-supinfo-0001" ref-type="">Supplementary Methods</xref>. We developed CAARS&#8208;4 categorizing CAA severity as none, mild, moderate, severe; and CAARS&#8208;2 to identify individuals at risk of developing CAA (none vs mild/moderate/severe). Each model addresses a different range and extent of severity to provide flexibility in clinical applications. This multi&#8208;model approach could possibly enhance clinical utility by providing tailored predictions for various stratification needs, paving the way for future research to determine the most effective risk assessment strategy.</p></sec><sec id="alz70057-sec-0120"><label>2.4</label><title>CAARS model evaluation</title><p>For CAARS&#8208;4, the model evaluation was conducted on the test set using two key metrics: the mean area under the receiver&#8208;operating characteristic (ROC) curve (mean AUC&#8208;ROC) and Harrell's generalized C&#8208;index. For classification tasks involving <italic toggle="yes">N</italic> categories, the problem was divided into <italic toggle="yes">N</italic>&#8722;1 binary classification tasks, and the mean AUC&#8208;ROC was calculated as the average AUC across these tasks.<xref rid="alz70057-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Harrell's generalized C&#8208;index measures the proportion of concordant pairs&#8212;those in which the predicted rankings correspond with the observed outcomes, including instances of tied ranks&#8212;relative to all possible observation pairs. This metric is widely utilized to assess the performance of classification models.<xref rid="alz70057-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70057-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> For both metrics, a value of 0.5 signifies random performance, whereas a value of 1 reflects perfect prediction. The evaluation results were supplemented with bias&#8208;corrected 95% bootstrap confidence intervals (CIs). Sensitivity and specificity were also calculated specifically for the CAARS&#8208;2 models, as these models address binary classification.</p><p>The performance of the CAARS models was compared against several baseline models, including a proportional odds model with LASSO feature selection (POM&#8208;1), a proportional odds model with stepwise feature selection (POM&#8208;2), and a proportional odds model utilizing features selected from Modules 1 and 4 of CAARS (POM&#8208;3). This comparison underscored the advantages of the CAARS&#8208;4 models, which employ AutoScore&#8208;Ordinal algorithms, over traditional ordinal outcome classification models. For binary classification, additional comparisons were made with logistic regression models that used random forest&#8211;based feature selection (logistic&#8208;base). These models were chosen as baselines due to their common use in binary classification tasks.</p></sec><sec id="alz70057-sec-0130"><label>2.5</label><title>External validation on ROSMAP data</title><p>To ensure the generalizability of the CAARS models, we conducted external validation using an independent cohort of 1727 participants from the ROSMAP. Due to differences between the two cohorts, only variables present in both were included. Although the AutoScore&#8208;Ordinal algorithm identifies features based on random forest feature selection and parsimony analysis, it is still possible to manually select variables for multi&#8208;cohort evaluations. To assess predictive accuracy, the CAARS model predictions were compared against clinical diagnoses. Performance was quantified using mean AUC&#8208;ROC and Harrell's generalized C&#8208;index, providing insights into the models&#8217; discriminative ability and overall concordance with clinical outcomes.</p></sec><sec id="alz70057-sec-0140"><label>2.6</label><title>Epidemiology analysis</title><p>A multivariable logistic regression model was employed to explore the targeted longitudinal associations between features selected for the CAARS and the risk of CAA. To avoid reverse causality between potential covariates and the risk of CAA, participants with a follow&#8208;up period of less than 5 years were excluded. A total of 2056 NACC participants were included for epidemiology analysis. To reduce survival and time&#8208;dependent biases, we adjusted for follow&#8208;up duration. In addition, to address potential confounding bias, we adjusted for sex, age, body mass index (BMI), apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 carrier status, and blood pressure (systolic and diastolic). All tests were two&#8208;sided, with statistical significance set at <italic toggle="yes">p&#160;</italic>&lt;&#160;.05.<xref rid="alz70057-tbl-0001" ref-type="table">&#8195;</xref>
</p></sec><sec id="alz70057-sec-0150"><label>2.7</label><title>Software and packages</title><p>All data preprocessing and analyses were performed using Python version 3.9, RStudio version 12.0+369, and Stata software (version 17.0). The developed model relies on the AutoScore package in the R 3.5.3 programming environment (R Foundation).<xref rid="alz70057-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> This package facilitates the streamlined creation of point&#8208;based clinical scoring models for outcome prediction, reducing the need for extensive manual input in tasks such as data processing, parameter tuning, and model optimization.</p></sec></sec><sec id="alz70057-sec-0160"><label>3</label><title>RESULTS</title><sec id="alz70057-sec-0170"><label>3.1</label><title>Participant characteristics</title><p>The CAARS model was developed using an AutoScore&#8208;Ordinal algorithm, based on data from 4134 participants in the NACC cohort, which is then externally evaluated on 1727 ROSMAP participants. For the NACC participants, the mean baseline age was 75.31 years (SD&#160;=&#160;10.01), with 43.7% <italic toggle="yes">APOE</italic> &#949;4 carriers. The cohort comprised 47.2% women, with an average education level of 15.68 years (SD&#160;=&#160;2.86). At the time of death, neuropathological diagnoses of CAA were distributed as follows: 39.1% none, 30.6% mild, 19.5% moderate, and 11.8% severe. The ROSMAP participants had a mean baseline age of 80.10 years (SD&#160;=&#160;7.00), with 25.8% <italic toggle="yes">APOE</italic> &#949;4 carriers. The cohort included 68.9% women and had an average education level of 16.29 years (SD&#160;=&#160;3.58). At the time of death, neuropathological diagnoses of CAA were distributed as follows: 21.3% none, 41.0% mild, 23.0% moderate, and 14.7% severe. Detailed participant characteristics are provided in Table&#160;<xref rid="alz70057-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="alz70057-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Features</th><th align="left" rowspan="1" colspan="1">NACC (<italic toggle="yes">n</italic>&#160;= 4134)</th><th align="left" rowspan="1" colspan="1">ROSMAP (<italic toggle="yes">n</italic>&#160;= 1727)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">75.31 (10.01)</td><td align="left" rowspan="1" colspan="1">80.10 (7.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Female: 1952, Male: 2182</td><td align="left" rowspan="1" colspan="1">Female: 1190, Male: 537</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="left" rowspan="1" colspan="1">26.44 (4.68)</td><td align="left" rowspan="1" colspan="1">26.77 (4.89)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years)</td><td align="left" rowspan="1" colspan="1">15.68 (2.86)</td><td align="left" rowspan="1" colspan="1">16.29 (3.58)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> genotype</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;3: 1962; &#949;4/&#949;3: 1339; &#949;3/&#949;2: 347; &#949;4/&#949;4: 340; &#949;4/&#949;2: 126; &#949;2/&#949;2: 20</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;3: 1061; &#949;4/&#949;3: 382; &#949;3/&#949;2: 211; &#949;4/&#949;4: 30; &#949;4/&#949;2: 33; &#949;2/&#949;2: 10</td></tr><tr><td align="left" rowspan="1" colspan="1">Time after baseline (years)</td><td align="left" rowspan="1" colspan="1">5.07 (3.60)</td><td align="left" rowspan="1" colspan="1">8.95 (5.81)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">74.08 (10.46)</td><td align="left" rowspan="1" colspan="1">72.62 (10.75)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">134.70 (18.66)</td><td align="left" rowspan="1" colspan="1">135.71 (17.81)</td></tr><tr><td align="left" rowspan="1" colspan="1">WAIS&#8208;R</td><td align="left" rowspan="1" colspan="1">33.66 (14.47)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (per minute)</td><td align="left" rowspan="1" colspan="1">67.50 (10.64)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Animal naming test<xref rid="alz70057-tbl1-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">14.84 (6.31)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Logical memory test<xref rid="alz70057-tbl1-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">8.35 (5.53)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Boston naming test (30 items)</td><td align="left" rowspan="1" colspan="1">24.00 (5.92)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Geriatric Depression Scale</td><td align="left" rowspan="1" colspan="1">2.17 (2.44)</td><td align="left" rowspan="1" colspan="1">1.14 (1.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mini&#8208;Mental State Examination</td><td align="left" rowspan="1" colspan="1">25.49 (4.95)</td><td align="left" rowspan="1" colspan="1">27.60 (2.83)</td></tr><tr><td align="left" rowspan="1" colspan="1">CAA pathology<xref rid="alz70057-tbl1-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0: 1616; 1: 1264; 2: 806; 3: 448</td><td align="left" rowspan="1" colspan="1">0: 367; 1: 708; 2: 398; 3: 254</td></tr></tbody></table><table-wrap-foot><fn id="alz70057-tbl1-note-0001"><p>
<italic toggle="yes">Notes</italic>: Data are presented as mean (SD). All data were collected at baseline except neuropathology data (i.e., CAA pathology).</p></fn><fn id="alz70057-tbl1-note-0002"><p>Abbreviations: ADCs, Alzheimer's Disease Centers; CAA, cerebral amyloid angiopathy; CAARS, CAA risk score; NA, not applicable; NACC, National Alzheimer's Coordinating Center; ROSMAP, Religious Orders Study and Memory and Aging Project. WAIS&#8208;R, Wechsler Adult Intelligence Scale&#8211;Revised.</p></fn><fn id="alz70057-tbl1-note-0004"><label>
<sup>a</sup>
</label><p>Total number of animals named in 60&#160;s.</p></fn><fn id="alz70057-tbl1-note-0005"><label>
<sup>b</sup>
</label><p>Total number of story units recalled from this current test administration.</p></fn><fn id="alz70057-tbl1-note-0006"><label>
<sup>c</sup>
</label><p>Neuropathological evaluations were conducted by individual ADCs following their own protocols, which may vary but are in accordance with consensus guidelines. The results were entered into the NACC database using a standardized NACC form. The presence of CAA was detected using amyloid stains (e.g., Congo red, thioflavin&#8208;S, or amyloid beta [A&#946;] immunostaining), as determined by each ADC's protocol. CAA severity was graded semi&#8208;quantitatively as none (0), mild (1), moderate (2), or severe (3). According to the NACC coding guidelines, severity was based on the neuropathologist's overall assessment of severity, rather than on the condition of an individual vessel.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70057-sec-0180"><label>3.2</label><title>Outcomes of CAARS&#8208;4 model construction and evaluation</title><p>The AutoScore&#8208;Ordinal algorithm employed a random forest method to rank variables by their importance in predicting CAA severity. As shown in Figure&#160;<xref rid="alz70057-fig-0001" ref-type="fig">1</xref>, time after baseline was the most important predictor, which is expected as aging is a risk factor for CAA.<xref rid="alz70057-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The <italic toggle="yes">APOE</italic> genotype is another important predictor, aligning with clinical evidence that the &#949;4 allele of <italic toggle="yes">APOE</italic> is a known risk factor for CAA.<xref rid="alz70057-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Moreover, BMI is also identified as a key predictor. Additional variables, including blood pressure, age at baseline, and education, are also highlighted as important, consistent with findings from clinical and epidemiological studies.<xref rid="alz70057-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70057-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70057-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Feature ranking. This plot depicts the relative importance of features derived from random forest&#8211;based feature selection. The <italic toggle="yes">x</italic>&#8208;axis quantifies the importance score of each feature, whereas the <italic toggle="yes">y</italic>&#8208;axis lists the names of the analyzed features. Wider bars correspond to higher feature importance, highlighting predictors that contribute most significantly to the model's performance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70057-g002.jpg"/></fig><p>To optimize the balance between complexity and performance in the CAARS&#8208;4 model, a parsimony analysis was conducted to determine the optimal number of predictors. As shown in Figure&#160;<xref rid="alz70057-fig-0002" ref-type="fig">2</xref>, the mean AUC&#8208;ROC increased rapidly when the model incorporated one to three features, rising from 0.47 to 0.60. However, when additional two predictors were included, the model's performance remained the same, and the performance then improved consistently as the number of predictors increased from 6 to 10, with the mean AUC&#8208;ROC rising from 0.59 to 0.67. No further improvement in the mean AUC&#8208;ROC was observed by including additional predictors. Therefore, the CAARS&#8208;4 model employed 10 predictors, striking a balance between simplicity and predictive accuracy.</p><fig position="float" fig-type="FIGURE" id="alz70057-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Parsimony plot for CAARS&#8208;4. This plot illustrates the relationship between the number of predictors incorporated into the CAARS&#8208;4 model and its performance, measured by the average mean AUC&#8208;ROC values. The numerical labels on the bars indicate the cumulative count of predictors included at each step. Higher bars reflect superior model performance. AUC, area under the curve; CAARS, cerebral amyloid angiopathy (CAA) risk score; ROC, receiver&#8208;operating characteristic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70057-g003.jpg"/></fig><p>After identifying the most relevant variables, we applied a cumulative log&#8208;link regression model to assign scores for each category or interval of the selected predictors (Table&#160;<xref rid="alz70057-tbl-0002" ref-type="table">2</xref>, left panel). The maximum CAARS score was set at 100. On the test set, the model achieved a mean AUC&#8208;ROC of 0.70 (95% CI: 0.68&#8211;0.72] and Harrell's generalized C&#8208;index of 0.67 (0.66&#8211;0.70) before fine&#8208;tuning. To improve clinical utility, we refined the intervals for each feature as per their clinical norms. For example, BMI categories were adjusted to [0, 18.5), [18.5, 25), [25, 30), and&#160;&#160;&#8805;30<xref rid="alz70057-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>; diastolic blood pressure intervals as&#160;&lt;60, [60, 80), [80, 90), and &#8805;90;0 systolic blood pressure intervals as&#160;&lt;120, [120, 150), and &#8805;150<xref rid="alz70057-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>; Wechsler Adult Intelligence Scale&#8208;Revised (WAIS&#8208;R) Digit Symbol test as&#160;&lt;30, [30, 40), [40, 49), and &#8805;49.<xref rid="alz70057-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The revised scores for each feature following fine tuning are presented in Table&#160;<xref rid="alz70057-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="alz70057-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Score table for CAARS&#8208;4 model.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Before fine&#8208;tuning</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">After fine&#8208;tuning</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Interval</th><th align="left" rowspan="1" colspan="1">Score</th><th align="left" rowspan="1" colspan="1">Interval</th><th align="left" rowspan="1" colspan="1">Score</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">Time after baseline</td><td align="left" rowspan="1" colspan="1">&lt;2.01</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&lt;2.01</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[2.01,8.16)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">[2.01,8.16)</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;8.16</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">&#8805;8.16</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td rowspan="3" align="left" colspan="1">Body mass index<xref rid="alz70057-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">&lt;29.9</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">&lt;25</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">[29.9,35.3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">[25,30)</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;35.3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">&#8805;30</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="6" align="left" colspan="1">
<italic toggle="yes">APOE</italic>
</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;3</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;3/&#949;4</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;4</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;3/&#949;2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#949;3/&#949;2</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;4/&#949;4</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">&#949;4/&#949;4</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;4/&#949;2</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">&#949;4/&#949;2</td><td align="left" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;2/&#949;2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#949;2/&#949;2</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="left" colspan="1">Blood pressure (systolic)<xref rid="alz70057-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">&lt;108</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">&lt;120</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[108,120)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">[120,150)</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">[120,150)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#8805;150</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;167</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="5" align="left" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">&lt;57</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">[57,67)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[57,67)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">[67,90)</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">[67,83)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">&#8805;90</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">[83,90)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;90</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="5" align="left" colspan="1">Wechsler Adult Intelligence Scale&#8208;Revised<xref rid="alz70057-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">&lt;7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">&lt;30</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">[7,22)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">[30,49)</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">[22,46)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">&#8805;49</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[46,57)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;57</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#160;</td><td align="left" rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="5" align="left" colspan="1">Heart rate</td><td align="left" rowspan="1" colspan="1">&lt;52</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">[52,60)</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">[52,60)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">&#8805;60</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">[60,76)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">[76,84)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;84</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="5" align="left" colspan="1">Blood pressure (diastolic)<xref rid="alz70057-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">&lt;59</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&lt;60</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[58,66)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">[60,90)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">[65,82)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">&#8805;90</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">[82,90)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;90</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#160;</td><td align="left" rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="5" align="left" colspan="1">Animal name test</td><td align="left" rowspan="1" colspan="1">&lt;4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&lt;4</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">[4,10)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">&#8805;4</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">[10,20)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">[20,25)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;25</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="left" colspan="1">Total number of stories recalled</td><td align="left" rowspan="1" colspan="1">&lt;3</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">&lt;3</td><td align="left" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">[3,14)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">[3,13)</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">[14,18)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">[13,18)</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8805;18</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#8805;18</td><td align="left" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="alz70057-tbl2-note-0001"><p>Abbreviation: <italic toggle="yes">APOE</italic>, apolipoprotein E; CAARS, cerebral amyloid angiopathy risk score.</p></fn><fn id="alz70057-tbl2-note-0002"><label>
<sup>a</sup>
</label><p>fine&#8208;tuning based on clinical norms.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>After fine&#8208;tuning, the CAARS&#8208;4 model retained comparable performance on the test set, with a mean AUC&#8208;ROC of 0.71 (95% CI: 0.69&#8211;0.72) and Harrell's generalized C&#8208;index of 0.69 (0.68&#8211;0.71). Although fine&#8208;tuning did not affect the model performance, the fine&#8208;tuned intervals based on clinical norms offer a more meaningful and interpretable scoring system compared to the quantile&#8208;based intervals generated by the AutoScore algorithm. We subsequently mapped the scores to CAA severity: none (0&#8211;50), mild (50&#8211;65), moderate (65&#8211;80), and severe (80&#8211;100). A risk plot (Figure&#160;<xref rid="alz70057-fig-0003" ref-type="fig">3</xref>) illustrated the relationship between score intervals and the probability of CAA severity, revealing a clear trend of increasing severity with higher scores. These findings underscore the ability if the CAARS&#8208;4 model to effectively stratify the severity of the condition.</p><fig position="float" fig-type="FIGURE" id="alz70057-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Score intervals and risk probability for CAARS&#8208;4. The <italic toggle="yes">x</italic>&#8208;axis represents CAARS score intervals, and the <italic toggle="yes">y</italic>&#8208;axis shows the probability of CAA severity, represented by color&#8208;coded bars (none: blue, mild: green, moderate: yellow, severe: pink). As the score increases, the probability of more severe CAA also rises. CAARS, cerebral amyloid angiopathy (CAA) risk score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70057-g001.jpg"/></fig></sec><sec id="alz70057-sec-0190"><label>3.3</label><title>Outcomes of CAARS&#8208;2 model construction and evaluation</title><p>The CAARS&#8208;2 model was developed using the AutoScore algorithm, which was designed to predict the binary classification of CAA (none vs mild/moderate/severe). The importance ranking of the predictors is presented in eFigure&#160;<xref rid="alz70057-supinfo-0001" ref-type="">2</xref>, which was highly consistent with those of the CAARS&#8208;4, with minor differences in importance values. Parsimony analysis for CAARS&#8208;2 is presented in eFigure <xref rid="alz70057-supinfo-0001" ref-type="">3</xref>, from which we determined that nine predictors were required to achieve the best model performance. The fine&#8208;tuned score table is provided as eTable&#160;<xref rid="alz70057-supinfo-0001" ref-type="">2</xref>. The CAARS&#8208;2 model achieved an AUC&#8208;ROC of 0.71 (95% CI: 0.67&#8211;0.73), sensitivity of 0.61 (95% CI: 0.56&#8211;0.74), and specificity of 0.79 (95% CI: 0.75&#8211;0.83) at a threshold of 55.</p></sec><sec id="alz70057-sec-0200"><label>3.4</label><title>Comparison between the baseline models and CAARS</title><p>The comparisons between the two CAARS models and their respective baseline models are summarized in Table&#160;<xref rid="alz70057-tbl-0003" ref-type="table">3A</xref>. The performance of CAARS&#8208;4 exceeded that of POM&#8208;1 (mean AUC&#8208;ROC: 0.64 [95% CI: 0.61&#8211;0.66]; Harrell's generalized C&#8208;index: 0.60 [95% CI, 0.57&#8211;0.62]), POM&#8208;2 (mean AUC&#8208;ROC: 0.66 [95% CI: 0.63&#8211;0.69]; Harrell's generalized C&#8208;index: 0.61 [95% CI: 0.59&#8211;0.63]), and POM&#8208;3 (mean AUC&#8208;ROC: 0.67 [95% CI: 0.64&#8211;0.70]; Harrell's generalized C&#8208;index: 0.63 [95% CI: 0.61&#8211;0.65]). Similarly, CAARS&#8208;2 outperformed the logistic&#8208;base model (AUC&#8208;ROC: 0.63 [95% CI 0.60&#8211;0.66]; sensitivity: 0.21 [95% CI: 0.12&#8211;0.34]; specificity: 0.83 [95% CI: 0.76&#8211;0.88]). Overall, the CAARS models demonstrated superior performance compared to their baseline models.</p><table-wrap position="float" id="alz70057-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Model performance evaluation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Model</th><th align="left" rowspan="1" colspan="1">Mean AUC&#8208;ROC</th><th align="left" rowspan="1" colspan="1">Generalized C&#8208;index</th><th align="left" rowspan="1" colspan="1">AUC&#8208;ROC</th><th align="left" rowspan="1" colspan="1">Specificity</th><th align="left" rowspan="1" colspan="1">Sensitivity</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1">
<bold>A: Comparison between CAARS models and baseline models</bold>
</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">CAARS&#8208;4</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.71 [95% CI: 0.69&#8211;0.72]</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.69 [95% CI, 0.68&#8211;0.71]</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">POM&#8208;1</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.64 (95% CI: 0.61&#8211;0.66)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.60 (95% CI, 0.57&#8211;0.62)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">POM&#8208;2</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.66 (95% CI: 0.63&#8211;0.69)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.61 (95% CI, 0.59&#8211;0.63)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">POM&#8208;3</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.67 (95% CI: 0.64&#8211;0.70)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.63 (95% CI, 0.61&#8211;0.65)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">CAAS&#8208;2</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.71 (95% CI: 0.67&#8211;0.73)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.79 (95% CI: 0.75&#8212;0.83)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.61 (95% CI: 0.56&#8211;0.74)</td></tr><tr><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">Logistic&#8208;all</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.62 (95% CI: 0.58&#8211;0.65)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.74 (95% CI: 0.67&#8211;0.75)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.43 (95% CI: 0.38&#8211;0.50)</td></tr><tr><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">Logistic&#8208;selected</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.63 (95% CI: 0.60&#8211;0.66)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.83 (95% CI: 0.76&#8211;0.88)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.21 (95% CI: 0.12&#8211;0.34)</td></tr><tr><td colspan="6" align="left" rowspan="1">
<bold>B: External evaluation of CAARS models</bold>
</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">CAARS&#8208;4<xref rid="alz70057-tbl3-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref> (NACC)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.70 (95% CI: 0.68&#8208;0.72)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.68 (95%CI: 0.67&#8211;0.71)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">CAARS&#8208;4<xref rid="alz70057-tbl3-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref> (ROSMAP)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.69 (95% CI: 0.68&#8211;0.71)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">0.68 (95% CI: 0.65&#8211;0.70)</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B6DDE8" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">CAARS&#8208;2<xref rid="alz70057-tbl3-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref> (NACC)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.71 (95% CI: 0.69&#8211;0.74)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.82 (95% CI: 0.78&#8211;0.85)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.60 (95% CI: 0.56&#8211;0.63)</td></tr><tr><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">CAARS&#8208;2<xref rid="alz70057-tbl3-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref> (ROSMAP)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">NA</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.70 (95% CI: 0.66&#8211;0.73)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.70 (95% CI: 0.68&#8211;0.72)</td><td style="background-color:#B2A1C7" align="left" rowspan="1" colspan="1">0.58 (95% CI: 0.53&#8211;0.64)</td></tr></tbody></table><table-wrap-foot><fn id="alz70057-tbl3-note-0001"><p>
<italic toggle="yes">Notes</italic>: Sky blue&#160;=&#160;classification of none, mild, moderate, severe. Purple&#160;=&#160;binary classification of none versus mild/moderate/severe. The AUC&#8208;ROC of each CAARS model was compared to the baseline models using the Wilcoxon signed&#8208;rank test, and the <italic toggle="yes">p</italic>&#8208;value for each comparison was annotated for the corresponding baseline.</p></fn><fn id="alz70057-tbl3-note-0002"><p>Abbreviations: AUC, area under the curve; CAARS, cerebral amyloid angiopathy risk score; NA, not applicable; NACC, National Alzheimer's Coordinating Center; POM, proportional odds model; ROC, receiver&#8208;operating characteristic; ROSMAP, Religious Orders Study and Memory and Aging Project.</p></fn><fn id="alz70057-tbl3-note-0003"><label>
<sup>a</sup>
</label><p>Model using predictors available in both NACC and ROSMAP datasets.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70057-sec-0210"><label>3.5</label><title>External evaluation results</title><p>We used the ROSMAP cohort for the external evaluation of CAARS; however, the predictors recorded by ROSMAP and NACC do not align perfectly. For CAARS&#8208;4, the WAIS&#8208;R Digit Symbol test, the total number of animals named in 60&#160;s, the total number of story units recalled, and heart rate were not available for ROSMAP participants. As a result, these were replaced by the Mini&#8208;Mental Status Examination (MMSE), Geriatric Depression Scale (GDS) score, and years of education, which are the next highest&#8208;ranked predictors. For CAARS&#8208;2, the external evaluation employed nine predictors, replacing WAIS&#8208;R Digit Symbol test, heart rate, and the total number of animals named in 60&#160;s by MMSE score, GDS score, and years of education. The model performance using ROSMAP data was comparable to that using NACC data (Table&#160;<xref rid="alz70057-tbl-0003" ref-type="table">3B</xref>). Overall, the external evaluation demonstrated that the CAARS can achieve good performance across independent datasets.</p></sec><sec id="alz70057-sec-0220"><label>3.6</label><title>Epidemiology analysis</title><p>We performed epidemiology analysis to justify some high importance predictors determined by CAARS. As shown in Table&#160;<xref rid="alz70057-tbl-0004" ref-type="table">4</xref>, after adjusting for potential covariates, a positive <italic toggle="yes">APOE</italic> &#949;4 carrier status was significantly associated with increased odds of CAA across all severity levels (mild: odds ratio [OR] 2.752; moderate: OR 4.501; severe: OR 4.491) compared to the reference group, with an increase in the strength of association as CAA severity increased. In contrast, a positive <italic toggle="yes">APOE</italic> &#949;2 carrier status was significantly associated with a decreased odds of mild/moderate CAA (mild: OR 0.602; moderate: OR 0.593) compared to the reference group. In addition, participants at hypertension stage 1 (systolic 130&#8211;139&#160;mmHg) had higher odds of CAA (mild: OR 1.442; moderate: OR 1.513) compared to the reference group. A similar trend was observed for participants at hypertension stage 2 (systolic&#160;&#8805;140&#160;mmHg), where the odds of moderate CAA were also increased (OR 1.504). For participants with elevated diastolic blood pressure, significantly increased odds of mild CAA were found (OR 3.115) compared to the reference group. Of interest, participants at hypertension stage 2 (diastolic&#160;&#8805;90&#160;mmHg) were found to have significantly decreased odds of CAA (OR 0.400).</p><table-wrap position="float" id="alz70057-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Longitudinal associations between <italic toggle="yes">APOE</italic> &#949;4 carrier status, BMI, blood pressure, and the risk of CAA.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th rowspan="2" align="left" colspan="1">Measures</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">OR [95% CI], <italic toggle="yes">p</italic>&#8208;value (<italic toggle="yes">n&#160;</italic>= 2056)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Mild CAA</th><th align="left" rowspan="1" colspan="1">Moderate CAA</th><th align="left" rowspan="1" colspan="1">Severe CAA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">APOE</italic> &#949;4 carrier status</bold>
</td><td colspan="3" align="left" rowspan="1">
<bold>Reference: without &#949;4</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>2.752 [2.180&#8211;3.474], <italic toggle="yes">p&#160;</italic>&lt;&#160;.001</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.501 [3.483&#8211;5.816], <italic toggle="yes">p&#160;</italic>&lt;&#160;.001</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.491 [3.283&#8211;6.144], <italic toggle="yes">p&#160;</italic>&lt;&#160;.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">APOE</italic> &#949;2 carrier status</bold>
</td><td colspan="3" align="left" rowspan="1">
<bold>Reference: without &#949;2</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.602 [0.434&#8211;0.836], <italic toggle="yes">p&#160;</italic>&lt;&#160;.001</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.593 [0.410&#8211;0.859], <italic toggle="yes">p&#160;</italic>&lt;&#160;.001</bold>
</td><td align="left" rowspan="1" colspan="1">0.669 [0.424&#8211;1.055], <italic toggle="yes">p&#160;</italic>=&#160;.008</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>BMI</bold>
<xref rid="alz70057-tbl4-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td colspan="3" align="left" rowspan="1">
<bold>Reference: normal</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Underweight</td><td align="left" rowspan="1" colspan="1">1.255 [0.463&#8211;3.404], <italic toggle="yes">p&#160;=&#160;</italic>.66</td><td align="left" rowspan="1" colspan="1">0.521 [0.131&#8211;2.075], <italic toggle="yes">p&#160;</italic>=&#160;.36</td><td align="left" rowspan="1" colspan="1">1.918 [0.618&#8211;;5.957], <italic toggle="yes">p&#160;</italic>=&#160;.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="left" rowspan="1" colspan="1">0.993 [0.776&#8211;1.271], <italic toggle="yes">p&#160;=&#160;</italic>.95</td><td align="left" rowspan="1" colspan="1">1.028 [0.782&#8211;1.352], <italic toggle="yes">p&#160;</italic>=&#160;.84</td><td align="left" rowspan="1" colspan="1">0.962 [0.690&#8211;1.342], <italic toggle="yes">p&#160;</italic>=&#160;.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity stage 1</td><td align="left" rowspan="1" colspan="1">0.961 [0.695&#8211;1.329], <italic toggle="yes">p&#160;=&#160;</italic>.81</td><td align="left" rowspan="1" colspan="1">0.834 [0.574&#8211;1.212], <italic toggle="yes">p&#160;</italic>=&#160;.34</td><td align="left" rowspan="1" colspan="1">0.649 [0.397&#8211;1.061], <italic toggle="yes">p&#160;</italic>=&#160;.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity stage 2</td><td align="left" rowspan="1" colspan="1">0.953 [0.565&#8211;1.607], <italic toggle="yes">p&#160;=&#160;</italic>.86</td><td align="left" rowspan="1" colspan="1">0.862 [0.474&#8211;1.568], <italic toggle="yes">p&#160;</italic>=&#160;.63</td><td align="left" rowspan="1" colspan="1">1.019 [0.500&#8211;;2.074], <italic toggle="yes">p&#160;</italic>=&#160;.96</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Blood pressure (systolic)</bold>
<xref rid="alz70057-tbl4-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td colspan="3" align="left" rowspan="1">
<bold>Reference: normal</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Elevated</td><td align="left" rowspan="1" colspan="1">0.478 [0.186&#8211;1.232], <italic toggle="yes">p&#160;</italic>=&#160;.13</td><td align="left" rowspan="1" colspan="1">1.117 [0.443&#8211;2.816], <italic toggle="yes">p&#160;</italic>=&#160;.82</td><td align="left" rowspan="1" colspan="1">0.564 [0.147&#8211;2.164], <italic toggle="yes">p&#160;</italic>=&#160;.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension stage 1</td><td align="left" rowspan="1" colspan="1">
<bold>1.442 [1.047&#8211;1.987], <italic toggle="yes">p&#160;</italic>=&#160;.03</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.513 [1.059&#8211;2.160], <italic toggle="yes">p&#160;</italic>=&#160;.02</bold>
</td><td align="left" rowspan="1" colspan="1">0.966 [0.633&#8211;1.473], <italic toggle="yes">p&#160;</italic>=&#160;.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension stage 2</td><td align="left" rowspan="1" colspan="1">1.332 [0.981&#8211;1.808], <italic toggle="yes">p&#160;</italic>=&#160;.07</td><td align="left" rowspan="1" colspan="1">
<bold>1.504 [1.073&#8211;2.110], <italic toggle="yes">p&#160;</italic>=&#160;.02</bold>
</td><td align="left" rowspan="1" colspan="1">0.936 [0.628&#8211;1.395], <italic toggle="yes">p&#160;</italic>=&#160;.75</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Blood pressure (diastolic)</bold>
<xref rid="alz70057-tbl4-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td colspan="3" align="left" rowspan="1">
<bold>Reference: normal</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Elevated</td><td align="left" rowspan="1" colspan="1">
<bold>3.115 [1.185&#8211;8.188], <italic toggle="yes">p&#160;</italic>=&#160;.02</bold>
</td><td align="left" rowspan="1" colspan="1">1.122 [0.431&#8211;2.916], <italic toggle="yes">p&#160;</italic>=&#160;.81</td><td align="left" rowspan="1" colspan="1">1.378 [0.343&#8211;5.529], <italic toggle="yes">p&#160;</italic>=&#160;.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension stage 1</td><td align="left" rowspan="1" colspan="1">1.003 [0.717&#8211;1.401], <italic toggle="yes">p&#160;</italic>=&#160;.99</td><td align="left" rowspan="1" colspan="1">0.729 [0.496&#8211;1.071], <italic toggle="yes">p&#160;</italic>=&#160;.11</td><td align="left" rowspan="1" colspan="1">0.631 [0.377&#8211;1.055], <italic toggle="yes">p&#160;</italic>=&#160;.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension stage 2</td><td align="left" rowspan="1" colspan="1">1.034 [0.619&#8211;1.725], <italic toggle="yes">p&#160;</italic>=&#160;.90</td><td align="left" rowspan="1" colspan="1">
<bold>0.400 [0.203&#8211;0.785], <italic toggle="yes">p&#160;</italic>=&#160;.008</bold>
</td><td align="left" rowspan="1" colspan="1">0.865 [0.425&#8211;1.761], <italic toggle="yes">p&#160;</italic>=&#160;.69</td></tr></tbody></table><table-wrap-foot><fn id="alz70057-tbl4-note-0001"><p>Abbreviation: CAARS, cerebral amyloid angiopathy risk score. CAA, cerebral amyloid angiopathy. <italic toggle="yes">APOE</italic>, apolipoprotein E. OR, odds ratio.</p></fn><fn id="alz70057-tbl4-note-0005"><p>Bold values represent statistically significant differences at <italic toggle="yes">p</italic> &lt;&#160;0.05.</p></fn><fn id="alz70057-tbl4-note-0002"><label>
<sup>a</sup>
</label><p>BMI: Body mass index, categorized as underweight (&lt;18.5), normal [18.5&#8211;25), overweight [25&#8211;30), obesity stage 1 [30&#8211;35), and obesity stage 2 (&gt;35).</p></fn><fn id="alz70057-tbl4-note-0003"><label>
<sup>b</sup>
</label><p>Blood pressure (systolic): normal (&#8804;120&#160;mmHg), elevated (120&#8211;129&#160;mmHg), hypertension stage 1 (130&#8211;139&#160;mmHg), and hypertension stage 2 (<mml:math id="jats-math-1" display="inline"><mml:mrow><mml:mo>&#8805;</mml:mo></mml:mrow></mml:math>140&#160;mmHg).</p></fn><fn id="alz70057-tbl4-note-0004"><label>
<sup>c</sup>
</label><p>Blood pressure (diastolic): normal (&#8804;80&#160;mmHg), elevated (&#8804;80&#160;mmHg, with; systolic being 120&#8211;129&#160;mmHg), hypertension stage 1 (80&#8211;89&#160;mmHg), and hypertension stage 2 (&#8805;90&#160;mmHg).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70057-sec-0230"><label>4</label><title>DISCUSSION</title><p>Developing models to predict the severity of CAA has gained increasing interest from AD researchers and clinicians. These models could potentially be used to inform antithrombotic use in people with CAA and may offer the possibility to predict intracerebral hemorrhage risk if the predicted CAA severity can be evaluated against clinical outcomes. In addition, given the possible link between CAA and ARIA risk from receiving MABs,<xref rid="alz70057-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70057-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70057-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> tools to predict CAA may be used for ARIA risk stratification.</p><p>Our team previously developed the Florey Cerebral Amyloid Angiopathy Score (FCAAS)&#160;model and conducted an epidemiological study to investigate the risk factors associated with CAA pathology.<xref rid="alz70057-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70057-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Using ROSMAP data, the FCAAS model predicts CAA severity based on postmortem neuropathological data (amyloid plaque density and tau tangle density), as well as clinical data collected at baseline. Although being the first model to predict CAA, the immediate clinical utility of FCAAS may be limited due to the absence of widely accepted biomarkers that are strongly correlated with pre&#8208;mortem CAA neuropathology. In this study we address this issue by utilizing predictors that can be measured in living patients. The new model CAARS was developed using NACC data and externally validated using ROSMAP data to ensure generalizability.<xref rid="alz70057-fig-0003" ref-type="fig">&#8195;</xref>
</p><p>The CAARS models exhibited strong predictive performance, consistently outperforming baseline models (Table&#160;<xref rid="alz70057-tbl-0003" ref-type="table">3A</xref>).<xref rid="alz70057-tbl-0004" ref-type="table">&#8195;</xref> This underscores the effectiveness of the AutoScore algorithm for ordinal and binary classification tasks, particularly in comparison to conventional methods used in the baseline models. We employed multi&#8208;cohort validation in the current study to evaluate the performance of the CAARS&#8208;4. CAARS&#8208;4 was developed and internally evaluated using the NACC dataset, with an external evaluation performed on the ROSMAP dataset. The external evaluation demonstrated a strong performance of the CAARS&#8208;4, achieving a mean AUC&#8208;ROC of 0.68 (95% CI: 0.67&#8211;0.70) and Harrell's generalized C&#8208;index of 0.68 (95% CI: 0.67&#8211;0.69), comparable to its performance on the NACC participants (Table&#160;<xref rid="alz70057-tbl-0003" ref-type="table">3B</xref>). We have also performed external evaluation for the CAARS&#8208;2, which also demonstrated a robust performance of the model. Of interest, despite some differences in demographics between NACC and ROSMAP, the external evaluation performance of the CAARS model remains strong. This is possibly due to age being the only demographic feature selected. Overall, this highlighted the robustness of the model and its generalizability.</p><p>Of note, the WAIS&#8208;R Digit Symbol test, the total number of animals named in 60&#160;s, and the total number of story units recalled are neuropsychological tests that are not commonly used in clinical practice. Clinicians in memory clinics often face time constraints during clinical appointments. Some cognitive assessments, such as the WAIS&#8208;R Digit Symbol test, require significant time, training, and the involvement of a neuropsychologist for accurate assessment. This can limit the clinical applicability of these tests, especially in settings with time and resource constraints, such as rural and remote areas where access to neuropsychologists could be limited. We have demonstrated the feasibility of replacing these predictors with alternative predictors&#8212;MMSE, GDS score, and years of education&#8212;that are routinely collected in clinical settings. Despite this substitution, the performance of the CAARS model remains robust. This adaptability underscores the advantage of using the AutoScore and AutoScore&#8208;Ordinal algorithms in developing CAARS, enhancing the model's potential clinical utility in practice.</p><p>We noted some interesting findings from the generated scoring tables (Table&#160;<xref rid="alz70057-tbl-0002" ref-type="table">2</xref>, eTable&#160;<xref rid="alz70057-supinfo-0001" ref-type="">2</xref>). It is evident that predictors such as <italic toggle="yes">APOE</italic> variants (&#949;4/&#949;2, &#949;4/&#949;3, &#949;4/&#949;4, and &#949;2/&#949;2), time after baseline, BMI, and age contribute significantly to the CAARS score. Notably, the <italic toggle="yes">APOE</italic> &#949;4/&#949;4 variant received the highest score among all <italic toggle="yes">APOE</italic> genotypes, consistent with its strong association with increased A&#946; accumulation.<xref rid="alz70057-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Although the <italic toggle="yes">APOE</italic> &#949;2 variant appears to be protective against CAA, it remains unclear whether this protective effect is related to <italic toggle="yes">APOE</italic> &#949;2&#8217;s known association with reduced AD risk.<xref rid="alz70057-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> This was re&#8208;illustrated by our epidemiology findings, where <italic toggle="yes">APOE</italic> &#949;4 was significantly associated with a higher odds of CAA and <italic toggle="yes">APOE</italic> &#949;2 was significantly associated with lower odds of CAA. It is interesting to note that the protective effect of <italic toggle="yes">APOE</italic> &#949;2 became invisible in the presence of <italic toggle="yes">APOE</italic> &#949;4, which could be explored in future studies. As illustrated in the score table, hypertension (stage 1) and hypertension (stage 2) contribute to CAA risk. This is well supported by our epidemiological data, showing that hypertension was associated with varying degrees of increased CAA risk. Unexpectedly, hypertension stage 2 (diastolic) was found to be significantly negatively associated with moderate CAA risk in the epidemiological analysis, which conflicted with the CAARS score table. This could possibly be explained by the small sample size (<italic toggle="yes">n&#160;</italic>=&#160;23), limiting the statistical power to uncover the true association. Overall, we demonstrated that the CAARS is evidence based and clinically relevant for predicting CAA severity.</p><p>One of the key strengths of the current study is that we have addressed the &#8220;black box&#8221; issue associated with machine learning models. The term &#8220;black box&#8221; refers to many machine learning models, especially complex ones, operating in a way that makes it difficult to understand how they arrive at their decisions or predictions. In our study, the AutoScore algorithm generated a score table, which enhanced transparency of CAARS models by providing clear and clinically interpretable results. This would allow clinicians and researchers to better understand the model's predictions, thereby fostering trust in its outputs. In addition, we validated the model further by verifying it with epidemiological analysis, ensuring that the score table is supported by findings from more traditional methods. Some of the identified predictors for CAA appeared to be linked to dementia, such as MMSE score, GDS score, and years of education. It must be noted that these predictors are not specific to dementia but rather are better studied in the context of dementia. Further epidemiological studies could explore the relationship between these predictors and CAA pathology. We encourage machine learning experts to collaborate with clinical epidemiologists in the development of future models.</p><p>The current study is not without limitations. Although the model was developed and internally validated on the NACC dataset and externally evaluated on the ROSMAP cohort, both datasets were collected in the United States, which limits the generalizability of the findings to middle&#8208; or low&#8208;income countries. Further evaluation of the CAARS should be conducted using data from other regions of the world. However, this could be challenging, as CAA neuropathology is not commonly assessed in cohort studies of aging and dementia. We recommend that all existing cohort studies and new studies consider collecting these important data. The NACC and ROSMAP studies primarily recruited White participants, with very limited African American and Asian participants. Ethnicity likely plays an important role in the pathogenesis and progression of many diseases. Future studies should aim to incorporate data from non&#8208;White participants to enhance the global applicability and relevance of the findings. Last but not least, due to data availability constraints, the development of the CAARS model did not include biomarkers and imaging data, despite their potential to enhance the model's performance. This limitation should be addressed in future studies.</p><p>In conclusion, CAARS has been developed to predict the severity of CAA neuropathology using data that can be collected from living patients. The score&#8208;based risk prediction system employed by the CAARS is more likely to be accepted by clinicians compared to using other machine learning models. Further studies should be conducted to expand the current work, and clinical evaluation will be required before this tool can be translated into clinical practice.</p></sec><sec sec-type="COI-statement" id="alz70057-sec-0250"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors have no conflicts to report. Author disclosures are available in the <xref rid="alz70057-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="alz70057-sec-0260"><title>CONSENT STATEMENT</title><p>Each Alzheimer's Disease Center (ADC) that contributed data to the National Alzheimer's Coordinating Center (NACC) employed its own protocol to obtain informed consent from participants or, when participants were unable to provide consent, from their next of kin, caregivers, or legal guardians. Written informed consent was obtained from all participants by Rush University. All participants have consented to allow secondary analysis of the de&#8208;identified data.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70057-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70057-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70057-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70057-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70057-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70057-sec-0240"><title>ACKNOWLEDGMENTS</title><p>The National Alzheimer's Coordinating Center (NACC) database is funded by National Institute on Aging/National Institutes of Health (NIA/NIH) Grant U24 AG072122. NACC data are contributed by the NIA&#8208;funded Alzheimer's Disease Research Centers (ADRCs): P30 AG062429 (principal investigator [PI] James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI David Holtzman, MD), P30 AG066518 (PI Lisa Silbert, MD, MCR), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie A. Schneider, MD, MS), P30 AG072978 (PI Ann McKee, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Jessica Langbaum, PhD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Glenn Smith, PhD, ABPP), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P30 AG086401 (PI Erik Roberson, MD, PhD), P30 AG086404 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD). The participating Alzheimer's disease centers include the Arizona Alzheimer's Center, Boston University, Columbia University, Duke University Medical Center, Emory University, Indiana University, Johns Hopkins University, Massachusetts ADRC, Mayo Clinic, Mount Sinai School of Medicine, New York University, Northwestern University, Oregon Health and Science University, Rush University Medical Center, University of California Davis, University of California Irvine, University of California Los Angeles, University of California San Diego, University of California San Francisco, University of Kansas, University of Kentucky, University of Pennsylvania, University of Pittsburgh, University of Southern California, University of Texas Southwestern, University of Washington, University of Wisconsin, and Washington University. This work would not have been possible without the contributions of the participants from the Religious Orders Study and Memory and Aging Project (ROSMAP), and their investigators and staff. This study received support from the NIA (Grant Numbers: P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356). Rush Alzheimer&#8217;s Disease Center (RADC) resources can be requested at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.radc.rush.edu" ext-link-type="uri">https://www.radc.rush.edu</ext-link>. This research is supported by the National Health and Medical Research Council, Australia (GNT2007912, GNT2022203) and the Alzheimer's Association, USA (23AARF&#8208;1020292) awarded to Dr Yijun Pan.</p></ack><ref-list id="alz70057-bibl-0001"><title>REFERENCES</title><ref id="alz70057-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70057-cite-0002"><string-name name-style="western"><surname>J&#228;kel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>De Kort</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Klijn</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Schreuder</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Verbeek</surname><given-names>MM</given-names></string-name>. <article-title>Prevalence of cerebral amyloid angiopathy: a systematic review and meta&#8208;analysis</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>10</fpage>&#8208;<lpage>28</lpage>.<pub-id pub-id-type="pmid">34057813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12366</pub-id><pub-id pub-id-type="pmcid">PMC9290643</pub-id></mixed-citation></ref><ref id="alz70057-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70057-cite-0003"><string-name name-style="western"><surname>Charidimou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boulouis</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Frosch</surname><given-names>MP</given-names></string-name>, et&#160;al. <article-title>The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI&#8211;neuropathology diagnostic accuracy study</article-title>. <source>Lancet Neurol</source>. <year>2022</year>;<volume>21</volume>:<fpage>714</fpage>&#8208;<lpage>725</lpage>.<pub-id pub-id-type="pmid">35841910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00208-3</pub-id><pub-id pub-id-type="pmcid">PMC9389452</pub-id></mixed-citation></ref><ref id="alz70057-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70057-cite-0004"><string-name name-style="western"><surname>Kozberg</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Perosa</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gurol</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>van Veluw</surname><given-names>SJ</given-names></string-name>. <article-title>A practical approach to the management of cerebral amyloid angiopathy</article-title>. <source>Int J Stroke</source>. <year>2021</year>;<volume>16</volume>:<fpage>356</fpage>&#8208;<lpage>369</lpage>.<pub-id pub-id-type="pmid">33252026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493020974464</pub-id><pub-id pub-id-type="pmcid">PMC9097498</pub-id></mixed-citation></ref><ref id="alz70057-bib-0004"><label>4</label><mixed-citation publication-type="book" id="alz70057-cite-0005"><string-name name-style="western"><surname>Kuhn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sharman</surname><given-names>T</given-names></string-name>. <source>Cerebral Amyloid Angiopathy. StatPearls</source>. <year>2024</year>.<pub-id pub-id-type="pmid">32310565</pub-id></mixed-citation></ref><ref id="alz70057-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70057-cite-0006"><string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Jack</surname><suffix>Jr</suffix><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;related imaging abnormalities in amyloid&#8208;modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup</article-title>. <source>Alzheimer Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>367</fpage>&#8208;<lpage>385</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.05.2351</pub-id><pub-id pub-id-type="pmcid">PMC3693547</pub-id><pub-id pub-id-type="pmid">21784348</pub-id></mixed-citation></ref><ref id="alz70057-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70057-cite-0007"><string-name name-style="western"><surname>Withington</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>RS</given-names></string-name>. <article-title>Amyloid&#8208;related imaging abnormalities with anti&#8208;amyloid antibodies for the treatment of dementia due to Alzheimer's disease</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>862369</elocation-id>.<pub-id pub-id-type="pmid">35401412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.862369</pub-id><pub-id pub-id-type="pmcid">PMC8985815</pub-id></mixed-citation></ref><ref id="alz70057-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70057-cite-0008"><string-name name-style="western"><surname>Doran</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Sawyer</surname><given-names>RP</given-names></string-name>. <article-title>Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications</article-title>. <source>Front Neurosci</source>. <year>2024</year>;<volume>18</volume>:<elocation-id>1326784</elocation-id>.<pub-id pub-id-type="pmid">38312931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2024.1326784</pub-id><pub-id pub-id-type="pmcid">PMC10834650</pub-id></mixed-citation></ref><ref id="alz70057-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70057-cite-0009"><string-name name-style="western"><surname>Bilodeau</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Kozberg</surname><given-names>MG</given-names></string-name>. <article-title>The impact of anti&#8208;amyloid immunotherapies on stroke care</article-title>. <source>J Clin Med</source>. <year>2024</year>;<volume>13</volume>:<fpage>1245</fpage>.<pub-id pub-id-type="pmid">38592119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13051245</pub-id><pub-id pub-id-type="pmcid">PMC10931618</pub-id></mixed-citation></ref><ref id="alz70057-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70057-cite-0010"><string-name name-style="western"><surname>Besser</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kukull</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, et&#160;al. <article-title>Version 3 of the national Alzheimer's coordinating center's uniform data set</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2018</year>;<volume>32</volume>:<fpage>351</fpage>&#8208;<lpage>358</lpage>.<pub-id pub-id-type="pmid">30376508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0000000000000279</pub-id><pub-id pub-id-type="pmcid">PMC6249084</pub-id></mixed-citation></ref><ref id="alz70057-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70057-cite-0011"><string-name name-style="western"><surname>Besser</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kukull</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Teylan</surname><given-names>MA</given-names></string-name>, et&#160;al. <article-title>The revised National Alzheimer's Coordinating Center's neuropathology form&#8212;available data and new analyses</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2018</year>;<volume>77</volume>:<fpage>717</fpage>&#8208;<lpage>726</lpage>.<pub-id pub-id-type="pmid">29945202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nly049</pub-id><pub-id pub-id-type="pmcid">PMC6044344</pub-id></mixed-citation></ref><ref id="alz70057-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70057-cite-0012"><string-name name-style="western"><surname>Weintraub</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Besser</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dodge</surname><given-names>HH</given-names></string-name>, et&#160;al. <article-title>Version 3 of the Alzheimer Disease Centers&#8217; neuropsychological test battery in the uniform data set (UDS)</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2018</year>;<volume>32</volume>:<fpage>10</fpage>&#8208;<lpage>17</lpage>.<pub-id pub-id-type="pmid">29240561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0000000000000223</pub-id><pub-id pub-id-type="pmcid">PMC5821520</pub-id></mixed-citation></ref><ref id="alz70057-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70057-cite-0013"><string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>. <article-title>Religious Orders Study and Rush Memory and Aging Project</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>64</volume>:<fpage>S161</fpage>&#8208;<lpage>S89</lpage>.<pub-id pub-id-type="pmid">29865057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-179939</pub-id><pub-id pub-id-type="pmcid">PMC6380522</pub-id></mixed-citation></ref><ref id="alz70057-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70057-cite-0014"><string-name name-style="western"><surname>Saffari</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Ning</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>AutoScore&#8208;Ordinal: an interpretable machine learning framework for generating scoring models for ordinal outcomes</article-title>. <source>BMC Med Res Method</source>. <year>2022</year>;<volume>22</volume>:<fpage>286</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12874-022-01770-y</pub-id><pub-id pub-id-type="pmcid">PMC9636613</pub-id><pub-id pub-id-type="pmid">36333672</pub-id></mixed-citation></ref><ref id="alz70057-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70057-cite-0015"><string-name name-style="western"><surname>Xie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chakraborty</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ong</surname><given-names>MEH</given-names></string-name>, <string-name name-style="western"><surname>Goldstein</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>. <article-title>Autoscore: a machine learning&#8208;based automatic clinical score generator and its application to mortality prediction using electronic health records</article-title>. <source>JMIR Med Inform</source>. <year>2020</year>;<volume>8</volume>:<elocation-id>e21798</elocation-id>.<pub-id pub-id-type="pmid">33084589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/21798</pub-id><pub-id pub-id-type="pmcid">PMC7641783</pub-id></mixed-citation></ref><ref id="alz70057-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70057-cite-0016"><string-name name-style="western"><surname>Xie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ning</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>A universal AutoScore framework to develop interpretable scoring systems for predicting common types of clinical outcomes</article-title>. <source>STAR Protoc</source>. <year>2023</year>;<volume>4</volume>:<elocation-id>102302</elocation-id>.<pub-id pub-id-type="pmid">37178115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xpro.2023.102302</pub-id><pub-id pub-id-type="pmcid">PMC10200969</pub-id></mixed-citation></ref><ref id="alz70057-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70057-cite-0017"><string-name name-style="western"><surname>Bouwmeester</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zuithoff</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Mallett</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Reporting and methods in clinical prediction research: a systematic review</article-title>. <source>PLoS Med</source>. <year>2012</year>;<volume>9</volume>:<elocation-id>e1001221</elocation-id>.<pub-id pub-id-type="pmid">22629234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001221</pub-id><pub-id pub-id-type="pmcid">PMC3358324</pub-id></mixed-citation></ref><ref id="alz70057-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70057-cite-0018"><string-name name-style="western"><surname>B&#252;rkner</surname><given-names>P&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Vuorre</surname><given-names>M</given-names></string-name>. <article-title>Ordinal regression models in psychology: a tutorial</article-title>. <source>Adv Methods Pract Psychol Sci</source>. <year>2019</year>;<volume>2</volume>:<fpage>77</fpage>&#8208;<lpage>101</lpage>.</mixed-citation></ref><ref id="alz70057-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70057-cite-0019"><string-name name-style="western"><surname>Landgrebe</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Duin</surname><given-names>RP</given-names></string-name>. <article-title>Approximating the multiclass ROC by pairwise analysis</article-title>. <source>Pattern Recognit Lett</source>. <year>2007</year>;<volume>28</volume>:<fpage>1747</fpage>&#8208;<lpage>1758</lpage>.</mixed-citation></ref><ref id="alz70057-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70057-cite-0020"><string-name name-style="western"><surname>Van Calster</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Van Belle</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vergouwe</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></string-name>. <article-title>Discrimination ability of prediction models for ordinal outcomes: relationships between existing measures and a new measure</article-title>. <source>Biom J</source>. <year>2012</year>;<volume>54</volume>:<fpage>674</fpage>&#8208;<lpage>685</lpage>.<pub-id pub-id-type="pmid">22711459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bimj.201200026</pub-id></mixed-citation></ref><ref id="alz70057-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70057-cite-0021"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>. <article-title>Overview of clinical prediction models</article-title>. <source>Ann Transl Med</source>. <year>2020</year>;<volume>8</volume>:<fpage>71</fpage>.<pub-id pub-id-type="pmid">32175364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2019.11.121</pub-id><pub-id pub-id-type="pmcid">PMC7049012</pub-id></mixed-citation></ref><ref id="alz70057-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70057-cite-0022"><string-name name-style="western"><surname>Tomonaga</surname><given-names>M</given-names></string-name>. <article-title>Cerebral amyloid angiopathy in the elderly</article-title>. <source>J Am Geriatr Soc</source>. <year>1981</year>;<volume>29</volume>:<fpage>151</fpage>&#8208;<lpage>157</lpage>.<pub-id pub-id-type="pmid">7204810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1981.tb01757.x</pub-id></mixed-citation></ref><ref id="alz70057-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70057-cite-0023"><string-name name-style="western"><surname>Greenberg</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>William Rebeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vonsattel</surname><given-names>JPG</given-names></string-name>, <string-name name-style="western"><surname>Gomez&#8208;Isla</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>. <article-title>Apolipoprotein E &#949;4 and cerebral hemorrhage associated with amyloid angiopathy</article-title>. <source>Ann Neurol</source>. <year>1995</year>;<volume>38</volume>:<fpage>254</fpage>&#8208;<lpage>259</lpage>.<pub-id pub-id-type="pmid">7654074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410380219</pub-id></mixed-citation></ref><ref id="alz70057-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70057-cite-0024"><string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Cerebral amyloid angiopathy and cognitive outcomes in community&#8208;based older persons</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>:<fpage>1930</fpage>&#8208;<lpage>1936</lpage>.<pub-id pub-id-type="pmid">26537052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002175</pub-id><pub-id pub-id-type="pmcid">PMC4664125</pub-id></mixed-citation></ref><ref id="alz70057-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70057-cite-0025"><string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huynh</surname><given-names>ALH</given-names></string-name>, et&#160;al. <article-title>Exploring epidemiological risk factors for cerebral amyloid angiopathy: considerations for monoclonal antibody therapy in people with Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>:<elocation-id>e14602</elocation-id> (In press).<pub-id pub-id-type="pmid">40042470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14602</pub-id><pub-id pub-id-type="pmcid">PMC11881626</pub-id></mixed-citation></ref><ref id="alz70057-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70057-cite-0026"><string-name name-style="western"><surname>Weir</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Jan</surname><given-names>A</given-names></string-name>. <article-title>BMI classification percentile and cut off points</article-title>. <source>StarPeals</source>. <year>2023</year>.</mixed-citation></ref><ref id="alz70057-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70057-cite-0027"><string-name name-style="western"><surname>Qaseem</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wilt</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Rich</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians</article-title>. <source>Ann Intern Med</source>. <year>2017</year>;<volume>166</volume>:<fpage>430</fpage>&#8208;<lpage>437</lpage>.<pub-id pub-id-type="pmid">28135725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M16-1785</pub-id></mixed-citation></ref><ref id="alz70057-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70057-cite-0028"><string-name name-style="western"><surname>Tsatali</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Poptsi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Moraitou</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Discriminant validity of the WAIS&#8208;R digit symbol substitution test in subjective cognitive decline, mild cognitive impairment (amnestic subtype) and Alzheimer's disease dementia (ADD) in Greece</article-title>. <source>Brain Sci</source>. <year>2021</year>;<volume>11</volume>:<fpage>881</fpage>.<pub-id pub-id-type="pmid">34209189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11070881</pub-id><pub-id pub-id-type="pmcid">PMC8301784</pub-id></mixed-citation></ref><ref id="alz70057-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70057-cite-0029"><string-name name-style="western"><surname>Chantran</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Capron</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alamowitch</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aucouturier</surname><given-names>P</given-names></string-name>. <article-title>Anti&#8208;A&#946; antibodies and cerebral amyloid angiopathy complications</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1534</fpage>.<pub-id pub-id-type="pmid">31333665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01534</pub-id><pub-id pub-id-type="pmcid">PMC6620823</pub-id></mixed-citation></ref><ref id="alz70057-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70057-cite-0030"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Elhage</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JAR</given-names></string-name>, <string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>. <article-title>Amyloid&#8208;related imaging abnormalities (ARIA): radiological, biological and clinical characteristics</article-title>. <source>Brain</source>. <year>2023</year>;<volume>146</volume>:<fpage>4414</fpage>&#8208;<lpage>4424</lpage>.<pub-id pub-id-type="pmid">37280110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad188</pub-id><pub-id pub-id-type="pmcid">PMC10629981</pub-id></mixed-citation></ref><ref id="alz70057-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70057-cite-0031"><string-name name-style="western"><surname>Roytman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mashriqi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Tawil</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;related imaging abnormalities: an update</article-title>. <source>Am J Roentgenol</source>. <year>2023</year>;<volume>220</volume>:<fpage>562</fpage>&#8208;<lpage>574</lpage>.<pub-id pub-id-type="pmid">36321981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.22.28461</pub-id></mixed-citation></ref><ref id="alz70057-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70057-cite-0032"><string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>:<elocation-id>e14583</elocation-id> (In press).<pub-id pub-id-type="pmid">40042448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14583</pub-id><pub-id pub-id-type="pmcid">PMC11881621</pub-id></mixed-citation></ref><ref id="alz70057-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70057-cite-0033"><string-name name-style="western"><surname>Drzezga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Grimmer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Henriksen</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>72</volume>:<fpage>1487</fpage>&#8208;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">19339712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181a2e8d0</pub-id></mixed-citation></ref><ref id="alz70057-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70057-cite-0034"><string-name name-style="western"><surname>Liu</surname><given-names>C&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Kanekiyo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bu</surname><given-names>G</given-names></string-name>. <article-title>Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy</article-title>. <source>Nat Rev Neurol</source>. <year>2013</year>;<volume>9</volume>:<fpage>106</fpage>&#8208;<lpage>118</lpage>.<pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2012.263</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>